[{"id":"ac-camargo","kind":"institution","name":"A.C. Camargo Cancer Center","aka":["A.C.Camargo","Hospital A.C. Camargo","Fundação Antônio Prudente"],"tldr":"Latin America's leading dedicated cancer centre, founded in 1953, with a large research institute and the region's biggest oncology residency.","summary":"A.C. Camargo Cancer Center was founded in São Paulo in 1953 by Antônio Prudente and his wife Carmen through the Fundação Antônio Prudente and is the largest cancer-only hospital in Latin America, combining care, teaching and research. It is known for surgical oncology (head and neck, breast, sarcoma, colorectal and hepatobiliary), one of the region's first robotic surgery programmes, a large hereditary cancer service that characterised the Brazilian TP53 R337H founder mutation in Li-Fraumeni syndrome, and the International Research Center (CIPE) for genomics, bioinformatics and clinical trials. A.C. Camargo runs Brazil's largest oncology residency and fellowship programme and a cancer registry that has tracked outcomes since the 1950s.","asOf":"2026-09-09","links":[{"label":"A.C. Camargo Cancer Center","url":"https://www.accamargo.org.br"}],"tags":[],"related":["li-fraumeni","hereditary-cancer-syndromes"],"cancers":["head-and-neck","breast-hr-positive","sarcoma","colorectal","melanoma"],"sections":["surgery","diagnostics"],"technologies":["robotic-surgery","germline-testing","cgp"],"targets":["tp53"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["victor-piana-de-andrade"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"São Paulo","country":"BR","lat":-23.563,"lng":-46.649,"institutionType":"cancer-center","website":"https://www.accamargo.org.br","programs":["Surgical oncology and robotics","Hereditary cancer (TP53 R337H)","International Research Center (CIPE)","Oncology residency"]},{"id":"aalborg-university-hospital","kind":"institution","name":"Aalborg University Hospital","aka":["Aalborg Universitetshospital"],"tldr":"Aalborg University Hospital is the largest hospital in the North Denmark Region and a full member of the Organisation of European Cancer Institutes.","summary":"Aalborg University Hospital is the largest hospital in the North Denmark Region and the region's centre for specialised cancer treatment, working with Aalborg University on clinical research. It is listed by the Organisation of European Cancer Institutes as a full member and takes part in the Danish Comprehensive Cancer Center, which links all Danish hospitals that treat cancer. OnCo records it as one of Denmark's four university hospital cancer centres; its programmes, trial portfolio and leadership are not yet recorded here and should be checked on the hospital's own pages.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Aalborg_University_Hospital","links":[{"label":"Official website","url":"https://aalborguh.rn.dk"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Aalborg_University_Hospital"}],"tags":[],"related":["rigshospitalet","aarhus-university-hospital"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["lars-dahl-pedersen"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Aalborg","country":"DK","lat":57.038,"lng":9.909,"institutionType":"hospital","website":"https://aalborguh.rn.dk","programs":[]},{"id":"aarhus-university-hospital","kind":"institution","name":"Aarhus University Hospital","aka":["AUH","Danish Centre for Particle Therapy"],"tldr":"Aarhus University Hospital hosts the Danish Centre for Particle Therapy, the national proton facility opened in 2019; its oncology department under Jens Overgaard has run the DAHANCA head and neck trials that established accelerated fractionation and the radiosensitiser nimorazole.","summary":"Aarhus University Hospital hosts the Danish Centre for Particle Therapy, the country's national proton facility, which opened in 2019 with Varian ProBeam gantries and treats patients from across Denmark within randomised trials. Its experimental clinical oncology department under Jens Overgaard has run the DAHANCA head and neck cancer trials for decades, establishing accelerated fractionation and the hypoxic radiosensitiser nimorazole, and pioneered clinical hyperthermia with radiotherapy for melanoma. The hospital is a major transplant, urological cancer and gastrointestinal surgery centre, contributes to Danish Breast Cancer Group trials, and leads registry-based studies through Aarhus University's clinical epidemiology department.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Aarhus_University_Hospital","links":[{"label":"Homepage","url":"https://www.en.auh.dk"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":["head-and-neck","prostate","melanoma","breast-hr-positive"],"sections":["radiation"],"technologies":["proton-therapy","imrt-igrt","hyperthermia","sbrt","proton-therapy-systems"],"targets":[],"drugs":[],"companies":["varian"],"institutions":["rigshospitalet"],"pathways":[],"terms":[],"trials":[],"people":["thomas-balle-kristensen","jens-overgaard"],"bottlenecks":["b-surgery-radiation-innovation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Aarhus","country":"DK","lat":56.194,"lng":10.19,"institutionType":"hospital","website":"https://www.en.auh.dk","university":"Aarhus University","programs":["Danish Centre for Particle Therapy","DAHANCA head and neck trials","Hyperthermia and radiobiology","Clinical epidemiology","Urological oncology"]},{"id":"aberdeen-royal-infirmary","kind":"institution","name":"Aberdeen Royal Infirmary","aka":["NHS Grampian"],"tldr":"A surgical centre for NHS Scotland North, serving Grampian and the islands; a Precision-Panc and ginisortamab trial site.","summary":"Pancreatic Cancer UK lists Aberdeen Royal Infirmary with Ninewells as the surgical centres for NHS Scotland North. It recruited to the Precision Panc master protocol and is a site of the phase 2 ginisortamab trial in metastatic pancreatic ductal adenocarcinoma.","asOf":"2026-09-24","links":[{"label":"NHS Grampian","url":"https://www.nhsgrampian.org/"},{"label":"Pancreatic Cancer UK centres list","url":"https://www.pancreaticcancer.org.uk/information-and-support/your-care/your-local-pancreatic-cancer-specialist-centre/"}],"tags":["hpb","nhs","uk"],"related":[],"cancers":["pancreatic","gallbladder","biliary-tract-cancer","cholangiocarcinoma","hcc"],"sections":["surgery"],"technologies":["whipple"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["precision-panc"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Aberdeen","country":"GB","lat":57.153,"lng":-2.135,"institutionType":"hospital","website":"https://www.nhsgrampian.org/","university":"University of Aberdeen","programs":["HPB surgery","North of Scotland HPB MDT"]},{"id":"penn-abramson","kind":"institution","name":"Abramson Cancer Center, University of Pennsylvania","aka":[],"tldr":"Where CAR-T became a drug (June, Levine; Emily Whitehead), mRNA was made druggable (Karikó, Weissman), and PARP PET was invented.","summary":"The Abramson Cancer Center at the University of Pennsylvania in Philadelphia, NCI-designated as comprehensive, is where CAR-T became a drug through Carl H. June, Bruce L. Levine and the treatment of Emily Whitehead, where Karikó and Drew Weissman made mRNA druggable, recognised by the 2023 Nobel Prize, and where PARP PET was invented. Its record covers CTL019, now tisagenlecleucel, proved in ELIANA and JULIET, the in vivo CAR-T origins behind Capstan and Interius BioTherapeutics, 18F-FluorThanatrace PARP PET, proton therapy and the Basser Center for BRCA, with Robert H. Vonderheide and Robert H. Mach among its people. OnCo links it to CAR-T for glioma, to the PROSE paper on preventive surgery in BRCA carriers, and to Children's Hospital of Philadelphia. Whether in vivo CAR-T can match ex vivo products is the question its spin-outs now test. Programmes are listed below.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.pennmedicine.org/cancer"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["car-t","in-vivo-car-t","parp-pet","neoantigen-mrna-vaccine","proton-therapy","proton-therapy-systems"],"targets":["brca","parp"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["robert-vonderheide","drew-weissman","angela-demichele","charu-aggarwal","robert-mach","leonard-abramson","jeffrey-bradley","alexander-perl","stephen-schuster","bruce-levine","carl-june","david-porter","susan-domchek"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Philadelphia","country":"US","lat":39.949,"lng":-75.194,"institutionType":"cancer-center","website":"https://www.pennmedicine.org/cancer","nci":"comprehensive","university":"University of Pennsylvania","programs":["CAR-T and in vivo CAR","mRNA","PARP PET","BRCA (Basser Center)"]},{"id":"accelerate-platform","kind":"institution","name":"ACCELERATE","aka":["ACCELERATE platform","ACCELERATE Paediatric Oncology Platform"],"tldr":"ACCELERATE is a Brussels-based forum where children's cancer doctors, drug companies, the EMA and FDA and parents agree which new cancer drugs should be tested in children and how, so that medicines developed for adults are not left untested in childhood cancers.","summary":"Founded in 2013 as a joint initiative of SIOP Europe, ITCC, the European Society for Paediatric Oncology's parent groups and industry, ACCELERATE is a multi-stakeholder platform for paediatric oncology drug development. Its Paediatric Strategy Forums, held with the EMA and the FDA Oncology Center of Excellence, take a mechanism of action (ALK, MEK, BCL2, CDK4/6, ADCs, immunotherapy, radiopharmaceuticals) and agree which products should advance in children and how, an approach that feeds directly into RACE Act and EU Paediatric Regulation obligations. Other workstreams are Fit-for-Filing (making academic trial data acceptable for regulatory submissions), the Long-Term Follow-Up initiative for children on novel agents, the ACCELERATE Paediatric Oncology Master Protocol concept, and the Paediatric Oncology Preclinical Proof-of-Concept programme.","asOf":"2026-09-10","links":[{"label":"ACCELERATE","url":"https://www.accelerate-platform.org"},{"label":"Paediatric Strategy Forums","url":"https://www.accelerate-platform.org/paediatric-strategy-forums/"}],"tags":["nci-coverage","paediatric"],"related":[],"cancers":["neuroblastoma","dipg-dmg","paediatric-low-grade-glioma","all-leukemia"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["itcc"],"institutions":["siop-europe","ema","fda-oce"],"pathways":[],"terms":["race-for-children-act"],"trials":[],"people":["nicole-scobie"],"bottlenecks":["b-rare-cancers","b-incentive-misalignment","b-regulatory-fragmentation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Brussels","country":"BE","lat":50.85,"lng":4.352,"institutionType":"consortium","website":"https://www.accelerate-platform.org","programs":["Paediatric Strategy Forums (with EMA and FDA)","Fit-for-Filing","Long-Term Follow-Up of children on novel agents","Pediatric Oncology Preclinical Proof-of-Concept","Annual ACCELERATE conference"]},{"id":"addenbrookes-cambridge","kind":"institution","name":"Addenbrooke's Hospital, Cambridge University Hospitals","aka":["Cambridge University Hospitals NHS Foundation Trust","CUH"],"tldr":"The East of England's HPB specialist centre, with liver transplantation; a BILCAP site and a site of the UK biliary microbiome study.","summary":"Cambridge University Hospitals is one of the trusts the National Pancreatic Cancer Audit identifies as an HPB specialist centre for England. Addenbrooke's recruited to BILCAP, the UK adjuvant capecitabine trial, and is a site of the UK study of the oral and gut microbiome in biliary tract cancer patients on chemotherapy with immunotherapy (ISRCTN11210442).","asOf":"2026-09-24","links":[{"label":"Cambridge University Hospitals","url":"https://www.cuh.nhs.uk/"},{"label":"NPaCA HPB specialist centres","url":"https://www.natcan.org.uk/wp-content/uploads/2025/11/NPaCA-SotN-2025-Methodology-Supplement.pdf"}],"tags":["hpb","nhs","uk"],"related":[],"cancers":["gallbladder","biliary-tract-cancer","cholangiocarcinoma","pancreatic","hcc","tnbc","skin-cancer"],"sections":["surgery"],"technologies":["hepatectomy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["bilcap","partner","molemate"],"people":["jean-abraham"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Cambridge","country":"GB","lat":52.175,"lng":0.14,"institutionType":"hospital","website":"https://www.cuh.nhs.uk/","university":"University of Cambridge","programs":["HPB surgery","Liver transplantation","Specialist HPB MDT","Biliary trials"]},{"id":"actrec","kind":"institution","name":"Advanced Centre for Treatment, Research and Education in Cancer","aka":["ACTREC","Tata Memorial Centre ACTREC"],"tldr":"The research and development campus of Tata Memorial Centre, where India's first indigenous CAR-T therapy was developed and low-cost trials are designed.","summary":"ACTREC opened in Kharghar, Navi Mumbai, in 2002 as the research wing of Tata Memorial Centre, combining basic science laboratories, a clinical research centre and a hospital that has since expanded into a large cancer hospital with bone marrow transplant, proton and paediatric services. Its scientists, with IIT Bombay and ImmunoACT, developed talicabtagene autoleucel (NexCAR19), India's first approved CD19 CAR-T therapy, and ACTREC hosts the Tata Memorial biobank, genomics and proteomics facilities and the Clinical Research Secretariat that ran the low-dose nivolumab and metronomic chemotherapy trials. The campus also houses the Homi Bhabha National Institute's cancer biology PhD programme and an early-phase trial unit.","asOf":"2026-09-09","links":[{"label":"ACTREC","url":"https://actrec.gov.in"},{"label":"Tata Memorial Centre","url":"https://tmc.gov.in"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":["global-oncology-access","point-of-care-cell-manufacturing"],"cancers":["all-leukemia","dlbcl","head-and-neck","cervical"],"sections":["cell-therapy","drug-discovery"],"technologies":["car-t","proton-therapy","proton-therapy-systems"],"targets":["cd19"],"drugs":["nivolumab"],"companies":[],"institutions":["tata-memorial"],"pathways":[],"terms":[],"trials":[],"people":["gupta-sudeep","badwe-rajendra","patil-vijay","prabhash-kumar","chaturvedi-pankaj"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Navi Mumbai","country":"IN","lat":19.061,"lng":73.02,"institutionType":"research-institute","website":"https://actrec.gov.in","university":"Homi Bhabha National Institute","programs":["Indigenous CAR-T (NexCAR19)","Clinical Research Secretariat","Cancer biology laboratories","Bone marrow transplant"]},{"id":"arpa-h","kind":"institution","name":"Advanced Research Projects Agency for Health","aka":["ARPA-H"],"tldr":"The US agency modelled on DARPA that funds high-risk, milestone-driven health programmes, including adaptive cancer therapy, rapid tumour-removal surgery and early detection.","summary":"Created in 2022 within the Department of Health and Human Services, ARPA-H funds programme managers to run time-limited, milestone-based projects that the NIH grant system does not, with an appropriation of roughly $1.5 billion per year in its first years. Cancer-relevant programmes include ADAPT (adaptive therapies that anticipate tumour evolution), POSEIDON (at-home multi-cancer screening), CUREIT (curative immunotherapy), Precision Surgical Interventions (removing all tumour tissue in one operation) and the Cancer Moonshot-aligned biomanufacturing efforts. It works through ARPANET-H hubs in Massachusetts, Texas and Washington and contracts rather than grants. Its model has drawn interest from other countries designing their own ARPA-style funders.","asOf":"2026-09-09","links":[{"label":"ARPA-H","url":"https://arpa-h.gov"},{"label":"Programs","url":"https://arpa-h.gov/research-and-funding/programs"}],"tags":[],"related":[],"cancers":[],"sections":["early-detection","surgery","immunotherapy"],"technologies":["mced","fluorescence-guided-surgery","car-t"],"targets":[],"drugs":[],"companies":[],"institutions":["nci"],"pathways":[],"terms":[],"trials":[],"people":["alicia-jackson"],"bottlenecks":["b-resistance","b-early-detection","b-funding-allocation","b-surgery-radiation-innovation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Washington, DC","country":"US","lat":38.907,"lng":-77.037,"institutionType":"government","website":"https://arpa-h.gov","programs":["ADAPT (adaptive cancer therapy)","POSEIDON (at-home multi-cancer screening)","CUREIT and Precision Surgical Interventions","ARPANET-H hub network"]},{"id":"aku-karachi","kind":"institution","name":"Aga Khan University Hospital, Karachi","aka":["AKUH Karachi"],"tldr":"Pakistan's leading private academic hospital, opened in 1985, with a comprehensive oncology service and the country's most active academic cancer research programme.","summary":"The Aga Khan University Hospital in Karachi opened in 1985 as the teaching hospital of the Aga Khan University and was the first hospital in Pakistan accredited by Joint Commission International. Its oncology services include medical oncology, radiation oncology, haematology and stem cell transplantation, surgical oncology, paediatric oncology and nuclear medicine, and its Section of Medical Oncology and Department of Oncology run one of the most productive cancer research programmes in the country, including the Karachi Cancer Registry work and hereditary breast cancer studies. The hospital also operates a nationwide clinical laboratory network.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://hospitals.aku.edu/karachi"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["aga-khan-university-hospital-nairobi","shaukat-khanum"],"pathways":[],"terms":[],"trials":[],"people":["farhat-abbas"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Karachi","country":"PK","lat":24.892,"lng":67.074,"institutionType":"hospital","website":"https://hospitals.aku.edu/karachi","university":"Aga Khan University","programs":["Radiation oncology","Stem cell transplantation","Cancer registry research"]},{"id":"aga-khan-university-hospital-nairobi","kind":"institution","name":"Aga Khan University Hospital, Nairobi","aka":["AKUH Nairobi","Heart and Cancer Centre"],"tldr":"East Africa's leading private teaching hospital, with a dedicated Heart and Cancer Centre offering radiotherapy, chemotherapy and bone marrow transplantation.","summary":"The Aga Khan University Hospital in Nairobi is the Kenyan teaching hospital of the Aga Khan University and is accredited by Joint Commission International. Its Heart and Cancer Centre provides medical oncology, radiation oncology including modern linear accelerator techniques, haemato-oncology with one of the first bone marrow transplant programmes in East Africa, surgical oncology, nuclear medicine and PET-CT, and it runs oncology fellowship training for the region. The hospital participates in research on cancers common in East Africa, such as cervical, breast and oesophageal cancer and Burkitt lymphoma, in partnership with the university's East Africa campuses and international collaborators.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Aga_Khan_University_Hospital,_Nairobi","links":[{"label":"Official website","url":"https://hospitals.aku.edu/nairobi"}],"tags":[],"related":[],"cancers":["cervical","esophageal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["kenyatta-national-hospital","aku-karachi"],"pathways":[],"terms":[],"trials":[],"people":["rashid-khalani"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Nairobi","country":"KE","lat":-1.262,"lng":36.813,"institutionType":"hospital","website":"https://hospitals.aku.edu/nairobi","university":"Aga Khan University","programs":["Heart and Cancer Centre","Radiation oncology","Bone marrow transplantation","Oncology fellowship training"]},{"id":"anvisa","kind":"institution","name":"Agência Nacional de Vigilância Sanitária","aka":["ANVISA","Brazilian Health Regulatory Agency"],"tldr":"ANVISA registers medicines in Brazil, Latin America's largest market, and joined the FDA's Project Orbis in 2019; public coverage is decided separately by CONITEC, so the gap between ANVISA registration and availability in the public system is a central issue in Brazilian oncology.","summary":"Created in 1999, ANVISA regulates medicines, devices, food, cosmetics and tobacco in Brazil and registers new drugs before they can be sold or considered for the public health system. It joined the FDA's Project Orbis in 2019, has adopted reliance and priority review pathways for oncology drugs, and is an ICH member. Coverage in the public Sistema Único de Saúde is decided separately by CONITEC, which conducts health technology assessment, while private insurers follow the ANS list; the gap between ANVISA registration and public availability is a central issue in Brazilian oncology. ANVISA's tobacco regulation includes some of the world's earliest bans on flavoured cigarettes.","asOf":"2026-09-09","links":[{"label":"ANVISA","url":"https://www.gov.br/anvisa"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["einstein-sao-paulo","sirio-libanes","fda-oce"],"pathways":[],"terms":[],"trials":[],"people":["barrios-carlos","hoff-paulo","leandro-pinheiro-safatle"],"bottlenecks":["b-global-access","b-regulatory-fragmentation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Brasília","country":"BR","lat":-15.794,"lng":-47.882,"institutionType":"government","website":"https://www.gov.br/anvisa","programs":["Drug registration and priority review","Project Orbis participation","ICH membership and reliance pathways","Tobacco regulation"]},{"id":"aichi-cancer-center","kind":"institution","name":"Aichi Cancer Center","aka":["愛知県がんセンター"],"tldr":"Nagoya's prefectural cancer centre with a research institute known for cancer epidemiology, molecular carcinogenesis and gastrointestinal oncology.","summary":"Aichi Cancer Center was founded in 1964 as a prefectural cancer hospital with an integrated research institute and is one of Japan's core cancer centres. Its Research Institute has a long tradition in cancer epidemiology (the HERPACC hospital-based case-control study), molecular carcinogenesis and the biology of gastric and lung cancer, including early ALK and EGFR resistance work, while the hospital is a leading Japanese site for gastric, oesophageal, colorectal, breast and haematological cancer trials and endoscopic resection. It participates in JCOG and WJOG and in the SCRUM-Japan genomic screening network. Patients can access a comprehensive genome profiling service and early-phase trials.","asOf":"2026-09-09","links":[{"label":"Aichi Cancer Center (archived copy)","url":"https://web.archive.org/web/20211206023820/https://www.pref.aichi.jp/cancer-center/"}],"tags":[],"related":[],"cancers":["gastric","esophageal","colorectal","breast-hr-positive","nsclc"],"sections":["prevention","diagnostics"],"technologies":["cgp"],"targets":["alk","egfr"],"drugs":[],"companies":["jcog"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["yasumasa-niwa"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Nagoya","country":"JP","lat":35.182,"lng":136.925,"institutionType":"cancer-center","website":"https://web.archive.org/web/20211206023820/https://www.pref.aichi.jp/cancer-center/","programs":["Cancer epidemiology (HERPACC)","Gastrointestinal oncology","Breast cancer","Molecular carcinogenesis"]},{"id":"aidport","kind":"institution","name":"AidPort Clinical Trial Hospital","aka":["AidPort"],"tldr":"A clinical trials hospital in Poznań, Poland, running cancer studies, and an associate member of the Organisation of European Cancer Institutes.","summary":"AidPort is a hospital in Poznań dedicated to clinical trials, including oncology and haematology studies such as lymphoma trials. It is an associate member of the Organisation of European Cancer Institutes (OECI). Its representative on the OECI list is Joanna Lorenc.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.aidport.pl/"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["joanna-lorenc"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Poznań","country":"PL","lat":52.406,"lng":16.925,"institutionType":"hospital","website":"https://www.aidport.pl/","programs":[]},{"id":"akershus-university-hospital","kind":"institution","name":"Akershus University Hospital","aka":["Ahus"],"tldr":"Akershus University Hospital is a public teaching hospital in the Greater Oslo region of Norway and a full member of the Organisation of European Cancer Institutes.","summary":"Akershus University Hospital (Ahus) is a Norwegian public university hospital in Lørenskog, north-east of Oslo, serving a large part of the Greater Oslo region and acting as a teaching hospital for the University of Oslo; the present hospital traces its history to 1961. It provides cancer diagnosis and treatment for its catchment and is listed by the Organisation of European Cancer Institutes as a full member. Programme, trial and leadership details are not yet recorded here and should be checked on the hospital's own pages.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Akershus_University_Hospital","links":[{"label":"Official website","url":"https://www.ahus.no"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Akershus_University_Hospital"}],"tags":[],"related":["haukeland-university-hospital"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["oystein-maeland"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Lørenskog","country":"NO","lat":59.933,"lng":10.952,"institutionType":"hospital","website":"https://www.ahus.no","programs":[]},{"id":"alsf","kind":"institution","name":"Alex's Lemonade Stand Foundation","aka":["ALSF"],"tldr":"The childhood cancer charity that grew from four-year-old Alex Scott's front-yard lemonade stand; it funds paediatric cancer research grants and the Childhood Cancer Data Lab.","summary":"Alex Scott, a child with neuroblastoma, held her first lemonade stand in 2000 to raise money for her hospital; after her death in 2004 her parents Liz and Jay Scott turned the stands into a national foundation. Alex's Lemonade Stand Foundation funds childhood cancer research grants across career stages, travel support for families in trials, and the Childhood Cancer Data Lab, which builds open data tools for paediatric cancer researchers. Its model, thousands of small community fundraisers pooled into research grants, is the pattern several later childhood cancer charities have followed.","asOf":"2026-09-10","links":[{"label":"Alex's Lemonade Stand Foundation","url":"https://www.alexslemonade.org/"}],"tags":[],"related":["alexs-lemonade-stand"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["alex-scott"],"bottlenecks":["b-rare-cancers","b-funding-allocation","b-data-silos"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Bala Cynwyd, PA","country":"US","lat":40.008,"lng":-75.234,"institutionType":"consortium","website":"https://www.alexslemonade.org","programs":["Childhood cancer research grants","Childhood Cancer Data Lab","Travel For Care family support","Lemonade Days community fundraising"]},{"id":"alfred-health-monash","kind":"institution","name":"Alfred Health / Monash University","aka":["The Alfred","Alfred Hospital","Monash University Central Clinical School"],"tldr":"Melbourne teaching hospital and university whose haematology and lymphoma services, including Constantine Tam's group, led the trials that established BTK inhibitors and venetoclax in lymphoma and leukaemia.","summary":"Alfred Health runs The Alfred, a large public teaching hospital in Melbourne, and is the clinical partner of Monash University's Central Clinical School. Its Department of Haematology is one of Australia's leading centres for lymphoma and leukaemia trials; Constantine Tam, who heads the lymphoma service and is professor of haematology at Monash, led the first-in-human and phase 3 studies of zanubrutinib and the early studies of venetoclax combinations in chronic lymphocytic leukaemia and mantle cell lymphoma.","asOf":"2026-09-18","links":[{"label":"Alfred Health","url":"https://www.alfredhealth.org.au"}],"tags":[],"related":[],"cancers":["cll","mantle-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["constantine-tam"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Melbourne","country":"AU","lat":-37.846,"lng":144.982,"institutionType":"hospital","website":"https://www.alfredhealth.org.au","university":"Monash University","programs":["Lymphoma and leukaemia trials","Haematology","Bone marrow transplantation"]},{"id":"aiims-delhi","kind":"institution","name":"All India Institute of Medical Sciences, New Delhi","aka":["AIIMS","Dr B.R. Ambedkar Institute Rotary Cancer Hospital","National Cancer Institute Jhajjar"],"tldr":"AIIMS New Delhi is India's flagship public medical institute; its Rotary Cancer Hospital and the National Cancer Institute campus at Jhajjar anchor government cancer research, and its investigators lead Indian studies in paediatric oncology, gallbladder cancer, PSMA radioligand therapy and low-cost CAR-T.","summary":"AIIMS New Delhi was created by an Act of Parliament in 1956 as India's flagship medical institute and hospital. Cancer care is concentrated in the Dr B.R. Ambedkar Institute Rotary Cancer Hospital, opened in 1983, and in the National Cancer Institute at Jhajjar, Haryana, a large AIIMS-run cancer campus commissioned from 2019 with proton therapy planned and a national biobank and screening research mandate. AIIMS investigators lead Indian studies in paediatric oncology, gallbladder cancer (unusually common in northern India), oral and cervical cancer screening, radiation oncology and nuclear medicine (PSMA and FAPI PET, radioligand therapy), and haematology including low-cost CAR-T development with IIT Bombay partners. It sets national training standards and publishes the largest volume of oncology research of any Indian public institution.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/All_India_Institute_of_Medical_Sciences,_Delhi","links":[{"label":"AIIMS New Delhi","url":"https://www.aiims.edu"}],"tags":[],"related":["global-oncology-access"],"cancers":["cervical","head-and-neck","cholangiocarcinoma","all-leukemia","prostate"],"sections":["radiopharma","prevention","radiation"],"technologies":["radioligand-therapy","psma-pet","fapi-pet","car-t","hpv-vaccine","gamma-knife","radiosurgery-srs"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["nikhil-tandon","raina-vinod"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"New Delhi","country":"IN","lat":28.567,"lng":77.21,"institutionType":"hospital","website":"https://www.aiims.edu","programs":["Rotary Cancer Hospital","National Cancer Institute Jhajjar","Nuclear medicine and theranostics","Paediatric oncology","Gallbladder cancer"]},{"id":"aacr","kind":"institution","name":"American Association for Cancer Research (AACR)","aka":[],"tldr":"The AACR is the oldest and largest cancer research society; its April meeting is where early-stage science and first-in-human data appear.","summary":"The American Association for Cancer Research, based in Philadelphia, is the oldest and largest cancer research society, and its Annual Meeting each April is where early-stage science and first-in-human data appear. It runs Project GENIE, the shared clinico-genomic registry that OnCo carries as a collection, publishes Cancer Research, Cancer Discovery, Clinical Cancer Research and Cancer Immunology Research, and issues a quarterly digest of FDA approvals, with Margaret Foti, Antoni Ribas and Philip D. Greenberg among the people linked. OnCo connects it to bottlenecks on data silos, irreproducible preclinical results and secrecy, and to ideas such as plenary slots for negative trials and universal sequencing at diagnosis. Whether a society can enforce data sharing its members resist is the fair question. Stand Up To Cancer and the Mark Foundation are linked partners.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.aacr.org"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["margaret-foti"],"bottlenecks":[],"keyPapers":[],"journals":["blood-cancer-discovery","cancer-epidemiology-biomarkers-prevention","cancer-prevention-research","cancer-research-communications","molecular-cancer-research"],"dependsOn":[],"notes":[],"city":"Philadelphia","country":"US","lat":39.952,"lng":-75.165,"institutionType":"consortium","website":"https://www.aacr.org","programs":["Annual Meeting","Project GENIE"]},{"id":"astro","kind":"institution","name":"American Society for Radiation Oncology","aka":["ASTRO"],"tldr":"The largest radiation oncology society, whose annual meeting, guidelines and Choosing Wisely lists drive adoption of hypofractionation and stereotactic radiotherapy.","summary":"Founded in 1958 as the American Club of Therapeutic Radiologists, ASTRO represents more than 10,000 radiation oncologists, physicists and allied professionals. It publishes the International Journal of Radiation Oncology Biology Physics, Practical Radiation Oncology and Advances in Radiation Oncology, issues evidence-based guidelines (including hypofractionation for breast and prostate cancer and SBRT for early lung cancer), runs the APEx practice accreditation programme and RO-ILS patient safety incident learning system, and advocates on Medicare payment models for radiotherapy. Its annual meeting each autumn is the principal venue for radiotherapy trial results, and it partners with ESTRO and the NRG on international standards.","asOf":"2026-09-09","links":[{"label":"ASTRO","url":"https://www.astro.org"},{"label":"Guidelines","url":"https://www.astro.org/patient-care-and-research/clinical-practice-statements"}],"tags":[],"related":["src-astro"],"cancers":[],"sections":["radiation"],"technologies":["imrt-igrt","sbrt","proton-therapy","brachytherapy","mr-linac","flash-rt"],"targets":[],"drugs":[],"companies":["nrg-oncology"],"institutions":["estro","asco"],"pathways":[],"terms":[],"trials":[],"people":["theodore-lawrence"],"bottlenecks":["b-surgery-radiation-innovation"],"keyPapers":[],"journals":["practical-radiation-oncology"],"dependsOn":[],"notes":[],"city":"Arlington, VA","country":"US","lat":38.88,"lng":-77.107,"institutionType":"consortium","website":"https://www.astro.org","programs":["ASTRO Annual Meeting","Clinical practice guidelines","APEx accreditation and RO-ILS safety","Red Journal and Practical Radiation Oncology"]},{"id":"asco","kind":"institution","name":"American Society of Clinical Oncology (ASCO)","aka":[],"tldr":"ASCO is the world's largest oncology professional society; its annual meeting each June is where most practice-changing trials are first presented.","summary":"The American Society of Clinical Oncology, based in Alexandria, Virginia, is the world's largest oncology professional society, and its Annual Meeting each June, with around forty thousand attendees, is where most practice-changing trials are first presented. It publishes the Journal of Clinical Oncology and its JCO sister journals, runs the TAPUR basket trial and CancerLinQ, and issues clinical practice guidelines including the 2021 guideline on immune-related side effects. OnCo connects it to bottlenecks on hidden failures and incentives that reward marginal gains, and to ideas such as a guideline fast track for repurposed drugs and independent validation of surrogate endpoints. Whether a society funded partly by industry can police value is the fair question. Its guidelines collection has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.asco.org"}],"tags":[],"related":["src-asco-post","src-asco-daily-news"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["clifford-hudis","robin-zon","lynn-schuchter","jane-cooke-wright","everett-vokes"],"bottlenecks":[],"keyPapers":[],"journals":["asco-educational-book","jco-clinical-cancer-informatics"],"dependsOn":[],"notes":[],"city":"Alexandria, VA","country":"US","lat":38.804,"lng":-77.047,"institutionType":"consortium","website":"https://www.asco.org","programs":["Annual Meeting","TAPUR","Guidelines"]},{"id":"ash","kind":"institution","name":"American Society of Hematology","aka":["ASH"],"tldr":"The world's largest haematology society, whose December annual meeting is where the pivotal leukaemia, lymphoma and myeloma results are first presented.","summary":"Founded in 1958, ASH has more than 18,000 members and publishes Blood and Blood Advances. Its annual meeting, held each December, is the venue for the major blood cancer trials, from CAR-T and bispecific antibody results to venetoclax combinations and MRD-guided therapy, and its late-breaking abstract session regularly changes practice. ASH issues clinical practice guidelines, runs the ASH Research Collaborative with its data hub and the Sickle Cell Disease and Cancer Clinical Trials Networks, funds scholar awards and global capacity building, and advocates on drug access and research funding. ASH-EHA and ASH-ASCO joint guidelines link it to its European and oncology counterparts.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/American_Society_of_Hematology","links":[{"label":"ASH","url":"https://www.hematology.org"},{"label":"Annual Meeting","url":"https://www.hematology.org/meetings/annual-meeting"}],"tags":[],"related":["leukemia-lymphoma-society","src-ash-annual","blood"],"cancers":["aml","all-leukemia","dlbcl","cll","multiple-myeloma","hodgkin-lymphoma"],"sections":[],"technologies":["car-t","bispecific-antibody","mrd-testing"],"targets":[],"drugs":[],"companies":[],"institutions":["eha","asco"],"pathways":[],"terms":["mrd"],"trials":[],"people":["kenneth-anderson","ross-levine","benjamin-ebert","robert-negrin"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Washington, DC","country":"US","lat":38.905,"lng":-77.036,"institutionType":"consortium","website":"https://www.hematology.org","programs":["ASH Annual Meeting (December)","Blood and Blood Advances","Clinical practice guidelines","ASH Research Collaborative data hub","Scholar awards and global programmes"]},{"id":"aubmc-basile-cancer-institute","kind":"institution","name":"American University of Beirut Medical Center / Naef K. Basile Cancer Institute","aka":["AUBMC","NKBCI"],"tldr":"Lebanon's leading academic medical centre, whose Naef K. Basile Cancer Institute is a regional referral centre for the Levant.","summary":"The American University of Beirut Medical Center is the teaching hospital of the American University of Beirut, founded in 1866, and is accredited by Joint Commission International. Its Naef K. Basile Cancer Institute brings together medical oncology, haematology and bone marrow transplantation, radiation oncology, surgical oncology and paediatric oncology (with the Children's Cancer Center of Lebanon, a St. Jude partner), and runs a clinical trials unit that participates in international phase 2 and 3 studies. AUBMC trains oncologists for Lebanon and the wider Arab world and has continued to operate through the country's economic crisis.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.aubmc.org.lb"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["st-jude","khcc"],"pathways":[],"terms":[],"trials":[],"people":["ali-taher"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Beirut","country":"LB","lat":33.899,"lng":35.482,"institutionType":"hospital","website":"https://www.aubmc.org.lb","university":"American University of Beirut","programs":["Naef K. Basile Cancer Institute","Bone marrow transplantation","Children's Cancer Center of Lebanon","Clinical trials"]},{"id":"ammf","kind":"institution","name":"AMMF, the Cholangiocarcinoma Charity","aka":["AMMF","Alan Morement Memorial Fund"],"tldr":"The UK's only charity dedicated to cholangiocarcinoma and the other biliary tract cancers: patient information, a list of UK centres with expertise, research grants, an annual conference and a nurse study day.","summary":"AMMF (registered charity 1198095, Stansted, Essex) is the UK's only cholangiocarcinoma charity. It publishes patient information on diagnosis, treatment, molecular profiling and clinical trials, keeps a list of UK and Irish centres with cholangiocarcinoma expertise, funds research grants, runs an annual cholangiocarcinoma conference and an HPB nurse study day, campaigns in Westminster (Rethink Liver Cancer) and is a patient representative on the British Society of Gastroenterology cholangiocarcinoma guideline. Its chief executive, Helen Morement, was a co-author of that guideline.","asOf":"2026-09-24","links":[{"label":"AMMF","url":"https://ammf.org.uk/"},{"label":"Centres with CCA expertise","url":"https://ammf.org.uk/centres-with-cca-expertise/"},{"label":"BSG cholangiocarcinoma guideline (Gut 2023)","url":"https://europepmc.org/article/MED/37770126"}],"tags":["charity","uk","biliary"],"related":["uk-hpb-specialist-centres"],"cancers":["gallbladder","biliary-tract-cancer","cholangiocarcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["macmillan-cancer-support","kings-college-hospital-london","royal-free-hospital","uclh","imperial-cancer-centre","newcastle-cancer-centre","liverpool-hpb-centre","birmingham-cancer-centre","leeds-cancer-centre","manchester-royal-infirmary","southampton-cancer","university-hospital-wales-cardiff","royal-infirmary-edinburgh","belfast-trust-hpb","the-christie","clatterbridge","beatson-glasgow"],"pathways":[],"terms":[],"trials":[],"people":["shahid-khan","john-bridgewater"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Stansted","country":"GB","lat":51.895,"lng":0.235,"institutionType":"consortium","website":"https://ammf.org.uk/","programs":["Patient information and discussion groups","UK centres with CCA expertise (the institutions linked here are its March 2023 list)","Research grants","Annual CCA conference","HPB nurse study day","Rethink Liver Cancer campaign"]},{"id":"amsterdam-umc","kind":"institution","name":"Amsterdam UMC / Cancer Center Amsterdam","aka":["AMC","VUmc","Cancer Center Amsterdam"],"tldr":"The merged Amsterdam university hospitals (AMC and VUmc), whose Cancer Center Amsterdam is one of the largest academic cancer research programmes in the Netherlands.","summary":"Amsterdam UMC was formed by the 2018 merger of the Academic Medical Center (University of Amsterdam) and VU University Medical Center (Vrije Universiteit). Cancer Center Amsterdam is its research and care institute for oncology, spanning medical oncology, haematology, radiotherapy, surgical oncology and imaging on two campuses. Strengths include pancreatic and hepatobiliary surgery, colorectal cancer biology and organoids, lymphoma and leukaemia, imaging and radiotherapy, and cancer immunology, and the centre works alongside the Netherlands Cancer Institute within the Amsterdam cancer ecosystem.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.amsterdamumc.org"}],"tags":[],"related":[],"cancers":["pancreatic","colorectal"],"sections":[],"technologies":["mr-linac"],"targets":[],"drugs":[],"companies":[],"institutions":["nki"],"pathways":[],"terms":[],"trials":[],"people":["hans-van-goudoever"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Amsterdam","country":"NL","lat":52.335,"lng":4.958,"institutionType":"hospital","website":"https://www.amsterdamumc.org","university":"University of Amsterdam / Vrije Universiteit Amsterdam","programs":["Pancreatic and hepatobiliary surgery","Colorectal cancer biology","Haematology","Imaging and radiotherapy"]},{"id":"anadolu-medical-center","kind":"institution","name":"Anadolu Medical Center","aka":["Anadolu Sağlık Merkezi"],"tldr":"A non-profit Turkish hospital near Istanbul affiliated with Johns Hopkins Medicine, and the only centre in Turkey accredited by OECI as a Cancer Centre.","summary":"Anadolu Medical Center is a non-profit hospital in Gebze on the eastern edge of Istanbul, founded by the Anadolu Foundation and affiliated with Johns Hopkins Medicine. Oncology is its main focus, with medical oncology, radiation oncology, a bone marrow transplant programme, surgical oncology and nuclear medicine, and it treats a large number of international patients. It is accredited by the Organisation of European Cancer Institutes as a Cancer Centre, the only Turkish centre on the OECI accredited list, and participates in international clinical trials.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Anadolu_Medical_Center","links":[{"label":"Official website","url":"https://www.anadolusaglik.org"}],"tags":["oeci-accredited","oeci-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci","johns-hopkins"],"pathways":[],"terms":[],"trials":[],"people":["timur-atsuren"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Gebze (Istanbul)","country":"TR","lat":40.803,"lng":29.431,"institutionType":"hospital","website":"https://www.anadolusaglik.org","programs":["Medical and radiation oncology","Bone marrow transplantation","International patients"]},{"id":"anchor-centre-aberdeen","kind":"institution","name":"ANCHOR Centre, Aberdeen Royal Infirmary","aka":["Aberdeen and North Centre for Haematology, Oncology and Radiotherapy","NHS Grampian"],"tldr":"The ANCHOR Centre is NHS Grampian's cancer centre at Aberdeen Royal Infirmary and one of Scotland's five regional cancer centres; it brings oncology, haematology and chemotherapy day care under one roof for Grampian, Orkney and Shetland.","summary":"The ANCHOR Centre (Aberdeen and North Centre for Haematology, Oncology and Radiotherapy) is NHS Grampian's dedicated cancer centre on the Foresterhill campus in Aberdeen, one of Scotland's five regional cancer centres alongside Glasgow, Edinburgh, Dundee and Inverness. It brings together outpatient oncology and haematology, chemotherapy and immunotherapy day care, and supportive services in a purpose-built facility next to the existing radiotherapy department, serving Grampian, Orkney and Shetland. Research with the University of Aberdeen's Institute of Medical Sciences covers cancer epidemiology, imaging and colorectal cancer.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.nhsgrampian.org"}],"tags":["nhs-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["beatson-glasgow","edinburgh-cancer-centre"],"pathways":[],"terms":[],"trials":[],"people":["laura-skaife-knight"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Aberdeen","country":"GB","lat":57.153,"lng":-2.134,"institutionType":"hospital","website":"https://www.nhsgrampian.org","university":"University of Aberdeen","programs":["Regional cancer centre for the north of Scotland","Radiotherapy","Haematology"]},{"id":"anthony-nolan","kind":"institution","name":"Anthony Nolan","aka":["Anthony Nolan Trust","Anthony Nolan Bone Marrow Trust"],"tldr":"The UK stem cell register, founded in 1974, and the charity behind the clinical nurse specialists who look after transplant patients in NHS centres.","summary":"Anthony Nolan is a registered charity (803716 in England and Wales, SC038827 in Scotland) and a registered company (2379280), with its registered address at the Royal Free Hospital in Hampstead. It runs the UK stem cell register that matches unrelated donors to people who need an allogeneic transplant, funds Anthony Nolan clinical nurse specialists placed in NHS transplant centres, runs cell therapy and laboratory services, and hosts a patients and families forum. For people with lymphoma it matters at the point where an allogeneic transplant becomes the option after CAR-T or chemotherapy has failed.","asOf":"2026-10-01","links":[{"label":"Anthony Nolan","url":"https://www.anthonynolan.org/"},{"label":"About us","url":"https://www.anthonynolan.org/about-us"}],"tags":["charity","uk","transplant","stem-cell"],"related":[],"cancers":["non-hodgkin-lymphoma","hodgkin-lymphoma","dlbcl","follicular-lymphoma","mantle-cell-lymphoma","marginal-zone-lymphoma","cutaneous-t-cell-lymphoma","burkitt-lymphoma","primary-cns-lymphoma","peripheral-t-cell-lymphoma","waldenstrom","aml","all-leukemia","cll"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"London","country":"GB","lat":51.553,"lng":-0.165,"institutionType":"consortium","website":"https://www.anthonynolan.org/","programs":["The UK stem cell register","Anthony Nolan clinical nurse specialists in NHS transplant centres","Cell therapy and laboratory services","Patients and families forum","Research into transplant outcomes"]},{"id":"blida-anti-cancer-center","kind":"institution","name":"Anti-Cancer Center of Blida","aka":["Centre de lutte contre le cancer de Blida","CLCC Blida","مركز مكافحة السرطان البليدة"],"tldr":"Algeria's specialised anti-cancer hospital in Blida, south of Algiers, and an associate member of the Organisation of European Cancer Institutes.","summary":"The Anti-Cancer Center of Blida (Centre de lutte contre le cancer, a specialised hospital establishment) is one of Algeria's regional cancer centres, in Blida south-west of Algiers. It is an associate member of the Organisation of European Cancer Institutes (OECI). Its representative on the OECI list is Adda Bounedjar.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://ehs-clccblida.dz"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["adda-bounedjar"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Blida","country":"DZ","lat":36.47,"lng":2.829,"institutionType":"hospital","website":"https://ehs-clccblida.dz","programs":[]},{"id":"antwerp-university-hospital","kind":"institution","name":"Antwerp University Hospital (UZA)","aka":["UZA","Universitair Ziekenhuis Antwerpen"],"tldr":"Belgium's Antwerp university hospital, where Jan Vermorken led EXTREME, the trial that made cetuximab plus chemotherapy the first-line standard for recurrent head and neck cancer for a decade.","summary":"Antwerp University Hospital (UZA) is the academic hospital of the University of Antwerp, at Edegem south of the city. Its Department of Medical Oncology, under Jan Vermorken, coordinated the EXTREME trial, reported in the New England Journal of Medicine in 2008, in which adding cetuximab to platinum and fluorouracil lengthened survival in recurrent or metastatic head and neck squamous-cell carcinoma. The department has long been active in EORTC gynaecological and head and neck trials.","asOf":"2026-09-18","links":[{"label":"UZA","url":"https://www.uza.be"}],"tags":[],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["jan-vermorken"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Edegem","country":"BE","lat":51.155,"lng":4.421,"institutionType":"hospital","website":"https://www.uza.be","university":"Universiteit Antwerpen","programs":["Head and neck cancer","Gynaecological cancer","EORTC trials"]},{"id":"henri-mondor","kind":"institution","name":"AP-HP Henri-Mondor University Hospitals Cancer Institute","aka":["Hôpital Henri-Mondor","CHU Henri-Mondor","Institut Universitaire du Cancer AP-HP Henri-Mondor"],"tldr":"The cancer institute of the Henri-Mondor university hospitals in Créteil, south-east of Paris, one of the Paris public hospital group's cancer institutes and a full member of the Organisation of European Cancer Institutes.","summary":"Hôpital Henri-Mondor in Créteil, opened in 1969, anchors the Henri-Mondor university hospital group of the Paris public hospitals (AP-HP) and Université Paris-Est Créteil. Its cancer institute brings together oncology, haematology, surgery and radiotherapy across the group's sites. It is a full member of the Organisation of European Cancer Institutes (OECI); its representative on the OECI list is Christophe Tournigand.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://iuc-hopitaux-u-mondor.aphp.fr/"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q2945751"}],"tags":[],"related":["carpem-aphp-centre","aphp-nord-cancer-institute","iuc-aphp-sorbonne"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["christophe-tournigand"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Créteil","country":"FR","lat":48.797,"lng":2.453,"institutionType":"hospital","website":"https://iuc-hopitaux-u-mondor.aphp.fr/","programs":[]},{"id":"aphp-paris-saclay-cancer-institute","kind":"institution","name":"AP-HP Paris-Saclay University Hospitals Cancer Institute","aka":["Institut du Cancer AP-HP. Université Paris-Saclay","Hôpital Bicêtre","Hôpitaux universitaires Paris-Saclay"],"tldr":"The cancer institute of the Paris public hospitals' Paris-Saclay group, anchored at Hôpital Bicêtre south of Paris, and a full member of the Organisation of European Cancer Institutes.","summary":"The Institut du Cancer of the AP-HP Université Paris-Saclay hospital group brings together the cancer services of the Paris public hospitals (AP-HP) in the southern suburbs, anchored at the Hôpital de Bicêtre in Le Kremlin-Bicêtre and including the Paul-Brousse and Antoine-Béclère sites, in partnership with Université Paris-Saclay. It is a full member of the Organisation of European Cancer Institutes (OECI); its representative on the OECI list is Pascal Hammel.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://institutducancer-hopitaux-universiteparissaclay.aphp.fr/"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikipedia (French): Hôpital de Bicêtre","url":"https://fr.wikipedia.org/wiki/Hôpital_Bicêtre"}],"tags":[],"related":["henri-mondor","carpem-aphp-centre","aphp-nord-cancer-institute","iuc-aphp-sorbonne","gustave-roussy"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["pascal-hammel"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Le Kremlin-Bicêtre","country":"FR","lat":48.81,"lng":2.354,"institutionType":"hospital","website":"https://institutducancer-hopitaux-universiteparissaclay.aphp.fr/","programs":[]},{"id":"apollo-hospitals","kind":"institution","name":"Apollo Hospitals (Apollo Cancer Centres)","aka":["Apollo Proton Cancer Centre","Apollo Cancer Institutes"],"tldr":"India's largest private hospital group, which opened South Asia's first proton therapy centre in Chennai in 2019 and runs cancer centres across the country.","summary":"Apollo Hospitals, founded in Chennai in 1983 by Prathap C. Reddy, is India's largest private hospital chain and operates a network of Apollo Cancer Centres in major cities. Its Apollo Proton Cancer Centre in Chennai, opened in 2019, was the first proton therapy facility in South Asia and treats paediatric and adult patients from India, the Middle East and Africa; the group also runs large bone marrow transplant, robotic surgery, radiosurgery and precision oncology services and participates in international registration trials. Apollo's clinical research and genomics arms and its tumour boards spanning the network make it a substantial contributor to Indian private-sector oncology research and training.","asOf":"2026-09-09","links":[{"label":"Apollo Hospitals","url":"https://www.apollohospitals.com"},{"label":"Apollo Proton Cancer Centre","url":"https://www.apollocancercentres.com/proton"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":["head-and-neck","breast-hr-positive","prostate","nsclc"],"sections":["radiation","surgery"],"technologies":["proton-therapy","robotic-surgery","sbrt","proton-therapy-systems","cyberknife","radiosurgery-srs"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["dcruz-anil"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Chennai","country":"IN","lat":13.061,"lng":80.251,"institutionType":"hospital","website":"https://www.apollohospitals.com","programs":["Apollo Proton Cancer Centre","Cancer centre network","Robotic surgery","Bone marrow transplant"]},{"id":"arc-institute","kind":"institution","name":"Arc Institute","aka":[],"tldr":"The Arc Institute is a well-funded nonprofit research institute building 'virtual cell' AI models and the datasets to train them.","summary":"The Arc Institute in Palo Alto is a well-funded nonprofit research institute founded in 2021 with Stanford, UCSF and Berkeley affiliations, building virtual cell AI models and the datasets needed to train them. It is home to the Evo and Evo 2 genome language models built with NVIDIA, the State perturbation-response model, the Arc Virtual Cell Atlas and the Tahoe-100M dataset, and it ran the Virtual Cell Challenge in 2025; its scale of perturbation data collection is unusual for an academic institute, and Silvana Konermann is among the people linked. OnCo connects it to the Chan Zuckerberg Biohub and to the virtual cell roadmap that runs from bulk omics to a predictive model of a cancer cell. Whether perturbation-trained models predict responses in patients, not just cell lines, is the open question. Its Evo, State and Virtual Cell Atlas programmes are listed below.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Arc_Institute","links":[{"label":"Official website","url":"https://arcinstitute.org"}],"tags":["ai","virtual-cell"],"related":[],"cancers":[],"sections":["ai-computation","drug-discovery"],"technologies":["evo2"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["silvana-konermann"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Palo Alto, CA","country":"US","lat":37.442,"lng":-122.143,"institutionType":"research-institute","website":"https://arcinstitute.org","programs":["Virtual Cell Atlas","Evo genome models","State perturbation model","Virtual Cell Challenge"]},{"id":"asan-medical-center","kind":"institution","name":"Asan Medical Center","aka":[],"tldr":"Asan Medical Center is Korea's largest hospital and a global leader in liver transplantation and gastric cancer surgery.","summary":"Asan Medical Center in Seoul is Korea's largest hospital and ranks fourth in the Newsweek/Statista World's Best Specialized Hospitals list for oncology. It is known for the highest-volume living-donor liver transplant programme in the world, led by Sung-Gyu Lee, and for gastric cancer surgery, which makes it a natural major site for hepatocellular carcinoma, biliary tract and gastric cancer trials. OnCo links it to liver transplantation for cancer within and beyond the Milan criteria, to the Korean Cancer Study Group, and to oncologists including Min-Hee Ryu and Dae Ho Lee. Whether its transplant outcomes can be reproduced by lower-volume centres is the question its data invite. Its liver and gastric programmes are the reason to read this page.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Asan_Medical_Center","links":[{"label":"Official website","url":"https://eng.amc.seoul.kr"}],"tags":[],"related":[],"cancers":["hcc","gastric"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["ryu-min-hee","lee-dae-ho","lee-sung-gyu","lee-jae-lyun","kim-sung-bae","kim-tae-won","kang-yoon-koo"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Seoul","country":"KR","lat":37.527,"lng":127.108,"institutionType":"hospital","website":"https://eng.amc.seoul.kr","newsweekOncology2026":4,"programs":["Liver cancer and transplant","Gastric cancer surgery"]},{"id":"spedali-civili-brescia","kind":"institution","name":"ASST Spedali Civili di Brescia","aka":[],"tldr":"One of Italy's largest public hospitals, the teaching hospital of the University of Brescia and an OECI Comprehensive Cancer Centre.","summary":"The Spedali Civili di Brescia is a large public hospital system in Lombardy and the teaching hospital of the University of Brescia. Its cancer programme spans medical oncology, radiotherapy, haematology with transplantation, surgical oncology and paediatric oncology, coordinated through a departmental cancer centre that is accredited by the Organisation of European Cancer Institutes as a Comprehensive Cancer Centre. Research strengths include head and neck cancer, thyroid and endocrine tumours, breast cancer and radiotherapy, and the hospital is a major enroller in Italian cooperative group trials.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.asst-spedalicivili.it"}],"tags":["oeci-accredited","oeci-comprehensive-cancer-centre"],"related":[],"cancers":["head-and-neck","thyroid"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["luigi-cajazzo"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Brescia","country":"IT","lat":45.556,"lng":10.226,"institutionType":"hospital","website":"https://www.asst-spedalicivili.it","university":"University of Brescia","programs":["Head and neck cancer","Haematology and transplantation","Radiotherapy"]},{"id":"asthra-health","kind":"institution","name":"Asthra Health","aka":[],"tldr":"Asthra Health, led by the neuro-oncologist Santosh Kesari in Santa Monica, gives outside clinical opinions on complex cancer cases with AI-assisted precision medicine.","summary":"Asthra Health delivers AI-driven precision medicine and concierge outside opinions for complex cancer cases under neuro-oncologist Santosh Kesari; Future of Cancer Care Today lists it among physicians open to considering options beyond standard of care. Patient-bookable.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://asthrahealth.com/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["multidisciplinary-tumour-board"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["santosh-kesari"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Santa Monica","country":"US","lat":34.02,"lng":-118.49,"institutionType":"hospital","website":"https://asthrahealth.com/","programs":[]},{"id":"wake-forest-cancer","kind":"institution","name":"Atrium Health Wake Forest Baptist Comprehensive Cancer Center","aka":["Wake Forest Baptist Comprehensive Cancer Center"],"tldr":"North Carolina's third NCI comprehensive centre, a national research base for cancer control and survivorship and a pioneer of tumour organoids.","summary":"NCI comprehensive since 1990, the Wake Forest Baptist centre is now part of Atrium Health, giving it reach across the Carolinas and Georgia. It hosts one of the NCI Community Oncology Research Program's research bases, running national trials on cancer-related cognitive impairment, survivorship and supportive care. Its radiation oncology group is known for brain metastasis radiosurgery, and the Wake Forest Institute for Regenerative Medicine builds patient tumour organoids and tumour-on-a-chip systems for drug testing. Director Boris Pasche studies TGF-beta signalling and colorectal cancer.","asOf":"2026-09-09","links":[{"label":"Wake Forest Baptist Comprehensive Cancer Center","url":"https://www.wakehealth.edu/cancer"}],"tags":[],"related":[],"cancers":["colorectal","glioblastoma"],"sections":["supportive-care"],"technologies":["organoids","sbrt","functional-drug-testing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["ruben-mesa"],"bottlenecks":["b-survivorship","b-preclinical-models"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Winston-Salem, NC","country":"US","lat":36.089,"lng":-80.276,"institutionType":"cancer-center","website":"https://www.wakehealth.edu/cancer","nci":"comprehensive","university":"Wake Forest University","programs":["NCORP Research Base (cancer control)","Brain metastasis radiosurgery","Tumour organoids (WFIRM)"]},{"id":"auckland-city-hospital","kind":"institution","name":"Auckland City Hospital / Te Pūriri o Te Ora Cancer and Blood Service","aka":["Auckland Regional Cancer and Blood Service","Te Whatu Ora Auckland","University of Auckland Centre for Cancer Research"],"tldr":"New Zealand's largest hospital and cancer service, working with the University of Auckland's Auckland Cancer Society Research Centre, which developed hypoxia-activated and DNA-targeting anticancer drugs.","summary":"Auckland City Hospital in Grafton is New Zealand's largest public hospital and hosts the country's biggest cancer and blood service, providing medical, radiation and surgical oncology, haematology and stem cell transplant for the upper North Island, along with the national phase 1 trials unit and paediatric oncology at Starship Children's Hospital. Its academic partner, the University of Auckland's Auckland Cancer Society Research Centre, has a long record in cancer drug discovery, including the hypoxia-activated prodrugs tirapazamine analogues and tarloxotinib, the topoisomerase poison amsacrine, DNA-intercalating agents, and kinase inhibitors licensed to industry, and the university's Centre for Cancer Research coordinates New Zealand's translational and Māori health equity oncology research.","asOf":"2026-09-09","links":[{"label":"Te Whatu Ora Auckland","url":"https://www.adhb.health.nz"}],"tags":[],"related":["cancer-health-disparities"],"cancers":["colorectal","melanoma","aml","nsclc"],"sections":["drug-discovery","chemotherapy"],"technologies":["kinase-inhibitors","topoisomerase-inhibitors"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["dale-bramley"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Auckland","country":"NZ","lat":-36.86,"lng":174.77,"institutionType":"hospital","website":"https://www.adhb.health.nz","university":"University of Auckland","programs":["Regional cancer and blood service","Auckland Cancer Society Research Centre drug discovery","Phase 1 trials","Paediatric oncology (Starship)"]},{"id":"ausl-irccs-reggio-emilia","kind":"institution","name":"AUSL-IRCCS di Reggio Emilia","aka":["Arcispedale Santa Maria Nuova","IRCCS in Tecnologie Avanzate e Modelli Assistenziali in Oncologia"],"tldr":"The Reggio Emilia health authority and its Santa Maria Nuova hospital, an IRCCS for advanced technologies and care models in oncology and an OECI Comprehensive Cancer Centre.","summary":"The Azienda USL-IRCCS di Reggio Emilia integrates the province's public health services with the Arcispedale Santa Maria Nuova, which holds IRCCS status in 'advanced technologies and care models in oncology'. The cancer programme covers medical oncology, radiotherapy, haematology, surgical oncology, nuclear medicine and pathology, and is known for its work on care organisation and outcomes research, cancer registries and screening evaluation as well as translational research in lymphoma and breast cancer. It is accredited by the Organisation of European Cancer Institutes as a Comprehensive Cancer Centre.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.ausl.re.it"}],"tags":["oeci-accredited","oeci-comprehensive-cancer-centre","irccs"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["davide-fornaciari"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Reggio Emilia","country":"IT","lat":44.698,"lng":10.63,"institutionType":"hospital","website":"https://www.ausl.re.it","programs":["Care models and outcomes research","Radiotherapy","Lymphoma and breast cancer research"]},{"id":"az-groeninge-kortrijk","kind":"institution","name":"AZ Groeninge Kortrijk Cancer Centre","aka":["Kortrijk Cancer Centre"],"tldr":"A large Flemish general hospital whose cancer centre holds OECI Cancer Centre accreditation, one of the few non-university hospitals in Europe to do so.","summary":"AZ Groeninge is the regional hospital for south-west Flanders, formed by the merger of Kortrijk's hospitals onto a single new campus. Its oncology centre brings medical oncology, radiotherapy, haematology, surgical oncology and supportive care together under one multidisciplinary structure and was accredited by the Organisation of European Cancer Institutes as a Cancer Centre, a distinction otherwise held mostly by university hospitals and dedicated cancer institutes. The hospital participates in Belgian and European clinical trials through its clinical trial unit and collaborates with the university hospitals of Leuven and Ghent on complex and rare tumours.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.azgroeninge.be"}],"tags":["oeci-accredited","oeci-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci","uz-leuven","uz-gent"],"pathways":[],"terms":[],"trials":[],"people":["inge-buyse"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Kortrijk","country":"BE","lat":50.828,"lng":3.265,"institutionType":"hospital","website":"https://www.azgroeninge.be","programs":["Multidisciplinary oncology centre","Radiotherapy","Clinical trials unit"]},{"id":"bahrain-oncology-centre","kind":"institution","name":"Bahrain Oncology Center, King Hamad University Hospital","aka":["KHUH Bahrain Oncology Centre"],"tldr":"Bahrain's national cancer centre, part of King Hamad University Hospital, offering radiotherapy, chemotherapy and bone marrow transplantation in the kingdom.","summary":"The Bahrain Oncology Center is the dedicated cancer facility of King Hamad University Hospital in Muharraq, built to give Bahraini patients comprehensive treatment at home instead of travelling abroad. It provides medical oncology, radiation oncology, haematology with a bone marrow transplant unit, nuclear medicine and PET-CT, surgical oncology and palliative care, and hosts the national cancer registry and screening activities with the Ministry of Health. The hospital is affiliated with the Royal College of Surgeons in Ireland Medical University of Bahrain for training.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.khuh.org.bh"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["kfshrc","hamad-medical-corporation"],"pathways":[],"terms":[],"trials":[],"people":["shaikh-fahad-bin-khalifa-al-khalifa"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Muharraq","country":"BH","lat":26.257,"lng":50.624,"institutionType":"hospital","website":"https://www.khuh.org.bh","programs":["National cancer centre","Radiation oncology","Bone marrow transplantation"]},{"id":"bank-of-cyprus-oncology-centre","kind":"institution","name":"Bank of Cyprus Oncology Centre","aka":["BOCOC","Ογκολογικό Κέντρο Τράπεζας Κύπρου"],"tldr":"The Bank of Cyprus Oncology Centre in Nicosia is Cyprus's main non-profit cancer treatment centre and a full member of the Organisation of European Cancer Institutes.","summary":"The Bank of Cyprus Oncology Centre is a non-profit cancer centre in Nicosia established jointly by the Bank of Cyprus and the Republic of Cyprus, providing medical oncology, radiotherapy, haematology and palliative care for patients across the island within the national health system. It is listed by the Organisation of European Cancer Institutes as a full member, one of two Cypriot institutions on the list with the German Oncology Center in Limassol. Programme, trial and leadership details are not yet recorded here and should be checked on the hospital's own pages.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.bococ.org.cy"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":["german-oncology-center-limassol"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["panos-ergatoudes"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Nicosia","country":"CY","lat":35.14,"lng":33.34,"institutionType":"cancer-center","website":"https://www.bococ.org.cy","programs":[]},{"id":"karmanos","kind":"institution","name":"Barbara Ann Karmanos Cancer Institute","aka":["Karmanos","Michigan Cancer Foundation"],"tldr":"Detroit's NCI comprehensive cancer centre, where the MCF-7 breast cancer cell line was derived in 1973, now part of McLaren Health Care.","summary":"Karmanos descends from the Michigan Cancer Foundation, where in 1973 Herbert Soule derived MCF-7, the oestrogen-receptor-positive breast cancer cell line that became the most studied cancer cell model in the world. NCI-designated since 1978, it is Wayne State University's cancer centre and, since 2014, part of McLaren Health Care, giving it a statewide network of cancer sites across Michigan. It has long run one of the larger academic phase 1 programmes and studies cancer in Detroit's predominantly Black population. Karmanos also operates the Detroit metropolitan SEER registry.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Karmanos_Cancer_Institute","links":[{"label":"Karmanos Cancer Institute","url":"https://www.karmanos.org"}],"tags":[],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":["endocrine-therapy"],"targets":["estrogen-receptor"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["real-world-evidence"],"trials":[],"people":["boris-pasche"],"bottlenecks":["b-preclinical-models","b-trial-diversity"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Detroit, MI","country":"US","lat":42.354,"lng":-83.058,"institutionType":"cancer-center","website":"https://www.karmanos.org","nci":"comprehensive","university":"Wayne State University","programs":["Phase 1 trials","Breast cancer biology (MCF-7 heritage)","Population science (Detroit SEER)"]},{"id":"barts-cancer-institute","kind":"institution","name":"Barts Cancer Institute / Barts Health NHS Trust","aka":["BCI","St Bartholomew's Hospital","Barts Cancer Centre"],"tldr":"London's oldest hospital paired with Queen Mary's cancer institute, known for pancreatic cancer, blood cancers and tumour microenvironment research.","summary":"St Bartholomew's Hospital, founded in 1123, hosts the Barts Cancer Centre of Barts Health NHS Trust, while the Barts Cancer Institute of Queen Mary University of London is a Cancer Research UK centre and part of the CRUK City of London Centre with UCL, King's and the Crick. Research strengths include pancreatic cancer (Barts Pancreas Tissue Bank), the tumour microenvironment (Frances Balkwill), haemato-oncology and CAR-T (John Gribben), prostate and lung cancer, and cancer prevention and screening in East London's diverse population. The hospital is a regional centre for CAR-T, stem cell transplantation, radiotherapy and robotic surgery.","asOf":"2026-09-09","links":[{"label":"Barts Cancer Institute","url":"https://www.bartscancer.london"}],"tags":[],"related":[],"cancers":["pancreatic","cll","dlbcl","prostate","nsclc"],"sections":["immunotherapy","cell-therapy"],"technologies":["car-t","robotic-surgery","checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":[],"institutions":["cruk","francis-crick","uclh"],"pathways":[],"terms":[],"trials":[],"people":["shane-degaris","jack-cuzick","peter-schmid","thomas-powles","nitzan-rosenfeld","peter-sasieni"],"bottlenecks":["b-trial-diversity","b-tme-immunosuppression"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"London","country":"GB","lat":51.517,"lng":-0.1,"institutionType":"cancer-center","website":"https://www.bartscancer.london","university":"Queen Mary University of London","programs":["Pancreatic cancer","Haemato-oncology and CAR-T","Tumour microenvironment","Cancer prevention in diverse populations","CRUK City of London Centre"]},{"id":"bc-cancer","kind":"institution","name":"BC Cancer","aka":["BC Cancer Agency","British Columbia Cancer Agency"],"tldr":"British Columbia's provincial cancer agency, a world leader in cancer genomics (Personalized OncoGenomics), lymphoma research and HPV-based cervical screening.","summary":"BC Cancer, part of the Provincial Health Services Authority, delivers cancer care through six regional centres and runs the province's screening programmes and registry. Its Michael Smith Genome Sciences Centre under Marco Marra launched the Personalized OncoGenomics programme in 2012, one of the first to sequence whole genomes and transcriptomes of patients' tumours to guide therapy. Sam Aparicio co-led METABRIC and pioneered single-cell genomics of breast cancer; David Huntsman's OVCARE group discovered ARID1A mutations in clear-cell ovarian cancer; Randy Gascoyne, Christian Steidl and Joseph Connors built one of the world's leading lymphoma programmes, including co-leadership of ECHELON-1 for brentuximab vedotin in Hodgkin lymphoma. Gina Ogilvie's HPV FOCAL trial helped move BC to HPV-based primary cervical screening, and Connie Eaves's Terry Fox Laboratory shaped stem cell biology.","asOf":"2026-09-09","links":[{"label":"BC Cancer","url":"https://www.bccancer.bc.ca"},{"label":"Michael Smith Genome Sciences Centre","url":"https://www.bcgsc.ca"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":["hodgkin-lymphoma","dlbcl","ovarian","cervical","breast-hr-positive"],"sections":["diagnostics","early-detection"],"technologies":["wes-wgs","rna-seq","single-cell-spatial","hpv-testing","proton-therapy","proton-therapy-systems"],"targets":[],"drugs":["brentuximab-vedotin"],"companies":["cctg"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["paris-ann-ingledew","kim-chi","laurie-sehn","joseph-connors"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Vancouver, BC","country":"CA","lat":49.263,"lng":-123.118,"institutionType":"cancer-center","website":"https://www.bccancer.bc.ca","university":"University of British Columbia","programs":["Personalized OncoGenomics","Lymphoma","Ovarian cancer (OVCARE)","HPV-based cervical screening","Terry Fox Laboratory"]},{"id":"beatson-glasgow","kind":"institution","name":"Beatson West of Scotland Cancer Centre / CRUK Scotland Institute","aka":["The Beatson","Cancer Research UK Beatson Institute","Beatson Institute for Cancer Research"],"tldr":"Scotland's largest cancer centre, named after the surgeon who first used endocrine therapy for breast cancer, next to a leading cancer biology institute.","summary":"The Beatson West of Scotland Cancer Centre at Gartnavel is the tertiary oncology centre for the west of Scotland and one of the largest in the UK. It takes its name from Sir George Beatson, who in 1896 reported that removing the ovaries could shrink advanced breast cancer, the first endocrine therapy. The adjacent Cancer Research UK Scotland Institute (formerly the Beatson Institute, founded 1967) under Owen Sansom is known for genetically engineered mouse models of colorectal and pancreatic cancer, cancer metabolism and cell death research, and the University of Glasgow's Wolfson Wohl Cancer Research Centre hosts Andrew Biankin's Precision-Panc programme for pancreatic cancer. Patients have access to a large radiotherapy service, early-phase trials and Scotland's molecular pathology network.","asOf":"2026-09-09","links":[{"label":"Beatson West of Scotland Cancer Centre","url":"https://www.beatson.scot.nhs.uk"},{"label":"CRUK Scotland Institute","url":"https://www.beatson.gla.ac.uk"},{"label":"Precision-Panc","url":"https://www.precisionpanc.org"}],"tags":[],"related":[],"cancers":["breast-hr-positive","pancreatic","colorectal","hcc"],"sections":["hormonal","drug-discovery"],"technologies":["endocrine-therapy","pdx-models","kras-inhibitors","cgp"],"targets":["kras","estrogen-receptor"],"drugs":[],"companies":[],"institutions":["cruk"],"pathways":[],"terms":[],"trials":["scot"],"people":["sharon-armstrong","owen-sansom"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Glasgow","country":"GB","lat":55.88,"lng":-4.325,"institutionType":"cancer-center","website":"https://www.beatson.scot.nhs.uk","university":"University of Glasgow","programs":["CRUK Scotland Institute","Precision-Panc pancreatic cancer","Radiotherapy","Early-phase trials","Glasgow Precision Oncology Laboratory"]},{"id":"beaumont-rcsi-cancer-centre","kind":"institution","name":"Beaumont RCSI Cancer Centre","aka":["Beaumont Hospital"],"tldr":"Beaumont Hospital's designated cancer centre with the Royal College of Surgeons in Ireland, home of Ireland's national neurosurgery centre and accredited by OECI as a Cancer Centre.","summary":"Beaumont Hospital is one of Ireland's eight designated cancer centres and the principal teaching hospital of RCSI University of Medicine and Health Sciences. It hosts the National Neurosurgical Centre, making it the national referral centre for brain tumours, alongside medical oncology, radiation oncology, haematology and surgical oncology for north Dublin and the north-east. RCSI's research in brain cancer, breast cancer and cancer bioinformatics underpins the centre's translational programme, and the Beaumont RCSI Cancer Centre is accredited by the Organisation of European Cancer Institutes as a Cancer Centre.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.beaumont.ie"}],"tags":["oeci-accredited","oeci-cancer-centre"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["patrick-morris","anne-coyle"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Dublin","country":"IE","lat":53.391,"lng":-6.225,"institutionType":"hospital","website":"https://www.beaumont.ie","university":"RCSI University of Medicine and Health Sciences","programs":["National Neurosurgical Centre","Designated cancer centre","Brain tumour research"]},{"id":"belfast-trust-hpb","kind":"institution","name":"Belfast Health and Social Care Trust HPB service","aka":["Belfast Trust","Mater Infirmorum Hospital","Belfast City Hospital liver, pancreas and bile duct service"],"tldr":"Northern Ireland's single HPB cancer service, within the Belfast Trust; systemic treatment at the Northern Ireland Cancer Centre.","summary":"Pancreatic Cancer UK lists the Belfast Trust as Northern Ireland's specialist centre and AMMF lists Belfast City Hospital's liver, pancreas and bile duct service among UK centres with cholangiocarcinoma expertise. Chemotherapy and immunotherapy are given at the Northern Ireland Cancer Centre on the same site; molecular testing runs through the Northern Ireland Regional Molecular Diagnostics Service.","asOf":"2026-09-24","links":[{"label":"Belfast Health and Social Care Trust","url":"https://belfasttrust.hscni.net/"},{"label":"Pancreatic Cancer UK centres list","url":"https://www.pancreaticcancer.org.uk/information-and-support/your-care/your-local-pancreatic-cancer-specialist-centre/"}],"tags":["hpb","nhs","uk"],"related":[],"cancers":["gallbladder","biliary-tract-cancer","cholangiocarcinoma","pancreatic","hcc"],"sections":["surgery"],"technologies":["hepatectomy"],"targets":[],"drugs":[],"companies":[],"institutions":["northern-ireland-cancer-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Belfast","country":"GB","lat":54.597,"lng":-5.93,"institutionType":"hospital","website":"https://belfasttrust.hscni.net/","university":"Queen's University Belfast","programs":["HPB surgery","Northern Ireland HPB MDT","Regional Molecular Diagnostics Service"]},{"id":"biomedical-research-center-sas","kind":"institution","name":"Biomedical Research Center of the Slovak Academy of Sciences","aka":["Biomedicínske centrum SAV","BMC SAV"],"tldr":"The Slovak Academy of Sciences' biomedical research centre in Bratislava, which includes the Cancer Research Institute, and an associate member of the Organisation of European Cancer Institutes.","summary":"The Biomedical Research Center (Biomedicínske centrum) of the Slovak Academy of Sciences in Bratislava groups the academy's biomedical institutes, including the Cancer Research Institute whose roots go back to 1953, working on tumour biology, DNA repair and experimental therapy. It is an associate member of the Organisation of European Cancer Institutes (OECI); its representative on the OECI list is Miroslav Chovanec.","asOf":"2026-09-09","links":[{"label":"Official website","url":"http://www.biomedcentrum.sav.sk/"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q36875415"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["miroslav-chovanec"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Bratislava","country":"SK","lat":48.172,"lng":17.068,"institutionType":"research-institute","website":"http://www.biomedcentrum.sav.sk/","programs":[]},{"id":"blood-cancer-uk","kind":"institution","name":"Blood Cancer UK","aka":["Bloodwise","Leukaemia and Lymphoma Research","Leukaemia Research Fund"],"tldr":"The UK's blood cancer research charity and support line, covering lymphoma alongside leukaemia and myeloma.","summary":"Blood Cancer UK is a registered charity in England and Wales (216032) and in Scotland (SC037529). It funds blood cancer research and runs an information and support service covering every blood cancer, including the lymphomas. It was previously called Bloodwise and, before that, Leukaemia and Lymphoma Research.","asOf":"2026-10-01","links":[{"label":"Blood Cancer UK","url":"https://bloodcancer.org.uk/"},{"label":"About us","url":"https://bloodcancer.org.uk/about-us/"}],"tags":["charity","uk","blood-cancer"],"related":[],"cancers":["non-hodgkin-lymphoma","hodgkin-lymphoma","dlbcl","follicular-lymphoma","mantle-cell-lymphoma","marginal-zone-lymphoma","cutaneous-t-cell-lymphoma","burkitt-lymphoma","primary-cns-lymphoma","peripheral-t-cell-lymphoma","waldenstrom","aml","cll","all-leukemia","multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"London","country":"GB","lat":51.526,"lng":-0.109,"institutionType":"consortium","website":"https://bloodcancer.org.uk/","programs":["Blood cancer research funding","Support line and online information","Campaigning on blood cancer care"]},{"id":"bowel-cancer-uk","kind":"institution","name":"Bowel Cancer UK","aka":[],"tldr":"The UK's bowel cancer charity: information and an email service answered by colorectal nurses, the Never Too Young campaign for younger patients, and the policy work that pushes the NHS on screening, Lynch syndrome testing and emergency diagnosis.","summary":"Bowel Cancer UK (registered charity 1071038 in England and Wales and SC040914 in Scotland, a company limited by guarantee number 3409832) describes itself as the UK's leading bowel cancer charity. It runs Ask the Nurse, a free email service answered by colorectal nurses within two working days for non-urgent enquiries, and publishes patient information covering symptoms, risk factors, screening in each of the four nations, diagnosis, treatment, prehabilitation, clinical trials, advanced disease, living with and beyond bowel cancer and end of life care, alongside an online community, a podcast and the National Colorectal Cancer Nurses Network.\n\nIts campaigning arm publishes the reports the NHS is measured against. Never Too Young, launched in 2013, is the campaign for younger patients: its 2020 report, drawn from a survey of over a thousand young people with bowel cancer, found that half did not know they could develop the disease before their diagnosis, that four in ten had to visit their GP three or more times before referral, that nearly half of those diagnosed after 2017 had not been offered Lynch syndrome testing, that one in five had no access to a clinical nurse specialist and that 40 percent were not satisfied with the information they were given about fertility and family planning. In 2026 the charity published Behind the emergency, paired clinician and patient reports on bowel cancer diagnosed in accident and emergency, and in 2024 Finding the missing 95 percent, on Lynch syndrome services.","asOf":"2026-09-24","links":[{"label":"Bowel Cancer UK","url":"https://www.bowelcanceruk.org.uk/"},{"label":"Ask the Nurse","url":"https://www.bowelcanceruk.org.uk/how-we-can-help/ask-the-nurse/"},{"label":"Never Too Young","url":"https://www.bowelcanceruk.org.uk/campaigning/never-too-young/"},{"label":"Screening in the four nations","url":"https://www.bowelcanceruk.org.uk/about-bowel-cancer/screening/"},{"label":"Policy reports","url":"https://www.bowelcanceruk.org.uk/campaigning/policy-reports-and-consultations/"}],"tags":["charity","uk","colorectal"],"related":[],"cancers":["colorectal","rectal-cancer","early-onset-colorectal"],"sections":["early-detection"],"technologies":["colorectal-screening"],"targets":[],"drugs":[],"companies":[],"institutions":["macmillan-cancer-support"],"pathways":[],"terms":["lynch-syndrome","fit-test"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"London","country":"GB","lat":51.5,"lng":-0.125,"institutionType":"consortium","website":"https://www.bowelcanceruk.org.uk/","programs":["Ask the Nurse email service","Never Too Young campaign","Screening information for the four nations","Policy reports and consultation responses","National Colorectal Cancer Nurses Network","Online community and Stage4You"]},{"id":"bowel-research-uk","kind":"institution","name":"Bowel Research UK","aka":[],"tldr":"The UK medical research charity for bowel disease: small proof-of-concept grants and PhDs in bowel cancer and inflammatory bowel disease, with patients on its review panels.","summary":"Bowel Research UK (registered charity 1186061, registered office at the Royal College of Surgeons of England in Lincoln's Inn Fields) funds research into bowel cancer, inflammatory bowel disease and other bowel disorders. Its site says it is funding around 30 research projects and PhDs across the UK, that most individual grants are around 50,000 pounds, enough for proof of concept, and that it has invested 3 million pounds in research since 2020, with 62 pence of every pound spent going to charitable work including research. It runs Take PaRT, its patient and public involvement programme, alongside a grants committee and a scientific advisory committee that includes practising bowel surgeons.","asOf":"2026-09-24","links":[{"label":"Bowel Research UK","url":"https://bowelresearchuk.org/"}],"tags":["charity","uk","colorectal","research-funding"],"related":[],"cancers":["colorectal","rectal-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"London","country":"GB","lat":51.516,"lng":-0.117,"institutionType":"consortium","website":"https://bowelresearchuk.org/","programs":["Research grants and PhD funding","Take PaRT patient involvement","Research Hub","Can I Butt In? podcast"]},{"id":"bowelbabe-fund","kind":"institution","name":"Bowelbabe Fund for Cancer Research UK","aka":["Bowelbabe Fund"],"tldr":"The fund Dame Deborah James launched in the last weeks of her life; a restricted fund within Cancer Research UK, it has raised £21 million and backed 16 research projects.","summary":"Dame Deborah James, the broadcaster known as Bowelbabe, launched the fund in May 2022 while in hospice care for bowel cancer. It is a restricted fund within Cancer Research UK. Its own site reports £21 million raised so far and 16 projects funded worth over £20.3 million, focused on early detection and personalised medicine, alongside work that continues her campaign to share information about bowel cancer and break down stigma around symptoms. It is one of the clearest recent examples of a single patient's public account becoming a durable research fund.","asOf":"2026-09-10","links":[{"label":"Bowelbabe Fund","url":"https://bowelbabe.org/"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cruk"],"pathways":[],"terms":[],"trials":[],"people":["deborah-james"],"bottlenecks":["b-early-detection","b-patient-voice"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"London","country":"GB","lat":51.505,"lng":-0.12,"institutionType":"consortium","website":"https://bowelbabe.org","programs":["Early detection research","Personalised medicine projects","Bowel cancer awareness and stigma"]},{"id":"bp-beneficencia-portuguesa","kind":"institution","name":"BP - A Beneficência Portuguesa de São Paulo","aka":["Beneficência Portuguesa","BP Mirante"],"tldr":"A Beneficência Portuguesa de São Paulo, founded in 1859, is one of Latin America's largest hospital complexes; its oncology centre and IEP-BP research institute make it a frequent Brazilian site for international phase 3 oncology trials, and it hosts a large oncology residency.","summary":"A Beneficência Portuguesa de São Paulo was founded in 1859 by the Portuguese community and has grown into one of Latin America's largest hospital complexes, serving both private and public health system patients. Its oncology programme brings together medical oncology, haematology and bone marrow transplantation, radiotherapy, surgical oncology and nuclear medicine, and its research institute (IEP-BP) runs clinical trials across oncology and cardiology. BP is a frequent Brazilian site for international phase 3 oncology trials and hosts a large oncology residency programme.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.bp.org.br"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["einstein-sao-paulo","sirio-libanes"],"pathways":[],"terms":[],"trials":[],"people":["denise-soares-dos-santos"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"São Paulo","country":"BR","lat":-23.57,"lng":-46.643,"institutionType":"hospital","website":"https://www.bp.org.br","programs":["Oncology centre","Bone marrow transplantation","Clinical trials"]},{"id":"breast-cancer-now","kind":"institution","name":"Breast Cancer Now","aka":["Breast Cancer Care","Breakthrough Breast Cancer"],"tldr":"The UK's breast cancer research and support charity: a free nurse helpline, the Someone Like Me peer service, Moving Forward courses, an online forum and patient information on triple-negative disease, alongside funding of the Toby Robins Research Centre at the ICR.","summary":"Breast Cancer Now is the UK charity formed from Breast Cancer Care and Breakthrough Breast Cancer. Its services page lists a free nurse helpline (0808 800 6000), Someone Like Me (peer support from someone who has had a similar diagnosis), Moving Forward courses for people finishing treatment and an online forum. Its information pages cover triple negative breast cancer (around 15 percent of breast cancers; more common in women with an altered BRCA1 gene and in Black women), olaparib, breast prostheses and reconstruction. It funds the Breast Cancer Now Toby Robins Research Centre at The Institute of Cancer Research, directed by Andrew Tutt.","asOf":"2026-09-24","links":[{"label":"Breast Cancer Now","url":"https://breastcancernow.org/"},{"label":"Services and information","url":"https://breastcancernow.org/all-services/services-and-information-at-breast-cancer-now"},{"label":"Triple negative breast cancer","url":"https://breastcancernow.org/about-breast-cancer/diagnosis/types-of-breast-cancer/triple-negative-breast-cancer"}],"tags":["charity","uk","breast"],"related":[],"cancers":["tnbc","breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["icr-london","macmillan-cancer-support"],"pathways":[],"terms":[],"trials":[],"people":["andrew-tutt"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"London","country":"GB","lat":51.507,"lng":-0.128,"institutionType":"consortium","website":"https://breastcancernow.org/","programs":["Nurse helpline 0808 800 6000","Someone Like Me peer support","Moving Forward courses","Online forum","Patient information on triple negative breast cancer","Toby Robins Research Centre at the ICR"]},{"id":"bcrf","kind":"institution","name":"Breast Cancer Research Foundation","aka":["BCRF"],"tldr":"The largest private funder of breast cancer research worldwide, giving annual grants to more than 250 investigators across the field's leading centres.","summary":"Founded in 1993 by Evelyn Lauder, the Breast Cancer Research Foundation funds investigators rather than projects, renewing annual grants to established scientists so they can pursue long-term questions in tumour biology, metastasis, prevention, survivorship and treatment. Its portfolio spans the major US and international centres, including Dana-Farber, MSK, the Royal Marsden and Peter Mac, and it co-funds the Translational Breast Cancer Research Consortium and the Evelyn H. Lauder Founder's Fund on metastasis. BCRF-supported researchers have contributed to CDK4/6 inhibitors, PARP inhibitors in BRCA carriers, immunotherapy in triple-negative disease and ctDNA-guided treatment. Funding figures are published in its annual report.","asOf":"2026-09-09","links":[{"label":"BCRF","url":"https://www.bcrf.org"},{"label":"About BCRF","url":"https://www.bcrf.org/about-bcrf/"}],"tags":[],"related":["src-bcrf"],"cancers":["tnbc","breast-hr-positive","breast-her2-positive"],"sections":[],"technologies":["cdk46-inhibitor","parp-inhibitor","liquid-biopsy"],"targets":[],"drugs":[],"companies":[],"institutions":["dana-farber","mskcc","royal-marsden","peter-mac"],"pathways":[],"terms":[],"trials":[],"people":["sara-tolaney","nancy-lin","ann-partridge","nicholas-turner","loi-sherene","donna-mckay","dorraya-el-ashry"],"bottlenecks":["b-metastasis-biology"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"New York","country":"US","lat":40.756,"lng":-73.981,"institutionType":"consortium","website":"https://www.bcrf.org","programs":["Investigator grants","Translational Breast Cancer Research Consortium","Founder's Fund for metastasis research","Drug Research Collaborative"]},{"id":"bristol-haematology-oncology-centre","kind":"institution","name":"Bristol Haematology and Oncology Centre","aka":["BHOC","University Hospitals Bristol and Weston"],"tldr":"The regional cancer centre for Bristol and the south west of England, run by University Hospitals Bristol and Weston.","summary":"The Bristol Haematology and Oncology Centre is the specialist non-surgical cancer centre of University Hospitals Bristol and Weston NHS Foundation Trust, providing radiotherapy, chemotherapy, immunotherapy, haematology and stem cell transplantation, and teenage and young adult cancer services for Bristol, Bath, Somerset, Gloucestershire and parts of Wiltshire. It works with the University of Bristol on cancer epidemiology (Bristol is home to the Avon Longitudinal Study and Integrative Cancer Epidemiology Programme), and hosts clinical trials in haematology, lung and urological cancers.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.uhbw.nhs.uk"}],"tags":["nhs-cancer-centre"],"related":[],"cancers":["pancreatic","prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["radiotherapy","stem-cell","clinical-trial"],"trials":["protect"],"people":["maria-kane","jenny-donovan"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Bristol","country":"GB","lat":51.458,"lng":-2.598,"institutionType":"hospital","website":"https://www.uhbw.nhs.uk","university":"University of Bristol","programs":["Radiotherapy","Haematology and stem cell transplant","Cancer epidemiology"]},{"id":"british-association-of-dermatologists","kind":"institution","name":"British Association of Dermatologists","aka":[],"tldr":"The professional body that writes the UK's skin cancer service standards and, because these cancers have almost no charity of their own, also writes most of the patient information a person with a basal cell carcinoma will be handed.","summary":"The British Association of Dermatologists sets the service standards British skin cancer surgery is judged against. Its 2020 service guidance and standards for Mohs micrographic surgery were developed within a NICE-accredited framework and co-badged by the Royal College of Pathologists, the British Association of Oral and Maxillofacial Surgeons, ENT UK, the British Society for Dermatological Surgery, the British Society for Dermatopathology and the British Oculoplastic Surgery Society; the Getting It Right First Time dermatology report treats them as the answer to unwarranted variation in how Mohs is done.\n\nIt was one of the bodies that developed NHS England's teledermatology roadmap and the multidisciplinary consensus group behind the timed skin cancer diagnostic pathway. Its patient information service publishes leaflets on basal cell carcinoma, squamous cell carcinoma and melanoma, which matters because the keratinocyte cancers have no large patient charity of their own in the way breast, prostate and bowel cancer do.","asOf":"2026-09-25","links":[{"label":"Skin Health Info: basal cell carcinoma","url":"https://www.skinhealthinfo.org.uk/condition/basal-cell-carcinoma/"}],"tags":["uk","professional-body","skin","standards"],"related":[],"cancers":["skin-cancer","basal-cell-carcinoma","cutaneous-scc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"London","country":"GB","lat":51.523,"lng":-0.139,"institutionType":"consortium","website":"https://www.skinhealthinfo.org.uk/condition/basal-cell-carcinoma/","programs":[]},{"id":"broad-institute","kind":"institution","name":"Broad Institute of MIT and Harvard","aka":[],"tldr":"The Broad Institute is the genomics powerhouse behind DepMap, cBioPortal co-development, and the Cancer Cell Line Encyclopedia.","summary":"The Broad Institute of MIT and Harvard in Cambridge, Massachusetts, is the genomics research institute behind DepMap, the Cancer Cell Line Encyclopedia, PRISM drug screening and the co-development of cBioPortal; its Cancer Program under Getz and Matthew Meyerson, with Zhang's CRISPR technology, makes it the reference source for functional genomics in cancer. OnCo links it to CRISPR functional genomics and synthetic lethality, to the Cancer Dependency Map and TCGA Pan-Cancer Atlas papers, and to people including Todd R. Golub and Francisca Vazquez. It bears on bottlenecks about preclinical models that do not predict people and undruggable drivers, and on the idea of an open foundation model of the cancer cell trained on perturbation data. Whether cell-line dependencies translate to patients is the open question. The Koch Institute and Wellcome Sanger Institute are its linked partners.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Broad_Institute","links":[{"label":"Official website","url":"https://www.broadinstitute.org"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["crispr-screens","synthetic-lethality-approaches"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["todd-golub","matthew-meyerson","francisca-vazquez","bradley-bernstein","eli-broad","viktor-adalsteinsson","faisal-mahmood","andrew-aguirre","feng-zhang","gad-getz"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Cambridge, MA","country":"US","lat":42.363,"lng":-71.087,"institutionType":"research-institute","website":"https://www.broadinstitute.org","programs":["DepMap","CCLE / PRISM","Cancer genome analysis"]},{"id":"uz-brussel-cancer-centre","kind":"institution","name":"Brussels Cancer Centre (UZ Brussel)","aka":["Brussels Cancer Centre - Centre du Cancer Bruxelles","Centre du Cancer Bruxelles","UZ Brussel"],"tldr":"Brussels Cancer Centre is the cancer centre of UZ Brussel, the university hospital of the Vrije Universiteit Brussel in Jette, and a full member of the Organisation of European Cancer Institutes.","summary":"Brussels Cancer Centre is the cancer centre of UZ Brussel, the university hospital of the Vrije Universiteit Brussel in Jette. It is listed by the Organisation of European Cancer Institutes as a full member, which is why it has a page on OnCo. Programme, trial and leadership details are not yet recorded here and should be checked on the institution's own pages.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.uzbrussel.be"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["mark-de-ridder"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Brussels","country":"BE","lat":50.891,"lng":4.312,"institutionType":"hospital","website":"https://www.uzbrussel.be","programs":[]},{"id":"bjcn","kind":"institution","name":"Bulgarian Joint Cancer Network (BJCN)","aka":["Съвместна онкологична национална мрежа","СОНМ"],"tldr":"A national network of Bulgarian cancer hospitals and specialists based in Sofia, and an associate member of the Organisation of European Cancer Institutes.","summary":"The Bulgarian Joint Cancer Network (BJCN) is a Sofia-based network linking Bulgarian cancer hospitals, clinicians and researchers to coordinate care and research. It is an associate member of the Organisation of European Cancer Institutes (OECI). Its representative on the OECI list is Assia Konsoulova.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://bjcn.bg/"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["assia-konsoulova"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Sofia","country":"BG","lat":42.698,"lng":23.322,"institutionType":"consortium","website":"https://bjcn.bg/","programs":[]},{"id":"bfarm","kind":"institution","name":"Bundesinstitut für Arzneimittel und Medizinprodukte","aka":["BfArM","Federal Institute for Drugs and Medical Devices"],"tldr":"Germany's medicines and medical devices agency, the default national regulator for every cancer drug that is not a biological product, and the operator of the national genome sequencing data platform.","summary":"Section 77 of the Arzneimittelgesetz makes the Bundesinstitut für Arzneimittel und Medizinprodukte the competent federal higher authority for medicinal products unless the Paul-Ehrlich-Institut is competent, so BfArM takes the cytotoxics, kinase inhibitors and hormonal agents while PEI takes the biologicals and advanced therapies. Based in Bonn and Cologne with about 1,350 staff and reporting to the Federal Ministry of Health, it licenses and registers medicines through the national, mutual recognition and decentralised procedures, supplies rapporteurs and assessors to the European Medicines Agency's centralised procedure, which is the route almost every new cancer medicine actually takes, assesses risks for medical devices, controls narcotics and publishes the German medical coding systems.\n\nIt authorises clinical trials under section 42(2) AMG alongside a Land ethics committee, through CTIS under EU Regulation 536/2014, with a shortened timetable and a specialised ethics committee added by the Medizinforschungsgesetz. Two further roles matter for oncology: the expert groups on off-label use under section 35c SGB V are seated at BfArM and their assessments are what the Gemeinsamer Bundesausschuss turns into the list of off-label uses statutory insurance will pay for, and since 2024 BfArM has been the platform operator for the section 64e SGB V model project on genome sequencing, licensing the clinical data nodes and genome computing centres and maintaining the public application register.","asOf":"2026-09-25","links":[{"label":"BfArM","url":"https://www.bfarm.de"},{"label":"Tasks","url":"https://www.bfarm.de/EN/BfArM/Tasks/_node.html"},{"label":"Clinical trial authorisation","url":"https://www.bfarm.de/DE/Arzneimittel/Klinische-Pruefung/Genehmigungsverfahren/_node.html"},{"label":"Modellvorhaben Genomsequenzierung","url":"https://www.bfarm.de/DE/Das-BfArM/Aufgaben/Modellvorhaben-Genomsequenzierung/_node.html"},{"label":"Section 77 AMG","url":"https://www.gesetze-im-internet.de/amg_1976/__77.html"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ema","paul-ehrlich-institut","g-ba-iqwig","mhra","nice"],"pathways":[],"terms":["hta","amnog","accelerated-approval"],"trials":[],"people":[],"bottlenecks":["b-regulatory-fragmentation","b-drug-pricing"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Bonn","country":"DE","lat":50.735,"lng":7.1,"institutionType":"government","website":"https://www.bfarm.de","programs":["National, mutual recognition and decentralised authorisation","Rapporteur in EMA centralised procedures","Clinical trial authorisation (CTIS)","Off-label use expert groups (section 35c SGB V)","Platform operator, Modellvorhaben Genomsequenzierung"]},{"id":"butaro-cancer-center","kind":"institution","name":"Butaro Cancer Center of Excellence","aka":["Butaro Hospital","Partners In Health Rwanda","University of Global Health Equity"],"tldr":"Rwanda's first cancer centre, opened in 2012 in a rural district hospital by Partners In Health and the Rwandan government, proving that complex cancer care can be delivered in low-income settings.","summary":"The Butaro Cancer Center of Excellence opened in 2012 at Butaro District Hospital in Rwanda's Northern Province, built by Partners In Health with the Rwanda Ministry of Health and support from Dana-Farber/Brigham and Women's Cancer Center and the Jeff Gordon Children's Foundation, as the country's first facility dedicated to cancer care. It provides pathology, chemotherapy, surgery and palliative care to Rwandan and regional patients, with radiotherapy referred to Kigali since the Rwanda Cancer Centre opened there, and it has published outcomes for Wilms tumour, Burkitt and Hodgkin lymphoma, breast and cervical cancer showing that protocol-based treatment with task-shifting and telepathology is feasible in a rural low-income setting. Butaro also hosts the University of Global Health Equity campus and trains oncology nurses and clinicians for East Africa.","asOf":"2026-09-09","links":[{"label":"Partners In Health Rwanda","url":"https://www.pih.org/country/rwanda"},{"label":"University of Global Health Equity","url":"https://ughe.org"}],"tags":[],"related":["global-oncology-access","who-essential-medicines","telemedicine-teleoncology"],"cancers":["hodgkin-lymphoma","dlbcl","breast-hr-positive","cervical"],"sections":["chemotherapy","supportive-care"],"technologies":["cytotoxic-chemotherapy","digital-pathology-ai"],"targets":[],"drugs":[],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":[],"people":["nadine-karema"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Butaro","country":"RW","lat":-1.456,"lng":29.85,"institutionType":"cancer-center","website":"https://www.pih.org/country/rwanda","programs":["Rural cancer care delivery","Paediatric and lymphoma outcomes","Telepathology and task-shifting","University of Global Health Equity"]},{"id":"canadian-cancer-society","kind":"institution","name":"Canadian Cancer Society","aka":["CCS","Société canadienne du cancer"],"tldr":"Canada's national cancer charity and largest charitable funder of cancer research, which also core-funds the Canadian Cancer Trials Group.","summary":"Founded in 1938, the Canadian Cancer Society funds research through competitive grants and provides core support to the Canadian Cancer Trials Group at Queen's University, the group behind the CHALLENGE exercise trial and MA.17. It merged with the Canadian Breast Cancer Foundation in 2017 and with Prostate Cancer Canada in 2020, publishes the Canadian Cancer Statistics reports with Statistics Canada and the Public Health Agency of Canada, runs a national helpline and lodges for patients travelling to treatment, and advocates on tobacco, screening and drug access. Its Cancer Information Service is bilingual and free.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Canadian_Cancer_Society","links":[{"label":"Canadian Cancer Society","url":"https://cancer.ca"},{"label":"Research","url":"https://cancer.ca/en/research"}],"tags":[],"related":[],"cancers":[],"sections":["prevention","supportive-care","nutrition-lifestyle"],"technologies":[],"targets":[],"drugs":[],"companies":["cctg"],"institutions":["princess-margaret"],"pathways":[],"terms":[],"trials":["challenge"],"people":["andrea-seale"],"bottlenecks":["b-trial-enrolment"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Toronto","country":"CA","lat":43.653,"lng":-79.383,"institutionType":"consortium","website":"https://cancer.ca","programs":["Research grants and CCTG core funding","Canadian Cancer Statistics","Patient support, lodges and helpline","Tobacco and screening advocacy"]},{"id":"cancer-care-alberta","kind":"institution","name":"Cancer Care Alberta (Alberta Health Services)","aka":["Arthur J.E. Child Comprehensive Cancer Centre","Tom Baker Cancer Centre","Cross Cancer Institute"],"tldr":"Alberta's provincial cancer programme, anchored by Calgary's new Arthur J.E. Child Comprehensive Cancer Centre and Edmonton's Cross Cancer Institute, birthplace of the linac-MR.","summary":"Cancer Care Alberta is the province-wide cancer programme of Alberta Health Services, running two tertiary centres, the Arthur J.E. Child Comprehensive Cancer Centre in Calgary (opened in 2024, replacing the Tom Baker Cancer Centre) and the Cross Cancer Institute in Edmonton, plus regional and community sites, the Alberta Cancer Registry and provincial screening programmes. Gino Fallone's team at the Cross Cancer Institute built the world's first prototype hybrid linear accelerator-MRI, the origin of the rotating-biplanar linac-MR concept, and Edmonton's cyclotron and PET programme was an early producer of radiotracers. Calgary's University of Calgary spawned Oncolytics Biotech's reovirus therapy, and Alberta's trial units are major contributors to the Canadian Cancer Trials Group. Provincial data systems support real-world outcome studies.","asOf":"2026-09-09","links":[{"label":"Cancer Care Alberta","url":"https://www.albertahealthservices.ca/cancer/cancer.aspx"},{"label":"Arthur J.E. Child Comprehensive Cancer Centre","url":"https://www.albertahealthservices.ca/ajecccc/ajecccc.aspx"},{"label":"Cross Cancer Institute","url":"https://www.albertahealthservices.ca/cci/cci.aspx"}],"tags":[],"related":[],"cancers":["breast-hr-positive","colorectal"],"sections":["radiation"],"technologies":["mr-linac","oncolytic-virus","pet"],"targets":[],"drugs":[],"companies":["cctg"],"institutions":[],"pathways":[],"terms":["real-world-evidence"],"trials":[],"people":["brenda-hubley"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Calgary, AB","country":"CA","lat":51.065,"lng":-114.132,"institutionType":"cancer-center","website":"https://www.albertahealthservices.ca/cancer/cancer.aspx","university":"University of Calgary / University of Alberta","programs":["Arthur J.E. Child Comprehensive Cancer Centre","Cross Cancer Institute (Edmonton)","Linac-MR development","Provincial screening and registry"]},{"id":"cancer-center-at-illinois","kind":"institution","name":"Cancer Center at Illinois","aka":["CCIL"],"tldr":"An engineering-led NCI basic cancer centre at the University of Illinois, working on chemical imaging of tissue, new anticancer chemistry and comparative oncology.","summary":"The Cancer Center at Illinois is one of the newest NCI-designated basic laboratory cancer centres and is unusual in being rooted in a college of engineering and a veterinary school rather than a medical centre. Rohit Bhargava's infrared chemical imaging reads tissue chemistry without stains; Paul Hergenrother's laboratory produced the procaspase-3 activator PAC-1 and other compounds that entered trials; Timothy Fan runs comparative oncology trials in pet dogs that inform human drug development. The Carle Illinois College of Medicine, the first engineering-based medical school, is its clinical partner, and computational and AI approaches to cancer are a growing theme.","asOf":"2026-09-09","links":[{"label":"Cancer Center at Illinois","url":"https://cancer.illinois.edu"},{"label":"University of Illinois Urbana-Champaign","url":"https://illinois.edu"}],"tags":[],"related":[],"cancers":[],"sections":["drug-discovery","ai-computation"],"technologies":["optical-imaging","ai-drug-design"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["rohit-bhargava"],"bottlenecks":["b-preclinical-models","b-translational-valley"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Urbana, IL","country":"US","lat":40.11,"lng":-88.228,"institutionType":"research-institute","website":"https://cancer.illinois.edu","nci":"basic","university":"University of Illinois Urbana-Champaign","programs":["Chemical imaging of tissue","Anticancer drug discovery","Comparative oncology"]},{"id":"cun-navarra","kind":"institution","name":"Cancer Center Clínica Universidad de Navarra / CIMA","aka":["CCUN","Clínica Universidad de Navarra","CIMA Universidad de Navarra"],"tldr":"The University of Navarra's cancer centre in Pamplona and Madrid, known for myeloma, immunotherapy research and one of Spain's first proton therapy units.","summary":"The Cancer Center Clínica Universidad de Navarra combines the university hospital's Pamplona and Madrid campuses with the CIMA research centre. Jesús San Miguel and Bruno Paiva have led international myeloma trials and developed next-generation flow cytometry for minimal residual disease, Ignacio Melero's laboratory is a reference in cancer immunotherapy and intratumoural immunostimulation, and Felipe Prósper's group works on cell therapy and gene therapy. The Madrid campus opened a proton therapy unit in 2020, among the first in Spain. The centre is OECI-accredited and offers early-phase trials, CAR-T and comprehensive genomic profiling to private and insured patients.","asOf":"2026-09-09","links":[{"label":"Cancer Center","url":"https://www.cun.es/en"},{"label":"CIMA","url":"https://cima.cun.es/en"}],"tags":[],"related":[],"cancers":["multiple-myeloma","hcc","melanoma","nsclc"],"sections":["immunotherapy","radiation"],"technologies":["proton-therapy","mrd-testing","checkpoint-inhibitor","til-therapy","car-t"],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":["mrd","abscopal-effect"],"trials":[],"people":["antonio-gonzalez-martin","bruno-sangro","jesus-san-miguel","ignacio-melero"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Pamplona","country":"ES","lat":42.808,"lng":-1.664,"institutionType":"cancer-center","website":"https://www.cun.es/en","university":"Universidad de Navarra","programs":["Multiple myeloma and MRD","Cancer immunotherapy (Melero)","Proton therapy (Madrid)","Cell and gene therapy","CIMA research"]},{"id":"cancer-council-australia","kind":"institution","name":"Cancer Council Australia","aka":["Cancer Council"],"tldr":"Australia's federated cancer charity, which funds research, writes national clinical guidelines and runs the prevention campaigns behind Australia's falling smoking and melanoma rates.","summary":"Cancer Council Australia is the national body of the eight state and territory Cancer Councils, which together are the largest non-government funder of cancer research in Australia. It publishes national clinical practice guidelines (including colorectal, melanoma and lung cancer), runs the Optimal Care Pathways with governments, and leads prevention campaigns on tobacco, sun protection (SunSmart), alcohol and screening participation. Cancer Councils also fund cooperative groups and provide the 13 11 20 information and support line. Its policy work has shaped plain packaging and the national bowel and cervical screening programmes.","asOf":"2026-09-09","links":[{"label":"Cancer Council Australia","url":"https://www.cancer.org.au"},{"label":"Clinical guidelines","url":"https://www.cancer.org.au/clinical-guidelines"}],"tags":[],"related":[],"cancers":["melanoma","colorectal","nsclc","cervical"],"sections":["prevention","early-detection"],"technologies":[],"targets":[],"drugs":[],"companies":["trog","anzup","agitg","breast-cancer-trials"],"institutions":["peter-mac"],"pathways":[],"terms":[],"trials":[],"people":["jacinta-reddan"],"bottlenecks":["b-prevention-adoption"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Sydney","country":"AU","lat":-33.868,"lng":151.209,"institutionType":"consortium","website":"https://www.cancer.org.au","programs":["Research grants via state Cancer Councils","National clinical practice guidelines","SunSmart and tobacco control","13 11 20 support line"]},{"id":"cancer-diseases-hospital-lusaka","kind":"institution","name":"Cancer Diseases Hospital, Lusaka","aka":["CDH Lusaka"],"tldr":"Zambia's national cancer hospital and its only public radiotherapy centre, on the University Teaching Hospital campus in Lusaka.","summary":"The Cancer Diseases Hospital is Zambia's dedicated public cancer hospital, established by the Ministry of Health on the University Teaching Hospital campus in Lusaka to bring radiotherapy and specialist cancer treatment into the country for the first time. It provides radiotherapy including brachytherapy, chemotherapy, nuclear medicine, paediatric oncology and palliative care for the whole nation, and hosts Zambia's oncology training with the University of Zambia School of Medicine. Cervical cancer, which is among the most common cancers in Zambian women, and HIV-associated cancers such as Kaposi sarcoma dominate its workload, and the hospital has partnered with international programmes on cervical screening and treatment.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.cdh.gov.zm"}],"tags":[],"related":[],"cancers":["cervical"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["susan-msadabwe"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Lusaka","country":"ZM","lat":-15.397,"lng":28.311,"institutionType":"cancer-center","website":"https://www.cdh.gov.zm","university":"University of Zambia","programs":["National radiotherapy centre","Brachytherapy","Cervical cancer treatment","Oncology training"]},{"id":"cancer-free-future-association","kind":"institution","name":"Cancer Free Future Association (CFFA)","aka":["Asociația Cancer Free Future","CFFA"],"tldr":"A Romanian association based in Cluj-Napoca working on cancer prevention and patient support, and an associate member of the Organisation of European Cancer Institutes.","summary":"The Cancer Free Future Association (Asociația Cancer Free Future) is a Romanian non-profit based in Cluj-Napoca focused on cancer prevention, awareness and support for patients. It is an associate member of the Organisation of European Cancer Institutes (OECI). Its representative on the OECI list is Delia Nicoară.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.cancerfreefuture.eu/"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["delia-nicoara"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Cluj-Napoca","country":"RO","lat":46.771,"lng":23.624,"institutionType":"consortium","website":"https://www.cancerfreefuture.eu/","programs":[]},{"id":"cancer-grand-challenges","kind":"institution","name":"Cancer Grand Challenges","aka":[],"tldr":"A Cancer Research UK and US National Cancer Institute partnership that gives up to £20 million to global teams to tackle a named cancer problem no single lab could solve.","summary":"Launched by Cancer Research UK in 2015 as Grand Challenge and relaunched with the NCI in 2020, Cancer Grand Challenges sets a series of open challenges, from mapping tumours at single-cell resolution to understanding cachexia, extrachromosomal DNA, early-onset colorectal cancer and the causes of cancers in never-smokers, and funds interdisciplinary international teams for five years. Funded teams include Mutographs (mutational signatures of exposures), eDyNAmiC (extrachromosomal DNA), CANCAN (cachexia), PROSPECT and SAMBAI. Patient advocates sit in every team and challenges are set with input from the global community. The programme is a model for goal-directed, cross-border funding.","asOf":"2026-09-09","links":[{"label":"Cancer Grand Challenges","url":"https://cancergrandchallenges.org"},{"label":"Funded teams (archived copy)","url":"https://web.archive.org/web/20240420075523/https://cancergrandchallenges.org/teams"}],"tags":[],"related":[],"cancers":["colorectal","nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cruk","nci","francis-crick","mark-foundation"],"pathways":[],"terms":["mutational-signature"],"trials":[],"people":["michelle-mitchell","iain-foulkes","douglas-lowy"],"bottlenecks":["b-cachexia-supportive","b-funding-allocation","b-tumor-heterogeneity"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"London","country":"GB","lat":51.522,"lng":-0.109,"institutionType":"consortium","website":"https://cancergrandchallenges.org","programs":["Challenge-setting and team awards (up to £20 million)","Funded teams: Mutographs, eDyNAmiC, CANCAN, PROSPECT, SAMBAI","Patient advocacy in every team"]},{"id":"cams-cancer-hospital","kind":"institution","name":"Cancer Hospital, Chinese Academy of Medical Sciences","aka":[],"tldr":"The CAMS Cancer Hospital is China's national cancer centre, leading regulatory-grade trials of domestic ADCs and PD-1 antibodies.","summary":"The Cancer Hospital of the Chinese Academy of Medical Sciences in Beijing is China's national cancer centre, ranked fiftieth in the Newsweek/Statista oncology list, and a lead site for regulatory-grade trials of domestic antibody-drug conjugates and PD-1 antibodies. It led pivotal Chinese studies including DAWNA-1 and the development of sacituzumab tirumotecan, known as SKB264, and disitamab vedotin, with Yuankai Shi, Jie Wang, Fei Ma, Jing Huang and Binghe Xu among the clinicians OnCo lists. OnCo links it to oesophageal cancer, to the CSCO guidelines, to Peking Union Medical College Hospital and the NMPA, and to the idea of family-based Helicobacter pylori test-and-treat to prevent stomach cancer. Regulatory divergence between regions is the bottleneck its work bears on most. Its national trials and ADC programmes are listed below.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.cicams.ac.cn"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["sacituzumab-tirumotecan","disitamab-vedotin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["shi-yuankai","wang-jie-cams","ma-fei","huang-jing-cams","xu-binghe","he-jie"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Beijing","country":"CN","lat":39.87,"lng":116.451,"institutionType":"cancer-center","website":"https://www.cicams.ac.cn","newsweekOncology2026":50,"programs":["National trials","ADC development"]},{"id":"cancer-institute-adyar","kind":"institution","name":"Cancer Institute (WIA), Adyar","aka":["Adyar Cancer Institute","Cancer Institute WIA"],"tldr":"India's second oldest cancer hospital (1954), founded by Muthulakshmi Reddy and led for decades by V. Shanta, and the home of India's first population cancer registry.","summary":"The Cancer Institute (WIA) was founded in 1954 in Adyar, Chennai, by Dr Muthulakshmi Reddy under the Women's Indian Association and built by Dr S. Krishnamurthi and Dr V. Shanta into a charitable comprehensive cancer centre that treats most patients free or at subsidised cost. It established India's first population-based cancer registry (Madras Metropolitan Tumour Registry, 1982), installed India's first cobalt teletherapy unit and later its first medical cyclotron in a cancer hospital, and pioneered Indian clinical trials in cervical cancer, paediatric leukaemia and oral cancer, including the landmark cluster-randomised trials of visual inspection screening for cervical cancer with IARC. It hosts a WHO collaborating centre for cancer registration and the Dr Krishnamurthi college of oncological sciences.","asOf":"2026-09-09","links":[{"label":"Cancer Institute (WIA)","url":"https://www.cancerinstitutewia.in"}],"tags":[],"related":["global-oncology-access","cancer-registries-surveillance"],"cancers":["cervical","head-and-neck","all-leukemia","breast-hr-positive"],"sections":["prevention","radiation"],"technologies":["brachytherapy","hpv-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":["iarc"],"pathways":[],"terms":[],"trials":[],"people":["shanta-v"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Chennai","country":"IN","lat":13.005,"lng":80.253,"institutionType":"cancer-center","website":"https://www.cancerinstitutewia.in","programs":["Madras cancer registry","Cervical cancer screening trials","Paediatric oncology","Charitable cancer care"]},{"id":"aphp-nord-cancer-institute","kind":"institution","name":"Cancer Institute AP-HP Nord, Université Paris Cité","aka":["Institut du Cancer AP-HP. Nord","Hôpital Saint-Louis"],"tldr":"The northern Paris university hospital cancer institute of AP-HP, built around Hôpital Saint-Louis, Europe's historic home of bone marrow transplantation, and accredited by OECI as a Comprehensive Cancer Centre.","summary":"The Cancer Institute AP-HP Nord groups the oncology and haematology services of the Assistance Publique-Hôpitaux de Paris hospitals in northern Paris and its suburbs, including Saint-Louis, Bichat, Beaujon, Lariboisière and Avicenne, with Université Paris Cité. Hôpital Saint-Louis is one of the world's leading haematology hospitals, where Jean Dausset described HLA and where early European bone marrow transplants were performed; today it hosts large leukaemia, lymphoma, myeloma and transplant programmes and the Saint-Louis Research Institute. The institute is accredited by the Organisation of European Cancer Institutes as a Comprehensive Cancer Centre.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.aphp.fr"}],"tags":["oeci-accredited","oeci-comprehensive-cancer-centre"],"related":[],"cancers":["aml","dlbcl","multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["nicolas-revel","gerard-zalcman"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Paris","country":"FR","lat":48.874,"lng":2.369,"institutionType":"hospital","website":"https://www.aphp.fr","university":"Université Paris Cité","programs":["Haematology and transplantation (Saint-Louis)","Hepatobiliary and pancreatic surgery (Beaujon)","Thoracic oncology (Bichat)"]},{"id":"jfcr","kind":"institution","name":"Cancer Institute Hospital of JFCR","aka":[],"tldr":"The Cancer Institute Hospital of JFCR is Japan's oldest cancer institute (1908), strong in gastric cancer surgery and breast oncology.","summary":"The Cancer Institute Hospital of JFCR, the Japanese Foundation for Cancer Research in Tokyo, is Japan's oldest cancer institute, founded in 1908, and ranks twenty-fifth in the Newsweek/Statista oncology list. It is strong in gastric cancer surgery, breast oncology and antibody-drug conjugate trials, and genomic medicine, with Takeshi Sano, Shinji Ohno, Takayuki Ueno and Shunji Takahashi among the clinicians OnCo lists. OnCo links it to gastric and gastro-oesophageal junction cancer, to the Japanese Society of Medical Oncology and Japanese oncology guidelines, and to the idea of active surveillance as the default for tiny papillary thyroid cancers. How far Japanese surgical standards for gastric cancer transfer to lower-incidence countries remains debated. Its gastric and breast programmes are the ones to follow.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.jfcr.or.jp/english/"}],"tags":[],"related":[],"cancers":["gastric"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["takahashi-shunji","ohno-shinji","ueno-takayuki","sano-takeshi"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Tokyo","country":"JP","lat":35.729,"lng":139.716,"institutionType":"cancer-center","website":"https://www.jfcr.or.jp/english/","newsweekOncology2026":25,"programs":["Gastric cancer","Breast oncology"]},{"id":"tehran-cancer-institute","kind":"institution","name":"Cancer Institute of Iran, Imam Khomeini Hospital Complex","aka":["Tehran Cancer Institute","Cancer Research Center, Tehran University of Medical Sciences","انستیتو کانسر"],"tldr":"Iran's oldest and largest cancer centre, founded in 1955 within Tehran's Imam Khomeini Hospital Complex, and the country's main oncology training and research hub.","summary":"The Cancer Institute of Iran was established in 1955 as part of the Imam Khomeini Hospital Complex of Tehran University of Medical Sciences and is the largest cancer hospital in Iran, offering surgical, medical and radiation oncology, breast and gastrointestinal cancer surgery, nuclear medicine and a Cancer Research Center that runs the Tehran cancer registry and epidemiological studies. TUMS investigators contribute to the Golestan Cohort Study of oesophageal cancer in north-eastern Iran, one of the most important cohorts in the Middle East and a long-running collaboration with IARC and the US National Cancer Institute, and to research on gastric cancer, breast cancer in younger women and the effects of sanctions on drug access. The institute trains most of Iran's oncology specialists.","asOf":"2026-09-09","links":[{"label":"Imam Khomeini Hospital Complex","url":"https://ikhc.tums.ac.ir"},{"label":"Tehran University of Medical Sciences","url":"https://en.tums.ac.ir"}],"tags":[],"related":["global-oncology-access","cancer-registries-surveillance"],"cancers":["esophageal","gastric","breast-hr-positive","colorectal"],"sections":["prevention","surgery"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["iarc","nci"],"pathways":[],"terms":[],"trials":[],"people":["seyed-rouhollah-miri"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Tehran","country":"IR","lat":35.708,"lng":51.381,"institutionType":"cancer-center","website":"https://ikhc.tums.ac.ir","university":"Tehran University of Medical Sciences","programs":["Cancer Research Center and registry","Golestan Cohort Study (oesophageal cancer)","Breast and GI oncology","Oncology training"]},{"id":"cprit","kind":"institution","name":"Cancer Prevention and Research Institute of Texas","aka":["CPRIT"],"tldr":"The Texas state agency created by voters in 2007 that is the second-largest public funder of cancer research in the US after the NCI.","summary":"CPRIT was created by a 2007 Texas constitutional amendment authorising $3 billion in bonds for cancer research and prevention, and voters approved a further $3 billion in 2019. It awards academic research grants, recruits scientists to Texas institutions through Scholar awards, funds prevention and screening services in underserved communities and invests in Texas-based cancer companies through its product development programme. CPRIT funding has helped build programmes at MD Anderson, UT Southwestern, Baylor and other Texas centres and has recruited hundreds of investigators to the state. Its oversight committee and peer-review panels are drawn largely from outside Texas.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Cancer_Prevention_and_Research_Institute_of_Texas","links":[{"label":"CPRIT","url":"https://www.cprit.texas.gov"},{"label":"Grants","url":"https://www.cprit.texas.gov/grants-funded"}],"tags":[],"related":[],"cancers":[],"sections":["prevention","early-detection","drug-discovery"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["md-anderson","nci"],"pathways":[],"terms":[],"trials":[],"people":["wayne-roberts"],"bottlenecks":["b-funding-allocation","b-workforce","b-translational-valley"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Austin, TX","country":"US","lat":30.267,"lng":-97.743,"institutionType":"government","website":"https://www.cprit.texas.gov","programs":["Academic research grants","Scholar recruitment awards","Prevention and screening services","Product development research (company investments)"]},{"id":"tomsk-cancer-research-institute","kind":"institution","name":"Cancer Research Institute, Tomsk National Research Medical Centre","aka":["НИИ онкологии Томского НИМЦ","Научно-исследовательский институт онкологии Томского национального исследовательского медицинского центра Российской академии наук","Tomsk NRMC Cancer Research Institute","Tomsk National Research Medical Center of the Russian Academy of Sciences"],"tldr":"The Siberian cancer research institute of the Tomsk National Research Medical Centre of the Russian Academy of Sciences, and the single most frequent Russian lead sponsor of cancer trials registered since 2023.","summary":"The Cancer Research Institute is one of the institutes of the Tomsk National Research Medical Centre of the Russian Academy of Sciences, combining a clinic, a reference centre and laboratories in Tomsk in western Siberia; its site lists a cervical cancer vaccination service, a reference centre, a scientific council and its own journal. Counting interventional cancer studies on ClinicalTrials.gov with at least one site in the Russian Federation and a start date from 2023 onwards, it is the most frequent lead sponsor of any organisation, Russian or foreign, ahead of the Blokhin centre and Biocad.","asOf":"2026-09-25","links":[{"label":"Official website (Russian)","url":"https://onco.tnimc.ru"},{"label":"Tomsk National Research Medical Centre","url":"https://www.tnimc.ru"},{"label":"ClinicalTrials.gov: studies led by the centre","url":"https://clinicaltrials.gov/search?lead=Tomsk%20National%20Research%20Medical%20Center%20of%20the%20Russian%20Academy%20of%20Sciences"}],"tags":[],"related":["blokhin-cancer-center","petrov-institute"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Tomsk","country":"RU","lat":56.484,"lng":84.948,"institutionType":"research-institute","website":"https://onco.tnimc.ru","programs":["Clinical trials of surgery, radiotherapy and drug therapy","Reference centre","Cervical cancer vaccination clinic"]},{"id":"cruk","kind":"institution","name":"Cancer Research UK","aka":[],"tldr":"Cancer Research UK is the world's largest independent cancer research charity, funding the Crick, ICR, Manchester, Cambridge, and the STAMPEDE and TRACERx trials.","summary":"Cancer Research UK is the world's largest independent cancer research charity, spending over four hundred million pounds a year and funding the Crick, the Institute of Cancer Research and the Manchester and Cambridge institutes, as well as trials including STAMPEDE, TRACERx, Add-Aspirin, BILCAP and INTERLACE. It runs the CRUK Centres network, the Cancer Grand Challenges with the NCI, clinical trials units and the British Journal of Cancer, and its commercial arm Cancer Research Horizons has its own record; Charles Swanton, Caroline Dive, Michelle Mitchell and Dame Deborah James are among the people linked. OnCo connects it to bottlenecks on funding that follows fashion, neglected metastasis research and no incentive to repurpose cheap drugs. Whether a charity can fund infrastructure that governments will not is the standing question. Its research infrastructure page names four core-funded institutes (the Cancer Research UK Scotland Institute in Glasgow, the Cambridge Institute, the Manchester Institute and the Francis Crick Institute) and seven centres (Cambridge, City of London with King's College London, UCL, Barts and the Crick, Convergence Science with the Institute of Cancer Research and Imperial College London, Manchester, Newcastle, Oxford and Scotland across Edinburgh and Glasgow); those with records are linked below, as are the centre directors OnCo lists and the trials whose sponsor field names the charity. The Bowelbabe Fund is linked below.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.cancerresearchuk.org"},{"label":"CRUK: our research infrastructure","url":"https://www.cancerresearchuk.org/funding-for-researchers/our-research-infrastructure"},{"label":"CRUK: our centres","url":"https://www.cancerresearchuk.org/for-researchers/how-we-deliver-research/our-research-infrastructure/centres"}],"tags":[],"related":["src-cruk-about-cancer"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["cancer-research-horizons"],"institutions":["cruk-city-of-london-centre","bowelbabe-fund","beatson-glasgow","cruk-cambridge-centre","cruk-manchester-institute","francis-crick","cruk-convergence-science-centre","edinburgh-cancer-centre","newcastle-cancer-centre","oxford-cancer","icr-london","uclh","barts-cancer-institute","imperial-cancer-centre","cancer-grand-challenges"],"pathways":[],"terms":[],"trials":["stampede","add-aspirin","bilcap","abc-02","act-ii","convert","determine-trial","focus4","hilo","ion-trial","national-lung-matrix-trial","persephone","plasmamatch","rathl","target-national"],"people":["iain-foulkes","michelle-mitchell","ruth-plummer","charles-swanton","caroline-dive","rebecca-fitzgerald","peter-sasieni","tariq-enver","axel-behrens","owen-sansom","charlie-gourley","mark-middleton"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"London","country":"GB","lat":51.523,"lng":-0.128,"institutionType":"consortium","website":"https://www.cancerresearchuk.org","programs":["Cancer Grand Challenges","CRUK Centres","Clinical Trials Units"]},{"id":"cruk-cambridge-centre","kind":"institution","name":"Cancer Research UK Cambridge Centre / CRUK Cambridge Institute","aka":["Addenbrooke's Hospital","Cambridge University Hospitals","Li Ka Shing Centre"],"tldr":"The Cancer Research UK Cambridge Centre unites the university, Addenbrooke's and the CRUK Cambridge Institute; its landmark work includes METABRIC breast cancer genomics, the circulating tumour DNA methods behind Inivata, and the Cytosponge test for oesophageal cancer.","summary":"The Cancer Research UK Cambridge Centre brings together the University of Cambridge, Cambridge University Hospitals (Addenbrooke's) and the CRUK Cambridge Institute in the Li Ka Shing Centre, opened in 2007. Landmark work includes Carlos Caldas's METABRIC breast cancer genomics, Nitzan Rosenfeld's circulating tumour DNA methods that spun out Inivata, Rebecca Fitzgerald's Cytosponge test for Barrett's oesophagus and oesophageal cancer, Greg Hannon's IMAXT spatial tumour mapping, and Richard Gilbertson's paediatric brain tumour research; Cambridge chemists Shankar Balasubramanian and David Klenerman invented the Solexa sequencing chemistry now sold by Illumina. A dedicated Cambridge Cancer Research Hospital is planned on the Biomedical Campus. Patients have access to a large early-phase unit, whole-genome sequencing through the NHS Genomic Medicine Service and the Wellcome Sanger Institute's neighbouring genomics resources.","asOf":"2026-09-09","links":[{"label":"CRUK Cambridge Centre","url":"https://www.cruk.cam.ac.uk"},{"label":"Cambridge Cancer Research Hospital","url":"https://www.cambridgecancer.org.uk"}],"tags":[],"related":[],"cancers":["breast-hr-positive","esophageal","glioblastoma","ovarian"],"sections":["early-detection","diagnostics"],"technologies":["liquid-biopsy","mrd-testing","single-cell-spatial","wes-wgs","rna-seq"],"targets":[],"drugs":[],"companies":["illumina"],"institutions":["cruk","wellcome-sanger"],"pathways":[],"terms":["ctdna","pam50"],"trials":[],"people":["jason-carroll","james-brenton","helena-earl","serena-nik-zainal","carlos-caldas","charlotte-coles","rebecca-fitzgerald","hugo-ford"],"bottlenecks":["b-early-detection"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Cambridge","country":"GB","lat":52.176,"lng":0.14,"institutionType":"cancer-center","website":"https://www.cruk.cam.ac.uk","university":"University of Cambridge","programs":["Breast cancer genomics (METABRIC)","Liquid biopsy and ctDNA","Early detection (Cytosponge)","Spatial tumour mapping (IMAXT)","Paediatric brain tumours"]},{"id":"cruk-city-of-london-centre","kind":"institution","name":"Cancer Research UK City of London Centre","aka":["CoL Centre"],"tldr":"The Cancer Research UK City of London Centre brings UCL, King's College London, Barts Cancer Institute and the Francis Crick Institute into one partnership focused on cancer biotherapeutics: cell and gene therapies, antibodies and immunotherapy, with shared manufacturing and trial platforms.","summary":"The Cancer Research UK City of London Centre is one of the seven Cancer Research UK Centres, bringing together University College London, King's College London, Queen Mary University of London's Barts Cancer Institute and the Francis Crick Institute with their partner NHS trusts. Its focus is on cancer biotherapeutics: cell and gene therapies, antibodies and immunotherapy, with shared platforms for manufacturing, imaging and trials, and a joint PhD training programme. Cancer Research UK lists Tariq Enver as its director. The centre links the clinical strengths of UCLH, Guy's and St Thomas' and Barts Health with the discovery science of the Crick.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.colcc.ac.uk"},{"label":"CRUK Centres","url":"https://www.cancerresearchuk.org/for-researchers/how-we-deliver-research/our-research-infrastructure/centres"}],"tags":["cruk-centre"],"related":[],"cancers":[],"sections":[],"technologies":["car-t"],"targets":[],"drugs":[],"companies":[],"institutions":["cruk","uclh","guys-st-thomas","barts-cancer-institute","francis-crick"],"pathways":[],"terms":[],"trials":[],"people":["tariq-enver"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"London","country":"GB","lat":51.524,"lng":-0.134,"institutionType":"consortium","website":"https://www.colcc.ac.uk","programs":["Cancer biotherapeutics","Cell and gene therapy","Joint PhD training"]},{"id":"cruk-convergence-science-centre","kind":"institution","name":"Cancer Research UK Convergence Science Centre","aka":[],"tldr":"The CRUK Centre run jointly by The Institute of Cancer Research and Imperial College London to bring engineering, physical sciences and AI to cancer.","summary":"The Cancer Research UK Convergence Science Centre is one of the seven Cancer Research UK Centres and a partnership between The Institute of Cancer Research and Imperial College London. Its mission is to converge engineering, physical, mathematical and data sciences with cancer biology and medicine: funding cross-disciplinary teams, a Convergence Science PhD programme and seed projects in areas such as imaging, sensors, mathematical oncology, AI for pathology and radiotherapy, and novel drug delivery. Cancer Research UK lists Axel Behrens as its director. It draws on The Royal Marsden and Imperial College Healthcare as clinical partners.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.convergencesciencecentre.ac.uk"},{"label":"CRUK Centres","url":"https://www.cancerresearchuk.org/for-researchers/how-we-deliver-research/our-research-infrastructure/centres"}],"tags":["cruk-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cruk","icr-london","imperial-cancer-centre","royal-marsden"],"pathways":[],"terms":[],"trials":[],"people":["axel-behrens"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"London","country":"GB","lat":51.499,"lng":-0.175,"institutionType":"consortium","website":"https://www.convergencesciencecentre.ac.uk","programs":["Convergence science PhD programme","AI and mathematical oncology","Imaging and sensors"]},{"id":"cruk-manchester-institute","kind":"institution","name":"Cancer Research UK Manchester Institute","aka":["Paterson Institute for Cancer Research","CRUK MI","Paterson Building"],"tldr":"The Cancer Research UK Manchester Institute sits beside The Christie; Caroline Dive's group pioneered small-cell lung cancer models grown from circulating tumour cells and leads the circulating tumour DNA work of TRACERx, and the institute anchors the Manchester Cancer Research Centre.","summary":"Founded as the Paterson Laboratories of the Christie Hospital and renamed the Cancer Research UK Manchester Institute in 2013, the institute moved into the rebuilt Paterson Building in 2023 after the 2017 fire. Director Caroline Dive's group pioneered circulating tumour cell-derived explant models of small-cell lung cancer and leads the ctDNA work of TRACERx with the Crick, and the institute anchors the Manchester Cancer Research Centre partnership and the CRUK Lung Cancer Centre of Excellence with UCL. Other groups study cancer inflammation, systems oncology, skin cancer, leukaemia biology and drug discovery. Its position within The Christie's campus gives rapid translation into early-phase trials.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.cruk.manchester.ac.uk"},{"label":"Manchester Cancer Research Centre","url":"https://www.mcrc.manchester.ac.uk"}],"tags":[],"related":[],"cancers":["sclc","nsclc","melanoma","aml"],"sections":["diagnostics","drug-discovery"],"technologies":["liquid-biopsy","pdx-models","mrd-testing","cgp"],"targets":[],"drugs":[],"companies":[],"institutions":["the-christie","cruk","francis-crick"],"pathways":[],"terms":["ctdna"],"trials":[],"people":["caroline-dive","fiona-blackhall","samra-turajlic","tim-somervaille"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Manchester","country":"GB","lat":53.43,"lng":-2.23,"institutionType":"research-institute","website":"https://www.cruk.manchester.ac.uk","university":"University of Manchester","programs":["Liquid biopsy and CTC-derived models","CRUK Lung Cancer Centre of Excellence","Manchester Cancer Research Centre","Drug discovery"]},{"id":"cancercare-manitoba","kind":"institution","name":"CancerCare Manitoba","aka":["CCMB"],"tldr":"Manitoba's provincial cancer agency, responsible for cancer and blood disorder services across the province, with its own research institute in Winnipeg.","summary":"CancerCare Manitoba is the provincial cancer authority responsible for setting strategic priorities and long-term planning for cancer and blood disorders in Manitoba, delivering prevention, screening, treatment, supportive and end-of-life care, and radiation protection across the province. Its main site at 675 McDermot Avenue in Winnipeg houses chemotherapy, radiation treatment, patient support services and the Paul Albrechtsen Research Institute; the Western Manitoba Cancer Centre in Brandon, run with Prairie Mountain Health, provides radiotherapy and chemotherapy closer to home. It is funded by Manitoba Health and supported by the CancerCare Manitoba Foundation, and is affiliated with the University of Manitoba.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.cancercare.mb.ca"},{"label":"About CancerCare Manitoba","url":"https://www.cancercare.mb.ca/About-Us"}],"tags":["provincial-cancer-agency"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["canadian-cancer-society"],"pathways":[],"terms":[],"trials":[],"people":["kent-stobart"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Winnipeg","country":"CA","lat":49.903,"lng":-97.159,"institutionType":"government","website":"https://www.cancercare.mb.ca","university":"University of Manitoba","programs":["Provincial cancer agency","Paul Albrechtsen Research Institute","Western Manitoba Cancer Centre (Brandon)","Screening programmes"]},{"id":"capio-st-goran","kind":"institution","name":"Capio S:t Göran's Hospital","aka":["Capio St Görans Sjukhus","S:t Görans sjukhus"],"tldr":"A privately run emergency hospital in Stockholm working within the Swedish public system, and a full member of the Organisation of European Cancer Institutes.","summary":"Capio S:t Göran's Hospital is an acute hospital in Stockholm run by Capio under contract to Region Stockholm, with cancer care including breast and colorectal surgery and oncology. It is a full member of the Organisation of European Cancer Institutes (OECI). Its representative on the OECI list is Gustaf Storm.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://capiostgoran.se/"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":["karolinska"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["gustaf-storm"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Stockholm","country":"SE","lat":59.334,"lng":18.02,"institutionType":"hospital","website":"https://capiostgoran.se/","programs":[]},{"id":"carilion-clinic","kind":"institution","name":"Carilion Clinic / Virginia Tech Carilion School of Medicine","aka":["Carilion Children's","Carilion Roanoke Memorial Hospital"],"tldr":"Health system in south-west Virginia whose children's hospital is the home base of Kimberly Dunsmore, chair of the Children's Oncology Group T-cell leukaemia trial AALL0434.","summary":"Carilion Clinic is a not-for-profit health system serving south-west Virginia from Roanoke, and with Virginia Tech runs the Virginia Tech Carilion School of Medicine. Its paediatric haematology-oncology service at Carilion Children's is led by Kimberly Dunsmore, who chaired the Children's Oncology Group trial AALL0434, the largest trial ever run in childhood T-cell acute lymphoblastic leukaemia, whose 2020 report established the addition of nelarabine.","asOf":"2026-09-18","links":[{"label":"Carilion Clinic","url":"https://www.carilionclinic.org"}],"tags":[],"related":[],"cancers":["all-paediatric-high-risk","childhood-cancers"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["kimberly-dunsmore"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Roanoke, VA","country":"US","lat":37.253,"lng":-79.943,"institutionType":"hospital","website":"https://www.carilionclinic.org","university":"Virginia Tech","programs":["Paediatric haematology-oncology","Children's Oncology Group"]},{"id":"case-ccc","kind":"institution","name":"Case Comprehensive Cancer Center","aka":["Case CCC"],"tldr":"The NCI comprehensive consortium uniting Case Western Reserve University, University Hospitals Seidman Cancer Center and Cleveland Clinic.","summary":"NCI-designated since 1987 and comprehensive since 1998, Case Comprehensive Cancer Center is a consortium of Case Western Reserve University, University Hospitals Seidman Cancer Center and Cleveland Clinic's Taussig Cancer Institute. Sanford Markowitz's colon cancer genetics (TGF-beta receptor II inactivation, 15-PGDH) led to stool methylated-DNA screening markers and chemoprevention concepts; UH Seidman opened a compact Mevion proton centre in 2016. The consortium offers patients across north-east Ohio a shared portfolio of NCI cooperative group and investigator-initiated trials, and its members include Cleveland Clinic's Lerner Research Institute.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Case_Comprehensive_Cancer_Center","links":[{"label":"Case Comprehensive Cancer Center","url":"https://case.edu/cancer/"},{"label":"UH Seidman Cancer Center","url":"https://www.uhhospitals.org/services/cancer-services"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":["early-detection"],"technologies":["colorectal-screening","proton-therapy","methylation-profiling"],"targets":[],"drugs":[],"companies":["mevion"],"institutions":["cleveland-clinic"],"pathways":[],"terms":[],"trials":[],"people":["daniel-spratt"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Cleveland, OH","country":"US","lat":41.505,"lng":-81.606,"institutionType":"consortium","website":"https://case.edu/cancer/","nci":"comprehensive","university":"Case Western Reserve University","programs":["Colorectal cancer genetics and screening","Proton therapy (UH Seidman)","Consortium trial network"]},{"id":"hull-castle-hill","kind":"institution","name":"Castle Hill Hospital, Hull (Queen's Centre)","aka":["Hull University Teaching Hospitals NHS Trust","Hull and East Yorkshire Hospitals"],"tldr":"The HPB specialist centre for Hull and East Yorkshire, one of the 23 English surgical hubs in the National Pancreatic Cancer Audit and a Precision-Panc site.","summary":"Hull University Teaching Hospitals NHS Trust (trust code RWA) is one of the 23 trusts the National Pancreatic Cancer Audit's 2026 methodology supplement lists as HPB specialist centres; Pancreatic Cancer UK lists the Queen's Centre at Castle Hill Hospital for Yorkshire. Castle Hill was a recruiting site for the Precision Panc master protocol.","asOf":"2026-09-24","links":[{"label":"Hull University Teaching Hospitals: HPB","url":"https://www.hull.nhs.uk/"},{"label":"NPaCA 2026 methodology supplement, Table 7","url":"https://www.natcan.org.uk/wp-content/uploads/2026/09/NPaCA-SotN-2026-Methodology-Supplement.pdf"}],"tags":["hpb","nhs","uk"],"related":[],"cancers":["pancreatic","gallbladder","biliary-tract-cancer","cholangiocarcinoma","hcc"],"sections":["surgery"],"technologies":["whipple"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["precision-panc"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Cottingham","country":"GB","lat":53.784,"lng":-0.427,"institutionType":"hospital","website":"https://www.hull.nhs.uk/","programs":["HPB surgery","Specialist HPB MDT"]},{"id":"ico-catalonia","kind":"institution","name":"Catalan Institute of Oncology (ICO)","aka":["Institut Català d'Oncologia","ICO L'Hospitalet","ICO Badalona","ICO Girona"],"tldr":"Catalonia's public cancer institute, created in 1995, running cancer centres in L'Hospitalet, Badalona and Girona and accredited by OECI as a Comprehensive Cancer Centre.","summary":"The Institut Català d'Oncologia was created by the Government of Catalonia in 1995 as a public monographic cancer institute. It operates cancer centres on the campuses of the Bellvitge (L'Hospitalet de Llobregat), Germans Trias i Pujol (Badalona) and Josep Trueta (Girona) hospitals, delivering medical oncology, radiation oncology, haematology and cancer prevention for a large share of the Catalan population. Its research is carried out with IDIBELL, IGTP and IDIBGI, with recognised programmes in HPV and cancer epidemiology, hereditary cancer, haematological malignancies and radiotherapy. The ICO is accredited by the Organisation of European Cancer Institutes as a Comprehensive Cancer Centre and coordinates Catalonia's cancer plan.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://ico.gencat.cat"}],"tags":["oeci-accredited","oeci-comprehensive-cancer-centre"],"related":[],"cancers":["cervical"],"sections":[],"technologies":["hpv-vaccine","germline-testing"],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["ramon-salazar-soler","helena-isabal-roca"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"L'Hospitalet de Llobregat","country":"ES","lat":41.348,"lng":2.106,"institutionType":"cancer-center","website":"https://ico.gencat.cat","programs":["Cancer epidemiology and HPV research","Hereditary cancer","Haematology","Radiation oncology"]},{"id":"cecurio","kind":"institution","name":"CeCurio (MVZ Tübingen oncology)","aka":["MVZ Tübingen"],"tldr":"CeCurio, the oncology and haematology practice of MVZ Tübingen, offers personalised peptide vaccines built with the sequencing laboratory CeGaT, with real-world survival data in glioblastoma.","summary":"The oncology and haematology practice at MVZ Tübingen offers personalised cancer therapy and advanced diagnostics, including personalised peptide vaccines developed in collaboration with CeGaT; Future of Cancer Care Today notes real-world survival data in glioblastoma and lists it as patient-bookable in Germany.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://mvz-tuebingen.de/en/oncology/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["fcct-directory"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":["neoantigen-mrna-vaccine"],"targets":[],"drugs":[],"companies":["cegat"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Tübingen","country":"DE","lat":48.52,"lng":9.06,"institutionType":"hospital","website":"https://mvz-tuebingen.de/en/oncology/","programs":[]},{"id":"cedars-sinai-cancer","kind":"institution","name":"Cedars-Sinai Cancer","aka":["Samuel Oschin Comprehensive Cancer Institute"],"tldr":"Los Angeles's largest non-profit hospital's cancer enterprise, known for bladder cancer biology, glioma immunotherapy and the Molecular Twin AI project.","summary":"Cedars-Sinai Cancer unites the Samuel Oschin Comprehensive Cancer Institute with Cedars-Sinai's regional network across Los Angeles. Director Dan Theodorescu's laboratory showed in 2023 that loss of the Y chromosome in bladder cancer drives immune evasion and sensitivity to checkpoint blockade; Keith Black's neurosurgery programme pioneered dendritic cell vaccines for glioma; and the Molecular Twin initiative combines multi-omics and AI to model individual patients, starting with pancreatic cancer. The centre has strong kidney, prostate, lung and women's cancer programmes and a phase 1 unit, and is pursuing NCI designation.","asOf":"2026-09-09","links":[{"label":"Cedars-Sinai Cancer","url":"https://www.cedars-sinai.org/programs/cancer.html"},{"label":"Clinical trials","url":"https://www.cedars-sinai.org/research/clinical-trials.html"}],"tags":[],"related":[],"cancers":["urothelial","glioblastoma","pancreatic","rcc"],"sections":["ai-computation"],"technologies":["digital-twins-trials","checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["robert-figlin","armando-giuliano","mark-faries"],"bottlenecks":["b-data-silos"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Los Angeles, CA","country":"US","lat":34.075,"lng":-118.38,"institutionType":"hospital","website":"https://www.cedars-sinai.org/programs/cancer.html","programs":["Bladder cancer biology","Neuro-oncology immunotherapy","Molecular Twin (AI and multi-omics)"]},{"id":"center-for-metabolic-oncology","kind":"institution","name":"Center for Metabolic Oncology","aka":[],"tldr":"The Center for Metabolic Oncology is a physician-led practice in Franklin, Tennessee that adds exercise, nutrition, sleep, stress and ketogenic interventions to standard cancer care, for prevention, treatment support and recovery.","summary":"Led by Mark Kelley for cancer, the Center for Metabolic Oncology provides metabolic health optimisation programmes as adjuncts to standard care across prevention, treatment support, survivorship and surgical recovery. Patient-bookable.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://cmo.health"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Franklin","country":"US","lat":35.93,"lng":-86.87,"institutionType":"hospital","website":"https://cmo.health","programs":[]},{"id":"cdsco","kind":"institution","name":"Central Drugs Standard Control Organization","aka":["CDSCO","Drugs Controller General of India","DCGI"],"tldr":"India's national drug regulator, headed by the Drugs Controller General of India, which approves new cancer drugs and oversees the generics and biosimilars industry that supplies much of the world.","summary":"CDSCO, under the Ministry of Health and Family Welfare, approves new drugs and clinical trials, licenses vaccine and biologic manufacturing and sets standards, while state authorities license most manufacturing and sale. India's generic and biosimilar manufacturers supply low-cost versions of trastuzumab, bevacizumab, rituximab and imatinib domestically and to many countries, and CDSCO's New Drugs and Clinical Trials Rules 2019 shortened trial approval timelines and introduced waivers of local trials for drugs approved by reference regulators. Price regulation of essential cancer medicines is handled by the National Pharmaceutical Pricing Authority. India's first domestically developed CAR-T (NexCAR19) was approved by CDSCO in 2023.","asOf":"2026-09-09","links":[{"label":"CDSCO","url":"https://cdsco.gov.in"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["car-t","monoclonal-antibody"],"targets":[],"drugs":["trastuzumab","imatinib"],"companies":[],"institutions":["tata-memorial","fda-oce","who"],"pathways":[],"terms":[],"trials":[],"people":["rajeev-singh-raghuvanshi"],"bottlenecks":["b-global-access","b-drug-pricing"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"New Delhi","country":"IN","lat":28.614,"lng":77.209,"institutionType":"government","website":"https://cdsco.gov.in","programs":["New drug and clinical trial approval","Biosimilar guidelines","Local trial waivers for reference-regulator approvals","CAR-T and cell therapy approvals"]},{"id":"centre-antoine-lacassagne","kind":"institution","name":"Centre Antoine Lacassagne","aka":["CAL"],"tldr":"Nice's cancer centre and a proton therapy pioneer in France, treating eye melanoma with protons since 1991.","summary":"Founded in 1961, the Centre Antoine Lacassagne is the UNICANCER centre for the Côte d'Azur. Its Institut Méditerranéen de Protonthérapie began treating uveal melanoma with the MEDICYC low-energy cyclotron in 1991 and added a high-energy IBA ProteusONE system in 2016, making it one of France's few proton facilities and a reference for ocular and paediatric tumours. Other programmes include head and neck oncology, breast surgery, nuclear medicine and an early-phase unit. Research with the Université Côte d'Azur focuses on radiobiology and medical physics.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.centreantoinelacassagne.org"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":["melanoma","head-and-neck","breast-hr-positive"],"sections":["radiation"],"technologies":["proton-therapy","imrt-igrt","pet-ct","proton-therapy-systems"],"targets":[],"drugs":[],"companies":["iba","unicancer"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["emmanuel-barranger"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Nice","country":"FR","lat":43.702,"lng":7.266,"institutionType":"cancer-center","website":"https://www.centreantoinelacassagne.org","university":"Université Côte d'Azur","programs":["Proton therapy (Institut Méditerranéen de Protonthérapie)","Uveal melanoma","Head and neck cancer","Nuclear medicine"]},{"id":"centre-eugene-marquis","kind":"institution","name":"Centre Eugène Marquis","aka":[],"tldr":"The Unicancer cancer centre for Brittany in Rennes, accredited by OECI as a Comprehensive Cancer Centre.","summary":"Centre Eugène Marquis is the Centre de Lutte Contre le Cancer for Rennes and Brittany, one of the 18 Unicancer centres in France. It provides medical oncology, radiotherapy, nuclear medicine and supportive care on the Pontchaillou campus shared with the CHU de Rennes, and its research groups work with Inserm and the University of Rennes on radiotherapy physics, medical imaging and cancer genomics. The centre is accredited by the Organisation of European Cancer Institutes as a Comprehensive Cancer Centre and coordinates regional cancer research through the Breton cancer network.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.centre-eugene-marquis.fr"}],"tags":["oeci-accredited","oeci-comprehensive-cancer-centre","unicancer"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["renaud-de-crevoisier"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Rennes","country":"FR","lat":48.117,"lng":-1.68,"institutionType":"cancer-center","website":"https://www.centre-eugene-marquis.fr","programs":["Radiotherapy physics","Nuclear medicine","Cancer genomics"]},{"id":"centre-francois-baclesse","kind":"institution","name":"Centre François Baclesse","aka":[],"tldr":"The Unicancer cancer centre for Lower Normandy, an OECI Comprehensive Cancer Centre and the base for Normandy's proton therapy programme.","summary":"Centre François Baclesse is the Centre de Lutte Contre le Cancer for Caen and Lower Normandy, one of the 18 Unicancer centres. It provides surgery, medical oncology, radiotherapy and nuclear medicine, and is the clinical partner of the ARCHADE hadron therapy project, whose proton therapy centre in Caen treats patients from across the region. Research with the University of Caen Normandy and the GANIL heavy-ion laboratory covers radiobiology, radiotherapy physics, epidemiology and neuro-oncology. The centre is accredited by the Organisation of European Cancer Institutes as a Comprehensive Cancer Centre.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.baclesse.fr"}],"tags":["oeci-accredited","oeci-comprehensive-cancer-centre","unicancer"],"related":[],"cancers":[],"sections":[],"technologies":["proton-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["roman-rouzier"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Caen","country":"FR","lat":49.182,"lng":-0.371,"institutionType":"cancer-center","website":"https://www.baclesse.fr","programs":["Proton therapy (ARCHADE)","Radiobiology","Radiotherapy"]},{"id":"centre-georges-francois-leclerc","kind":"institution","name":"Centre Georges-François Leclerc","aka":["CGFL"],"tldr":"The Centre Georges-François Leclerc is the Unicancer comprehensive cancer centre in Dijon, Burgundy, and a full member of the Organisation of European Cancer Institutes.","summary":"The Centre Georges-François Leclerc (CGFL) in Dijon is the comprehensive cancer centre for Burgundy and one of the centres de lutte contre le cancer in the Unicancer network, established in 1967. It combines cancer care with research in radiotherapy, imaging and immuno-oncology in partnership with the University of Burgundy. It is listed by the Organisation of European Cancer Institutes as a full member. Programme, trial and leadership details are not yet recorded here and should be checked on the centre's own pages.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.cgfl.fr"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":["aphp-nord-cancer-institute","centre-eugene-marquis"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["unicancer"],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["charles-coutant"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Dijon","country":"FR","lat":47.32,"lng":5.069,"institutionType":"cancer-center","website":"https://www.cgfl.fr","programs":[]},{"id":"centre-henri-becquerel","kind":"institution","name":"Centre Henri Becquerel","aka":[],"tldr":"Centre Henri Becquerel is the Unicancer centre for Rouen and Upper Normandy; its unusually large haematology department and its lymphoma group, linked to the LYSA cooperative group, have led practice-changing diffuse large B-cell lymphoma trials, and OECI accredits it as a Comprehensive Cancer Centre.","summary":"Centre Henri Becquerel is the Centre de Lutte Contre le Cancer for Rouen and Upper Normandy, one of the 18 Unicancer centres. Alongside surgery, radiotherapy and medical oncology it has an unusually large clinical haematology department, and its lymphoma group, historically linked to the GELA and now LYSA cooperative groups, has led or co-led practice-changing trials in diffuse large B-cell lymphoma. The centre hosts an Inserm unit on lymphoma genomics with the University of Rouen Normandy and is accredited by the Organisation of European Cancer Institutes as a Comprehensive Cancer Centre.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.becquerel.fr"}],"tags":["oeci-accredited","oeci-comprehensive-cancer-centre","unicancer"],"related":[],"cancers":["dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["lysa"],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["pierre-vera"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Rouen","country":"FR","lat":49.446,"lng":1.096,"institutionType":"cancer-center","website":"https://www.becquerel.fr","programs":["Lymphoma and clinical haematology","Radiotherapy","Breast cancer"]},{"id":"chum","kind":"institution","name":"Centre hospitalier de l'Université de Montréal (CHUM)","aka":["CHUM","CRCHUM"],"tldr":"The CHUM is the Université de Montréal's adult teaching hospital; Bertrand Routy's 2018 work here showed that gut bacteria shape response to checkpoint inhibitors, Fred Saad co-led prostate cancer trials such as PROpel, and it runs Quebec's largest oncology trial programme.","summary":"The CHUM is the Université de Montréal's adult teaching hospital, consolidated on a new downtown campus in 2017, with the Centre de recherche du CHUM (CRCHUM) and the Institut du cancer de Montréal as its research arms. Bertrand Routy's 2018 Science paper showed that antibiotics blunt checkpoint inhibitor efficacy and that specific gut bacteria predict response, launching faecal microbiota transplant trials to overcome immunotherapy resistance. Urologist Fred Saad has led or co-led landmark prostate cancer trials, including PROpel (olaparib plus abiraterone), and Réjean Lapointe's group develops TIL and T-cell therapies. The hospital runs Quebec's largest oncology clinical trial programme in French and English.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Centre_hospitalier_de_l'Universit%C3%A9_de_Montr%C3%A9al","links":[{"label":"CHUM","url":"https://www.chumontreal.qc.ca"},{"label":"CRCHUM (archived copy)","url":"https://web.archive.org/web/20180506044652/http://crchum.chumontreal.qc.ca/"}],"tags":[],"related":[],"cancers":["prostate","melanoma","ovarian","nsclc"],"sections":[],"technologies":["microbiome-modulation-io","til-therapy","checkpoint-inhibitor"],"targets":[],"drugs":["olaparib","abiraterone"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["marie-eve-desrosiers"],"bottlenecks":["b-immunotherapy-response"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Montréal, QC","country":"CA","lat":45.511,"lng":-73.557,"institutionType":"hospital","website":"https://www.chumontreal.qc.ca","university":"Université de Montréal","programs":["Microbiome and immunotherapy","Prostate cancer trials","T-cell immunotherapy","Ovarian cancer biobanking"]},{"id":"centre-jean-perrin","kind":"institution","name":"Centre Jean Perrin","aka":[],"tldr":"The Unicancer cancer centre for the Auvergne region, accredited by OECI as a Comprehensive Cancer Centre.","summary":"Centre Jean Perrin is the Centre de Lutte Contre le Cancer for Clermont-Ferrand and the Auvergne, one of the 18 Unicancer centres in France. It provides surgical oncology, medical oncology, radiotherapy, nuclear medicine and supportive care, and hosts an Inserm research unit (Imagerie Moléculaire et Stratégies Théranostiques) focused on molecular imaging and radiopharmaceuticals, including melanoma-targeting tracers. The centre is accredited by the Organisation of European Cancer Institutes as a Comprehensive Cancer Centre and works closely with the CHU de Clermont-Ferrand and the Université Clermont Auvergne.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.cjp.fr"}],"tags":["oeci-accredited","oeci-comprehensive-cancer-centre","unicancer"],"related":[],"cancers":[],"sections":[],"technologies":["radioligand-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["frederique-penault-llorca"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Clermont-Ferrand","country":"FR","lat":45.759,"lng":3.089,"institutionType":"cancer-center","website":"https://www.cjp.fr","programs":["Molecular imaging and theranostics","Radiotherapy","Breast cancer"]},{"id":"centre-leon-berard","kind":"institution","name":"Centre Léon Bérard","aka":["CLB","Centre de Lutte Contre le Cancer de Lyon"],"tldr":"Lyon's cancer centre, a world reference for sarcoma and rare cancers, led by Jean-Yves Blay, who also presides over UNICANCER.","summary":"Founded in 1923, the Centre Léon Bérard is the UNICANCER centre for the Auvergne-Rhône-Alpes region and the clinical arm of the Cancer Research Center of Lyon (CRCL, with Inserm, CNRS and Lyon 1). Under Jean-Yves Blay it coordinates the French NetSarc sarcoma network and the European Reference Network for rare adult solid cancers (EURACAN). Programmes include the ProfiLER molecular profiling study, a large early-phase unit, breast oncology under Thomas Bachelot, paediatric oncology (IHOPe) and a Lyon Integrated Cancer Research Site (LYriCAN). The International Agency for Research on Cancer sits in the same city.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.centreleonberard.fr"},{"label":"Cancer Research Center of Lyon","url":"https://www.crcl.fr"},{"label":"EURACAN","url":"https://euracan.eu"}],"tags":[],"related":[],"cancers":["sarcoma","breast-hr-positive","breast-her2-positive","melanoma"],"sections":["targeted-therapy"],"technologies":["cgp","kinase-inhibitors","checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":["unicancer"],"institutions":["iarc"],"pathways":[],"terms":[],"trials":[],"people":["jean-yves-blay","thomas-bachelot","patrick-mehlen","isabelle-ray-coquard"],"bottlenecks":["b-rare-cancers"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Lyon","country":"FR","lat":45.743,"lng":4.856,"institutionType":"cancer-center","website":"https://www.centreleonberard.fr","university":"Université Claude Bernard Lyon 1","programs":["Sarcoma and rare cancers (NetSarc, EURACAN)","ProfiLER precision oncology","Early-phase trials","Breast oncology","Paediatric oncology (IHOPe)"]},{"id":"centre-oscar-lambret","kind":"institution","name":"Centre Oscar Lambret","aka":["COL","Centre de Lutte Contre le Cancer de Lille"],"tldr":"The regional cancer centre for northern France, known for paediatric oncology, sarcoma, gynaecological cancers and radiotherapy.","summary":"The Centre Oscar Lambret is the UNICANCER comprehensive cancer centre for the Hauts-de-France region, serving one of the most cancer-burdened populations in France. It runs a large radiotherapy department with brachytherapy and stereotactic programmes, paediatric and adolescent oncology, sarcoma and rare tumour services, and an early-phase trials unit. Research is carried out with the Université de Lille and Inserm within the ONCOLille institute, with themes in tumour dormancy, chemoresistance and cancer epidemiology. The centre co-leads regional cancer screening and prevention work.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.centreoscarlambret.fr"},{"label":"UNICANCER","url":"https://www.unicancer.fr"}],"tags":[],"related":[],"cancers":["sarcoma","cervical","ovarian","head-and-neck","neuroblastoma"],"sections":["radiation"],"technologies":["brachytherapy","sbrt","imrt-igrt"],"targets":[],"drugs":[],"companies":["unicancer"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["eric-felix-lartigau"],"bottlenecks":["b-dormancy-mrd"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Lille","country":"FR","lat":50.607,"lng":3.036,"institutionType":"cancer-center","website":"https://www.centreoscarlambret.fr","university":"Université de Lille","programs":["Radiotherapy and brachytherapy","Paediatric oncology","Sarcoma","Gynaecological oncology","Early-phase trials"]},{"id":"cro-aviano","kind":"institution","name":"Centro di Riferimento Oncologico di Aviano (CRO)","aka":["CRO Aviano","IRCCS CRO"],"tldr":"The national cancer institute of north-east Italy in Aviano, an IRCCS accredited by OECI as a Comprehensive Cancer Centre.","summary":"The Centro di Riferimento Oncologico is a dedicated cancer hospital and research institute in Aviano, Friuli Venezia Giulia, recognised by the Italian Ministry of Health as an IRCCS. It provides medical oncology, radiotherapy, surgical oncology, haematology, nuclear medicine and a large clinical trials programme, and hosts research divisions in cancer epidemiology, molecular oncology, immunopathology and experimental pharmacology. CRO Aviano is accredited by the Organisation of European Cancer Institutes as a Comprehensive Cancer Centre and coordinates the Friuli Venezia Giulia cancer network with the universities of Udine and Trieste.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.cro.sanita.fvg.it"}],"tags":["oeci-accredited","oeci-comprehensive-cancer-centre","irccs"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["giuseppe-tonutti"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Aviano","country":"IT","lat":46.07,"lng":12.59,"institutionType":"cancer-center","website":"https://www.cro.sanita.fvg.it","programs":["Cancer epidemiology","Radiotherapy","Experimental pharmacology and trials"]},{"id":"clara-campal-oncology-centre","kind":"institution","name":"Centro Integral Oncológico Clara Campal (HM CIOCC)","aka":["Centro Integral Oncológico Clara Campal","HM CIOCC","Clara Campal"],"tldr":"Centro Integral Oncológico Clara Campal is the private comprehensive cancer centre of the HM Hospitales group at HM Sanchinarro in Madrid, with a large early-phase trials unit, and a full member of the Organisation of European Cancer Institutes.","summary":"Centro Integral Oncológico Clara Campal is the private comprehensive cancer centre of the HM Hospitales group at HM Sanchinarro in Madrid, with a large early-phase trials unit. It is listed by the Organisation of European Cancer Institutes as a full member, which is why it has a page on OnCo. Programme, trial and leadership details are not yet recorded here and should be checked on the institution's own pages.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.hmciocc.com"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["cesar-gregorio-munoz-sanchez-miguel"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Madrid","country":"ES","lat":40.494,"lng":-3.665,"institutionType":"cancer-center","website":"https://www.hmciocc.com","programs":[]},{"id":"cnio","kind":"institution","name":"Centro Nacional de Investigaciones Oncológicas (CNIO)","aka":["Spanish National Cancer Research Centre","CNIO"],"tldr":"Spain's national cancer research centre, founded by RAS pioneer Mariano Barbacid and known for oncogene, telomere and senescence biology.","summary":"The CNIO was created in 1998 with Mariano Barbacid, who had isolated the first human oncogene (HRAS) in 1982, as founding director; María Blasco (telomeres and telomerase) directed it from 2011 to 2025. Its groups made foundational contributions to KRAS-driven pancreatic and lung cancer models, cellular senescence (Manuel Serrano), replication stress (Óscar Fernández-Capetillo), melanoma metastasis (Marisol Soengas) and structural biology, and its Experimental Therapeutics Programme discovers small molecules for academic and industry partners. Clinical research units embedded in Madrid hospitals, including the H12O-CNIO lung unit and breast and prostate units, translate discoveries into trials. The centre runs a familial cancer clinical unit and a large biobank.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.cnio.es/en/"},{"label":"Research programmes","url":"https://www.cnio.es/en/research-innovation/"}],"tags":[],"related":[],"cancers":["pancreatic","nsclc","melanoma","breast-hr-positive"],"sections":["drug-discovery","targeted-therapy"],"technologies":["kras-inhibitors","pdx-models","crispr-screens","ai-drug-design"],"targets":["kras","tp53"],"drugs":[],"companies":[],"institutions":["12-de-octubre","vall-dhebron"],"pathways":[],"terms":["oncogene-addiction"],"trials":[],"people":["fernando-pelaez"],"bottlenecks":["b-undruggable-targets"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Madrid","country":"ES","lat":40.497,"lng":-3.69,"institutionType":"research-institute","website":"https://www.cnio.es/en/","programs":["Molecular oncology (RAS, telomeres, senescence)","Experimental Therapeutics Programme","Clinical research units in Madrid hospitals","Familial cancer unit","Structural biology"]},{"id":"champalimaud","kind":"institution","name":"Champalimaud Foundation, Champalimaud Clinical Centre","aka":["Fundação Champalimaud","Champalimaud Centre for the Unknown"],"tldr":"Lisbon's private research foundation and clinic, known for advanced breast cancer guidelines, digestive cancer surgery and cancer-neuroscience research.","summary":"The Champalimaud Centre for the Unknown opened in 2010 on the Lisbon waterfront as a neuroscience and cancer research institute with an attached clinical centre. Fátima Cardoso directs its breast unit and chairs the international ESO-ESMO Advanced Breast Cancer (ABC) consensus guidelines, the digestive unit is a reference for rectal cancer organ preservation and pancreatic surgery, and the radiation oncology department was among the first in Europe to install new-generation stereotactic and MR-guided systems. Research groups study cancer-nervous system interactions, exosome-mediated metastasis (Bruno Costa-Silva), tumour immunology and computational oncology. The foundation also runs the Champalimaud Vision Award and public engagement programmes.","asOf":"2026-09-09","links":[{"label":"Homepage (archived copy)","url":"https://web.archive.org/web/20200904070334/https://fchampalimaud.org/en/"}],"tags":[],"related":[],"cancers":["breast-hr-positive","breast-her2-positive","colorectal","pancreatic"],"sections":["radiation","surgery"],"technologies":["sbrt","mr-linac","robotic-surgery","liquid-biopsy"],"targets":[],"drugs":[],"companies":[],"institutions":["esmo","ipo-lisboa"],"pathways":[],"terms":[],"trials":[],"people":["leonor-beleza","teresa-cotta-dias"],"bottlenecks":["b-metastasis-biology"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Lisbon","country":"PT","lat":38.693,"lng":-9.221,"institutionType":"research-institute","website":"https://web.archive.org/web/20200904070334/https://fchampalimaud.org/en/","programs":["Advanced Breast Cancer (ABC) guidelines","Digestive oncology and rectal organ preservation","Precision radiotherapy","Cancer and neuroscience research"]},{"id":"cz-biohub","kind":"institution","name":"Chan Zuckerberg Biohub","aka":["CZ Biohub","Chan Zuckerberg Biohub Network"],"tldr":"The Chan Zuckerberg Initiative's network of research institutes building cell atlases, imaging and AI tools that cancer researchers rely on, including the Tabula Sapiens single-cell atlas.","summary":"Founded in 2016 in San Francisco as a collaboration of UCSF, Stanford and UC Berkeley, and expanded into a network with Biohubs in Chicago and New York, the CZ Biohub builds technologies for measuring and modelling human biology rather than pursuing single diseases. Its Tabula Sapiens project produced a whole-body single-cell atlas, its imaging and microscopy programmes enable spatial and live-cell measurement, and the Chan Zuckerberg Initiative's Virtual Cell effort funds AI models of cellular state. Biohub New York engineers immune cells to detect and treat disease, including cancer, while Biohub Chicago builds sensors for inflammation. The Investigator programme funds faculty at the founding universities.","asOf":"2026-09-09","links":[{"label":"CZ Biohub","url":"https://www.czbiohub.org"},{"label":"Chan Zuckerberg Initiative Science","url":"https://chanzuckerberg.com/science/"}],"tags":[],"related":["cellxgene-hca"],"cancers":[],"sections":["ai-computation","cell-therapy"],"technologies":["single-cell-spatial","pathology-foundation-model","car-t"],"targets":[],"drugs":[],"companies":[],"institutions":["ucsf","stanford","arc-institute"],"pathways":[],"terms":[],"trials":[],"people":["priscilla-chan"],"bottlenecks":["b-data-silos","b-preclinical-models"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"San Francisco","country":"US","lat":37.767,"lng":-122.391,"institutionType":"research-institute","website":"https://www.czbiohub.org","programs":["Tabula Sapiens single-cell atlas","Biohub New York (engineered immune cells)","Imaging and microscopy platforms","CZI Virtual Cell and open-source tools (cellxgene)"]},{"id":"chang-gung-memorial-hospital","kind":"institution","name":"Chang Gung Memorial Hospital","aka":["CGMH","Linkou Chang Gung","長庚紀念醫院"],"tldr":"Chang Gung Memorial Hospital's Linkou campus is Taiwan's largest hospital; it treats the betel-quid-related oral and head and neck cancers that dominate Taiwan's disease burden, opened Taiwan's first proton therapy centre in 2015, and performs liver transplantation for liver cancer at Kaohsiung.","summary":"Founded in 1976 by Formosa Plastics' Wang Yung-ching, Chang Gung Memorial Hospital's Linkou flagship is the largest hospital in Taiwan and one of the largest in Asia, with branches in Kaohsiung, Keelung, Chiayi and Taipei. Its oncology strengths reflect Taiwan's disease burden: oral cavity and head and neck cancer (betel-quid related) including microvascular reconstruction, hepatocellular carcinoma and liver transplantation at Kaohsiung Chang Gung, and lung, breast and lymphoma trials. Linkou opened Taiwan's first proton therapy centre in 2015 and has since been a leading proton site for HCC and paediatric tumours. The hospital's research institute is active in cancer genomics, immunotherapy and health services research using Taiwan's national insurance data.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Linkou_Chang_Gung_Memorial_Hospital","links":[{"label":"Chang Gung Memorial Hospital","url":"https://www.cgmh.org.tw"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":["head-and-neck","hcc","nsclc","esophageal"],"sections":["radiation","surgery"],"technologies":["proton-therapy","fluorescence-guided-surgery","robotic-surgery","proton-therapy-systems"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["chen-chien-tzung"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Taoyuan","country":"TW","lat":25.061,"lng":121.367,"institutionType":"hospital","website":"https://www.cgmh.org.tw","university":"Chang Gung University","programs":["Oral and head and neck cancer","Proton therapy","Liver transplantation (Kaohsiung)","Lung cancer"]},{"id":"uci-chao","kind":"institution","name":"Chao Family Comprehensive Cancer Center, UC Irvine","aka":["UCI Chao Family CCC"],"tldr":"Orange County's NCI comprehensive cancer centre, pairing UCI Health clinical care with the Beckman Laser Institute's optical imaging science.","summary":"NCI-designated since 1994, the Chao Family Comprehensive Cancer Center is the only NCI comprehensive centre in Orange County. Its distinctive research asset is UCI's Beckman Laser Institute, a birthplace of biomedical optics and optical imaging of tissue, alongside programmes in cancer systems biology, GI and head and neck cancers, and haematologic malignancies. UCI Health opened a new Irvine medical campus in the mid-2020s, expanding cancer care alongside the Orange hospital. Patients can access NCI cooperative group and investigator-initiated trials.","asOf":"2026-09-09","links":[{"label":"Chao Family Comprehensive Cancer Center","url":"https://cancer.uci.edu"}],"tags":[],"related":[],"cancers":["head-and-neck","colorectal","aml"],"sections":["imaging"],"technologies":["optical-imaging","fluorescence-guided-surgery"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["richard-van-etten"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Orange, CA","country":"US","lat":33.788,"lng":-117.853,"institutionType":"cancer-center","website":"https://cancer.uci.edu","nci":"comprehensive","university":"University of California, Irvine","programs":["Optical imaging (Beckman Laser Institute)","GI oncology","Head and neck cancer"]},{"id":"charite","kind":"institution","name":"Charité Universitätsmedizin Berlin","aka":["Charité Comprehensive Cancer Center","Charité Comprehensive Cancer Center (CCCC)"],"tldr":"Charité is Europe's largest university hospital, with a Comprehensive Cancer Center and the Berlin Institute of Health.","summary":"Charité, Universitätsmedizin Berlin, is Europe's largest university hospital and hosts the Charité Comprehensive Cancer Center and the Berlin Institute of Health; it ranks twelfth in the Newsweek/Statista oncology list. Its cancer strengths lie in haematology, cell therapy and translational research carried out with the Max Delbrück Center for Molecular Medicine, with Ulrich Keilholz, Christof von Kalle, Lars Bullinger and the paediatric oncologist Angelika Eggert among its leaders. OnCo links it to the Atlas pathology foundation model developed with Aignostics and Mayo Clinic, to Deutsche Krebshilfe and SIOP Europe, and to the idea of hospital-exemption cell therapies made at scale with a shared registry. Whether academic cell therapy manufacturing can match industry on quality and cost is the open question. Its cell therapy programme is the place to start.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.charite.de"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["proton-therapy","proton-therapy-systems","cyberknife","radiosurgery-srs"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["ulrich-keilholz","christof-von-kalle","angelika-eggert","lars-bullinger"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Berlin","country":"DE","lat":52.527,"lng":13.377,"institutionType":"university","website":"https://www.charite.de","newsweekOncology2026":12,"programs":["Cell therapy","Haematology","Precision oncology"]},{"id":"baylor-sammons-dallas","kind":"institution","name":"Charles A. Sammons Cancer Center, Baylor University Medical Center","aka":["Baylor Scott & White Sammons Cancer Center","Baylor Dallas"],"tldr":"Dallas cancer centre of the Baylor Scott & White system, directed by Ronan Kelly, who led CheckMate 577 in oesophageal cancer; not to be confused with Baylor College of Medicine in Houston.","summary":"The Charles A. Sammons Cancer Center is the cancer centre of Baylor University Medical Center in Dallas, part of Baylor Scott & White Health, and one of the largest community cancer programmes in Texas. Its director, Ronan Kelly, was first author of the 2021 New England Journal of Medicine report of CheckMate 577, in which adjuvant nivolumab lengthened disease-free survival after chemoradiotherapy and surgery for oesophageal and gastro-oesophageal junction cancer. It is unrelated to Baylor College of Medicine's Dan L Duncan Comprehensive Cancer Center in Houston.","asOf":"2026-09-18","links":[{"label":"Baylor Scott & White Health","url":"https://www.bswhealth.com"}],"tags":[],"related":[],"cancers":["esophageal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["ronan-kelly"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Dallas, TX","country":"US","lat":32.788,"lng":-96.78,"institutionType":"cancer-center","website":"https://www.bswhealth.com","programs":["Oesophageal and gastric cancer","Community cancer care","Blood and marrow transplantation"]},{"id":"wits-charlotte-maxeke","kind":"institution","name":"Charlotte Maxeke Johannesburg Academic Hospital / University of the Witwatersrand","aka":["CMJAH","Wits Health Sciences","Johannesburg General Hospital"],"tldr":"Johannesburg's flagship academic hospital and Wits University's oncology hub, running South Africa's largest public radiation and medical oncology service and pioneering African cancer cohorts.","summary":"Charlotte Maxeke Johannesburg Academic Hospital, formerly the Johannesburg General Hospital, is the main tertiary hospital of the University of the Witwatersrand and hosts the largest public-sector oncology service in South Africa, with radiation oncology, medical oncology, haematology and bone marrow transplant, gynaecological and surgical oncology, and paediatric oncology. Wits research includes the Johannesburg Cancer Study, one of Africa's largest case-control studies of cancer risk factors and HIV, breast cancer outcomes in Black South African women, cervical cancer screening and HPV vaccination studies, Kaposi sarcoma and lymphoma in HIV, and the Wits Donald Gordon Medical Centre's transplant and hepatobiliary programmes. Wits also partners with the National Health Laboratory Service and the National Cancer Registry.","asOf":"2026-09-09","links":[{"label":"Wits Faculty of Health Sciences","url":"https://www.wits.ac.za/health"},{"label":"CMJAH (Gauteng Health) (archived copy)","url":"https://web.archive.org/web/20250917092427/https://www.gauteng.gov.za/Departments/DepartmentDetails/CPM-001004"}],"tags":[],"related":["global-oncology-access","cancer-health-disparities"],"cancers":["cervical","breast-hr-positive","dlbcl","esophageal","prostate"],"sections":["radiation","prevention"],"technologies":["imrt-igrt","hpv-vaccine","allogeneic-cell-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["shabir-madhi"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Johannesburg","country":"ZA","lat":-26.176,"lng":28.045,"institutionType":"hospital","website":"https://www.wits.ac.za/health","university":"University of the Witwatersrand","programs":["Public-sector radiation and medical oncology","Johannesburg Cancer Study","HIV-associated malignancy","Cervical cancer prevention"]},{"id":"cheshire-merseyside-cancer-alliance","kind":"institution","name":"Cheshire and Merseyside Cancer Alliance","aka":["CMCA"],"tldr":"The NHS England Cancer Alliance for Cheshire and Merseyside, including Liverpool, Wirral, Warrington and Chester: the partnership that plans and improves cancer services across its hospitals, GPs and community services.","summary":"One of the 20 Cancer Alliances set up by NHS England from 2016, following the Independent Cancer Taskforce strategy, to bring together the hospital trusts, integrated care boards, primary care, hospices and charities serving Cheshire and Merseyside, including Liverpool, Wirral, Warrington and Chester. Alliances lead local delivery of the NHS cancer ambitions: earlier diagnosis (including rapid diagnostic centres and targeted lung health checks), the Faster Diagnosis Standard, personalised care and follow-up, and workforce and pathway improvement. They hold transformation funding from NHS England and publish local performance and improvement plans.","asOf":"2026-09-09","links":[{"label":"Cheshire and Merseyside Cancer Alliance","url":"https://www.cmcanceralliance.nhs.uk"},{"label":"NHS England: Cancer Alliances","url":"https://www.england.nhs.uk/cancer/cancer-alliances-improving-care-locally/"}],"tags":["nhs-cancer-alliance"],"related":[],"cancers":[],"sections":["early-detection"],"technologies":["low-dose-ct-screening"],"targets":[],"drugs":[],"companies":[],"institutions":["clatterbridge"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Liverpool","country":"GB","lat":53.408,"lng":-2.992,"institutionType":"consortium","website":"https://www.cmcanceralliance.nhs.uk","programs":["Earlier diagnosis and rapid diagnostic centres","Faster Diagnosis Standard","Personalised care and follow-up","Cancer pathway improvement"]},{"id":"cche-57357","kind":"institution","name":"Children's Cancer Hospital Egypt 57357","aka":["CCHE 57357","57357 Hospital","مستشفى سرطان الأطفال 57357"],"tldr":"One of the world's largest paediatric cancer hospitals, built entirely through public donations and treating Egyptian children with cancer free of charge since 2007.","summary":"Children's Cancer Hospital Egypt 57357, named after the bank account number to which Egyptians donated, opened in Cairo in 2007 as a charitable, donation-funded hospital providing free care to children with cancer and has grown into one of the largest paediatric oncology hospitals in the world. It offers chemotherapy, surgery, radiotherapy, bone marrow transplant and supportive care under protocols adapted from international paediatric cooperative groups, runs a research and education centre with genomics, biobanking and clinical pharmacy programmes, and has published survival outcomes for acute leukaemia, retinoblastoma, brain tumours and neuroblastoma in Egyptian children. 57357 also operates an outreach and Tanta branch, twinning programmes across the Arab world and Africa, and a health-economics unit on childhood cancer.","asOf":"2026-09-09","links":[{"label":"CCHE 57357","url":"https://www.57357.org"}],"tags":[],"related":["global-oncology-access"],"cancers":["all-leukemia","aml","neuroblastoma","glioblastoma","sarcoma"],"sections":["chemotherapy","supportive-care"],"technologies":["allogeneic-cell-therapy","imrt-igrt","mrd-testing"],"targets":[],"drugs":[],"companies":["childrens-oncology-group"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["sherif-abouel-naga"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Cairo","country":"EG","lat":30.02,"lng":31.23,"institutionType":"cancer-center","website":"https://www.57357.org","programs":["Free paediatric cancer care","Paediatric transplant and radiotherapy","Research and education centre","Regional twinning"]},{"id":"chop","kind":"institution","name":"Children's Hospital of Philadelphia","aka":["CHOP"],"tldr":"The children's hospital where CAR-T therapy first cured a child's leukaemia (Emily Whitehead, 2012) and where neuroblastoma genomics found ALK.","summary":"Founded in 1855 as the first children's hospital in the United States, CHOP is the paediatric partner of the University of Pennsylvania's Abramson Cancer Center. Stephan Grupp treated Emily Whitehead with CD19 CAR-T cells in 2012 and led the global ELIANA trial that made tisagenlecleucel the first approved CAR-T therapy in 2017. John Maris's group discovered activating ALK mutations in neuroblastoma in 2008, leading Yael Mossé to bring crizotinib and lorlatinib into paediatric trials, and CHOP's Cancer Center runs one of the largest paediatric cancer predisposition and precision medicine programmes. Peter Adamson chaired the Children's Oncology Group from CHOP, and the hospital's cell therapy, proton therapy (through Penn) and neuro-oncology programmes draw referrals internationally.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Children's_Hospital_of_Philadelphia","links":[{"label":"Children's Hospital of Philadelphia","url":"https://www.chop.edu"},{"label":"CHOP Cancer Center","url":"https://www.chop.edu/centers-programs/cancer-center"}],"tags":[],"related":[],"cancers":["all-leukemia","neuroblastoma"],"sections":[],"technologies":["car-t","proton-therapy","germline-testing"],"targets":["cd19","alk"],"drugs":["tisagenlecleucel","crizotinib","lorlatinib"],"companies":["novartis","childrens-oncology-group"],"institutions":["penn-abramson"],"pathways":[],"terms":["crs"],"trials":[],"people":["carl-june","madeline-bell","susan-furth","john-maris","yael-mosse","stephen-hunger","stephan-grupp"],"bottlenecks":["b-manufacturing-cell-therapy","b-rare-cancers"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Philadelphia, PA","country":"US","lat":39.948,"lng":-75.194,"institutionType":"hospital","website":"https://www.chop.edu","university":"University of Pennsylvania","programs":["CAR-T for paediatric leukaemia","Neuroblastoma genomics and ALK therapy","Cancer predisposition","Paediatric proton therapy"]},{"id":"childrens-national-hospital","kind":"institution","name":"Children's National Hospital","aka":["Children's National","Children's National Medical Center"],"tldr":"Washington's children's hospital, whose Center for Cancer and Blood Disorders is led by Jeffrey Dome, the paediatric oncologist who chaired the Children's Oncology Group renal tumour trials.","summary":"Children's National Hospital is the paediatric hospital of Washington, DC, affiliated with the George Washington University School of Medicine. Its Center for Cancer and Blood Disorders, led by Jeffrey Dome, runs a large paediatric oncology and cellular therapy programme; Dome chaired the Children's Oncology Group Renal Tumor Committee and led the studies that tailored Wilms tumour treatment to tumour biology, including loss of heterozygosity at 1p and 16q.","asOf":"2026-09-18","wikipedia":"https://en.wikipedia.org/wiki/Children's_National_Hospital","links":[{"label":"Children's National","url":"https://www.childrensnational.org"}],"tags":[],"related":[],"cancers":["wilms-tumor"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["jeffrey-dome"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Washington, DC","country":"US","lat":38.926,"lng":-77.014,"institutionType":"hospital","website":"https://www.childrensnational.org","university":"George Washington University","programs":["Paediatric oncology","Wilms tumour (Children's Oncology Group)","Cellular therapy"]},{"id":"caca","kind":"institution","name":"China Anti-Cancer Association","aka":["CACA","中国抗癌协会"],"tldr":"The China Anti-Cancer Association is the country's largest cancer society, publishing the CACA guidelines that aim to reflect Chinese patients and Chinese drugs rather than imported recommendations.","summary":"Founded in 1984 and based at Tianjin Medical University Cancer Institute and Hospital, CACA has more than a hundred professional committees and publishes the CACA Guidelines for Holistic Integrative Management of Cancer, released annually since 2022 with an emphasis on domestic evidence, traditional and integrative medicine and the whole care pathway. Alongside CSCO it is one of the two societies whose guidance shapes oncology practice in China.","asOf":"2026-09-10","links":[{"label":"CACA","url":"https://www.caca.org.cn/"}],"tags":["china"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["tmucih","csco"],"pathways":[],"terms":[],"trials":[],"people":["fan-daiming"],"bottlenecks":[],"keyPapers":[],"journals":["cancer-biology-and-medicine","cancer-communications","chinese-journal-of-lung-cancer"],"dependsOn":[],"notes":[],"city":"Tianjin","country":"CN","lat":39.104,"lng":117.163,"institutionType":"consortium","website":"https://www.caca.org.cn/","programs":["CACA guidelines","Professional committees by cancer and modality","Public education"]},{"id":"pla-general-hospital","kind":"institution","name":"Chinese PLA General Hospital","aka":["301 Hospital","解放军总医院"],"tldr":"China's military flagship hospital, known in oncology for early CAR-T and gene-edited T-cell trials, minimally invasive liver surgery and nuclear medicine.","summary":"The Chinese PLA General Hospital, commonly called 301 Hospital, is the largest military hospital in China and a comprehensive tertiary centre in Beijing. Its Department of Bio-therapeutics under Weidong Han ran some of the earliest Chinese CAR-T and CRISPR-edited T-cell studies in lymphoma and solid tumours, and its haematology, hepatobiliary surgery (including laparoscopic and robotic hepatectomy), urology and interventional radiology departments are national leaders. The hospital has a large PET/CT and nuclear medicine service and serves as a national referral centre for complex cases from across China.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/People's_Liberation_Army_General_Hospital_and_Medical_School","links":[{"label":"Chinese PLA General Hospital","url":"https://www.301hospital.com.cn"}],"tags":[],"related":[],"cancers":["dlbcl","hcc","prostate","aml"],"sections":["cell-therapy","surgery","imaging"],"technologies":["car-t","crispr-screens","robotic-surgery","pet-ct"],"targets":["cd19"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["xu-jianming"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Beijing","country":"CN","lat":39.907,"lng":116.283,"institutionType":"hospital","website":"https://www.301hospital.com.cn","programs":["CAR-T and gene-edited T-cell trials","Hepatobiliary and robotic surgery","Nuclear medicine","Haematology"]},{"id":"csco","kind":"institution","name":"Chinese Society of Clinical Oncology","aka":["CSCO","中国临床肿瘤学会"],"tldr":"China's clinical oncology society, whose annual meeting and disease guidelines are the reference for treatment in the world's largest cancer patient population.","summary":"Founded in 1997, CSCO is China's national society of clinical oncologists with tens of thousands of members and a large annual meeting each September that presents Chinese trial data on PD-1 antibodies, antibody-drug conjugates and targeted therapies. Its CSCO guidelines, published annually for each major cancer, grade recommendations by evidence and by accessibility in China and are the guidelines most Chinese oncologists use; they are increasingly cited internationally as Chinese drugs reach global markets. CSCO runs the CSCO Foundation for research grants, expert committees by disease, and a young oncologists' programme, and it holds joint sessions with ASCO, ESMO and JSMO. Its leadership includes the heads of the major Chinese cancer centres.","asOf":"2026-09-09","links":[{"label":"CSCO","url":"https://www.csco.org.cn"}],"tags":[],"related":["csco-guidelines"],"cancers":["nsclc","gastric","hcc","esophageal"],"sections":[],"technologies":["checkpoint-inhibitor","adc","bispecific-antibody"],"targets":[],"drugs":["ivonescimab"],"companies":[],"institutions":["sysucc","fuscc","cams-cancer-hospital","west-china","nmpa-cde","asco","esmo"],"pathways":[],"terms":[],"trials":[],"people":["wu-yi-long","li-jin-fuscc","xu-rui-hua"],"bottlenecks":[],"keyPapers":[],"journals":["asia-pacific-journal-of-clinical-oncology"],"dependsOn":[],"notes":[],"city":"Beijing","country":"CN","lat":39.904,"lng":116.407,"institutionType":"consortium","website":"https://www.csco.org.cn","programs":["CSCO Annual Meeting","CSCO clinical guidelines (annual, by cancer)","CSCO Foundation research grants","Expert committees and international collaboration"]},{"id":"chongqing-university-cancer-hospital","kind":"institution","name":"Chongqing University Cancer Hospital","aka":["Chongqing Cancer Hospital","重庆大学附属肿瘤医院"],"tldr":"Chongqing University Cancer Hospital is the main cancer centre for south-west China's largest city and a growing site for domestic trials.","summary":"Chongqing University Cancer Hospital, formerly Chongqing Cancer Hospital, is the main cancer centre for south-west China's largest city and a growing site for domestic trials. It is a municipal cancer centre with more than a thousand beds, holds the regional cancer registry role for Chongqing, takes part in national screening programmes, and enrols patients in registration trials of Chinese PD-1 antibodies, antibody-drug conjugates and kinase inhibitors. Its place in OnCo is as one of the large provincial and municipal centres through which China's domestic drug pipeline reaches patients outside Beijing, Shanghai and Guangzhou. Whether its registry data become publicly usable for research is the question a reader should ask. Its regional centre and clinical trials programmes are listed below.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.cqch.cn/"}],"tags":["china"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["screening","pivotal-trial","tki-term"],"trials":[],"people":["wang-ying"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Chongqing","country":"CN","lat":29.532,"lng":106.469,"institutionType":"cancer-center","website":"https://www.cqch.cn/","university":"Chongqing University","programs":["Regional cancer centre for Chongqing","Clinical trials"]},{"id":"chris-hani-baragwanath","kind":"institution","name":"Chris Hani Baragwanath Academic Hospital","aka":["Baragwanath Hospital","Bara"],"tldr":"One of the largest hospitals in the world, in Soweto, and a University of the Witwatersrand teaching hospital with a large medical oncology and paediatric oncology service.","summary":"Chris Hani Baragwanath Academic Hospital in Soweto is among the largest hospitals in the world by bed numbers and is a teaching hospital of the University of the Witwatersrand. Its cancer services include medical oncology, paediatric haematology-oncology, surgical oncology and breast and gynaecological cancer clinics for a very large public-sector population, with radiotherapy referred to the Charlotte Maxeke Johannesburg Academic Hospital. The hospital hosts research on breast cancer in African women (the South African Breast Cancer and HIV Outcomes study), HIV-associated malignancies and paediatric cancer outcomes, and trains a large share of South Africa's oncology workforce.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.chrishanibaragwanathhospital.co.za"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["wits-charlotte-maxeke"],"pathways":[],"terms":[],"trials":[],"people":["sandile-mfenyana"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Johannesburg (Soweto)","country":"ZA","lat":-26.261,"lng":27.942,"institutionType":"hospital","website":"https://www.chrishanibaragwanathhospital.co.za","university":"University of the Witwatersrand","programs":["Medical oncology","Paediatric oncology","Breast cancer research in African women"]},{"id":"chris-obrien-lifehouse","kind":"institution","name":"Chris O'Brien Lifehouse","aka":["Lifehouse","Sydney Cancer Centre"],"tldr":"Sydney's not-for-profit comprehensive cancer hospital, founded in memory of head and neck surgeon Chris O'Brien and integrated with Royal Prince Alfred and the University of Sydney.","summary":"Chris O'Brien Lifehouse opened in Camperdown in 2013, realising the vision of Professor Chris O'Brien, a head and neck surgeon who died of glioblastoma in 2009, for a single integrated cancer hospital on the Royal Prince Alfred campus. It combines surgical, medical and radiation oncology, one of Australia's largest head and neck cancer units and the Sydney Head and Neck Cancer Institute, sarcoma and gynaecological oncology, a phase 1 unit, and integrative and supportive care under one roof, with research through the University of Sydney and the Melanoma Institute Australia next door. Lifehouse has been an early Australian adopter of robotic surgery, MR-guided radiotherapy and theranostics.","asOf":"2026-09-09","links":[{"label":"Chris O'Brien Lifehouse","url":"https://www.mylifehouse.org.au"},{"label":"Sydney Head and Neck Cancer Institute","url":"https://www.shnci.org"}],"tags":[],"related":["integrative-oncology"],"cancers":["head-and-neck","sarcoma","melanoma","ovarian"],"sections":["surgery","radiation","supportive-care"],"technologies":["robotic-surgery","mr-linac","radioligand-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["michael-boyer"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Sydney","country":"AU","lat":-33.889,"lng":151.185,"institutionType":"cancer-center","website":"https://www.mylifehouse.org.au","university":"University of Sydney","programs":["Head and neck cancer","Sarcoma","Phase 1 trials","Integrative and supportive care"]},{"id":"cmc-vellore","kind":"institution","name":"Christian Medical College, Vellore","aka":["CMC Vellore"],"tldr":"A mission hospital and medical college with India's leading haematology department, known for low-cost bone marrow transplant, gene therapy research and paediatric leukaemia care.","summary":"Christian Medical College, Vellore, was founded in 1900 by American missionary Ida Scudder and is one of India's most respected teaching hospitals. Its Department of Haematology, built by Mammen Chandy and Alok Srivastava, performed India's first successful bone marrow transplant in 1986 and pioneered low-cost transplant, thalassaemia and haemophilia gene therapy, and its Centre for Stem Cell Research is a national translational hub; paediatric and adult leukaemia care and the Indian Collaborative Childhood Leukaemia group's trials are anchored here. CMC also runs large head and neck, gastrointestinal, gynaecological and radiation oncology services and pioneered India's community health and palliative care models.","asOf":"2026-09-09","links":[{"label":"CMC Vellore","url":"https://www.cmch-vellore.edu"}],"tags":[],"related":["global-oncology-access","palliative-care"],"cancers":["all-leukemia","aml","multiple-myeloma","head-and-neck"],"sections":["cell-therapy","supportive-care"],"technologies":["allogeneic-cell-therapy","car-t"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["biju-george"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Vellore","country":"IN","lat":12.925,"lng":79.135,"institutionType":"hospital","website":"https://www.cmch-vellore.edu","programs":["Haematology and bone marrow transplant","Centre for Stem Cell Research","Paediatric leukaemia","Palliative care"]},{"id":"chu-de-quebec","kind":"institution","name":"CHU de Québec - Université Laval","aka":["L'Hôtel-Dieu de Québec","CHU de Québec"],"tldr":"Quebec City's university hospital network, whose L'Hôtel-Dieu de Québec site is the cancer centre for eastern Quebec.","summary":"The CHU de Québec - Université Laval is one of Canada's largest academic hospital networks, formed from five Quebec City hospitals. Its L'Hôtel-Dieu de Québec site is the regional cancer centre for eastern Quebec, with radiation oncology, medical oncology, haematology, surgical oncology and one of the province's busiest clinical trials programmes; a new integrated cancer centre is being built as part of the network's hospital complex. The CHU de Québec research centre, with the Université Laval Cancer Research Centre, is known for prostate cancer genetics and endocrinology, breast cancer, and radiotherapy physics.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.chudequebec.ca"}],"tags":[],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["chum"],"pathways":[],"terms":[],"trials":[],"people":["martin-beaumont"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Québec City","country":"CA","lat":46.813,"lng":-71.222,"institutionType":"hospital","website":"https://www.chudequebec.ca","university":"Université Laval","programs":["Regional cancer centre (L'Hôtel-Dieu de Québec)","Prostate cancer research","Radiotherapy"]},{"id":"chulabhorn-hospital","kind":"institution","name":"Chulabhorn Hospital / Chulabhorn Royal Academy","aka":["Chulabhorn Cancer Center","HRH Princess Chulabhorn College of Medical Science","โรงพยาบาลจุฬาภรณ์"],"tldr":"A royal-founded cancer hospital in Bangkok specialising in advanced diagnostics and nuclear medicine, home to Thailand's first cyclotron-based PET and radioligand therapy programme.","summary":"Chulabhorn Hospital opened in 2009 under the patronage of Princess Chulabhorn as a specialist cancer hospital attached to the Chulabhorn Research Institute, later becoming part of the Chulabhorn Royal Academy with its own college of medical science. It was established to bring advanced cancer diagnostics and treatment to Thai patients regardless of means, and is known for molecular imaging and nuclear medicine, including PSMA and DOTATATE PET and lutetium and actinium radioligand therapy, for a national cancer screening and early detection programme in underserved provinces, and for chemical carcinogenesis research at the Chulabhorn Research Institute. The academy operates a growing cancer centre and trains medical and allied health professionals.","asOf":"2026-09-09","links":[{"label":"Chulabhorn Hospital","url":"https://www.chulabhornhospital.com"},{"label":"Chulabhorn Royal Academy","url":"https://www.cra.ac.th"}],"tags":[],"related":[],"cancers":["prostate","neuroendocrine","hcc","cervical"],"sections":["radiopharma","early-detection"],"technologies":["radioligand-therapy","psma-pet","pet-ct","targeted-alpha-therapy"],"targets":[],"drugs":["lutathera","pluvicto"],"companies":[],"institutions":[],"pathways":[],"terms":["theranostics"],"trials":[],"people":["princess-chulabhorn"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Bangkok","country":"TH","lat":13.885,"lng":100.571,"institutionType":"cancer-center","website":"https://www.chulabhornhospital.com","programs":["Nuclear medicine and theranostics","Cancer screening outreach","Chulabhorn Research Institute","Medical education"]},{"id":"city-of-hope","kind":"institution","name":"City of Hope","aka":[],"tldr":"Los Angeles cancer centre where synthetic insulin and humanised antibodies were developed; a CAR-T manufacturing leader.","summary":"City of Hope in Duarte, near Los Angeles, is an NCI comprehensive cancer centre where synthetic insulin and humanised antibodies were developed, and it is now a leader in CAR-T manufacturing and in CAR-T for brain tumours. Christine E. Brown and Behnam Badie developed IL13Rα2 CAR-T for glioblastoma, the centre runs in-house cell manufacturing and a large transplant programme, and it acquired Cancer Treatment Centers of America, with Robert W. Stone, Steven T. Rosen, Stephen J. Forman, Michael A. Caligiuri, Hope S. Rugo and Alex F. Herrera among the people OnCo lists. OnCo links it to glioma and paediatric neuroblastoma, to the idea of delivering CAR-T straight into the cerebrospinal fluid, and to City of Hope Orange County. The brain as a barrier and sanctuary is the bottleneck its flagship programme confronts. Its CAR-T for glioma and transplant programmes are the ones to read.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.cityofhope.org"}],"tags":[],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":["car-t","biology-guided-radiotherapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["robert-stone","steven-rosen","christine-brown","behnam-badie","virginia-sun","stephen-forman","sumanta-pal","yuman-fong","alex-herrera","hope-rugo","michael-caligiuri","annette-walker"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Duarte, CA","country":"US","lat":34.13,"lng":-117.971,"institutionType":"cancer-center","website":"https://www.cityofhope.org","nci":"comprehensive","programs":["CAR-T for glioma","Transplant"]},{"id":"city-of-hope-orange-county","kind":"institution","name":"City of Hope Orange County","aka":["Lennar Foundation Cancer Center"],"tldr":"City of Hope's Orange County campus, opened in 2022 to bring NCI comprehensive centre-level cancer care and trials to Irvine.","summary":"City of Hope Orange County opened the Lennar Foundation Cancer Center in Irvine in 2022, extending City of Hope's Duarte-based NCI comprehensive cancer centre into Orange County, with a specialty cancer hospital planned on the same campus. The site offers City of Hope's clinical trial portfolio, precision medicine, cellular therapy and surgical oncology closer to a population of more than three million people, and is part of a national network that also includes the former Cancer Treatment Centers of America hospitals in Atlanta, Chicago and Phoenix. It complements UC Irvine's Chao Family Comprehensive Cancer Center in the same county.","asOf":"2026-09-09","links":[{"label":"City of Hope Orange County","url":"https://www.cityofhope.org/orange-county"},{"label":"City of Hope","url":"https://www.cityofhope.org"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["car-t","cgp"],"targets":[],"drugs":[],"companies":[],"institutions":["city-of-hope","uci-chao"],"pathways":[],"terms":[],"trials":[],"people":["annette-walker"],"bottlenecks":["b-care-fragmentation","b-trial-enrolment"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Irvine, CA","country":"US","lat":33.657,"lng":-117.76,"institutionType":"cancer-center","website":"https://www.cityofhope.org/orange-county","programs":["Community access to phase 1-3 trials","Precision medicine","Cellular therapy"]},{"id":"cleveland-clinic-abu-dhabi","kind":"institution","name":"Cleveland Clinic Abu Dhabi","aka":["CCAD","Fatima bint Mubarak Center"],"tldr":"The Gulf's most advanced private academic hospital, whose Fatima bint Mubarak Center opened in 2023 as the UAE's first integrated cancer centre with proton therapy planned.","summary":"Cleveland Clinic Abu Dhabi opened on Al Maryah Island in 2015 as a Mubadala-owned hospital run by the US Cleveland Clinic, replicating its institute model and physician-led culture. In 2023 it opened the Fatima bint Mubarak Center, a purpose-built integrated cancer centre offering medical, surgical and radiation oncology, haematology and bone marrow transplant, CAR-T therapy, theranostics and precision oncology with molecular tumour boards linked to Cleveland Clinic's Taussig Cancer Institute, and it is developing proton therapy for the UAE. The hospital's research and innovation units run clinical trials and AI-in-oncology projects and it serves as a regional destination for complex cancer surgery and multi-organ transplant.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Cleveland_Clinic_Abu_Dhabi","links":[{"label":"Cleveland Clinic Abu Dhabi","url":"https://www.clevelandclinicabudhabi.ae"}],"tags":[],"related":[],"cancers":["breast-hr-positive","colorectal","dlbcl","prostate"],"sections":["cell-therapy","radiopharma"],"technologies":["car-t","radioligand-therapy","robotic-surgery","proton-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["cleveland-clinic","tawam-hospital"],"pathways":[],"terms":[],"trials":[],"people":["georges-pascal-haber","florian-roser"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Abu Dhabi","country":"AE","lat":24.5,"lng":54.379,"institutionType":"hospital","website":"https://www.clevelandclinicabudhabi.ae","programs":["Fatima bint Mubarak Center","CAR-T and transplant","Theranostics and precision oncology","Robotic surgery"]},{"id":"cleveland-clinic","kind":"institution","name":"Cleveland Clinic Taussig Cancer Institute","aka":[],"tldr":"Cleveland Clinic is a top US hospital with a Comprehensive Cancer Center (with Case Western) and a TNBC preventive vaccine programme.","summary":"Cleveland Clinic Taussig Cancer Institute is the cancer arm of a top US hospital, NCI-designated as comprehensive through its partnership in the Case Comprehensive Cancer Center with Case Western, and twentieth in the Newsweek/Statista oncology ranking. It is best known in OnCo for Vincent K. Tuohy's alpha-lactalbumin preventive vaccine for triple-negative breast cancer, which is in phase 1, and for strengths in genitourinary oncology and haematology, with Eric A. Klein, Jaroslaw P. Maciejewski and Jame Abraham among its people. OnCo links it to work on bariatric surgery and cancer incidence, to the idea of joining bariatric and GLP-1 registries to cancer registries, and to Cleveland Clinic Abu Dhabi and the Ellison Institute of Technology. Whether a preventive vaccine can be proved in healthy women is the open question its flagship programme faces. Its programmes are listed below.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://my.clevelandclinic.org/departments/cancer"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":["tnbc"],"sections":[],"technologies":["shared-antigen-vaccine","proton-therapy","proton-therapy-systems","gamma-knife","radiosurgery-srs"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["vincent-tuohy","timothy-chan","jame-abraham","justin-lathia","jaroslaw-maciejewski","nathan-pennell","eric-klein","shilpa-gupta"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Cleveland","country":"US","lat":41.503,"lng":-81.621,"institutionType":"hospital","website":"https://my.clevelandclinic.org/departments/cancer","nci":"comprehensive","newsweekOncology2026":20,"programs":["TNBC preventive vaccine","GU oncology","Haematology"]},{"id":"cdisc","kind":"institution","name":"Clinical Data Interchange Standards Consortium","aka":["CDISC"],"tldr":"The non-profit that writes the clinical trial data standards (SDTM, ADaM, CDASH) that FDA, PMDA and NMPA require for every cancer drug submission.","summary":"Founded in 1997, CDISC develops open, global standards for collecting, structuring and submitting clinical research data. Its Study Data Tabulation Model and Analysis Data Model are mandatory for new drug applications to the US FDA and Japan's PMDA and accepted by China's NMPA, and its Controlled Terminology, CDASH data collection standards and Therapeutic Area User Guides (including for breast, prostate and lung cancer and for oncology endpoints such as RECIST) make trial data comparable across sponsors. CDISC standards underpin data sharing platforms such as Vivli and Project Data Sphere and the pooled analyses that regulators and academics run on legacy oncology trials. It works with HL7 on mapping trial standards to FHIR healthcare data.","asOf":"2026-09-09","links":[{"label":"CDISC","url":"https://www.cdisc.org"},{"label":"Standards","url":"https://www.cdisc.org/standards"}],"tags":[],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["fda-oce","pmda","nmpa-cde","nci","hl7","vivli"],"pathways":[],"terms":["recist","real-world-evidence"],"trials":[],"people":["chris-decker"],"bottlenecks":["b-data-silos","b-regulatory-fragmentation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Austin, TX","country":"US","lat":30.267,"lng":-97.743,"institutionType":"consortium","website":"https://www.cdisc.org","programs":["SDTM, ADaM and CDASH standards","Oncology Therapeutic Area User Guides","Controlled Terminology (with NCI EVS)","CDISC-HL7 FHIR alignment"]},{"id":"cold-spring-harbor","kind":"institution","name":"Cold Spring Harbor Laboratory","aka":[],"tldr":"Basic-science cancer centre where RAS biology, tumour suppressors, and organoid models were advanced.","summary":"Cold Spring Harbor Laboratory in New York is a basic-science cancer centre with NCI basic designation, where RAS biology, tumour suppressors and organoid models were advanced. Its best-known cancer work is David A. Tuveson's pancreatic cancer organoids, Lowe's p53 and senescence biology and Christopher R. Vakoc's BET and SWI/SNF work, with Bruce W. Stillman, Adrian R. Krainer, Tobias Janowitz and Semir Beyaz also listed. OnCo links it to pancreatic ductal adenocarcinoma, to patient-derived organoids and PDAC organoid pharmacotyping, to the autophagy, cachexia, senescence, MYC and TGF-beta pathways, and to the Lustgarten Foundation. Lab models that fail to predict what happens in patients are the bottleneck its organoid work is meant to relieve, and an open organoid bank for rare cancers is one idea it is linked to. Its pancreatic organoid and p53 programmes are listed below.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Cold_Spring_Harbor_Laboratory","links":[{"label":"Official website","url":"https://www.cshl.edu"}],"tags":[],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":["organoids"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["bruce-stillman","christopher-vakoc","adrian-krainer","tobias-janowitz","semir-beyaz","david-tuveson"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Cold Spring Harbor, NY","country":"US","lat":40.859,"lng":-73.468,"institutionType":"research-institute","website":"https://www.cshl.edu","nci":"basic","programs":["Pancreatic organoids","p53 biology"]},{"id":"cofepris","kind":"institution","name":"Comisión Federal para la Protección contra Riesgos Sanitarios","aka":["COFEPRIS"],"tldr":"Mexico's federal health regulator, which registers cancer medicines and has adopted reliance on FDA and EMA approvals to speed access.","summary":"COFEPRIS, part of Mexico's Secretaría de Salud, was created in 2001 and regulates medicines, devices, food and sanitary risks. It has implemented equivalence and reliance agreements that recognise approvals by the FDA, EMA, Health Canada and other reference regulators, shortening review times for new oncology drugs, and is recognised by the Pan American Health Organization as a regional reference authority. Public sector access depends on separate inclusion in the national formulary and procurement by IMSS, ISSSTE and the federal system, so registration is only the first hurdle for Mexican patients. COFEPRIS also regulates tobacco and clinical trial authorisation.","asOf":"2026-09-09","links":[{"label":"COFEPRIS","url":"https://www.gob.mx/cofepris"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["fda-oce","ema","anvisa"],"pathways":[],"terms":[],"trials":[],"people":["victor-hugo-borja-aburto"],"bottlenecks":["b-global-access","b-regulatory-fragmentation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Mexico City","country":"MX","lat":19.433,"lng":-99.133,"institutionType":"government","website":"https://www.gob.mx/cofepris","programs":["Drug registration and reliance on reference regulators","Clinical trial authorisation","PAHO regional reference authority","Tobacco and sanitary risk regulation"]},{"id":"ccc-freiburg","kind":"institution","name":"Comprehensive Cancer Center Freiburg (CCCF)","aka":["Tumorzentrum Freiburg","Universitätsklinikum Freiburg"],"tldr":"Freiburg's university cancer centre, known for transplant immunology, graft-versus-host disease research and PSMA-PET-guided radiotherapy.","summary":"The CCCF is a German Cancer Aid Oncology Center of Excellence and a DKTK partner site within the Medical Center, University of Freiburg. Its haematology department is a leading centre for allogeneic transplantation and for the biology and treatment of graft-versus-host disease, where Robert Zeiser's work underpinned the ruxolitinib REACH trials. Radiation oncology under Anca-Ligia Grosu pioneered PSMA-PET-guided planning for prostate cancer, and the centre runs tumour immunology, urology, gastrointestinal surgery and paediatric programmes. Freiburg's Signalling Research clusters and the Max Planck Institute of Immunobiology feed basic science into the clinic.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.uniklinik-freiburg.de/cccf.html"},{"label":"Medical Center Freiburg","url":"https://www.uniklinik-freiburg.de"}],"tags":[],"related":[],"cancers":["aml","prostate","cll","colorectal"],"sections":["radiation","cell-therapy"],"technologies":["psma-pet","imrt-igrt","allogeneic-cell-therapy","sbrt"],"targets":[],"drugs":[],"companies":[],"institutions":["dkfz"],"pathways":[],"terms":[],"trials":[],"people":["elisabeth-schorb"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Freiburg im Breisgau","country":"DE","lat":48.005,"lng":7.837,"institutionType":"cancer-center","website":"https://www.uniklinik-freiburg.de/cccf.html","university":"Albert-Ludwigs-Universität Freiburg","programs":["Allogeneic transplantation and GVHD","PSMA-PET-guided radiotherapy","Tumour immunology","Urological oncology"]},{"id":"ccc-wuerzburg","kind":"institution","name":"Comprehensive Cancer Center Mainfranken, University Hospital Würzburg","aka":["CCC Mainfranken","Universitätsklinikum Würzburg","NCT WERA"],"tldr":"The university where Röntgen discovered X-rays, now a world centre for CAR-T and bispecific antibodies in multiple myeloma under Hermann Einsele.","summary":"Wilhelm Conrad Röntgen discovered X-rays at Würzburg in 1895, the founding moment of radiation medicine. Today the CCC Mainfranken is a German Cancer Aid Oncology Center of Excellence and, with Erlangen, Regensburg and Augsburg, one of the National Center for Tumor Diseases sites (NCT WERA) since 2023. Hermann Einsele's Department of Internal Medicine II has been a leading European site for BCMA-directed CAR-T and bispecific antibodies in myeloma, including the CARTITUDE and MajesTEC programmes, and was among the first in Europe to treat patients with these agents. The centre also has strong programmes in stem cell transplantation, neuro-oncology, nuclear medicine and theranostics, and translational immunology.","asOf":"2026-09-09","links":[{"label":"CCC Mainfranken","url":"https://www.ccc.ukw.de"},{"label":"Universitätsklinikum Würzburg","url":"https://www.ukw.de"},{"label":"NCT WERA","url":"https://www.nct-wera.de"}],"tags":[],"related":[],"cancers":["multiple-myeloma","aml","dlbcl"],"sections":["cell-therapy","radiation"],"technologies":["car-t","bispecific-antibody","t-cell-engager","radioligand-therapy"],"targets":["bcma","gprc5d"],"drugs":["ciltacabtagene-autoleucel","teclistamab"],"companies":["johnson-johnson","legend-biotech"],"institutions":[],"pathways":[],"terms":["crs","icans"],"trials":[],"people":["ralf-c-bargou"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Würzburg","country":"DE","lat":49.802,"lng":9.957,"institutionType":"cancer-center","website":"https://www.ccc.ukw.de","university":"Julius-Maximilians-Universität Würzburg","programs":["Multiple myeloma CAR-T and bispecifics","Stem cell transplantation","Theranostics","NCT WERA"]},{"id":"ccc-tuebingen","kind":"institution","name":"Comprehensive Cancer Center Tübingen-Stuttgart","aka":["CCC Tübingen","Universitätsklinikum Tübingen","NCT SouthWest"],"tldr":"The CCC Tübingen-Stuttgart is where Hans-Georg Rammensee's group mapped tumour-presented HLA peptides and spawned Immatics and CureVac; its dermatology clinic is one of Europe's largest melanoma centres and its imaging centre pioneered combined PET/MRI.","summary":"The CCC Tübingen-Stuttgart is a German Cancer Aid Oncology Center of Excellence, DKTK partner site and, since 2023, part of the National Center for Tumor Diseases SouthWest. Hans-Georg Rammensee's immunology department mapped tumour-presented HLA peptides and spawned Immatics (TCR-based therapies) and, with Ingmar Hoerr, CureVac (mRNA), while the university's dermatology clinic is one of Europe's major melanoma centres. The Werner Siemens Imaging Center under Bernd Pichler pioneered combined PET/MRI, and the hospital runs large haematology, neuro-oncology and paediatric oncology programmes. Patients have access to peptide vaccine and TCR-T trials as well as molecular tumour boards.","asOf":"2026-09-09","links":[{"label":"CCC Tübingen-Stuttgart","url":"https://www.medizin.uni-tuebingen.de/ccc"},{"label":"Universitätsklinikum Tübingen","url":"https://www.medizin.uni-tuebingen.de"},{"label":"NCT SouthWest","url":"https://www.nct-suedwest.de"}],"tags":[],"related":[],"cancers":["melanoma","glioblastoma","aml","hcc"],"sections":["immunotherapy","imaging"],"technologies":["shared-antigen-vaccine","tcr-t","pet-mri","neoantigen-mrna-vaccine"],"targets":[],"drugs":["afamitresgene-autoleucel"],"companies":["immatics"],"institutions":["dkfz"],"pathways":[],"terms":["neoantigen"],"trials":[],"people":["maximilian-niyazi","lars-zender","sara-brucker"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Tübingen","country":"DE","lat":48.521,"lng":9.057,"institutionType":"cancer-center","website":"https://www.medizin.uni-tuebingen.de/ccc","university":"Eberhard Karls Universität Tübingen","programs":["Tumour immunology and peptide vaccines","Melanoma","PET/MRI and preclinical imaging","NCT SouthWest","Paediatric oncology"]},{"id":"ccc-vienna","kind":"institution","name":"Comprehensive Cancer Center Vienna, Medical University of Vienna / AKH","aka":["CCC Vienna","MedUni Wien","Allgemeines Krankenhaus Wien"],"tldr":"Austria's leading academic cancer centre at the Vienna General Hospital, known for the ABCSG breast trials, brain metastasis research and the MedAustron ion therapy centre.","summary":"The Comprehensive Cancer Center Vienna joins the Medical University of Vienna and the Vienna General Hospital (AKH), one of Europe's largest hospitals. Michael Gnant's Austrian Breast and Colorectal Cancer Study Group ran the ABCSG-12 and ABCSG-18 trials that defined adjuvant bone-targeted therapy and co-led the PALLAS trial of adjuvant palbociclib, Matthias Preusser's neuro-oncology group is a European reference for brain metastases and glioma trials, and Ulrich Jäger's haematology division leads lymphoma and CAR-T programmes. The university's radiation oncology department under Dietmar Georg provides the clinical programme at MedAustron in Wiener Neustadt, Austria's proton and carbon-ion therapy centre. The CCC also hosts the Institute of Cancer Research and a large phase 1 unit.","asOf":"2026-09-09","links":[{"label":"CCC Vienna","url":"https://www.ccc.ac.at"},{"label":"ABCSG","url":"https://www.abcsg.at"},{"label":"MedAustron","url":"https://www.medaustron.at/en/"}],"tags":[],"related":[],"cancers":["breast-hr-positive","glioblastoma","cll","dlbcl","colorectal"],"sections":["hormonal","radiation"],"technologies":["cdk46-inhibitor","carbon-ion","proton-therapy","car-t","endocrine-therapy"],"targets":[],"drugs":["palbociclib"],"companies":["curie-nki-eortc","big"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["shahrokh-f-shariat","nicole-concin"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Vienna","country":"AT","lat":48.22,"lng":16.347,"institutionType":"cancer-center","website":"https://www.ccc.ac.at","university":"Medizinische Universität Wien","programs":["Austrian Breast and Colorectal Cancer Study Group","Brain metastases and neuro-oncology","MedAustron proton and carbon-ion therapy","Haematology and CAR-T","Phase 1 unit"]},{"id":"cork-university-hospital","kind":"institution","name":"Cork University Hospital / UCC Cancer Centre","aka":["CUH"],"tldr":"The largest hospital in Ireland and the designated cancer centre for the south of the country, accredited by OECI as a Cancer Centre with University College Cork.","summary":"Cork University Hospital is the largest university teaching hospital in Ireland and one of the eight designated cancer centres of the National Cancer Control Programme, serving Munster. The CUH/UCC Cancer Centre combines medical oncology, radiation oncology, haematology and surgical oncology with the research of University College Cork's Cancer Research @UCC and APC Microbiome Ireland, and is accredited by the Organisation of European Cancer Institutes as a Cancer Centre. Its trials unit is part of Cancer Trials Ireland and the hospital hosts the regional radiotherapy centre for the south-west.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.cuh.hse.ie"}],"tags":["oeci-accredited","oeci-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["dearbhaile-collins"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Cork","country":"IE","lat":51.884,"lng":-8.503,"institutionType":"hospital","website":"https://www.cuh.hse.ie","university":"University College Cork","programs":["Designated cancer centre","Radiation oncology","Cancer Research @UCC"]},{"id":"curanosticum","kind":"institution","name":"Curanosticum Wiesbaden-Frankfurt","aka":[],"tldr":"Curanosticum is a nuclear medicine practice in Wiesbaden and Frankfurt led by Richard Baum, one of the pioneers of peptide receptor radionuclide therapy, offering FAPI PET and investigational radioligand therapies.","summary":"Curanosticum Wiesbaden-Frankfurt describes itself as modern nuclear medicine in the Rhine-Main region: precise diagnostics and individual therapy from an experienced team. Led by Richard Baum, it offers FAPI PET imaging and investigational radioligand therapies alongside established theranostics, and is patient-bookable through an oncology referral.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.curanosticum.de/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["radioligand-therapy","fapi-pet","lu177-radioligand-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["richard-baum"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Wiesbaden","country":"DE","lat":50.08,"lng":8.24,"institutionType":"hospital","website":"https://www.curanosticum.de/","programs":[]},{"id":"damon-runyon","kind":"institution","name":"Damon Runyon Cancer Research Foundation","aka":["Damon Runyon"],"tldr":"A New York foundation that has funded early-career cancer scientists since 1946; its alumni include a dozen Nobel laureates.","summary":"Founded in 1946 in memory of the writer Damon Runyon, the foundation supports young scientists at the riskiest stage of their careers through Fellowship, Clinical Investigator, Physician-Scientist Training and Innovation awards, on the view that bold early bets pay off. Its alumni have gone on to lead cancer centres and to win the Nobel Prize, and its Clinical Investigator Award protects time for physician-scientists to run trials. Damon Runyon funds across all cancers and all approaches and spends every dollar donated on research, with administrative costs covered by its endowment.","asOf":"2026-09-09","links":[{"label":"Damon Runyon","url":"https://www.damonrunyon.org"}],"tags":[],"related":[],"cancers":[],"sections":["drug-discovery"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mskcc","dana-farber","ucsf","stanford"],"pathways":[],"terms":[],"trials":[],"people":["walter-winchell","yung-s-lie"],"bottlenecks":["b-workforce","b-funding-allocation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"New York","country":"US","lat":40.751,"lng":-73.987,"institutionType":"consortium","website":"https://www.damonrunyon.org","programs":["Damon Runyon Fellowship Award","Clinical Investigator Award","Physician-Scientist Training Award","Innovation Award"]},{"id":"baylor-duncan","kind":"institution","name":"Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine","aka":["Duncan Cancer Center"],"tldr":"Baylor's Duncan Comprehensive Cancer Center sits in Houston's Texas Medical Center; its Center for Cell and Gene Therapy pioneered virus-specific T cells and ran the first GD2 CAR-T trial in neuroblastoma in 2008, and its genome centre sequenced tumours for The Cancer Genome Atlas.","summary":"NCI-designated in 2007 and comprehensive since 2015, the Duncan Comprehensive Cancer Center sits beside MD Anderson in Houston's Texas Medical Center and works through Baylor St. Luke's, Texas Children's and the Michael E. DeBakey VA hospitals. Its Center for Cell and Gene Therapy (Malcolm Brenner, Helen Heslop, Cliona Rooney) pioneered virus-specific T cells, multi-antigen T cells and, in 2008, the first GD2 CAR-T trial in neuroblastoma; it spun out several cell therapy companies. The Human Genome Sequencing Center under Richard Gibbs sequenced tumours for The Cancer Genome Atlas, and the Lester and Sue Smith Breast Center (Kent Osborne, Matthew Ellis, Rachel Schiff) is a leader in endocrine resistance.","asOf":"2026-09-09","links":[{"label":"Dan L Duncan Comprehensive Cancer Center (page moved; nearest live section)","url":"https://www.bcm.edu/"}],"tags":[],"related":[],"cancers":["neuroblastoma","breast-hr-positive","hodgkin-lymphoma"],"sections":["cell-therapy"],"technologies":["car-t","allogeneic-cell-therapy","wes-wgs","endocrine-therapy"],"targets":["gd2"],"drugs":[],"companies":[],"institutions":["texas-childrens"],"pathways":[],"terms":[],"trials":[],"people":["pavan-reddy"],"bottlenecks":["b-manufacturing-cell-therapy"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Houston, TX","country":"US","lat":29.709,"lng":-95.398,"institutionType":"cancer-center","website":"https://www.bcm.edu/","nci":"comprehensive","university":"Baylor College of Medicine","programs":["Cell and gene therapy","Cancer genomics (HGSC)","Breast cancer endocrine resistance"]},{"id":"dana-farber","kind":"institution","name":"Dana-Farber Brigham Cancer Center","aka":[],"tldr":"Where chemotherapy began (Farber, 1948) and where much of modern breast, lung, and myeloma oncology was defined.","summary":"Dana-Farber Brigham Cancer Center in Boston is where chemotherapy began, with Farber's aminopterin remissions in 1948, and through Dana-Farber/Harvard Cancer Center it is the largest NCI-designated centre by grant funding and fifteenth in the Newsweek/Statista oncology list. Its firsts include the discovery of EGFR mutations in lung cancer by Jänne and Johnson, KEYNOTE-522 leadership by Tolaney with Schmid in triple-negative breast cancer, Anderson's myeloma drug development and the Profile genomic testing programme. OnCo links it to BWEL and RASolute 302, to pathology foundation models from the Mahmood and Yu labs, to the Cancer Dependency Map and clonal haematopoiesis papers, and to people including Paul G. Richardson, Benjamin L. Ebert and Ann H. Partridge. Data silos are the bottleneck OnCo records against it. Its breast, lung, myeloma and paediatric programmes are listed below.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.dana-farber.org"}],"tags":[],"related":["break-through-cancer"],"cancers":["tnbc","nsclc","multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["keynote-522"],"people":["paul-richardson","eliezer-van-allen","elizabeth-mittendorf","anthony-damico","joaquim-bellmunt","patrick-wen","ravindra-uppaluri","george-demetri","richard-stone","steven-treon","jennifer-brown","nikhil-munshi","gordon-freeman","catherine-wu","alan-dandrea","ann-partridge","benjamin-ebert","f-stephen-hodi","judy-garber","kenneth-anderson","nancy-lin","pasi-janne","sara-tolaney","toni-choueiri","ursula-matulonis","william-kaelin"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Boston","country":"US","lat":42.338,"lng":-71.108,"institutionType":"cancer-center","website":"https://www.dana-farber.org","nci":"comprehensive","newsweekOncology2026":15,"university":"Harvard University","programs":["Breast oncology (KEYNOTE-522, ADCs)","Lung cancer genomics","Myeloma","Paediatric oncology"]},{"id":"dartmouth-cancer-center","kind":"institution","name":"Dartmouth Cancer Center","aka":["Norris Cotton Cancer Center"],"tldr":"Dartmouth Cancer Center serves rural northern New England as an NCI comprehensive centre; its immunologists founded Medarex, whose human antibody platform produced ipilimumab and nivolumab, and the Dartmouth Institute's work on overdiagnosis has shaped the cancer screening debate.","summary":"NCI-designated since 1978 and comprehensive since 1990, Dartmouth Cancer Center (renamed from Norris Cotton in 2022) serves northern New England from Dartmouth-Hitchcock Medical Center. Medarex, the company whose fully human antibody platform produced ipilimumab and nivolumab before Bristol Myers Squibb acquired it in 2009, was founded in 1987 by Dartmouth immunologists. The Dartmouth Institute's health-policy research, including Gilbert Welch's work on overdiagnosis, has shaped debate on cancer screening. Current research programmes cover immunology and cancer immunotherapy, cancer biology, and rural cancer control.","asOf":"2026-09-09","links":[{"label":"Dartmouth Cancer Center","url":"https://cancer.dartmouth.edu"},{"label":"Clinical trials","url":"https://cancer.dartmouth.edu/clinical-trials"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":[],"technologies":["checkpoint-inhibitor","monoclonal-antibody"],"targets":["ctla4","pd1"],"drugs":["ipilimumab","nivolumab"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-overdiagnosis","b-care-fragmentation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Lebanon, NH","country":"US","lat":43.676,"lng":-72.273,"institutionType":"cancer-center","website":"https://cancer.dartmouth.edu","nci":"comprehensive","university":"Dartmouth College","programs":["Cancer immunology","Overdiagnosis and screening policy","Rural cancer care"]},{"id":"mit-koch","kind":"institution","name":"David H. Koch Institute for Integrative Cancer Research at MIT","aka":["Koch Institute","MIT Center for Cancer Research"],"tldr":"MIT's cancer research institute, where the first human oncogene and RB were found and where biology meets engineering; Moderna's academic root.","summary":"Founded in 1974 by Salvador Luria as the MIT Center for Cancer Research and reborn as the Koch Institute in 2007, this NCI basic laboratory centre pairs cancer biologists with engineers. Robert Weinberg identified the first human oncogene (RAS) and the first tumour suppressor gene (RB) and co-wrote 'The Hallmarks of Cancer'; Phillip Sharp discovered RNA splicing (Nobel Prize 1993); Tyler Jacks built the genetically engineered mouse models of KRAS/p53 lung cancer used worldwide. Robert Langer's drug-delivery laboratory co-founded Moderna and dozens of companies, Sangeeta Bhatia develops synthetic biomarkers and nanotechnology for early detection, and Darrell Irvine designs nanoparticle vaccines and cytokine engineering. The institute's Bridge Project funds joint work with the Dana-Farber/Harvard Cancer Center.","asOf":"2026-09-09","links":[{"label":"Koch Institute","url":"https://ki.mit.edu"}],"tags":[],"related":["break-through-cancer"],"cancers":[],"sections":["drug-discovery"],"technologies":["neoantigen-mrna-vaccine","cytokine-therapy","pdx-models"],"targets":["kras","tp53"],"drugs":[],"companies":["moderna"],"institutions":["dana-farber","broad-institute"],"pathways":[],"terms":["oncogene-addiction"],"trials":[],"people":["matthew-vander-heiden","robert-langer","regina-barzilay"],"bottlenecks":["b-preclinical-models","b-early-detection"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Cambridge, MA","country":"US","lat":42.362,"lng":-71.091,"institutionType":"research-institute","website":"https://ki.mit.edu","nci":"basic","university":"Massachusetts Institute of Technology","programs":["Cancer biology (oncogenes, mouse models)","Drug delivery and nanomedicine","Engineered immunotherapy","Bridge Project with DF/HCC"]},{"id":"rabin-davidoff-center","kind":"institution","name":"Davidoff Cancer Center, Rabin Medical Center","aka":["Beilinson Hospital","Davidoff Center"],"tldr":"One of Israel's largest cancer centres, at the Clalit-run Rabin Medical Center (Beilinson) near Tel Aviv.","summary":"The Davidoff Cancer Center is the oncology institute of Rabin Medical Center, the Clalit Health Services hospital in Petah Tikva affiliated with Tel Aviv University's Faculty of Medicine. It provides medical oncology, radiotherapy, haematology and bone marrow transplantation, surgical oncology and supportive care for a large population and is one of the country's busiest clinical trial sites, with research strengths in lung cancer, breast cancer, gastrointestinal oncology and cancer genetics. The Felsenstein Medical Research Center on the campus supports translational research.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://hospitals.clalit.co.il/rabin"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["tel-aviv-sourasky","sheba","tel-aviv-university"],"pathways":[],"terms":[],"trials":[],"people":["erez-barenboim","gal-markel"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Petah Tikva","country":"IL","lat":32.088,"lng":34.862,"institutionType":"hospital","website":"https://hospitals.clalit.co.il/rabin","university":"Tel Aviv University","programs":["Medical oncology and trials","Radiotherapy","Bone marrow transplantation"]},{"id":"dbt-india","kind":"institution","name":"Department of Biotechnology, Government of India","aka":["DBT","BIRAC","Biotechnology Industry Research Assistance Council"],"tldr":"The government department that funds India's life-science institutes and, through BIRAC, the start-ups behind the country's indigenous CAR-T therapies and HPV vaccine.","summary":"The Department of Biotechnology was created in 1986 under the Ministry of Science and Technology. It runs autonomous institutes including the National Institute of Immunology (Delhi), the National Centre for Cell Science (Pune), the Institute for Stem Cell Science and Regenerative Medicine (Bengaluru), the Translational Health Science and Technology Institute (Faridabad), the Rajiv Gandhi Centre for Biotechnology (Thiruvananthapuram) and the Institute of Life Sciences (Bhubaneswar), and funds industry through the Biotechnology Industry Research Assistance Council (BIRAC), a public sector undertaking that supports biotech commercialisation.\n\nFor cancer, DBT and BIRAC grants sit behind much of the indigenous pipeline: the IIT Bombay and Tata Memorial CAR-T programme that became NexCAR19, academic cell therapy and gene therapy at inStem and CMC Vellore, and the development and rollout of the Serum Institute's quadrivalent HPV vaccine.","asOf":"2026-09-10","links":[{"label":"Department of Biotechnology (archived copy)","url":"https://web.archive.org/web/20260209042353/https://dbtindia.gov.in/"},{"label":"BIRAC","url":"https://birac.nic.in"}],"tags":[],"related":[],"cancers":[],"sections":["cell-therapy","drug-discovery","prevention"],"technologies":["car-t","hpv-vaccine","point-of-care-cell-manufacturing"],"targets":[],"drugs":[],"companies":["immunoact","serum-institute-of-india"],"institutions":["instem","iit-bombay","cmc-vellore"],"pathways":[],"terms":[],"trials":[],"people":["rajesh-gokhale"],"bottlenecks":["b-translational-valley","b-manufacturing-cell-therapy"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"New Delhi","country":"IN","lat":28.588,"lng":77.222,"institutionType":"government","website":"https://web.archive.org/web/20260209042353/https://dbtindia.gov.in/","programs":["Autonomous life-science institutes","BIRAC start-up and translational grants","Cell and gene therapy programmes","Vaccine development support"]},{"id":"derriford-plymouth","kind":"institution","name":"Derriford Hospital, University Hospitals Plymouth","aka":["University Hospitals Plymouth NHS Trust"],"tldr":"The HPB specialist centre for the South West Peninsula (Devon, Cornwall and the Isles of Scilly); a BILCAP site.","summary":"University Hospitals Plymouth is one of the trusts the National Pancreatic Cancer Audit identifies as an HPB specialist centre for England; Pancreatic Cancer UK lists Derriford as serving the South West Peninsula. Derriford recruited to BILCAP.","asOf":"2026-09-24","links":[{"label":"University Hospitals Plymouth","url":"https://www.plymouthhospitals.nhs.uk/"},{"label":"Pancreatic Cancer UK centres list","url":"https://www.pancreaticcancer.org.uk/information-and-support/your-care/your-local-pancreatic-cancer-specialist-centre/"}],"tags":["hpb","nhs","uk"],"related":[],"cancers":["gallbladder","biliary-tract-cancer","cholangiocarcinoma","pancreatic","hcc"],"sections":["surgery"],"technologies":["hepatectomy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["bilcap"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Plymouth","country":"GB","lat":50.417,"lng":-4.113,"institutionType":"hospital","website":"https://www.plymouthhospitals.nhs.uk/","programs":["HPB surgery","Specialist HPB MDT"]},{"id":"deutsche-krebsgesellschaft","kind":"institution","name":"Deutsche Krebsgesellschaft","aka":["DKG","German Cancer Society","OnkoZert","Nationales Zertifizierungsprogramm Krebs"],"tldr":"The German Cancer Society, which with Deutsche Krebshilfe writes the published criteria that a German cancer centre must meet, has them audited on site every year by OnkoZert, and publishes every centre's numbers against them.","summary":"The Deutsche Krebsgesellschaft is the largest scientific oncological society in the German-speaking countries, based in Berlin, and it runs two systems that shape German cancer care more than any guideline elsewhere does. The first is certification. Commissions of about thirty mandated members, drawn from some fifty learned societies, professional bodies and patient organisations, write an Erhebungsbogen per entity setting minimum case numbers per centre and per named surgeon, tumour board frequency and attendance, psycho-oncology and social work staffing, a study participation quota and follow-up rates; OnkoZert, an independent institute in Neu-Ulm, audits centres on site with trained oncologist auditors; a separate committee awards the certificate, which is valid three years with an annual surveillance audit. The first breast centres were certified against a 2003 Erhebungsbogen and entities have been added almost every year since. At 31 December 2025 there were 2,294 certified centres across 2,429 sites, more than 190 of them outside Germany, and certified centres reported 322,486 primary cases for the 2024 data year.\n\nThe second is the Leitlinienprogramm Onkologie, which the society runs with the AWMF and Deutsche Krebshilfe, producing 38 S3 guidelines and 36 patient versions. The two are linked: the quality indicators extracted from the guidelines are what the certification audits measure. The WiZen study of AOK claims linked to four cancer registries found lower mortality after first treatment in a certified hospital for most of eleven cancers, though the authors and their critics disagree about how much of that is case volume and case mix.","asOf":"2026-09-25","links":[{"label":"Deutsche Krebsgesellschaft","url":"https://www.krebsgesellschaft.de"},{"label":"Certification","url":"https://www.krebsgesellschaft.de/zertifizierung.html"},{"label":"OnkoZert","url":"https://www.onkozert.de"},{"label":"OncoMap","url":"https://www.oncomap.de"},{"label":"Leitlinienprogramm Onkologie","url":"https://www.leitlinienprogramm-onkologie.de"},{"label":"WiZen (Dtsch Arztebl Int 2023)","url":"https://doi.org/10.3238/arztebl.m2023.0169"}],"tags":[],"related":[],"cancers":[],"sections":["supportive-care"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["deutsche-krebshilfe","dkfz","g-ba-iqwig","charite","heidelberg-nct","nct-dresden","essen-wtz"],"pathways":[],"terms":["hta"],"trials":[],"people":[],"bottlenecks":["b-care-fragmentation","b-knowledge-diffusion"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Berlin","country":"DE","lat":52.507,"lng":13.286,"institutionType":"consortium","website":"https://www.krebsgesellschaft.de","programs":["Certification of organ cancer centres, oncology centres and modules (with OnkoZert)","Leitlinienprogramm Onkologie (S3 guidelines, with AWMF and Deutsche Krebshilfe)","Annual reports of quality indicators per entity","OncoMap centre directory","Deutscher Krebskongress"]},{"id":"deutsche-krebshilfe","kind":"institution","name":"Deutsche Krebshilfe","aka":["German Cancer Aid","Stiftung Deutsche Krebshilfe"],"tldr":"Deutsche Krebshilfe, founded in 1974 by Mildred Scheel, is Germany's largest donation-funded cancer charity; since 2007 it has funded and audited the Oncology Centres of Excellence network that certifies Germany's comprehensive cancer centres.","summary":"Founded in 1974 by Mildred Scheel, Deutsche Krebshilfe is funded entirely by donations and finances research, structural programmes and patient information. Its Oncology Centres of Excellence programme has funded and audited Germany's comprehensive cancer centres (including Heidelberg, Cologne, Berlin, Hamburg and Munich) since 2007, and it co-created the National Cancer Plan and the Mildred Scheel early-career programmes. It funds clinical trials, paediatric oncology, cancer prevention research and the Krebsinformationsdienst partnership with DKFZ, and it runs the INFONETZ KREBS patient information service.","asOf":"2026-09-09","links":[{"label":"Deutsche Krebshilfe","url":"https://www.krebshilfe.de"}],"tags":[],"related":[],"cancers":[],"sections":["prevention"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["dkfz","heidelberg-nct","uniklinik-koeln","charite","uke-hamburg","lmu-munich"],"pathways":[],"terms":[],"trials":[],"people":["rita-schmutzler"],"bottlenecks":["b-care-fragmentation","b-funding-allocation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Bonn","country":"DE","lat":50.737,"lng":7.098,"institutionType":"consortium","website":"https://www.krebshilfe.de","programs":["Oncology Centres of Excellence (Onkologische Spitzenzentren)","Mildred Scheel early-career programmes","Clinical trial and prevention research funding","INFONETZ KREBS patient information"]},{"id":"dnpm","kind":"institution","name":"Deutsches Netzwerk für Personalisierte Medizin","aka":["DNPM","Zentren für Personalisierte Medizin","ZPM"],"tldr":"The network of German university centres for personalised medicine, which gives patients one route into a molecular tumour board wherever they live and is now named in the social code as a route into the national genome sequencing project.","summary":"The Deutsches Netzwerk für Personalisierte Medizin describes itself as a cooperation of 26 German university hospitals building Zentren für Personalisierte Medizin (ZPM) alongside the existing centres in Freiburg, Heidelberg, Tübingen and Ulm; its centre list names 27 sites. The oldest constituent, the ZPM in Tübingen, was founded in 2015 and has been named in the Baden-Württemberg hospital plan since November 2019; the Charité has run a molecular tumour conference since 2016. Its stated purpose is transparent and standardised routes of access to personalised medicine, regional networks around each centre, and the linking of data holdings for care and research. The mechanism at each site is the molecular tumour board: an interdisciplinary case conference that analyses the molecular profile and issues a molecularly directed treatment recommendation, which the referring doctor then delivers.\n\nSection 64e SGB V names the DNPM, the nNGM, the German Consortium for Hereditary Breast and Ovarian Cancer, the DKTK and the NCT as the networked oncology centres that may take part in the national model project on genome sequencing, so the network now has a statutory role. The same statute's contract cuts the other way too: patients already diagnosed through a DNPM centre are in principle excluded from the model project, which is how Germany avoids paying twice for the same sequencing.","asOf":"2026-09-25","links":[{"label":"DNPM","url":"https://dnpm.de"},{"label":"The DNPM centres","url":"https://dnpm.de/de/zentren-des-dnpm"},{"label":"Section 64e SGB V","url":"https://www.gesetze-im-internet.de/sgb_5/__64e.html"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["ngs","genomic-profiling"],"targets":[],"drugs":[],"companies":[],"institutions":["heidelberg-nct","nct-dresden","charite","ccc-tuebingen","ccc-freiburg","ulm-university-hospital","uniklinik-koeln","bfarm","nngm"],"pathways":[],"terms":[],"trials":[],"people":["stefan-froehling","hanno-glimm","lars-zender"],"bottlenecks":["b-biomarker-validation","b-care-fragmentation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Tübingen","country":"DE","lat":48.521,"lng":9.058,"institutionType":"consortium","website":"https://dnpm.de","programs":["Zentren für Personalisierte Medizin at university hospitals","Molecular tumour boards","Standardised access routes and data linkage","Named participant in the section 64e model project"]},{"id":"dharmais-cancer-hospital","kind":"institution","name":"Dharmais National Cancer Center","aka":["Dharmais Cancer Hospital","RS Kanker Dharmais","Pusat Kanker Nasional"],"tldr":"Indonesia's national cancer centre and referral hospital, coordinating cancer registration, screening and treatment standards for the world's fourth most populous country.","summary":"Dharmais Cancer Hospital opened in Jakarta in 1993 and was designated Indonesia's National Cancer Center by the Ministry of Health, serving as the top referral hospital for cancer and the coordinator of the national cancer registry, cancer control programme and clinical guidelines. It offers surgical, medical, radiation and paediatric oncology, nuclear medicine, bone marrow transplant and palliative care, and hosts Indonesia's largest oncology training and research programmes, including cervical cancer screening initiatives, breast cancer early-detection campaigns and participation in Asian multicentre trials. Dharmais collaborates with international partners on capacity building for radiotherapy and cancer registration across Indonesia's provinces.","asOf":"2026-09-09","links":[{"label":"Dharmais National Cancer Center","url":"https://dharmais.co.id"}],"tags":[],"related":["global-oncology-access","cancer-registries-surveillance"],"cancers":["cervical","breast-hr-positive","head-and-neck","hcc"],"sections":["prevention","radiation"],"technologies":["hpv-vaccine","brachytherapy"],"targets":[],"drugs":[],"companies":[],"institutions":["iarc"],"pathways":[],"terms":[],"trials":[],"people":["eniarti"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Jakarta","country":"ID","lat":-6.187,"lng":106.792,"institutionType":"cancer-center","website":"https://dharmais.co.id","programs":["National Cancer Center","Indonesian cancer registry","Cervical and breast screening","Radiotherapy capacity"]},{"id":"rogachev-centre","kind":"institution","name":"Dmitry Rogachev National Medical Research Centre of Paediatric Haematology, Oncology and Immunology","aka":["НМИЦ ДГОИ им. Дмитрия Рогачева","Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии имени Дмитрия Рогачева","Rogachev Centre","Federal Research Institute of Pediatric Hematology, Oncology and Immunology"],"tldr":"Russia's national children's cancer and blood-disease hospital in south-west Moscow, which runs the country's paediatric transplant, immunology and reference-diagnosis programmes.","summary":"The centre, on Samory Mashela Street in Moscow, is the Russian federal hospital for childhood leukaemia, solid tumours, bone marrow failure and primary immunodeficiency. Its own site describes consultation, day-case and inpatient services, a bone marrow donor programme, reference centres for partner hospitals, residency and doctoral training, and the journal Voprosy gematologii/onkologii i immunopatologii v pediatrii (Вопросы гематологии/онкологии и иммунопатологии в педиатрии). It appears on ClinicalTrials.gov as the Federal Research Institute of Pediatric Hematology, Oncology and Immunology, and is among the most frequent Russian academic sponsors of registered cancer trials both before and after 2022.","asOf":"2026-09-25","links":[{"label":"Official website (Russian)","url":"https://fnkc.ru"},{"label":"About the centre (Russian)","url":"https://fnkc.ru/o-tsentre/"},{"label":"ClinicalTrials.gov: studies led by the institute","url":"https://clinicaltrials.gov/search?lead=Federal%20Research%20Institute%20of%20Pediatric%20Hematology%2C%20Oncology%20and%20Immunology"}],"tags":[],"related":["blokhin-cancer-center"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Moscow","country":"RU","lat":55.643,"lng":37.52,"institutionType":"hospital","website":"https://fnkc.ru","programs":["Paediatric leukaemia and lymphoma","Haematopoietic stem cell transplantation","Primary immunodeficiency","Reference diagnosis for partner hospitals"]},{"id":"docrates","kind":"institution","name":"Docrates Cancer Center","aka":[],"tldr":"Docrates is a private cancer clinic in Helsinki, founded in 2009, that serves international patients with diagnostics, treatment and follow-up under one personal care team.","summary":"Docrates Cancer Center in Helsinki provides high-quality individual diagnostics and the latest treatments to Finnish and international patients under a personal care team model, and is bookable internationally according to Future of Cancer Care Today.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Docrates_Cancer_Center","links":[{"label":"Official website","url":"https://docrates.mehilainen.fi/en/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["multidisciplinary-tumour-board"],"targets":[],"drugs":[],"companies":["future-of-cancer-care-today"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Helsinki","country":"FI","lat":60.16,"lng":24.93,"institutionType":"cancer-center","website":"https://docrates.mehilainen.fi/en/","programs":[]},{"id":"dokuz-eylul-institute-of-oncology","kind":"institution","name":"Dokuz Eylül University Institute of Oncology","aka":["Dokuz Eylul University Instıtute of Oncology","DEÜ Onkoloji Enstitüsü"],"tldr":"Dokuz Eylül University Institute of Oncology is the oncology institute of Dokuz Eylül University in İzmir, combining cancer research with graduate training, and an associate member of the Organisation of European Cancer Institutes.","summary":"Dokuz Eylül University Institute of Oncology is the oncology institute of Dokuz Eylül University in İzmir, combining cancer research with graduate training. It is listed by the Organisation of European Cancer Institutes as an associate member, which is why it has a page on OnCo. Programme, trial and leadership details are not yet recorded here and should be checked on the institution's own pages.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://onkoloji.deu.edu.tr"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["refik-emre-cecen"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"İzmir","country":"TR","lat":38.392,"lng":27.046,"institutionType":"research-institute","website":"https://onkoloji.deu.edu.tr","programs":[]},{"id":"duke-cancer-institute","kind":"institution","name":"Duke Cancer Institute","aka":[],"tldr":"One of the original NCI comprehensive centres (1973), famous for brain tumour research including the polio-virus immunotherapy for glioblastoma.","summary":"Duke has held NCI comprehensive designation since 1973. The Preston Robert Tisch Brain Tumor Center, built by Darell Bigner, developed the recombinant polio-rhinovirus PVSRIPO oncolytic immunotherapy for recurrent glioblastoma and, with Hai Yan, helped define IDH mutations in glioma. Duke investigators helped lead pivotal HER2 breast cancer trials including EMILIA (trastuzumab emtansine), and its prostate programme (Andrew Armstrong, Daniel George) is a fixture of Alliance and NCI trials. The Duke Clinical Research Institute is the largest academic clinical research organisation in the world and runs many oncology trials. Michael Kastan's DNA-damage biology and dendritic cell vaccine work under Smita Nair anchor the basic and immunology programmes.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Duke_Cancer_Institute","links":[{"label":"Duke Cancer Institute","url":"https://dukecancerinstitute.org"},{"label":"Clinical trials","url":"https://dukecancerinstitute.org/clinical-trials"},{"label":"Tisch Brain Tumor Center","url":"https://tischbraintumorcenter.duke.edu"}],"tags":[],"related":[],"cancers":["glioblastoma","prostate","breast-her2-positive"],"sections":[],"technologies":["oncolytic-virus"],"targets":["idh"],"drugs":["trastuzumab-emtansine"],"companies":["alliance-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["scott-antonia","andrew-armstrong"],"bottlenecks":["b-brain-delivery","b-trial-design"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Durham, NC","country":"US","lat":36.008,"lng":-78.94,"institutionType":"cancer-center","website":"https://dukecancerinstitute.org","nci":"comprehensive","university":"Duke University","programs":["Neuro-oncology (Tisch Brain Tumor Center)","Oncolytic virus immunotherapy","Prostate cancer","Clinical trials (DCRI)"]},{"id":"ospedali-galliera","kind":"institution","name":"E.O. Ospedali Galliera","aka":["Galliera Hospital","Ospedale Galliera Genova"],"tldr":"Genoa hospital whose medical oncology division, under Andrea DeCensi, ran TAM-01, the trial that showed low-dose tamoxifen prevents breast cancer recurrence after non-invasive disease.","summary":"The Ospedali Galliera is a public hospital in the centre of Genoa. Its Division of Medical Oncology, led by Andrea DeCensi, has specialised in breast cancer prevention and low-dose drug strategies, coordinating TAM-01, the Italian randomised trial reported in the Journal of Clinical Oncology in 2019 in which tamoxifen at 5 mg a day reduced recurrence and new breast cancers after ductal carcinoma in situ and other non-invasive lesions.","asOf":"2026-09-18","links":[{"label":"Ospedali Galliera","url":"https://www.galliera.it"}],"tags":[],"related":[],"cancers":["breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["andrea-decensi"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Genoa","country":"IT","lat":44.399,"lng":8.947,"institutionType":"hospital","website":"https://www.galliera.it","programs":["Breast cancer prevention","Low-dose tamoxifen trials"]},{"id":"east-midlands-cancer-alliance","kind":"institution","name":"East Midlands Cancer Alliance","aka":["EMCA"],"tldr":"The NHS England Cancer Alliance for the East Midlands, including Nottinghamshire, Derbyshire, Leicestershire, Lincolnshire and Northamptonshire: the partnership that plans and improves cancer services across its hospitals, GPs and community services.","summary":"One of the 20 Cancer Alliances set up by NHS England from 2016, following the Independent Cancer Taskforce strategy, to bring together the hospital trusts, integrated care boards, primary care, hospices and charities serving the East Midlands, including Nottinghamshire, Derbyshire, Leicestershire, Lincolnshire and Northamptonshire. Alliances lead local delivery of the NHS cancer ambitions: earlier diagnosis (including rapid diagnostic centres and targeted lung health checks), the Faster Diagnosis Standard, personalised care and follow-up, and workforce and pathway improvement. They hold transformation funding from NHS England and publish local performance and improvement plans.","asOf":"2026-09-09","links":[{"label":"East Midlands Cancer Alliance","url":"https://www.eastmidlandscanceralliance.nhs.uk"},{"label":"NHS England: Cancer Alliances","url":"https://www.england.nhs.uk/cancer/cancer-alliances-improving-care-locally/"}],"tags":["nhs-cancer-alliance"],"related":[],"cancers":[],"sections":["early-detection"],"technologies":["low-dose-ct-screening"],"targets":[],"drugs":[],"companies":[],"institutions":["nottingham-cancer-centre","leicester-cancer-research-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Nottingham","country":"GB","lat":52.954,"lng":-1.158,"institutionType":"consortium","website":"https://www.eastmidlandscanceralliance.nhs.uk","programs":["Earlier diagnosis and rapid diagnostic centres","Faster Diagnosis Standard","Personalised care and follow-up","Cancer pathway improvement"]},{"id":"east-of-england-cancer-alliance","kind":"institution","name":"East of England Cancer Alliance","aka":["EoE Cancer Alliance"],"tldr":"The NHS England Cancer Alliance for the East of England, from Norfolk and Suffolk through Cambridgeshire, Bedfordshire and Hertfordshire to Essex: the partnership that plans and improves cancer services across its hospitals, GPs and community services.","summary":"One of the 20 Cancer Alliances set up by NHS England from 2016, following the Independent Cancer Taskforce strategy, to bring together the hospital trusts, integrated care boards, primary care, hospices and charities serving the East of England, from Norfolk and Suffolk through Cambridgeshire, Bedfordshire and Hertfordshire to Essex. Alliances lead local delivery of the NHS cancer ambitions: earlier diagnosis (including rapid diagnostic centres and targeted lung health checks), the Faster Diagnosis Standard, personalised care and follow-up, and workforce and pathway improvement. They hold transformation funding from NHS England and publish local performance and improvement plans.","asOf":"2026-09-09","links":[{"label":"East of England Cancer Alliance","url":"https://www.canceralliance.co.uk"},{"label":"NHS England: Cancer Alliances","url":"https://www.england.nhs.uk/cancer/cancer-alliances-improving-care-locally/"}],"tags":["nhs-cancer-alliance"],"related":[],"cancers":[],"sections":["early-detection"],"technologies":["low-dose-ct-screening"],"targets":[],"drugs":[],"companies":[],"institutions":["cruk-cambridge-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Cambridge","country":"GB","lat":52.205,"lng":0.119,"institutionType":"consortium","website":"https://www.canceralliance.co.uk","programs":["Earlier diagnosis and rapid diagnostic centres","Faster Diagnosis Standard","Personalised care and follow-up","Cancer pathway improvement"]},{"id":"east-tallinn-central-hospital","kind":"institution","name":"East Tallinn Central Hospital","aka":["Ida-Tallinna Keskhaigla","ITK"],"tldr":"East Tallinn Central Hospital is a Tallinn hospital providing cancer care and a full member of the Organisation of European Cancer Institutes.","summary":"East Tallinn Central Hospital (Ida-Tallinna Keskhaigla) is a hospital in the Veerenni area of Tallinn, formed in 2001 by merging earlier city hospitals, that provides surgical, medical and radiation treatment for cancer among its general services. It is listed by the Organisation of European Cancer Institutes as a full member, one of two Tallinn hospitals on the list together with the North Estonia Medical Centre. Programme, trial and leadership details are not yet recorded here and should be checked on the hospital's own pages.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/East_Tallinn_Central_Hospital","links":[{"label":"Official website","url":"https://www.itk.ee"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/East_Tallinn_Central_Hospital"}],"tags":[],"related":["north-estonia-medical-centre"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["tarmo-bakler"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Tallinn","country":"EE","lat":59.426,"lng":24.751,"institutionType":"hospital","website":"https://www.itk.ee","programs":[]},{"id":"edinburgh-cancer-centre","kind":"institution","name":"Edinburgh Cancer Centre / CRUK Scotland Centre","aka":["Western General Hospital","Institute of Genetics and Cancer","NHS Lothian cancer services"],"tldr":"Edinburgh's cancer centre at the Western General, backed by the university's Institute of Genetics and Cancer and known for breast, colorectal genetics and brain tumour research.","summary":"The Edinburgh Cancer Centre at the Western General Hospital serves south-east Scotland with medical and clinical oncology, and sits beside the University of Edinburgh's Institute of Genetics and Cancer, which incorporates the MRC Human Genetics Unit and the CRUK Scotland Centre shared with Glasgow. David Cameron chairs the Breast International Group and leads breast cancer trials from Edinburgh, Malcolm Dunlop's group identified inherited risk variants for colorectal cancer in Scottish populations, and Steven Pollard's laboratory studies glioblastoma stem cells. The Edinburgh Breast Unit is a UK reference for oncoplastic surgery and endocrine therapy studies. The centre is a hub for cancer informatics and the Scottish population health data used in screening research.","asOf":"2026-09-09","links":[{"label":"Edinburgh Cancer Research Centre","url":"https://www.ed.ac.uk/cancer-centre"},{"label":"Institute of Genetics and Cancer","url":"https://www.ed.ac.uk/institute-genetics-cancer"}],"tags":[],"related":[],"cancers":["breast-hr-positive","colorectal","glioblastoma","ovarian"],"sections":["hormonal","diagnostics"],"technologies":["germline-testing","endocrine-therapy","cdk46-inhibitor"],"targets":[],"drugs":[],"companies":["big"],"institutions":["cruk","beatson-glasgow"],"pathways":[],"terms":[],"trials":[],"people":["david-cameron","charlie-gourley"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Edinburgh","country":"GB","lat":55.962,"lng":-3.235,"institutionType":"hospital","website":"https://www.ed.ac.uk/cancer-centre","university":"University of Edinburgh","programs":["Breast cancer trials (BIG)","Colorectal cancer genetics","Glioblastoma biology","CRUK Scotland Centre","Cancer informatics"]},{"id":"ellison-institute","kind":"institution","name":"Ellison Institute of Technology","aka":["EIT","Lawrence J. Ellison Institute for Transformative Medicine","Ellison Medical Institute"],"tldr":"Larry Ellison's research institute, which began in 2016 as a cancer-care institute in Los Angeles and is building a campus at Oxford with a £130 million alliance with the university.","summary":"The Lawrence J. Ellison Institute for Transformative Medicine was founded in 2016 in Los Angeles with a mission to reimagine and redefine cancer care, combining clinical care, research and technology. The Ellison Institute of Technology in Oxford extends the model: its own site describes a campus set for completion in 2027, eventually 2 million square feet for up to 7,000 people, a strategic alliance with the University of Oxford involving an investment of £130 million, a collaboration with Cleveland Clinic to advance research, education and patient care, and scholarships that fully fund Oxford degrees. Its institutes span generative biology, AI and robotics, pathogens and plant biology alongside health and medical science.","asOf":"2026-09-10","links":[{"label":"About EIT","url":"https://eit.org/about/"},{"label":"Ellison Medical Institute","url":"https://ellisonmedicalinstitute.org/"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cleveland-clinic"],"pathways":[],"terms":[],"trials":[],"people":["larry-ellison"],"bottlenecks":["b-funding-allocation","b-translational-valley"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Oxford","country":"GB","lat":51.72,"lng":-1.22,"institutionType":"research-institute","website":"https://eit.org","programs":["Health and medical science","Generative Biology Institute","AI and Robotics Institute","Oxford scholarships"]},{"id":"embl-ebi","kind":"institution","name":"EMBL's European Bioinformatics Institute","aka":["EMBL-EBI","European Bioinformatics Institute","European Molecular Biology Laboratory"],"tldr":"Europe's public data institute for molecular biology, running Ensembl, ChEMBL, Europe PMC, the European Genome-phenome Archive and Open Targets.","summary":"EMBL-EBI is the bioinformatics site of the European Molecular Biology Laboratory (founded 1974; the EBI opened in Hinxton in 1994). It maintains open resources that cancer research runs on: Ensembl genome annotation, UniProt (with SIB and PIR), ChEMBL drug and bioactivity data, the PDBe structure archive, Expression Atlas, Europe PMC literature, the European Genome-phenome Archive for controlled-access patient genomes, and the AlphaFold Protein Structure Database built with Google DeepMind. It is a founding partner of Open Targets with the Sanger Institute and pharmaceutical companies, and trains thousands of scientists a year. EMBL's Heidelberg and other sites contribute structural, cell and imaging biology.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/European_Bioinformatics_Institute","links":[{"label":"Homepage","url":"https://www.ebi.ac.uk"},{"label":"Open Targets","url":"https://www.opentargets.org"},{"label":"Europe PMC","url":"https://europepmc.org"}],"tags":[],"related":["drugbank-chembl","open-targets","pubmed-europepmc","isomorphic-labs"],"cancers":[],"sections":["ai-computation","drug-discovery"],"technologies":["ai-drug-design","proteomics","wes-wgs","rna-seq"],"targets":[],"drugs":[],"companies":[],"institutions":["wellcome-sanger"],"pathways":[],"terms":[],"trials":[],"people":["ewan-birney","julio-saez-rodriguez"],"bottlenecks":["b-data-silos","b-knowledge-diffusion"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Hinxton","country":"GB","lat":52.08,"lng":0.186,"institutionType":"research-institute","website":"https://www.ebi.ac.uk","programs":["Ensembl","ChEMBL","Europe PMC","European Genome-phenome Archive","Open Targets","AlphaFold DB"]},{"id":"emerson-collective","kind":"institution","name":"Emerson Collective","aka":[],"tldr":"Laurene Powell Jobs's philanthropic and investment organisation, whose health programme funds cancer research collaborations and immunotherapy science.","summary":"Emerson Collective, founded by Laurene Powell Jobs, works across education, immigration, climate and health, using grants, investments and convenings. Its health work has funded cancer research including immunotherapy and cancer immunology programmes, collaborations that pair academic centres with technologists, and the Emerson Collective Cancer Research Fund. It has partnered with the Parker Institute for Cancer Immunotherapy and academic centres on data-driven cancer projects and supports patient-navigation and health-equity work. Emerson's model blends philanthropy with venture investing in health companies.","asOf":"2026-09-09","links":[{"label":"Emerson Collective","url":"https://www.emersoncollective.com"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy","ai-computation"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["stanford","ucsf"],"pathways":[],"terms":[],"trials":[],"people":["laurene-powell-jobs"],"bottlenecks":["b-funding-allocation","b-incentive-misalignment"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Palo Alto, CA","country":"US","lat":37.442,"lng":-122.143,"institutionType":"consortium","website":"https://www.emersoncollective.com","programs":["Cancer research and immunotherapy funding","Health-equity and patient navigation","Venture investment in health companies"]},{"id":"erasmus-mc","kind":"institution","name":"Erasmus MC Cancer Institute","aka":["Erasmus MC","Daniel den Hoed","Erasmus University Medical Center"],"tldr":"Rotterdam's OECI-accredited comprehensive cancer centre, where peptide receptor radionuclide therapy with lutetium-177 was pioneered and Europe's largest screening trials were led.","summary":"Erasmus MC Cancer Institute unites the former Daniel den Hoed cancer clinic with the oncology departments of Erasmus University Medical Center and holds OECI comprehensive cancer centre accreditation. Its nuclear medicine group under Eric Krenning and Dik Kwekkeboom developed somatostatin-receptor imaging and then 177Lu-DOTATATE peptide receptor radionuclide therapy for neuroendocrine tumours, the treatment later validated in NETTER-1 and approved as Lutathera. Erasmus MC epidemiologists coordinated the European Randomized Study of Screening for Prostate Cancer and the NELSON lung screening trial, which showed a mortality reduction from low-dose CT screening. The institute co-founded the Holland Proton Therapy Centre in Delft with LUMC and TU Delft, and is a leading sarcoma, breast and neuro-oncology trial site under Stefan Sleijfer.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.erasmusmc.nl/en/cancer-institute"},{"label":"HollandPTC","url":"https://www.hollandptc.nl"}],"tags":[],"related":[],"cancers":["neuroendocrine","prostate","nsclc","sarcoma","glioblastoma"],"sections":["radiopharma","early-detection"],"technologies":["radioligand-therapy","spect","pet-ct","proton-therapy","ct"],"targets":["sstr2"],"drugs":["lutathera"],"companies":["novartis"],"institutions":["nki","oeci"],"pathways":[],"terms":["theranostics","stage-shift"],"trials":[],"people":["harry-de-koning","jan-van-lanschot","martin-van-den-bent","pieter-sonneveld","h-m-w-verheul"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Rotterdam","country":"NL","lat":51.91,"lng":4.468,"institutionType":"cancer-center","website":"https://www.erasmusmc.nl/en/cancer-institute","university":"Erasmus University Rotterdam","programs":["Peptide receptor radionuclide therapy","Cancer screening trials (ERSPC, NELSON)","Holland Proton Therapy Centre","Sarcoma","Neuro-oncology"]},{"id":"eacr","kind":"institution","name":"European Association for Cancer Research","aka":["EACR"],"tldr":"Europe's professional society for cancer researchers, running the EACR Congress and the open-access journal Molecular Oncology.","summary":"Founded in 1968 and based at the University of Nottingham, the European Association for Cancer Research is the membership society for basic, translational and clinical cancer scientists in Europe and beyond. It organises the biennial EACR Congress and a programme of focused conferences and training courses, publishes Molecular Oncology as an open-access journal with FEBS Press, awards travel fellowships and prizes for early-career researchers, and works with the AACR and other societies on global research policy and open science. It is a member of the European Cancer Organisation.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.eacr.org"},{"label":"Molecular Oncology","url":"https://febs.onlinelibrary.wiley.com/journal/18780261"}],"tags":[],"related":[],"cancers":[],"sections":["drug-discovery"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["aacr","ecco","cruk"],"pathways":[],"terms":[],"trials":[],"people":["johanna-joyce"],"bottlenecks":["b-reproducibility","b-knowledge-diffusion","b-translational-valley"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Nottingham","country":"GB","lat":52.938,"lng":-1.197,"institutionType":"consortium","website":"https://www.eacr.org","programs":["EACR Congress","Molecular Oncology journal","Fellowships and training","Research policy"]},{"id":"eanm","kind":"institution","name":"European Association of Nuclear Medicine","aka":["EANM"],"tldr":"Europe's nuclear medicine society, whose congress and guidelines shaped the clinical adoption of PSMA PET and lutetium radioligand therapy that began in European centres.","summary":"Founded in 1985 and based in Vienna, EANM represents nuclear medicine across Europe and publishes the European Journal of Nuclear Medicine and Molecular Imaging. Its annual congress is the largest nuclear medicine meeting in Europe and was the early forum for PSMA-PET and Lu-177 PSMA work from Heidelberg, Munich, Bad Berka and other centres before the VISION trial. EANM issues procedure guidelines with SNMMI on PSMA PET, PRRT for neuroendocrine tumours, dosimetry and FDG PET response criteria, runs the EARL accreditation programme that harmonises PET scanners across trial sites, and operates the European School of Multimodality Imaging and Therapy. It advocates on isotope supply and reimbursement for theranostics in Europe.","asOf":"2026-09-09","links":[{"label":"EANM","url":"https://www.eanm.org"}],"tags":[],"related":[],"cancers":[],"sections":["radiopharma","imaging"],"technologies":["psma-pet","fapi-pet","pet-ct","radioligand-therapy","targeted-alpha-therapy"],"targets":[],"drugs":["pluvicto","lutathera"],"companies":[],"institutions":["snmmi","heidelberg-nct","lmu-munich","estro"],"pathways":[],"terms":["theranostics","dosimetry"],"trials":[],"people":["uwe-haberkorn","frederik-giesel","clemens-kratochwil","paola-anna-erba"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Vienna","country":"AT","lat":48.208,"lng":16.373,"institutionType":"consortium","website":"https://www.eanm.org","programs":["EANM Congress","EARL PET accreditation","Procedure guidelines (with SNMMI)","European Journal of Nuclear Medicine and Molecular Imaging","ESMIT education"]},{"id":"ecco","kind":"institution","name":"European Cancer Organisation","aka":["ECCO","E.C.O.","Federation of European Cancer Societies"],"tldr":"The Brussels-based federation of European oncology societies and patient groups that speaks for the whole cancer community on policy.","summary":"Founded in 1981 as the Federation of European Cancer Societies and later known as ECCO, the European Cancer Organisation is the multidisciplinary umbrella of European professional oncology societies together with a patient advisory committee. It convenes the annual European Cancer Summit, publishes the Essential Requirements for Quality Cancer Care and works through focused networks on topics such as workforce, inequalities, HPV elimination, survivorship and digital health; its 'Time to Act' campaign documented the effect of the COVID-19 pandemic on cancer care. It advocates for Europe's Beating Cancer Plan and the EU Cancer Mission.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.europeancancer.org"},{"label":"European Cancer Summit","url":"https://www.europeancancer.org/summit"}],"tags":[],"related":[],"cancers":[],"sections":["prevention","supportive-care"],"technologies":["hpv-vaccine"],"targets":[],"drugs":[],"companies":["curie-nki-eortc"],"institutions":["esmo","eacr","oeci"],"pathways":[],"terms":[],"trials":[],"people":["elisabetta-zanon"],"bottlenecks":["b-care-fragmentation","b-workforce","b-global-access","b-survivorship"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Brussels","country":"BE","lat":50.836,"lng":4.375,"institutionType":"consortium","website":"https://www.europeancancer.org","programs":["European Cancer Summit","Essential Requirements for Quality Cancer Care","Focused topic networks","Patient Advisory Committee"]},{"id":"eha","kind":"institution","name":"European Hematology Association","aka":["EHA"],"tldr":"Europe's haematology society, whose June congress is the second global venue for blood cancer trials and whose guidelines and curriculum shape European haematology.","summary":"Founded in 1992, EHA represents haematologists across Europe and beyond, with its annual congress each June attracting more than 15,000 delegates and presenting the year's leukaemia, lymphoma and myeloma trial data, second only to ASH. It publishes HemaSphere, issues clinical guidelines and the European Hematology Curriculum, runs research fellowships and the EHA-ASH Translational Research Training in Hematology programme, and advocates in Brussels on medicines regulation, rare diseases and research funding. Its Scientific Working Groups on CLL, myeloma, AML, MDS and lymphoma link the national cooperative groups such as HOVON, GIMEMA and the German study groups.","asOf":"2026-09-09","links":[{"label":"EHA","url":"https://ehaweb.org"}],"tags":[],"related":[],"cancers":["aml","all-leukemia","dlbcl","cll","multiple-myeloma","hodgkin-lymphoma"],"sections":[],"technologies":["car-t","bispecific-antibody","mrd-testing"],"targets":[],"drugs":[],"companies":["hovon","gimema"],"institutions":["ash","ema","esmo"],"pathways":[],"terms":["mrd"],"trials":[],"people":["michael-hallek","lars-bullinger","konstanze-doehner","brian-huntly"],"bottlenecks":[],"keyPapers":[],"journals":["haematologica"],"dependsOn":[],"notes":[],"city":"The Hague","country":"NL","lat":52.08,"lng":4.311,"institutionType":"consortium","website":"https://ehaweb.org","programs":["EHA Congress (June)","HemaSphere","Clinical guidelines and European Hematology Curriculum","Fellowships and EHA-ASH training"]},{"id":"ema","kind":"institution","name":"European Medicines Agency","aka":["EMA","CHMP"],"tldr":"The EU agency whose Committee for Medicinal Products for Human Use recommends the marketing authorisations for cancer drugs across all member states.","summary":"Founded in 1995 in London and relocated to Amsterdam in 2019, the EMA coordinates the scientific evaluation of medicines for the European Union through the centralised procedure, which is mandatory for cancer drugs and advanced therapies. The Committee for Medicinal Products for Human Use (CHMP) issues opinions that the European Commission converts into EU-wide authorisations, while the Committee for Advanced Therapies handles CAR-T and gene therapies and PRIME gives early support to promising medicines. The agency publishes European Public Assessment Reports and clinical data, runs conditional marketing authorisation for unmet need, and since 2025 works alongside the EU Health Technology Assessment Regulation's joint clinical assessments, which begin with oncology medicines. Trial registration runs through CTIS.","asOf":"2026-09-09","links":[{"label":"EMA","url":"https://www.ema.europa.eu"},{"label":"CHMP","url":"https://www.ema.europa.eu/en/committees/committee-medicinal-products-human-use-chmp"}],"tags":[],"related":["src-ema-chmp","eudract-ctis"],"cancers":[],"sections":[],"technologies":["car-t"],"targets":[],"drugs":[],"companies":["curie-nki-eortc"],"institutions":["fda-oce","mhra","nice","has-france","g-ba-iqwig"],"pathways":[],"terms":["accelerated-approval"],"trials":[],"people":["emer-cooke"],"bottlenecks":["b-regulatory-fragmentation","b-global-access"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Amsterdam","country":"NL","lat":52.339,"lng":4.873,"institutionType":"government","website":"https://www.ema.europa.eu","programs":["Centralised procedure and CHMP opinions","Committee for Advanced Therapies","PRIME and conditional marketing authorisation","Clinical data publication and CTIS"]},{"id":"espen","kind":"institution","name":"European Society for Clinical Nutrition and Metabolism","aka":["ESPEN"],"tldr":"The European clinical nutrition society whose guidelines on nutrition in cancer patients define screening for malnutrition and the treatment of cachexia in oncology.","summary":"Founded in 1979, ESPEN promotes research and education in clinical nutrition and metabolism and publishes Clinical Nutrition and its companion journals. Its ESPEN guidelines on nutrition in cancer patients (2017, updated as practical guidelines in 2021) and its expert group recommendations on cancer cachexia set out screening, energy and protein targets, exercise and pharmacological approaches, and they are referenced by ESMO and by national oncology guidelines. ESPEN's GLIM criteria for diagnosing malnutrition, developed with the other regional societies, are used in oncology trials and clinical practice, and its annual congress and Life Long Learning programme train clinicians across Europe.","asOf":"2026-09-09","links":[{"label":"ESPEN","url":"https://www.espen.org"},{"label":"Guidelines","url":"https://www.espen.org/guidelines-home/espen-guidelines"}],"tags":[],"related":[],"cancers":[],"sections":["nutrition-lifestyle","supportive-care"],"technologies":["exercise-oncology","geriatric-assessment"],"targets":[],"drugs":[],"companies":[],"institutions":["mascc","esmo"],"pathways":[],"terms":[],"trials":[],"people":["stanislaw-klek"],"bottlenecks":["b-cachexia-supportive","b-aging-comorbidity"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Luxembourg","country":"LU","lat":49.612,"lng":6.13,"institutionType":"consortium","website":"https://www.espen.org","programs":["ESPEN guidelines on nutrition in cancer","GLIM malnutrition criteria","Clinical Nutrition journals","ESPEN Congress and Life Long Learning"]},{"id":"esmo","kind":"institution","name":"European Society for Medical Oncology (ESMO)","aka":[],"tldr":"ESMO is Europe's oncology society, known for its Congress each autumn and the ESMO-MCBS scale for grading the value of new drugs.","summary":"The European Society for Medical Oncology, based in Lugano, is Europe's oncology society, known for its Congress each autumn, the ESMO Breast meeting, the journals Annals of Oncology and ESMO Open, and the ESMO Magnitude of Clinical Benefit Scale that grades the value of new drugs. It issues clinical practice guidelines that OnCo carries as a collection, and its people include Pilar Garrido, Josep Tabernero, Fabrice André, Giuseppe Curigliano and Andrés Cervantes. OnCo links it to bottlenecks on knowledge reaching practice too slowly and the exclusion of older patients, and to ideas such as capping public drug prices to tiers of the ESMO and ASCO value scales. Whether the MCBS can be made to bite on prices is the open question. Its Congress, MCBS and guideline programmes are listed below.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.esmo.org"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["pilar-garrido","andres-cervantes","nathan-cherny","solange-peters"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Lugano","country":"CH","lat":46.004,"lng":8.951,"institutionType":"consortium","website":"https://www.esmo.org","programs":["ESMO Congress","ESMO-MCBS","Guidelines"]},{"id":"estro","kind":"institution","name":"European Society for Radiotherapy and Oncology","aka":["ESTRO"],"tldr":"Europe's radiation oncology society, running the ESTRO congress, a school that trains much of the world's radiotherapy workforce, and the standards behind brachytherapy and adaptive radiotherapy.","summary":"Founded in 1980, ESTRO represents radiation oncologists, physicists, radiobiologists and radiation therapists across Europe and beyond. Its annual congress is the main European venue for radiotherapy trials, its ESTRO School has taught courses for decades across the world, and it publishes Radiotherapy & Oncology (the Green Journal), Clinical and Translational Radiation Oncology and physics and technical journals. ESTRO consensus guidelines on target volume delineation, GEC-ESTRO brachytherapy recommendations and its ACROP practice guidelines are used globally, and its HERO project quantifies the gap between radiotherapy need and capacity in Europe. ESTRO Vision 2030 argues for radiotherapy for every patient who needs it.","asOf":"2026-09-09","links":[{"label":"ESTRO","url":"https://www.estro.org"}],"tags":[],"related":[],"cancers":[],"sections":["radiation"],"technologies":["imrt-igrt","brachytherapy","mr-linac","proton-therapy","carbon-ion","sbrt"],"targets":[],"drugs":[],"companies":["curie-nki-eortc"],"institutions":["astro","iaea","esmo"],"pathways":[],"terms":[],"trials":[],"people":["vincenzo-valentini","uwe-oelfke","juergen-debus","barbara-jereczek-fossa","matthias-guckenberger"],"bottlenecks":["b-surgery-radiation-innovation","b-global-access"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Brussels","country":"BE","lat":50.85,"lng":4.352,"institutionType":"consortium","website":"https://www.estro.org","programs":["ESTRO annual congress","ESTRO School","GEC-ESTRO brachytherapy and ACROP guidelines","HERO health economics project"]},{"id":"esgo","kind":"institution","name":"European Society of Gynaecological Oncology","aka":["ESGO"],"tldr":"Europe's gynaecologic oncology society, whose joint guidelines with ESTRO and ESP and its centre accreditation programme set European standards for ovarian, cervical and endometrial cancer care.","summary":"Founded in 1983 and headquartered in Prague, ESGO represents gynaecologic oncologists and allied professionals across Europe and runs a biennial congress and a second scientific conference in the alternate years. Its guidelines with ESTRO and ESP on endometrial cancer introduced the molecular classification into routine care, its cervical cancer guidelines with ESTRO and ESP and its ovarian cancer guidelines with ESMO are widely used beyond Europe, and it accredits centres for advanced ovarian cancer surgery and for training through the ESGO Accreditation Programme and the European Network of Young Gynaecological Oncologists. ESGO publishes the International Journal of Gynecological Cancer with IGCS and works with ENGOT on trials and with patient advocacy through ENGAGe.","asOf":"2026-09-09","links":[{"label":"ESGO","url":"https://www.esgo.org"},{"label":"Guidelines","url":"https://guidelines.esgo.org"}],"tags":[],"related":[],"cancers":["ovarian","endometrial","cervical"],"sections":["surgery","radiation"],"technologies":["hipec","robotic-surgery","brachytherapy","parp-inhibitor"],"targets":[],"drugs":[],"companies":["arcagy-gineco"],"institutions":["sgo","gemelli","estro","esmo"],"pathways":[],"terms":[],"trials":[],"people":["anna-fagotti","giovanni-scambia","jalid-sehouli","ane-gerda-eriksson"],"bottlenecks":[],"keyPapers":[],"journals":["international-journal-of-gynecological-cancer"],"dependsOn":[],"notes":[],"city":"Prague","country":"CZ","lat":50.076,"lng":14.437,"institutionType":"consortium","website":"https://www.esgo.org","programs":["ESGO Congress and State of the Art meetings","Joint guidelines (with ESTRO, ESP, ESMO)","Centre accreditation for ovarian cancer surgery","ENGAGe patient advocacy network"]},{"id":"esso","kind":"institution","name":"European Society of Surgical Oncology","aka":["ESSO"],"tldr":"Europe's surgical oncology society, which runs the ESSO congress and courses and sets the European curriculum and examination for cancer surgeons.","summary":"Founded in 1981, ESSO promotes the highest standards of cancer surgery in Europe through its biennial congress (jointly with national societies), hands-on courses in minimally invasive, hepatobiliary, peritoneal and breast surgery, and the European Board of Surgery Qualification in surgical oncology that it runs with UEMS. It publishes the European Journal of Surgical Oncology and works with ESMO and ESTRO on multidisciplinary standards, with the European CanCer Organisation on the essential requirements for quality cancer care, and with the EORTC on surgical quality assurance in trials. ESSO's Young Surgeons and Alumni Club develops the next generation of cancer surgeons across Europe.","asOf":"2026-09-09","links":[{"label":"ESSO","url":"https://www.essoweb.org"}],"tags":[],"related":[],"cancers":[],"sections":["surgery"],"technologies":["robotic-surgery","hipec","sentinel-node","fluorescence-guided-surgery"],"targets":[],"drugs":[],"companies":["curie-nki-eortc"],"institutions":["sso","esmo","estro"],"pathways":[],"terms":[],"trials":[],"people":["alessandro-gronchi","paolo-veronesi","geerard-beets","isabel-rubio"],"bottlenecks":["b-surgery-radiation-innovation","b-care-fragmentation"],"keyPapers":[],"journals":["european-journal-of-surgical-oncology"],"dependsOn":[],"notes":[],"city":"Brussels","country":"BE","lat":50.85,"lng":4.352,"institutionType":"consortium","website":"https://www.essoweb.org","programs":["ESSO Congress and courses","European Board of Surgery Qualification (Surgical Oncology)","European Journal of Surgical Oncology","Surgical quality assurance in trials"]},{"id":"excel-diagnostics-nuclear-oncology","kind":"institution","name":"Excel Diagnostics and Nuclear Oncology Center","aka":[],"tldr":"Excel Diagnostics is a Houston nuclear medicine centre offering molecular imaging and radioligand therapies, bookable through an oncology referral.","summary":"Excel Diagnostics and Nuclear Oncology Center in Houston provides molecular imaging and theranostic treatments, the pairing of a targeted scan with a matched radioactive drug, for patients referred by their oncologists.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://exceldiagnostics.com/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["radioligand-therapy","psma-pet"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["ebrahim-delpassand"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Houston","country":"US","lat":29.74,"lng":-95.56,"institutionType":"hospital","website":"https://exceldiagnostics.com/","programs":[]},{"id":"favo","kind":"institution","name":"FAVO, Italian Federation of Voluntary Associations in Oncology","aka":["Federazione italiana delle Associazioni di Volontariato in Oncologia","FAVO"],"tldr":"Italy's federation of cancer patient and volunteer associations, based in Rome, which publishes an annual report on the condition of people with cancer and is an associate member of the Organisation of European Cancer Institutes.","summary":"FAVO (Federazione italiana delle Associazioni di Volontariato in Oncologia) brings together Italian cancer patient and volunteer associations. Based in Piazza Barberini, Rome, it publishes an annual report on the condition of people living with cancer in Italy and campaigns on patients' rights. It is an associate member of the Organisation of European Cancer Institutes (OECI); its representative on the OECI list is Francesco De Lorenzo.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.favo.it/"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q3741454"}],"tags":[],"related":["airc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["francesco-de-lorenzo"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Rome","country":"IT","lat":41.903,"lng":12.496,"institutionType":"consortium","website":"https://www.favo.it/","programs":[]},{"id":"fda-oce","kind":"institution","name":"FDA Oncology Center of Excellence","aka":["OCE","US Food and Drug Administration","FDA"],"tldr":"The US regulator's oncology hub, which approves cancer drugs, runs accelerated approval and Project Orbis, and is pushing better dose-finding through Project Optimus.","summary":"Created in 2017 under the 21st Century Cures Act and led from its founding by Richard Pazdur, the Oncology Center of Excellence coordinates cancer drug, biologic and device review across FDA centres. Its programmes include Real-Time Oncology Review, Assessment Aid, Project Orbis (concurrent review with Australia, Canada, the UK, Switzerland, Singapore, Brazil and Israel), Project Optimus (dose optimisation before approval), Project FrontRunner (testing new drugs earlier in the disease course), Project Facilitate for expanded access, and Project Confirm, which tracks accelerated approvals and their confirmatory trials. The OCE has led guidance on tissue-agnostic approvals, ctDNA and MRD as endpoints, and patient-reported outcomes, and its Oncologic Drugs Advisory Committee is the public forum where contested approvals are debated.","asOf":"2026-09-09","links":[{"label":"Oncology Center of Excellence","url":"https://www.fda.gov/about-fda/fda-organization/oncology-center-excellence"},{"label":"Hematology/oncology approvals","url":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications"}],"tags":[],"related":["fda-approvals"],"cancers":[],"sections":[],"technologies":["companion-diagnostic","mrd-testing"],"targets":[],"drugs":[],"companies":[],"institutions":["nci","ema","mhra","health-canada","tga","swissmedic"],"pathways":[],"terms":["accelerated-approval","breakthrough-designation","companion-diagnostic-term","tumour-agnostic","real-world-evidence"],"trials":[],"people":["r-angelo-de-claro"],"bottlenecks":["b-dose-optimisation","b-regulatory-fragmentation","b-negative-results"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Silver Spring, MD","country":"US","lat":39.036,"lng":-76.983,"institutionType":"government","website":"https://www.fda.gov/about-fda/fda-organization/oncology-center-excellence","programs":["Accelerated approval and Project Confirm","Project Orbis","Project Optimus (dose optimisation)","Real-Time Oncology Review","Oncologic Drugs Advisory Committee"]},{"id":"fican","kind":"institution","name":"Finnish Cancer Center (FICAN)","aka":["Kansallinen syöpäkeskus","FICAN"],"tldr":"Finland's national cancer centre, a network of the five university hospital regions coordinated from Helsinki, and a full member of the Organisation of European Cancer Institutes.","summary":"The Finnish Cancer Center (Kansallinen syöpäkeskus, FICAN) is a national network linking the five regional cancer centres of Finland's university hospitals, with its coordinating unit in Helsinki alongside Helsinki University Hospital. It works on equal access to care, clinical research and data across the country. It is a full member of the Organisation of European Cancer Institutes (OECI); its representative on the OECI list is Tomi P. Mäkelä.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.fican.fi"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":["helsinki-hus","kuopio-university-hospital","oulu-university-hospital"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["tomi-p-makela"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Helsinki","country":"FI","lat":60.17,"lng":24.938,"institutionType":"consortium","website":"https://www.fican.fi","programs":[]},{"id":"sysu-first-affiliated-hospital","kind":"institution","name":"First Affiliated Hospital of Sun Yat-sen University","aka":["FAH-SYSU","中山大学附属第一医院"],"tldr":"The First Affiliated Hospital of Sun Yat-sen University, founded in 1910, is South China's largest general hospital and the surgical counterpart to SYSUCC; its surgeons ran the CLASS laparoscopic gastrectomy trials and it leads Chinese studies of perioperative immunotherapy in gastric cancer and organ preservation in rectal cancer.","summary":"The First Affiliated Hospital of Sun Yat-sen University, founded in 1910, is one of China's national regional medical centres and a high-volume surgical hospital with recognised gastrointestinal surgery (laparoscopic gastrectomy trials of the CLASS group), hepatobiliary and transplant, thyroid, urological and neuro-oncology services. Its Sixth Affiliated Hospital sister institution is one of China's largest colorectal centres. Investigators have led Chinese trials of perioperative chemotherapy and immunotherapy in gastric cancer and studies of organ preservation in rectal cancer. Patients can access SYSU's shared early-phase infrastructure across the university's hospitals.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/First_Affiliated_Hospital_of_Sun_Yat-sen_University","links":[{"label":"First Affiliated Hospital of SYSU","url":"https://www.fah-sysu.org.cn"},{"label":"Sun Yat-sen University","url":"https://www.sysu.edu.cn"}],"tags":[],"related":[],"cancers":["gastric","colorectal","hcc","thyroid"],"sections":["surgery"],"technologies":["robotic-surgery","hipec"],"targets":[],"drugs":[],"companies":[],"institutions":["sysucc"],"pathways":[],"terms":[],"trials":[],"people":["xiao-haipeng"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Guangzhou","country":"CN","lat":23.128,"lng":113.285,"institutionType":"hospital","website":"https://www.fah-sysu.org.cn","university":"Sun Yat-sen University","programs":["Gastric cancer surgery (CLASS trials)","Hepatobiliary surgery and transplant","Colorectal cancer","Thyroid cancer"]},{"id":"fondation-arc","kind":"institution","name":"Fondation ARC pour la recherche sur le cancer","aka":["ARC","Fondation ARC"],"tldr":"France's largest charitable foundation devoted entirely to cancer research, funding laboratory and clinical projects across the country.","summary":"Founded in 1962 and recognised as a public-utility foundation, Fondation ARC funds cancer research in France through competitive calls: young investigator fellowships, programme grants, translational and clinical research and international collaborations such as the SIGN'IT and PAIR programmes with the Institut National du Cancer. It is based in Villejuif beside Gustave Roussy and publishes patient information on prevention and treatment. ARC has supported early work in tumour immunology, precision oncology and paediatric cancer across French centres including Gustave Roussy, Institut Curie and the UNICANCER network.","asOf":"2026-09-09","links":[{"label":"Fondation ARC","url":"https://www.fondation-arc.org"}],"tags":[],"related":[],"cancers":[],"sections":["drug-discovery","prevention"],"technologies":[],"targets":[],"drugs":[],"companies":["unicancer"],"institutions":["gustave-roussy","institut-curie","ligue-contre-le-cancer"],"pathways":[],"terms":[],"trials":[],"people":["dominique-bazy"],"bottlenecks":["b-funding-allocation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Villejuif","country":"FR","lat":48.792,"lng":2.365,"institutionType":"consortium","website":"https://www.fondation-arc.org","programs":["Programme grants and young investigator fellowships","SIGN'IT and PAIR programmes (with INCa)","Patient information"]},{"id":"airc","kind":"institution","name":"Fondazione AIRC per la ricerca sul cancro","aka":["AIRC","Associazione Italiana per la Ricerca sul Cancro"],"tldr":"Italy's main charitable funder of cancer research, supporting thousands of investigators at IEO, the Istituto Nazionale dei Tumori and universities nationwide.","summary":"Founded in 1965 by Umberto Veronesi and colleagues, AIRC funds investigator grants, the large multi-centre 5x1000 programmes, fellowships and start-up grants, and is the largest non-governmental funder of cancer research in Italy. It has supported the Milan groups behind breast-conserving surgery, sentinel node biopsy and the molecular oncology of leukaemia, and continues to fund immunotherapy, metastasis and early-detection programmes. AIRC's public campaigns (Oranges for Health, Azaleas for Research) are a national fixture, and its FIRC-Institute of Molecular Oncology (IFOM) in Milan is a dedicated research institute.","asOf":"2026-09-09","links":[{"label":"AIRC","url":"https://www.airc.it"}],"tags":[],"related":[],"cancers":[],"sections":["drug-discovery"],"technologies":[],"targets":[],"drugs":[],"companies":["gimema"],"institutions":["ieo-milan","int-milan","gemelli"],"pathways":[],"terms":[],"trials":[],"people":["pier-giuseppe-pelicci","giuseppe-curigliano","andrea-sironi"],"bottlenecks":["b-funding-allocation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Milan","country":"IT","lat":45.464,"lng":9.19,"institutionType":"consortium","website":"https://www.airc.it","programs":["Investigator grants and 5x1000 programmes","IFOM institute","Fellowships and early-career awards","Public fundraising campaigns"]},{"id":"int-milan","kind":"institution","name":"Fondazione IRCCS Istituto Nazionale dei Tumori","aka":[],"tldr":"The Istituto Nazionale dei Tumori is Italy's national cancer institute and a leader in sarcoma, thoracic oncology, and immunotherapy.","summary":"Fondazione IRCCS Istituto Nazionale dei Tumori in Milan is Italy's national cancer institute and ranks twenty-seventh in the Newsweek/Statista oncology list. It is a sarcoma reference centre, with Alessandro Gronchi, Silvia Stacchiotti and Filippo de Braud among its clinicians, and it leads in peritoneal surface malignancy through HIPEC and PIPAC intraperitoneal chemotherapy, alongside thoracic oncology, immunotherapy and early-phase trials. OnCo links it to sarcomas of soft tissue, bone and GIST, to Fondazione AIRC, and to fellow IRCCS institutes San Raffaele and Regina Elena. Whether intraperitoneal chemotherapy earns its place against systemic treatment in randomised trials is the open question its surgical programme faces. Its sarcoma programme is the reason most readers come.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Istituto_Nazionale_dei_Tumori","links":[{"label":"Official website","url":"https://www.istitutotumori.mi.it"}],"tags":[],"related":[],"cancers":["sarcoma"],"sections":[],"technologies":["hipec"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["filippo-de-braud","silvia-stacchiotti","alessandro-gronchi","marco-guzzo","gustavo-galmozzi"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Milan","country":"IT","lat":45.479,"lng":9.213,"institutionType":"cancer-center","website":"https://www.istitutotumori.mi.it","newsweekOncology2026":27,"programs":["Sarcoma","Peritoneal surface malignancy"]},{"id":"policlinico-san-matteo","kind":"institution","name":"Fondazione IRCCS Policlinico San Matteo","aka":["Policlinico San Matteo","San Matteo Pavia"],"tldr":"The Policlinico San Matteo in Pavia, founded in 1449, is one of Italy's oldest and largest teaching hospitals and an associate member of the Organisation of European Cancer Institutes.","summary":"The Fondazione IRCCS Policlinico San Matteo in Pavia, founded in 1449, is one of the oldest and largest teaching hospitals in Italy and a national research hospital (IRCCS) linked to the University of Pavia. Its cancer services include haematology with transplantation, medical oncology and radiotherapy, and it is listed by the Organisation of European Cancer Institutes as an associate member. Programme, trial and leadership details are not yet recorded here and should be checked on the hospital's own pages.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Policlinico_San_Matteo","links":[{"label":"Official website","url":"https://www.sanmatteo.org"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Policlinico_San_Matteo"}],"tags":[],"related":["humanitas","ieo-milan"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["alessandro-venturi"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Pavia","country":"IT","lat":45.196,"lng":9.149,"institutionType":"hospital","website":"https://www.sanmatteo.org","programs":[]},{"id":"fondazione-michelangelo","kind":"institution","name":"Fondazione Michelangelo","aka":["Michelangelo Foundation for the Advancement of the Study and Treatment of Cancer"],"tldr":"Milan research foundation, led by Luca Gianni, that designs and runs academic breast cancer trials such as NeoSphere and the neoadjuvant HER2 studies.","summary":"The Fondazione Michelangelo is an independent, not-for-profit clinical research organisation in Milan founded to run investigator-led cancer trials, chiefly in breast cancer. Under its president Luca Gianni it has coordinated the NeoSphere, NOAH and neoadjuvant biomarker studies that helped establish pathological complete response as an endpoint for HER2-positive breast cancer, and it collaborates with the Fondazione IRCCS Istituto Nazionale dei Tumori and hospitals across Italy.","asOf":"2026-09-18","links":[],"tags":[],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["int-milan"],"pathways":[],"terms":[],"trials":[],"people":["luca-gianni"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Milan","country":"IT","lat":45.478,"lng":9.191,"institutionType":"research-institute","programs":["Breast cancer trials","Neoadjuvant HER2 studies","Translational biomarkers"]},{"id":"fondazione-poliambulanza","kind":"institution","name":"Fondazione Poliambulanza","aka":["Fondazione Poliambulanza Istituto Ospedaliero","Poliambulanza Brescia"],"tldr":"Fondazione Poliambulanza is a non-profit hospital in Brescia, northern Italy, with a cancer programme, and a full member of the Organisation of European Cancer Institutes.","summary":"Fondazione Poliambulanza Istituto Ospedaliero is a private non-profit hospital in Brescia in Lombardy, with origins in 1903, that provides medical oncology, surgery and radiotherapy as part of a general hospital service accredited within the Italian national health system. It is listed by the Organisation of European Cancer Institutes as a full member, one of a small number of Italian general hospitals on the list. Programme, trial and leadership details are not yet recorded here and should be checked on the hospital's own pages.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.poliambulanza.it"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":["humanitas"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["mario-taccolini"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Brescia","country":"IT","lat":45.52,"lng":10.237,"institutionType":"hospital","website":"https://www.poliambulanza.it","programs":[]},{"id":"fondazione-the-bridge","kind":"institution","name":"Fondazione The Bridge","aka":["Fondazione The Bridge ETS"],"tldr":"A Milan-based foundation working on health policy, patient rights and research in cancer, and an associate member of the Organisation of European Cancer Institutes.","summary":"Fondazione The Bridge is a Milan-based non-profit foundation that works across health policy, patient advocacy and research, including cancer. It is an associate member of the Organisation of European Cancer Institutes (OECI). Its representative on the OECI list is Maria Rosaria Iardino.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.fondazionethebridge.it/"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":["int-milan"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["maria-rosaria-iardino"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Milan","country":"IT","lat":45.464,"lng":9.19,"institutionType":"consortium","website":"https://www.fondazionethebridge.it/","programs":[]},{"id":"fox-chase","kind":"institution","name":"Fox Chase Cancer Center","aka":["Fox Chase","Temple Health Fox Chase"],"tldr":"Philadelphia's free-standing cancer centre, where the Philadelphia chromosome, the two-hit hypothesis and hepatitis B were discovered.","summary":"Formed in 1974 from the American Oncologic Hospital (1904) and the Institute for Cancer Research (1927), Fox Chase has held NCI comprehensive designation since 1974 and joined Temple University Health System in 2012. Its scientific record is exceptional: David Hungerford co-discovered the Philadelphia chromosome in 1960, Alfred Knudson proposed the two-hit hypothesis of tumour suppressor genes in 1971, Baruch Blumberg identified hepatitis B and developed its vaccine (Nobel Prize 1976), a cornerstone of liver cancer prevention, and Beatrice Mintz pioneered transgenic mice. Clinical strengths today include kidney and prostate cancer, hereditary cancer risk assessment and radiation oncology.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Fox_Chase_Cancer_Center","links":[{"label":"Fox Chase Cancer Center","url":"https://www.foxchase.org"}],"tags":[],"related":[],"cancers":["cml","hcc","retinoblastoma","rcc","prostate"],"sections":["prevention"],"technologies":["germline-testing"],"targets":["bcr-abl"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["robert-uzzo"],"bottlenecks":["b-hereditary-risk"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Philadelphia, PA","country":"US","lat":40.072,"lng":-75.086,"institutionType":"cancer-center","website":"https://www.foxchase.org","nci":"comprehensive","university":"Temple University","programs":["Kidney cancer","Hereditary cancer risk assessment","Radiation oncology"]},{"id":"nebraska-buffett","kind":"institution","name":"Fred & Pamela Buffett Cancer Center","aka":["UNMC Eppley Cancer Center","Nebraska Medicine cancer center"],"tldr":"Nebraska's NCI-designated centre, a longstanding leader in lymphoma classification and transplant and in pancreatic cancer early detection research.","summary":"The Fred & Pamela Buffett Cancer Center, whose research and hospital tower opened in Omaha in 2017, is the NCI-designated centre of the University of Nebraska Medical Center and Nebraska Medicine, descended from the Eppley Institute (1961). James Armitage and the Nebraska Lymphoma Study Group shaped lymphoma classification and pioneered autologous transplant for lymphoma, a tradition continued by Julie Vose. The pancreatic cancer programme under Michael Hollingsworth holds an NCI SPORE and coordinates early-detection consortia on mucins and biomarkers. Rural outreach across the Great Plains is a defining feature of its catchment.","asOf":"2026-09-09","links":[{"label":"Fred & Pamela Buffett Cancer Center","url":"https://www.unmc.edu/cancercenter/"},{"label":"Nebraska Medicine cancer care","url":"https://www.nebraskamed.com/cancer"}],"tags":[],"related":[],"cancers":["dlbcl","follicular-lymphoma","pancreatic"],"sections":["early-detection"],"technologies":["allogeneic-hsct","pancreatic-surveillance"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["joann-sweasy"],"bottlenecks":["b-early-detection"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Omaha, NE","country":"US","lat":41.255,"lng":-95.977,"institutionType":"cancer-center","website":"https://www.unmc.edu/cancercenter/","nci":"clinical","university":"University of Nebraska Medical Center","programs":["Lymphoma","Pancreatic cancer SPORE and early detection","Transplant"]},{"id":"fred-hutch","kind":"institution","name":"Fred Hutchinson Cancer Center","aka":[],"tldr":"Birthplace of bone marrow transplantation (Thomas, Nobel 1990) and a CAR-T pioneer (Riddell).","summary":"Fred Hutchinson Cancer Center in Seattle, NCI-designated as comprehensive and tied to the University of Washington, is the birthplace of bone marrow transplantation, for which Thomas won the Nobel Prize in 1990, and a CAR-T pioneer through Stanley R. Riddell and Philip D. Greenberg, whose work fed the origins of Juno. It runs HPV vaccine trials, the SWOG statistical centre and the Hutch Cancer Immunotherapy Integrated Research Center, with Denise A. Galloway, Joseph M. Unger, Hans-Peter Kiem and Gary H. Lyman also listed. OnCo links it to the cancer cachexia and RNA splicing pathways, to Unger's paper on how few patients are ever offered a trial, and to the Uganda Cancer Institute. Whether splice-derived neoantigens can become off-the-shelf vaccine targets is one open question it is linked to. Its transplant, CAR-T and SWOG programmes are listed below.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Fred_Hutchinson_Cancer_Center","links":[{"label":"Official website","url":"https://www.fredhutch.org"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["car-t","proton-therapy","proton-therapy-systems"],"targets":[],"drugs":[],"companies":["blaze-bioscience"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["thomas-lynch","stanley-riddell","michael-leblanc","philip-greenberg","hans-peter-kiem","gary-lyman","joseph-unger","denise-galloway","sara-hurvitz"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Seattle","country":"US","lat":47.627,"lng":-122.332,"institutionType":"cancer-center","website":"https://www.fredhutch.org","nci":"comprehensive","university":"University of Washington","programs":["Transplant","CAR-T","SWOG"]},{"id":"frederick-national-lab","kind":"institution","name":"Frederick National Laboratory for Cancer Research","aka":["FNLCR","NCI-Frederick","NCI at Frederick"],"tldr":"The only US national laboratory dedicated to biomedical research, run for the NCI; home of the RAS Initiative and NCI's experimental drug manufacturing.","summary":"Frederick National Laboratory is a federally funded research and development centre sponsored by the NCI and operated under contract by Leidos Biomedical Research on the Fort Detrick campus. Its RAS Initiative, launched in 2013 with Frank McCormick as scientific advisor, built the structural, biochemical and screening infrastructure that helped make KRAS druggable. The laboratory manufactures experimental biologics, cell therapies and vaccines to cGMP standards for NCI and NIH trials (its Vaccine Clinical Materials Program produced the first clinical lots for Moderna's COVID-19 vaccine), hosts the National Cryo-EM Facility, and provides genomics, proteomics, nanotechnology characterisation and AI-driven drug design through the ATOM consortium. It also supports NCI's AIDS and cancer virus, natural products and biorepository programmes.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Frederick_National_Laboratory_for_Cancer_Research","links":[{"label":"Frederick National Laboratory","url":"https://frederick.cancer.gov"},{"label":"NCI RAS Initiative","url":"https://www.cancer.gov/research/key-initiatives/ras"}],"tags":[],"related":[],"cancers":[],"sections":["drug-discovery"],"technologies":["kras-inhibitors","ai-drug-design","proteomics"],"targets":["kras"],"drugs":[],"companies":["moderna"],"institutions":["nci","nci-ccr"],"pathways":[],"terms":[],"trials":[],"people":["frank-mccormick","jay-schnitzer"],"bottlenecks":["b-undruggable-targets","b-manufacturing-cell-therapy"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Frederick, MD","country":"US","lat":39.437,"lng":-77.393,"institutionType":"government","website":"https://frederick.cancer.gov","programs":["RAS Initiative","Biopharmaceutical development and cGMP manufacturing","National Cryo-EM Facility","ATOM AI drug discovery"]},{"id":"fuscc","kind":"institution","name":"Fudan University Shanghai Cancer Center","aka":[],"tldr":"Fudan University Shanghai Cancer Center is China's leading breast cancer centre and the site of first-in-human TROP2 PET imaging.","summary":"Fudan University Shanghai Cancer Center is China's leading breast cancer centre, ranked fifty-fifth in the Newsweek/Statista oncology list, and the site of the first-in-human TROP2 PET imaging study. Shao Zhimin's molecular subtyping of triple-negative breast cancer and the FUTURE umbrella trial built on it, the gallium-68 TROP2 nanobody PET tracer from Shaoli Song, and the highest breast cancer surgical volume in the world are its distinguishing contributions, with Yi-Zhou Jiang, Xichun Hu and Dingwei Ye also listed. OnCo links it to triple-negative breast cancer, to TROP2 as a target and TROP2 PET as a technology, and to Zhongshan Hospital and the Chinese Society of Clinical Oncology. Whether subtype-directed treatment of TNBC improves on a single standard is the question FUTURE was designed to answer. Its TNBC, TROP2 PET and surgery programmes are listed below.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Shanghai_Cancer_Center","links":[{"label":"Official website","url":"https://www.shca.org.cn"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":["tnbc"],"sections":[],"technologies":["trop2-pet","proton-therapy","proton-therapy-systems","carbon-ion","carbon-ion-synchrotrons"],"targets":["trop2"],"drugs":["fda018-adc"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["jiang-yi-zhou","song-shaoli","ye-dingwei","li-jin-fuscc","hu-xichun","shao-zhi-ming"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Shanghai","country":"CN","lat":31.191,"lng":121.437,"institutionType":"cancer-center","website":"https://www.shca.org.cn","newsweekOncology2026":55,"programs":["TNBC subtyping (FUTURE trial)","TROP2 PET","Breast surgery"]},{"id":"falp-chile","kind":"institution","name":"Fundación Arturo López Pérez","aka":["FALP","Instituto Oncológico FALP"],"tldr":"Chile's largest dedicated cancer institute, a non-profit foundation founded in 1954 and the country's most active site for oncology trials and advanced radiotherapy.","summary":"The Fundación Arturo López Pérez was created in Santiago in 1954 under the will of businessman Arturo López Pérez to fight cancer in Chile, and its Instituto Oncológico is the country's largest cancer-only hospital. FALP provides surgical, medical and radiation oncology, haematology and bone marrow transplant, nuclear medicine and palliative care, was the first Chilean centre with robotic cancer surgery and stereotactic and intraoperative radiotherapy, and runs one of Latin America's most active clinical research units with a large portfolio of international registration trials. The foundation also operates preventive medicine and screening programmes, a tumour bank and research into gastric cancer, which is unusually common in Chile, and gallbladder cancer, for which Chile has among the highest rates in the world.","asOf":"2026-09-09","links":[{"label":"FALP","url":"https://www.falp.org"}],"tags":[],"related":["intraoperative-radiotherapy"],"cancers":["gastric","cholangiocarcinoma","breast-hr-positive","prostate"],"sections":["surgery","radiation"],"technologies":["robotic-surgery","sbrt","pet-ct"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["cristian-ayala-munita","rolando-medeiros"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Santiago","country":"CL","lat":-33.437,"lng":-70.618,"institutionType":"cancer-center","website":"https://www.falp.org","programs":["Cancer institute","Clinical trials unit","Robotic surgery and advanced radiotherapy","Gastric and gallbladder cancer research"]},{"id":"ivo-valencia","kind":"institution","name":"Fundación Instituto Valenciano de Oncología (IVO)","aka":["IVO"],"tldr":"A private non-profit dedicated cancer hospital in Valencia, accredited by OECI as a Cancer Centre.","summary":"The Instituto Valenciano de Oncología is a non-profit foundation hospital devoted entirely to cancer, providing surgical oncology, medical oncology, radiation oncology, nuclear medicine, diagnostic imaging and pathology for patients from the Valencian Community and beyond under agreements with the public health system. It runs a clinical trials unit and research programmes in breast, urological and gastrointestinal cancers, radiotherapy techniques and hereditary cancer, and is accredited by the Organisation of European Cancer Institutes as a Cancer Centre.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.ivo.es"}],"tags":["oeci-accredited","oeci-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci","incliva-valencia","la-fe-valencia"],"pathways":[],"terms":[],"trials":[],"people":["antonio-llombart-bosch","manuel-llombart-fuertes"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Valencia","country":"ES","lat":39.481,"lng":-0.389,"institutionType":"cancer-center","website":"https://www.ivo.es","programs":["Dedicated cancer hospital","Radiation oncology","Clinical trials unit"]},{"id":"fundacion-valle-del-lili","kind":"institution","name":"Fundación Valle del Lili","aka":[],"tldr":"Colombia's leading private university hospital, in Cali, with a comprehensive cancer institute and a busy clinical trials centre.","summary":"Fundación Valle del Lili is a non-profit university hospital in Cali affiliated with the Universidad Icesi, regularly ranked among the top hospitals in Latin America. Its cancer institute provides medical oncology, radiotherapy, haematology and bone marrow transplantation, surgical oncology, paediatric oncology and nuclear medicine, and its clinical research centre is one of Colombia's most active sites for international oncology trials. The hospital is accredited by Joint Commission International and runs oncology fellowship programmes for the south-west of the country.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://valledellili.org"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["inc-colombia"],"pathways":[],"terms":[],"trials":[],"people":["vicente-borrero"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Cali","country":"CO","lat":3.373,"lng":-76.527,"institutionType":"hospital","website":"https://valledellili.org","university":"Universidad Icesi","programs":["Cancer institute","Bone marrow transplantation","Clinical research centre"]},{"id":"garvan-institute","kind":"institution","name":"Garvan Institute of Medical Research / Kinghorn Cancer Centre","aka":["Garvan","The Kinghorn Cancer Centre","St Vincent's Hospital Sydney"],"tldr":"One of Australia's leading genomics institutes, whose Kinghorn Cancer Centre with St Vincent's pioneered genomics-guided treatment of pancreatic cancer and rare tumours.","summary":"The Garvan Institute was founded in 1963 at St Vincent's Hospital in Darlinghurst and became a leader in medical genomics, hosting the Kinghorn Centre for Clinical Genomics and, with St Vincent's, The Kinghorn Cancer Centre, opened in 2012 as an integrated research and treatment facility. Garvan investigators led the Australian Pancreatic Cancer Genome Initiative within the International Cancer Genome Consortium (Andrew Biankin, Sean Grimmond), established the Molecular Screening and Therapeutics (MoST) programme for rare and advanced cancers with Omico, and run leading programmes in breast cancer biology, prostate cancer, single-cell and spatial genomics, and epigenetics (Susan Clark). Patients access precision oncology trials, phase 1 studies and germline genomics through the Kinghorn Cancer Centre.","asOf":"2026-09-09","links":[{"label":"Garvan Institute","url":"https://www.garvan.org.au"},{"label":"The Kinghorn Cancer Centre (archived copy)","url":"https://web.archive.org/web/20230614152013/http://www.thekinghorncancercentre.org.au/"},{"label":"Omico","url":"https://www.omico.com.au"}],"tags":[],"related":[],"cancers":["pancreatic","breast-hr-positive","prostate","sarcoma"],"sections":["diagnostics","drug-discovery"],"technologies":["wes-wgs","single-cell-spatial","methylation-profiling","cgp"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["basket-umbrella-platform","rare-cancers"],"trials":[],"people":["benjamin-kile","susan-clark"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Sydney","country":"AU","lat":-33.88,"lng":151.221,"institutionType":"research-institute","website":"https://www.garvan.org.au","university":"UNSW Sydney","programs":["Pancreatic cancer genomics (APGI)","MoST precision oncology trials","Kinghorn Centre for Clinical Genomics","Epigenetics and single-cell biology"]},{"id":"gates-foundation","kind":"institution","name":"Gates Foundation","aka":["Bill & Melinda Gates Foundation","BMGF"],"tldr":"The world's largest private foundation; its cancer work focuses on HPV vaccination and cervical cancer elimination in low- and middle-income countries.","summary":"Founded in 2000, the Gates Foundation funds global health, development and US education. Cancer is not a core programme, but the foundation is a major force behind the WHO cervical cancer elimination strategy: it co-founded Gavi, which finances HPV vaccination in low-income countries, funded the trials and modelling behind single-dose HPV vaccination, and supports screening and treatment access work in Africa and South Asia. It also funds low-cost diagnostics, hepatitis B vaccination that prevents liver cancer, and data and modelling through the Institute for Health Metrics and Evaluation. Its scale means its choices shape which cancer problems in poorer countries get attention.","asOf":"2026-09-09","links":[{"label":"Gates Foundation","url":"https://www.gatesfoundation.org"},{"label":"Gavi HPV programme","url":"https://www.gavi.org/types-support/vaccine-support/human-papillomavirus"}],"tags":[],"related":[],"cancers":["cervical","hcc"],"sections":["prevention"],"technologies":["hpv-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":["who","iarc","uicc"],"pathways":[],"terms":[],"trials":[],"people":["bill-gates","mark-suzman","trevor-mundel"],"bottlenecks":["b-global-access","b-prevention-adoption"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Seattle, WA","country":"US","lat":47.623,"lng":-122.346,"institutionType":"consortium","website":"https://www.gatesfoundation.org","programs":["HPV vaccination and cervical cancer elimination (with Gavi and WHO)","Single-dose HPV vaccine evidence","Hepatitis B vaccination","Global health data (IHME)"]},{"id":"g-ba-iqwig","kind":"institution","name":"Gemeinsamer Bundesausschuss / IQWiG","aka":["G-BA","Federal Joint Committee","IQWiG","Institute for Quality and Efficiency in Health Care"],"tldr":"Germany's decision-making body for what statutory insurance covers (G-BA) and the institute that assesses added benefit of new drugs (IQWiG), which together set cancer drug prices under the AMNOG process.","summary":"The Gemeinsamer Bundesausschuss is the self-governing body of insurers, physicians and hospitals that determines the benefits covered by Germany's statutory health insurance, and the Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen in Cologne is the independent institute it commissions to assess evidence. Under the AMNOG early benefit assessment since 2011, every new drug is judged for added benefit against the appropriate comparator within a year of launch, and the rating (from major added benefit to none) drives the price negotiated with the insurers' association. IQWiG's demanding view of surrogate endpoints, single-arm trials and quality-of-life data has shaped how companies design oncology trials for Europe, and G-BA decisions also govern screening programmes and quality requirements for cancer centres.","asOf":"2026-09-09","links":[{"label":"G-BA","url":"https://www.g-ba.de"},{"label":"IQWiG","url":"https://www.iqwig.de"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ema","nice","has-france","dkfz","deutsche-krebshilfe"],"pathways":[],"terms":["pfs","os","hazard-ratio","real-world-evidence"],"trials":[],"people":["sonja-optendrenk","thomas-kaiser"],"bottlenecks":["b-drug-pricing","b-biomarker-validation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Berlin","country":"DE","lat":52.52,"lng":13.405,"institutionType":"government","website":"https://www.g-ba.de","programs":["AMNOG early benefit assessment","IQWiG evidence reports","Coverage decisions for screening and diagnostics","Quality assurance requirements"]},{"id":"hug-geneva","kind":"institution","name":"Geneva University Hospitals (HUG)","aka":["HUG","Hôpitaux Universitaires de Genève","Centre des cancers HUG"],"tldr":"Geneva University Hospitals form part of the Swiss Cancer Center Léman with Lausanne; Denis Migliorini's neuro-oncology group develops CAR-T cells against glioblastoma, one of Europe's first academic efforts, and the hospital houses Switzerland's oldest population-based cancer registry.","summary":"The Geneva University Hospitals cancer centre coordinates oncology across Switzerland's largest public hospital and is part of the Swiss Cancer Center Léman with Lausanne. Pierre-Yves Dietrich built its immuno-oncology programme, and Denis Migliorini's neuro-oncology group develops CAR-T cells against glioblastoma, one of the first academic efforts in Europe; the breast centre, haematology and translational research groups at the University of Geneva contribute to Swiss Group for Clinical Cancer Research trials. The hospital houses the Geneva Cancer Registry, Switzerland's oldest population-based registry, and its proximity to WHO headquarters supports global oncology work.","asOf":"2026-09-09","links":[{"label":"HUG Oncology","url":"https://www.hug.ch/en/oncology"}],"tags":[],"related":[],"cancers":["glioblastoma","breast-hr-positive","dlbcl","melanoma"],"sections":["cell-therapy","immunotherapy"],"technologies":["car-t","checkpoint-inhibitor","imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":["chuv-lausanne","iarc"],"pathways":[],"terms":[],"trials":[],"people":["alfredo-addeo","marie-catherine-vozenin"],"bottlenecks":["b-brain-delivery"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Geneva","country":"CH","lat":46.193,"lng":6.15,"institutionType":"hospital","website":"https://www.hug.ch/en/oncology","university":"Université de Genève","programs":["Immuno-oncology and CAR-T in glioblastoma","Breast centre","Haematology","Geneva Cancer Registry","Swiss Cancer Center Léman"]},{"id":"georgetown-lombardi","kind":"institution","name":"Georgetown Lombardi Comprehensive Cancer Center","aka":[],"tldr":"The only NCI comprehensive cancer centre in Washington, DC, known for breast cancer research including leadership of the CLEOPATRA pertuzumab trial.","summary":"NCI-designated since 1974, Georgetown Lombardi is Washington's only comprehensive cancer centre and since 2019 has formed a consortium with Hackensack Meridian's John Theurer Cancer Center in New Jersey. Breast cancer has been its signature: Marc Lippman and Robert Clarke built the hormone-receptor and endocrine-resistance programme, and Sandra Swain led CLEOPATRA, which established pertuzumab plus trastuzumab and docetaxel as first-line therapy for HER2-positive metastatic breast cancer. Louis Weiner's antibody immunotherapy laboratory and a cancer-prevention and population-science programme focused on the DC region round out the portfolio. Care is delivered at MedStar Georgetown University Hospital.","asOf":"2026-09-09","links":[{"label":"Georgetown Lombardi","url":"https://lombardi.georgetown.edu"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":["breast-her2-positive","breast-hr-positive"],"sections":[],"technologies":["monoclonal-antibody","endocrine-therapy","proton-therapy","proton-therapy-systems","cyberknife","radiosurgery-srs"],"targets":["her2","estrogen-receptor"],"drugs":["pertuzumab","trastuzumab","docetaxel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["cleopatra"],"people":["sandra-swain"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Washington, DC","country":"US","lat":38.911,"lng":-77.075,"institutionType":"cancer-center","website":"https://lombardi.georgetown.edu","nci":"comprehensive","university":"Georgetown University","programs":["Breast cancer (CLEOPATRA)","Antibody immunotherapy","Consortium with John Theurer Cancer Center"]},{"id":"dktk","kind":"institution","name":"German Cancer Consortium (DKTK)","aka":["Deutsches Konsortium für Translationale Krebsforschung","DKTK"],"tldr":"Germany's national translational cancer research network: the DKFZ in Heidelberg as core centre plus university hospitals and institutes at seven other sites, so that laboratory findings reach patients across the country rather than in one city.","summary":"The German Cancer Consortium (Deutsches Konsortium für Translationale Krebsforschung, DKTK) is one of the German Centres for Health Research funded by the federal and state governments. Its own site describes more than twenty institutions and teaching hospitals joined in translational research centres at eight locations: Heidelberg as the core centre at the German Cancer Research Center (DKFZ), with partner sites in Berlin (Charité), Dresden (TU Dresden, University Hospital Carl Gustav Carus and the Helmholtz-Zentrum Dresden-Rossendorf), Essen and Düsseldorf, Frankfurt and Mainz (including the Georg-Speyer-Haus), Freiburg (including the Max Planck Institute of Immunobiology and Epigenetics), Munich (LMU and TUM with their university hospitals) and Tübingen. The consortium runs joint research programmes and shared platforms, among them the NCT/DKTK MASTER programme that sequences the genomes of rare and young-adult cancers to guide treatment, run from Heidelberg by Stefan Fröhling. OnCo links it to the partner-site records that already exist and to the DKFZ, which coordinates it.","asOf":"2026-09-17","links":[{"label":"DKTK: partner sites","url":"https://dktk.dkfz.de/en/sites/overview"},{"label":"DKTK: about","url":"https://dktk.dkfz.de/en"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["wes-wgs","cgp"],"targets":[],"drugs":[],"companies":[],"institutions":["dkfz","charite","nct-dresden","essen-wtz","uct-frankfurt","uct-mainz","ccc-freiburg","lmu-munich","tum-munich","ccc-tuebingen"],"pathways":[],"terms":[],"trials":[],"people":["stefan-froehling"],"bottlenecks":["b-translational-valley","b-data-silos"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Heidelberg","country":"DE","lat":49.416,"lng":8.676,"institutionType":"consortium","website":"https://dktk.dkfz.de","programs":["Eight partner sites and one core centre","NCT/DKTK MASTER precision oncology programme","Joint funding programmes and shared platforms","School of Oncology"]},{"id":"dkfz","kind":"institution","name":"German Cancer Research Center (DKFZ)","aka":[],"tldr":"The DKFZ is Germany's largest cancer research institute, where Harald zur Hausen linked HPV to cervical cancer (Nobel 2008).","summary":"The German Cancer Research Center, the DKFZ in Heidelberg, is Germany's largest cancer research institute and the place where Harald zur Hausen linked HPV to cervical cancer, work recognised by the Nobel Prize in 2008. It leads the National Center for Tumor Diseases network of university hospitals, produced the CNS tumour DNA methylation classifier and runs cancer prevention research, with Hermann Brenner, Andreas Trumpp, Andreas von Deimling and Michael Baumann among the people OnCo lists. OnCo links it to HPV and HBV vaccination and DNA methylation profiling, to cervical cancer and the paediatric brain tumours ependymoma, ATRT and diffuse midline glioma, to Xilis, and to the idea of machine-readable portfolio reporting for large funders. The valley of death between lab and product is the bottleneck it confronts. Its Heidelberg hospital partner has its own page, as does the German Cancer Consortium (DKTK), the national translational network for which the DKFZ is the core centre.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.dkfz.de"}],"tags":[],"related":["heidelberg-nct"],"cancers":[],"sections":[],"technologies":["hpv-vaccine","methylation-profiling"],"targets":[],"drugs":[],"companies":[],"institutions":["dktk"],"pathways":[],"terms":[],"trials":[],"people":["hermann-brenner","andreas-trumpp","michael-baumann","stefan-pfister","stefan-froehling","andreas-von-deimling","uwe-haberkorn","harald-zur-hausen"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Heidelberg","country":"DE","lat":49.414,"lng":8.673,"institutionType":"research-institute","website":"https://www.dkfz.de","programs":["HPV / prevention","CNS tumour classification","NCT network","DKTK core centre"]},{"id":"german-oncology-center-limassol","kind":"institution","name":"German Oncology Center","aka":["GOC Limassol","German Oncology Centre"],"tldr":"German Oncology Center is a private cancer centre in Limassol offering radiotherapy, medical oncology and diagnostics, and a full member of the Organisation of European Cancer Institutes.","summary":"German Oncology Center is a private cancer centre in Limassol offering radiotherapy, medical oncology and diagnostics. It is listed by the Organisation of European Cancer Institutes as a full member, which is why it has a page on OnCo. Programme, trial and leadership details are not yet recorded here and should be checked on the institution's own pages.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.goc.com.cy"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["nikolaos-zamboglou"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Limassol","country":"CY","lat":34.707,"lng":33.022,"institutionType":"cancer-center","website":"https://www.goc.com.cy","programs":[]},{"id":"uz-gent","kind":"institution","name":"Ghent University Hospital / Cancer Research Institute Ghent","aka":["UZ Gent","CRIG","Kankercentrum UZ Gent"],"tldr":"Ghent's OECI-accredited university cancer centre, known for neuroblastoma genomics, early-phase trials and immuno-oncology.","summary":"The Cancer Centre of Ghent University Hospital is accredited by the OECI and works with the Cancer Research Institute Ghent (CRIG), which federates cancer research across Ghent University, the hospital and VIB. Frank Speleman and Katleen De Preter's groups have made major contributions to the genomics of neuroblastoma and the role of MYCN and ALK, and the Drug Research Unit Ghent under Sylvie Rottey is one of Belgium's most active phase 1 sites. Clinical strengths include head and neck and thoracic oncology, urology, melanoma immunotherapy and paediatric haemato-oncology. The hospital runs a regional radiotherapy programme and molecular tumour board.","asOf":"2026-09-09","links":[{"label":"Cancer Centre (page moved; nearest live section)","url":"https://www.uzgent.be/"},{"label":"CRIG","url":"https://www.crig.ugent.be"}],"tags":[],"related":[],"cancers":["neuroblastoma","melanoma","head-and-neck","prostate"],"sections":["targeted-therapy","immunotherapy"],"technologies":["cgp","checkpoint-inhibitor","kinase-inhibitors"],"targets":["alk"],"drugs":[],"companies":[],"institutions":["oeci","uz-leuven"],"pathways":[],"terms":[],"trials":[],"people":["karim-vermaelen","frank-vermassen"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Ghent","country":"BE","lat":51.024,"lng":3.727,"institutionType":"hospital","website":"https://www.uzgent.be/","university":"Ghent University","programs":["Neuroblastoma genomics","Drug Research Unit Ghent (phase 1)","Immuno-oncology","Head and neck oncology"]},{"id":"glasgow-royal-infirmary","kind":"institution","name":"Glasgow Royal Infirmary","aka":["NHS Greater Glasgow and Clyde","West of Scotland HPB unit"],"tldr":"The HPB surgical centre for the West of Scotland Cancer Network; chemotherapy and immunotherapy are given at the Beatson.","summary":"Pancreatic Cancer UK lists Glasgow Royal Infirmary as the surgical centre for the West of Scotland Cancer Network, with the Beatson West of Scotland Cancer Centre providing non-surgical treatment.","asOf":"2026-09-24","links":[{"label":"NHS Greater Glasgow and Clyde","url":"https://www.nhsggc.scot/"},{"label":"Pancreatic Cancer UK centres list","url":"https://www.pancreaticcancer.org.uk/information-and-support/your-care/your-local-pancreatic-cancer-specialist-centre/"}],"tags":["hpb","nhs","uk"],"related":[],"cancers":["gallbladder","biliary-tract-cancer","cholangiocarcinoma","pancreatic","hcc"],"sections":["surgery"],"technologies":["hepatectomy"],"targets":[],"drugs":[],"companies":[],"institutions":["beatson-glasgow"],"pathways":[],"terms":[],"trials":["precision-panc","europac"],"people":["andrew-biankin"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Glasgow","country":"GB","lat":55.865,"lng":-4.235,"institutionType":"hospital","website":"https://www.nhsggc.scot/","university":"University of Glasgow","programs":["HPB surgery","West of Scotland HPB MDT"]},{"id":"great-ormond-street","kind":"institution","name":"Great Ormond Street Hospital for Children","aka":["GOSH","UCL Great Ormond Street Institute of Child Health"],"tldr":"London's children's hospital, where gene-edited 'universal' CAR-T cells were first given to a child with leukaemia.","summary":"Founded in 1852, Great Ormond Street Hospital is the UK's largest children's hospital and, with the UCL Great Ormond Street Institute of Child Health, one of Europe's leading paediatric research centres. In 2015 Waseem Qasim's team treated an infant with refractory leukaemia using TALEN-edited allogeneic CAR-T cells, the first such use in humans, and in 2022 the team delivered the first base-edited CAR-T (CD7-directed) for T-cell leukaemia. The hospital runs one of the UK's largest paediatric oncology and haematology services, including bone marrow transplantation, neuro-oncology and neuroblastoma programmes, and hosts the Zayed Centre for Research into Rare Disease in Children. It is a principal treatment centre for London and a national referral site for rare childhood cancers.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Great_Ormond_Street_Hospital_for_Children_NHS_Foundation_Trust","links":[{"label":"Homepage","url":"https://www.gosh.nhs.uk"},{"label":"UCL GOS Institute of Child Health","url":"https://www.ucl.ac.uk/child-health/"}],"tags":[],"related":[],"cancers":["all-leukemia","neuroblastoma","aml","glioblastoma"],"sections":["cell-therapy"],"technologies":["car-t","allogeneic-cell-therapy","germline-testing"],"targets":["cd19"],"drugs":[],"companies":[],"institutions":["uclh"],"pathways":[],"terms":[],"trials":[],"people":["karl-munslow-ong","sophia-varadkar","waseem-qasim"],"bottlenecks":["b-manufacturing-cell-therapy","b-rare-cancers"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"London","country":"GB","lat":51.522,"lng":-0.12,"institutionType":"hospital","website":"https://www.gosh.nhs.uk","university":"University College London","programs":["Gene-edited CAR-T (Qasim)","Paediatric haematology and transplant","Neuro-oncology","Neuroblastoma","Zayed Centre for Research"]},{"id":"greater-manchester-cancer-alliance","kind":"institution","name":"Greater Manchester Cancer Alliance","aka":["GM Cancer","Greater Manchester Cancer"],"tldr":"The NHS England Cancer Alliance for the ten boroughs of Greater Manchester: the partnership that plans and improves cancer services across its hospitals, GPs and community services.","summary":"One of the 20 Cancer Alliances set up by NHS England from 2016, following the Independent Cancer Taskforce strategy, to bring together the hospital trusts, integrated care boards, primary care, hospices and charities serving the ten boroughs of Greater Manchester. Alliances lead local delivery of the NHS cancer ambitions: earlier diagnosis (including rapid diagnostic centres and targeted lung health checks), the Faster Diagnosis Standard, personalised care and follow-up, and workforce and pathway improvement. They hold transformation funding from NHS England and publish local performance and improvement plans.","asOf":"2026-09-09","links":[{"label":"Greater Manchester Cancer Alliance","url":"https://gmcancer.org.uk"},{"label":"NHS England: Cancer Alliances","url":"https://www.england.nhs.uk/cancer/cancer-alliances-improving-care-locally/"}],"tags":["nhs-cancer-alliance"],"related":[],"cancers":[],"sections":["early-detection"],"technologies":["low-dose-ct-screening"],"targets":[],"drugs":[],"companies":[],"institutions":["the-christie","cruk-manchester-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Manchester","country":"GB","lat":53.483,"lng":-2.244,"institutionType":"consortium","website":"https://gmcancer.org.uk","programs":["Earlier diagnosis and rapid diagnostic centres","Faster Diagnosis Standard","Personalised care and follow-up","Cancer pathway improvement"]},{"id":"greater-poland-cancer-centre","kind":"institution","name":"Greater Poland Cancer Centre","aka":["Wielkopolskie Centrum Onkologii","WCO Poznań"],"tldr":"Poznań's regional cancer centre, founded in 1953, with radiotherapy, surgery, chemotherapy and a medical physics research tradition, and a full member of the Organisation of European Cancer Institutes.","summary":"The Greater Poland Cancer Centre (Wielkopolskie Centrum Onkologii) in Poznań, founded in 1953, is the specialist cancer hospital for the Greater Poland region, with radiotherapy, surgical and clinical oncology departments and a medical physics group active in European radiotherapy research. It is a full member of the Organisation of European Cancer Institutes (OECI); its representative on the OECI list is Julian Malicki.","asOf":"2026-09-09","links":[{"label":"Official website","url":"http://www.wco.pl/"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q30281661"}],"tags":[],"related":["nio-warsaw","nio-gliwice"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["julian-malicki"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Poznań","country":"PL","lat":52.402,"lng":16.936,"institutionType":"cancer-center","website":"http://www.wco.pl/","programs":[]},{"id":"groote-schuur-uct","kind":"institution","name":"Groote Schuur Hospital / University of Cape Town","aka":["Groote Schuur","UCT Faculty of Health Sciences"],"tldr":"South Africa's most famous academic hospital, site of the first heart transplant, and with UCT a leading African centre for cancer research, radiation oncology and oesophageal and cervical cancer studies.","summary":"Groote Schuur Hospital, opened in 1938, is the principal teaching hospital of the University of Cape Town and serves the Western Cape's public patients. Its radiation oncology, medical oncology, haematology, surgical and paediatric oncology (with Red Cross War Memorial Children's Hospital) departments are among the strongest in Africa, and UCT's research groups work on oesophageal squamous cell carcinoma in African populations, cervical cancer and HIV-associated malignancies, Kaposi sarcoma, breast cancer genetics in African women, and cancer registration through the South African Children's Tumour Registry. UCT's Institute of Infectious Disease and Molecular Medicine, the SA Medical Research Council units and the Cancer Association of South Africa collaborate with the hospital, which also trains oncologists for much of sub-Saharan Africa.","asOf":"2026-09-09","links":[{"label":"Groote Schuur Hospital (archived copy)","url":"https://web.archive.org/web/20240909081739/https://www.westerncape.gov.za/your_gov/163/"},{"label":"UCT Faculty of Health Sciences","url":"https://health.uct.ac.za"}],"tags":[],"related":["global-oncology-access","cancer-health-disparities"],"cancers":["esophageal","cervical","breast-hr-positive","all-leukemia","head-and-neck"],"sections":["radiation","prevention"],"technologies":["imrt-igrt","brachytherapy","germline-testing"],"targets":[],"drugs":[],"companies":[],"institutions":["tygerberg-hospital"],"pathways":[],"terms":[],"trials":[],"people":["shaheem-de-vries"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Cape Town","country":"ZA","lat":-33.941,"lng":18.463,"institutionType":"hospital","website":"https://web.archive.org/web/20240909081739/https://www.westerncape.gov.za/your_gov/163/","university":"University of Cape Town","programs":["Radiation and medical oncology","HIV-associated and oesophageal cancer research","Paediatric oncology (Red Cross Children's Hospital)","African cancer genetics"]},{"id":"guangdong-provincial-peoples-hospital","kind":"institution","name":"Guangdong Provincial People's Hospital","aka":["GDPH","Guangdong Lung Cancer Institute","Guangdong Academy of Medical Sciences","广东省人民医院"],"tldr":"Home of the Guangdong Lung Cancer Institute, where Yi-Long Wu's group ran the trials that made EGFR-mutant lung cancer a targeted-therapy disease in Asia.","summary":"Guangdong Provincial People's Hospital, founded in 1946, houses the Guangdong Lung Cancer Institute led by Yi-Long Wu, one of the most influential lung cancer trial groups in the world. Its investigators led or co-led OPTIMAL (erlotinib), CTONG 1104/ADJUVANT (adjuvant gefitinib), the Chinese arms of ADAURA and FLAURA, and studies of neoadjuvant immunotherapy in NSCLC, and founded the Chinese Thoracic Oncology Group (CTONG). Beyond lung cancer the hospital is strong in cardiology, cardiothoracic surgery and precision pathology, and runs a large next-generation sequencing service for lung cancer.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Guangdong_Provincial_People's_Hospital","links":[{"label":"Guangdong Provincial People's Hospital","url":"https://www.gdghospital.org.cn"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":["targeted-therapy"],"technologies":["kinase-inhibitors","cgp","checkpoint-inhibitor"],"targets":["egfr","alk","pd1"],"drugs":["osimertinib","gefitinib","erlotinib"],"companies":[],"institutions":[],"pathways":[],"terms":["neoadjuvant-adjuvant","oncogene-addiction"],"trials":["adaura","flaura2"],"people":["wu-yi-long","nu-zhang","wen-zhao-zhong","qing-zhou"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Guangzhou","country":"CN","lat":23.125,"lng":113.281,"institutionType":"hospital","website":"https://www.gdghospital.org.cn","university":"Southern Medical University","programs":["Guangdong Lung Cancer Institute","EGFR-mutant NSCLC trials (CTONG)","Neoadjuvant immunotherapy","Molecular pathology"]},{"id":"gunma-heavy-ion-medical-center","kind":"institution","name":"Gunma University Heavy Ion Medical Center","aka":["GHMC","群馬大学重粒子線医学センター"],"tldr":"The first compact university-based carbon-ion therapy centre in Japan, treating prostate, liver, lung and bone and soft-tissue tumours since 2010.","summary":"Gunma University Heavy Ion Medical Center began treatment in 2010 as the first compact carbon-ion facility built on a university campus, using a downsized synchrotron designed with NIRS (now QST). It treats prostate, hepatocellular, lung, pancreatic, head and neck and sarcoma patients and has published widely on hypofractionated carbon-ion schedules and on radiobiology of high-LET radiation. The centre is linked to Gunma University's Graduate School of Medicine and to the Japan Carbon-ion Radiation Oncology Study Group (J-CROS), which pooled outcomes across Japanese facilities to support national insurance coverage for carbon-ion therapy.","asOf":"2026-09-09","links":[{"label":"Gunma University Heavy Ion Medical Center","url":"https://heavy-ion.showa.gunma-u.ac.jp"},{"label":"Gunma University","url":"https://www.gunma-u.ac.jp"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":["prostate","hcc","pancreatic","sarcoma","head-and-neck"],"sections":["radiation"],"technologies":["carbon-ion","carbon-ion-synchrotrons"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["tatsuya-ohno"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Maebashi","country":"JP","lat":36.397,"lng":139.061,"institutionType":"hospital","website":"https://heavy-ion.showa.gunma-u.ac.jp","university":"Gunma University","programs":["Carbon-ion therapy","Radiobiology of high-LET radiation","J-CROS multicentre outcomes"]},{"id":"gustave-roussy","kind":"institution","name":"Gustave Roussy","aka":[],"tldr":"Gustave Roussy, outside Paris, is Europe's largest cancer centre; its DITEP phase 1 unit and its breast antibody-drug conjugate and immunotherapy trials (trastuzumab deruxtecan, datopotamab deruxtecan) make it a lead site for industry studies, and it created the ESMO-MCBS scale for grading how much benefit a new drug offers.","summary":"Gustave Roussy in Villejuif, outside Paris, is Europe's largest cancer centre and ranks sixth in the Newsweek/Statista World's Best Specialized Hospitals list for oncology. It houses the DITEP phase 1 unit, holds a Paris-Saclay affiliation, and has led breast antibody-drug conjugate work on trastuzumab deruxtecan and datopotamab deruxtecan alongside a strong immuno-oncology programme, with Fabrice André, Caroline Robert, Laurence Albiges and Martin Schlumberger among its clinicians. OnCo links it to PEACE-1 and ESTIMABL2, to the Inter-B-NHL Ritux 2010 paediatric lymphoma trial, to the ITCC paediatric network, and to ideas on microbiome transplant and the timing of immunotherapy dosing. How an academic centre keeps independent judgement while leading so many industry-sponsored trials is a live question. Its phase 1 unit is the part most visitors come to see.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Institut_Gustave_Roussy","links":[{"label":"Official website","url":"https://www.gustaveroussy.fr"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["zap-x","radiosurgery-srs"],"targets":[],"drugs":["trastuzumab-deruxtecan","datopotamab-deruxtecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["fabrice-andre","laurence-albiges","caroline-robert","martin-schlumberger","aurelien-marabelle","benjamin-besse","fabrice-barlesi","jean-charles-soria","karim-fizazi","laurence-zitvogel"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Villejuif","country":"FR","lat":48.795,"lng":2.349,"institutionType":"cancer-center","website":"https://www.gustaveroussy.fr","newsweekOncology2026":6,"programs":["Phase 1 (DITEP)","Breast ADC trials","Immuno-oncology"]},{"id":"guys-st-thomas","kind":"institution","name":"Guy's and St Thomas' NHS Foundation Trust / King's Health Partners Cancer Centre","aka":["Guy's Cancer Centre","GSTT","King's College London Comprehensive Cancer Centre"],"tldr":"South London's cancer centre with King's College London, strong in breast and prostate cancer, radiotherapy and large screening trials such as NHS-Galleri.","summary":"Guy's Cancer Centre, opened in 2016, brings together cancer care for Guy's and St Thomas' and forms, with King's College London and King's College Hospital, the King's Health Partners Comprehensive Cancer Centre. King's School of Cancer and Pharmaceutical Sciences hosts the Breast Cancer Now Research Unit, where Andrew Tutt led clinical development of PARP inhibitors in BRCA-mutated breast cancer including the OlympiA trial, and the Cancer Prevention Trials Unit under Peter Sasieni, which runs the NHS-Galleri multi-cancer early detection trial with Cancer Research UK. The trust has one of the largest radiotherapy services in the UK, a leading robotic urology and prostate programme, and is part of the CRUK City of London Centre.","asOf":"2026-09-09","links":[{"label":"Cancer services","url":"https://www.guysandstthomas.nhs.uk/our-services/cancer"},{"label":"NHS-Galleri trial","url":"https://www.nhs-galleri.org"}],"tags":[],"related":[],"cancers":["tnbc","breast-hr-positive","prostate","urothelial","skin-cancer","basal-cell-carcinoma","cutaneous-scc","merkel-cell-carcinoma"],"sections":["early-detection","targeted-therapy"],"technologies":["parp-inhibitor","mced","robotic-surgery","imrt-igrt"],"targets":[],"drugs":["olaparib","galleri"],"companies":["grail"],"institutions":["cruk","icr-london"],"pathways":[],"terms":[],"trials":["olympia","nhs-galleri"],"people":["andrew-tutt","amanda-pritchard","claire-harrison"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"London","country":"GB","lat":51.503,"lng":-0.088,"institutionType":"hospital","website":"https://www.guysandstthomas.nhs.uk/our-services/cancer","university":"King's College London","programs":["Breast cancer and PARP inhibitors","Cancer Prevention Trials Unit (NHS-Galleri)","Prostate and urology","Radiotherapy","Haemato-oncology"]},{"id":"hacettepe-cancer-institute","kind":"institution","name":"Hacettepe University Cancer Institute","aka":["Hacettepe Üniversitesi Kanser Enstitüsü","Hacettepe Oncology Hospital"],"tldr":"Turkey's pioneering academic cancer institute in Ankara, with strong paediatric oncology, radiation oncology and preventive oncology programmes.","summary":"Hacettepe University's Cancer Institute was established in 1982 alongside the university's oncology hospital and trains Turkey's medical, radiation and paediatric oncologists. Its paediatric oncology department, built by Münevver Büyükpamukçu, is a national referral centre for childhood cancers, the radiation oncology department has advanced brachytherapy and stereotactic programmes, and the institute runs departments of preventive oncology, basic oncology and clinical oncology. Hacettepe investigators contribute to Turkish Oncology Group trials and international studies in lung, breast and gastrointestinal cancers, and the university's hospitals provide surgery, transplantation and nuclear medicine for patients from across Turkey.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.kanser.hacettepe.edu.tr"},{"label":"Hacettepe University Hospitals","url":"https://www.hastane.hacettepe.edu.tr"}],"tags":[],"related":[],"cancers":["neuroblastoma","head-and-neck","cervical","breast-hr-positive"],"sections":["radiation","prevention"],"technologies":["brachytherapy","imrt-igrt","sbrt"],"targets":[],"drugs":[],"companies":[],"institutions":["istanbul-oncology-institute"],"pathways":[],"terms":[],"trials":[],"people":["kadir-mutlu-hayran"],"bottlenecks":["b-global-access"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Ankara","country":"TR","lat":39.936,"lng":32.863,"institutionType":"cancer-center","website":"https://www.kanser.hacettepe.edu.tr","university":"Hacettepe Üniversitesi","programs":["Paediatric oncology","Radiation oncology and brachytherapy","Preventive oncology","Turkish Oncology Group trials"]},{"id":"hadassah","kind":"institution","name":"Hadassah Medical Center","aka":["Hadassah University Hospital","Sharett Institute of Oncology","Hadassah Ein Kerem"],"tldr":"Jerusalem's university hospital and Sharett Institute of Oncology, known for in-house CAR-T, BRCA founder mutation research and melanoma immunotherapy.","summary":"Hadassah Medical Center's Ein Kerem and Mount Scopus campuses house the Sharett Institute of Oncology and the Hebrew University's medical faculty. Polina Stepensky's bone marrow transplantation and immunotherapy department manufactures its own CD19 and BCMA CAR-T products, making Hadassah one of the first hospitals worldwide to deliver academic point-of-care CAR-T at scale; Michal Lotem's melanoma unit has long run tumour vaccine and immunotherapy trials, Tamar Peretz's oncogenetics group characterised BRCA founder mutations in Ashkenazi Jewish populations, and Aron Popovtzer leads head and neck oncology. The centre provides radiotherapy, gamma knife, paediatric haemato-oncology and a phase 1 unit for Jerusalem and the surrounding region.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Hadassah_Medical_Center","links":[{"label":"Homepage","url":"https://www.hadassah.org.il/en/"},{"label":"Sharett Institute of Oncology","url":"https://www.hadassah.org.il/en/departments/sharett-institute-of-oncology/"}],"tags":[],"related":[],"cancers":["all-leukemia","dlbcl","multiple-myeloma","breast-hr-positive","melanoma"],"sections":["cell-therapy","diagnostics"],"technologies":["car-t","germline-testing","checkpoint-inhibitor","sbrt"],"targets":["cd19","bcma","brca"],"drugs":[],"companies":[],"institutions":["sheba","hebrew-university-of-jerusalem"],"pathways":[],"terms":[],"trials":[],"people":["yoram-weiss","polina-stepensky"],"bottlenecks":["b-manufacturing-cell-therapy","b-hereditary-risk"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Jerusalem","country":"IL","lat":31.765,"lng":35.148,"institutionType":"hospital","website":"https://www.hadassah.org.il/en/","university":"Hebrew University of Jerusalem","programs":["Point-of-care CAR-T","Oncogenetics and BRCA","Melanoma immunotherapy","Head and neck oncology","Paediatric haemato-oncology"]},{"id":"hamad-medical-corporation","kind":"institution","name":"Hamad Medical Corporation / National Center for Cancer Care and Research","aka":["HMC","NCCCR","Al Amal Hospital","مؤسسة حمد الطبية"],"tldr":"Qatar's public health system, whose National Center for Cancer Care and Research is the country's sole comprehensive cancer centre and the hub of its national cancer strategy.","summary":"Hamad Medical Corporation, established in 1979, runs Qatar's public hospitals, and its National Center for Cancer Care and Research (formerly Al Amal Hospital) is the national cancer centre delivering medical, surgical and radiation oncology, haematology and bone marrow transplant, palliative care and a growing clinical trials programme. Qatar's National Cancer Strategy and National Cancer Program, with Sidra Medicine for paediatrics and the Qatar Biobank and Qatar Genome Programme for research, position HMC as a testbed for population genomics and early-detection initiatives in an Arab population, and NCCCR has been accredited by the Joint Commission and partners with academic centres in Europe and North America on training and trials.","asOf":"2026-09-09","links":[{"label":"Hamad Medical Corporation","url":"https://www.hamad.qa"},{"label":"NCCCR","url":"https://www.hamad.qa/EN/Hospitals-and-services/NCCCR/Pages/default.aspx"}],"tags":[],"related":[],"cancers":["breast-hr-positive","colorectal","dlbcl","aml"],"sections":["chemotherapy","prevention"],"technologies":["allogeneic-cell-therapy","imrt-igrt","germline-testing"],"targets":[],"drugs":[],"companies":[],"institutions":["sultan-qaboos-cccrc"],"pathways":[],"terms":[],"trials":[],"people":["mohammed-bin-khalifa-al-suwaidi"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Doha","country":"QA","lat":25.293,"lng":51.514,"institutionType":"hospital","website":"https://www.hamad.qa","programs":["National Center for Cancer Care and Research","National cancer strategy","Bone marrow transplant","Qatar Genome collaboration"]},{"id":"utsw-simmons","kind":"institution","name":"Harold C. Simmons Comprehensive Cancer Center, UT Southwestern","aka":["Simmons Cancer Center"],"tldr":"North Texas's NCI comprehensive centre, where the HIF-2 inhibitor belzutifan, stereotactic body radiotherapy and the cGAS-STING pathway were born.","summary":"NCI-designated in 2010 and comprehensive since 2015, Simmons is the only NCI comprehensive centre in North Texas and is directed by breast oncologist Carlos Arteaga. James Brugarolas's kidney cancer programme and the UTSW spin-out Peloton Therapeutics produced the HIF-2 alpha inhibitor belzutifan, acquired by Merck in 2019 and approved for VHL disease and renal cell carcinoma. Robert Timmerman pioneered stereotactic body radiotherapy for lung and other tumours, and Zhijian 'James' Chen discovered the cGAS-STING innate immune sensing pathway that STING agonists exploit. Ralph DeBerardinis's cancer metabolism work at Children's Medical Center Research Institute adds a strong basic science programme.","asOf":"2026-09-09","links":[{"label":"Simmons Comprehensive Cancer Center","url":"https://www.utsouthwestern.edu/education/medical-school/departments/simmons/"}],"tags":[],"related":[],"cancers":["rcc","nsclc","breast-hr-positive"],"sections":["radiation"],"technologies":["sbrt","sting-agonist","metabolic-therapy"],"targets":["hif2a"],"drugs":["belzutifan"],"companies":["merck"],"institutions":[],"pathways":[],"terms":["oligometastatic"],"trials":[],"people":["robert-timmerman"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Dallas, TX","country":"US","lat":32.813,"lng":-96.841,"institutionType":"cancer-center","website":"https://www.utsouthwestern.edu/education/medical-school/departments/simmons/","nci":"comprehensive","university":"UT Southwestern Medical Center","programs":["Kidney cancer and HIF-2","Stereotactic body radiotherapy","Innate immunity (cGAS-STING)","Cancer metabolism"]},{"id":"haukeland-university-hospital","kind":"institution","name":"Haukeland University Hospital","aka":["Helse Bergen","Haukeland universitetssjukehus"],"tldr":"Haukeland University Hospital in Bergen is Norway's largest hospital by number of patients and the cancer centre for western Norway, and a full member of the Organisation of European Cancer Institutes.","summary":"Haukeland University Hospital is the main hospital of Bergen Hospital Trust (Helse Bergen), one of eleven institutions in the trust, and is described as the largest hospital in Norway by number of patients; it dates from 1912 and is the university hospital of the University of Bergen. It provides the specialised cancer care for Western Norway and is listed by the Organisation of European Cancer Institutes as a full member. Programme, trial and leadership details are not yet recorded here and should be checked on the hospital's own pages.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Haukeland_University_Hospital","links":[{"label":"Official website","url":"https://helse-bergen.no"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Haukeland_University_Hospital"}],"tags":[],"related":["akershus-university-hospital"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["oddbjorn-straume"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Bergen","country":"NO","lat":60.374,"lng":5.359,"institutionType":"hospital","website":"https://helse-bergen.no","programs":[]},{"id":"has-france","kind":"institution","name":"Haute Autorité de Santé","aka":["HAS","Commission de la Transparence"],"tldr":"France's health technology assessment authority, whose Transparency Committee rates the added clinical benefit of each new cancer drug and so sets its price and reimbursement.","summary":"Created in 2004, the HAS is an independent public authority that evaluates medicines, devices and procedures for reimbursement and produces clinical guidelines. Its Commission de la Transparence assigns each drug a clinical benefit score (SMR) and an improvement in clinical benefit rating (ASMR I-V) that drive price negotiations with the Comité Économique des Produits de Santé; France's early access programme (accès précoce, formerly ATU) lets patients receive promising cancer drugs before marketing authorisation, with HAS deciding eligibility. HAS also accredits hospitals, runs the screening programme guidance and participates in the EU joint clinical assessments beginning with oncology in 2025.","asOf":"2026-09-09","links":[{"label":"HAS","url":"https://www.has-sante.fr"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["unicancer"],"institutions":["ema","gustave-roussy","institut-curie","nice","g-ba-iqwig"],"pathways":[],"terms":["real-world-evidence"],"trials":[],"people":["lionel-collet","jean-lessi"],"bottlenecks":["b-drug-pricing","b-global-access"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Saint-Denis","country":"FR","lat":48.918,"lng":2.348,"institutionType":"government","website":"https://www.has-sante.fr","programs":["Transparency Committee (SMR / ASMR ratings)","Early access programme (accès précoce)","Clinical guidelines and screening guidance","EU joint clinical assessment participation"]},{"id":"health-canada","kind":"institution","name":"Health Canada","aka":["Santé Canada","Health Products and Food Branch"],"tldr":"Canada's federal health department and drug regulator, which authorises cancer medicines and works with the provinces and Canada's Drug Agency on reimbursement.","summary":"Health Canada's Health Products and Food Branch reviews and authorises drugs, biologics, radiopharmaceuticals and devices for the Canadian market, with priority review and Notice of Compliance with Conditions pathways for serious diseases including cancer. It is a founding participant in Project Orbis and the Access Consortium and has aligned its review with health technology assessment through the aligned review process with Canada's Drug Agency (formerly CADTH) and the pan-Canadian Pharmaceutical Alliance, which negotiates prices for the provinces. Health Canada also funds the Canadian Institutes of Health Research and regulates tobacco and cannabis, both relevant to cancer prevention.","asOf":"2026-09-09","links":[{"label":"Health Canada","url":"https://www.canada.ca/en/health-canada.html"},{"label":"Drug and health products","url":"https://www.canada.ca/en/health-canada/services/drugs-health-products.html"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["cctg"],"institutions":["canadian-cancer-society","princess-margaret","fda-oce","tga","mhra"],"pathways":[],"terms":[],"trials":[],"people":["shalene-curtis-micallef"],"bottlenecks":["b-regulatory-fragmentation","b-drug-pricing"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Ottawa","country":"CA","lat":45.421,"lng":-75.699,"institutionType":"government","website":"https://www.canada.ca/en/health-canada.html","programs":["Drug and biologic authorisation (Notice of Compliance)","Project Orbis and Access Consortium","Aligned review with Canada's Drug Agency","Tobacco regulation"]},{"id":"hcg","kind":"institution","name":"HealthCare Global Enterprises","aka":["HCG","HCG Cancer Centre"],"tldr":"India's largest private cancer hospital network, with dozens of centres across South Asia and Africa and an early lead in CyberKnife, PET-CT and molecular diagnostics.","summary":"HealthCare Global Enterprises was founded by B.S. Ajaikumar in Bengaluru and grew into the largest specialist cancer chain in India, with a network of comprehensive cancer centres across India plus units in Kenya and elsewhere in Africa. HCG introduced several technologies early to India, including CyberKnife robotic radiosurgery, hospital-based cyclotrons and PET-CT, and its Triesta Sciences and Strand Life Sciences diagnostic arms provide next-generation sequencing, liquid biopsy and molecular pathology. The group runs a sizeable clinical trials business, a bone marrow transplant network and academic training, and publishes on outcomes of cancer care in Indian private practice.","asOf":"2026-09-09","links":[{"label":"HCG","url":"https://hcgoncology.com"}],"tags":[],"related":[],"cancers":["head-and-neck","breast-hr-positive","cervical","nsclc"],"sections":["radiation","diagnostics"],"technologies":["sbrt","pet-ct","cgp","liquid-biopsy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["ajaikumar-b-s"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Bengaluru","country":"IN","lat":12.971,"lng":77.594,"institutionType":"hospital","website":"https://hcgoncology.com","programs":["Cancer hospital network","Radiosurgery and PET-CT","Molecular diagnostics (Triesta, Strand)","Clinical trials"]},{"id":"heart-and-brain-pleven","kind":"institution","name":"Heart and Brain Hospital, Pleven","aka":["Многопрофилна болница за активно лечение Сърце и Мозък Плевен","Heart and Brain Center of Excellence Pleven"],"tldr":"A multi-specialty hospital in Pleven, Bulgaria, with a cancer centre, and a full member of the Organisation of European Cancer Institutes.","summary":"The Heart and Brain Hospital in Pleven is a multi-specialty hospital for active treatment in northern Bulgaria, part of the Cardiac Institute group, with an oncology centre alongside its cardiology and neurology services. It is a full member of the Organisation of European Cancer Institutes (OECI). Its representative on the OECI list is Toni Vekov.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://cardiacinstitute.bg/en/hospitals-and-centers/heart-and-brain-center-of-excellence-pleven/"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["toni-vekov"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Pleven","country":"BG","lat":43.417,"lng":24.607,"institutionType":"hospital","website":"https://cardiacinstitute.bg/en/hospitals-and-centers/heart-and-brain-center-of-excellence-pleven/","programs":[]},{"id":"hebrew-university-of-jerusalem","kind":"institution","name":"Hebrew University of Jerusalem","aka":["HUJI","Hebrew University","Hebrew University-Hadassah Medical School","Yissum"],"tldr":"Jerusalem's research university, whose Hadassah medical school produced Doxil, the first nanomedicine any regulator approved, and whose technology transfer company Yissum licensed it.","summary":"The Hebrew University of Jerusalem, opened in 1925, runs the Hebrew University-Hadassah Medical School jointly with Hadassah Medical Center and the Institute for Medical Research Israel-Canada. Its most consequential oncology contribution is pegylated liposomal doxorubicin: Yechezkel Barenholz's Laboratory of Membrane and Liposome Research, working with the clinician Alberto Gabizon, devised the ammonium-sulfate remote-loading gradient and the polyethylene-glycol coat that let doxorubicin circulate for days and accumulate in tumours, and the product was approved by the FDA in 1995 as Doxil, the first nano-drug any regulator approved. Barenholz's own retrospective in Journal of Controlled Release sets out the three unrelated principles it combined and what twenty years of use taught. The university's technology transfer company, Yissum, licensed the patents. Barenholz's laboratory continues to publish on liposome and PEGylation chemistry from the Hadassah Medical School campus.","asOf":"2026-09-25","wikipedia":"https://en.wikipedia.org/wiki/Hebrew_University_of_Jerusalem","links":[{"label":"Hebrew University of Jerusalem","url":"https://en.huji.ac.il"},{"label":"Barenholz, Doxil, the first FDA-approved nano-drug: lessons learned (J Control Release 2012)","url":"https://doi.org/10.1016/j.jconrel.2012.03.020"},{"label":"Yissum technology transfer","url":"https://www.yissum.co.il"}],"tags":[],"related":[],"cancers":["ovarian","kaposi-sarcoma"],"sections":["drug-discovery"],"technologies":[],"targets":[],"drugs":["pegylated-liposomal-doxorubicin"],"companies":[],"institutions":["hadassah","shaare-zedek"],"pathways":[],"terms":[],"trials":[],"people":["yechezkel-barenholz"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Jerusalem","country":"IL","lat":31.794,"lng":35.243,"institutionType":"university","website":"https://en.huji.ac.il","programs":["Liposome and nanomedicine chemistry (Barenholz)","Hebrew University-Hadassah Medical School","Yissum technology transfer"]},{"id":"heidelberg-nct","kind":"institution","name":"Heidelberg University Hospital / NCT / DKFZ","aka":[],"tldr":"Heidelberg is Germany's cancer research capital, home to the DKFZ (largest cancer research institute in Germany) and the NCT, and the birthplace of FAPI PET and the brain tumour methylation classifier.","summary":"Heidelberg University Hospital, with the National Center for Tumor Diseases and the German Cancer Research Center (DKFZ), is Germany's cancer research capital and ranks eighteenth in the Newsweek/Statista oncology list. Its record includes the FAPI PET tracers from Haberkorn, Giesel and Kratochwil, the first-in-human actinium-225 PSMA therapy, the Heidelberg Ion-Beam Therapy Center for carbon ions, the DKFZ brain tumour methylation classifier from Pfister and von Deimling, and the MASTER precision oncology programme, with Stefan Fröhling among its leaders. OnCo links it to FAP and PSMA as targets, to SOFIE Biosciences, to the first vaccine trial against shared neoantigens of mismatch-repair-deficient cancers, and to ideas for a university cyclotron network and core-funded radiotherapy trials. Turning tracers into approved therapies at scale is the open problem. The DKFZ has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.nct-heidelberg.de"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["fapi-pet","targeted-alpha-therapy","carbon-ion","methylation-profiling","proton-therapy","proton-therapy-systems","carbon-ion-synchrotrons","mr-linac","tomotherapy"],"targets":["fap","psma"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["stefan-froehling","andreas-von-deimling","clemens-kratochwil","frederik-giesel","juergen-debus","uwe-haberkorn"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Heidelberg","country":"DE","lat":49.417,"lng":8.67,"institutionType":"cancer-center","website":"https://www.nct-heidelberg.de","newsweekOncology2026":18,"university":"Heidelberg University","programs":["FAPI PET","Alpha PSMA therapy","Carbon-ion therapy","CNS methylation classifier","DKFZ basic research"]},{"id":"hellenic-cancer-federation","kind":"institution","name":"Hellenic Cancer Federation (ELLOK)","aka":["Ελληνική Ομοσπονδία Καρκίνου","ELLOK"],"tldr":"Greece's national federation of cancer patient organisations, based in Athens, which represents patients in policy and is an associate member of the Organisation of European Cancer Institutes.","summary":"The Hellenic Cancer Federation (ELLOK) is the umbrella body for cancer patient associations in Greece, based in Athens. It represents patients in national cancer policy, runs awareness campaigns and takes part in European patient networks. It is an associate member of the Organisation of European Cancer Institutes (OECI); its representative on the OECI list is Georgios Kapetanakis.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://ellok.org/"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q131899773"}],"tags":[],"related":["saint-savvas-athens","metaxa-cancer-hospital"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["georgios-kapetanakis"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Athens","country":"GR","lat":37.984,"lng":23.728,"institutionType":"consortium","website":"https://ellok.org/","programs":[]},{"id":"henan-cancer-hospital","kind":"institution","name":"Henan Cancer Hospital","aka":["Affiliated Cancer Hospital of Zhengzhou University","河南省肿瘤医院"],"tldr":"The cancer hospital for China's most populous province, known worldwide for oesophageal cancer research in the high-incidence Taihang Mountain region.","summary":"Henan Cancer Hospital, founded in 1977 and affiliated to Zhengzhou University, serves a province of roughly 100 million people and is a national reference for oesophageal squamous cell carcinoma, which is endemic in northern Henan (Linzhou, formerly Linxian). Its investigators have contributed to the genomic characterisation of oesophageal cancer, to endoscopic screening with Lugol's iodine, and to Chinese trials of PD-1 antibodies and ADCs in oesophageal and gastric cancer. The hospital also has large lymphoma, lung, breast and paediatric oncology services and cell therapy manufacturing collaborations.","asOf":"2026-09-09","links":[{"label":"Henan Cancer Hospital","url":"https://www.anti-cancer.com.cn"},{"label":"Zhengzhou University","url":"https://www.zzu.edu.cn"}],"tags":[],"related":[],"cancers":["esophageal","gastric","dlbcl","nsclc"],"sections":["early-detection","immunotherapy"],"technologies":["checkpoint-inhibitor","car-t"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["zhang-jiangong"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Zhengzhou","country":"CN","lat":34.775,"lng":113.679,"institutionType":"cancer-center","website":"https://www.anti-cancer.com.cn","university":"Zhengzhou University","programs":["Oesophageal cancer","Endoscopic screening","Lymphoma","Cell therapy"]},{"id":"columbia-hicc","kind":"institution","name":"Herbert Irving Comprehensive Cancer Center, Columbia University","aka":["HICCC"],"tldr":"Columbia's Herbert Irving Comprehensive Cancer Center in Upper Manhattan has held NCI designation since 1972; its scientists defined the genetic lesions of B-cell lymphoma, discovered and named ferroptosis in 2012, and spun out the systems biology company DarwinHealth, while Dawn Hershman leads SWOG's cancer care delivery research.","summary":"NCI-designated since 1972, the Herbert Irving Comprehensive Cancer Center is the cancer centre of Columbia University Irving Medical Center and NewYork-Presbyterian in Upper Manhattan. Riccardo Dalla-Favera defined BCL6 and the genetic lesions of B-cell lymphoma; Andrea Califano's systems biology of master regulators spun out DarwinHealth; Brent Stockwell discovered and named ferroptosis in 2012; Adolfo Ferrando dissected T-cell acute lymphoblastic leukaemia. Dawn Hershman leads SWOG's cancer care delivery research from here, and Siddhartha Mukherjee, author of The Emperor of All Maladies, runs a leukaemia laboratory. Director Anil Rustgi is a GI cancer biologist.","asOf":"2026-09-09","links":[{"label":"Herbert Irving Comprehensive Cancer Center","url":"https://www.cancer.columbia.edu"}],"tags":[],"related":[],"cancers":["dlbcl","all-leukemia","breast-hr-positive","prostate"],"sections":["ai-computation"],"technologies":[],"targets":[],"drugs":[],"companies":["swog"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["dawn-hershman","herbert-irving","michel-sadelain"],"bottlenecks":["b-tumor-heterogeneity"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"New York, NY","country":"US","lat":40.841,"lng":-73.942,"institutionType":"cancer-center","website":"https://www.cancer.columbia.edu","nci":"comprehensive","university":"Columbia University","programs":["Lymphoma and leukaemia genetics","Systems biology","Ferroptosis","Cancer care delivery (SWOG)"]},{"id":"herlev-hospital","kind":"institution","name":"Herlev Hospital, Copenhagen University Hospital","aka":["Herlev og Gentofte Hospital","Herlev Hospital","Copenhagen Comprehensive Cancer Center at Herlev"],"tldr":"The large Copenhagen University Hospital site at Herlev, opened in 1976, home to one of Denmark's biggest cancer departments and part of the Copenhagen Comprehensive Cancer Center, a full member of the Organisation of European Cancer Institutes.","summary":"Herlev Hospital, part of Copenhagen University Hospital (Herlev and Gentofte), opened in 1976 north-west of Copenhagen and runs one of Denmark's largest oncology departments together with haematology, surgery and radiotherapy. Its cancer service takes part in the Copenhagen Comprehensive Cancer Center alongside Rigshospitalet. It is listed as a full member of the Organisation of European Cancer Institutes (OECI); its representative on the OECI list is Lisbet Isenbeg Ravn.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.herlevhospital.dk/"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q3375948"}],"tags":[],"related":["rigshospitalet"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["lisbet-isenbeg-ravn"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Herlev","country":"DK","lat":55.731,"lng":12.444,"institutionType":"hospital","website":"https://www.herlevhospital.dk/","programs":[]},{"id":"histiocyte-society","kind":"institution","name":"Histiocyte Society","aka":[],"tldr":"The international society of doctors and scientists who study histiocytic disorders; its LCH trials, run since the 1990s, set the worldwide standard for treating Langerhans cell histiocytosis in children.","summary":"Founded in 1985, the Histiocyte Society brings together clinicians and researchers working on Langerhans cell histiocytosis, haemophagocytic lymphohistiocytosis, Erdheim-Chester disease, Rosai-Dorfman disease and juvenile xanthogranuloma. It has run the sequential international LCH-I (1991), LCH-II, LCH-III (2001-2008) and LCH-IV trials, which established vinblastine-prednisone as standard therapy and defined its duration, and the HLH-94 and HLH-2004 protocols. It publishes classification and consensus guidelines, holds an annual scientific meeting, and maintains registries that supported the recognition of histiocytoses as MAPK-driven clonal neoplasms.","asOf":"2026-09-10","links":[{"label":"Histiocyte Society","url":"https://histiocytesociety.org"}],"tags":["nci-coverage","paediatric"],"related":[],"cancers":["langerhans-cell-histiocytosis","histiocytoses"],"sections":[],"technologies":[],"targets":[],"drugs":["vinblastine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["lch-iii"],"people":["vasanta-nanduri"],"bottlenecks":["b-rare-cancers"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Pitman","country":"US","lat":39.733,"lng":-75.132,"institutionType":"consortium","website":"https://histiocytesociety.org","programs":["LCH-I to LCH-IV international trials","HLH-94 and HLH-2004 protocols","Histiocytosis classification and consensus guidelines","Annual meeting and registries"]},{"id":"hl7","kind":"institution","name":"HL7 International","aka":["Health Level Seven","HL7","FHIR"],"tldr":"The standards body behind FHIR, the healthcare data interface now used to pull oncology records into trials, registries and AI tools, and home of the mCODE cancer data standard.","summary":"Founded in 1987, Health Level Seven International develops the messaging and data standards that let health IT systems exchange information, including HL7 v2, CDA and, since 2011, Fast Healthcare Interoperability Resources (FHIR), which US regulation now requires electronic health record vendors to support. For oncology, the minimal Common Oncology Data Elements (mCODE) implementation guide developed with ASCO's CodeX accelerator defines a core set of structured cancer data (diagnosis, staging, biomarkers, treatments, outcomes) so that records can feed registries, trial matching, real-world evidence and quality measurement without manual abstraction. HL7's work groups also cover genomics reporting and patient-reported outcomes.","asOf":"2026-09-09","links":[{"label":"HL7","url":"https://www.hl7.org"},{"label":"mCODE","url":"https://hl7.org/fhir/us/mcode/"}],"tags":[],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":["ai-trial-matching"],"targets":[],"drugs":[],"companies":[],"institutions":["asco","cdisc","nci"],"pathways":[],"terms":["real-world-evidence"],"trials":[],"people":["rachel-dunscombe"],"bottlenecks":["b-data-silos","b-real-world-evidence","b-trial-enrolment"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Ann Arbor, MI","country":"US","lat":42.281,"lng":-83.743,"institutionType":"consortium","website":"https://www.hl7.org","programs":["FHIR standard","mCODE oncology data standard (with ASCO CodeX)","Genomics reporting implementation guide","HL7 v2 and CDA"]},{"id":"hcmc-oncology-hospital","kind":"institution","name":"Ho Chi Minh City Oncology Hospital","aka":["Bệnh viện Ung Bướu TP.HCM","HCMC Oncology Hospital"],"tldr":"Ho Chi Minh City Oncology Hospital is the referral cancer centre for southern Vietnam and one of the busiest cancer hospitals in South-east Asia; it opened a second campus in Thu Duc in 2020 to relieve overcrowding and runs the city's population-based cancer registry.","summary":"Ho Chi Minh City Oncology Hospital is the referral cancer centre for southern Vietnam and one of the highest-volume cancer hospitals in the region, serving patients from the Mekong Delta and central highlands. It opened a large second campus in Thu Duc in 2020 to relieve severe overcrowding, provides surgical, medical and radiation oncology, nuclear medicine and paediatric oncology, runs the Ho Chi Minh City population-based cancer registry, and trains oncologists for the southern provinces. The hospital collaborates internationally on breast, cervical, liver and nasopharyngeal cancer studies and radiotherapy capacity building, and is expanding trial participation.","asOf":"2026-09-09","links":[{"label":"HCMC Oncology Hospital","url":"https://benhvienungbuou.vn"}],"tags":[],"related":["global-oncology-access","cancer-registries-surveillance"],"cancers":["breast-hr-positive","cervical","hcc","head-and-neck","colorectal"],"sections":["radiation"],"technologies":["imrt-igrt","brachytherapy"],"targets":[],"drugs":[],"companies":[],"institutions":["k-hospital-hanoi"],"pathways":[],"terms":[],"trials":[],"people":["diep-bao-tuan"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Ho Chi Minh City","country":"VN","lat":10.795,"lng":106.68,"institutionType":"cancer-center","website":"https://benhvienungbuou.vn","programs":["Southern Vietnam referral centre","Ho Chi Minh City cancer registry","Radiation oncology","Training"]},{"id":"hokkaido-university-hospital","kind":"institution","name":"Hokkaido University Hospital","aka":["北海道大学病院"],"tldr":"Sapporo's university hospital, which pioneered real-time tumour-tracking radiotherapy and gated proton therapy with Hitachi.","summary":"Hokkaido University Hospital is the main academic hospital of Japan's northern island and is internationally known in radiation oncology: Hiroki Shirato's group developed real-time tumour-tracking radiotherapy using implanted fiducial markers, which became the basis of the gated spot-scanning proton system built with Hitachi and opened at the hospital in 2014. The hospital also has strong gastroenterological surgery, urology (a leading Japanese site for prostate cancer research) and haematology, and Hokkaido University's Institute for Genetic Medicine and Global Center for Biomedical Science and Engineering work on cancer immunology and quantum medical science. It is a core hospital for genome medicine in Hokkaido.","asOf":"2026-09-09","links":[{"label":"Hokkaido University Hospital","url":"https://www.huhp.hokudai.ac.jp"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":["prostate","hcc","nsclc","head-and-neck"],"sections":["radiation"],"technologies":["proton-therapy","imrt-igrt","sbrt","proton-therapy-systems"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["yasuyuki-nasuhara"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Sapporo","country":"JP","lat":43.071,"lng":141.343,"institutionType":"hospital","website":"https://www.huhp.hokudai.ac.jp","university":"Hokkaido University","programs":["Real-time tumour-tracking radiotherapy","Gated spot-scanning proton therapy","Urological oncology","Gastroenterological surgery"]},{"id":"iowa-holden","kind":"institution","name":"Holden Comprehensive Cancer Center, University of Iowa","aka":[],"tldr":"Iowa's only NCI-designated centre, home to the national neuroendocrine tumour SPORE and pharmacological ascorbate research.","summary":"NCI-designated since 2000, Holden serves the state of Iowa and is the only NCI comprehensive centre between Chicago and Omaha. It holds the NCI's only Specialized Program of Research Excellence dedicated to neuroendocrine tumours, building on decades of somatostatin-receptor work, and offers peptide receptor radionuclide therapy. Its free-radical radiation biology programme has carried high-dose intravenous vitamin C (pharmacological ascorbate) from bench to randomised trials in pancreatic cancer and glioblastoma. The centre also runs a statewide cancer registry and rural outreach programmes.","asOf":"2026-09-09","links":[{"label":"Holden Comprehensive Cancer Center","url":"https://uihc.org/holden-comprehensive-cancer-center"},{"label":"Cancer research","url":"https://cancer.uiowa.edu"}],"tags":[],"related":[],"cancers":["neuroendocrine","pancreatic","glioblastoma"],"sections":["radiopharma"],"technologies":["radioligand-therapy","metabolic-therapy","high-dose-vitamin-c"],"targets":["sstr2"],"drugs":["lutathera"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["mark-burkard"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Iowa City, IA","country":"US","lat":41.661,"lng":-91.548,"institutionType":"cancer-center","website":"https://uihc.org/holden-comprehensive-cancer-center","nci":"comprehensive","university":"University of Iowa","programs":["Neuroendocrine tumour SPORE","Pharmacological ascorbate","Radiation biology"]},{"id":"homi-bhabha-cancer-hospital-varanasi","kind":"institution","name":"Homi Bhabha Cancer Hospital and Mahamana Pandit Madan Mohan Malaviya Cancer Centre, Varanasi","aka":["HBCH Varanasi","MPMMCC","Tata Memorial Centre Varanasi"],"tldr":"Tata Memorial Centre's two hospitals in Varanasi bring comprehensive cancer care to the Gangetic plain, one of the most under-served and highest-burden regions in India for oral, cervical and gallbladder cancer.","summary":"The Homi Bhabha Cancer Hospital (Lahartara) and the Mahamana Pandit Madan Mohan Malaviya Cancer Centre (Sundar Bagiya) are units of the Tata Memorial Centre under the Department of Atomic Energy, and part of a national expansion that also includes Tata Memorial units in Sangrur and Mullanpur (Punjab), Visakhapatnam, Muzaffarpur (Bihar) and the Dr B. Borooah Cancer Institute in Guwahati. Varanasi was chosen because eastern Uttar Pradesh and Bihar have very high rates of tobacco-related oral cancer, cervical cancer and gallbladder cancer and had almost no tertiary cancer capacity.\n\nThe centres deliver surgical, medical, radiation and paediatric oncology on the Tata Memorial model of free or subsidised care for most patients, and have become research sites in their own right: the METRO PLUS randomised trial from Varanasi (JCO Global Oncology 2026, 238 patients) found that adding low-cost oral metronomic chemotherapy to paclitaxel-carboplatin in advanced head and neck cancer doubled median survival from 5 to 10 months, and the INSIGHT-HRR cohort mapped germline homologous recombination repair variants in a large north Indian cohort.","asOf":"2026-09-10","links":[{"label":"Tata Memorial Centre (units)","url":"https://tmc.gov.in"},{"label":"METRO PLUS trial (JCO Glob Oncol 2026)","url":"https://doi.org/10.1200/GO-25-00721"}],"tags":[],"related":[],"cancers":["head-and-neck","cervical","cholangiocarcinoma","esophageal"],"sections":["chemotherapy","surgery","radiation"],"technologies":["cytotoxic-chemotherapy","global-oncology-access"],"targets":[],"drugs":[],"companies":[],"institutions":["tata-memorial","national-cancer-grid"],"pathways":[],"terms":[],"trials":["metro-plus-varanasi"],"people":["kapoor-akhil"],"bottlenecks":["b-global-access","b-care-fragmentation"],"keyPapers":["paper-kapoor-jco-glob-oncol"],"journals":[],"dependsOn":[],"notes":[],"city":"Varanasi","country":"IN","lat":25.318,"lng":82.973,"institutionType":"cancer-center","website":"https://tmc.gov.in","university":"Homi Bhabha National Institute","programs":["Head and neck cancer","Gallbladder and gastrointestinal cancers","Cervical cancer","Paediatric oncology","Low-cost trials (METRO PLUS)"]},{"id":"ap-hm-timone","kind":"institution","name":"Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille","aka":["AP-HM","La Timone","CHU de Marseille","Aix-Marseille University Hospital"],"tldr":"Marseille's university hospital, where Jean-Jacques Grob's dermatology department, Olivier Chinot's neuro-oncology unit and Florence Duffaud's sarcoma group have each led international trials.","summary":"Hôpital de la Timone is the largest hospital of Assistance Publique-Hôpitaux de Marseille and the main teaching hospital of Aix-Marseille University. Its Department of Dermatology and Skin Cancer under Jean-Jacques Grob led KEYNOTE-629 in cutaneous squamous-cell carcinoma and contributed to the major melanoma trials; the neuro-oncology unit under Olivier Chinot led AVAglio in glioblastoma; and the medical oncology department under Florence Duffaud coordinated the French Sarcoma Group's REGOBONE trial in bone sarcomas. The Institut Paoli-Calmettes, the region's dedicated cancer centre, is a separate institution across the city.","asOf":"2026-09-18","links":[{"label":"AP-HM","url":"https://www.ap-hm.fr"}],"tags":[],"related":[],"cancers":["melanoma","advanced-cutaneous-scc","glioblastoma","osteosarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["institut-paoli-calmettes"],"pathways":[],"terms":[],"trials":[],"people":["jean-jacques-grob","olivier-chinot","florence-duffaud"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Marseille","country":"FR","lat":43.289,"lng":5.404,"institutionType":"hospital","website":"https://www.ap-hm.fr","university":"Aix-Marseille Université","programs":["Dermato-oncology","Neuro-oncology","Sarcoma (French Sarcoma Group)"]},{"id":"ciusss-emtl-maisonneuve-rosemont","kind":"institution","name":"Hôpital Maisonneuve-Rosemont / CIUSSS de l'Est-de-l'Île-de-Montréal","aka":["HMR","CIUSSS EMTL"],"tldr":"The east Montreal university hospital that runs Quebec's largest stem cell transplant and cell therapy programme.","summary":"Hôpital Maisonneuve-Rosemont is the flagship hospital of the CIUSSS de l'Est-de-l'Île-de-Montréal and a teaching hospital of the Université de Montréal. It hosts Quebec's largest haematology and stem cell transplant programme, the Centre d'excellence en thérapie cellulaire (CETC) for manufacturing cell therapies, and a designated cancer programme with radiotherapy, medical oncology and surgical oncology serving eastern Montreal and Laval. Its research centre is known for immunology and transplantation, leukaemia biology and the Institute for Research in Immunology and Cancer partnership, and it participates in Canadian Cancer Trials Group and cell therapy trials.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://ciusss-estmtl.gouv.qc.ca"}],"tags":[],"related":[],"cancers":["aml"],"sections":[],"technologies":["car-t"],"targets":[],"drugs":[],"companies":[],"institutions":["chum"],"pathways":[],"terms":[],"trials":[],"people":["jean-francois-fortin-verreault"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Montréal","country":"CA","lat":45.575,"lng":-73.561,"institutionType":"hospital","website":"https://ciusss-estmtl.gouv.qc.ca","university":"Université de Montréal","programs":["Stem cell transplantation","Cell therapy manufacturing (CETC)","Haematology research"]},{"id":"hospital-clinic-barcelona","kind":"institution","name":"Hospital Clínic de Barcelona / IDIBAPS","aka":["Hospital Clínic","IDIBAPS","Clínic Barcelona Comprehensive Cancer Center"],"tldr":"Barcelona's university hospital, home of the BCLC liver cancer staging system, the first European academic CAR-T and leading breast and lymphoma genomics.","summary":"Hospital Clínic and its research institute IDIBAPS form one of Spain's strongest academic medical centres. The Barcelona Clinic Liver Cancer group of Jordi Bruix and Josep Maria Llovet created the BCLC staging and treatment algorithm and led the SHARP trial that made sorafenib the first systemic therapy for hepatocellular carcinoma. Elías Campo's group mapped the genome of chronic lymphocytic leukaemia within the ICGC and co-edits the WHO haematolymphoid classification, Aleix Prat's group advanced intrinsic subtyping (PAM50, HER2DX) in breast cancer, and the hospital's ARI-0001 CD19 CAR-T, developed by Manel Juan and Álvaro Urbano-Ispizua, became the first academic CAR-T authorised in Europe under Spain's hospital exemption in 2021. The centre is OECI-accredited and runs a large early-phase and haematology programme.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.clinicbarcelona.org/en"},{"label":"IDIBAPS","url":"https://www.clinicbarcelona.org/en/idibaps"}],"tags":[],"related":[],"cancers":["hcc","cll","all-leukemia","breast-hr-positive","multiple-myeloma"],"sections":["cell-therapy","targeted-therapy"],"technologies":["car-t","rna-seq","wes-wgs","kinase-inhibitors"],"targets":["cd19","bcma"],"drugs":[],"companies":[],"institutions":["vall-dhebron","oeci"],"pathways":[],"terms":["pam50"],"trials":[],"people":["josep-maria-campistol","susana-puig","josep-llovet","aleix-prat"],"bottlenecks":["b-manufacturing-cell-therapy","b-drug-pricing"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Barcelona","country":"ES","lat":41.389,"lng":2.152,"institutionType":"hospital","website":"https://www.clinicbarcelona.org/en","university":"Universitat de Barcelona","programs":["BCLC liver cancer group","Academic CAR-T (ARI-0001, ARI-0002h)","Lymphoid neoplasm genomics","Breast cancer intrinsic subtypes","Early-phase trials"]},{"id":"clinico-san-carlos","kind":"institution","name":"Hospital Clínico San Carlos","aka":["Hospital Clínico Universitario San Carlos","San Carlos Clinical Hospital","IdISSC"],"tldr":"The Complutense University's teaching hospital in Madrid, on its 1951 site, with a large cancer service, and a full member of the Organisation of European Cancer Institutes.","summary":"The Hospital Clínico San Carlos is a public university hospital in the Moncloa district of Madrid, on its current site since 1951, and the main teaching hospital of the Complutense University. Its cancer care spans medical oncology, haematology, surgery and radiotherapy, with research through the San Carlos Health Research Institute (IdISSC). It is a full member of the Organisation of European Cancer Institutes (OECI); its representative on the OECI list is César Adolfo Gómez Derch.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Hospital_Cl%C3%ADnico_San_Carlos","links":[{"label":"Official website","url":"https://www.comunidad.madrid/hospital/clinicosancarlos"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q6673106"}],"tags":[],"related":["12-de-octubre","la-paz","gregorio-maranon"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["cesar-adolfo-gomez-derch"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Madrid","country":"ES","lat":40.441,"lng":-3.72,"institutionType":"hospital","website":"https://www.comunidad.madrid/hospital/clinicosancarlos","programs":[]},{"id":"hospital-de-amor-barretos","kind":"institution","name":"Hospital de Amor (Barretos Cancer Hospital)","aka":["Hospital de Câncer de Barretos","Fundação Pio XII","Barretos"],"tldr":"A philanthropic cancer hospital in rural São Paulo state that treats entirely through Brazil's public system, famous for mobile screening units and a large research centre.","summary":"The Barretos Cancer Hospital, renamed Hospital de Amor, grew from a small clinic founded by Paulo Prata in 1962 into one of the largest cancer hospitals in Brazil, treating patients from every state free of charge through the SUS and funded largely by donations and the country music charity events for which Barretos is known. It pioneered mobile mammography, cervical screening and skin cancer units that travel to remote regions, hosts a paediatric cancer hospital and a Molecular Oncology Research Center with strengths in HPV epidemiology, glioma genomics and cancer prevention, and runs hospital cancer registries and screening programmes used by national policy. Barretos was the first Latin American site for several international prevention and HPV self-sampling studies with IARC.","asOf":"2026-09-09","links":[{"label":"Hospital de Amor","url":"https://hospitaldeamor.com.br"}],"tags":[],"related":["global-oncology-access"],"cancers":["cervical","breast-hr-positive","glioblastoma","melanoma"],"sections":["prevention","early-detection"],"technologies":["mammography","hpv-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":["iarc"],"pathways":[],"terms":[],"trials":[],"people":["henrique-prata"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Barretos","country":"BR","lat":-20.557,"lng":-48.568,"institutionType":"cancer-center","website":"https://hospitaldeamor.com.br","programs":["Mobile screening units","Cancer prevention research","Molecular Oncology Research Center","Paediatric cancer hospital"]},{"id":"hcpa-porto-alegre","kind":"institution","name":"Hospital de Clínicas de Porto Alegre","aka":["HCPA"],"tldr":"Southern Brazil's leading public university hospital, known for cancer genetics, Li-Fraumeni research and one of Brazil's strongest clinical research programmes.","summary":"Hospital de Clínicas de Porto Alegre opened in 1971 as the teaching hospital of the Universidade Federal do Rio Grande do Sul and is one of Brazil's top public research hospitals and a designated high-complexity oncology centre. Its oncology and medical genetics services, under Patricia Ashton-Prolla and colleagues, characterised the high prevalence of the TP53 R337H founder mutation in southern Brazil and built hereditary cancer clinics and registries, and its haematology, paediatric oncology, breast and gastrointestinal cancer programmes contribute to Latin American and international cooperative trials, including through the Latin American Cooperative Oncology Group (LACOG) headquartered in Porto Alegre. HCPA runs a large clinical research centre and a radiotherapy and bone marrow transplant service for the public system.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Hospital_de_Cl%C3%ADnicas_de_Porto_Alegre","links":[{"label":"HCPA","url":"https://www.hcpa.edu.br"},{"label":"LACOG","url":"https://lacog.org.br"}],"tags":[],"related":["li-fraumeni","hereditary-cancer-syndromes"],"cancers":["breast-hr-positive","colorectal","all-leukemia","prostate"],"sections":["diagnostics","prevention"],"technologies":["germline-testing"],"targets":["tp53","brca"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["barrios-carlos","brasil-silva-neto"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Porto Alegre","country":"BR","lat":-30.039,"lng":-51.207,"institutionType":"hospital","website":"https://www.hcpa.edu.br","university":"Universidade Federal do Rio Grande do Sul","programs":["Hereditary cancer and Li-Fraumeni research","Clinical research centre","Haematology and transplant","LACOG collaboration"]},{"id":"hospital-de-sant-pau","kind":"institution","name":"Hospital de la Santa Creu i Sant Pau","aka":["Hospital de Sant Pau","Sant Pau","Campus Sant Pau – Puigvert","Campus Sant Pau Puigvert"],"tldr":"Hospital de Sant Pau is a Barcelona university hospital, famous for its modernista buildings, whose cancer campus with the Puigvert Foundation is an associate member of the Organisation of European Cancer Institutes.","summary":"The Hospital de la Santa Creu i Sant Pau in Barcelona is a university hospital of the Autonomous University of Barcelona with origins in 1905, whose historic complex by Lluís Domènech i Montaner was built between 1901 and 1930 and is a UNESCO World Heritage Site; clinical care now runs in a modern hospital beside it. Together with the Puigvert Foundation, a urology and nephrology institute on the same campus, it is listed by the Organisation of European Cancer Institutes as an associate member (Campus Sant Pau Puigvert). Programme, trial and leadership details are not yet recorded here and should be checked on the hospital's own pages.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Hospital_de_Sant_Pau","links":[{"label":"Official website","url":"https://www.santpaubarcelona.org"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Hospital_de_Sant_Pau"}],"tags":[],"related":["vall-dhebron","ico-catalonia"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["adria-comella-carnice"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Barcelona","country":"ES","lat":41.413,"lng":2.174,"institutionType":"hospital","website":"https://www.santpaubarcelona.org","programs":[]},{"id":"imss-oncologia-siglo-xxi","kind":"institution","name":"Hospital de Oncología, Centro Médico Nacional Siglo XXI (IMSS)","aka":["Hospital de Oncología CMN Siglo XXI","IMSS Oncology Hospital"],"tldr":"The flagship cancer hospital of Mexico's social security institute (IMSS), which treats a large share of the country's insured cancer patients.","summary":"The Hospital de Oncología of the Centro Médico Nacional Siglo XXI is the principal cancer hospital of the Instituto Mexicano del Seguro Social, the social security system covering most formally employed Mexicans and their families. It provides surgical oncology, medical oncology, radiotherapy, haematology, nuclear medicine and palliative care as a national referral centre, trains a large proportion of Mexico's oncologists through IMSS residency programmes, and hosts an oncology research unit within the IMSS Coordinación de Investigación en Salud. Together with the Instituto Nacional de Cancerología it anchors cancer care in Mexico City.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.imss.gob.mx"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["incan-mexico"],"pathways":[],"terms":[],"trials":[],"people":["zoe-robledo"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Mexico City","country":"MX","lat":19.407,"lng":-99.155,"institutionType":"hospital","website":"https://www.imss.gob.mx","programs":["IMSS national referral cancer hospital","Radiotherapy","Oncology residency training"]},{"id":"hospital-del-mar","kind":"institution","name":"Hospital del Mar / Hospital del Mar Research Institute","aka":["IMIM","Parc de Salut Mar"],"tldr":"Barcelona's seaside university hospital, whose research institute under Joaquín Arribas leads HER2 biology and CAR-T against breast cancer.","summary":"Hospital del Mar and the Hospital del Mar Research Institute (formerly IMIM) form a cancer programme with Universitat Pompeu Fabra and the Universitat Autònoma de Barcelona. Joaquín Arribas, director of the institute, characterised the truncated p95HER2 receptor and developed CAR-T and T-cell engager approaches against it, and Joan Albanell's medical oncology group is a leading breast cancer trialist within the SOLTI network. The hospital runs a comprehensive cancer service including radiotherapy, hepatobiliary surgery and haematology, an early-phase unit, and population cancer epidemiology through its public health research groups.","asOf":"2026-09-09","links":[{"label":"Hospital del Mar","url":"https://www.hospitaldelmar.cat"}],"tags":[],"related":[],"cancers":["breast-her2-positive","breast-hr-positive","colorectal"],"sections":["cell-therapy","targeted-therapy"],"technologies":["car-t","t-cell-engager","monoclonal-antibody"],"targets":["her2"],"drugs":["trastuzumab"],"companies":[],"institutions":["vall-dhebron","hospital-clinic-barcelona"],"pathways":[],"terms":[],"trials":[],"people":["joaquin-arribas","jaume-raventos-i-monjo"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Barcelona","country":"ES","lat":41.384,"lng":2.193,"institutionType":"hospital","website":"https://www.hospitaldelmar.cat","university":"Universitat Pompeu Fabra","programs":["HER2 biology and p95HER2 CAR-T","Breast cancer trials (SOLTI)","Cancer epidemiology","Early-phase trials"]},{"id":"erasto-gaertner","kind":"institution","name":"Hospital Erasto Gaertner","aka":[],"tldr":"The dedicated cancer hospital of Paraná state in southern Brazil, founded in 1972 by the Liga Paranaense de Combate ao Câncer.","summary":"Hospital Erasto Gaertner in Curitiba is a philanthropic cancer hospital opened in 1972 by the Liga Paranaense de Combate ao Câncer, and is the largest dedicated cancer centre in Paraná, treating mostly public health system patients. It provides surgical oncology, medical oncology, radiotherapy, paediatric oncology, haematology and palliative care, is accredited as a CACON (high-complexity oncology centre) by Brazil's Ministry of Health, and runs a research institute and clinical trials centre that participates in the Latin American Cooperative Oncology Group and industry trials.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Erasto_Gaertner_Hospital","links":[{"label":"Official website","url":"https://erastogaertner.com.br"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["inca-brazil"],"pathways":[],"terms":[],"trials":[],"people":["flavio-tomasich"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Curitiba","country":"BR","lat":-25.454,"lng":-49.27,"institutionType":"cancer-center","website":"https://erastogaertner.com.br","programs":["Dedicated cancer hospital","Radiotherapy","Paediatric oncology","Clinical trials"]},{"id":"gregorio-maranon","kind":"institution","name":"Hospital General Universitario Gregorio Marañón","aka":[],"tldr":"Gregorio Marañón is a Madrid public hospital with a leading breast cancer research group (GEICAM).","summary":"Hospital General Universitario Gregorio Marañón is a Madrid public hospital ranked fortieth in the Newsweek/Statista World's Best Specialized Hospitals list for oncology, and it matters for breast cancer research. Its breast oncology group is associated with Miguel Martín, founder of the GEICAM Spanish Breast Cancer Group, and Sara López-Tarruella, and it also has a gastrointestinal oncology programme. OnCo links it to HR-positive, HER2-negative breast cancer and to triple-negative breast cancer, and GEICAM has its own institution page. How an academic cooperative group housed in a public hospital keeps influence as breast trials become industry-led is the question its history raises. Its breast programme is the reason to read on.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Hospital_General_Universitario_Gregorio_Mara%C3%B1%C3%B3n","links":[{"label":"Official website","url":"https://www.comunidad.madrid/hospital/gregoriomaranon"}],"tags":[],"related":[],"cancers":["breast-hr-positive","tnbc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["miguel-martin","sara-lopez-tarruella","sonia-garcia-de-san-jose"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Madrid","country":"ES","lat":40.419,"lng":-3.668,"institutionType":"hospital","website":"https://www.comunidad.madrid/hospital/gregoriomaranon","newsweekOncology2026":40,"programs":["Breast cancer (GEICAM)"]},{"id":"einstein-sao-paulo","kind":"institution","name":"Hospital Israelita Albert Einstein","aka":[],"tldr":"Hospital Israelita Albert Einstein is Latin America's top-ranked hospital and cancer programme.","summary":"Hospital Israelita Albert Einstein in São Paulo is Latin America's top-ranked hospital and cancer programme, placed seventeenth in the Newsweek/Statista World's Best Specialized Hospitals list for oncology. It is the leading Brazilian centre for clinical trials, precision oncology and radiotherapy, and a major Latin American enroller in global phase 3 trials, which gives it outsized influence on how new drugs reach the region. OnCo links it to Rafael Kaliks and Carlos Barrios, to the Brazilian regulator ANVISA, and to the idea of burden-matched funding for trials led in low- and middle-income countries. Whether trial leadership, rather than enrolment alone, can shift to centres like this is the open question. Its trials and precision oncology programmes are the ones to follow.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Albert_Einstein_Israelite_Hospital","links":[{"label":"Official website","url":"https://www.einstein.br"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["kaliks-rafael"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"São Paulo","country":"BR","lat":-23.599,"lng":-46.714,"institutionType":"hospital","website":"https://www.einstein.br","newsweekOncology2026":17,"programs":["Clinical trials","Precision oncology"]},{"id":"hospital-italiano-buenos-aires","kind":"institution","name":"Hospital Italiano de Buenos Aires","aka":["HIBA"],"tldr":"Argentina's leading academic hospital, founded in 1853, with a large oncology programme and one of Latin America's most active clinical research units.","summary":"The Hospital Italiano de Buenos Aires was founded in 1853 by the Italian community and is today a university hospital with its own Instituto Universitario. Its oncology services span medical oncology, haematology and transplantation, radiation oncology, surgical oncology, nuclear medicine and palliative care, supported by one of the region's most developed electronic health record and research infrastructures. The hospital is a major Argentine site for international oncology trials, runs a hereditary cancer programme and a precision oncology unit, and trains oncologists through its residency and fellowship programmes.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Hospital_Italiano_de_Buenos_Aires","links":[{"label":"Official website","url":"https://www.hospitalitaliano.org.ar"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["instituto-alexander-fleming"],"pathways":[],"terms":[],"trials":[],"people":["esteban-langlois"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Buenos Aires","country":"AR","lat":-34.606,"lng":-58.424,"institutionType":"hospital","website":"https://www.hospitalitaliano.org.ar","programs":["Medical and radiation oncology","Clinical research unit","Hereditary cancer programme"]},{"id":"kauno-klinikos","kind":"institution","name":"Hospital of the Lithuanian University of Health Sciences Kauno Klinikos","aka":["Kauno klinikos","Lietuvos sveikatos mokslų universiteto ligoninė Kauno klinikos","LSMU Kauno klinikos"],"tldr":"Hospital of the Lithuanian University of Health Sciences Kauno Klinikos is the largest hospital in Lithuania and the teaching hospital of the Lithuanian University of Health Sciences, and a full member of the Organisation of European Cancer Institutes.","summary":"Hospital of the Lithuanian University of Health Sciences Kauno Klinikos is the largest hospital in Lithuania and the teaching hospital of the Lithuanian University of Health Sciences. It is listed by the Organisation of European Cancer Institutes as a full member, which is why it has a page on OnCo. Programme, trial and leadership details are not yet recorded here and should be checked on the institution's own pages.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.kaunoklinikos.lt"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["renaldas-jurkevicius"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Kaunas","country":"LT","lat":54.899,"lng":23.903,"institutionType":"hospital","website":"https://www.kaunoklinikos.lt","programs":[]},{"id":"sirio-libanes","kind":"institution","name":"Hospital Sírio-Libanês","aka":[],"tldr":"Brazil's second top-ranked oncology hospital with strong radiotherapy and research programmes.","summary":"Hospital Sírio-Libanês in São Paulo is Brazil's second top-ranked oncology hospital, placed nineteenth in the Newsweek/Statista World's Best Specialized Hospitals list for oncology. It runs an oncology centre with radiotherapy and proton therapy planning, a precision medicine programme and a research institute, and its clinicians include Artur Katz and Paulo Hoff, both linked in OnCo. It sits alongside Hospital Israelita Albert Einstein and BP, A Beneficência Portuguesa de São Paulo, in the group of private Brazilian centres that carry much of the country's cancer trial activity, under the oversight of ANVISA. How much of its work reaches Brazil's public system is the fair question to ask. Its radiotherapy and precision oncology programmes are the starting points.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Hospital_S%C3%ADrio-Liban%C3%AAs","links":[{"label":"Official website","url":"https://www.hospitalsiriolibanes.org.br"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["katz-artur","hoff-paulo"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"São Paulo","country":"BR","lat":-23.558,"lng":-46.654,"institutionType":"hospital","website":"https://www.hospitalsiriolibanes.org.br","newsweekOncology2026":19,"programs":["Radiotherapy","Precision oncology"]},{"id":"la-fe-valencia","kind":"institution","name":"Hospital Universitari i Politècnic La Fe","aka":["Hospital La Fe","IIS La Fe"],"tldr":"Valencia's flagship public hospital, with a haematology department that shaped the treatment of acute promyelocytic leukaemia through the PETHEMA group.","summary":"La Fe is the largest hospital complex of the Valencian region and hosts the IIS La Fe research institute. Its haematology department, long led by Miguel Ángel Sanz, designed the PETHEMA protocols that established risk-adapted all-trans retinoic acid and anthracycline therapy for acute promyelocytic leukaemia and remains a reference for acute leukaemias and transplantation within Spain's PETHEMA cooperative group. The hospital runs a large medical oncology service, paediatric oncology, radiotherapy including stereotactic programmes, a nuclear medicine and PET unit and an early-phase trials unit. It is a regional hub for molecular diagnostics and hereditary cancer counselling.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.lafe.san.gva.es"},{"label":"IIS La Fe","url":"https://www.iislafe.es"}],"tags":[],"related":[],"cancers":["aml","all-leukemia","breast-hr-positive","colorectal"],"sections":["chemotherapy","radiation"],"technologies":["allogeneic-cell-therapy","sbrt","pet-ct","germline-testing"],"targets":[],"drugs":[],"companies":[],"institutions":["incliva-valencia"],"pathways":[],"terms":[],"trials":[],"people":["jose-luis-poveda-andres"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Valencia","country":"ES","lat":39.443,"lng":-0.376,"institutionType":"hospital","website":"https://www.lafe.san.gva.es","university":"Universitat de València","programs":["Acute leukaemia (PETHEMA)","Transplantation","Paediatric oncology","Radiotherapy","Molecular diagnostics"]},{"id":"hospital-sant-joan-de-reus","kind":"institution","name":"Hospital Universitari Sant Joan de Reus","aka":["Southern Catalonia Oncology Institute University Hospital Sant Joan of Reus","Sant Joan de Reus","Institut d'Oncologia de la Catalunya Sud"],"tldr":"Hospital Universitari Sant Joan de Reus hosts the Southern Catalonia Oncology Institute and is a full member of the Organisation of European Cancer Institutes.","summary":"The Hospital Universitari Sant Joan de Reus is the university hospital of Reus in the province of Tarragona, affiliated with Rovira i Virgili University and housed in a hospital opened in 2010. It hosts the Southern Catalonia Oncology Institute (Institut d'Oncologia de la Catalunya Sud), the cancer service for the south of Catalonia, and in that capacity is listed by the Organisation of European Cancer Institutes as a full member. Programme, trial and leadership details are not yet recorded here and should be checked on the hospital's own pages.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.hospitalsantjoan.cat"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":["ico-catalonia","vall-dhebron"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["anton-benet-catala"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Reus","country":"ES","lat":41.145,"lng":1.122,"institutionType":"hospital","website":"https://www.hospitalsantjoan.cat","programs":[]},{"id":"12-de-octubre","kind":"institution","name":"Hospital Universitario 12 de Octubre","aka":["H12O","i+12 Research Institute"],"tldr":"One of Madrid's largest hospitals, a leading site for lung cancer and myeloma trials and for academic CAR-T development.","summary":"The Hospital Universitario 12 de Octubre and its research institute i+12 host the H12O-CNIO Lung Cancer Clinical Research Unit led by Luis Paz-Ares, one of the most active investigators in small-cell and non-small-cell lung cancer trials including the tarlatamab programme, and a haematology department under Joaquín Martínez-López that pioneered next-generation sequencing for minimal residual disease in myeloma and co-developed the academic BCMA CAR-T ARI-0002h with Hospital Clínic. The hospital is a major transplant centre, runs paediatric oncology and neuro-oncology services and a phase 1 unit. Its proximity to the CNIO underpins joint translational programmes.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Hospital_Universitario_12_de_Octubre","links":[{"label":"Homepage","url":"https://www.comunidad.madrid/hospital/12octubre/"},{"label":"i+12","url":"https://imas12.es"}],"tags":[],"related":[],"cancers":["sclc","nsclc","multiple-myeloma","aml"],"sections":["immunotherapy","cell-therapy"],"technologies":["t-cell-engager","car-t","mrd-testing","checkpoint-inhibitor"],"targets":["dll3","bcma"],"drugs":["tarlatamab","durvalumab"],"companies":[],"institutions":["cnio","hospital-clinic-barcelona"],"pathways":[],"terms":["mrd"],"trials":[],"people":["luis-paz-ares","joaquin-martinez-lopez","carmen-martinez-de-pancorbo-gonzalez"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Madrid","country":"ES","lat":40.375,"lng":-3.697,"institutionType":"hospital","website":"https://www.comunidad.madrid/hospital/12octubre/","university":"Universidad Complutense de Madrid","programs":["H12O-CNIO Lung Cancer Unit","Myeloma and MRD by NGS","Academic CAR-T","Transplantation","Phase 1 unit"]},{"id":"la-princesa","kind":"institution","name":"Hospital Universitario de La Princesa","aka":["La Princesa University Hospital","Hospital de La Princesa"],"tldr":"A public university hospital in central Madrid, opened in 1955, with a cancer service and research institute, and a full member of the Organisation of European Cancer Institutes.","summary":"The Hospital Universitario de La Princesa is a public teaching hospital in the Salamanca district of Madrid, opened in 1955 and affiliated to the Autonomous University of Madrid, with oncology, haematology and radiotherapy services and its own health research institute. It is a full member of the Organisation of European Cancer Institutes (OECI); its representative on the OECI list is Jose Julián Díaz Melguizo.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Hospital_Universitario_de_la_Princesa","links":[{"label":"Official website","url":"https://www.comunidad.madrid/hospital/laprincesa/"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q5903033"}],"tags":[],"related":["12-de-octubre","la-paz","gregorio-maranon"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["jose-julian-diaz-melguizo"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Madrid","country":"ES","lat":40.434,"lng":-3.676,"institutionType":"hospital","website":"https://www.comunidad.madrid/hospital/laprincesa/","programs":[]},{"id":"doctor-peset-valencia","kind":"institution","name":"Hospital Universitario Doctor Peset","aka":["Doctor Peset University Hospital","Hospital Doctor Peset"],"tldr":"Hospital Universitario Doctor Peset is a public university hospital of the Valencian health service, and a full member of the Organisation of European Cancer Institutes.","summary":"Hospital Universitario Doctor Peset is a public university hospital of the Valencian health service. It is listed by the Organisation of European Cancer Institutes as a full member, which is why it has a page on OnCo. Programme, trial and leadership details are not yet recorded here and should be checked on the institution's own pages.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://doctorpeset.san.gva.es"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["luis-ibanez-gadea"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Valencia","country":"ES","lat":39.453,"lng":-0.383,"institutionType":"hospital","website":"https://doctorpeset.san.gva.es","programs":[]},{"id":"fundacion-jimenez-diaz","kind":"institution","name":"Hospital Universitario Fundación Jiménez Díaz","aka":["FJD","OncoHealth Institute"],"tldr":"A Madrid university hospital founded by Carlos Jiménez Díaz in 1955, whose OncoHealth Institute is accredited by OECI as a Comprehensive Cancer Centre.","summary":"The Fundación Jiménez Díaz was founded in 1955 by the clinician Carlos Jiménez Díaz and is today a university hospital affiliated with the Universidad Autónoma de Madrid and managed within the Quirónsalud group under a public-private concession. Its cancer programme is organised as the OncoHealth Institute, integrating medical oncology, radiation oncology, haematology, surgical oncology and a large early-phase trials unit, and is accredited by the Organisation of European Cancer Institutes as a Comprehensive Cancer Centre. Research through the IIS-FJD health research institute covers lung and breast cancer, haematological malignancies and precision oncology.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.fjd.es"}],"tags":["oeci-accredited","oeci-comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["javier-arcos"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Madrid","country":"ES","lat":40.439,"lng":-3.719,"institutionType":"hospital","website":"https://www.fjd.es","university":"Universidad Autónoma de Madrid","programs":["OncoHealth Institute","Early-phase trials","Precision oncology"]},{"id":"la-paz","kind":"institution","name":"Hospital Universitario La Paz","aka":[],"tldr":"La Paz is Madrid's flagship public hospital, with a large oncology programme.","summary":"Hospital Universitario La Paz is Madrid's flagship public hospital and ranks thirty-sixth in the Newsweek/Statista World's Best Specialized Hospitals list for oncology. It offers comprehensive oncology services and runs clinical trials, and OnCo lists Jaime Feliu, Enrique Espinosa and Beatriz Castelo among the oncologists based there. Its place in the corpus is as one of the large public Spanish hospitals, alongside Gregorio Marañón and the Barcelona centres, through which trial access reaches patients in the national health system. How much of its trial activity is investigator-led rather than company-sponsored is not recorded here and is the question a reader should ask. Its clinical trials programme is the entry point.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Hospital_Universitario_La_Paz","links":[{"label":"Official website","url":"https://www.comunidad.madrid/hospital/lapaz"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["jaime-feliu","enrique-espinosa","beatriz-castelo","rafael-perez-santamarina"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Madrid","country":"ES","lat":40.481,"lng":-3.687,"institutionType":"hospital","website":"https://www.comunidad.madrid/hospital/lapaz","newsweekOncology2026":36,"programs":["Clinical trials"]},{"id":"puerta-de-hierro","kind":"institution","name":"Hospital Universitario Puerta de Hierro Majadahonda","aka":["Puerta de Hierro University Hospital","Hospital Puerta de Hierro"],"tldr":"A public university hospital west of Madrid, founded in 1964 and rebuilt in Majadahonda, with a cancer service and a strong transplant record, and a full member of the Organisation of European Cancer Institutes.","summary":"The Hospital Universitario Puerta de Hierro, founded in 1964 in Madrid and moved to a new campus in Majadahonda in 2008, is a public teaching hospital of the Autonomous University of Madrid known for transplantation and with oncology, haematology and radiotherapy services. It is a full member of the Organisation of European Cancer Institutes (OECI); its representative on the OECI list is Julio García Pondal.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.comunidad.madrid/hospital/puertadehierro/"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q5661215"}],"tags":[],"related":["12-de-octubre","la-paz"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["julio-garcia-pondal"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Majadahonda","country":"ES","lat":40.45,"lng":-3.874,"institutionType":"hospital","website":"https://www.comunidad.madrid/hospital/puertadehierro/","programs":[]},{"id":"ramon-y-cajal","kind":"institution","name":"Hospital Universitario Ramón y Cajal","aka":["Ramón y Cajal University Hospital","Hospital Ramón y Cajal","IRYCIS"],"tldr":"A large public university hospital in north Madrid, opened in 1977, with a full cancer service and research institute, and a full member of the Organisation of European Cancer Institutes.","summary":"The Hospital Universitario Ramón y Cajal is one of Madrid's large public teaching hospitals, opened in 1977 and run by the regional health service. Its oncology, haematology and radiotherapy departments work with the Ramón y Cajal Institute for Health Research (IRYCIS). It is a full member of the Organisation of European Cancer Institutes (OECI); its representative on the OECI list is Carlos Mingo Rodriguez.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Hospital_Universitario_Ram%C3%B3n_y_Cajal","links":[{"label":"Official website","url":"https://www.comunidad.madrid/hospital/ramonycajal/"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q5902966"}],"tags":[],"related":["12-de-octubre","la-paz","gregorio-maranon"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["carlos-mingo-rodriguez"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Madrid","country":"ES","lat":40.487,"lng":-3.694,"institutionType":"hospital","website":"https://www.comunidad.madrid/hospital/ramonycajal/","programs":[]},{"id":"virgen-de-la-victoria-malaga","kind":"institution","name":"Hospital Universitario Virgen de la Victoria","aka":["Hospital Virgen de la Victoria","Hospital Clínico Universitario Virgen de la Victoria"],"tldr":"Hospital Universitario Virgen de la Victoria is one of the two public university hospitals of Málaga in the Andalusian health service, and a full member of the Organisation of European Cancer Institutes.","summary":"Hospital Universitario Virgen de la Victoria is one of the two public university hospitals of Málaga in the Andalusian health service. It is listed by the Organisation of European Cancer Institutes as a full member, which is why it has a page on OnCo. Programme, trial and leadership details are not yet recorded here and should be checked on the institution's own pages.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.sspa.juntadeandalucia.es/servicioandaluzdesalud/hospital/virgen-victoria/"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["jesus-fernandez-galan"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Málaga","country":"ES","lat":36.718,"lng":-4.478,"institutionType":"hospital","website":"https://www.sspa.juntadeandalucia.es/servicioandaluzdesalud/hospital/virgen-victoria/","programs":[]},{"id":"houston-methodist-rna-therapeutics","kind":"institution","name":"Houston Methodist Center for RNA Therapeutics","aka":[],"tldr":"Houston Methodist's Center for RNA Therapeutics, led by John Cooke, is an academic mRNA vaccine programme with cancer studies opening for enrolment.","summary":"The Center for RNA Therapeutics at Houston Methodist Academic Institute develops mRNA-based therapies and vaccines, including cancer vaccines, under John Cooke; Future of Cancer Care Today lists it for trial enrolment as studies open.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.houstonmethodist.org/academic-institute/department-programs/center-for-rna-therapeutics/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["neoantigen-mrna-vaccine"],"targets":[],"drugs":[],"companies":["future-of-cancer-care-today"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Houston","country":"US","lat":29.71,"lng":-95.4,"institutionType":"research-institute","website":"https://www.houstonmethodist.org/academic-institute/department-programs/center-for-rna-therapeutics/","programs":[]},{"id":"houston-methodist-neal-cancer-center","kind":"institution","name":"Houston Methodist Dr. Mary and Ron Neal Cancer Center","aka":["Houston Methodist Cancer Center","Houston Methodist Hospital"],"tldr":"Cancer centre of Houston Methodist Hospital in the Texas Medical Center, where Pedro Ramirez, who led the LACC trial that changed cervical cancer surgery, chairs obstetrics and gynaecology.","summary":"The Dr. Mary and Ron Neal Cancer Center is the cancer service of Houston Methodist Hospital, a large academic hospital in the Texas Medical Center a few blocks from MD Anderson. Pedro Ramirez, who at MD Anderson led the LACC trial showing that minimally invasive radical hysterectomy gave worse survival than open surgery in early cervical cancer, became chair of its Department of Obstetrics and Gynecology in 2022. The hospital's research institute also hosts the Center for RNA Therapeutics.","asOf":"2026-09-18","links":[{"label":"Houston Methodist","url":"https://www.houstonmethodist.org"}],"tags":[],"related":[],"cancers":["cervical"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["houston-methodist-rna-therapeutics","md-anderson"],"pathways":[],"terms":[],"trials":[],"people":["pedro-ramirez"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Houston, TX","country":"US","lat":29.71,"lng":-95.4,"institutionType":"cancer-center","website":"https://www.houstonmethodist.org","programs":["Gynaecological oncology","Surgical oncology","RNA therapeutics"]},{"id":"hhmi","kind":"institution","name":"Howard Hughes Medical Institute","aka":["HHMI"],"tldr":"The Howard Hughes Medical Institute funds scientists rather than projects through its Investigator Program; its roster has included Bert Vogelstein, William Kaelin, Charles Sawyers, Benjamin Ebert and Feng Zhang, the researchers behind colorectal cancer genetics, hypoxia sensing, kinase inhibitor resistance and CRISPR tools.","summary":"Founded in 1953 by Howard Hughes, HHMI is one of the largest private funders of biomedical research in the United States. Its Investigator Program gives long-term, flexible support to scientists at their home institutions, and its roster has included cancer researchers such as Bert Vogelstein (colorectal cancer genetics), William Kaelin (VHL and hypoxia sensing, Nobel 2019), Charles Sawyers (androgen receptor and kinase inhibitor resistance), Benjamin Ebert (lenalidomide's mechanism, clonal haematopoiesis) and Feng Zhang (CRISPR tools). HHMI also runs the Janelia Research Campus, the Hanna Gray and Freeman Hrabowski early-career fellowships, and it co-founded the open-access journal eLife.","asOf":"2026-09-09","links":[{"label":"HHMI","url":"https://www.hhmi.org"},{"label":"Investigators","url":"https://www.hhmi.org/scientists"}],"tags":[],"related":[],"cancers":[],"sections":["drug-discovery"],"technologies":["crispr-screens"],"targets":[],"drugs":[],"companies":[],"institutions":["johns-hopkins","dana-farber","mskcc","broad-institute"],"pathways":[],"terms":[],"trials":[],"people":["bert-vogelstein","william-kaelin","charles-sawyers","benjamin-ebert","feng-zhang","erin-oshea","david-baker"],"bottlenecks":["b-funding-allocation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Chevy Chase, MD","country":"US","lat":38.983,"lng":-77.086,"institutionType":"consortium","website":"https://www.hhmi.org","programs":["HHMI Investigator Program","Janelia Research Campus","Hanna Gray and Freeman Hrabowski fellowships","Open science (eLife, preprints)"]},{"id":"humber-north-yorkshire-cancer-alliance","kind":"institution","name":"Humber & North Yorkshire Cancer Alliance","aka":["Humber and North Yorkshire Cancer Alliance","HNY Cancer Alliance"],"tldr":"The NHS England Cancer Alliance for Hull, the East Riding, North and North East Lincolnshire, York and North Yorkshire: the partnership that plans and improves cancer services across its hospitals, GPs and community services.","summary":"One of the 20 Cancer Alliances set up by NHS England from 2016, following the Independent Cancer Taskforce strategy, to bring together the hospital trusts, integrated care boards, primary care, hospices and charities serving Hull, the East Riding, North and North East Lincolnshire, York and North Yorkshire. Alliances lead local delivery of the NHS cancer ambitions: earlier diagnosis (including rapid diagnostic centres and targeted lung health checks), the Faster Diagnosis Standard, personalised care and follow-up, and workforce and pathway improvement. They hold transformation funding from NHS England and publish local performance and improvement plans.","asOf":"2026-09-09","links":[{"label":"Humber & North Yorkshire Cancer Alliance","url":"https://www.hnycanceralliance.org.uk"},{"label":"NHS England: Cancer Alliances","url":"https://www.england.nhs.uk/cancer/cancer-alliances-improving-care-locally/"}],"tags":["nhs-cancer-alliance"],"related":[],"cancers":[],"sections":["early-detection"],"technologies":["low-dose-ct-screening"],"targets":[],"drugs":[],"companies":[],"institutions":["queens-centre-hull"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Hull","country":"GB","lat":53.745,"lng":-0.336,"institutionType":"consortium","website":"https://www.hnycanceralliance.org.uk","programs":["Earlier diagnosis and rapid diagnostic centres","Faster Diagnosis Standard","Personalised care and follow-up","Cancer pathway improvement"]},{"id":"hunan-cancer-hospital","kind":"institution","name":"Hunan Cancer Hospital","aka":["Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University","湖南省肿瘤医院"],"tldr":"Central China's provincial cancer hospital, a high-enrolling trial site in lung and gastrointestinal cancer with a large radiotherapy department.","summary":"Hunan Cancer Hospital was founded in 1972 and is the affiliated cancer hospital of Central South University's Xiangya School of Medicine. It is one of the most active Chinese sites for registration trials of domestic PD-1 antibodies, EGFR and ALK inhibitors and ADCs, and has particular strength in lung cancer, gastric and colorectal cancer, head and neck surgery and gynaecological radiotherapy. The hospital operates the Hunan cancer registry and a phase 1 clinical trial centre, and participates in the national cancer screening programmes for rural China.","asOf":"2026-09-09","links":[{"label":"Hunan Cancer Hospital","url":"https://www.hnszlyy.com"},{"label":"Central South University","url":"https://www.csu.edu.cn"}],"tags":[],"related":[],"cancers":["nsclc","gastric","colorectal","cervical"],"sections":["radiation","immunotherapy"],"technologies":["checkpoint-inhibitor","kinase-inhibitors","imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["xiang-hua"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Changsha","country":"CN","lat":28.196,"lng":112.943,"institutionType":"cancer-center","website":"https://www.hnszlyy.com","university":"Central South University","programs":["Lung cancer trials","Gastrointestinal oncology","Radiotherapy","Phase 1 centre"]},{"id":"huntsman","kind":"institution","name":"Huntsman Cancer Institute, University of Utah","aka":["HCI"],"tldr":"The Mountain West's NCI comprehensive centre, built on Utah's genealogy-linked population database that helped find BRCA1 and other hereditary cancer genes.","summary":"Founded by Jon Huntsman and NCI-designated in 1999 (comprehensive since 2015), Huntsman Cancer Institute serves Utah, Idaho, Montana, Nevada and Wyoming. The Utah Population Database, which links genealogies to medical records, enabled the cloning of BRCA1 by Mark Skolnick's group in 1994 and discoveries in familial colorectal cancer and melanoma, and remains a unique resource for hereditary cancer research. Neeraj Agarwal leads major prostate cancer trials, including TALAPRO-2 (talazoparib plus enzalutamide), and the institute operates its own cancer hospital with inpatient and outpatient care. Mary Beckerle is its long-time CEO.","asOf":"2026-09-09","links":[{"label":"Huntsman Cancer Institute","url":"https://healthcare.utah.edu/huntsmancancerinstitute"},{"label":"Clinical trials","url":"https://healthcare.utah.edu/huntsmancancerinstitute/clinical-trials"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":["prostate","melanoma","colorectal"],"sections":[],"technologies":["germline-testing","parp-inhibitor","proton-therapy","proton-therapy-systems"],"targets":["brca"],"drugs":["talazoparib","enzalutamide"],"companies":["swog"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["neeraj-agarwal","jon-huntsman","bradley-cairns"],"bottlenecks":["b-hereditary-risk"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Salt Lake City, UT","country":"US","lat":40.77,"lng":-111.835,"institutionType":"cancer-center","website":"https://healthcare.utah.edu/huntsmancancerinstitute","nci":"comprehensive","university":"University of Utah","programs":["Hereditary cancer (Utah Population Database)","Prostate cancer trials","Melanoma"]},{"id":"helsinki-hus","kind":"institution","name":"HUS Comprehensive Cancer Center, Helsinki University Hospital","aka":["HUS Syöpäkeskus","Helsinki University Hospital Comprehensive Cancer Center","HUCH Cancer Center"],"tldr":"Finland's largest cancer centre and an OECI-accredited comprehensive cancer centre, known for hereditary cancer genetics and functional precision medicine in leukaemia.","summary":"The HUS Comprehensive Cancer Center is the tertiary cancer centre for the Helsinki region and a national referral centre, accredited by the OECI. University of Helsinki research includes Lauri Aaltonen's discoveries in hereditary colorectal cancer and uterine fibroid genetics, the Hematology Research Unit Helsinki (Kimmo Porkka, Satu Mustjoki) on leukaemia immunology, Sirpa Leppä's lymphoma trials for the Nordic Lymphoma Group, and the Institute for Molecular Medicine Finland, where Olli Kallioniemi's group developed drug sensitivity and resistance testing of patient leukaemia cells. The centre coordinates the national FICAN network and benefits from Finland's cancer registry and biobank infrastructure.","asOf":"2026-09-09","links":[{"label":"HUS Comprehensive Cancer Center (page moved; nearest live section)","url":"https://www.hus.fi/"},{"label":"FIMM","url":"https://www.helsinki.fi/en/hilife-helsinki-institute-life-science/units/fimm"}],"tags":[],"related":[],"cancers":["colorectal","aml","dlbcl","breast-hr-positive"],"sections":["diagnostics","cell-therapy"],"technologies":["functional-drug-testing","germline-testing","wes-wgs","car-t"],"targets":[],"drugs":[],"companies":[],"institutions":["oeci","karolinska"],"pathways":[],"terms":["germline-vs-somatic"],"trials":[],"people":["johanna-mattson"],"bottlenecks":["b-hereditary-risk"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Helsinki","country":"FI","lat":60.19,"lng":24.91,"institutionType":"cancer-center","website":"https://www.hus.fi/","university":"University of Helsinki","programs":["Hereditary cancer genetics","Functional precision medicine (FIMM)","Haematology","Nordic lymphoma trials","FICAN national network"]},{"id":"iasi-regional-oncology-institute","kind":"institution","name":"Iași Regional Oncology Institute","aka":["Institutul Regional de Oncologie Iași","IRO Iași"],"tldr":"Iași Regional Oncology Institute is the regional cancer institute for north-eastern Romania, opened in Iași in 2012, and an associate member of the Organisation of European Cancer Institutes.","summary":"Iași Regional Oncology Institute is the regional cancer institute for north-eastern Romania, opened in Iași in 2012. It is listed by the Organisation of European Cancer Institutes as an associate member, which is why it has a page on OnCo. Programme, trial and leadership details are not yet recorded here and should be checked on the institution's own pages.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.iroiasi.ro"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["mirela-grosu"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Iași","country":"RO","lat":47.16,"lng":27.588,"institutionType":"cancer-center","website":"https://www.iroiasi.ro","programs":[]},{"id":"icmr-nicpr","kind":"institution","name":"ICMR-National Institute of Cancer Prevention and Research","aka":["NICPR","Institute of Cytology and Preventive Oncology","ICPO"],"tldr":"ICMR's cancer prevention institute near Delhi, focused on the cancers India can prevent: cervical cancer through HPV screening and vaccination, and oral cancer through tobacco control.","summary":"The institute began as the Institute of Cytology and Preventive Oncology and was renamed the National Institute of Cancer Prevention and Research; it sits in Noida on the edge of Delhi and, in ICMR's words, conducts basic, clinical and applied research on the common cancers prevalent in India. Its work centres on cervical cancer screening (cytology and HPV testing), HPV vaccination studies, oral cancer and smokeless tobacco, including a WHO Framework Convention on Tobacco Control knowledge hub on smokeless tobacco, and training of health workers for the national screening programme for oral, breast and cervical cancer.","asOf":"2026-09-10","links":[{"label":"ICMR institutes","url":"https://www.icmr.gov.in"}],"tags":[],"related":[],"cancers":["cervical","head-and-neck"],"sections":["prevention","early-detection"],"technologies":["hpv-testing","hpv-vaccine","chemoprevention"],"targets":[],"drugs":[],"companies":[],"institutions":["icmr","iarc","who"],"pathways":[],"terms":[],"trials":[],"people":["shalini-singh"],"bottlenecks":["b-prevention-adoption","b-early-detection"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Noida","country":"IN","lat":28.535,"lng":77.391,"institutionType":"research-institute","website":"https://www.icmr.gov.in","programs":["Cervical cancer screening and HPV research","Smokeless tobacco and oral cancer","Screening training for health workers"]},{"id":"ieo-milan","kind":"institution","name":"IEO (European Institute of Oncology)","aka":[],"tldr":"Founded by Umberto Veronesi, pioneer of breast-conserving surgery and sentinel node biopsy.","summary":"IEO, the European Institute of Oncology in Milan, was founded by Umberto Veronesi, the surgeon who pioneered breast-conserving surgery and sentinel lymph node biopsy, and it ranks eleventh in the Newsweek/Statista World's Best Specialized Hospitals list for oncology. Its strengths are breast surgery de-escalation, early-phase drug development under Giuseppe Curigliano, and HER2-low and antibody-drug conjugate research, with Paolo Veronesi, Roberto Orecchia, Nicoletta Colombo and Pier Giuseppe Pelicci among its leaders. OnCo links it to triple-negative and HER2-positive breast cancer, to Fondazione AIRC, and to the Organisation of European Cancer Institutes. How much further surgery and radiotherapy can safely be scaled back in early breast cancer is the question it keeps testing. Its breast programme is the one to read.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.ieo.it"}],"tags":[],"related":[],"cancers":["tnbc","breast-her2-positive"],"sections":[],"technologies":["sentinel-node"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["roberto-orecchia","nicoletta-colombo","giuseppe-curigliano","paolo-veronesi","pier-giuseppe-pelicci","carlo-cimbri"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Milan","country":"IT","lat":45.435,"lng":9.19,"institutionType":"cancer-center","website":"https://www.ieo.it","newsweekOncology2026":11,"programs":["Breast surgery","Breast medical oncology","Early drug development"]},{"id":"immunocine","kind":"institution","name":"Immunocine","aka":[],"tldr":"Immunocine is a Cancún clinic offering personalised dendritic cell therapy, self-paid, to patients with stage IV solid tumours who do not qualify for trials in the United States.","summary":"Immunocine provides personalised dendritic cell immunotherapy at a clinic in Cancún for patients with stage IV solid tumours who cannot access US trials; it is patient-bookable and self-pay. As with any therapy offered outside a regulated trial, readers should weigh the evidence and costs carefully.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://immunocine.com/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["dendritic-cell-vaccines"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Cancún","country":"MX","lat":21.16,"lng":-86.85,"institutionType":"hospital","website":"https://immunocine.com/","programs":[]},{"id":"imperial-cancer-centre","kind":"institution","name":"Imperial College Healthcare NHS Trust / Imperial College London Cancer Research","aka":["Hammersmith Hospital","Charing Cross Hospital"],"tldr":"West London's academic cancer centre across Hammersmith and Charing Cross hospitals, partner with the ICR in the CRUK Convergence Science Centre.","summary":"Imperial College Healthcare NHS Trust provides cancer services across Hammersmith, Charing Cross, St Mary's and Queen Charlotte's hospitals, including radiotherapy, haematology and stem cell transplantation, and the national gestational trophoblastic disease service at Charing Cross. Imperial College London's cancer research spans surgical innovation and imaging, gynaecological and hepatobiliary cancers, leukaemia and the MRC Laboratory of Medical Sciences at Hammersmith, and Imperial partners with The Institute of Cancer Research in the Cancer Research UK Convergence Science Centre, applying engineering and physical sciences to cancer. The trust is an Experimental Cancer Medicine Centre and part of the Imperial College Academic Health Science Centre.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.imperial.nhs.uk"}],"tags":["nhs-cancer-centre","cruk-centre-partner"],"related":[],"cancers":["pancreatic","colorectal","prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cruk-convergence-science-centre","icr-london"],"pathways":[],"terms":[],"trials":["ukfss","promis","transform-prostate"],"people":["julian-redhead","rakesh-heer"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"London","country":"GB","lat":51.517,"lng":-0.235,"institutionType":"hospital","website":"https://www.imperial.nhs.uk","university":"Imperial College London","programs":["Gestational trophoblastic disease service","Haematology and transplant","Convergence science (engineering and cancer)","Imaging and surgical innovation"]},{"id":"incliva-valencia","kind":"institution","name":"INCLIVA Biomedical Research Institute / Hospital Clínico Universitario de Valencia","aka":["INCLIVA","Hospital Clínico de Valencia"],"tldr":"Valencia's university hospital and research institute, base of former ESMO president Andrés Cervantes and a leading gastrointestinal and breast oncology group.","summary":"INCLIVA is the health research institute of the Hospital Clínico Universitario de Valencia and the University of Valencia. Its medical oncology department under Andrés Cervantes, ESMO president in 2023-2024, is a European reference for colorectal and gastric cancer trials and for circulating tumour DNA studies in localised colorectal cancer, and Ana Lluch's breast cancer group helped found the GEICAM and SOLTI cooperative groups. Research lines include tumour microenvironment, precision oncology and cancer genomics, and the hospital runs a phase 1 unit and hereditary cancer clinic. It cooperates with La Fe across the Valencian cancer network.","asOf":"2026-09-09","links":[{"label":"INCLIVA","url":"https://www.incliva.es/en/"},{"label":"Hospital Clínico Universitario de Valencia","url":"https://clinicomalvarrosa.san.gva.es"}],"tags":[],"related":[],"cancers":["colorectal","gastric","breast-hr-positive","pancreatic"],"sections":["diagnostics","targeted-therapy"],"technologies":["liquid-biopsy","mrd-testing","cgp"],"targets":[],"drugs":[],"companies":[],"institutions":["esmo","la-fe-valencia"],"pathways":[],"terms":["ctdna","mrd"],"trials":[],"people":["andres-cervantes","alvaro-bonet-pla"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Valencia","country":"ES","lat":39.478,"lng":-0.365,"institutionType":"hospital","website":"https://www.incliva.es/en/","university":"Universitat de València","programs":["Gastrointestinal oncology trials","ctDNA in colorectal cancer","Breast cancer (GEICAM, SOLTI)","Phase 1 unit"]},{"id":"icmr","kind":"institution","name":"Indian Council of Medical Research","aka":["ICMR"],"tldr":"India's apex medical research council, which runs the National Cancer Registry Programme, a cancer prevention institute and a network of research institutes, and sets national research and ethics policy.","summary":"The ICMR traces its origin to the Indian Research Fund Association of 1911 and was reconstituted under its present name in 1949. It is the apex body for the formulation, coordination and promotion of biomedical research in India, with 28 permanent institutes and a budget of about 4,200 crore rupees in 2026-27 across all fields.\n\nFor cancer it matters in three ways: it funds and hosts the National Cancer Registry Programme (through the National Institute of Noncommunicable Disease Epidemiology in Bengaluru, formerly NCDIR), whose reports estimate India's burden at about 1.39 million new cases in 2020 and 1.46 million in 2022; it runs the National Institute of Cancer Prevention and Research at Noida and a Centre for Cancer Pathology in Delhi; and it issues the national ethical guidelines and research consortia (including the India Cancer Research Consortium) that shape how Indian trials are run.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Indian_Council_of_Medical_Research","links":[{"label":"ICMR","url":"https://www.icmr.gov.in"},{"label":"Cancer Statistics 2020 (JCO Glob Oncol)","url":"https://doi.org/10.1200/GO.20.00122"}],"tags":[],"related":[],"cancers":[],"sections":["prevention","ai-computation"],"technologies":["cancer-registries-surveillance"],"targets":[],"drugs":[],"companies":[],"institutions":["icmr-ncrp","icmr-nicpr","cdsco"],"pathways":[],"terms":[],"trials":[],"people":["mathur-prashant","shalini-singh"],"bottlenecks":["b-data-silos","b-funding-allocation"],"keyPapers":["paper-mathur-ncrp-cancer-statistics-2020"],"journals":[],"dependsOn":[],"notes":[],"city":"New Delhi","country":"IN","lat":28.591,"lng":77.222,"institutionType":"government","website":"https://www.icmr.gov.in","programs":["National Cancer Registry Programme","ICMR-NICPR Noida","National ethical guidelines","Research funding and consortia"]},{"id":"iisc","kind":"institution","name":"Indian Institute of Science","aka":["IISc","IISc Bengaluru"],"tldr":"India's top-ranked research university, with cancer biology groups in genetics, biochemistry and bioengineering, and a new medical school and hospital funded by the largest gift in its history.","summary":"The Indian Institute of Science was established in 1909 in Bengaluru and is consistently India's highest-ranked research institution. Cancer-relevant work runs through the Department of Molecular Reproduction, Development and Genetics, the Department of Biochemistry, the Centre for BioSystems Science and Engineering and the Department of Computational and Data Sciences, spanning DNA repair, cell signalling, tumour organoids, biomaterials and machine learning on pathology and genomics. In 2022 IISc received a private donation of 425 crore rupees, the largest in its history, to establish a postgraduate medical institute and hospital on campus, which is intended to link its laboratories directly to clinical research.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Indian_Institute_of_Science","links":[{"label":"Indian Institute of Science","url":"https://iisc.ac.in"}],"tags":[],"related":[],"cancers":[],"sections":["drug-discovery","ai-computation"],"technologies":["cgp","pathology-foundation-model"],"targets":[],"drugs":[],"companies":[],"institutions":["instem","ncbs"],"pathways":[],"terms":[],"trials":[],"people":["govindan-rangarajan"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Bengaluru","country":"IN","lat":13.021,"lng":77.567,"institutionType":"university","website":"https://iisc.ac.in","programs":["Cancer cell biology and genetics","Bioengineering and organoids","Computational biology","Postgraduate medical school (planned)"]},{"id":"iit-bombay","kind":"institution","name":"Indian Institute of Technology Bombay","aka":["IIT Bombay","IITB"],"tldr":"The engineering institute whose bioscience department, with Tata Memorial, built India's first home-grown CAR-T cell therapy and spun it out as ImmunoACT.","summary":"IIT Bombay, founded in 1958 on a 545-acre campus at Powai, is one of India's leading technical universities. Its Department of Biosciences and Bioengineering hosts the laboratory of Rahul Purwar, where research on a humanised CD19 CAR-T construct began in 2013; the programme partnered with Tata Memorial Centre and ACTREC for clinical development, was spun out as ImmunoACT in 2018, dosed its first patients at Tata Memorial Hospital in 2021 and won India's first CAR-T approval (NexCAR19, talicabtagene autoleucel) in 2023. The institute also works on cancer imaging, medical devices and computational biology.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/IIT_Bombay","links":[{"label":"IIT Bombay","url":"https://www.iitb.ac.in"},{"label":"ImmunoACT (spin-off)","url":"https://immunoact.com"}],"tags":[],"related":[],"cancers":[],"sections":["cell-therapy","drug-discovery"],"technologies":["car-t","point-of-care-cell-manufacturing"],"targets":["cd19"],"drugs":["talicabtagene-autoleucel"],"companies":["immunoact"],"institutions":["tata-memorial","actrec"],"pathways":[],"terms":[],"trials":[],"people":["purwar-rahul"],"bottlenecks":["b-manufacturing-cell-therapy","b-global-access"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Mumbai","country":"IN","lat":19.133,"lng":72.915,"institutionType":"university","website":"https://www.iitb.ac.in","programs":["Biosciences and Bioengineering (CAR-T origin)","Medical devices and imaging","Digital health"]},{"id":"iu-simon","kind":"institution","name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center","aka":["IU Simon Cancer Center"],"tldr":"Home of Lawrence Einhorn's cisplatin regimen that turned testicular cancer into a curable disease, and Indiana's NCI comprehensive centre.","summary":"NCI-designated in 1999 and comprehensive since 2019, IU Simon is Indiana's only NCI comprehensive centre. In 1974 Lawrence Einhorn combined cisplatin with vinblastine and bleomycin, raising cure rates in disseminated testicular cancer from a minority to the large majority of patients, one of the great successes of chemotherapy; the centre remains an international referral site for germ cell tumours. Hal Broxmeyer's work on cord blood underpinned cord blood transplantation. Current programmes include the Vera Bradley Foundation Center for Breast Cancer Research, precision genomics for triple-negative breast cancer and a growing early-phase unit.","asOf":"2026-09-09","links":[{"label":"IU Simon Comprehensive Cancer Center","url":"https://cancer.iu.edu"}],"tags":[],"related":[],"cancers":["testicular","tnbc"],"sections":["chemotherapy"],"technologies":["platinum","cytotoxic-chemotherapy","allogeneic-hsct"],"targets":[],"drugs":["cisplatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["d-wade-clapp"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Indianapolis, IN","country":"US","lat":39.777,"lng":-86.176,"institutionType":"cancer-center","website":"https://cancer.iu.edu","nci":"comprehensive","university":"Indiana University","programs":["Testicular and germ cell tumours","Breast cancer (Vera Bradley Foundation Center)","Cord blood transplantation"]},{"id":"inkosi-albert-luthuli-hospital","kind":"institution","name":"Inkosi Albert Luthuli Central Hospital","aka":["IALCH"],"tldr":"KwaZulu-Natal's quaternary referral hospital in Durban, opened in 2002, and the province's main academic centre for radiation oncology and haematology.","summary":"Inkosi Albert Luthuli Central Hospital opened in 2002 as a purpose-built quaternary and tertiary referral hospital for KwaZulu-Natal, run by the provincial health department in a public-private partnership and serving as a teaching hospital of the University of KwaZulu-Natal's Nelson R Mandela School of Medicine. It provides radiation oncology, medical oncology, clinical haematology, paediatric oncology and specialist surgery for a province with one of the highest HIV burdens in the world, making cervical cancer, Kaposi sarcoma and HIV-associated lymphoma prominent in its case mix. It is the only public radiotherapy provider for much of the province.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.ialch.co.za"}],"tags":[],"related":[],"cancers":["cervical"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["lp-mtshali"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Durban","country":"ZA","lat":-29.872,"lng":30.985,"institutionType":"hospital","website":"https://www.ialch.co.za","university":"University of KwaZulu-Natal","programs":["Radiation oncology","Paediatric oncology","HIV-associated cancers"]},{"id":"inselspital-bern","kind":"institution","name":"Inselspital, Bern University Hospital / University Cancer Center Inselspital","aka":["Inselspital","UCI Bern","Bern Center for Precision Medicine"],"tldr":"Bern's university hospital, a high-volume radioligand therapy centre and home to the Bern Center for Precision Medicine and the SAKK trial group.","summary":"The University Cancer Center Inselspital coordinates cancer care at Switzerland's capital university hospital. Its nuclear medicine department under Axel Rominger is one of Europe's largest PSMA and somatostatin-receptor radioligand therapy centres with a strong dosimetry programme, and Mark Rubin, co-discoverer of the TMPRSS2-ERG fusion in prostate cancer, directs the Department for BioMedical Research and the Bern Center for Precision Medicine. The hospital runs neuro-oncology and neurosurgery, thoracic and gastrointestinal surgery, haematology and CAR-T, and is a lead site for the Swiss Group for Clinical Cancer Research (SAKK), whose coordinating centre is in Bern. The Insel Gruppe covers a large catchment across the Bernese region.","asOf":"2026-09-09","links":[{"label":"Tumorzentrum Inselspital","url":"https://www.tumorzentrum.insel.ch"},{"label":"Bern Center for Precision Medicine","url":"https://www.bcpm.unibe.ch"},{"label":"SAKK","url":"https://www.sakk.ch"}],"tags":[],"related":[],"cancers":["prostate","neuroendocrine","glioblastoma","nsclc"],"sections":["radiopharma","diagnostics"],"technologies":["radioligand-therapy","psma-pet","cgp","car-t"],"targets":["psma","sstr2"],"drugs":["pluvicto","lutathera"],"companies":[],"institutions":["usz-zurich"],"pathways":[],"terms":["dosimetry","gene-fusion","theranostics"],"trials":[],"people":["daniel-aebersold","adrian-ochsenbein"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Bern","country":"CH","lat":46.948,"lng":7.423,"institutionType":"hospital","website":"https://www.tumorzentrum.insel.ch","university":"Universität Bern","programs":["Radioligand therapy and dosimetry","Bern Center for Precision Medicine","Prostate cancer genomics","Neuro-oncology","SAKK trials"]},{"id":"institut-bergonie","kind":"institution","name":"Institut Bergonié","aka":["Bergonié","Centre Régional de Lutte Contre le Cancer de Bordeaux"],"tldr":"Bordeaux's dedicated cancer hospital, a UNICANCER centre known for sarcoma, early-phase trials and precision medicine.","summary":"Founded in 1923 and named after the radiobiologist Jean Bergonié, the Institut Bergonié is the UNICANCER comprehensive cancer centre for Nouvelle-Aquitaine. It is a national reference centre for sarcomas within the French Sarcoma Group and NetSarc network, and runs an early-phase trials unit that is part of INCa's CLIP² network. Research with Université de Bordeaux and Inserm covers sarcoma biology, tumour genomics and radiotherapy. Patients can access phase 1 trials, molecular tumour boards, reconstructive surgery and supportive care on one site.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.bergonie.fr"},{"label":"UNICANCER","url":"https://www.unicancer.fr"}],"tags":[],"related":[],"cancers":["sarcoma","breast-hr-positive","ovarian"],"sections":["targeted-therapy","surgery"],"technologies":["cgp","imrt-igrt","brachytherapy"],"targets":[],"drugs":[],"companies":["unicancer"],"institutions":["inca"],"pathways":[],"terms":[],"trials":[],"people":["nicolas-penel"],"bottlenecks":["b-rare-cancers"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Bordeaux","country":"FR","lat":44.833,"lng":-0.59,"institutionType":"cancer-center","website":"https://www.bergonie.fr","university":"Université de Bordeaux","programs":["Sarcoma reference centre","Early-phase trials (CLIP²)","Precision medicine","Radiotherapy"]},{"id":"institut-curie","kind":"institution","name":"Institut Curie","aka":[],"tldr":"Founded by Marie Curie; a leader in breast cancer, radiotherapy, and proton therapy.","summary":"Institut Curie in Paris was founded by Marie Curie and is a comprehensive cancer centre and research institute, ranked twenty-first in the Newsweek/Statista World's Best Specialized Hospitals list for oncology. Its strengths are breast cancer and the biology of triple-negative disease, radiotherapy and the Orsay proton centre, uveal melanoma and paediatric oncology, with François-Clément Bidard, Olivier Delattre, Christophe Le Tourneau, Eliane Piaggio and Sergio Roman-Roman among its scientists. OnCo links it to the tumour microenvironment pathway, to the question of what holds T cells at the tumour border, and to Institut National du Cancer, Fondation ARC and the LYSA lymphoma group. How to turn microenvironment biology into treatments is the problem its immunology work chases. Its breast and proton programmes are the ones most readers want.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://curie.fr"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":["tnbc","melanoma"],"sections":[],"technologies":["proton-therapy","proton-therapy-systems"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["francois-clement-bidard","sergio-roman-roman","eliane-piaggio","olivier-delattre","steven-le-gouill"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Paris","country":"FR","lat":48.844,"lng":2.344,"institutionType":"cancer-center","website":"https://curie.fr","newsweekOncology2026":21,"programs":["Breast cancer","Proton therapy","Uveal melanoma"]},{"id":"ico-angers-nantes","kind":"institution","name":"Institut de Cancérologie de l'Ouest (ICO)","aka":["ICO Paul Papin","ICO René Gauducheau","Integrated Center for Oncology"],"tldr":"The Unicancer cancer centre for western France, with sites in Angers and Nantes, accredited by OECI as a Comprehensive Cancer Centre.","summary":"The Institut de Cancérologie de l'Ouest was created by merging the Centre Paul Papin in Angers and the Centre René Gauducheau in Saint-Herblain near Nantes, and is one of the 18 Centres de Lutte Contre le Cancer of the Unicancer network. It delivers surgery, radiotherapy, medical oncology and nuclear medicine across the Pays de la Loire, hosts an early-phase trials unit, and works with the universities of Angers and Nantes and Inserm on radiopharmaceuticals, alpha-emitter therapy and immuno-oncology, drawing on the Nantes nuclear medicine and cyclotron infrastructure. The ICO is accredited by the Organisation of European Cancer Institutes as a Comprehensive Cancer Centre.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.institut-cancerologie-ouest.com"}],"tags":["oeci-accredited","oeci-comprehensive-cancer-centre","unicancer"],"related":[],"cancers":[],"sections":[],"technologies":["targeted-alpha-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["mario-campone"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Angers","country":"FR","lat":47.478,"lng":-0.563,"institutionType":"cancer-center","website":"https://www.institut-cancerologie-ouest.com","programs":["Radiopharmaceuticals and alpha therapy","Early-phase trials","Radiotherapy"]},{"id":"institut-de-cancerologie-de-lorraine","kind":"institution","name":"Institut de Cancérologie de Lorraine","aka":["ICL","Centre Alexis Vautrin"],"tldr":"The Institut de Cancérologie de Lorraine, formerly the Centre Alexis Vautrin, is the Unicancer comprehensive cancer centre for Lorraine near Nancy and a full member of the Organisation of European Cancer Institutes.","summary":"The Institut de Cancérologie de Lorraine (ICL), previously known as the Centre Alexis Vautrin, is the comprehensive cancer centre for the Lorraine region, located at Vandœuvre-lès-Nancy on the Brabois hospital campus near Nancy, with origins going back to 1924. It is one of the centres de lutte contre le cancer in the Unicancer network and works with the University of Lorraine and the Nancy university hospital. It is listed by the Organisation of European Cancer Institutes as a full member. Programme, trial and leadership details are not yet recorded here.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.icl-lorraine.fr"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["unicancer"],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["didier-peiffert"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Vandœuvre-lès-Nancy","country":"FR","lat":48.657,"lng":6.167,"institutionType":"cancer-center","website":"https://www.icl-lorraine.fr","programs":[]},{"id":"icm-montpellier","kind":"institution","name":"Institut du Cancer de Montpellier (ICM)","aka":["Institut régional du Cancer de Montpellier","Val d'Aurelle"],"tldr":"The Unicancer cancer centre for Montpellier and Occitanie, an OECI Comprehensive Cancer Centre known for radiotherapy research and early-phase trials.","summary":"The Institut du Cancer de Montpellier is one of the 18 French Centres de Lutte Contre le Cancer (CLCC) that make up the Unicancer network. It combines a dedicated cancer hospital with the Montpellier Cancer Research Institute (IRCM, Inserm and University of Montpellier) and an early-phase trials unit, and is accredited by the Organisation of European Cancer Institutes as a Comprehensive Cancer Centre. Research strengths include radiotherapy and radiobiology, biomarkers and circulating tumour DNA, colorectal and breast cancer, and supportive care. The institute is part of the Montpellier SIRIC and hosts Unicancer national trials.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.icm.unicancer.fr"}],"tags":["oeci-accredited","oeci-comprehensive-cancer-centre","unicancer"],"related":[],"cancers":[],"sections":[],"technologies":["liquid-biopsy"],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["marc-ychou"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Montpellier","country":"FR","lat":43.611,"lng":3.877,"institutionType":"cancer-center","website":"https://www.icm.unicancer.fr","programs":["Radiotherapy and radiobiology","Early-phase trials","ctDNA and biomarkers"]},{"id":"carpem-aphp-centre","kind":"institution","name":"Institut du Cancer Paris CARPEM, AP-HP Centre","aka":["CARPEM","Hôpital Européen Georges-Pompidou","Hôpital Cochin"],"tldr":"The central Paris university cancer institute of AP-HP, built on the CARPEM personalised medicine programme at the Georges-Pompidou, Cochin and Necker hospitals, and an OECI Comprehensive Cancer Centre.","summary":"The Institut du Cancer Paris CARPEM groups the oncology services of AP-HP Centre (Hôpital Européen Georges-Pompidou, Cochin, Necker-Enfants Malades and associated hospitals) with Université Paris Cité. It grew out of CARPEM (Cancer Research for Personalized Medicine), one of the French SIRIC integrated cancer research sites, and combines molecular profiling, immuno-oncology research, digestive and urological surgery, lung and breast oncology and paediatric oncology at Necker. The institute is accredited by the Organisation of European Cancer Institutes as a Comprehensive Cancer Centre and its research is anchored in the Paris Cardiovascular Research Center and the Cochin Institute.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.aphp.fr"}],"tags":["oeci-accredited","oeci-comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":["cgp"],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["pierre-laurent-puig"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Paris","country":"FR","lat":48.839,"lng":2.275,"institutionType":"hospital","website":"https://www.aphp.fr","university":"Université Paris Cité","programs":["Personalised medicine (CARPEM SIRIC)","Digestive and urological oncology","Paediatric oncology (Necker)"]},{"id":"institut-godinot","kind":"institution","name":"Institut Godinot","aka":["Institut Jean Godinot"],"tldr":"Institut Godinot is the Unicancer comprehensive cancer centre for the Reims region of north-eastern France and a full member of the Organisation of European Cancer Institutes.","summary":"Institut Godinot in Reims is one of the French comprehensive cancer centres (centres de lutte contre le cancer) that make up the Unicancer network, providing cancer diagnosis, medical oncology, surgery and radiotherapy for the Champagne-Ardenne area. Like the other Unicancer centres it is a private non-profit hospital with a public service mission and takes part in the network's clinical trials. It is listed by the Organisation of European Cancer Institutes as a full member. Programme, trial and leadership details are not yet recorded here.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.institutgodinot.fr"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["unicancer"],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["yacine-merrouche"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Reims","country":"FR","lat":49.227,"lng":4.024,"institutionType":"cancer-center","website":"https://www.institutgodinot.fr","programs":[]},{"id":"institut-jules-bordet","kind":"institution","name":"Institut Jules Bordet","aka":["Jules Bordet Institute","Bordet","Hôpital Universitaire de Bruxelles"],"tldr":"Belgium's only hospital devoted entirely to cancer, birthplace of the Breast International Group and a world centre for breast cancer trials.","summary":"The Institut Jules Bordet opened in 1939, named after the Nobel laureate immunologist Jules Bordet, and moved to a new building beside Erasme Hospital in Anderlecht in 2021 as part of the Hôpital Universitaire de Bruxelles. It is OECI-accredited as a comprehensive cancer centre. Martine Piccart co-founded the Breast International Group here and led the HERA trial of adjuvant trastuzumab; Christos Sotiriou's laboratory developed gene expression signatures for breast cancer and Michail Ignatiadis leads circulating tumour DNA studies, while Ahmad Awada's early-phase unit tests new agents. Bordet is also strong in haematology, nuclear medicine and surgical oncology, and Brussels hosts both BIG and EORTC headquarters.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Institut_Jules_Bordet","links":[{"label":"Homepage","url":"https://www.bordet.be"},{"label":"Breast International Group","url":"https://www.bigagainstbreastcancer.org"}],"tags":[],"related":[],"cancers":["breast-her2-positive","breast-hr-positive","tnbc","dlbcl"],"sections":["targeted-therapy"],"technologies":["liquid-biopsy","monoclonal-antibody","rna-seq","endocrine-therapy"],"targets":[],"drugs":["trastuzumab","pembrolizumab"],"companies":["big","curie-nki-eortc"],"institutions":["oeci"],"pathways":[],"terms":["ctdna"],"trials":[],"people":["martine-piccart","evandro-de-azambuja","renaud-witmeur","sacha-gougnard"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Brussels","country":"BE","lat":50.813,"lng":4.265,"institutionType":"cancer-center","website":"https://www.bordet.be","university":"Université libre de Bruxelles","programs":["Breast International Group","Breast cancer genomics and ctDNA","Early-phase trials","Haematology","Nuclear medicine"]},{"id":"institut-national-oncologie-rabat","kind":"institution","name":"Institut National d'Oncologie, Rabat","aka":["INO Rabat","Institut National d'Oncologie Sidi Mohamed Ben Abdellah","Fondation Lalla Salma"],"tldr":"Morocco's national oncology institute, the reference cancer centre of the Rabat university hospital and the anchor of the Lalla Salma Foundation's national cancer plan.","summary":"The Institut National d'Oncologie Sidi Mohamed Ben Abdellah in Rabat opened in 1985 as Morocco's national cancer institute within the Ibn Sina University Hospital Centre (CHU Ibn Sina) and the Université Mohammed V medical school, providing surgical, medical and radiation oncology, brachytherapy, nuclear medicine and paediatric oncology as the national referral centre. With the Fondation Lalla Salma (Prévention et traitement des cancers), founded in 2005 by Princess Lalla Salma, INO has led Morocco's national cancer prevention and control plan, which built regional oncology centres, introduced free breast and cervical screening, expanded radiotherapy and palliative care and improved access to cancer medicines across the country. INO researchers publish on breast and cervical cancer in North African women, nasopharyngeal carcinoma, which is common in the Maghreb, and cancer registration for Rabat.","asOf":"2026-09-09","links":[{"label":"CHU Ibn Sina","url":"http://www.chuis.ma"},{"label":"Fondation Lalla Salma","url":"https://www.contrelecancer.ma"}],"tags":[],"related":["global-oncology-access","who-essential-medicines"],"cancers":["breast-hr-positive","cervical","head-and-neck","colorectal"],"sections":["prevention","radiation"],"technologies":["brachytherapy","imrt-igrt","hpv-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["brahim-lakhal"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Rabat","country":"MA","lat":33.99,"lng":-6.847,"institutionType":"cancer-center","website":"http://www.chuis.ma","university":"Université Mohammed V","programs":["National oncology institute","Lalla Salma Foundation cancer plan","Radiotherapy and brachytherapy","Nasopharyngeal carcinoma"]},{"id":"inca","kind":"institution","name":"Institut National du Cancer","aka":["INCa","French National Cancer Institute"],"tldr":"France's national cancer agency, which steers the national cancer strategy and funds and labels research, trial networks and early-phase units.","summary":"Created by the 2004 public health law as the operational arm of the first Plan Cancer, INCa is a public interest group under the health and research ministries. It coordinates the ten-year national cancer strategy, funds research through calls such as PAIR and PHRC-K, labels the SIRIC integrated research sites and the CLIP² early-phase trial network, and ran the AcSé programme that gave patients access to targeted drugs outside their approved indication based on molecular profile. It publishes national guidelines, screening programmes and cancer statistics with Santé publique France.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.cancer.fr"},{"label":"Research","url":"https://www.cancer.fr/professionnels-de-la-recherche"}],"tags":[],"related":[],"cancers":[],"sections":["prevention","early-detection"],"technologies":[],"targets":[],"drugs":[],"companies":["unicancer"],"institutions":["gustave-roussy","institut-curie","iarc"],"pathways":[],"terms":["tumour-agnostic","basket-umbrella-platform"],"trials":[],"people":["suzette-delaloge","nicolas-scotte"],"bottlenecks":["b-trial-enrolment","b-funding-allocation","b-early-detection"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Boulogne-Billancourt","country":"FR","lat":48.835,"lng":2.24,"institutionType":"government","website":"https://www.cancer.fr","programs":["National cancer strategy","SIRIC sites","CLIP² early-phase network","AcSé access programme","Screening and guidelines"]},{"id":"inc-luxembourg","kind":"institution","name":"Institut National du Cancer, Luxembourg","aka":["INC Luxembourg","Institut National du Cancer (INC)"],"tldr":"Luxembourg's national cancer institute, a coordinating body in Strassen that steers the national cancer plan rather than treating patients, and an associate member of the Organisation of European Cancer Institutes.","summary":"The Institut National du Cancer (INC) is Luxembourg's national cancer coordination body, based in Strassen. It supports the national cancer plan, publishes care guidelines and quality indicators, and coordinates the country's hospitals, registry and research actors rather than delivering treatment itself. It is an associate member of the Organisation of European Cancer Institutes (OECI); its representative on the OECI list is Nikolai Goncharenko.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://institutnationalducancer.lu/"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["nikolai-goncharenko"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Strassen","country":"LU","lat":49.62,"lng":6.073,"institutionType":"government","website":"https://institutnationalducancer.lu/","programs":[]},{"id":"institut-paoli-calmettes","kind":"institution","name":"Institut Paoli-Calmettes","aka":["IPC","Centre de Lutte Contre le Cancer de Marseille","University Hospitals of Marseille","Institut Paoli-Calmettes (IPC)"],"tldr":"The Institut Paoli-Calmettes is the Unicancer comprehensive cancer centre for Marseille and Provence, founded in 1925; it runs a large allogeneic transplant and leukaemia programme, high-volume pancreatic surgery and an early-phase unit within the Marseille Immunopôle cluster.","summary":"Founded in 1925, the Institut Paoli-Calmettes is the UNICANCER comprehensive cancer centre for Provence-Alpes-Côte d'Azur. Its research arm is the Centre de Recherche en Cancérologie de Marseille (CRCM, with Inserm, CNRS and Aix-Marseille Université), and it belongs to the Marseille Immunopôle cluster alongside the Centre d'Immunologie de Marseille-Luminy. Clinical strengths include a major allogeneic transplant and leukaemia programme, high-volume pancreatic and hepatobiliary surgery, breast oncology under Anthony Gonçalves, and an early-phase unit. It runs a large tumour biobank and a molecular profiling programme for patients across the region.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.institutpaolicalmettes.fr"},{"label":"CRCM","url":"https://crcm.fr"}],"tags":[],"related":[],"cancers":["aml","pancreatic","breast-hr-positive","tnbc"],"sections":["cell-therapy","surgery"],"technologies":["allogeneic-cell-therapy","car-t","cgp"],"targets":[],"drugs":[],"companies":["unicancer"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["anthony-goncalves","norbert-vey"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Marseille","country":"FR","lat":43.289,"lng":5.401,"institutionType":"cancer-center","website":"https://www.institutpaolicalmettes.fr","university":"Aix-Marseille Université","programs":["Haematology and allogeneic transplant","Pancreatic surgery","Breast oncology","Early-phase trials","Marseille Immunopôle"]},{"id":"institut-pasteur","kind":"institution","name":"Institut Pasteur","aka":["Pasteur Institute"],"tldr":"The historic Paris research institute founded by Louis Pasteur, whose cancer work centres on tumour viruses, immunology and the microbiome.","summary":"Founded in 1887, the Institut Pasteur is a private foundation known for microbiology, immunology and ten Nobel laureates, including the 2008 prize for the discovery of HIV. Its Cancer Initiative gathers units working on oncogenic viruses (HPV, hepatitis B, EBV), tumour immunology, cell biology of metastasis, the gut microbiome and cancer, and computational biology, and it collaborates with Institut Curie and Gustave Roussy through Paris-area programmes. The institute also trains scientists from a worldwide network of Pasteur institutes, several of which run cancer registries and HPV programmes in low-income countries.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Pasteur_Institute","links":[{"label":"Homepage","url":"https://www.pasteur.fr/en"},{"label":"Cancer research","url":"https://research.pasteur.fr/en/research-area/cancer/"}],"tags":[],"related":[],"cancers":["cervical","hcc","head-and-neck"],"sections":["prevention","immunotherapy"],"technologies":["hpv-vaccine","single-cell-spatial","crispr-screens"],"targets":[],"drugs":[],"companies":[],"institutions":["institut-curie","gustave-roussy"],"pathways":[],"terms":[],"trials":[],"people":["laurence-zitvogel","yasmine-belkaid"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Paris","country":"FR","lat":48.841,"lng":2.311,"institutionType":"research-institute","website":"https://www.pasteur.fr","university":"Université Paris Cité","programs":["Cancer Initiative","Oncogenic viruses","Tumour immunology","Microbiome and cancer"]},{"id":"institut-sainte-catherine","kind":"institution","name":"Institut Sainte Catherine","aka":["Institut du Cancer Avignon-Provence","ICAP"],"tldr":"A private non-profit cancer centre in Avignon, Provence, offering radiotherapy, chemotherapy and supportive care, and an associate member of the Organisation of European Cancer Institutes.","summary":"The Institut Sainte Catherine, now branded Institut du Cancer Avignon-Provence (ICAP), is a private non-profit cancer treatment centre in Avignon founded in 1993 that provides radiotherapy, medical oncology, haematology and supportive care for the Vaucluse and surrounding area. It is an associate member of the Organisation of European Cancer Institutes (OECI). Its representative on the OECI list is Daniel Serin.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.icap84.org/"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q30273611"}],"tags":[],"related":["institut-paoli-calmettes"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["daniel-serin"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Avignon","country":"FR","lat":43.923,"lng":4.8,"institutionType":"cancer-center","website":"https://www.icap84.org/","programs":[]},{"id":"institut-salah-azaiez","kind":"institution","name":"Institut Salah Azaïez","aka":["ISA Tunis","Institut Salah Azaiz"],"tldr":"The Institut Salah Azaïez in Tunis, founded in 1969, is Tunisia's national cancer institute and one of Africa's oldest; it runs the Tunis cancer registry, a contributor to IARC's Cancer Incidence in Five Continents, and researches breast cancer in young women and nasopharyngeal carcinoma.","summary":"The Institut Salah Azaïez in Tunis was founded in 1969 and named for the Tunisian surgeon who championed cancer care; it is Tunisia's national cancer institute and reference hospital, attached to the Université de Tunis El Manar faculty of medicine, providing surgical, medical and radiation oncology, brachytherapy, nuclear medicine, paediatric oncology and pathology. The institute runs the Tunis population-based cancer registry, one of the longest-running in Africa and a contributor to IARC's Cancer Incidence in Five Continents, and its research addresses breast cancer in young North African women, nasopharyngeal carcinoma and EBV, cervical cancer screening, hereditary cancer, and radiotherapy quality across the Maghreb. It trains oncologists for Tunisia and francophone Africa.","asOf":"2026-09-09","links":[{"label":"Institut Salah Azaïez","url":"http://www.institutsalahazaiez.com"}],"tags":[],"related":["global-oncology-access","cancer-registries-surveillance"],"cancers":["breast-hr-positive","head-and-neck","cervical","colorectal"],"sections":["prevention","radiation"],"technologies":["brachytherapy","imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":["iarc"],"pathways":[],"terms":[],"trials":[],"people":["senda-tounsi"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Tunis","country":"TN","lat":36.808,"lng":10.165,"institutionType":"cancer-center","website":"http://www.institutsalahazaiez.com","university":"Université de Tunis El Manar","programs":["National cancer institute","Tunis cancer registry","Breast cancer and nasopharyngeal carcinoma research","Francophone Africa training"]},{"id":"institut-strauss","kind":"institution","name":"Institut Strauss","aka":["Institut de cancérologie Strasbourg Europe","ICANS"],"tldr":"The cancer centre of Strasbourg and Alsace, and a full member of the Organisation of European Cancer Institutes.","summary":"The Institut Strauss describes itself as the cancer centre of Strasbourg and Alsace, bringing together cancer care and research in the region. It is a full member of the Organisation of European Cancer Institutes (OECI). Its representative on the OECI list is Xavier Pivot.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.institut-strauss.fr/"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["xavier-pivot"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Strasbourg","country":"FR","lat":48.573,"lng":7.752,"institutionType":"cancer-center","website":"https://www.institut-strauss.fr/","programs":[]},{"id":"iuc-aphp-sorbonne","kind":"institution","name":"Institut Universitaire de Cancérologie AP-HP Sorbonne Université","aka":["IUC AP-HP. Sorbonne Université","Pitié-Salpêtrière","Hôpital Saint-Antoine","Hôpital Tenon","Assistance Publique – Hôpitaux de Paris Institut Universitaire de Cancérologie APHP. Sorbonne Université (IUC APHP.SU)","IUC APHP.SU"],"tldr":"The university cancer institute of AP-HP and Sorbonne Université, spanning the Pitié-Salpêtrière, Saint-Antoine and Tenon hospitals, and accredited by OECI as a Comprehensive Cancer Centre.","summary":"The Institut Universitaire de Cancérologie brings together the oncology activity of the Assistance Publique-Hôpitaux de Paris hospitals affiliated with Sorbonne Université: Pitié-Salpêtrière (neuro-oncology, haematology, sarcoma), Saint-Antoine (haematology and transplantation, digestive oncology) and Tenon (urological and gynaecological cancers, thoracic oncology). It coordinates multidisciplinary meetings, molecular tumour boards, clinical research and teaching across the sites and is accredited by the Organisation of European Cancer Institutes as a Comprehensive Cancer Centre. Sorbonne Université's Inserm units contribute research in neuro-oncology, leukaemia biology and tumour immunology.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.aphp.fr"}],"tags":["oeci-accredited","oeci-comprehensive-cancer-centre"],"related":[],"cancers":["glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["joseph-gligorov","jean-philippe-spano"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Paris","country":"FR","lat":48.838,"lng":2.365,"institutionType":"hospital","website":"https://www.aphp.fr","university":"Sorbonne Université","programs":["Neuro-oncology (Pitié-Salpêtrière)","Haematology and transplantation (Saint-Antoine)","Urological and gynaecological cancers (Tenon)"]},{"id":"institute-for-protein-design","kind":"institution","name":"Institute for Protein Design (University of Washington)","aka":[],"tldr":"David Baker's institute, where de novo protein design and the RFdiffusion models come from (Nobel Prize in Chemistry 2024).","summary":"The Institute for Protein Design at the University of Washington in Seattle is David Baker's institute, the origin of de novo protein design and the RFdiffusion models, work recognised by the Nobel Prize in Chemistry in 2024. It produced Rosetta, ProteinMPNN, RFdiffusion and RFdiffusion2, and the de novo binder design methods now used to make cancer-targeting proteins and antibodies from scratch, and its spin-outs include Xaira Therapeutics and Monod. OnCo connects it to the RFdiffusion and ProteinMPNN technology record and to Xaira. Whether designed binders reach the clinic faster and more safely than conventional antibodies is the question its spin-outs will answer. Its RFdiffusion, ProteinMPNN and de novo binder programmes are listed below.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://www.ipd.uw.edu"}],"tags":["ai","protein-design"],"related":[],"cancers":[],"sections":["drug-discovery","ai-computation"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["david-baker"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Seattle","country":"US","lat":47.65,"lng":-122.308,"institutionType":"research-institute","website":"https://www.ipd.uw.edu","university":"University of Washington","programs":["RFdiffusion","ProteinMPNN","De novo binders"]},{"id":"instem","kind":"institution","name":"Institute for Stem Cell Science and Regenerative Medicine","aka":["inStem"],"tldr":"A Department of Biotechnology institute in Bengaluru that develops stem cell and gene editing approaches to cancer and blood disorders, and shares a campus with NCBS.","summary":"inStem was established in 2009 as an autonomous institute of the Department of Biotechnology and now sits under the Biotechnology Research and Innovation Council. Its stated focus is cellular therapies for cancer, cardiovascular and neurodegenerative disease, using stem cell biology, disease modelling, CRISPR-based gene editing and bioinformatics. It is part of the Bangalore Life Science Cluster with NCBS and C-CAMP, collaborates with CMC Vellore's Centre for Stem Cell Research on haematological gene therapy, and had a budget of about 60.6 crore rupees in 2022-23.","asOf":"2026-09-10","links":[{"label":"inStem","url":"https://www.instem.res.in"}],"tags":[],"related":[],"cancers":[],"sections":["cell-therapy","drug-discovery"],"technologies":["crispr-screens","allogeneic-cell-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["ncbs","dbt-india","cmc-vellore"],"pathways":[],"terms":[],"trials":[],"people":["maneesha-inamdar"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Bengaluru","country":"IN","lat":13.071,"lng":77.58,"institutionType":"research-institute","website":"https://www.instem.res.in","programs":["Stem cell biology and disease modelling","CRISPR gene editing","Cell therapy translation"]},{"id":"iba-masaryk","kind":"institution","name":"Institute of Biostatistics and Analyses, Masaryk University","aka":["Institut biostatistiky a analýz","IBA MU"],"tldr":"Masaryk University's biostatistics institute in Brno, which runs Czech cancer registries and data analyses, and an associate member of the Organisation of European Cancer Institutes.","summary":"The Institute of Biostatistics and Analyses of the Faculty of Medicine and Faculty of Science at Masaryk University in Brno provides biostatistics, health data analysis and registry infrastructure, including for Czech cancer data. It is an associate member of the Organisation of European Cancer Institutes (OECI). Its representative on the OECI list is Ladislav Dušek.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://iba.med.muni.cz/"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":["mou-brno"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["ladislav-dusek"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Brno","country":"CZ","lat":49.195,"lng":16.608,"institutionType":"research-institute","website":"https://iba.med.muni.cz/","programs":[]},{"id":"cams-hematology","kind":"institution","name":"Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences","aka":["Blood Diseases Hospital CAMS","中国医学科学院血液病医院","IH-CAMS"],"tldr":"China's national blood disease hospital in Tianjin is where the CD19 binder behind the CAR-T inati-cel was made; it runs large leukaemia and myelodysplastic syndrome registries and early-phase trials of domestic bispecifics and cell therapies.","summary":"The national centre for haematology within CAMS, with the State Key Laboratory of Experimental Hematology; origin of the CNCT19 CAR-T (inaticabtagene autoleucel, approved 2023 for adult B-ALL with Juventas), large leukaemia and myelodysplastic syndrome registries and early-phase trials of domestic bispecifics and cell therapies.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.chinablood.com.cn/"}],"tags":["china"],"related":[],"cancers":["all-leukemia","aml","mds"],"sections":[],"technologies":["car-t"],"targets":[],"drugs":["inaticabtagene-autoleucel"],"companies":[],"institutions":["cams-cancer-hospital"],"pathways":[],"terms":[],"trials":[],"people":["tao-cheng"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Tianjin","country":"CN","lat":39.117,"lng":117.18,"institutionType":"hospital","website":"https://www.chinablood.com.cn/","university":"Chinese Academy of Medical Sciences and Peking Union Medical College","programs":["State Key Laboratory of Experimental Hematology","CAR-T development","Leukaemia registries and trials"]},{"id":"institute-of-mother-and-child","kind":"institution","name":"Institute of Mother and Child, Warsaw","aka":["Instytut Matki i Dziecka","IMiD"],"tldr":"A Warsaw research hospital founded in 1948 for maternal and child health, including paediatric oncology and surgical oncology, and a full member of the Organisation of European Cancer Institutes.","summary":"The Institute of Mother and Child (Instytut Matki i Dziecka) in Warsaw is a research hospital founded in 1948 that covers obstetrics, neonatology and paediatrics, including paediatric oncology and oncological surgery, and hosts national screening and rare-disease programmes. It is a full member of the Organisation of European Cancer Institutes (OECI); its representative on the OECI list is Tomasz Maciejewski.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://imid.med.pl/pl/"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q11713115"}],"tags":[],"related":["nio-warsaw"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["tomasz-maciejewski"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Warsaw","country":"PL","lat":52.227,"lng":20.97,"institutionType":"hospital","website":"https://imid.med.pl/pl/","programs":[]},{"id":"onkoloski-institut-ljubljana","kind":"institution","name":"Institute of Oncology Ljubljana","aka":["Onkološki inštitut Ljubljana","OIL"],"tldr":"Slovenia's national cancer centre, OECI-accredited, home of one of Europe's oldest cancer registries and a pioneer of electrochemotherapy.","summary":"Founded in 1938, the Institute of Oncology Ljubljana is Slovenia's only comprehensive cancer centre and is accredited by the OECI. It hosts the Cancer Registry of Republic of Slovenia, established in 1950 as one of the earliest population-based registries in Europe, and runs the national screening programmes. Gregor Serša and Maja Čemažar's group pioneered electrochemotherapy, combining electric pulses with bleomycin or cisplatin, and the institute led the European ESOPE standard operating procedures; it also has strong programmes in melanoma, breast and head and neck cancer, radiotherapy and brachytherapy, and medical oncology trials. The institute serves as the teaching base for oncology at the University of Ljubljana.","asOf":"2026-09-09","links":[{"label":"Homepage (page moved; nearest live section)","url":"https://www.onko-i.si/"},{"label":"Cancer Registry","url":"https://www.onko-i.si/eng/crs/"}],"tags":[],"related":[],"cancers":["melanoma","head-and-neck","breast-hr-positive","colorectal"],"sections":["radiation","prevention"],"technologies":["irreversible-electroporation","brachytherapy","imrt-igrt","hpv-vaccine"],"targets":[],"drugs":["carboplatin"],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["zlata-stiblar-kisic","janja-ocvirk"],"bottlenecks":[],"keyPapers":[],"journals":["radiology-and-oncology"],"dependsOn":[],"notes":[],"city":"Ljubljana","country":"SI","lat":46.056,"lng":14.515,"institutionType":"cancer-center","website":"https://www.onko-i.si/","university":"Univerza v Ljubljani","programs":["Slovenian cancer registry and screening","Electrochemotherapy","Melanoma","Radiotherapy and brachytherapy","Head and neck oncology"]},{"id":"instituto-alexander-fleming","kind":"institution","name":"Instituto Alexander Fleming","aka":["IAF","Fleming"],"tldr":"The Instituto Alexander Fleming in Buenos Aires, founded in 1994, is Argentina's most research-active cancer centre; it has enrolled Argentine patients in the pivotal HER2, CDK4/6, lung and colorectal trials of the last three decades and hosts the GAICO cooperative group.","summary":"The Instituto Alexander Fleming was founded in Buenos Aires in 1994 as a dedicated cancer institute by a group of oncologists including Reinaldo Chacón, and has become Argentina's most research-active cancer centre, with medical, surgical and radiation oncology, haematology, nuclear medicine and a large clinical research department that has enrolled Argentine patients in pivotal breast (HER2, CDK4/6), lung and colorectal cancer trials of the last three decades. It hosts the Grupo Argentino de Investigación Clínica en Oncología (GAICO) and links with the Latin American Cooperative Oncology Group, offers a fellowship programme and tumour banking, and was an early adopter in Argentina of precision oncology and next-generation sequencing.","asOf":"2026-09-09","links":[{"label":"Instituto Alexander Fleming","url":"https://www.alexanderfleming.org"}],"tags":[],"related":[],"cancers":["breast-her2-positive","breast-hr-positive","nsclc","colorectal"],"sections":["targeted-therapy"],"technologies":["cgp"],"targets":["her2","cdk4-6"],"drugs":["trastuzumab","palbociclib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["bernardo-rubinstein"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Buenos Aires","country":"AR","lat":-34.552,"lng":-58.452,"institutionType":"cancer-center","website":"https://www.alexanderfleming.org","programs":["International clinical trials","Breast and lung oncology","Cooperative group (GAICO)","Precision oncology"]},{"id":"instituto-roffo","kind":"institution","name":"Instituto de Oncología Ángel H. Roffo","aka":["Instituto Roffo"],"tldr":"Argentina's first cancer institute, founded in 1922 by Ángel Roffo and run by the University of Buenos Aires.","summary":"The Instituto de Oncología Ángel H. Roffo was founded in 1922 by the pathologist Ángel Roffo as Latin America's first institute devoted to experimental and clinical cancer research, and it remains part of the Universidad de Buenos Aires. It is a public cancer hospital with surgical oncology, medical oncology, radiotherapy, haematology and palliative care, and its research departments in tumour biology, immunology and epidemiology continue the tradition of Roffo, who was among the first to link tobacco tar to cancer experimentally. The institute trains oncologists for the university and hosts national tumour registries.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.institutoroffo.uba.ar"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["inc-argentina","instituto-alexander-fleming"],"pathways":[],"terms":[],"trials":[],"people":["roxana-del-aguila"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Buenos Aires","country":"AR","lat":-34.598,"lng":-58.475,"institutionType":"cancer-center","website":"https://www.institutoroffo.uba.ar","university":"Universidad de Buenos Aires","programs":["University cancer institute","Radiotherapy","Tumour biology research"]},{"id":"icesp","kind":"institution","name":"Instituto do Câncer do Estado de São Paulo (ICESP)","aka":["ICESP Octavio Frias de Oliveira","Hospital das Clínicas FMUSP"],"tldr":"ICESP is the São Paulo state cancer institute within Hospital das Clínicas and the University of São Paulo medical school; it treats patients only through Brazil's public health system, with 520 beds across four sites, and is the main Brazilian public-sector site for international trials.","summary":"ICESP was created by the State of São Paulo as the cancer institute of the Hospital das Clínicas of the Faculdade de Medicina da Universidade de São Paulo, managed by the Fundação Faculdade de Medicina, and treats patients exclusively through Brazil's public health system (SUS). In February 2026 the institute reported 520 operational beds, around 40,000 active patients and more than 150,000 patients treated since it opened, across four sites. It provides medical oncology, radiotherapy, surgical oncology, haematology, nuclear medicine and palliative care, hosts a large research and teaching programme in translational oncology, and is the principal Brazilian public-sector site for many international trials.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.icesp.org.br"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["inca-brazil","ac-camargo"],"pathways":[],"terms":[],"trials":[],"people":["arthur-violante-sapia"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"São Paulo","country":"BR","lat":-23.556,"lng":-46.669,"institutionType":"cancer-center","website":"https://www.icesp.org.br","university":"Universidade de São Paulo","programs":["Public-sector cancer institute","Radiotherapy","Translational oncology research","Clinical trials"]},{"id":"inca-brazil","kind":"institution","name":"Instituto Nacional de Câncer (INCA)","aka":["INCA","Instituto Nacional de Câncer José Alencar Gomes da Silva"],"tldr":"Brazil's national cancer institute, the Ministry of Health body that runs cancer control, registries and screening for the country and treats patients in its Rio hospitals.","summary":"INCA was created in 1937 and is the Brazilian Ministry of Health's agency for national cancer policy, running the population and hospital cancer registries, cancer incidence estimates, the national tobacco control programme (a global model recognised by WHO), and cervical and breast screening guidelines for the public health system (SUS). It operates several hospital units in Rio de Janeiro providing surgical, medical, radiation and paediatric oncology and bone marrow transplant, hosts a research centre in cancer biology, epidemiology and clinical trials, and coordinates Brazil's national bone marrow donor registry (REDOME), one of the largest in the world. INCA trains oncology specialists nationally and publishes the reference Estimativa reports on Brazil's cancer burden.","asOf":"2026-09-09","links":[{"label":"INCA","url":"https://www.gov.br/inca"}],"tags":[],"related":["global-oncology-access","cancer-registries-surveillance"],"cancers":["cervical","breast-hr-positive","prostate","nsclc","all-leukemia"],"sections":["prevention","early-detection"],"technologies":["allogeneic-cell-therapy","hpv-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":["iarc"],"pathways":[],"terms":[],"trials":[],"people":["roberto-de-almeida-gil"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Rio de Janeiro","country":"BR","lat":-22.911,"lng":-43.185,"institutionType":"government","website":"https://www.gov.br/inca","programs":["National cancer control and registries","Tobacco control","REDOME bone marrow registry","Hospital units and research centre"]},{"id":"inc-colombia","kind":"institution","name":"Instituto Nacional de Cancerología (Colombia)","aka":["INC Colombia","Instituto Nacional de Cancerología ESE"],"tldr":"Colombia's national cancer institute, responsible for cancer control policy, the national cancer observatory and specialist care in Bogotá.","summary":"The Instituto Nacional de Cancerología in Bogotá was founded in 1934 as the Instituto Nacional de Radium and is Colombia's state cancer institute, combining a specialist hospital with a public-health mandate for the national cancer control plan, cancer surveillance (the National Cancer Observatory and incidence estimates with regional registries in Cali and elsewhere) and clinical guidelines. It provides surgical, medical, radiation and paediatric oncology, runs research in cancer epidemiology, HPV and cervical cancer prevention (Colombia introduced HPV vaccination and HPV-based screening with INC studies), gastric cancer in the Andean high-risk region, and health services research, and trains specialists with the Universidad Nacional de Colombia.","asOf":"2026-09-09","links":[{"label":"Instituto Nacional de Cancerología Colombia","url":"https://www.cancer.gov.co"}],"tags":[],"related":["global-oncology-access","cancer-registries-surveillance"],"cancers":["cervical","gastric","breast-hr-positive","all-leukemia"],"sections":["prevention"],"technologies":["hpv-vaccine","brachytherapy"],"targets":[],"drugs":[],"companies":[],"institutions":["iarc"],"pathways":[],"terms":[],"trials":[],"people":["nubia-munoz","carolina-wiesner"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Bogotá","country":"CO","lat":4.594,"lng":-74.081,"institutionType":"cancer-center","website":"https://www.cancer.gov.co","programs":["National cancer control plan","Cancer surveillance and observatory","HPV and cervical cancer research","Gastric cancer"]},{"id":"incan-mexico","kind":"institution","name":"Instituto Nacional de Cancerología (Mexico)","aka":["INCan","INCAN Mexico"],"tldr":"Mexico's national cancer institute, the federal referral hospital for uninsured cancer patients and the country's main oncology research and training centre.","summary":"The Instituto Nacional de Cancerología was founded in 1946 as one of Mexico's National Institutes of Health and is the federal reference hospital for cancer, treating mostly uninsured adults from across the country and setting national treatment guidelines. It runs surgical, medical and radiation oncology, haematology, nuclear medicine and palliative care, hosts the Mexican national cancer registry effort and cancer epidemiology, and its research units in genomics (with the National Institute of Genomic Medicine), tumour biology and clinical trials have made it Latin America's most productive Spanish-language cancer research institution. INCan investigators lead studies in cervical cancer, breast cancer in Hispanic women, gastric cancer and lung cancer in never-smokers, and it trains a large share of Mexico's oncologists.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Instituto_Nacional_de_Cancerolog%C3%ADa_(Mexico)","links":[{"label":"INCan","url":"https://www.incan.salud.gob.mx"}],"tags":[],"related":["global-oncology-access","cancer-registries-surveillance"],"cancers":["cervical","breast-hr-positive","gastric","nsclc","dlbcl"],"sections":["prevention","radiation"],"technologies":["hpv-vaccine","brachytherapy","cgp"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["oscar-arrieta-rodriguez"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Mexico City","country":"MX","lat":19.297,"lng":-99.156,"institutionType":"cancer-center","website":"https://www.incan.salud.gob.mx","programs":["National reference cancer hospital","Cancer epidemiology and registry","Genomics and clinical trials","Oncology training"]},{"id":"inen-peru","kind":"institution","name":"Instituto Nacional de Enfermedades Neoplásicas","aka":["INEN","INEN Peru"],"tldr":"Peru's national cancer institute, the largest cancer hospital in the Andean region and the coordinator of Peru's national cancer plan and registry.","summary":"INEN was founded in Lima in 1939 as the Instituto Nacional del Cáncer and is Peru's national cancer institute and its largest oncology hospital, treating patients from across the country and coordinating the Plan Esperanza national cancer plan, the Lima metropolitan cancer registry and the network of regional cancer institutes in Trujillo, Arequipa and Concepción. It provides surgical, medical, radiation and paediatric oncology, nuclear medicine and bone marrow transplant, and its research department leads Latin American work on gastric cancer (Peru has among the region's highest rates), cervical cancer screening and HPV self-sampling, paediatric leukaemia outcomes, and clinical trials in breast and lung cancer, and it trains most Peruvian oncologists.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/National_Institute_of_Neoplastic_Diseases","links":[{"label":"INEN","url":"https://portal.inen.sld.pe"}],"tags":[],"related":["global-oncology-access","cancer-registries-surveillance","inca-uruguay","inc-chile"],"cancers":["gastric","cervical","breast-hr-positive","all-leukemia"],"sections":["prevention","radiation"],"technologies":["hpv-vaccine","brachytherapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["francisco-berrospi-espinoza"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Lima","country":"PE","lat":-12.109,"lng":-76.998,"institutionType":"cancer-center","website":"https://portal.inen.sld.pe","programs":["National cancer plan (Plan Esperanza)","Lima cancer registry","Gastric and cervical cancer research","Paediatric oncology"]},{"id":"inor-cuba","kind":"institution","name":"Instituto Nacional de Oncología y Radiobiología (INOR)","aka":["INOR Havana"],"tldr":"INOR in Havana is Cuba's national cancer hospital and coordinates the national cancer control programme; it is the clinical partner of the Center of Molecular Immunology, whose home-grown lung cancer vaccine CIMAvax-EGF and antibody nimotuzumab were tested in INOR-led trials.","summary":"The Instituto Nacional de Oncología y Radiobiología is Cuba's national cancer hospital and research institute, under the Ministry of Public Health, providing surgical oncology, medical oncology, radiotherapy, nuclear medicine and palliative care and coordinating the national cancer control programme. It is the main clinical partner of the Center of Molecular Immunology (CIM), where Cuban biotechnology developed the EGF-targeted lung cancer vaccine CIMAvax-EGF, the anti-EGFR antibody nimotuzumab and other immunotherapies that were tested in INOR-led trials. INOR also trains oncologists for Cuba and partner countries.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://instituciones.sld.cu/inor"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":["egfr"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["luis-eduardo-martin-rodriguez"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Havana","country":"CU","lat":23.136,"lng":-82.39,"institutionType":"cancer-center","website":"https://instituciones.sld.cu/inor","programs":["National cancer institute","Cuban immunotherapy trials (CIMAvax-EGF, nimotuzumab)","Radiotherapy"]},{"id":"inc-argentina","kind":"institution","name":"Instituto Nacional del Cáncer (Argentina)","aka":["INC Argentina"],"tldr":"Argentina's national cancer institute, created in 2010 within the Ministry of Health to run cancer control, screening and registries.","summary":"The Instituto Nacional del Cáncer of Argentina was created in 2010 as the Ministry of Health's agency for cancer control. Rather than a hospital, it is a policy and programme body that runs the national breast, cervical and colorectal cancer screening programmes, the Argentine Institutional Hospital Cancer Registry network (RITA), the national childhood cancer registry, clinical guidelines and training, and the national cancer control plan, and it funds research grants. It coordinates with provincial health ministries and with the Roffo and Alexander Fleming institutes and the paediatric Hospital Garrahan on quality of cancer care.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.argentina.gob.ar/salud/inc"}],"tags":[],"related":["inca-uruguay","inc-chile"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["instituto-roffo","instituto-alexander-fleming"],"pathways":[],"terms":[],"trials":[],"people":["susana-blanco"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Buenos Aires","country":"AR","lat":-34.609,"lng":-58.386,"institutionType":"government","website":"https://www.argentina.gob.ar/salud/inc","programs":["National screening programmes","Hospital cancer registry network (RITA)","Guidelines and training"]},{"id":"inc-chile","kind":"institution","name":"Instituto Nacional del Cáncer (Chile)","aka":["INCANCER","Instituto Nacional del Cáncer Dr. Caupolicán Pardo Correa"],"tldr":"Chile's Instituto Nacional del Cáncer in Santiago is the public system's main referral hospital for complex adult cancers; it works with the Ministry of Health on the national cancer plan and the GES guaranteed-care cancer pathways.","summary":"The Instituto Nacional del Cáncer Dr. Caupolicán Pardo Correa is Chile's public specialised cancer hospital, part of the Metropolitan North health service in Santiago, and the national referral centre for complex adult cancer care in the public system. It provides surgical oncology, medical oncology, radiotherapy, nuclear medicine and palliative care, hosts training for oncologists and radiotherapists, and works with the Ministry of Health on the national cancer plan and the GES guaranteed-care cancer pathways. It collaborates with the Fundación Arturo López Pérez and university hospitals on clinical trials and registries.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.incancer.cl"}],"tags":[],"related":["inca-uruguay"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["falp-chile"],"pathways":[],"terms":[],"trials":[],"people":["berta-cerda-alvarez"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Santiago","country":"CL","lat":-33.418,"lng":-70.656,"institutionType":"cancer-center","website":"https://www.incancer.cl","programs":["Public cancer hospital","Radiotherapy","National cancer plan"]},{"id":"inca-uruguay","kind":"institution","name":"Instituto Nacional del Cáncer (Uruguay)","aka":["INCA Uruguay"],"tldr":"Uruguay's Instituto Nacional del Cáncer in Montevideo is the public national cancer hospital run by the state provider ASSE; it is the referral centre for public-sector patients in a country with among the highest cancer incidence in Latin America.","summary":"The Instituto Nacional del Cáncer is Uruguay's public specialised cancer hospital, run by the Administración de los Servicios de Salud del Estado (ASSE) in Montevideo. It provides surgical oncology, medical oncology, radiotherapy, haematology and palliative care as the national referral centre for public-sector patients, hosts the Universidad de la República's oncology training, and works with the Comisión Honoraria de Lucha contra el Cáncer, which runs Uruguay's national cancer registry and screening programmes. Uruguay has among the highest cancer incidence rates in Latin America, and the institute is central to the national cancer control plan.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.inca.com.uy"}],"tags":[],"related":["inc-chile"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["inc-argentina"],"pathways":[],"terms":[],"trials":[],"people":["mauricio-cuello"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Montevideo","country":"UY","lat":-34.884,"lng":-56.166,"institutionType":"cancer-center","website":"https://www.inca.com.uy","programs":["National public cancer hospital","Radiotherapy","Oncology training"]},{"id":"ipo-coimbra","kind":"institution","name":"Instituto Português de Oncologia de Coimbra Francisco Gentil","aka":["IPO Coimbra"],"tldr":"The third of Portugal's three IPO cancer institutes, serving the centre of the country and accredited by OECI as a Cancer Centre.","summary":"IPO Coimbra is one of the three Portuguese Institutes of Oncology named after Francisco Gentil, alongside IPO Lisboa and IPO Porto, and is the public dedicated cancer hospital for central Portugal. It provides surgical oncology, medical oncology, radiotherapy, haematology, nuclear medicine and palliative care, hosts the regional cancer registry, and collaborates with the University of Coimbra on clinical and translational research. The institute is accredited by the Organisation of European Cancer Institutes as a Cancer Centre.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.ipocoimbra.min-saude.pt"}],"tags":["oeci-accredited","oeci-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci","ipo-lisboa","ipo-porto"],"pathways":[],"terms":[],"trials":[],"people":["maria-margarida-torres-de-ornelas"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Coimbra","country":"PT","lat":40.212,"lng":-8.412,"institutionType":"cancer-center","website":"https://www.ipocoimbra.min-saude.pt","programs":["Dedicated cancer hospital","Radiotherapy","Regional cancer registry"]},{"id":"ipo-lisboa","kind":"institution","name":"Instituto Português de Oncologia de Lisboa Francisco Gentil","aka":["IPO Lisboa","IPO-Lisboa","Instituto Português de Oncologia"],"tldr":"Portugal's first cancer institute, founded in 1923 by Francisco Gentil, and the national reference cancer hospital for the Lisbon region.","summary":"The Instituto Português de Oncologia was founded in Lisbon in 1923 by the surgeon Francisco Gentil and gave rise to the national IPO network; IPO Lisboa remains the country's largest dedicated cancer hospital and is OECI-accredited. It provides surgical, medical, radiation and paediatric oncology, haematology and bone marrow transplantation, nuclear medicine and palliative care, and hosts a research unit working on molecular pathology, haematological malignancies and cancer epidemiology, together with Portugal's southern regional cancer registry. Patients access national referral services for rare tumours, sarcoma and paediatric cancers and a growing clinical trials programme.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.ipolisboa.min-saude.pt"},{"label":"IPO network","url":"https://www.ipoporto.pt"}],"tags":[],"related":[],"cancers":["all-leukemia","breast-hr-positive","sarcoma","colorectal"],"sections":["surgery","supportive-care"],"technologies":["allogeneic-cell-therapy","imrt-igrt","pet-ct"],"targets":[],"drugs":[],"companies":[],"institutions":["ipo-porto","oeci"],"pathways":[],"terms":[],"trials":[],"people":["carla-goncalo","maria-margarida-torres-de-ornelas"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Lisbon","country":"PT","lat":38.742,"lng":-9.163,"institutionType":"cancer-center","website":"https://www.ipolisboa.min-saude.pt","university":"Universidade de Lisboa","programs":["National cancer hospital","Haematology and transplantation","Paediatric oncology","Rare tumours and sarcoma","Regional cancer registry"]},{"id":"ipo-porto","kind":"institution","name":"Instituto Português de Oncologia do Porto Francisco Gentil","aka":["IPO Porto","IPO-Porto"],"tldr":"Northern Portugal's dedicated cancer hospital, an OECI-accredited comprehensive cancer centre known for hereditary cancer genetics and epigenetic biomarkers.","summary":"IPO Porto is the public cancer hospital and research institute for northern Portugal and holds OECI accreditation as a comprehensive cancer centre. Its cancer genetics department under Manuel Teixeira is a national reference for hereditary breast, ovarian and gastric cancer syndromes, and Rui Henrique and Carmen Jerónimo's epigenetics group developed DNA methylation biomarkers for prostate and other cancers. The hospital delivers surgery, radiotherapy including brachytherapy, medical oncology, haematology with transplantation and CAR-T, and paediatric oncology, and runs a large tumour bank and a portfolio of academic and industry trials. It coordinates the Porto Comprehensive Cancer Center with the University of Porto's i3S institute.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.ipoporto.pt"},{"label":"Research","url":"https://www.ipoporto.pt/en/investigacao/"}],"tags":[],"related":[],"cancers":["prostate","gastric","colorectal","breast-hr-positive","ovarian"],"sections":["diagnostics","radiation"],"technologies":["methylation-profiling","germline-testing","brachytherapy","car-t"],"targets":["brca"],"drugs":[],"companies":[],"institutions":["oeci","ipo-lisboa"],"pathways":[],"terms":[],"trials":[],"people":["julio-oliveira"],"bottlenecks":["b-hereditary-risk"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Porto","country":"PT","lat":41.181,"lng":-8.604,"institutionType":"cancer-center","website":"https://www.ipoporto.pt","university":"Universidade do Porto","programs":["Hereditary cancer genetics","Epigenetic biomarkers","Haematology and transplantation","Radiotherapy and brachytherapy","Porto Comprehensive Cancer Center"]},{"id":"intermountain-cancer","kind":"institution","name":"Intermountain Health Cancer Center","aka":["Intermountain Healthcare Oncology","Intermountain Precision Genomics"],"tldr":"The Mountain West health system that was among the first to bring in-house tumour sequencing to community oncology, via Intermountain Precision Genomics.","summary":"Intermountain Health is a non-profit system across Utah and the surrounding Mountain West whose cancer programme spans Intermountain Medical Center and regional hospitals. Its Precision Genomics programme, launched in St. George under Lincoln Nadauld, was one of the first health-system-run tumour sequencing services and reported that targeted therapy guided by its panel improved outcomes and costs in community practice; the biobank and data assets were spun into Culmination Bio in 2022. Intermountain has a long record in clinical informatics dating to Homer Warner's HELP system, and collaborates with Huntsman Cancer Institute on trials and referrals. Its research emphasises real-world evidence and care delivery.","asOf":"2026-09-09","links":[{"label":"Intermountain cancer care","url":"https://intermountainhealthcare.org/services/cancer-care"},{"label":"Intermountain Precision Genomics","url":"https://intermountainhealthcare.org/services/cancer-care/precision-genomics"}],"tags":[],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":["cgp"],"targets":[],"drugs":[],"companies":[],"institutions":["huntsman"],"pathways":[],"terms":["real-world-evidence"],"trials":[],"people":["derrick-haslem"],"bottlenecks":["b-data-silos","b-real-world-evidence","b-care-fragmentation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Salt Lake City, UT","country":"US","lat":40.663,"lng":-111.891,"institutionType":"hospital","website":"https://intermountainhealthcare.org/services/cancer-care","programs":["Intermountain Precision Genomics","Real-world data and informatics","Community oncology network"]},{"id":"iarc","kind":"institution","name":"International Agency for Research on Cancer (IARC / WHO)","aka":[],"tldr":"IARC is the WHO's cancer agency, responsible for global cancer statistics (GLOBOCAN), carcinogen classification, and prevention research.","summary":"The International Agency for Research on Cancer in Lyon is the World Health Organization's cancer agency, responsible for the GLOBOCAN global cancer statistics, the IARC Monographs that classify carcinogens, the WHO Classification of Tumours known as the Blue Books, and the cervical cancer elimination effort. Its verdicts that excess body fat causes thirteen cancers and that alcohol caused an estimated 741,000 cancers worldwide in 2020 are carried as papers in OnCo, as are its Indian trials of HPV vaccine dosing and of cervical and oral cancer screening. OnCo connects it to bottlenecks on the absence of cancer and palliative care in most of the world, and to the idea of a Global Fund for cancer. Whether single-dose HPV vaccination becomes the norm is one question its own trials raised. Its GLOBOCAN collection has its own page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.iarc.who.int"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["bray-freddie","cree-ian","weiderpass-elisabete","basu-partha","sankaranarayanan-rengaswamy"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Lyon","country":"FR","lat":45.741,"lng":4.856,"institutionType":"government","website":"https://www.iarc.who.int","programs":["GLOBOCAN","Monographs","WHO tumour classification"]},{"id":"iaslc","kind":"institution","name":"International Association for the Study of Lung Cancer","aka":["IASLC"],"tldr":"The only global society devoted to lung and thoracic cancers, whose World Conference on Lung Cancer and TNM staging project define the field.","summary":"Founded in 1974, IASLC has more than 8,000 members in over 100 countries and publishes the Journal of Thoracic Oncology and JTO Clinical and Research Reports. Its Staging and Prognostic Factors Committee runs the international database behind the TNM classification for lung cancer, mesothelioma and thymic tumours (ninth edition 2024), and its World Conference on Lung Cancer is the annual venue for thoracic oncology trials, from EGFR and ALK inhibitors to neoadjuvant immunotherapy and ADCs. IASLC issues pathology and biomarker atlases (PD-L1, ALK, MET), the Lung Cancer Screening guidelines and the Grading System for lung adenocarcinoma, and its Tobacco Control Committee and Early Detection Committee drive global screening advocacy.","asOf":"2026-09-09","links":[{"label":"IASLC","url":"https://www.iaslc.org"},{"label":"World Conference on Lung Cancer","url":"https://wclc.iaslc.org"}],"tags":[],"related":["lungevity"],"cancers":["nsclc","sclc","mesothelioma"],"sections":["early-detection","targeted-therapy"],"technologies":["cgp","kinase-inhibitors","checkpoint-inhibitor","ct","radiology-ai-screening"],"targets":[],"drugs":[],"companies":[],"institutions":["esmo","asco"],"pathways":[],"terms":["tnm-staging","oncogene-addiction"],"trials":[],"people":["wu-yi-long","pasi-janne","solomon-benjamin","fiona-blackhall","zhou-caicun","karen-kelly"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Denver, CO","country":"US","lat":39.739,"lng":-104.99,"institutionType":"consortium","website":"https://www.iaslc.org","programs":["World Conference on Lung Cancer","TNM staging project for thoracic cancers","Journal of Thoracic Oncology","Biomarker and pathology atlases","Screening and tobacco control advocacy"]},{"id":"iaea","kind":"institution","name":"International Atomic Energy Agency: Rays of Hope","aka":["IAEA","Rays of Hope","PACT"],"tldr":"The UN nuclear agency's programme to bring radiotherapy and nuclear medicine to the dozens of countries that have no or too few treatment machines.","summary":"The IAEA has supported radiotherapy and nuclear medicine in member states for decades through technical cooperation, dosimetry audits and the Human Health Programme, and in 2022 launched Rays of Hope to close the gap in countries where most cancer patients who need radiotherapy cannot get it. Rays of Hope funds equipment, training and quality assurance, working first in African countries with no linear accelerators, and creates Anchor Centres of expertise. The agency's Programme of Action for Cancer Therapy (PACT) runs imPACT reviews of national cancer control capacity with WHO and IARC, and its Dosimetry Laboratory underpins radiotherapy calibration worldwide. The IAEA also supports radiopharmaceutical production capacity for theranostics.","asOf":"2026-09-09","links":[{"label":"Rays of Hope","url":"https://www.iaea.org/services/rays-of-hope"},{"label":"IAEA cancer","url":"https://www.iaea.org/topics/cancer"}],"tags":[],"related":[],"cancers":[],"sections":["radiation","radiopharma"],"technologies":["imrt-igrt","brachytherapy","radioligand-therapy","pet-ct"],"targets":[],"drugs":[],"companies":[],"institutions":["who","iarc","uicc","estro"],"pathways":[],"terms":["dosimetry"],"trials":[],"people":["rafael-mariano-grossi"],"bottlenecks":["b-global-access","b-surgery-radiation-innovation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Vienna","country":"AT","lat":48.234,"lng":16.416,"institutionType":"government","website":"https://www.iaea.org/services/rays-of-hope","programs":["Rays of Hope (radiotherapy access)","imPACT reviews (with WHO and IARC)","Dosimetry and quality audit services","Radiopharmaceutical capacity building"]},{"id":"isoqol","kind":"institution","name":"International Society for Quality of Life Research","aka":["ISOQOL"],"tldr":"The society for patient-reported outcomes and quality of life research, whose standards guide how symptoms and quality of life are measured in cancer trials.","summary":"Founded in 1994, ISOQOL brings together researchers, clinicians, regulators and patients working on health-related quality of life and patient-reported outcomes (PROs). It publishes Quality of Life Research and the Journal of Patient-Reported Outcomes, and its guidance on PRO measure selection, minimal standards, and the SPIRIT-PRO and CONSORT-PRO extensions for trial protocols and reports are used by oncology trialists and by regulators assessing quality-of-life claims. ISOQOL's special interest groups on cancer, digital health and clinical practice work with the FDA, EMA and HTA bodies on how PRO data should inform approvals and value, and its annual conference draws the field's methodologists.","asOf":"2026-09-09","links":[{"label":"ISOQOL","url":"https://www.isoqol.org"}],"tags":[],"related":[],"cancers":[],"sections":["supportive-care"],"technologies":[],"targets":[],"drugs":[],"companies":["curie-nki-eortc"],"institutions":["ispor","mascc","fda-oce"],"pathways":[],"terms":[],"trials":[],"people":["sandra-nolte"],"bottlenecks":["b-toxicity-qol","b-patient-voice"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Milwaukee, WI","country":"US","lat":43.039,"lng":-87.906,"institutionType":"consortium","website":"https://www.isoqol.org","programs":["Quality of Life Research and Journal of Patient-Reported Outcomes","PRO standards (SPIRIT-PRO, CONSORT-PRO, minimum standards)","Annual conference","Regulatory and HTA engagement"]},{"id":"sant-orsola-bologna","kind":"institution","name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola","aka":["Sant'Orsola-Malpighi","Policlinico Sant'Orsola","Istituto di Ematologia Seràgnoli"],"tldr":"Bologna's university hospital, home of the Seràgnoli haematology institute and a leading Italian centre for myeloma, lymphoma and CAR-T.","summary":"The Policlinico Sant'Orsola is the university hospital of the world's oldest university and an IRCCS for transplant and oncology. Its Seràgnoli Institute of Haematology, associated with Michele Cavo (myeloma), Pier Luigi Zinzani (lymphoma) and the GIMEMA cooperative group, has run pivotal Italian trials in myeloma transplantation and lymphoma and is one of Italy's principal CAR-T and allogeneic transplant centres. Medical oncology under Andrea Ardizzoni is active in thoracic and gastrointestinal trials, and the hospital has large paediatric oncology, surgical oncology and nuclear medicine departments. The Emilia-Romagna regional network links it with IRST Meldola.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.aosp.bo.it"},{"label":"Haematology","url":"https://www.aosp.bo.it/content/ematologia"}],"tags":[],"related":[],"cancers":["multiple-myeloma","dlbcl","hodgkin-lymphoma","aml","nsclc"],"sections":["cell-therapy"],"technologies":["car-t","bispecific-antibody","allogeneic-cell-therapy"],"targets":["bcma","cd20"],"drugs":["glofitamab","teclistamab"],"companies":[],"institutions":["irst-meldola"],"pathways":[],"terms":[],"trials":[],"people":["chiara-gibertoni"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Bologna","country":"IT","lat":44.496,"lng":11.36,"institutionType":"hospital","website":"https://www.aosp.bo.it","university":"Università di Bologna","programs":["Seràgnoli haematology institute","Myeloma and lymphoma trials (GIMEMA)","CAR-T and transplantation","Thoracic oncology","Paediatric oncology"]},{"id":"crob-rionero","kind":"institution","name":"IRCCS CROB, Centro di Riferimento Oncologico della Basilicata","aka":["CROB"],"tldr":"The regional cancer institute of Basilicata in southern Italy, an IRCCS accredited by OECI as a Cancer Centre.","summary":"The Centro di Riferimento Oncologico della Basilicata (CROB) in Rionero in Vulture is the dedicated cancer hospital and research institute of the Basilicata region, recognised by the Ministry of Health as an IRCCS. It provides medical oncology, radiotherapy, haematology, surgical oncology, nuclear medicine and clinical trials for a largely rural southern Italian population and runs research laboratories in translational oncology, with programmes in myeloma and lymphoma, breast and gastrointestinal cancers and cancer epidemiology. CROB is accredited by the Organisation of European Cancer Institutes as a Cancer Centre.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.crob.it"}],"tags":["oeci-accredited","oeci-cancer-centre","irccs"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["massimo-de-fino"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Rionero in Vulture","country":"IT","lat":40.925,"lng":15.674,"institutionType":"cancer-center","website":"https://www.crob.it","programs":["Regional cancer institute","Haematology","Translational oncology laboratories"]},{"id":"humanitas","kind":"institution","name":"IRCCS Humanitas Research Hospital","aka":["Humanitas Cancer Center","Istituto Clinico Humanitas"],"tldr":"A Milan research hospital known for Alberto Mantovani's work on tumour-associated macrophages and for stereotactic radiotherapy and liver cancer trials.","summary":"Humanitas Research Hospital, founded in 1996 in Rozzano, is a private IRCCS teaching hospital with its own Humanitas University. Alberto Mantovani, its scientific director, established the concept of cancer-related inflammation and the role of tumour-associated macrophages, complement and pentraxin 3 in tumour progression. The Humanitas Cancer Center under Armando Santoro has been a major site for hepatocellular carcinoma and biliary cancer trials, including with Lorenza Rimassa, and Marta Scorsetti's radiotherapy department is a leader in stereotactic body radiotherapy for oligometastatic disease. The hospital also runs haematology, thoracic and colorectal surgery and an early-phase unit, and holds OECI accreditation.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.humanitas.net"},{"label":"Cancer Center","url":"https://www.humanitas.net/cancer-center/"}],"tags":[],"related":[],"cancers":["hcc","cholangiocarcinoma","dlbcl","nsclc"],"sections":["radiation","immunotherapy"],"technologies":["sbrt","checkpoint-inhibitor","car-nk-macrophage","imrt-igrt"],"targets":[],"drugs":["durvalumab","atezolizumab"],"companies":[],"institutions":["oeci"],"pathways":[],"terms":["oligometastatic","cold-vs-hot"],"trials":[],"people":["simona-sancini","armando-santoro","domenica-lorusso","riccardo-bui"],"bottlenecks":["b-tme-immunosuppression"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Rozzano (Milan)","country":"IT","lat":45.399,"lng":9.167,"institutionType":"hospital","website":"https://www.humanitas.net","university":"Humanitas University","programs":["Tumour-associated macrophages and innate immunity","Hepatobiliary oncology trials","Stereotactic body radiotherapy","Haematology","Early-phase trials"]},{"id":"irst-meldola","kind":"institution","name":"IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)","aka":["IRST Meldola","IRST IRCCS"],"tldr":"The Romagna cancer institute, known for radioligand therapy, nuclear medicine and genitourinary and sarcoma trials.","summary":"IRST opened in 2007 in Meldola near Forlì as the cancer research institute for the Romagna area of Emilia-Romagna and was named after its founder, the oncologist Dino Amadori. Its nuclear medicine department under Giovanni Paganelli, a pioneer of peptide receptor radionuclide therapy with yttrium-90 and lutetium-177 DOTATOC, is one of Italy's leading radioligand therapy centres, and Ugo De Giorgi's genitourinary and sarcoma unit runs PSMA and immunotherapy trials. The institute has an osteoncology and rare tumour centre, a bioscience laboratory for genomics and liquid biopsy, and an early-phase unit, and delivers medical oncology across the Romagna hospital network.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.irst.emr.it"}],"tags":[],"related":[],"cancers":["neuroendocrine","prostate","sarcoma","urothelial"],"sections":["radiopharma"],"technologies":["radioligand-therapy","psma-pet","liquid-biopsy"],"targets":["sstr2","psma"],"drugs":["lutathera","pluvicto"],"companies":[],"institutions":["sant-orsola-bologna","ieo-milan"],"pathways":[],"terms":["theranostics","dosimetry"],"trials":[],"people":["cristina-marchesi","nicola-normanno"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Meldola","country":"IT","lat":44.129,"lng":12.061,"institutionType":"cancer-center","website":"https://www.irst.emr.it","university":"Università di Bologna","programs":["Radioligand therapy and nuclear medicine","Genitourinary oncology","Osteoncology and rare tumours","Liquid biopsy laboratory"]},{"id":"istituto-tumori-bari","kind":"institution","name":"IRCCS Istituto Tumori Giovanni Paolo II","aka":["Istituto Tumori Bari","IRCCS Oncologico Bari"],"tldr":"The dedicated cancer institute of Puglia in Bari, an IRCCS accredited by OECI as a Cancer Centre.","summary":"The Istituto Tumori Giovanni Paolo II is the public cancer hospital and research institute of the Puglia region, recognised as an IRCCS by the Italian Ministry of Health. It provides medical oncology, radiotherapy, surgical oncology, haematology, nuclear medicine and diagnostic services for southern Italy and runs laboratories in molecular diagnostics, tumour biology and pharmacology, with clinical research programmes in breast, lung, gastrointestinal and haematological cancers and a phase 1 unit. The institute is accredited by the Organisation of European Cancer Institutes as a Cancer Centre.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.oncologico.bari.it"}],"tags":["oeci-accredited","oeci-cancer-centre","irccs"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["alessandro-delle-donne"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Bari","country":"IT","lat":41.11,"lng":16.878,"institutionType":"cancer-center","website":"https://www.oncologico.bari.it","programs":["Regional cancer institute","Phase 1 unit","Molecular diagnostics"]},{"id":"san-martino-genoa","kind":"institution","name":"IRCCS Ospedale Policlinico San Martino","aka":["San Martino Hospital","IST Genoa"],"tldr":"Genoa's university hospital, which absorbed Italy's National Cancer Research Institute (IST) and is an OECI Comprehensive Cancer Centre.","summary":"The Ospedale Policlinico San Martino is the largest hospital in Liguria and the teaching hospital of the University of Genoa. It incorporates the former Istituto Nazionale per la Ricerca sul Cancro (IST), giving it an IRCCS research mandate in oncology and neuroscience, and it is accredited by the Organisation of European Cancer Institutes as a Comprehensive Cancer Centre. Clinical and research strengths include medical oncology and early drug development, haematology and transplantation, neuro-oncology, breast cancer, and cancer immunology and immunotherapy, with strong participation in Italian and European cooperative trials.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.ospedalesanmartino.it"}],"tags":["oeci-accredited","oeci-comprehensive-cancer-centre","irccs"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["monica-calamai","ilaria-panzini"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Genoa","country":"IT","lat":44.409,"lng":8.961,"institutionType":"hospital","website":"https://www.ospedalesanmartino.it","university":"University of Genoa","programs":["Medical oncology and early-phase trials","Haematology and transplantation","Cancer immunology"]},{"id":"san-raffaele","kind":"institution","name":"IRCCS Ospedale San Raffaele","aka":["San Raffaele Hospital","OSR","Università Vita-Salute San Raffaele"],"tldr":"Milan's research hospital known for engineered T-cell therapies, gene therapy, high-volume pancreatic surgery and HER2 breast cancer trials.","summary":"Ospedale San Raffaele is a private IRCCS research hospital with its own university and a strong gene and cell therapy tradition through the San Raffaele Telethon Institute for Gene Therapy. Fabio Ciceri's haematology and transplant unit and Chiara Bonini's experimental haematology laboratory developed suicide-gene-modified donor lymphocytes and TCR-edited T cells, Luca Gianni's breast oncology programme led the NeoSphere trial of dual HER2 blockade with pertuzumab and trastuzumab, and Massimo Falconi's pancreatic surgery unit is among Europe's highest-volume centres. The hospital runs neuro-oncology, urology, radiotherapy and a phase 1 unit, and pathology under Claudio Doglioni supports genomics-driven trials.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/San_Raffaele_Hospital","links":[{"label":"Homepage","url":"https://www.hsr.it"},{"label":"Research","url":"https://research.hsr.it"}],"tags":[],"related":[],"cancers":["all-leukemia","aml","pancreatic","breast-her2-positive","neuroendocrine"],"sections":["cell-therapy","surgery"],"technologies":["tcr-t","car-t","allogeneic-cell-therapy","robotic-surgery"],"targets":["her2"],"drugs":["trastuzumab"],"companies":[],"institutions":["ieo-milan","int-milan"],"pathways":[],"terms":[],"trials":[],"people":["gianvito-martino","andrea-necchi","andres-ferreri","marco-centenari"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Milan","country":"IT","lat":45.505,"lng":9.264,"institutionType":"hospital","website":"https://www.hsr.it","university":"Università Vita-Salute San Raffaele","programs":["Engineered T-cell and gene therapy","Haematology and transplantation","Pancreatic surgery","HER2-positive breast cancer trials","Neuro-oncology"]},{"id":"regina-elena-rome","kind":"institution","name":"IRCCS Regina Elena National Cancer Institute","aka":["Istituto Nazionale Tumori Regina Elena","IFO","Istituti Fisioterapici Ospitalieri"],"tldr":"Rome's national cancer institute, which coordinates Italy's Alliance Against Cancer research network.","summary":"The Regina Elena National Cancer Institute, part of the Istituti Fisioterapici Ospitalieri with the San Gallicano dermatological institute, is Rome's IRCCS cancer hospital and coordinates Alleanza Contro il Cancro, the network of Italian oncology research institutes founded in 2002. Under scientific director Gennaro Ciliberto its research groups work on cancer vaccines and immunotherapy, p53 and non-coding RNA biology (Giovanni Blandino), tumour immunology (Paola Nisticò) and translational oncogenomics. Clinical programmes include melanoma and skin cancers, breast, thoracic and gynaecological oncology, robotic surgery, radiotherapy and a phase 1 unit, and the institute runs the Lazio regional oncology network with a large molecular tumour board.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.ifo.it/en/"},{"label":"Alleanza Contro il Cancro","url":"https://www.alleanzacontroilcancro.it"}],"tags":[],"related":[],"cancers":["melanoma","nsclc","breast-hr-positive","ovarian"],"sections":["immunotherapy","surgery"],"technologies":["checkpoint-inhibitor","robotic-surgery","neoantigen-mrna-vaccine","digital-pathology-ai"],"targets":["tp53"],"drugs":[],"companies":[],"institutions":["int-milan","pascale-naples","gemelli"],"pathways":[],"terms":[],"trials":[],"people":["giovanni-blandino","livio-de-angelis"],"bottlenecks":[],"keyPapers":[],"journals":["journal-of-experimental-and-clinical-cancer-research"],"dependsOn":[],"notes":[],"city":"Rome","country":"IT","lat":41.8,"lng":12.446,"institutionType":"cancer-center","website":"https://www.ifo.it/en/","university":"Sapienza Università di Roma","programs":["Alleanza Contro il Cancro coordination","Immunotherapy and vaccine research","Melanoma and skin cancers","Robotic surgery","Phase 1 unit"]},{"id":"sacro-cuore-don-calabria","kind":"institution","name":"IRCCS Sacro Cuore Don Calabria Hospital","aka":["Ospedale Sacro Cuore Don Calabria, Negrar"],"tldr":"Sacro Cuore Don Calabria Hospital in Negrar, near Verona, is a Catholic non-profit hospital recognised as an IRCCS research hospital; it runs medical oncology, radiotherapy, robotic and hepatobiliary surgery and an early-phase trials unit, and OECI accredits it as a Cancer Centre.","summary":"The Sacro Cuore Don Calabria Hospital in Negrar, run by the Opera Don Calabria, is a private non-profit hospital recognised by the Italian Ministry of Health as an IRCCS (scientific research hospital). It has a large oncology department with medical oncology, radiotherapy, oncological surgery including robotic and hepatobiliary surgery, nuclear medicine and an early-phase trials unit, and is accredited by the Organisation of European Cancer Institutes as a Cancer Centre. Its research also covers infectious and tropical diseases, and the hospital collaborates with the University of Verona.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.sacrocuore.it"}],"tags":["oeci-accredited","oeci-cancer-centre","irccs"],"related":[],"cancers":[],"sections":[],"technologies":["robotic-surgery"],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["claudio-cracco"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Negrar di Valpolicella (Verona)","country":"IT","lat":45.53,"lng":10.938,"institutionType":"hospital","website":"https://www.sacrocuore.it","programs":["Medical oncology and early-phase trials","Robotic and hepatobiliary surgery","Radiotherapy"]},{"id":"irish-cancer-society","kind":"institution","name":"Irish Cancer Society","aka":["ICS"],"tldr":"Ireland's national cancer charity, funding research and Cancer Trials Ireland and providing night nursing, support lines and Daffodil Centres in hospitals.","summary":"Founded in 1963, the Irish Cancer Society is Ireland's largest voluntary funder of cancer research, supporting fellowships, research scholarships and collaborative centres, and contributing to Cancer Trials Ireland, the national academic trials organisation. Its services include the Support Line, Daffodil Centres in public hospitals, free night nursing for people dying at home, and travel and financial support. Daffodil Day is its national fundraising day. The Society advocates on the National Cancer Strategy, tobacco control, alcohol labelling and access to new medicines.","asOf":"2026-09-09","links":[{"label":"Irish Cancer Society","url":"https://www.cancer.ie"}],"tags":[],"related":[],"cancers":[],"sections":["supportive-care","prevention"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cruk","macmillan-cancer-support"],"pathways":[],"terms":[],"trials":[],"people":["nikki-gallagher","emma-browne"],"bottlenecks":["b-palliative","b-trial-enrolment"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Dublin","country":"IE","lat":53.349,"lng":-6.26,"institutionType":"consortium","website":"https://www.cancer.ie","programs":["Research fellowships and scholarships","Support for Cancer Trials Ireland","Daffodil Centres and night nursing","Daffodil Day"]},{"id":"ispor","kind":"institution","name":"ISPOR (The Professional Society for Health Economics and Outcomes Research)","aka":["ISPOR","International Society for Pharmacoeconomics and Outcomes Research"],"tldr":"The society of health economists and outcomes researchers whose methods and good-practice reports underpin how cancer drugs are valued by HTA bodies and payers.","summary":"Founded in 1995, ISPOR has more than 20,000 members in over 100 countries and publishes Value in Health. Its Good Practices Task Force reports set methodological standards for cost-effectiveness modelling, indirect treatment comparisons, real-world evidence, patient-reported outcomes and value frameworks that health technology assessment agencies including NICE, CADTH and IQWiG reference, and its ISPOR and ISPOR Europe conferences are where HTA bodies, industry and academics debate oncology pricing, surrogate endpoints and managed-access schemes. ISPOR also runs the HTA Roundtables, the Value Assessment Frameworks initiative and a large student network, and it partnered with the FDA and payers on the RWE Transparency Initiative.","asOf":"2026-09-09","links":[{"label":"ISPOR","url":"https://www.ispor.org"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nice","g-ba-iqwig","has-france","pbac","smc","isoqol"],"pathways":[],"terms":["real-world-evidence","hazard-ratio","os","pfs"],"trials":[],"people":["beth-devine","rob-abbott"],"bottlenecks":["b-drug-pricing","b-real-world-evidence"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Lawrenceville, NJ","country":"US","lat":40.297,"lng":-74.729,"institutionType":"consortium","website":"https://www.ispor.org","programs":["Good Practices Task Force reports","Value in Health","ISPOR and ISPOR Europe conferences","HTA Roundtables and RWE Transparency Initiative"]},{"id":"israel-cancer-association","kind":"institution","name":"Israel Cancer Association","aka":["ICA","האגודה למלחמה בסרטן","Israeli Cancer Association"],"tldr":"A charity, founded in 1952 and funded by public donations alone, that started both of Israel's national cancer screening programmes and still helps monitor one of them.","summary":"The Israel Cancer Association is a registered charity, not a government body, and its own annual report states that its activity is made possible by public donations alone. Its distinctive contribution is that it started the screening: the national breast programme began nationally in 1995 after an Association awareness campaign from 1990, and the national colorectal programme, annual faecal occult blood testing from 50 to 74, began in 2005, both on its initiative with the Ministry of Health and the four health funds. It funds and assists the monitoring of the breast programme end to end, bought the first mobile mammography unit in 2001 and added a second with ultrasound in 2024, and reports about 22,600 mobile examinations in 2025.\n\nIts appropriations in the 2025 financial year were 47.6 million shekels: 41.9 percent to rehabilitation and support including the Sir Charles Clore hostel, 29.6 percent to public information, education and early detection, 10.4 percent, about 5.0 million shekels, to research and clinical protocols, and the rest to administration, services and professional training. It reports more than 55 million shekels awarded to Israeli researchers over the past decade and lists 26 grants awarded in 2026 across eleven institutions. Services include support centres used by more than 12,000 patients and survivors, a breast-cancer survivor mentoring line, a hostel for patients in treatment, tutoring for children of patients, and a helpline for exercising rights against the health basket. The National Cancer Registry's own melanoma report credits part of the rise in in-situ melanoma detection to the Association's early-detection work with the health funds from the early 1990s. It does not run the cancer registry, which is a Ministry of Health function.","asOf":"2026-09-25","links":[{"label":"Israel Cancer Association (English)","url":"https://en.cancer.org.il/"},{"label":"Israel Cancer Association annual report 2025 (English PDF)","url":"https://d2mp61vkno2eva.cloudfront.net/pdfs/2026-08/a9eb4639f5fd45f32da9363b.pdf"},{"label":"Registrar of Associations record (Guidestar, registration 580030039)","url":"https://www.guidestar.org.il/organization/580030039"}],"tags":[],"related":[],"cancers":["breast-hr-positive","colorectal","melanoma"],"sections":["prevention","supportive-care"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["israel-national-cancer-registry","iscort"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Givatayim","country":"IL","lat":32.072,"lng":34.812,"institutionType":"consortium","website":"https://en.cancer.org.il/","programs":["National breast cancer early detection programme","National colorectal early detection programme","Mobile mammography units","Research grants","Patient support and rehabilitation"]},{"id":"israel-national-cancer-registry","kind":"institution","name":"Israel National Cancer Registry","aka":["INCR","Israel Center for Disease Control","ICDC","National Cancer Registry, Ministry of Health Israel"],"tldr":"Israel's cancer count, kept since 1960 and compulsory since 1982, run from the Israel Center for Disease Control on the Sheba hospital campus. It audited itself and found it was holding about 94 of every 100 reportable cancers.","summary":"The Israel National Cancer Registry was established in 1960 and notification has been mandatory since 1982. It sits inside the Israel Center for Disease Control, a unit of the Ministry of Health based on the Sheba Medical Center campus at Tel Hashomer, and links to the population registry by national identity number, which is what makes follow-up and family linkage possible at national scale.\n\nWhat is reportable is worth knowing before quoting Israeli figures: all invasive and in-situ malignancies, neoplasms of uncertain or unknown behaviour, and benign as well as malignant tumours of the brain and central nervous system, but not basal or squamous cell carcinoma of the skin. Israeli non-melanoma skin cancer statistics are therefore not a count of those cancers and should not be compared with registries that do record them.\n\nThe registry audited itself by sending abstractors into the medical records departments, pathology and cytology laboratories and oncology and haematology institutes of 39 medical facilities to identify every reportable case diagnosed or treated in 2005, then linking to the database. Completeness was 93.7 percent for all reportable disease, 96.8 percent for invasive solid tumours and 88.0 percent for haematopoietic tumours; cases from the index year were less likely to be present than older cases, which is the signature of a reporting lag and the reason the most recent year of any registry report should be read as provisional. The registry reports separately for Jews, Arabs and others, and publishes around World Cancer Day each February.","asOf":"2026-09-25","links":[{"label":"Israel Center for Disease Control, cancer registry (Ministry of Health)","url":"https://www.gov.il/en/departments/units/icdc-cancer-registry"},{"label":"Moore et al., An assessment of the completeness and timeliness of the Israel National Cancer Registry (IMAJ 2021)","url":"https://pubmed.ncbi.nlm.nih.gov/33443338/"}],"tags":[],"related":[],"cancers":[],"sections":["prevention"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["sheba","israel-cancer-association"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-moore-israel-cancer-registry-completeness-imaj-2021"],"journals":[],"dependsOn":[],"notes":[],"city":"Ramat Gan","country":"IL","lat":32.045,"lng":34.842,"institutionType":"government","website":"https://www.gov.il/en/departments/units/icdc-cancer-registry","programs":["National cancer notification since 1982","Linkage to the population registry","Reporting by population group","Israel Center for Disease Control"]},{"id":"iscort","kind":"institution","name":"Israel Society of Clinical Oncology and Radiation Therapy","aka":["ISCORT","האיגוד הישראלי לאונקולוגיה קלינית ורדיותרפיה","Israeli Society of Clinical Oncology and Radiation Therapy"],"tldr":"The professional society of the doctors who treat cancer without operating. It is small, about a hundred specialists, and it does something no other national society does: it ranks every new cancer drug for the committee that decides what the state will pay for.","summary":"The Israel Society of Clinical Oncology and Radiation Therapy is a union within the Israel Medical Association, describing itself as bringing together the doctors who treat cancer non-surgically in Israel. Its published membership is about 100 specialists and about 80 juniors and residents, which is society membership rather than a national headcount of oncologists. Its chair is Ravit Geva, and it runs an annual conference, held in Eilat in January 2026, with grants and presentation prizes, a monthly bulletin and teaching materials, and works with the national cancer council on radiation therapy.\n\nThe role that matters beyond Israel is its part in the health basket. Each year, with the National Council for the Prevention, Detection and Treatment of Malignant Diseases, it produces the ranked list of candidate solid-tumour drugs that goes to the public basket committee, in a two-step process informed by the ESMO Magnitude of Clinical Benefit Scale. The Israeli authors who described it believe it is the only annual formal national ranking of new cancer drugs anywhere. Note that iscort.org.il is a patients' rights site, not the society.","asOf":"2026-09-25","links":[{"label":"Israel Medical Association union page (Hebrew)","url":"https://www.ima.org.il/MainSiteNew/EditUnion.aspx?UnionId=741"},{"label":"Shapira-Frommer et al., ranking new cancer drugs for the Israeli national basket (ESMO Open 2022)","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8818899/"}],"tags":[],"related":[],"cancers":[],"sections":["targeted-therapy","radiation"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["esmo"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-drug-pricing"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Ramat Gan","country":"IL","lat":32.084,"lng":34.824,"institutionType":"consortium","website":"https://www.ima.org.il/MainSiteNew/EditUnion.aspx?UnionId=741","programs":["Annual ranking of new cancer drugs for the health basket committee","Annual conference","Training and bulletins"]},{"id":"istanbul-oncology-institute","kind":"institution","name":"Istanbul University Institute of Oncology","aka":["İstanbul Üniversitesi Onkoloji Enstitüsü","Çapa Oncology Institute"],"tldr":"Istanbul University's Institute of Oncology, established in 1982, combines medical, radiation and paediatric oncology with cancer epidemiology; its breast programme is one of Turkey's largest, its paediatric unit is a national referral centre, and it trains a large share of Turkish oncologists.","summary":"Established in 1982 within Istanbul University, the Institute of Oncology combines clinical departments of medical, radiation and paediatric oncology with basic oncology, cancer epidemiology and prevention. Its breast cancer programme under investigators such as Adnan Aydıner and Pınar Saip is one of the largest in Turkey, Rejin Kebudi's paediatric oncology unit is a national referral centre, and the institute trains a large share of Turkish oncologists. It participates in Turkish Oncology Group and international trials, runs molecular pathology and genetic counselling services, and works with the Istanbul Faculty of Medicine's surgical and nuclear medicine departments.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://onkoloji.istanbul.edu.tr/en/"},{"label":"Istanbul University","url":"https://www.istanbul.edu.tr/en/"}],"tags":[],"related":[],"cancers":["breast-hr-positive","neuroblastoma","nsclc","head-and-neck"],"sections":["radiation","chemotherapy"],"technologies":["imrt-igrt","brachytherapy","cgp"],"targets":[],"drugs":[],"companies":[],"institutions":["hacettepe-cancer-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-global-access"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Istanbul","country":"TR","lat":41.013,"lng":28.937,"institutionType":"cancer-center","website":"https://onkoloji.istanbul.edu.tr/en/","university":"İstanbul Üniversitesi","programs":["Breast oncology","Paediatric oncology","Radiation oncology","Cancer epidemiology and prevention"]},{"id":"candiolo","kind":"institution","name":"Istituto di Candiolo IRCCS (FPO)","aka":["Candiolo Cancer Institute","Fondazione Piemontese per l'Oncologia","IRCCS Candiolo","INOC - Istituto Nazionale Oncologico Candiolo","Istituto Nazionale Oncologico Candiolo"],"tldr":"Piedmont's cancer institute near Turin, a world reference for colorectal cancer genomics, patient-derived xenografts and MET biology.","summary":"The Candiolo Cancer Institute is a private not-for-profit IRCCS run by the Fondazione Piemontese per l'Oncologia with the University of Turin. Paolo Comoglio's laboratory discovered and characterised the MET oncogene, Livio Trusolino and Andrea Bertotti built a large colorectal cancer patient-derived xenograft platform ('xenopatients') that identified HER2 amplification as a target and led to the HERACLES trial of trastuzumab plus lapatinib, and Alberto Bardelli's group pioneered liquid biopsy tracking of resistance to anti-EGFR therapy. The hospital provides surgery, radiotherapy, medical oncology and a phase 1 unit, and hosts a large biobank and a molecular tumour board for the Piedmont network.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.fpoircc.it/en/"},{"label":"Research","url":"https://www.fpoircc.it/en/research/"}],"tags":[],"related":[],"cancers":["colorectal","gastric","breast-her2-positive"],"sections":["targeted-therapy","diagnostics"],"technologies":["pdx-models","liquid-biopsy","kinase-inhibitors","monoclonal-antibody"],"targets":["met","her2","egfr","kras"],"drugs":["trastuzumab"],"companies":[],"institutions":[],"pathways":[],"terms":["ctdna","resistance"],"trials":[],"people":["anna-sapino","alberto-bardelli","andrea-agnelli"],"bottlenecks":["b-resistance","b-preclinical-models"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Candiolo","country":"IT","lat":44.958,"lng":7.593,"institutionType":"cancer-center","website":"https://www.fpoircc.it/en/","university":"Università degli Studi di Torino","programs":["Colorectal cancer genomics and xenopatients","MET oncogene biology","Liquid biopsy and resistance","Phase 1 trials"]},{"id":"pascale-naples","kind":"institution","name":"Istituto Nazionale Tumori IRCCS Fondazione G. Pascale","aka":["Pascale","INT Napoli","National Cancer Institute of Naples"],"tldr":"The Fondazione Pascale in Naples is the national cancer institute for southern Italy; Paolo Ascierto's unit was a lead investigator in the CheckMate and RELATIVITY melanoma trials, and Nicola Normanno's group is a reference for liquid biopsy in lung and colorectal cancer.","summary":"The Fondazione Pascale is the IRCCS national cancer institute for southern Italy and one of the largest cancer hospitals in the country. Paolo Ascierto's melanoma, immunotherapy and innovative therapies unit has been a leading investigator in the CheckMate and RELATIVITY trials that established checkpoint blockade and the nivolumab-relatlimab combination in melanoma, and the institute hosts the Melanoma Bridge and Immunotherapy Bridge meetings. Nicola Normanno's molecular biology group is a reference for liquid biopsy and predictive biomarkers in lung and colorectal cancer. Clinical programmes span thoracic, gastrointestinal, breast, urological and head and neck oncology, radiotherapy and haematology, with a phase 1 unit and a Campania-wide oncology network role.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.istitutotumori.na.it"},{"label":"Melanoma Bridge","url":"https://www.melanomabridge.org"}],"tags":[],"related":[],"cancers":["melanoma","nsclc","colorectal","hcc"],"sections":["immunotherapy"],"technologies":["checkpoint-inhibitor","liquid-biopsy","companion-diagnostic"],"targets":["pd1","lag3","ctla4"],"drugs":["nivolumab","ipilimumab","relatlimab-nivolumab"],"companies":["bms"],"institutions":[],"pathways":[],"terms":[],"trials":["checkmate-067"],"people":["maurizio-di-mauro","paolo-ascierto"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Naples","country":"IT","lat":40.862,"lng":14.229,"institutionType":"cancer-center","website":"https://www.istitutotumori.na.it","university":"Università degli Studi di Napoli Federico II","programs":["Melanoma immunotherapy trials","Predictive biomarkers and liquid biopsy","Thoracic oncology","Campania oncology network"]},{"id":"iov-veneto","kind":"institution","name":"Istituto Oncologico Veneto IRCCS","aka":["IOV","Veneto Institute of Oncology"],"tldr":"The Veneto region's OECI-accredited comprehensive cancer centre in Padua, strong in breast cancer trials, melanoma and tumour immunology.","summary":"Founded in 2005, the Istituto Oncologico Veneto is the IRCCS cancer institute of the Veneto region and coordinates the regional oncology network; it is accredited by the OECI as a comprehensive cancer centre. Pierfranco Conte and Valentina Guarneri's breast oncology group led the ShortHER trial of trastuzumab duration and many neoadjuvant studies, the melanoma unit is a leading Italian immunotherapy trial site, and Vincenzo Bronte's immunology programme is known for myeloid-derived suppressor cells. The institute runs gastrointestinal, thoracic and gynaecological oncology, radiotherapy and nuclear medicine across Padua and Castelfranco Veneto, with a phase 1 unit and the University of Padua's oncology school.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.ioveneto.it"},{"label":"Research","url":"https://www.ioveneto.it/ricerca/"}],"tags":[],"related":[],"cancers":["breast-her2-positive","breast-hr-positive","melanoma","colorectal"],"sections":["targeted-therapy","immunotherapy"],"technologies":["monoclonal-antibody","checkpoint-inhibitor","cdk46-inhibitor"],"targets":[],"drugs":["trastuzumab"],"companies":[],"institutions":["oeci","ieo-milan"],"pathways":[],"terms":[],"trials":[],"people":["patrizia-simionato","antonio-rosato"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Padua","country":"IT","lat":45.407,"lng":11.894,"institutionType":"cancer-center","website":"https://www.ioveneto.it","university":"Università degli Studi di Padova","programs":["Breast cancer trials","Melanoma immunotherapy","Tumour immunology (myeloid cells)","Veneto oncology network","Phase 1 unit"]},{"id":"iuct-oncopole","kind":"institution","name":"IUCT Oncopole (Institut Universitaire du Cancer de Toulouse)","aka":["IUCT-O","Institut Claudius Regaud","Oncopole Toulouse"],"tldr":"Toulouse's cancer campus, joining the Institut Claudius Regaud and the university hospital, and a world leader in multiple myeloma research.","summary":"The IUCT Oncopole opened in 2014 on the site of the former AZF chemical plant, combining the Institut Claudius Regaud (a UNICANCER centre founded in 1923) with the oncology services of the CHU de Toulouse, next to the Cancer Research Center of Toulouse (CRCT) and Pierre Fabre's research centre. Its haematology group (Michel Attal, Hervé Avet-Loiseau) anchors the Intergroupe Francophone du Myélome, whose trials established transplant, lenalidomide maintenance and minimal residual disease as pillars of myeloma care. Other strengths are melanoma, gynaecological and head and neck cancers, radiotherapy and an early-phase unit. Patients from Occitanie access molecular tumour boards, CAR-T and bispecifics through the site.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.iuct-oncopole.fr"},{"label":"CRCT","url":"https://www.crct-inserm.fr"}],"tags":[],"related":[],"cancers":["multiple-myeloma","melanoma","head-and-neck","cervical"],"sections":["cell-therapy"],"technologies":["mrd-testing","car-t","bispecific-antibody","imrt-igrt"],"targets":[],"drugs":["teclistamab","ciltacabtagene-autoleucel"],"companies":["unicancer"],"institutions":[],"pathways":[],"terms":["mrd"],"trials":[],"people":["jean-pierre-delord"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Toulouse","country":"FR","lat":43.548,"lng":1.421,"institutionType":"cancer-center","website":"https://www.iuct-oncopole.fr","university":"Université de Toulouse","programs":["Multiple myeloma (IFM)","Early-phase trials","Melanoma","Radiotherapy","Cancer Research Center of Toulouse"]},{"id":"jsmo","kind":"institution","name":"Japanese Society of Medical Oncology","aka":["JSMO","日本臨床腫瘍学会"],"tldr":"Japan's medical oncology society, which certifies Japan's medical oncologists, holds a large annual meeting and publishes clinical guidelines with the Japan Society of Clinical Oncology.","summary":"Founded in 2002 from the earlier Japanese Society of Medical Oncology study group, JSMO established medical oncology as a board-certified specialty in Japan and now has more than 10,000 members. Its annual meeting, held in English and Japanese, presents Japanese trial data and hosts joint sessions with ASCO, ESMO and the Korean and Chinese societies, and it publishes guidelines on cancer genomic profiling, molecular testing, febrile neutropenia and antiemetics together with the Japan Society of Clinical Oncology. JSMO has been central to Japan's national programme of comprehensive genomic profiling under public insurance and to the certification of core cancer genomic medicine hospitals.","asOf":"2026-09-09","links":[{"label":"JSMO","url":"https://www.jsmo.or.jp"}],"tags":[],"related":["jsmo-jsco-guidelines"],"cancers":[],"sections":["targeted-therapy"],"technologies":["cgp","companion-diagnostic"],"targets":[],"drugs":[],"companies":["jcog","wjog"],"institutions":["ncc-japan","jfcr","pmda","asco","esmo"],"pathways":[],"terms":[],"trials":[],"people":["yoshino-takayuki","ohe-yuichiro","hidetoshi-hayashi"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Tokyo","country":"JP","lat":35.69,"lng":139.7,"institutionType":"consortium","website":"https://www.jsmo.or.jp","programs":["Board certification of medical oncologists","JSMO Annual Meeting","Clinical guidelines (with JSCO)","Cancer genomic medicine policy"]},{"id":"jiangsu-cancer-hospital","kind":"institution","name":"Jiangsu Cancer Hospital","aka":["Jiangsu Institute of Cancer Research","Affiliated Cancer Hospital of Nanjing Medical University","江苏省肿瘤医院"],"tldr":"Jiangsu Cancer Hospital in Nanjing is a large provincial cancer centre and a frequent lead site for Chinese oesophageal, lung and gastric cancer trials.","summary":"Jiangsu Cancer Hospital in Nanjing, also known as the Jiangsu Institute of Cancer Research and the Affiliated Cancer Hospital of Nanjing Medical University, is a large provincial cancer centre and a frequent lead site for Chinese oesophageal, lung and gastric cancer trials. It has high oesophageal and lung cancer volumes, hosts domestic PD-1, antibody-drug conjugate and radiotherapy trials, and runs the province's screening programmes in one of China's oesophageal cancer high-incidence regions. OnCo connects it to oesophageal cancer, non-small-cell lung cancer and gastric cancer. How much of its trial activity produces evidence that regulators outside China accept is the open question for centres of this kind. Its oesophageal, thoracic and screening programmes are listed below.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.jszlyy.com.cn/"}],"tags":["china"],"related":[],"cancers":["esophageal","nsclc","gastric"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Nanjing","country":"CN","lat":32.061,"lng":118.778,"institutionType":"cancer-center","website":"https://www.jszlyy.com.cn/","university":"Nanjing Medical University","programs":["Oesophageal cancer","Thoracic oncology","Provincial screening"]},{"id":"jilin-cancer-hospital","kind":"institution","name":"Jilin Cancer Hospital","aka":["吉林省肿瘤医院"],"tldr":"Jilin Cancer Hospital in Changchun is the centre that led China's small cell lung cancer immunotherapy trials, including ASTRUM-005 and CAPSTONE-1.","summary":"Provincial cancer centre whose thoracic oncology department under Cheng Ying has been principal investigator for serplulimab (ASTRUM-005), adebrelimab (CAPSTONE-1), benmelstobart plus anlotinib and other extensive-stage SCLC trials, making a north-eastern provincial hospital one of the most cited sites in the disease.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.jlszlyy.com/"}],"tags":["china"],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["serplulimab","adebrelimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["astrum-005","capstone-1"],"people":["cheng-ying"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Changchun","country":"CN","lat":43.88,"lng":125.323,"institutionType":"cancer-center","website":"https://www.jlszlyy.com/","programs":["Small cell lung cancer trials","Thoracic oncology"]},{"id":"jinshazhou-hospital","kind":"institution","name":"Jinshazhou Hospital of Guangzhou University of Chinese Medicine","aka":["广州中医药大学金沙洲医院","Jinshazhou Hospital"],"tldr":"A Guangzhou hospital affiliated to the Guangzhou University of Chinese Medicine with an international cancer treatment centre, and an associate member of the Organisation of European Cancer Institutes.","summary":"Jinshazhou Hospital, affiliated to the Guangzhou University of Chinese Medicine, is a general hospital in Guangzhou whose international cancer treatment centre combines conventional oncology with traditional Chinese medicine. It is an associate member of the Organisation of European Cancer Institutes (OECI). Its representative on the OECI list is Wensheng Liu.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.jsz120.com/szll_gjzlylzx.html"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":["sysucc"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["wensheng-liu"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Guangzhou","country":"CN","lat":23.129,"lng":113.264,"institutionType":"hospital","website":"https://www.jsz120.com/szll_gjzlylzx.html","programs":[]},{"id":"johns-hopkins","kind":"institution","name":"Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center","aka":[],"tldr":"Johns Hopkins is the birthplace of cancer genomics (Vogelstein), MSI-high immunotherapy (Le, Diaz), and liquid biopsy and MCED science (CancerSEEK).","summary":"Johns Hopkins Hospital and its Sidney Kimmel Comprehensive Cancer Center in Baltimore are where cancer genomics began with Vogelstein and Kinzler, and the centre holds NCI comprehensive designation and tenth place in the Newsweek/Statista oncology ranking. Its record includes pembrolizumab in mismatch-repair-deficient tumours, the first tumour-agnostic approval, led by Le and Diaz, the CancerSEEK liquid biopsy that fed Exact Sciences' multi-cancer early detection programme, and the Bloomberg-Kimmel Institute for Cancer Immunotherapy under Drew M. Pardoll and Elizabeth M. Jaffee. OnCo links it to DELFI Diagnostics, to the DETECT-A, DYNAMIC and CheckMate 816 papers, and to pathways from epigenetic reprogramming to telomere maintenance. Whether blood-based early detection lowers harm as well as finding cancers is the question its own work posed. Programmes and people are listed below.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.hopkinsmedicine.org/kimmel-cancer-center"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":["break-through-cancer"],"cancers":[],"sections":[],"technologies":["mced","liquid-biopsy","proton-therapy","proton-therapy-systems","gamma-knife","radiosurgery-srs"],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":["msi"],"trials":[],"people":["william-nelson","elizabeth-jaffee","stephen-baylin","kellie-smith","nickolas-papadopoulos","bert-vogelstein","drew-pardoll","dung-le","julie-brahmer","kenneth-kinzler","patrick-forde","suzanne-topalian"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Baltimore","country":"US","lat":39.297,"lng":-76.593,"institutionType":"cancer-center","website":"https://www.hopkinsmedicine.org/kimmel-cancer-center","nci":"comprehensive","newsweekOncology2026":10,"university":"Johns Hopkins University","programs":["Cancer genomics","MSI-H immunotherapy","Liquid biopsy / MCED","Bloomberg-Kimmel Immunotherapy"]},{"id":"juravinski","kind":"institution","name":"Juravinski Cancer Centre / Escarpment Cancer Research Institute","aka":["JCC","Hamilton Health Sciences cancer program"],"tldr":"Hamilton's regional cancer centre with McMaster University, home of the trials that made hypofractionated breast radiotherapy standard and of brain tumour stem cell research.","summary":"The Juravinski Cancer Centre is the tertiary cancer centre of Hamilton Health Sciences and McMaster University, serving south-central Ontario, with the Escarpment Cancer Research Institute as its research arm. The Ontario Clinical Oncology Group at McMaster, founded by Mark Levine, ran pragmatic trials that changed practice, above all Tim Whelan's trial showing three-week hypofractionated whole-breast radiotherapy is as effective as five weeks, and Ralph Meyer led the CCTG HD.6 trial in Hodgkin lymphoma. Sheila Singh's laboratory studies brain tumour-initiating cells in glioblastoma and medulloblastoma, and Jonathan Bramson's T-cell antigen coupler technology offers an alternative to CAR-T. The centre runs one of Ontario's largest transplant and haematology programmes.","asOf":"2026-09-09","links":[{"label":"Juravinski Cancer Centre","url":"https://www.hamiltonhealthsciences.ca/areas-of-care/cancer-care/"},{"label":"Escarpment Cancer Research Institute","url":"https://ecri.mcmaster.ca"}],"tags":[],"related":[],"cancers":["breast-hr-positive","hodgkin-lymphoma","glioblastoma","medulloblastoma"],"sections":["radiation"],"technologies":["imrt-igrt","car-t","allogeneic-hsct"],"targets":[],"drugs":[],"companies":["cctg"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["chris-hillis","timothy-whelan"],"bottlenecks":["b-trial-design"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Hamilton, ON","country":"CA","lat":43.241,"lng":-79.891,"institutionType":"cancer-center","website":"https://www.hamiltonhealthsciences.ca/areas-of-care/cancer-care/","university":"McMaster University","programs":["Radiotherapy trials (hypofractionation)","Lymphoma trials","Brain tumour stem cells","Engineered T cells (TAC)"]},{"id":"kaiser-permanente-research","kind":"institution","name":"Kaiser Permanente Division of Research","aka":["KPNC Division of Research","Kaiser Permanente Washington Health Research Institute"],"tldr":"The research arm of America's largest integrated health system, whose cohorts and screening programmes generate much of the real-world evidence on cancer screening and prevention.","summary":"Founded in 1961 by Morris Collen, the Kaiser Permanente Division of Research in Oakland studies the millions of members of Kaiser Permanente Northern California, and with the Kaiser Permanente Washington Health Research Institute in Seattle forms one of the most productive health-services research enterprises in cancer. Its organised colorectal screening programme, studied by Douglas Corley and colleagues, showed that population-wide FIT outreach roughly doubled screening uptake and halved colorectal cancer deaths within the health plan; the Breast Cancer Surveillance Consortium and the Cancer Research Network have anchored national studies of mammography performance and screening intervals. Kaiser cohorts have measured HPV vaccine effectiveness, aspirin and statin associations with cancer, and survivorship outcomes (the Pathways breast cancer cohort). The division is a leading source of real-world evidence for cancer guidelines.","asOf":"2026-09-09","links":[{"label":"Kaiser Permanente Division of Research","url":"https://divisionofresearch.kaiserpermanente.org"},{"label":"KP Washington Health Research Institute","url":"https://www.kpwashingtonresearch.org"}],"tags":[],"related":[],"cancers":["colorectal","breast-hr-positive","cervical"],"sections":["early-detection","prevention"],"technologies":["colorectal-screening","mammography","hpv-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["real-world-evidence","stage-shift"],"trials":[],"people":["rachel-ramoni","theodore-levin"],"bottlenecks":["b-real-world-evidence","b-prevention-adoption"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Oakland, CA","country":"US","lat":37.804,"lng":-122.271,"institutionType":"research-institute","website":"https://divisionofresearch.kaiserpermanente.org","programs":["Colorectal cancer screening outcomes","Breast Cancer Surveillance Consortium","Cancer Research Network","Survivorship cohorts"]},{"id":"karolinska","kind":"institution","name":"Karolinska University Hospital","aka":["Karolinska Comprehensive Cancer Center"],"tldr":"Sweden's leading cancer hospital, linked to the Karolinska Institutet and Nobel Assembly, with strong registry-based research.","summary":"Karolinska University Hospital in Stockholm is Sweden's leading cancer hospital, linked to the Karolinska Institutet and the Nobel Assembly, and ranks thirty-ninth in the Newsweek/Statista oncology list. Its Comprehensive Cancer Centre is known for registry-based research, because Sweden's national quality registries make real-world evidence and registry-randomised trials possible, and it collaborates with the Skandion proton clinic in Uppsala; Per Hall, Jonas Bergh and Thomas Helleday are among the people OnCo lists. OnCo links it to the ALASCCA aspirin trial, to the Swedish registry study of HPV vaccination and cervical cancer, and to ideas on randomising inside cancer registries and a registry-based MCED trial. Whether registry designs can carry regulatory weight outside the Nordics is the open question. Its registry and haematology programmes are listed below.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Karolinska_University_Hospital","links":[{"label":"Official website","url":"https://www.karolinska.se"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["gamma-knife","radiosurgery-srs"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["real-world-evidence"],"trials":[],"people":["per-hall","rolf-kiessling","hans-gustaf-ljunggren","thomas-helleday","jonas-bergh","patrik-rossi"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Stockholm","country":"SE","lat":59.35,"lng":18.034,"institutionType":"university","website":"https://www.karolinska.se","newsweekOncology2026":39,"university":"Karolinska Institutet","programs":["Registry research","Haematology"]},{"id":"keio-university-hospital","kind":"institution","name":"Keio University Hospital","aka":["慶應義塾大学病院"],"tldr":"Tokyo's oldest private university hospital, known for gastrointestinal and oesophageal cancer surgery, cancer genome profiling and translational research.","summary":"Keio University Hospital, opened in 1920, is one of Japan's core hospitals for cancer genome medicine and a leader in gastrointestinal cancer surgery: Yuko Kitagawa's department is a JCOG oesophageal cancer study group leader and pioneered sentinel node navigation surgery in the upper GI tract. Keio's Cancer Center integrates the PleSSision genomic profiling programme, one of the first hospital-based comprehensive genomic tests in Japan, with molecular tumour boards, and Keio researchers have contributed to organoid biobanks of colorectal cancer, haematological malignancy research and cancer immunology. Patients can access early-phase trials, robotic surgery and precision oncology through the Keio Cancer Center.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Keio_University_Hospital","links":[{"label":"Keio University Hospital","url":"https://www.hosp.keio.ac.jp"},{"label":"Keio University School of Medicine","url":"https://www.med.keio.ac.jp"}],"tags":[],"related":[],"cancers":["esophageal","gastric","colorectal","dlbcl"],"sections":["surgery","diagnostics"],"technologies":["cgp","organoids","sentinel-node","robotic-surgery"],"targets":[],"drugs":[],"companies":["jcog"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["kitagawa-yuko","koichi-fukunaga"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Tokyo","country":"JP","lat":35.682,"lng":139.719,"institutionType":"hospital","website":"https://www.hosp.keio.ac.jp","university":"Keio University","programs":["Oesophageal and gastric surgery (JCOG)","Cancer genome profiling (PleSSision)","Colorectal organoids","Haematology"]},{"id":"kent-medway-cancer-alliance","kind":"institution","name":"Kent and Medway Cancer Alliance","aka":["KMCA"],"tldr":"The NHS England Cancer Alliance for Kent and Medway: the partnership that plans and improves cancer services across its hospitals, GPs and community services.","summary":"One of the 20 Cancer Alliances set up by NHS England from 2016, following the Independent Cancer Taskforce strategy, to bring together the hospital trusts, integrated care boards, primary care, hospices and charities serving Kent and Medway. Alliances lead local delivery of the NHS cancer ambitions: earlier diagnosis (including rapid diagnostic centres and targeted lung health checks), the Faster Diagnosis Standard, personalised care and follow-up, and workforce and pathway improvement. They hold transformation funding from NHS England and publish local performance and improvement plans.","asOf":"2026-09-09","links":[{"label":"Kent and Medway Cancer Alliance","url":"https://www.kentandmedway.icb.nhs.uk/your-health/local-services/kent-and-medway-cancer-alliance"},{"label":"NHS England: Cancer Alliances","url":"https://www.england.nhs.uk/cancer/cancer-alliances-improving-care-locally/"}],"tags":["nhs-cancer-alliance"],"related":["south-east-london-cancer-alliance","surrey-sussex-cancer-alliance"],"cancers":[],"sections":["early-detection"],"technologies":["low-dose-ct-screening"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Maidstone","country":"GB","lat":51.272,"lng":0.529,"institutionType":"consortium","website":"https://www.kentandmedway.icb.nhs.uk/your-health/local-services/kent-and-medway-cancer-alliance","programs":["Earlier diagnosis and rapid diagnostic centres","Faster Diagnosis Standard","Personalised care and follow-up","Cancer pathway improvement"]},{"id":"kenyatta-national-hospital","kind":"institution","name":"Kenyatta National Hospital","aka":["KNH","University of Nairobi College of Health Sciences"],"tldr":"Kenyatta National Hospital in Nairobi is Kenya's national referral hospital and East Africa's largest; for decades it ran the country's only public radiotherapy service, and it leads Kenya's cervical screening, HPV vaccination and Burkitt lymphoma research.","summary":"Kenyatta National Hospital in Nairobi, founded in 1901 and Kenya's oldest and largest hospital, is the national teaching and referral hospital of the University of Nairobi and for decades hosted the only public radiotherapy service in Kenya, treating patients from across East Africa. Its Cancer Treatment Centre provides radiotherapy including brachytherapy, medical oncology, haematology and paediatric oncology, and KNH is a lead site for Kenya's national cancer control programme, the Nairobi cancer registry, cervical cancer screening and HPV vaccination roll-out studies, Burkitt lymphoma and HIV-associated cancer research, and paediatric oncology twinning programmes with international partners. The hospital's newer linear accelerators and the planned Kenyatta University cancer hospital are expanding radiotherapy access.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Kenyatta_National_Hospital","links":[{"label":"Kenyatta National Hospital","url":"https://knh.or.ke"},{"label":"University of Nairobi","url":"https://www.uonbi.ac.ke"}],"tags":[],"related":["global-oncology-access","cancer-registries-surveillance"],"cancers":["cervical","breast-hr-positive","esophageal","dlbcl","prostate"],"sections":["radiation","prevention"],"technologies":["brachytherapy","imrt-igrt","hpv-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["richard-lesiyampe"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Nairobi","country":"KE","lat":-1.301,"lng":36.806,"institutionType":"hospital","website":"https://knh.or.ke","university":"University of Nairobi","programs":["Cancer Treatment Centre and radiotherapy","Nairobi cancer registry","Cervical cancer screening","Paediatric oncology"]},{"id":"kidwai-memorial-institute-of-oncology","kind":"institution","name":"Kidwai Memorial Institute of Oncology","aka":["KMIO","Kidwai"],"tldr":"Kidwai Memorial Institute of Oncology in Bengaluru is Karnataka's state cancer institute and one of India's Regional Cancer Centres; it treats a predominantly poor population from southern India at low cost and hosts the Bangalore cancer registry, one of India's oldest.","summary":"Kidwai Memorial Institute of Oncology was founded in 1973 in Bengaluru, named after Rafi Ahmed Kidwai, and is an autonomous institute of the Government of Karnataka and a Regional Cancer Centre under India's National Cancer Control Programme. It provides surgical, medical, radiation and paediatric oncology to a predominantly poor population, hosts the Bangalore population-based cancer registry (one of India's oldest), and trains a large cohort of oncology specialists. Kidwai participates in Indian cooperative trials, hosts hereditary cancer and tobacco cessation clinics, and has expanded with new radiotherapy machines and peripheral cancer centres across the state.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Kidwai_Memorial_Institute_of_Oncology","links":[{"label":"Kidwai Memorial Institute of Oncology","url":"https://kidwai.karnataka.gov.in"}],"tags":[],"related":["global-oncology-access","cancer-registries-surveillance"],"cancers":["cervical","head-and-neck","breast-hr-positive","all-leukemia"],"sections":["radiation","prevention"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["t-naveen"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Bengaluru","country":"IN","lat":12.94,"lng":77.594,"institutionType":"cancer-center","website":"https://kidwai.karnataka.gov.in","programs":["Regional Cancer Centre","Bangalore cancer registry","Paediatric oncology","Radiotherapy access"]},{"id":"kindai-university-hospital","kind":"institution","name":"Kindai University Faculty of Medicine and Hospital","aka":["Kindai University","Kinki University","近畿大学医学部"],"tldr":"Osaka-area university hospital whose gastroenterology and hepatology department, under Masatoshi Kudo, has led many of the global trials of liver cancer drugs, including REFLECT of lenvatinib.","summary":"Kindai University's Faculty of Medicine and its hospital in Osakasayama, south of Osaka, run one of Japan's largest hepatocellular carcinoma programmes. The Department of Gastroenterology and Hepatology, chaired by Masatoshi Kudo, was the lead centre for REFLECT, the 2018 Lancet trial that showed lenvatinib was non-inferior to sorafenib in unresectable liver cancer, and has led or co-led the trials of atezolizumab-bevacizumab, durvalumab-tremelimumab and transarterial therapies. The faculty also has a strong medical oncology department in lung cancer.","asOf":"2026-09-18","links":[{"label":"Kindai University","url":"https://www.kindai.ac.jp"}],"tags":[],"related":[],"cancers":["hcc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["masatoshi-kudo"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Osakasayama, Osaka","country":"JP","lat":34.503,"lng":135.556,"institutionType":"hospital","website":"https://www.kindai.ac.jp","university":"Kindai University","programs":["Hepatocellular carcinoma trials","Interventional hepatology","Thoracic oncology"]},{"id":"king-albert-ii-cancer-institute","kind":"institution","name":"King Albert II Cancer Institute, Cliniques universitaires Saint-Luc","aka":["Institut Roi Albert II","Cliniques universitaires Saint-Luc","Saint-Luc University Hospital","UCLouvain Saint-Luc"],"tldr":"The cancer institute of the Saint-Luc university hospital in Brussels, the teaching hospital of UCLouvain opened in 1976, and a full member of the Organisation of European Cancer Institutes.","summary":"The Institut Roi Albert II is the cancer and haematology institute of the Cliniques universitaires Saint-Luc in Woluwe-Saint-Lambert, Brussels, the university hospital of UCLouvain that opened in 1976. It brings the hospital's oncology, haematology, radiotherapy and surgical cancer services together with the university's research groups. It is a full member of the Organisation of European Cancer Institutes (OECI); its representative on the OECI list is Philippe Leroy.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.institutroialbertdeux.be/"},{"label":"Cliniques universitaires Saint-Luc","url":"http://www.saintluc.be"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q2979314"}],"tags":[],"related":["institut-jules-bordet","uz-brussel-cancer-centre"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["philippe-leroy"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Brussels","country":"BE","lat":50.852,"lng":4.452,"institutionType":"hospital","website":"https://www.institutroialbertdeux.be/","programs":[]},{"id":"kfshrc","kind":"institution","name":"King Faisal Specialist Hospital and Research Centre","aka":["KFSH&RC","KFSHRC","مستشفى الملك فيصل التخصصي"],"tldr":"Saudi Arabia's flagship tertiary hospital, whose Oncology Centre runs the Gulf's largest transplant, CAR-T and proton therapy programmes.","summary":"King Faisal Specialist Hospital and Research Centre opened in Riyadh in 1975 and, with campuses in Jeddah and Madinah, is the leading referral hospital of Saudi Arabia and the wider Gulf. Its Oncology Centre and King Fahad National Centre for Children's Cancer deliver high-volume adult and paediatric cancer care, including one of the largest haematopoietic stem cell transplant programmes in the region, locally manufactured CAR-T therapy, robotic surgery, radioligand therapy and the first proton therapy facility in the Middle East, opened in Riyadh. The Research Centre hosts genomics under the Saudi Human Genome Program, cancer biology and clinical trials units, and the hospital houses the Saudi Cancer Registry's largest contributing service and pioneering work on thyroid, breast and hereditary cancers common in the Kingdom.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/King_Faisal_Specialist_Hospital_and_Research_Centre","links":[{"label":"KFSH&RC","url":"https://www.kfshrc.edu.sa"}],"tags":[],"related":[],"cancers":["all-leukemia","thyroid","breast-hr-positive","dlbcl","colorectal"],"sections":["cell-therapy","radiation"],"technologies":["proton-therapy","car-t","allogeneic-cell-therapy","radioligand-therapy","germline-testing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["majid-alfayyadh"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Riyadh","country":"SA","lat":24.69,"lng":46.674,"institutionType":"hospital","website":"https://www.kfshrc.edu.sa","programs":["Oncology Centre and children's cancer centre","Stem cell transplant and CAR-T","Proton therapy","Saudi Human Genome Program"]},{"id":"khcc","kind":"institution","name":"King Hussein Cancer Center","aka":["KHCC","مركز الحسين للسرطان"],"tldr":"Jordan's cancer-only hospital and the leading comprehensive cancer centre in the Arab world, the first outside the US accredited as a cancer centre by Joint Commission International.","summary":"The King Hussein Cancer Center in Amman was reorganised in 2001 from the Al-Amal Center under the King Hussein Cancer Foundation and has become the reference cancer centre for Jordan and for patients from across the Middle East, treating adults and children. It was the first cancer centre outside the United States to earn Joint Commission International disease-specific accreditation for oncology, has one of the region's largest paediatric oncology and bone marrow transplant programmes with St. Jude affiliation, and runs a hereditary cancer clinic, a phase 1 unit, PET-CT and radioligand therapy, and Jordan's tobacco control research. KHCC has led regional cooperative research through its Office of Scientific Affairs and the Jordan Cancer Registry, and cares for large numbers of refugees and patients funded by charity.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/King_Hussein_Cancer_Center","links":[{"label":"King Hussein Cancer Center","url":"https://www.khcc.jo"},{"label":"King Hussein Cancer Foundation","url":"https://www.khcf.jo"}],"tags":[],"related":["global-oncology-access"],"cancers":["all-leukemia","breast-hr-positive","colorectal","nsclc","dlbcl"],"sections":["chemotherapy","prevention"],"technologies":["allogeneic-cell-therapy","pet-ct","radioligand-therapy","germline-testing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["asem-mansour"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Amman","country":"JO","lat":31.978,"lng":35.887,"institutionType":"cancer-center","website":"https://www.khcc.jo","programs":["Paediatric oncology and transplant","Regional referral care","Hereditary cancer clinic","Tobacco control research"]},{"id":"kings-college-hospital-london","kind":"institution","name":"King's College Hospital, London","aka":["King's College Hospital NHS Foundation Trust","KCH","Institute of Liver Studies"],"tldr":"One of London's specialist liver and hepatobiliary centres, with a liver transplant programme; listed by the national audit as an HPB specialist centre and by AMMF as a centre with cholangiocarcinoma expertise.","summary":"King's College Hospital (Denmark Hill) houses the Institute of Liver Studies and a hepatobiliary and pancreatic surgery service. It is one of the trusts the National Pancreatic Cancer Audit identifies as an HPB specialist centre for England and appears on AMMF's list of UK centres with cholangiocarcinoma expertise. HPB surgeon Nigel Heaton was a co-author of the 2023 British Society of Gastroenterology cholangiocarcinoma guideline.","asOf":"2026-09-24","links":[{"label":"Hepatobiliary and pancreatic (HPB) service","url":"https://www.kch.nhs.uk/services/services-a-to-z/hepatobiliary-and-pancreatic-hpb/"},{"label":"AMMF centres list","url":"https://ammf.org.uk/second-opinions-and-liver-disease-centres/"}],"tags":["hpb","nhs","uk"],"related":[],"cancers":["gallbladder","biliary-tract-cancer","cholangiocarcinoma","pancreatic","hcc"],"sections":["surgery"],"technologies":["hepatectomy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"London","country":"GB","lat":51.468,"lng":-0.094,"institutionType":"hospital","website":"https://www.kch.nhs.uk/","university":"King's College London","programs":["Hepatobiliary and pancreatic surgery","Liver transplantation","Specialist HPB MDT"]},{"id":"klaipeda-university-hospital","kind":"institution","name":"Klaipėda University Hospital","aka":["Klaipedos universitetine ligonine","Klaipėdos universitetinė ligoninė"],"tldr":"Klaipėda University Hospital is the main hospital of western Lithuania and a full member of the Organisation of European Cancer Institutes.","summary":"Klaipėda University Hospital is the largest hospital in western Lithuania, established in 1976 and affiliated with Klaipėda University, providing surgical, medical and radiation treatment for cancer to the coastal region. It is one of three Lithuanian hospitals listed by the Organisation of European Cancer Institutes as full members, with Santaros Klinikos in Vilnius and Kauno Klinikos in Kaunas. Programme, trial and leadership details are not yet recorded here and should be checked on the hospital's own pages.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.kul.lt"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":["santaros-klinikos","nci-vilnius"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["audrius-simaitis"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Klaipėda","country":"LT","lat":55.754,"lng":21.126,"institutionType":"hospital","website":"https://www.kul.lt","programs":[]},{"id":"kliniken-essen-mitte","kind":"institution","name":"Kliniken Essen-Mitte","aka":["KEM","Evang. Kliniken Essen-Mitte","Evangelische Huyssens-Stiftung"],"tldr":"Essen hospital whose gynaecological oncology department runs the German AGO ovarian cancer trials and whose medical oncologists led RAINBOW in stomach cancer.","summary":"Kliniken Essen-Mitte is a Protestant hospital group in Essen. Its Department of Gynecology and Gynecologic Oncology, led by Andreas du Bois and Philipp Harter, is the coordinating centre of the AGO Study Group and ran the DESKTOP III surgery trial and the PAOLA-1 and PRIMA-era maintenance studies in ovarian cancer. The medical oncology department, where Hansjochen Wilke practised, led RAINBOW, the 2014 trial that established ramucirumab plus paclitaxel as second-line treatment in advanced gastric cancer.","asOf":"2026-09-18","links":[{"label":"Kliniken Essen-Mitte","url":"https://www.kem-med.com"}],"tags":[],"related":[],"cancers":["ovarian","gastric"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["essen-wtz"],"pathways":[],"terms":[],"trials":[],"people":["hansjochen-wilke","andreas-du-bois"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Essen","country":"DE","lat":51.443,"lng":7.004,"institutionType":"hospital","website":"https://www.kem-med.com","programs":["Gynaecological oncology (AGO Study Group)","Ovarian cancer surgery trials","Gastrointestinal oncology"]},{"id":"klinikum-stuttgart-olgahospital","kind":"institution","name":"Klinikum Stuttgart / Olgahospital","aka":["Olgahospital","Stuttgart Cancer Center","Zentrum für Kinder-, Jugend- und Frauenmedizin"],"tldr":"Stuttgart's municipal hospital, whose children's hospital is the home of the Cooperative Osteosarcoma Study Group that ran EURAMOS-1, the largest trial ever in bone cancer.","summary":"Klinikum Stuttgart is one of Germany's largest municipal hospitals. Its Olgahospital is the children's hospital, and its Department of Paediatric Oncology, Haematology and Immunology, headed by Stefan Bielack, is the study office of the Cooperative Osteosarcoma Study Group (COSS). From there Bielack led the German arm of EURAMOS-1, the international randomised trial in osteosarcoma, and maintains the COSS registry that underpins much of what is known about the disease's outcomes.","asOf":"2026-09-18","links":[{"label":"Klinikum Stuttgart","url":"https://www.klinikum-stuttgart.de"}],"tags":[],"related":[],"cancers":["osteosarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["stefan-bielack"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Stuttgart","country":"DE","lat":48.782,"lng":9.165,"institutionType":"hospital","website":"https://www.klinikum-stuttgart.de","programs":["Paediatric oncology","Osteosarcoma (COSS)","Stuttgart Cancer Center"]},{"id":"komfo-anokye-teaching-hospital","kind":"institution","name":"Komfo Anokye Teaching Hospital","aka":["KATH"],"tldr":"Ghana's second-largest hospital, in Kumasi, with one of the country's two public radiotherapy centres and an oncology directorate serving the north and middle belt.","summary":"Komfo Anokye Teaching Hospital is the tertiary referral hospital for Ghana's Ashanti region and the northern half of the country, and the teaching hospital of the Kwame Nkrumah University of Science and Technology School of Medicine and Dentistry. Its Oncology Directorate provides radiotherapy, chemotherapy, paediatric oncology and palliative care, and with Korle Bu in Accra it is one of Ghana's two long-standing public radiotherapy centres. The hospital contributes to research on breast cancer in West African women, Burkitt lymphoma and cervical cancer screening, and trains clinical oncologists through the Ghana College of Physicians and Surgeons.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Komfo_Anokye_Teaching_Hospital","links":[{"label":"Official website","url":"https://kath.gov.gh"}],"tags":[],"related":[],"cancers":["cervical"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["korle-bu-teaching-hospital"],"pathways":[],"terms":[],"trials":[],"people":["paa-kwesi-baidoo"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Kumasi","country":"GH","lat":6.694,"lng":-1.627,"institutionType":"hospital","website":"https://kath.gov.gh","university":"Kwame Nkrumah University of Science and Technology","programs":["Oncology Directorate","Radiotherapy","Paediatric oncology"]},{"id":"koo-foundation-sun-yat-sen-cancer-center","kind":"institution","name":"Koo Foundation Sun Yat-Sen Cancer Center","aka":["KF-SYSCC","和信治癌中心醫院"],"tldr":"Taiwan's first dedicated cancer hospital, founded 1990 on the MD Anderson model and known for multidisciplinary care and outcome transparency.","summary":"The Koo Foundation Sun Yat-Sen Cancer Center was established in 1990 by the Koo family with early guidance from MD Anderson and Memorial Sloan Kettering, and was Taiwan's first hospital devoted entirely to cancer. Under founding CEO Andrew Huang it introduced multidisciplinary team care, tumour-board review of every case and public reporting of survival outcomes, and it has been an early adopter of stereotactic radiotherapy, brachytherapy and precision oncology programmes. It is known for breast, head and neck, lung and lymphoma care, for cancer survivorship and palliative services, and for an outsized publication record for its size in health services research and quality of care.","asOf":"2026-09-09","links":[{"label":"KF-SYSCC","url":"https://www.kfsyscc.org"}],"tags":[],"related":["multidisciplinary-tumour-board","survivorship-care-plan"],"cancers":["breast-hr-positive","head-and-neck","nsclc","dlbcl"],"sections":["radiation","supportive-care"],"technologies":["sbrt","brachytherapy"],"targets":[],"drugs":[],"companies":[],"institutions":["md-anderson"],"pathways":[],"terms":[],"trials":[],"people":["nei-min-chu"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Taipei","country":"TW","lat":25.114,"lng":121.523,"institutionType":"cancer-center","website":"https://www.kfsyscc.org","programs":["Multidisciplinary cancer care","Breast cancer","Head and neck cancer","Outcomes reporting"]},{"id":"korle-bu-teaching-hospital","kind":"institution","name":"Korle Bu Teaching Hospital","aka":["Korle Bu","National Radiotherapy Oncology and Nuclear Medicine Centre"],"tldr":"Ghana's premier teaching hospital and West Africa's largest, hosting the National Radiotherapy, Oncology and Nuclear Medicine Centre and leading African breast cancer research.","summary":"Korle Bu Teaching Hospital opened in 1923 and is the main teaching hospital of the University of Ghana Medical School and the largest hospital in West Africa. Its National Radiotherapy, Oncology and Nuclear Medicine Centre, established with IAEA support in 1997, was one of the first radiotherapy centres in the sub-region and provides external beam and brachytherapy, chemotherapy and nuclear medicine; the hospital also runs surgical, gynaecological and paediatric oncology and haematology services. Korle Bu and the University of Ghana are lead African partners in studies of triple-negative and hereditary breast cancer in West African women, prostate cancer genetics, Burkitt lymphoma and hepatocellular carcinoma, and the hospital hosts the Accra cancer registry and trains oncologists across Anglophone West Africa.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Korle-Bu_Teaching_Hospital","links":[{"label":"Korle Bu Teaching Hospital","url":"https://kbth.gov.gh"},{"label":"University of Ghana Medical School","url":"https://ugms.ug.edu.gh"}],"tags":[],"related":["global-oncology-access","cancer-health-disparities"],"cancers":["tnbc","breast-hr-positive","prostate","cervical","hcc"],"sections":["radiation","prevention"],"technologies":["brachytherapy","imrt-igrt","germline-testing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["yakubu-seidu-adam"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Accra","country":"GH","lat":5.537,"lng":-0.227,"institutionType":"hospital","website":"https://kbth.gov.gh","university":"University of Ghana","programs":["National Radiotherapy and Nuclear Medicine Centre","West African breast cancer research","Paediatric oncology","Accra cancer registry"]},{"id":"krankenhaus-nordwest","kind":"institution","name":"Krankenhaus Nordwest / Institute of Clinical Cancer Research (IKF)","aka":["Institut für Klinisch-Onkologische Forschung","IKF Frankfurt","UCT Frankfurt partner hospital"],"tldr":"Frankfurt teaching hospital whose Institute of Clinical Cancer Research ran FLOT4, the trial that made FLOT chemotherapy the standard before and after surgery for stomach cancer.","summary":"Krankenhaus Nordwest is a teaching hospital of Goethe University in the north-west of Frankfurt. Its Institute of Clinical Cancer Research (IKF), directed by Salah-Eddin Al-Batran, is a trial office for the German AIO cooperative group in gastrointestinal cancer and coordinated the FLOT4 trial, whose 2019 Lancet report established perioperative FLOT for resectable gastric and gastro-oesophageal junction adenocarcinoma. The hospital is a partner site of the University Cancer Center Frankfurt.","asOf":"2026-09-18","links":[{"label":"Krankenhaus Nordwest","url":"https://www.krankenhaus-nordwest.de"}],"tags":[],"related":[],"cancers":["gastric","esophageal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["uct-frankfurt"],"pathways":[],"terms":[],"trials":["flot4"],"people":["salah-eddin-al-batran"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Frankfurt am Main","country":"DE","lat":50.13,"lng":8.633,"institutionType":"hospital","website":"https://www.krankenhaus-nordwest.de","programs":["Gastro-oesophageal cancer trials (AIO)","Perioperative chemotherapy"]},{"id":"kuopio-university-hospital","kind":"institution","name":"Kuopio University Hospital Cancer Center","aka":["KYS","FICAN East"],"tldr":"The university hospital for eastern Finland and host of the FICAN East regional cancer centre, accredited by OECI as a Cancer Centre.","summary":"Kuopio University Hospital (KYS) is one of Finland's five university hospitals and the teaching hospital of the University of Eastern Finland. Its Cancer Center hosts the Eastern Finland Cancer Centre (FICAN East), one of the five regional centres of the national Finnish Cancer Centre network, coordinating cancer care, clinical trials and research across the eastern part of the country. Research strengths include radiotherapy physics, neuro-oncology, breast cancer genetics and the population cohorts of eastern Finland. The centre holds OECI Cancer Centre accreditation.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.pshyvinvointialue.fi"}],"tags":["oeci-accredited","oeci-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci","helsinki-hus"],"pathways":[],"terms":[],"trials":[],"people":["satu-tiainen","arto-mannermaa"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Kuopio","country":"FI","lat":62.892,"lng":27.678,"institutionType":"hospital","website":"https://www.pshyvinvointialue.fi","university":"University of Eastern Finland","programs":["FICAN East regional cancer centre","Radiotherapy","Neuro-oncology"]},{"id":"kwf","kind":"institution","name":"KWF Dutch Cancer Society","aka":["KWF Kankerbestrijding","KWF"],"tldr":"The Netherlands' cancer charity and the main funder of Dutch cancer research, including much of the work at the Netherlands Cancer Institute.","summary":"Founded in 1949 with a donation from Queen Wilhelmina, KWF is the largest charitable funder of cancer research in the Netherlands, supporting basic, translational and clinical projects at the Netherlands Cancer Institute, the university medical centres and the Princess Máxima paediatric centre. It funds HOVON and other cooperative group trials, the Dutch DRUP drug-repurposing trial, prevention and survivorship research and implementation projects, and it runs public campaigns on smoking, sun and screening. KWF also co-funds the Oncode Institute and Dutch participation in European programmes.","asOf":"2026-09-09","links":[{"label":"KWF","url":"https://www.kwf.nl"}],"tags":[],"related":[],"cancers":[],"sections":["drug-discovery","prevention"],"technologies":[],"targets":[],"drugs":[],"companies":["hovon"],"institutions":["nki"],"pathways":[],"terms":[],"trials":[],"people":["emile-voest","carla-van-gils"],"bottlenecks":["b-generic-repurposing"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Amsterdam","country":"NL","lat":52.37,"lng":4.895,"institutionType":"consortium","website":"https://www.kwf.nl","programs":["Research grants across Dutch centres","Oncode Institute co-funding","DRUP and cooperative group trials","Prevention campaigns"]},{"id":"kyoto-university-hospital","kind":"institution","name":"Kyoto University Hospital","aka":["京都大学医学部附属病院","Kyoto University Cancer Center"],"tldr":"The university where Tasuku Honjo discovered PD-1 and Shinya Yamanaka created iPS cells; its hospital leads Japanese immunotherapy and cell therapy research.","summary":"Kyoto University Hospital is the clinical arm of a university whose Graduate School of Medicine produced two Nobel prizes relevant to cancer: Tasuku Honjo's discovery of PD-1 (2018 Nobel), which led to nivolumab, and Shinya Yamanaka's induced pluripotent stem cells (2012 Nobel), now the basis of iPS-derived NK and T-cell products from the Center for iPS Cell Research and Application. The hospital runs Japan's largest early-phase immunotherapy programme with Ono Pharmaceutical partnerships, a leading haematology and transplant department, hepatobiliary and pancreatic surgery, and a core institution role in JCOG and WJOG trials. Its Institute for Advancement of Clinical and Translational Science supports investigator-initiated trials, and Kyoto's cancer research includes the Kyoto Prize-associated work on immune checkpoint biology.","asOf":"2026-09-09","links":[{"label":"Kyoto University Hospital","url":"https://www.kuhp.kyoto-u.ac.jp"},{"label":"Center for iPS Cell Research and Application","url":"https://www.cira.kyoto-u.ac.jp"},{"label":"Kyoto University Graduate School of Medicine","url":"https://www.med.kyoto-u.ac.jp"}],"tags":[],"related":["jsmo-jsco-guidelines"],"cancers":["melanoma","nsclc","gastric","aml"],"sections":["immunotherapy","cell-therapy"],"technologies":["checkpoint-inhibitor","allogeneic-cell-therapy","car-nk-macrophage"],"targets":["pd1","pdl1"],"drugs":["nivolumab"],"companies":["jcog"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["akifumi-takaori"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Kyoto","country":"JP","lat":35.02,"lng":135.775,"institutionType":"hospital","website":"https://www.kuhp.kyoto-u.ac.jp","university":"Kyoto University","programs":["PD-1 biology and immunotherapy","iPS-derived cell therapy","Haematology","Hepatobiliary-pancreatic surgery"]},{"id":"kyushu-university-hospital","kind":"institution","name":"Kyushu University Hospital","aka":["九州大学病院"],"tldr":"Kyushu University Hospital in Fukuoka is the largest academic hospital in western Japan; its surgeons lead gastric and oesophageal cancer surgery and living-donor liver transplantation for liver cancer, and its researchers co-discovered the RET fusion in lung cancer with the National Cancer Center.","summary":"Kyushu University Hospital in Fukuoka is the largest academic hospital in western Japan and the base of the Kyushu-area cooperative trial groups. Its Department of Surgery and Science has a long tradition in gastric and oesophageal cancer surgery and living-donor liver transplantation for hepatocellular carcinoma, and its haematology and medical oncology groups lead Japanese lymphoma and myeloma studies. Kyushu University's research institutes contribute to cancer biology (including the discovery of the RET fusion in lung cancer in collaboration with NCC Japan) and to medical AI. The hospital is a core institution for genome medicine and offers early-phase trials and cell therapy.","asOf":"2026-09-09","links":[{"label":"Kyushu University Hospital","url":"https://www.hosp.kyushu-u.ac.jp"},{"label":"Kyushu University Faculty of Medical Sciences","url":"https://www.med.kyushu-u.ac.jp"}],"tags":[],"related":[],"cancers":["gastric","esophageal","hcc","dlbcl","nsclc"],"sections":["surgery"],"technologies":["robotic-surgery","cgp"],"targets":["ret"],"drugs":[],"companies":["jcog"],"institutions":["ncc-japan"],"pathways":[],"terms":[],"trials":[],"people":["yasuharu-nakashima"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Fukuoka","country":"JP","lat":33.612,"lng":130.407,"institutionType":"hospital","website":"https://www.hosp.kyushu-u.ac.jp","university":"Kyushu University","programs":["Gastrointestinal surgery","Liver transplantation","Haematology","Cancer genome medicine"]},{"id":"luth-lagos","kind":"institution","name":"Lagos University Teaching Hospital","aka":["LUTH","NSIA-LUTH Cancer Centre"],"tldr":"Nigeria's leading teaching hospital in its largest city, home of the NSIA-LUTH Cancer Centre, the country's most advanced radiotherapy facility.","summary":"Lagos University Teaching Hospital was founded in 1962 as the teaching hospital of the University of Lagos College of Medicine and is one of Nigeria's foremost tertiary hospitals. In 2019 it opened the NSIA-LUTH Cancer Centre, a public-private partnership with the Nigeria Sovereign Investment Authority that brought multiple linear accelerators and brachytherapy to a country that had long suffered from broken radiotherapy machines, making it West Africa's most advanced radiotherapy centre alongside chemotherapy and surgical oncology services. LUTH researchers contribute to studies of breast cancer in Nigerian women (including the genetic work with the University of Chicago showing high rates of aggressive and hereditary disease), prostate cancer, cervical cancer screening and paediatric oncology, and the hospital hosts oncology fellowship training for Nigeria.","asOf":"2026-09-09","links":[{"label":"LUTH","url":"https://luth.gov.ng"},{"label":"NSIA-LUTH Cancer Centre","url":"https://nlcc.ng"}],"tags":[],"related":["global-oncology-access","cancer-health-disparities"],"cancers":["tnbc","breast-hr-positive","prostate","cervical"],"sections":["radiation","prevention"],"technologies":["imrt-igrt","brachytherapy","germline-testing"],"targets":["brca"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["wasiu-lanre-adeyemo"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Lagos","country":"NG","lat":6.518,"lng":3.354,"institutionType":"hospital","website":"https://luth.gov.ng","university":"University of Lagos","programs":["NSIA-LUTH Cancer Centre radiotherapy","Breast cancer genetics in Nigerian women","Prostate cancer","Oncology training"]},{"id":"lancashire-south-cumbria-cancer-alliance","kind":"institution","name":"Lancashire and South Cumbria Cancer Alliance","aka":["LSC Cancer Alliance"],"tldr":"The NHS England Cancer Alliance for Lancashire and South Cumbria, including Preston, Blackpool, Blackburn, Lancaster and Barrow: the partnership that plans and improves cancer services across its hospitals, GPs and community services.","summary":"One of the 20 Cancer Alliances set up by NHS England from 2016, following the Independent Cancer Taskforce strategy, to bring together the hospital trusts, integrated care boards, primary care, hospices and charities serving Lancashire and South Cumbria, including Preston, Blackpool, Blackburn, Lancaster and Barrow. Alliances lead local delivery of the NHS cancer ambitions: earlier diagnosis (including rapid diagnostic centres and targeted lung health checks), the Faster Diagnosis Standard, personalised care and follow-up, and workforce and pathway improvement. They hold transformation funding from NHS England and publish local performance and improvement plans.","asOf":"2026-09-09","links":[{"label":"Lancashire and South Cumbria Cancer Alliance","url":"https://www.healthierlsc.co.uk/canceralliance"},{"label":"NHS England: Cancer Alliances","url":"https://www.england.nhs.uk/cancer/cancer-alliances-improving-care-locally/"}],"tags":["nhs-cancer-alliance"],"related":["greater-manchester-cancer-alliance","cheshire-merseyside-cancer-alliance","west-yorkshire-harrogate-cancer-alliance"],"cancers":[],"sections":["early-detection"],"technologies":["low-dose-ct-screening"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Preston","country":"GB","lat":53.763,"lng":-2.703,"institutionType":"consortium","website":"https://www.healthierlsc.co.uk/canceralliance","programs":["Earlier diagnosis and rapid diagnostic centres","Faster Diagnosis Standard","Personalised care and follow-up","Cancer pathway improvement"]},{"id":"landspitali","kind":"institution","name":"Landspítali, the National University Hospital of Iceland","aka":["Landspitali","Landspítali University Hospital","The National University Hospital of Iceland"],"tldr":"Landspítali is Iceland's national university hospital and the country's cancer centre, and a full member of the Organisation of European Cancer Institutes.","summary":"Landspítali, the National University Hospital of Iceland, is the country's main hospital and the centre for specialised cancer diagnosis and treatment for a population of under half a million people, with a history going back to 1930. It works with the University of Iceland and refers some rare or highly specialised treatment abroad, mainly to the Nordic countries. It is listed by the Organisation of European Cancer Institutes as a full member. OnCo records it as Iceland's cancer centre; programme, trial and leadership details are not yet recorded here.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.landspitali.is"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Landspítali"}],"tags":[],"related":["rigshospitalet"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["vigdis-hallgrimsdottir"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Reykjavík","country":"IS","lat":64.138,"lng":-21.927,"institutionType":"hospital","website":"https://www.landspitali.is","programs":[]},{"id":"lasker-foundation","kind":"institution","name":"Lasker Foundation","aka":["Albert and Mary Lasker Foundation"],"tldr":"The foundation Albert and Mary Lasker set up in 1942 to push medical research up the public agenda; its Lasker Awards became the most watched prize in American medicine.","summary":"Albert Lasker, the advertising pioneer (1880-1952), and Mary Woodard Lasker (1901-1994) founded the Lasker Foundation in 1942. Its stated mission is to improve health by accelerating support for medical research through recognition of research excellence, advocacy, and education. The Lasker Awards, given since the mid-1940s, honour basic and clinical research and public service; the Foundation also runs education and advocacy programmes. Alongside Mary Lasker's lobbying for the National Cancer Act of 1971, the Foundation was the platform from which the Laskers turned cancer research into a matter of national policy.","asOf":"2026-09-10","links":[{"label":"About the Lasker Foundation","url":"https://laskerfoundation.org/about/"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["mary-lasker","albert-lasker"],"bottlenecks":["b-funding-allocation","b-knowledge-diffusion"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"New York","country":"US","lat":40.76,"lng":-73.98,"institutionType":"consortium","website":"https://laskerfoundation.org","programs":["Lasker Awards","Research advocacy","Education programmes"]},{"id":"nyu-perlmutter","kind":"institution","name":"Laura and Isaac Perlmutter Cancer Center at NYU Langone Health","aka":["Perlmutter Cancer Center","NYU Cancer Institute"],"tldr":"NYU's cancer centre, comprehensive since 2019, known for melanoma immunotherapy, RAS and SHP2 biology, and early deep-learning pathology.","summary":"NCI-designated since the 1970s and comprehensive since 2019, Perlmutter Cancer Center spans NYU Langone's Manhattan, Brooklyn and Long Island hospitals. Its melanoma programme (Jeffrey Weber, Iman Osman, Anna Pavlick) led adjuvant nivolumab trials; Benjamin Neel, the director, discovered the phosphatase SHP2 (PTPN11), now a drug target in RAS-driven cancers; Dafna Bar-Sagi's laboratory defined how KRAS-mutant pancreatic cancers scavenge nutrients. Aristotelis Tsirigos's 2018 study of deep learning on lung cancer histology slides was an early landmark in computational pathology. Michele Pagano's work on ubiquitin ligases underpins targeted protein degradation.","asOf":"2026-09-09","links":[{"label":"Perlmutter Cancer Center","url":"https://nyulangone.org/locations/perlmutter-cancer-center"},{"label":"Clinical trials","url":"https://nyulangone.org/locations/perlmutter-cancer-center/clinical-trials"}],"tags":[],"related":[],"cancers":["melanoma","pancreatic","nsclc"],"sections":["immunotherapy","ai-computation"],"technologies":["digital-pathology-ai","protac-degrader","gamma-knife","radiosurgery-srs"],"targets":["kras","pd1"],"drugs":["nivolumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["arjun-balar","douglas-levine","jeffrey-weber"],"bottlenecks":["b-undruggable-targets"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"New York, NY","country":"US","lat":40.742,"lng":-73.974,"institutionType":"cancer-center","website":"https://nyulangone.org/locations/perlmutter-cancer-center","nci":"comprehensive","university":"New York University","programs":["Melanoma immunotherapy","RAS and SHP2 biology","Computational pathology"]},{"id":"chuv-lausanne","kind":"institution","name":"Lausanne University Hospital (CHUV) / Ludwig Institute Lausanne","aka":["CHUV","Centre hospitalier universitaire vaudois","Swiss Cancer Center Léman","AGORA Cancer Research Center"],"tldr":"Lausanne's university hospital and Ludwig branch, home of the temozolomide glioblastoma trial, Solange Peters and a leading personalised T-cell therapy programme.","summary":"The CHUV Department of Oncology, headed by Solange Peters (ESMO president 2020-2021), works with the Ludwig Institute for Cancer Research Lausanne branch under George Coukos, the University of Lausanne, EPFL's ISREC institute and the Geneva hospitals within the Swiss Cancer Center Léman, housed in the AGORA research building opened in 2018. Roger Stupp led from Lausanne the EORTC/NCIC trial that made radiotherapy plus temozolomide the standard for glioblastoma, and Douglas Hanahan, author of 'The Hallmarks of Cancer', directed ISREC. The Ludwig groups run personalised tumour-infiltrating lymphocyte and neoantigen-targeted T-cell trials in ovarian and other cancers, and the hospital is a major thoracic oncology and immunotherapy trial site with a phase 1 unit.","asOf":"2026-09-09","links":[{"label":"CHUV Oncology (page moved; nearest live section)","url":"https://www.chuv.ch/"},{"label":"Ludwig Lausanne","url":"https://www.ludwigcancerresearch.org/location/lausanne-branch/"},{"label":"AGORA","url":"https://www.agora-cancer.ch"}],"tags":[],"related":[],"cancers":["glioblastoma","ovarian","nsclc","melanoma"],"sections":["immunotherapy","cell-therapy"],"technologies":["til-therapy","tcr-t","checkpoint-inhibitor","neoantigen-mrna-vaccine"],"targets":[],"drugs":["pembrolizumab"],"companies":["curie-nki-eortc"],"institutions":["esmo","hug-geneva"],"pathways":[],"terms":["neoantigen"],"trials":[],"people":["solange-peters","roger-stupp","monika-hegi","jean-bourhis"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Lausanne","country":"CH","lat":46.525,"lng":6.642,"institutionType":"hospital","website":"https://www.chuv.ch/","university":"Université de Lausanne","programs":["Ludwig Lausanne immuno-oncology","Personalised TIL and T-cell therapy","Thoracic oncology","Neuro-oncology heritage","Swiss Cancer Center Léman"]},{"id":"leeds-cancer-centre","kind":"institution","name":"Leeds Cancer Centre, St James's University Hospital","aka":["Leeds Teaching Hospitals NHS Trust","Bexley Wing","Leeds Institute of Medical Research"],"tldr":"One of the largest cancer centres in the UK, known for colorectal cancer pathology and trials, melanoma research, myeloma and MR-guided radiotherapy.","summary":"The Leeds Cancer Centre at St James's University Hospital is among the UK's largest single-site cancer centres, serving Yorkshire with radiotherapy, surgery, haematology and paediatric oncology. University of Leeds research includes Philip Quirke's pathology work that established circumferential resection margin assessment in rectal cancer, the Leeds Clinical Trials Research Unit that ran FOxTROT (neoadjuvant chemotherapy in colon cancer) and UK myeloma trials, and melanoma epidemiology and genetics. Leeds was an early UK adopter of the Elekta Unity MR-linac and hosts the Leeds Institute of Medical Research at St James's and a CRUK Centre. The centre also has a national profile in teenage and young adult cancer and in health data research.","asOf":"2026-09-09","links":[{"label":"Leeds Cancer Centre","url":"https://www.leedsth.nhs.uk/services/leeds-cancer-centre/"}],"tags":[],"related":[],"cancers":["colorectal","melanoma","multiple-myeloma","dlbcl","pancreatic","rectal-cancer","nsclc","lung-cancer","skin-cancer","basal-cell-carcinoma"],"sections":["radiation","surgery"],"technologies":["mr-linac","imrt-igrt","histopathology-ihc"],"targets":[],"drugs":[],"companies":["elekta"],"institutions":["cruk"],"pathways":[],"terms":["neoadjuvant-adjuvant"],"trials":["cr07","foxtrot","star-trec","ylst"],"people":["brendan-brown","david-sebag-montefiore","matt-seymour","matthew-callister"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Leeds","country":"GB","lat":53.807,"lng":-1.52,"institutionType":"hospital","website":"https://www.leedsth.nhs.uk/services/leeds-cancer-centre/","university":"University of Leeds","programs":["Colorectal cancer pathology and trials","MR-linac radiotherapy","Myeloma trials","Melanoma epidemiology","Clinical Trials Research Unit"]},{"id":"leicester-cancer-research-centre","kind":"institution","name":"Leicester Cancer Research Centre / University Hospitals of Leicester","aka":["Hope Clinical Trials Facility","Leicester Royal Infirmary"],"tldr":"Leicester's academic cancer centre, joining University Hospitals of Leicester with the University of Leicester's cancer research and the Hope clinical trials facility.","summary":"The Leicester Cancer Research Centre is the University of Leicester's cancer research institute, working with University Hospitals of Leicester NHS Trust, whose oncology services at the Leicester Royal Infirmary and Glenfield Hospital include radiotherapy, systemic therapy, haematology and thoracic surgery. The Hope Clinical Trials Facility on the Royal Infirmary site is a dedicated early-phase cancer trials unit funded largely by the Hope Against Cancer charity. Leicester's research is known for lung cancer and mesothelioma, chemoprevention and cancer biomarkers, and it is an Experimental Cancer Medicine Centre with the University of Nottingham.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://le.ac.uk/cancer-research-centre"}],"tags":["nhs-cancer-centre"],"related":[],"cancers":["nsclc","mesothelioma","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["richard-mitchell"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Leicester","country":"GB","lat":52.628,"lng":-1.135,"institutionType":"hospital","website":"https://le.ac.uk/cancer-research-centre","university":"University of Leicester","programs":["Hope Clinical Trials Facility","Lung cancer and mesothelioma","Chemoprevention"]},{"id":"lumc-leiden","kind":"institution","name":"Leiden University Medical Center","aka":["LUMC","Leiden Oncology Center"],"tldr":"Leiden's university hospital, a cradle of therapeutic cancer vaccines and tumour immunology and the base for the Dutch TME rectal cancer trial.","summary":"The LUMC's tumour immunology tradition runs from Cornelis Melief's synthetic long peptide HPV16 vaccine, developed with ISA Pharmaceuticals, to the immunology groups of Sjoerd van der Burg and Ferry Ossendorp, and Ton Schumacher and John Haanen of the Netherlands Cancer Institute hold Leiden professorships. Cornelis van de Velde's Dutch TME trial established total mesorectal excision with short-course radiotherapy as the standard for rectal cancer, and Judith Bovée's pathology group is a world reference for bone and soft tissue tumours. Leiden co-owns the Holland Proton Therapy Centre and runs a large haematology and transplant programme. The Leiden Oncology Center coordinates care with regional hospitals.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Leiden_University_Medical_Center","links":[{"label":"Homepage","url":"https://www.lumc.nl/en/"}],"tags":[],"related":[],"cancers":["cervical","colorectal","sarcoma","melanoma"],"sections":["immunotherapy","surgery"],"technologies":["shared-antigen-vaccine","hpv-vaccine","checkpoint-inhibitor","proton-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["nki","erasmus-mc"],"pathways":[],"terms":["neoantigen"],"trials":[],"people":["ton-schumacher","john-haanen","martin-jan-schalij","carien-creutzberg","cornelis-van-de-velde"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Leiden","country":"NL","lat":52.166,"lng":4.476,"institutionType":"university","website":"https://www.lumc.nl/en/","university":"Leiden University","programs":["Therapeutic cancer vaccines","Tumour immunology","Rectal cancer surgery and radiotherapy","Bone and soft tissue tumour pathology","HollandPTC"]},{"id":"university-hospital-leipzig","kind":"institution","name":"Leipzig University Hospital / University Cancer Center Leipzig (UCCL)","aka":["Universitätsklinikum Leipzig","UCCL","Universitäres Krebszentrum Leipzig"],"tldr":"Saxony's university hospital, whose cancer centre is led by gastro-oesophageal oncologist Florian Lordick and whose haematology department, under Uwe Platzbecker, leads European trials in myelodysplastic syndromes.","summary":"Leipzig University Hospital houses the University Cancer Center Leipzig (UCCL), directed by Florian Lordick, a leader of European gastro-oesophageal cancer trials and guidelines. The Department of Hematology, Cellular Therapy and Hemostaseology, led by Uwe Platzbecker, coordinates the German MDS Study Group and led the COMMANDS and MEDALIST trials of luspatercept in anaemic myelodysplastic syndromes. The hospital is part of the Comprehensive Cancer Center Central Germany with Jena.","asOf":"2026-09-18","links":[{"label":"Universitätsklinikum Leipzig","url":"https://www.uniklinikum-leipzig.de"}],"tags":[],"related":[],"cancers":["gastric","esophageal","mds"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["florian-lordick","uwe-platzbecker"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Leipzig","country":"DE","lat":51.33,"lng":12.386,"institutionType":"hospital","website":"https://www.uniklinikum-leipzig.de","university":"Universität Leipzig","programs":["Gastro-oesophageal cancer","Myelodysplastic syndromes","Cellular therapy"]},{"id":"li-ka-shing-foundation","kind":"institution","name":"Li Ka Shing Foundation","aka":["LKSF"],"tldr":"Li Ka-shing's foundation, which since 1980 has given more than HK$30 billion, mostly in China and Hong Kong, including free hospice care for tens of thousands of poor cancer patients and the building that houses the Cancer Research UK Cambridge Institute.","summary":"Founded in 1980, the Li Ka Shing Foundation states that Mr Li has invested over HK$30 billion in it, with more than 80% of projects in mainland China and Hong Kong. Its cornerstone project is Shantou University, founded in 1981 and supported with HK$12 billion, which it describes as the only privately funded public university in China. Its Heart of Gold hospice programme in Hong Kong ran from 2007 to 2020 through 10 centres and served over 38,000 low-income terminal cancer patients and their families with palliative care. In Cambridge, the Cancer Research UK Cambridge Institute is housed in the Li Ka Shing Centre on Robinson Way.","asOf":"2026-09-10","links":[{"label":"Li Ka Shing Foundation","url":"https://www.lksf.org/"},{"label":"Heart of Gold hospice programme","url":"https://www.lksf.org/heart-of-gold/"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["palliative-care"],"targets":[],"drugs":[],"companies":[],"institutions":["cruk-cambridge-centre"],"pathways":[],"terms":[],"trials":[],"people":["li-ka-shing"],"bottlenecks":["b-palliative","b-global-access","b-funding-allocation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Hong Kong","country":"HK","lat":22.28,"lng":114.16,"institutionType":"consortium","website":"https://www.lksf.org","programs":["Heart of Gold hospice programme","Shantou University and its medical college","Li Ka Shing Centre, Cambridge","Healthcare subsidies and medical technology donations"]},{"id":"ligue-contre-le-cancer","kind":"institution","name":"Ligue nationale contre le cancer","aka":["La Ligue","Ligue contre le cancer"],"tldr":"France's oldest and largest cancer charity, with a committee in every département, funding research and supporting patients and prevention since 1918.","summary":"Founded in 1918, the Ligue is a federation of 103 departmental committees and one of the largest private funders of cancer research in France, including the Cartes d'Identité des Tumeurs tumour-genomics programme, team labelling grants and support for clinical research. It provides patient support (helplines, financial aid, Espaces Ligue), campaigns on tobacco, alcohol and screening, and advocates on drug prices and access. The Ligue co-funds programmes with the Institut National du Cancer and Fondation ARC.","asOf":"2026-09-09","links":[{"label":"Ligue contre le cancer","url":"https://www.ligue-cancer.net"}],"tags":[],"related":[],"cancers":[],"sections":["prevention","supportive-care"],"technologies":[],"targets":[],"drugs":[],"companies":["unicancer"],"institutions":["fondation-arc","gustave-roussy"],"pathways":[],"terms":[],"trials":[],"people":["philippe-bergerot"],"bottlenecks":["b-prevention-adoption","b-drug-pricing"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Paris","country":"FR","lat":48.857,"lng":2.352,"institutionType":"consortium","website":"https://www.ligue-cancer.net","programs":["Research funding (labelled teams, Cartes d'Identité des Tumeurs)","Patient support and Espaces Ligue","Prevention and screening campaigns","Policy advocacy"]},{"id":"chu-lille","kind":"institution","name":"Lille University Hospital (CHU de Lille)","aka":["CHU Lille","Hôpital Claude Huriez","Service des Maladies du Sang"],"tldr":"The university hospital of Lille, whose blood diseases department under Thierry Facon led MAIA, the trial that made daratumumab-based treatment the standard for older people with myeloma.","summary":"The CHU de Lille is one of France's largest university hospitals. Its Service des Maladies du Sang, led for many years by Thierry Facon, is a founding centre of the Intergroupe Francophone du Myélome and led MAIA, the 2019 New England Journal of Medicine trial in which daratumumab plus lenalidomide and dexamethasone lengthened survival in newly diagnosed myeloma patients not eligible for transplant. The Centre Oscar Lambret, Lille's dedicated cancer centre, is a separate institution next door.","asOf":"2026-09-18","links":[{"label":"CHU de Lille","url":"https://www.chu-lille.fr"}],"tags":[],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["centre-oscar-lambret"],"pathways":[],"terms":[],"trials":[],"people":["thierry-facon"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Lille","country":"FR","lat":50.61,"lng":3.034,"institutionType":"hospital","website":"https://www.chu-lille.fr","university":"Université de Lille","programs":["Multiple myeloma (IFM)","Haematology","Transplantation"]},{"id":"linkoping-university-hospital","kind":"institution","name":"Linköping University Hospital Cancer Center","aka":["Universitetssjukhuset i Linköping"],"tldr":"The university hospital for south-east Sweden, accredited by OECI as a Comprehensive Cancer Centre and home to one of Sweden's regional cancer centres.","summary":"Linköping University Hospital is the tertiary hospital of Region Östergötland and the teaching hospital of Linköping University. It coordinates specialised cancer care for the South-East Healthcare Region of Sweden (Östergötland, Jönköping and Kalmar) and hosts the Regional Cancer Centre South-East, one of the six regional cancer centres created under Sweden's national cancer strategy. The hospital's cancer centre holds OECI Comprehensive Cancer Centre accreditation and its research spans radiotherapy, clinical cancer genetics, gastrointestinal surgery and cancer epidemiology.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.regionostergotland.se"}],"tags":["oeci-accredited","oeci-comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci","karolinska","uppsala-akademiska"],"pathways":[],"terms":[],"trials":[],"people":["ida-danmark","karl-landergren"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Linköping","country":"SE","lat":58.403,"lng":15.622,"institutionType":"hospital","website":"https://www.regionostergotland.se","university":"Linköping University","programs":["Regional Cancer Centre South-East","Radiotherapy","Cancer genetics"]},{"id":"liverpool-heart-and-chest","kind":"institution","name":"Liverpool Heart and Chest Hospital NHS Foundation Trust","aka":[],"tldr":"The specialist heart and chest hospital for Cheshire and Merseyside, which calls its thoracic service one of the largest and busiest specialist thoracic surgical units in the country.","summary":"Liverpool Heart and Chest Hospital NHS Foundation Trust runs one of the highest-volume thoracic surgical services in the NHS: its own service page describes it as one of the largest and busiest specialist thoracic units in the country, and the National Lung Cancer Audit's 2026 data tables record 568 lung cancer resections there in 2024, the third highest of the 28 units in England and Wales. It delivered the UK Lung Cancer Screening trial with Papworth, hosts the Cheshire and Merseyside lung cancer screening programme sites used by the APPLIED-LUNG and P4-LHC studies, and works with the University of Liverpool's lung cancer research programme.","asOf":"2026-09-25","links":[{"label":"Thoracic surgery at Liverpool Heart and Chest Hospital","url":"https://www.lhch.nhs.uk/thoracic-surgery"},{"label":"National Lung Cancer Audit data tables 2026","url":"https://www.natcan.org.uk/wp-content/uploads/2026/02/NLCA-SotN-2026-Data-Tables.xlsx"}],"tags":["nhs","uk","thoracic-surgery"],"related":[],"cancers":["nsclc","lung-cancer","resectable-nsclc"],"sections":["surgery","early-detection"],"technologies":["low-dose-ct-screening"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["john-field"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Liverpool","country":"GB","lat":53.41,"lng":-2.888,"institutionType":"hospital","website":"https://www.lhch.nhs.uk/","programs":["Thoracic surgery","Lung cancer screening programme delivery for Cheshire and Merseyside","Thoracic gym and enhanced recovery"]},{"id":"liverpool-hpb-centre","kind":"institution","name":"Liverpool University Hospitals HPB centre (Aintree)","aka":["Liverpool University Hospitals NHS Foundation Trust","North Western Hepatobiliary Centre","Aintree University Hospital"],"tldr":"The North Western Hepatobiliary Centre at Aintree, serving Merseyside, Cheshire, North Wales and the Isle of Man; HPB surgeon Hassan Malik co-wrote the BSG cholangiocarcinoma guideline.","summary":"Liverpool University Hospitals is one of the trusts the National Pancreatic Cancer Audit identifies as an HPB specialist centre for England; Pancreatic Cancer UK lists its HPB team as covering Merseyside, Cheshire, the Isle of Man and North Wales. The liver surgery unit at Aintree (the North Western Hepatobiliary Centre) is on AMMF's list of centres with cholangiocarcinoma expertise. Non-surgical treatment is given with The Clatterbridge Cancer Centre.","asOf":"2026-09-24","links":[{"label":"Hepatobiliary surgery","url":"https://www.uhliverpool.nhs.uk/services/service-finder/hepatobiliary-surgery"},{"label":"Pancreatic Cancer UK centres list","url":"https://www.pancreaticcancer.org.uk/information-and-support/your-care/your-local-pancreatic-cancer-specialist-centre/"}],"tags":["hpb","nhs","uk"],"related":[],"cancers":["gallbladder","biliary-tract-cancer","cholangiocarcinoma","pancreatic","hcc"],"sections":["surgery"],"technologies":["hepatectomy"],"targets":[],"drugs":[],"companies":[],"institutions":["clatterbridge"],"pathways":[],"terms":[],"trials":["espac-3","espac-4","espac-5","europac"],"people":["hassan-malik","paula-ghaneh","daniel-palmer","chris-halloran","bill-greenhalf"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Liverpool","country":"GB","lat":53.466,"lng":-2.936,"institutionType":"hospital","website":"https://www.uhliverpool.nhs.uk/","university":"University of Liverpool","programs":["HPB and liver surgery","Specialist HPB MDT","Cross-border care for North Wales"]},{"id":"lmu-munich","kind":"institution","name":"LMU Klinikum München","aka":[],"tldr":"LMU Klinikum is Munich's university cancer centre, with strengths in PSMA theranostics and haematology.","summary":"LMU Klinikum München is the university hospital of Ludwig-Maximilians-Universität and, with TUM, forms the Comprehensive Cancer Center Munich; it ranks thirty-first in the Newsweek/Statista World's Best Specialized Hospitals list for oncology. Its nuclear medicine leadership in PSMA imaging and radioligand therapy is the reason it appears on theranostics pages, and haematology is its other declared strength, with Peter Bartenstein, Michael von Bergwelt, Martin Dreyling, Nadia Harbeck, Volker Heinemann and Claus Belka among the people OnCo lists. OnCo links it to PSMA PET, to the European Association of Nuclear Medicine and Deutsche Krebshilfe, and to its partner TUM Klinikum rechts der Isar. How theranostics scales from a few academic centres to routine care is the open question. Its theranostics and haematology programmes are listed below.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.lmu-klinikum.de"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["psma-pet"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["volker-heinemann","peter-bartenstein","michael-von-bergwelt","claus-belka","nadia-harbeck","martin-dreyling"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Munich","country":"DE","lat":48.11,"lng":11.47,"institutionType":"university","website":"https://www.lmu-klinikum.de","newsweekOncology2026":31,"university":"Ludwig-Maximilians-Universität","programs":["Theranostics","Haematology"]},{"id":"ludwig-cancer-research","kind":"institution","name":"Ludwig Cancer Research","aka":["Ludwig Institute for Cancer Research","LICR"],"tldr":"The cancer research institute that shipping magnate Daniel K. Ludwig endowed in 1971 with nearly all of his international holdings; it has spent more than $1.8 billion of its own money on cancer science.","summary":"Founded in 1971, the Ludwig Institute for Cancer Research is an international not-for-profit that funds and runs its own laboratories rather than making grants from donations. Its own account states that it has invested more than $1.8 billion of its resources in cancer research and holds an endowment valued at $1.5 billion. In 2006 the Ludwig gift also created Ludwig Centers and professorships at six leading US institutions, each with more than $2 million a year in perpetuity. Ludwig scientists worked on the biology that became checkpoint immunotherapy, on tumour antigens and on cancer genomics. Headquartered in New York with historic roots in Zurich.","asOf":"2026-09-10","links":[{"label":"About Ludwig Cancer Research","url":"https://www.ludwigcancerresearch.org/about/"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["immunotherapy","checkpoint-inhibitor","cgp"],"targets":[],"drugs":[],"companies":[],"institutions":["mskcc","mit-koch","stanford","uchicago-cancer","johns-hopkins"],"pathways":[],"terms":[],"trials":[],"people":["daniel-ludwig"],"bottlenecks":["b-funding-allocation","b-translational-valley"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"New York","country":"US","lat":40.751,"lng":-73.975,"institutionType":"research-institute","website":"https://www.ludwigcancerresearch.org","programs":["Ludwig Institute branches","Ludwig Centers at six US institutions (since 2006)","Cancer immunology and tumour antigens","Cancer genomics and metabolism"]},{"id":"lungenclinic-grosshansdorf","kind":"institution","name":"LungenClinic Grosshansdorf","aka":["Lung Clinic Grosshansdorf","Airway Research Center North (ARCN)"],"tldr":"Specialist lung hospital near Hamburg whose thoracic oncology department, under Martin Reck, has led many of the pivotal immunotherapy trials in lung cancer, including KEYNOTE-024.","summary":"LungenClinic Grosshansdorf is a specialist hospital for lung disease outside Hamburg and a site of the German Center for Lung Research (Airway Research Center North). Its Department of Thoracic Oncology, headed by Martin Reck, was the lead centre for KEYNOTE-024, the 2016 trial that established first-line pembrolizumab for PD-L1-high non-small-cell lung cancer, and has contributed to most large lung cancer immunotherapy and small-cell lung cancer trials since.","asOf":"2026-09-18","links":[{"label":"LungenClinic Grosshansdorf","url":"https://www.lungenclinic.de"}],"tags":[],"related":[],"cancers":["lung-cancer","nsclc","pdl1-high-nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["martin-reck"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Großhansdorf","country":"DE","lat":53.658,"lng":10.283,"institutionType":"hospital","website":"https://www.lungenclinic.de","programs":["Thoracic oncology","Lung cancer immunotherapy trials","Small-cell lung cancer"]},{"id":"lustgarten-foundation","kind":"institution","name":"Lustgarten Foundation","aka":["Lustgarten Foundation for Pancreatic Cancer Research"],"tldr":"The largest private funder of pancreatic cancer research, which funds dedicated laboratories at Cold Spring Harbor, Johns Hopkins, Dana-Farber and MIT.","summary":"Founded in 1998 in memory of Cablevision executive Marc Lustgarten, the foundation devotes all donations to pancreatic cancer research, with administrative costs underwritten by Cablevision and later Altice. It funds Lustgarten Laboratories, including the Lustgarten Foundation Pancreatic Cancer Research Laboratory at Cold Spring Harbor led by David Tuveson, dedicated labs at Johns Hopkins (Vogelstein and Kinzler, early detection), Dana-Farber and MIT, and it co-sponsors the Stand Up To Cancer-Lustgarten Pancreatic Cancer Dream Teams. Its Clinical Accelerator Initiative funds early trials of new agents and its Pancreatic Cancer Collective with SU2C funds computational and interception projects.","asOf":"2026-09-09","links":[{"label":"Lustgarten Foundation","url":"https://lustgarten.org"},{"label":"Research","url":"https://lustgarten.org/research/"}],"tags":[],"related":["pancan"],"cancers":["pancreatic"],"sections":[],"technologies":["organoids","liquid-biopsy","kras-inhibitors"],"targets":[],"drugs":[],"companies":[],"institutions":["cold-spring-harbor","johns-hopkins","dana-farber","stand-up-to-cancer"],"pathways":[],"terms":[],"trials":[],"people":["david-tuveson","bert-vogelstein","kenneth-kinzler","andrew-aguirre","eileen-oreilly","marc-lustgarten","linda-tantawi"],"bottlenecks":["b-early-detection","b-undruggable-targets"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Woodbury, NY","country":"US","lat":40.826,"lng":-73.469,"institutionType":"consortium","website":"https://lustgarten.org","programs":["Lustgarten Laboratories (CSHL, Johns Hopkins, Dana-Farber, MIT)","SU2C-Lustgarten Dream Teams and Pancreatic Cancer Collective","Clinical Accelerator Initiative","Early detection research"]},{"id":"lymphoma-action","kind":"institution","name":"Lymphoma Action","aka":["Lymphoma Association","Lymphoma Action (registered charity 1068395 and SC045850)"],"tldr":"The United Kingdom's only charity dedicated to lymphoma: a freephone helpline, support groups, a buddy scheme, a lymphoma trials database and a seat at the table when NICE and the Scottish Medicines Consortium appraise a lymphoma medicine.","summary":"Lymphoma Action is a registered charity in England and Wales (1068395) and in Scotland (SC045850) and describes itself as the UK's only charity dedicated to lymphoma, the most common blood cancer. It runs a freephone helpline on 0808 808 5555 with live chat and email, support groups and a buddy scheme, a Preparing for Treatment Service and Live your Life workshops for people on active monitoring or finishing treatment, and Lymphoma TrialsLink, a lymphoma clinical trial database and information service. For professionals it runs an education and training programme and an interactive map of specialist cutaneous T-cell lymphoma centres in the UK. Its advocacy work includes submitting the patient perspective to health technology assessments of lymphoma medicines.","asOf":"2026-10-01","links":[{"label":"Lymphoma Action","url":"https://lymphoma-action.org.uk/"},{"label":"About us","url":"https://lymphoma-action.org.uk/about-us"},{"label":"Helpline","url":"https://lymphoma-action.org.uk/support-you/helpline"},{"label":"Find a CTCL treatment centre","url":"https://lymphoma-action.org.uk/healthcare-professionals/find-ctcl-treatment-centre"}],"tags":["charity","uk","lymphoma","patient-support"],"related":[],"cancers":["non-hodgkin-lymphoma","hodgkin-lymphoma","dlbcl","follicular-lymphoma","mantle-cell-lymphoma","marginal-zone-lymphoma","cutaneous-t-cell-lymphoma","burkitt-lymphoma","primary-cns-lymphoma","peripheral-t-cell-lymphoma","waldenstrom"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Aylesbury","country":"GB","lat":51.816,"lng":-0.813,"institutionType":"consortium","website":"https://lymphoma-action.org.uk/","programs":["Freephone helpline 0808 808 5555, live chat and email","Support groups and the buddy scheme","Lymphoma TrialsLink: a UK lymphoma trial database","Preparing for Treatment Service","Live your Life workshops","Find a CTCL treatment centre map","Education and training for healthcare professionals"]},{"id":"maastricht-umc","kind":"institution","name":"Maastricht UMC+ Comprehensive Cancer Center","aka":["MUMC+","Maastro"],"tldr":"The university hospital of Maastricht, whose cancer centre with the Maastro radiotherapy clinic is accredited by OECI as a Comprehensive Cancer Centre.","summary":"Maastricht UMC+ is the academic hospital of Maastricht University and the tertiary cancer centre for Limburg and the south-east Netherlands. Its Comprehensive Cancer Center works with Maastro, the independent radiotherapy institute on the same campus, which operates one of the Netherlands' proton therapy centres and is internationally known for radiomics and decision-support research. The GROW School for Oncology and Reproduction provides the research base, with strengths in radiotherapy, tumour hypoxia and metabolism, colorectal and head and neck cancer, and the centre leads the OncoZON regional cancer network. It is accredited by the Organisation of European Cancer Institutes as a Comprehensive Cancer Centre.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.mumc.nl"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":["oeci-accredited","oeci-comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":["proton-therapy","proton-therapy-systems"],"targets":[],"drugs":[],"companies":[],"institutions":["oeci","oncozon"],"pathways":[],"terms":[],"trials":[],"people":["helen-mertens","r-r-w-j-van-der-hulst"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Maastricht","country":"NL","lat":50.836,"lng":5.717,"institutionType":"hospital","website":"https://www.mumc.nl","university":"Maastricht University","programs":["Radiotherapy and proton therapy (Maastro)","Radiomics and AI","GROW research school"]},{"id":"macmillan-cancer-support","kind":"institution","name":"Macmillan Cancer Support","aka":["Macmillan"],"tldr":"The UK charity that funds Macmillan nurses and support workers in the NHS and provides information, financial and emotional support to people living with cancer.","summary":"Founded in 1911 by Douglas Macmillan, the charity funds specialist nurses, allied health professionals and information centres inside the NHS, runs the Macmillan Support Line and online community, gives grants and benefits advice to patients facing financial hardship, and campaigns on cancer workforce, personalised care and the cost of living with cancer. Its research programme focuses on survivorship, the experience of care and the needs of people living with cancer as a long-term condition, and its Living With and Beyond Cancer work shaped NHS England's recovery package. Macmillan is one of the largest charities in the UK by income.","asOf":"2026-09-09","links":[{"label":"Macmillan","url":"https://www.macmillan.org.uk"}],"tags":[],"related":["src-macmillan"],"cancers":[],"sections":["supportive-care"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cruk","marie-curie-uk","nice"],"pathways":[],"terms":[],"trials":[],"people":["gemma-peters"],"bottlenecks":["b-survivorship","b-workforce","b-toxicity-qol"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"London","country":"GB","lat":51.507,"lng":-0.106,"institutionType":"consortium","website":"https://www.macmillan.org.uk","programs":["Macmillan nurses and professionals in the NHS","Support Line and online community","Financial grants and benefits advice","Survivorship and personalised care research"]},{"id":"manchester-royal-infirmary","kind":"institution","name":"Manchester Royal Infirmary HPB Unit","aka":["Manchester University NHS Foundation Trust","MRI"],"tldr":"Greater Manchester's HPB surgical unit; works with The Christie, where the region's biliary oncology and the ABC trial series are based.","summary":"The Hepato-Pancreato-Biliary Unit at the Manchester Royal Infirmary is the surgical centre for Greater Manchester and works closely with The Christie, the specialist cancer centre that led the ABC series of UK biliary trials. Manchester University NHS Foundation Trust is one of the trusts the National Pancreatic Cancer Audit identifies as an HPB specialist centre for England.","asOf":"2026-09-24","links":[{"label":"HPB Unit","url":"https://mft.nhs.uk/mri/services/hepato-pancreato-biliary-hpb-unit/"},{"label":"AMMF centres list","url":"https://ammf.org.uk/second-opinions-and-liver-disease-centres/"}],"tags":["hpb","nhs","uk"],"related":[],"cancers":["gallbladder","biliary-tract-cancer","cholangiocarcinoma","pancreatic","hcc"],"sections":["surgery"],"technologies":["hepatectomy"],"targets":[],"drugs":[],"companies":[],"institutions":["the-christie"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Manchester","country":"GB","lat":53.462,"lng":-2.226,"institutionType":"hospital","website":"https://mft.nhs.uk/","university":"University of Manchester","programs":["HPB surgery","Specialist HPB MDT"]},{"id":"nio-warsaw","kind":"institution","name":"Maria Skłodowska-Curie National Research Institute of Oncology","aka":["NIO-PIB","Centrum Onkologii","Instytut im. Marii Skłodowskiej-Curie","Maria Sklodowska- Curie National Research Institute of Oncology","Maria Sklodowska-Curie National Research Institute of Oncology"],"tldr":"Poland's national cancer institute, founded on Marie Curie's initiative in 1932, with branches in Gliwice and Kraków and the national cancer registry.","summary":"The Radium Institute opened in Warsaw in 1932 at the initiative of Maria Skłodowska-Curie, who donated a gram of radium, and today the National Research Institute of Oncology is Poland's largest cancer centre and national reference institution, with branches in Gliwice and Kraków. It hosts the Polish National Cancer Registry, coordinates the national cancer strategy and cooperative trials, and its Kraków branch treats patients with protons at the Bronowice Cyclotron Centre. Piotr Rutkowski's sarcoma and melanoma department is a European reference and contributes to ESMO guidelines, and the institute has large radiotherapy, brachytherapy, surgical and haematology departments. It runs early-phase trials and the national precision oncology programme.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Maria_Sk%C5%82odowska-Curie_National_Research_Institute_of_Oncology","links":[{"label":"Homepage","url":"https://www.pib-nio.pl"},{"label":"Polish National Cancer Registry","url":"https://onkologia.org.pl"}],"tags":[],"related":[],"cancers":["melanoma","sarcoma","nsclc","breast-hr-positive","colorectal"],"sections":["radiation","prevention"],"technologies":["brachytherapy","proton-therapy","imrt-igrt","checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":["curie-nki-eortc"],"institutions":["esmo"],"pathways":[],"terms":[],"trials":[],"people":["beata-jagielska","michal-mikula","andrzej-kawecki"],"bottlenecks":["b-global-access"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Warsaw","country":"PL","lat":52.16,"lng":21.019,"institutionType":"cancer-center","website":"https://www.pib-nio.pl","programs":["National cancer registry and strategy","Sarcoma and melanoma","Radiotherapy and brachytherapy","Proton therapy (Kraków branch)","Haematology"]},{"id":"marie-curie-uk","kind":"institution","name":"Marie Curie","aka":["Marie Curie UK","Marie Curie Cancer Care"],"tldr":"The UK's leading end-of-life charity, running hospices and home nursing for people with terminal illness and funding palliative care research.","summary":"Founded in 1948 as the Marie Curie Memorial Foundation, the charity provides hospice care and community nursing to people dying at home, originally for cancer and now for all terminal illnesses, and runs a free support line and information service. It is the largest charitable funder of palliative and end-of-life care research in the UK, supporting the Marie Curie Palliative Care Research Centres at Cardiff, UCL and elsewhere, and it campaigns on access to palliative care, bereavement support and dying well. Its Great Daffodil Appeal is its main fundraiser. Marie Curie nurses and hospices care for tens of thousands of people each year.","asOf":"2026-09-09","links":[{"label":"Marie Curie","url":"https://www.mariecurie.org.uk"},{"label":"Research","url":"https://www.mariecurie.org.uk/research"}],"tags":[],"related":[],"cancers":[],"sections":["supportive-care"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["macmillan-cancer-support","cruk"],"pathways":[],"terms":[],"trials":[],"people":["matthew-reed"],"bottlenecks":["b-palliative","b-toxicity-qol"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"London","country":"GB","lat":51.523,"lng":-0.079,"institutionType":"consortium","website":"https://www.mariecurie.org.uk","programs":["Hospices and community nursing","Palliative care research centres","Support line and bereavement services","Policy on end-of-life care"]},{"id":"kentucky-markey","kind":"institution","name":"Markey Cancer Center, University of Kentucky","aka":[],"tldr":"Kentucky's NCI comprehensive centre, serving Appalachia where lung and colorectal cancer rates are among the highest in the United States.","summary":"NCI-designated in 2013 and comprehensive since 2023, Markey is the only NCI centre in Kentucky, a state with some of the highest cancer incidence and mortality in the US, concentrated in Appalachian counties. Its research and outreach are built around that burden: lung cancer screening and tobacco control, colorectal screening uptake, HPV vaccination and cervical cancer prevention. The Markey Cancer Center Research Network and Affiliate Network extend trials and specialist care to community hospitals across the state. Basic science strengths include cancer metabolism and DNA damage.","asOf":"2026-09-09","links":[{"label":"Markey Cancer Center","url":"https://ukhealthcare.uky.edu/markey-cancer-center"}],"tags":[],"related":[],"cancers":["nsclc","colorectal","cervical"],"sections":["prevention","early-detection"],"technologies":["low-dose-ct-screening","colorectal-screening","hpv-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["lucille-markey"],"bottlenecks":["b-care-fragmentation","b-prevention-adoption"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Lexington, KY","country":"US","lat":38.032,"lng":-84.508,"institutionType":"cancer-center","website":"https://ukhealthcare.uky.edu/markey-cancer-center","nci":"comprehensive","university":"University of Kentucky","programs":["Appalachian cancer control","Lung cancer screening","Affiliate hospital network"]},{"id":"mou-brno","kind":"institution","name":"Masaryk Memorial Cancer Institute","aka":["Masarykův onkologický ústav","MOÚ","MMCI"],"tldr":"The Czech Republic's only dedicated comprehensive cancer centre, OECI-accredited and known for its RECAMO translational research centre.","summary":"The Masaryk Memorial Cancer Institute opened in 1935 as the 'House of Comfort' with the support of President Tomáš Garrigue Masaryk and is the only specialised comprehensive cancer centre in the Czech Republic, accredited by the OECI. Its Regional Centre for Applied Molecular Oncology (RECAMO), founded by Bořivoj Vojtěšek, develops antibodies and biomarkers for p53 and other targets in collaboration with Edinburgh and international groups, and the institute runs the Czech phase 1 unit for academic trials under Regina Demlová. Clinical services span surgical oncology, radiotherapy with brachytherapy and stereotactic techniques, medical oncology, nuclear medicine and a large prevention and screening centre, and the institute contributes to the national cancer registry and screening programmes.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.mou.cz/en/"},{"label":"RECAMO","url":"https://www.recamo.cz"}],"tags":[],"related":[],"cancers":["breast-hr-positive","colorectal","melanoma","prostate"],"sections":["prevention","radiation"],"technologies":["imrt-igrt","brachytherapy","cgp","checkpoint-inhibitor"],"targets":["tp53"],"drugs":[],"companies":[],"institutions":["oeci","edinburgh-cancer-centre"],"pathways":[],"terms":[],"trials":[],"people":["marek-svoboda","tomas-kazda","igor-kiss"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Brno","country":"CZ","lat":49.187,"lng":16.583,"institutionType":"cancer-center","website":"https://www.mou.cz/en/","university":"Masarykova univerzita","programs":["RECAMO translational research","Phase 1 unit","Prevention and screening centre","Radiotherapy","Surgical oncology"]},{"id":"minnesota-masonic","kind":"institution","name":"Masonic Cancer Center, University of Minnesota","aka":[],"tldr":"The Masonic Cancer Center is where Robert Good performed the first successful human bone marrow transplant in 1968; today Jeffrey Miller's group runs natural killer cell therapy trials, and Stephen Hecht's laboratory defined the tobacco-specific carcinogens used in tobacco regulation.","summary":"NCI comprehensive since 1998, the Masonic Cancer Center inherits the University of Minnesota's transplant legacy: Robert Good performed the first successful human bone marrow transplant here in 1968, and John Wagner's group pioneered unrelated cord blood transplantation. Jeffrey Miller's programme ran the first haploidentical natural killer cell infusions in leukaemia and now partners with Fate Therapeutics on iPSC-derived NK products; Daniel Vallera's tri-specific killer engagers extend the NK concept. Stephen Hecht's laboratory defined the tobacco-specific carcinogens and biomarkers used in tobacco regulation. Clinical care is delivered through M Health Fairview.","asOf":"2026-09-09","links":[{"label":"Masonic Cancer Center","url":"https://cancer.umn.edu"}],"tags":[],"related":[],"cancers":["aml","all-leukemia"],"sections":["cell-therapy","prevention"],"technologies":["allogeneic-hsct","car-nk-macrophage","allogeneic-cell-therapy"],"targets":[],"drugs":[],"companies":["fate-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["jeffrey-miller"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Minneapolis, MN","country":"US","lat":44.973,"lng":-93.233,"institutionType":"cancer-center","website":"https://cancer.umn.edu","nci":"comprehensive","university":"University of Minnesota","programs":["Transplant and cord blood","NK cell therapy","Tobacco carcinogenesis"]},{"id":"mgh","kind":"institution","name":"Massachusetts General Hospital Cancer Center","aka":[],"tldr":"Harvard's largest hospital; leaders in lung cancer targeted therapy, proton therapy, and ctDNA research.","summary":"Massachusetts General Hospital Cancer Center in Boston is Harvard's largest hospital cancer programme, NCI-designated as comprehensive and sixteenth in the Newsweek/Statista oncology ranking, and it matters most for lung cancer targeted therapy. Its Termeer Center for targeted therapies is the home of its ALK, ROS1 and EGFR resistance research, its Francis H. Burr Proton Center anchors a proton therapy programme, and it holds a Broad Institute affiliation for circulating tumour DNA work. OnCo links it to CAR-T for glioma, to the Sybil lung risk and Mirai breast risk models developed with MIT, to Temel's early palliative care paper, and to the losartan pancreatic cancer idea. The brain as a barrier and sanctuary is the bottleneck its neuro-oncology work confronts. Daniel A. Haber, Keith T. Flaherty, Lecia V. Sequist and Ryan B. Corcoran are among the people listed here.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.massgeneral.org/cancer-center"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["proton-therapy","kinase-inhibitors","proton-therapy-systems","gamma-knife","radiosurgery-srs"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["daniel-haber","keith-flaherty","lecia-sequist","justin-gainor","ryan-corcoran","theodore-hong","leif-ellisen","matthew-smith","lori-wirth","noopur-raje","marcela-maus","howard-kaufman","anthony-zietman","constance-lehman","jennifer-temel","ryan-sullivan"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Boston","country":"US","lat":42.363,"lng":-71.069,"institutionType":"hospital","website":"https://www.massgeneral.org/cancer-center","nci":"comprehensive","newsweekOncology2026":16,"university":"Harvard University","programs":["Targeted therapy (lung)","Proton therapy","Neuro-oncology"]},{"id":"mater-misericordiae","kind":"institution","name":"Mater Misericordiae University Hospital","aka":["The Mater","Mater Hospital Dublin"],"tldr":"The Mater is a Dublin teaching hospital founded in 1861, one of Ireland's two major trauma centres and a designated cancer centre, and a full member of the Organisation of European Cancer Institutes.","summary":"The Mater Misericordiae University Hospital, commonly known as the Mater, is a teaching hospital on Eccles Street in Dublin, founded in 1861 and managed within the Ireland East Hospital Group. It is one of Ireland's two major trauma centres and one of the eight designated cancer centres of the national cancer control programme, working with University College Dublin. It is listed by the Organisation of European Cancer Institutes as a full member. OnCo records it alongside St Vincent's and Beaumont as Irish cancer centres; programme and trial details are not yet recorded here.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Mater_Misericordiae_University_Hospital","links":[{"label":"Official website","url":"https://www.mater.ie"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Mater_Misericordiae_University_Hospital"}],"tags":[],"related":["st-vincents-ucd-cancer-centre","beaumont-rcsi-cancer-centre"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["tracey-fitzpatrick"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Dublin","country":"IE","lat":53.359,"lng":-6.269,"institutionType":"hospital","website":"https://www.mater.ie","programs":[]},{"id":"mater-private","kind":"institution","name":"Mater Private Network","aka":["Mater Private Hospital","Mater Private Dublin"],"tldr":"Mater Private Network is an Irish private hospital group whose Dublin hospital sits beside the Mater Misericordiae, and a full member of the Organisation of European Cancer Institutes.","summary":"Mater Private Network is a private hospital business whose main hospital, opened in 1986, stands just east of the Mater Misericordiae University Hospital in Dublin, with further sites elsewhere in Ireland. It provides private cancer diagnosis and treatment including radiotherapy and is listed by the Organisation of European Cancer Institutes as a full member, one of five Irish institutions on the list. Programme, trial and leadership details are not yet recorded here and should be checked on the hospital's own pages.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.materprivate.ie"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":["mater-misericordiae"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["jerome-coffey"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Dublin","country":"IE","lat":53.358,"lng":-6.264,"institutionType":"hospital","website":"https://www.materprivate.ie","programs":[]},{"id":"mdc-berlin","kind":"institution","name":"Max Delbrück Center for Molecular Medicine","aka":["MDC","Max-Delbrück-Centrum","Max Delbrück Center"],"tldr":"Berlin's Helmholtz molecular medicine institute, whose cancer research spans T-cell receptor therapies, single-cell biology and systems medicine.","summary":"Founded in 1992 on the Berlin-Buch campus, the Max Delbrück Center is a Helmholtz Association institute that works closely with Charité through the Experimental and Clinical Research Center and the Berlin Institute of Health. Thomas Blankenstein's group developed T-cell receptor gene therapy approaches that led to the spin-out T-knife, and the Berlin Institute for Medical Systems Biology under Nikolaus Rajewsky is a centre for single-cell and spatial transcriptomics. Other groups study cancer genomics, oncogenic signalling, tumour immunology and MYC-driven lymphoma. The centre contributes to the DKTK and the German Human Cell Atlas efforts.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Max_Delbr%C3%BCck_Center_for_Molecular_Medicine_in_the_Helmholtz_Association","links":[{"label":"Homepage","url":"https://www.mdc-berlin.de/en"},{"label":"BIMSB","url":"https://www.mdc-berlin.de/bimsb"}],"tags":[],"related":["cellxgene-hca"],"cancers":["dlbcl","melanoma","colorectal"],"sections":["cell-therapy","drug-discovery"],"technologies":["tcr-t","single-cell-spatial","crispr-screens","rna-seq"],"targets":[],"drugs":[],"companies":[],"institutions":["charite","dkfz"],"pathways":[],"terms":[],"trials":[],"people":["maike-sander","nikolaus-rajewsky"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Berlin","country":"DE","lat":52.634,"lng":13.503,"institutionType":"research-institute","website":"https://www.mdc-berlin.de","programs":["TCR gene therapy","Berlin Institute for Medical Systems Biology","Cancer genomics and signalling","Systems medicine with Charité"]},{"id":"max-healthcare","kind":"institution","name":"Max Healthcare (Max Institute of Cancer Care)","aka":["Max Hospitals","Max Cancer Centre","Max Super Speciality Hospital Saket"],"tldr":"One of north India's largest private hospital groups, with a network of cancer units, a standalone cancer centre in Delhi and a large share of India's private-sector oncology trials.","summary":"Max Healthcare opened its first centre in Panchsheel Park, Delhi, in 2000 and in June 2025 operated 22 hospitals with more than 5,000 beds, mainly in north India; it is listed on the BSE and NSE and is a NIFTY 50 constituent. A standalone Max Cancer Centre was commissioned in Lajpat Nagar, Delhi, in 2016, and the group's oncology programme (marketed as the Max Institute of Cancer Care) spans surgical, medical, radiation and haemato-oncology, bone marrow transplant, robotic surgery and precision oncology across its network. Max is a frequent site for international registration trials in India.","asOf":"2026-09-10","links":[{"label":"Max Healthcare","url":"https://www.maxhealthcare.in"}],"tags":[],"related":[],"cancers":["breast-hr-positive","head-and-neck","dlbcl","nsclc"],"sections":["surgery","cell-therapy"],"technologies":["robotic-surgery","car-t","cgp"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["abhay-soi"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"New Delhi","country":"IN","lat":28.528,"lng":77.212,"institutionType":"hospital","website":"https://www.maxhealthcare.in","programs":["Cancer centre network","Bone marrow transplant","Robotic surgery","Industry clinical trials"]},{"id":"mayo-clinic","kind":"institution","name":"Mayo Clinic","aka":[],"tldr":"Consistently the top-ranked US hospital overall, with strong proton therapy and the first US carbon-ion centre under construction.","summary":"Mayo Clinic, headquartered in Rochester, Minnesota, is consistently the top-ranked US hospital overall and holds NCI comprehensive designation through the Mayo Clinic Comprehensive Cancer Center, which spans Rochester, Phoenix and Jacksonville; it sits fifth in the Newsweek/Statista oncology ranking. Its cancer strengths are multiple myeloma, lymphoma and individualised medicine, with proton therapy and the first US carbon-ion facility under construction in Jacksonville. OnCo links it to the Atlas pathology model built with Aignostics and Charité, to liver transplantation for cancer, to senescence and JAK-STAT pathway work, and to people including S. Vincent Rajkumar, Shaji K. Kumar and Matthew P. Goetz. Whether carbon-ion therapy earns its cost against protons is the open question its new centre will help answer. The Arizona and Florida campuses have their own OnCo pages.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Mayo_Clinic","links":[{"label":"Official website","url":"https://www.mayoclinic.org"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["carbon-ion","proton-therapy","proton-therapy-systems","gamma-knife","radiosurgery-srs"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["evanthia-galanis","vincent-rajkumar","shaji-kumar","matthew-goetz","oliver-sartor","cheryl-willman","mark-litzow","tanios-bekaii-saab"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Rochester, MN","country":"US","lat":44.022,"lng":-92.467,"institutionType":"hospital","website":"https://www.mayoclinic.org","nci":"comprehensive","newsweekOncology2026":5,"programs":["Carbon-ion therapy (Jacksonville)","Myeloma","Proton therapy"]},{"id":"mayo-clinic-arizona","kind":"institution","name":"Mayo Clinic Comprehensive Cancer Center in Arizona","aka":["Mayo Clinic Phoenix","Mayo Clinic Scottsdale"],"tldr":"Mayo Clinic's Arizona campus, spanning Phoenix and Scottsdale, is one of three sites under Mayo's NCI comprehensive designation; it opened a proton therapy centre in 2016, runs bone marrow transplant, CAR-T and a myeloma programme, and hosts Mayo's Arizona early-phase trials under Tanios Bekaii-Saab.","summary":"Mayo Clinic Arizona, spanning the Phoenix hospital and Scottsdale clinic, is one of the three campuses covered by Mayo Clinic Comprehensive Cancer Center's NCI designation. Its proton beam therapy centre opened in 2016, and the campus runs bone marrow transplant, CAR-T and a myeloma programme built by A. Keith Stewart and Rafael Fonseca. Tanios Bekaii-Saab leads GI oncology and Mayo's Arizona early-phase trials, and the Mayo Clinic Alix School of Medicine and an alliance with Arizona State University support research in medical technology and data science. The campus serves patients across the south-western US.","asOf":"2026-09-09","links":[{"label":"Mayo Clinic Arizona","url":"https://www.mayoclinic.org/patient-visitor-guide/arizona"},{"label":"Mayo Clinic Comprehensive Cancer Center","url":"https://www.mayo.edu/research/centers-programs/cancer-research/"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":["multiple-myeloma","colorectal","pancreatic"],"sections":[],"technologies":["proton-therapy","car-t","proton-therapy-systems"],"targets":[],"drugs":[],"companies":[],"institutions":["mayo-clinic"],"pathways":[],"terms":[],"trials":[],"people":["tanios-bekaii-saab","keith-stewart"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Phoenix, AZ","country":"US","lat":33.658,"lng":-111.955,"institutionType":"hospital","website":"https://www.mayoclinic.org/patient-visitor-guide/arizona","nci":"comprehensive","programs":["Proton therapy","Multiple myeloma","GI oncology and phase 1 trials"]},{"id":"mayo-clinic-florida","kind":"institution","name":"Mayo Clinic Comprehensive Cancer Center in Florida","aka":["Mayo Clinic Jacksonville"],"tldr":"Mayo Clinic's Florida campus, building North America's first carbon-ion therapy facility alongside proton therapy and a cancer vaccine programme.","summary":"Mayo Clinic's Jacksonville campus is one of the three sites of the Mayo Clinic Comprehensive Cancer Center, sharing its single NCI comprehensive designation with Rochester and Phoenix. It is constructing an integrated oncology facility that houses proton beam therapy and will add carbon-ion therapy, planned as the first such facility in North America. Keith Knutson's immunology programme develops breast cancer vaccines targeting HER2 and folate receptor alpha, and the campus runs bone marrow transplant, CAR-T and a large lung, GI and haematologic oncology practice serving the south-eastern US.","asOf":"2026-09-09","links":[{"label":"Mayo Clinic Florida","url":"https://www.mayoclinic.org/patient-visitor-guide/florida"},{"label":"Mayo Clinic Comprehensive Cancer Center","url":"https://www.mayo.edu/research/centers-programs/cancer-research/"}],"tags":[],"related":[],"cancers":["breast-her2-positive"],"sections":["radiation"],"technologies":["carbon-ion","proton-therapy","shared-antigen-vaccine","car-t"],"targets":["folr1","her2"],"drugs":[],"companies":[],"institutions":["mayo-clinic"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Jacksonville, FL","country":"US","lat":30.264,"lng":-81.442,"institutionType":"hospital","website":"https://www.mayoclinic.org/patient-visitor-guide/florida","nci":"comprehensive","programs":["Carbon-ion therapy (in development)","Proton therapy","Breast cancer vaccines","Transplant and CAR-T"]},{"id":"mays-cancer-center","kind":"institution","name":"Mays Cancer Center at UT Health San Antonio","aka":["CTRC","Cancer Therapy & Research Center"],"tldr":"Mays Cancer Center in San Antonio, NCI-designated since 1991, hosts the San Antonio Breast Cancer Symposium and descends from the CTRC phase 1 institute where Daniel Von Hoff ran early trials of gemcitabine and nab-paclitaxel; it serves South Texas's predominantly Latino population.","summary":"Mays Cancer Center descends from the Cancer Therapy & Research Center, NCI-designated since 1991, whose Institute for Drug Development under Daniel Von Hoff conducted early trials of gemcitabine and nab-paclitaxel among other agents. UT Health San Antonio founded the San Antonio Breast Cancer Symposium in 1977, now the world's largest breast cancer meeting, co-hosted with the AACR and Baylor's Smith Breast Center. The centre serves South Texas's predominantly Latino population, with Amelie Ramirez's Salud America! programme addressing Latino cancer disparities, and hosts the Greehey Children's Cancer Research Institute. It is an MD Anderson affiliate and has strengths in myeloproliferative neoplasms and breast oncology.","asOf":"2026-09-09","links":[{"label":"Mays Cancer Center","url":"https://cancer.uthscsa.edu"},{"label":"SABCS","url":"https://www.sabcs.org"}],"tags":[],"related":["src-sabcs"],"cancers":["breast-hr-positive","tnbc","myeloproliferative-neoplasms","pancreatic"],"sections":["chemotherapy"],"technologies":[],"targets":[],"drugs":["gemcitabine","ruxolitinib"],"companies":[],"institutions":["aacr","md-anderson"],"pathways":[],"terms":[],"trials":["nct01906385"],"people":["lei-zheng"],"bottlenecks":["b-trial-diversity"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"San Antonio, TX","country":"US","lat":29.508,"lng":-98.575,"institutionType":"cancer-center","website":"https://cancer.uthscsa.edu","nci":"clinical","university":"UT Health San Antonio","programs":["San Antonio Breast Cancer Symposium","Phase 1 drug development (IDD heritage)","Latino cancer disparities","Paediatric research (Greehey CCRI)"]},{"id":"muhc-cedars-cancer-centre","kind":"institution","name":"McGill University Health Centre / Cedars Cancer Centre","aka":["MUHC","Cedars Cancer Centre"],"tldr":"McGill's university hospital network, whose Cedars Cancer Centre at the Glen site is one of Quebec's largest cancer programmes.","summary":"The McGill University Health Centre is the academic hospital network of McGill University, and its Cedars Cancer Centre at the Glen site, which opened in 2015, brings radiation oncology, medical oncology, haematology, surgical oncology and supportive care together in one building. Research through the Research Institute of the MUHC and McGill's Rosalind and Morris Goodman Cancer Institute covers cancer genomics, metabolism, immuno-oncology and clinical trials, and the centre hosts the Segal Cancer Centre partnership with the Jewish General Hospital within the Rossy Cancer Network, which aims to improve outcomes across McGill's affiliated hospitals.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://muhc.ca"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mcgill-goodman"],"pathways":[],"terms":[],"trials":[],"people":["lucie-opatrny"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Montréal","country":"CA","lat":45.473,"lng":-73.601,"institutionType":"hospital","website":"https://muhc.ca","university":"McGill University","programs":["Cedars Cancer Centre","Rossy Cancer Network","Research Institute of the MUHC"]},{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","aka":[],"tldr":"MD Anderson is the largest cancer centre in the world by patient volume, with the biggest phase 1 programme and a leading CAR-NK effort.","summary":"MD Anderson Cancer Center in Houston, part of the University of Texas and founded in 1941, is the largest cancer centre in the world by patient volume and holds NCI comprehensive designation and second place in the Newsweek/Statista oncology ranking. It runs the biggest early-phase trial unit anywhere, the Moon Shots programme, a proton therapy centre and a leading CAR-NK effort with Takeda, and its breast group under Symmans defined the Residual Cancer Burden index used to grade response after neoadjuvant treatment. OnCo links it to LACC in cervical cancer and the ROAR anaplastic thyroid cohort, to work on the gut microbiome and dietary fibre in immunotherapy response, and to pathways from cancer neuroscience to cachexia. Whether its scale translates into faster answers than smaller centres remains a fair question. The people listed here show who leads which programme.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/MD_Anderson_Cancer_Center","links":[{"label":"Official website","url":"https://www.mdanderson.org"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":["newsweek-hospitals","break-through-cancer"],"cancers":[],"sections":[],"technologies":["car-nk-macrophage","proton-therapy","proton-therapy-systems","gamma-knife","radiosurgery-srs","mr-linac"],"targets":[],"drugs":[],"companies":["alaunos"],"institutions":[],"pathways":[],"terms":["rcb"],"trials":[],"people":["peter-pisters","giulio-draetta","christopher-flowers","debu-tripathy","john-heymach","funda-meric-bernstam","anirban-maitra","jennifer-litton","albert-koong","mariana-chavez-macgregor","monroe-anderson","gabriel-hortobagyi","ferdinandos-skoulidis","tina-cascone","joe-chang","scott-kopetz","jaffer-ajani","ashish-kamat","hussein-tawbi","jennifer-wargo","maura-gillison","maria-cabanillas","james-yao","courtney-dinardo","ghayas-issa","elias-jabbour","sattva-neelapu","jason-westin","michael-wang","william-wierda","katy-rezvani","hagop-kantarjian","james-allison","padmanee-sharma"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Houston","country":"US","lat":29.707,"lng":-95.397,"institutionType":"cancer-center","website":"https://www.mdanderson.org","nci":"comprehensive","newsweekOncology2026":2,"university":"University of Texas","programs":["Phase 1 trials","CAR-NK","Residual Cancer Burden index","Proton therapy","Moon Shots"]},{"id":"mcw-cancer-center","kind":"institution","name":"Medical College of Wisconsin Cancer Center","aka":["MCW Cancer Center","Froedtert & the Medical College of Wisconsin","Froedtert Hospital"],"tldr":"Milwaukee academic cancer centre run by the Medical College of Wisconsin and Froedtert Hospital, where precision oncology pioneer Razelle Kurzrock holds an endowed chair.","summary":"The Medical College of Wisconsin Cancer Center is the academic cancer centre of the Medical College of Wisconsin and Froedtert Hospital in Milwaukee, and is separate from the NCI-designated University of Wisconsin Carbone Cancer Center in Madison. Razelle Kurzrock, who founded the phase 1 programme at MD Anderson and the Center for Personalized Cancer Therapy at UC San Diego, joined it in 2021 as the Mellowes Endowed Chair in Precision Oncology and leads its precision medicine programme.","asOf":"2026-09-18","links":[{"label":"Medical College of Wisconsin","url":"https://www.mcw.edu"}],"tags":[],"related":[],"cancers":["cancer-of-unknown-primary"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["uw-carbone"],"pathways":[],"terms":[],"trials":[],"people":["razelle-kurzrock"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Milwaukee, WI","country":"US","lat":43.044,"lng":-88.024,"institutionType":"cancer-center","website":"https://www.mcw.edu","university":"Medical College of Wisconsin","programs":["Precision oncology","Early-phase trials","Blood and marrow transplantation"]},{"id":"mhra","kind":"institution","name":"Medicines and Healthcare products Regulatory Agency","aka":["MHRA"],"tldr":"The UK medicines and devices regulator, which since Brexit runs its own approvals, joins Project Orbis and uses international reliance routes to speed cancer drug access.","summary":"Formed in 2003 by merging the Medicines Control Agency and the Medical Devices Agency, the MHRA became the UK's standalone regulator for new medicines after the UK left the EU in 2021. It participates in the FDA-led Project Orbis and the Access Consortium (with Australia, Canada, Singapore and Switzerland), uses the International Recognition Procedure to rely on approvals by trusted regulators, and runs the Innovative Licensing and Access Pathway with NICE and the Scottish Medicines Consortium to align licensing and reimbursement. The MHRA also regulates clinical trials, devices including AI software, and blood and tissue products, and operates the Yellow Card safety scheme.","asOf":"2026-09-09","links":[{"label":"MHRA","url":"https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["radiology-ai-screening","digital-pathology-ai"],"targets":[],"drugs":[],"companies":[],"institutions":["nice","smc","fda-oce","ema","cruk"],"pathways":[],"terms":["accelerated-approval"],"trials":[],"people":["lawrence-tallon"],"bottlenecks":["b-regulatory-fragmentation","b-ai-validation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"London","country":"GB","lat":51.503,"lng":-0.02,"institutionType":"government","website":"https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency","programs":["Project Orbis and Access Consortium","International Recognition Procedure","Innovative Licensing and Access Pathway (with NICE and SMC)","Clinical trials and device regulation"]},{"id":"mediterranean-institute-of-oncology","kind":"institution","name":"Mediterranean Institute of Oncology (IOM)","aka":["Istituto Oncologico del Mediterraneo","IOM Viagrande"],"tldr":"Mediterranean Institute of Oncology is a private cancer centre at Viagrande near Catania in Sicily, part of the SAMED group, offering medical oncology, radiotherapy and nuclear medicine, and a full member of the Organisation of European Cancer Institutes.","summary":"Mediterranean Institute of Oncology is a private cancer centre at Viagrande near Catania in Sicily, part of the SAMED group, offering medical oncology, radiotherapy and nuclear medicine. It is listed by the Organisation of European Cancer Institutes as a full member, which is why it has a page on OnCo. Programme, trial and leadership details are not yet recorded here and should be checked on the institution's own pages.","asOf":"2026-09-09","links":[{"label":"Official website","url":"http://www.grupposamed.com"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":["spedali-civili-brescia","ausl-irccs-reggio-emilia"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["roberto-cunsolo"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Viagrande","country":"IT","lat":37.613,"lng":15.099,"institutionType":"cancer-center","website":"http://www.grupposamed.com","programs":[]},{"id":"melanoma-focus","kind":"institution","name":"Melanoma Focus","aka":[],"tldr":"The UK melanoma charity whose free nurse helpline is the one place a frightened person can ask a specialist skin cancer nurse a question without waiting for an appointment, and which says up front that it cannot tell you from a photograph.","summary":"Melanoma Focus runs the Melanoma Helpline, a confidential freephone service on 0808 801 0777 staffed by specialist skin cancer nurses. It is open 1pm to 2pm and 7pm to 9pm Monday to Friday and 7pm to 9pm on Sunday, with a message service outside those hours and an email contact form. The charity states plainly on the helpline page that its nurses cannot diagnose melanoma on the telephone or from a photograph, and points people who have been asked by a GP to send an image to its own teledermatology guidance on how to take one.\n\nIt also runs support groups and produces guidelines and information for healthcare professionals as well as patients. Its remit is melanoma rather than the keratinocyte cancers, which is worth knowing: a person with a basal cell carcinoma who telephones will be helped, but the charity built for them is the British Association of Dermatologists' patient information service, and the charity built for the consequences of facial skin surgery is Changing Faces.","asOf":"2026-09-25","links":[{"label":"Melanoma Helpline","url":"https://melanomafocus.org/melanoma-helpline/"}],"tags":["uk","charity","skin","support"],"related":[],"cancers":["melanoma","skin-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Cambridge","country":"GB","lat":52.205,"lng":0.119,"institutionType":"consortium","website":"https://melanomafocus.org/","programs":[]},{"id":"melanoma-institute-australia","kind":"institution","name":"Melanoma Institute Australia","aka":["MIA","Sydney Melanoma Unit"],"tldr":"Sydney institute treating and studying more melanoma patients than any other centre in the world, whose co-directors Georgina Long and Richard Scolyer led the trials that established combination immunotherapy.","summary":"Melanoma Institute Australia grew out of the Sydney Melanoma Unit and is affiliated with the University of Sydney, Royal North Shore and Mater Hospitals. It treats and follows more melanoma patients than any other centre and holds one of the largest melanoma biobanks. Its co-medical directors, Georgina Long and Richard Scolyer, were Australians of the Year in 2024; Long led the COMBI-AD adjuvant trial and neoadjuvant immunotherapy trials such as NADINA, and Scolyer's pathology work defines how melanoma is staged.","asOf":"2026-09-18","wikipedia":"https://en.wikipedia.org/wiki/Melanoma_Institute_Australia","links":[{"label":"Melanoma Institute Australia","url":"https://www.melanoma.org.au"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["combi-ad"],"people":["georgina-long"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Sydney","country":"AU","lat":-33.828,"lng":151.19,"institutionType":"research-institute","website":"https://www.melanoma.org.au","university":"University of Sydney","programs":["Melanoma medical oncology","Neoadjuvant immunotherapy","Melanoma pathology and biobanking"]},{"id":"mra","kind":"institution","name":"Melanoma Research Alliance","aka":["MRA"],"tldr":"The melanoma research funder Debra and Leon Black started in 2007; it has put more than $200 million into research and every donated dollar goes to science because the founders cover the running costs.","summary":"The Melanoma Research Alliance was founded in 2007 by Debra and Leon Black after Debra's melanoma diagnosis. Its own overview states that it has directly invested over $200 million through more than 500 grant awards, that MRA-funded researchers have contributed to 20 new FDA-approved melanoma treatments since its founding, and that because the Blacks cover administrative and fundraising costs, 100% of every donation goes to melanoma research. It funds young investigators, team science and academic-industry partnerships, and convenes an annual scientific retreat. Headquartered in Washington, DC.","asOf":"2026-09-10","links":[{"label":"MRA overview","url":"https://www.curemelanoma.org/mra-overview/mra-overview"}],"tags":[],"related":["melanoma-research-alliance"],"cancers":["melanoma"],"sections":[],"technologies":["checkpoint-inhibitor","immunotherapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["debra-black","leon-black"],"bottlenecks":["b-funding-allocation","b-translational-valley"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Washington, DC","country":"US","lat":38.9,"lng":-77.034,"institutionType":"consortium","website":"https://www.curemelanoma.org","programs":["Young Investigator Awards","Team Science Awards","Academic-industry partnership awards","Annual scientific retreat"]},{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","aka":[],"tldr":"The world's top-ranked cancer hospital, home of MSK-IMPACT sequencing, the dostarlimab rectal cancer study, and CAR-T pioneers.","summary":"Memorial Sloan Kettering Cancer Center is a New York cancer centre founded in 1884, NCI-designated as comprehensive and ranked first in the Newsweek/Statista World's Best Specialized Hospitals list for oncology, which makes it the reference point against which other cancer hospitals are measured. Its firsts include MSK-IMPACT, an FDA-authorised tumour sequencing panel that feeds OncoKB and cBioPortal, co-development of CD19 CAR-T cell therapy with Sadelain's group, the dostarlimab study in mismatch-repair-deficient rectal cancer led by Andrea Cercek, and the Paige AI digital pathology spin-out. It runs one of the largest oncology trial portfolios in the United States. The open question for a centre this large is how quickly its knowledge reaches practice elsewhere, a bottleneck OnCo tracks explicitly. Its people and trials pages are the best way into the detail.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Memorial_Sloan_Kettering_Cancer_Center","links":[{"label":"Official website","url":"https://www.mskcc.org"}],"tags":[],"related":["newsweek-hospitals","break-through-cancer"],"cancers":[],"sections":[],"technologies":["cgp","car-t","digital-pathology-ai"],"targets":[],"drugs":["dostarlimab"],"companies":["paige"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["bob-li","alexander-drilon","helena-yu","jae-park","david-solit","sharon-belvin","evelyn-lauder","jimmie-holland","john-jacob-astor-iii","komal-jhaveri","shanu-modi","monica-morrow","charles-rudin","julio-garcia-aguilar","vinod-balachandran","ghassan-abou-alfa","jonathan-rosenberg","dean-bajorin","robert-motzer","michael-postow","ingo-mellinghoff","william-tap","sandra-dangelo","nai-kong-cheung","eytan-stein","gilles-salles","steven-horwitz","jason-lewis","michael-berger","valerie-rusch","deb-schrag","andrea-cercek","charles-sawyers","eileen-oreilly","howard-scher","luis-diaz","michael-morris","ross-levine","saad-usmani","selwyn-vickers","yelena-janjigian"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"New York","country":"US","lat":40.764,"lng":-73.956,"institutionType":"cancer-center","website":"https://www.mskcc.org","nci":"comprehensive","newsweekOncology2026":1,"programs":["MSK-IMPACT / OncoKB","CAR-T (Sadelain)","dMMR rectal organ preservation","Paige AI","Radiopharmaceutical development"]},{"id":"metaxa-cancer-hospital","kind":"institution","name":"Metaxa Cancer Hospital, Piraeus","aka":["Γενικο Αντικαρκινικο Νοσοκομειο Πειραια Μεταξα","Metaxa Memorial Cancer Hospital","Metaxa Anticancer Hospital"],"tldr":"Metaxa Cancer Hospital, Piraeus is a public specialist cancer hospital serving Piraeus and the wider Athens area, and a full member of the Organisation of European Cancer Institutes.","summary":"Metaxa Cancer Hospital, Piraeus is a public specialist cancer hospital serving Piraeus and the wider Athens area. It is listed by the Organisation of European Cancer Institutes as a full member, which is why it has a page on OnCo. Programme, trial and leadership details are not yet recorded here and should be checked on the institution's own pages.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.metaxa-hospital.gov.gr"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":["saint-savvas-athens"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["sarantos-efstathopoulos"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Piraeus","country":"GR","lat":37.943,"lng":23.647,"institutionType":"cancer-center","website":"https://www.metaxa-hospital.gov.gr","programs":[]},{"id":"mid-western-cancer-centre","kind":"institution","name":"Mid-Western Cancer Centre, University Hospital Limerick","aka":["University Hospital Limerick cancer centre","UHL Cancer Centre","Mid-Western Regional Hospital"],"tldr":"The cancer centre of University Hospital Limerick, serving Ireland's Mid-West, and a full member of the Organisation of European Cancer Institutes.","summary":"The Mid-Western Cancer Centre is the cancer service of University Hospital Limerick (formerly the Mid-Western Regional Hospital, opened in 1955), the acute hospital for Limerick, Clare and North Tipperary within Ireland's HSE. It is a full member of the Organisation of European Cancer Institutes (OECI). Its representative on the OECI list is Breda Duggan.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www2.hse.ie/services/hospitals/university-hospital-limerick/"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q6840848"}],"tags":[],"related":["cork-university-hospital","galway-university-hospital-cancer-centre"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["breda-duggan"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Limerick","country":"IE","lat":52.635,"lng":-8.656,"institutionType":"hospital","website":"https://www2.hse.ie/services/hospitals/university-hospital-limerick/","programs":[]},{"id":"moffitt","kind":"institution","name":"Moffitt Cancer Center","aka":[],"tldr":"Moffitt is Florida's cancer centre and the leading US site for TIL therapy and evolutionary ('adaptive') therapy research.","summary":"Moffitt Cancer Center in Tampa is Florida's NCI comprehensive cancer centre and the leading US site for tumour-infiltrating lymphocyte therapy and for evolutionary, or adaptive, therapy research. It ran the pivotal lifileucel trials under Amod A. Sarnaik, reported in C-144-01, hosts Robert A. Gatenby's adaptive therapy programme, and runs the ORIEN data network and a broad immuno-oncology effort, with Frederick L. Locke, Eric B. Haura, Christine H. Chung and Shari Pilon-Thomas among its people. OnCo links it to melanoma and lifileucel, to the ZUMA-1 and ZUMA-7 CAR-T papers, and to ideas on dose-holiday platform trials, evolutionary tumour boards and switching drugs at maximum response. Acquired resistance and tumour heterogeneity are the bottlenecks its adaptive therapy work attacks. Its TIL and adaptive therapy programmes are the reasons to read on.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/H._Lee_Moffitt_Cancer_Center_%26_Research_Institute","links":[{"label":"Official website","url":"https://www.moffitt.org"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["til-therapy"],"targets":[],"drugs":["lifileucel"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["robert-gatenby","eric-haura","hatem-soliman","christine-chung","shari-pilon-thomas","jonathan-strosberg","amod-sarnaik","frederick-locke","patrick-hwu"],"bottlenecks":[],"keyPapers":[],"journals":["cancer-control"],"dependsOn":[],"notes":[],"city":"Tampa, FL","country":"US","lat":28.066,"lng":-82.42,"institutionType":"cancer-center","website":"https://www.moffitt.org","nci":"comprehensive","programs":["TIL therapy","Adaptive therapy","Immuno-oncology"]},{"id":"moi-teaching-referral-hospital","kind":"institution","name":"Moi Teaching and Referral Hospital / AMPATH Oncology","aka":["MTRH","Chandaria Cancer and Chronic Diseases Centre"],"tldr":"Moi Teaching and Referral Hospital in Eldoret is Kenya's second national referral hospital; through the AMPATH partnership led by Indiana University it built one of East Africa's strongest public cancer programmes, adding radiotherapy in western Kenya at the Chandaria centre.","summary":"Moi Teaching and Referral Hospital is Kenya's second national referral hospital and the teaching hospital of Moi University School of Medicine. Through AMPATH (the Academic Model Providing Access to Healthcare), a consortium led by Indiana University with Moi University and other North American partners, it developed a comprehensive oncology programme with medical oncology, paediatric oncology, palliative care, a pharmacy and pathology infrastructure, and the Chandaria Cancer and Chronic Diseases Centre, which added radiotherapy in western Kenya. AMPATH Oncology has published widely on breast and cervical cancer screening, Burkitt lymphoma and Kaposi sarcoma, and on delivering cancer care in low-resource settings.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.mtrh.go.ke"}],"tags":[],"related":[],"cancers":["cervical"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["kenyatta-national-hospital","iu-simon"],"pathways":[],"terms":[],"trials":[],"people":["philip-kirwa"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Eldoret","country":"KE","lat":0.514,"lng":35.27,"institutionType":"hospital","website":"https://www.mtrh.go.ke","university":"Moi University","programs":["AMPATH Oncology","Chandaria Cancer and Chronic Diseases Centre","Cervical and breast screening","Paediatric oncology"]},{"id":"montefiore-einstein","kind":"institution","name":"Montefiore Einstein Comprehensive Cancer Center","aka":["Albert Einstein Cancer Center"],"tldr":"The Bronx's NCI comprehensive cancer centre, where Joseph Sparano ran TAILORx, the trial that let most women with early HR-positive breast cancer skip chemotherapy.","summary":"The Albert Einstein Cancer Center has been NCI-designated since 1972 and, as Montefiore Einstein Comprehensive Cancer Center, now holds comprehensive status while serving one of the poorest urban counties in the United States. Joseph Sparano chaired TAILORx from here for ECOG-ACRIN, showing that a mid-range Oncotype DX recurrence score identifies women who do not need adjuvant chemotherapy. John Condeelis's intravital imaging revealed the TMEM 'doorways' through which breast cancer cells enter the bloodstream; Ulrich Steidl and Amit Verma lead work on MDS and leukaemia stem cells. Director Edward Chu is a GI oncologist and cancer pharmacologist.","asOf":"2026-09-09","links":[{"label":"Montefiore Einstein Comprehensive Cancer Center","url":"https://montefioreeinstein.org/cancer"},{"label":"Clinical trials","url":"https://montefioreeinstein.org/cancer/research/clinical-trials"}],"tags":[],"related":[],"cancers":["breast-hr-positive","mds","aml"],"sections":[],"technologies":["optical-imaging"],"targets":[],"drugs":["oncotype-dx"],"companies":["ecog-acrin"],"institutions":[],"pathways":[],"terms":[],"trials":["tailorx"],"people":["ulrich-steidl"],"bottlenecks":["b-metastasis-biology","b-trial-diversity"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Bronx, NY","country":"US","lat":40.88,"lng":-73.879,"institutionType":"cancer-center","website":"https://montefioreeinstein.org/cancer","nci":"comprehensive","university":"Albert Einstein College of Medicine","programs":["Breast cancer (TAILORx)","Metastasis imaging","MDS and leukaemia stem cells","Bronx community oncology"]},{"id":"morriston-swansea","kind":"institution","name":"Morriston Hospital, Swansea","aka":["Swansea Bay University Health Board","South Wales HPB unit"],"tldr":"The HPB surgical centre for South Wales; oncology at Singleton Hospital and Velindre.","summary":"Pancreatic Cancer UK lists Morriston Hospital (Swansea Bay University Health Board) as the South Wales HPB surgical centre, with oncology at Singleton Hospital and Velindre Cancer Centre. Patients from North Wales are referred to Liverpool and some from mid Wales to Stoke-on-Trent.","asOf":"2026-09-24","links":[{"label":"Swansea Bay University Health Board","url":"https://sbuhb.nhs.wales/"},{"label":"Pancreatic Cancer UK centres list","url":"https://www.pancreaticcancer.org.uk/information-and-support/your-care/your-local-pancreatic-cancer-specialist-centre/"}],"tags":["hpb","nhs","uk"],"related":[],"cancers":["gallbladder","biliary-tract-cancer","cholangiocarcinoma","pancreatic","hcc"],"sections":["surgery"],"technologies":["hepatectomy"],"targets":[],"drugs":[],"companies":[],"institutions":["velindre-cardiff"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Swansea","country":"GB","lat":51.677,"lng":-3.934,"institutionType":"hospital","website":"https://sbuhb.nhs.wales/","programs":["HPB surgery","South Wales HPB MDT"]},{"id":"motol-university-hospital","kind":"institution","name":"Motol University Hospital","aka":["Fakultní nemocnice v Motole","FN Motol","Motol Hospital"],"tldr":"Motol University Hospital in Prague is the largest hospital in the Czech Republic, a teaching base for Charles University and a full member of the Organisation of European Cancer Institutes.","summary":"Motol University Hospital is a large teaching hospital in the Motol district of Prague, described as the largest medical facility in the Czech Republic and one of the largest in Europe. It is a major teaching base for the Second Faculty of Medicine of Charles University and provides adult and paediatric cancer care, including the country's main paediatric haematology and oncology service. It is listed by the Organisation of European Cancer Institutes as a full member. OnCo records it alongside the Masaryk Memorial Cancer Institute in Brno as a Czech OECI member; programme and trial details are not yet recorded here.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Motol_University_Hospital","links":[{"label":"Official website","url":"https://www.fnmotol.cz"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Motol_University_Hospital"}],"tags":[],"related":["mou-brno"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["petr-poloucek"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Prague","country":"CZ","lat":50.074,"lng":14.344,"institutionType":"hospital","website":"https://www.fnmotol.cz","programs":[]},{"id":"mount-vernon-cancer-centre","kind":"institution","name":"Mount Vernon Cancer Centre","aka":[],"tldr":"A long-established specialist cancer centre north-west of London, historically home of the Gray Laboratory for radiobiology.","summary":"Mount Vernon Cancer Centre in Northwood, Middlesex, is a specialist non-surgical cancer centre run by East and North Hertfordshire NHS Trust, providing radiotherapy, chemotherapy, immunotherapy and brachytherapy for a population spanning north-west London, Hertfordshire and Bedfordshire. Its site was home to the Gray Laboratory, one of the world's leading radiobiology laboratories, and it retains a strong research tradition in radiotherapy trials, including landmark UK breast and prostate radiotherapy fractionation studies, together with the Paul Strickland Scanner Centre for imaging research. Plans to move the centre to a new host and site have been under NHS review.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.enherts-tr.nhs.uk"}],"tags":["nhs-specialist-cancer-centre"],"related":[],"cancers":["colorectal","rectal-cancer","nsclc","lung-cancer"],"sections":[],"technologies":["brachytherapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["radiotherapy","hypofractionation"],"trials":["chart-lung"],"people":["martin-armstrong"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Northwood","country":"GB","lat":51.618,"lng":-0.426,"institutionType":"cancer-center","website":"https://www.enherts-tr.nhs.uk","programs":["Radiotherapy trials","Brachytherapy","Imaging research (Paul Strickland Scanner Centre)"]},{"id":"movember","kind":"institution","name":"Movember","aka":["Movember Foundation"],"tldr":"The moustache-growing men's health charity that has become one of the largest global funders of prostate and testicular cancer research.","summary":"Founded in Melbourne in 2003, Movember raises money each November and funds men's health in three areas: prostate cancer, testicular cancer and mental health and suicide prevention. In cancer it funds global collaborations rather than single labs, including the Global Action Plan programmes on biomarkers, active surveillance (GAP3) and precision medicine, the TrueNTH survivorship programmes, the IRONMAN international registry of advanced prostate cancer, and partnerships with the Prostate Cancer Foundation and Prostate Cancer UK. Movember-funded work has supported PSMA theranostics and tests to distinguish aggressive from indolent disease.","asOf":"2026-09-09","links":[{"label":"Movember","url":"https://movember.com"}],"tags":[],"related":["prostate-cancer-foundation"],"cancers":["prostate"],"sections":["supportive-care"],"technologies":["psma-pet","radioligand-therapy","germline-testing"],"targets":[],"drugs":[],"companies":["anzup"],"institutions":["peter-mac"],"pathways":[],"terms":[],"trials":[],"people":["hofman-michael","andrew-little"],"bottlenecks":["b-overdiagnosis","b-survivorship"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Melbourne","country":"AU","lat":-37.814,"lng":144.963,"institutionType":"consortium","website":"https://movember.com","programs":["Global Action Plan (GAP) research collaborations","IRONMAN registry","TrueNTH survivorship","PCF-Movember partnership"]},{"id":"mascc","kind":"institution","name":"Multinational Association of Supportive Care in Cancer","aka":["MASCC"],"tldr":"The international society for supportive care in cancer, whose antiemetic, mucositis, febrile neutropenia and immunotherapy toxicity guidelines are used worldwide.","summary":"Founded in 1990, MASCC is a multidisciplinary organisation of physicians, nurses, pharmacists and other professionals dedicated to preventing and managing the side effects of cancer and its treatment. Its MASCC/ESMO antiemetic guidelines, the MASCC risk index for febrile neutropenia, mucositis guidelines with ISOO, and guidance on bone health, skin toxicity, cancer-related fatigue, immunotherapy toxicities and survivorship are widely adopted, and it publishes Supportive Care in Cancer. The MASCC annual meeting brings together supportive care researchers with the palliative care and oncology societies, and its study groups cover nutrition and cachexia, geriatrics, psychosocial care, oral care, neurological complications and palliative care.","asOf":"2026-09-09","links":[{"label":"MASCC","url":"https://mascc.org"}],"tags":[],"related":[],"cancers":[],"sections":["supportive-care","nutrition-lifestyle"],"technologies":["scalp-cooling","geriatric-assessment","exercise-oncology","cardio-oncology"],"targets":[],"drugs":[],"companies":[],"institutions":["esmo","isoqol","espen","asco"],"pathways":[],"terms":["irae"],"trials":[],"people":["alexandre-chan"],"bottlenecks":["b-toxicity-qol","b-cachexia-supportive","b-aging-comorbidity"],"keyPapers":[],"journals":["supportive-care-in-cancer"],"dependsOn":[],"notes":[],"city":"Aurora, ON","country":"CA","lat":44.006,"lng":-79.451,"institutionType":"consortium","website":"https://mascc.org","programs":["MASCC/ESMO antiemetic guidelines","MASCC febrile neutropenia risk index","Supportive Care in Cancer journal","Annual meeting and study groups"]},{"id":"musc-hollings","kind":"institution","name":"MUSC Hollings Cancer Center","aka":["Hollings"],"tldr":"South Carolina's only NCI-designated cancer centre, known for tobacco control, colorectal cancer prevention science and lipid signalling research.","summary":"NCI-designated since 2009, Hollings Cancer Center at the Medical University of South Carolina is the state's only NCI centre and covers a catchment with pronounced rural and racial disparities. Director Raymond DuBois's work on COX-2 and prostaglandins in colorectal cancer established a basis for aspirin and NSAID chemoprevention, and the centre's sphingolipid signalling programme (built by Yusuf Hannun and Lina Obeid) is internationally known. Hollings runs statewide tobacco cessation and lung screening programmes, a strong head and neck cancer service, and proton therapy through MUSC Health. It participates in NCI cooperative group trials and runs an early-phase unit.","asOf":"2026-09-09","links":[{"label":"MUSC Hollings Cancer Center","url":"https://hollingscancercenter.musc.edu"},{"label":"Clinical trials","url":"https://hollingscancercenter.musc.edu/research/clinical-trials"}],"tags":[],"related":[],"cancers":["colorectal","head-and-neck","nsclc"],"sections":["prevention"],"technologies":["chemoprevention","proton-therapy","low-dose-ct-screening"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["raymond-dubois"],"bottlenecks":["b-prevention-adoption"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Charleston, SC","country":"US","lat":32.786,"lng":-79.947,"institutionType":"cancer-center","website":"https://hollingscancercenter.musc.edu","nci":"clinical","university":"Medical University of South Carolina","programs":["Colorectal chemoprevention","Tobacco control","Head and neck cancer","Proton therapy"]},{"id":"blokhin-cancer-center","kind":"institution","name":"N. N. Blokhin National Medical Research Center of Oncology","aka":["НМИЦ онкологии им. Н. Н. Блохина","Blokhin Cancer Center","N.N. Blokhin Russian Cancer Research Centre","Российский онкологический научный центр им. Н. Н. Блохина"],"tldr":"Russia's largest cancer centre, in Moscow, made up of five research institutes including a children's oncology institute, and an associate member of the Organisation of European Cancer Institutes.","summary":"The N. N. Blokhin National Medical Research Center of Oncology of the Russian Ministry of Health, on the Kashirskoye Highway in south Moscow, describes itself as the largest oncology clinic in Russia and Europe. It comprises five institutes, among them clinical oncology, paediatric oncology and haematology, and experimental diagnostics and therapy, and serves as the federal reference centre for cancer care and research. It is an associate member of the Organisation of European Cancer Institutes (OECI); its representative on the OECI list is Ivan S. Stilidi.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.ronc.ru"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikipedia (Russian)","url":"https://ru.wikipedia.org/wiki/Национальный_медицинский_исследовательский_центр_онкологии_имени_Н._Н._Блохина"}],"tags":[],"related":["nmrrc-moscow","tatarstan-cancer-center","petrov-institute","rogachev-centre","tomsk-cancer-research-institute","russco"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["ivan-s-stilidi"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Moscow","country":"RU","lat":55.66,"lng":37.645,"institutionType":"cancer-center","website":"https://www.ronc.ru","programs":[]},{"id":"petrov-institute","kind":"institution","name":"N. N. Petrov National Medical Research Centre of Oncology","aka":["НМИЦ онкологии им. Н.Н. Петрова","ФГБУ «Национальный медицинский исследовательский центр онкологии имени Н.Н. Петрова» Минздрава России","Petrov Institute","NMRC of Oncology named after N.N. Petrov"],"tldr":"Russia's oldest cancer institute, founded in Leningrad in 1927 by Nikolai Petrov, now the federal cancer centre for the north-west in the Pesochny suburb of Saint Petersburg.","summary":"The institute's own history page dates its founding to 15 March 1927, when Nikolai Nikolaevich Petrov, the founder of Russian oncology, opened a cancer research institute on the site of the Mechnikov general hospital in Leningrad with 100 beds; its history page records that in 1966 it passed to the USSR Ministry of Health, was given Petrov’s name and opened a 40-bed childhood tumour department, and that it marked its ninetieth anniversary in 2017. Its present official name, from the footer of its own site, is ФГБУ «Национальный медицинский исследовательский центр онкологии имени Н.Н.Петрова» Минздрава России. It now sits at Leningradskaya 68 in Pesochny, north of Saint Petersburg, running surgery, radiotherapy, drug therapy, paediatric oncology, molecular diagnostics and residency training, and publishing the journal Voprosy Onkologii (Вопросы онкологии). It is one of the lead sponsors of cancer trials registered on ClinicalTrials.gov with a Russian site since 2023.","asOf":"2026-09-25","links":[{"label":"Official website","url":"https://www.niioncologii.ru"},{"label":"History of the institute (Russian)","url":"https://www.niioncologii.ru/institute/institutehistory"},{"label":"ClinicalTrials.gov: studies led by the centre","url":"https://clinicaltrials.gov/search?lead=N.N.%20Petrov%20National%20Medical%20Research%20Center%20of%20Oncology"}],"tags":[],"related":["blokhin-cancer-center","nmrrc-moscow"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-barchuk-registry-validity-acta-oncol-2021","paper-barchuk-registry-completeness-bmc-cancer-2023"],"journals":[],"dependsOn":[],"notes":[],"city":"Saint Petersburg","country":"RU","lat":60.128,"lng":30.145,"institutionType":"cancer-center","website":"https://www.niioncologii.ru","programs":["Surgical oncology","Radiotherapy","Paediatric oncology","Molecular diagnostics","Voprosy Onkologii journal"]},{"id":"chu-nantes","kind":"institution","name":"Nantes University Hospital (CHU de Nantes)","aka":["Hôtel-Dieu de Nantes","CHU Nantes","University Hospital Hôtel-Dieu"],"tldr":"The university hospital of Nantes, whose haematology department under Philippe Moreau is one of the two French centres that lead the Intergroupe Francophone du Myélome trials.","summary":"The CHU de Nantes is the university hospital of Nantes in western France; its Hôtel-Dieu site houses the Department of Hematology, led by Philippe Moreau. With Lille, Nantes anchors the Intergroupe Francophone du Myélome, and Moreau was first author of the IKEMA and MAIA-era trials and of the 2022 New England Journal of Medicine report of teclistamab in relapsed myeloma. The Institut de Cancérologie de l'Ouest, the region's dedicated cancer centre, is a separate institution.","asOf":"2026-09-18","links":[{"label":"CHU de Nantes","url":"https://www.chu-nantes.fr"}],"tags":[],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["ico-angers-nantes"],"pathways":[],"terms":[],"trials":[],"people":["philippe-moreau"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Nantes","country":"FR","lat":47.212,"lng":-1.553,"institutionType":"hospital","website":"https://www.chu-nantes.fr","university":"Nantes Université","programs":["Multiple myeloma (IFM)","Haematology","Bispecific antibody trials"]},{"id":"narayana-health","kind":"institution","name":"Narayana Health (Mazumdar Shaw Medical Centre)","aka":["Narayana Hrudayalaya","Mazumdar Shaw Medical Center","Narayana Health City"],"tldr":"Devi Shetty's low-cost hospital network, whose Mazumdar Shaw cancer centre in Bengaluru applies high-volume, low-price surgery and transplant to cancer and hosts India's second CAR-T developer.","summary":"Narayana Health began in 2001 when cardiac surgeon Devi Shetty founded Narayana Hrudayalaya at Bommasandra outside Bengaluru; it grew into a listed group of 24 hospitals and 7 heart centres across India and the Cayman Islands, known for driving procedure costs down through volume and process. Cancer care is concentrated at the Mazumdar Shaw Medical Centre at Narayana Health City, established in 2009 with Biocon founder Kiran Mazumdar-Shaw as a 1,400-bed cancer and multispecialty campus, with large bone marrow transplant, paediatric haematology-oncology, radiation and surgical programmes. The campus is also home to Immuneel Therapeutics, whose CAR-T Qartemi was developed and trialled there.","asOf":"2026-09-10","links":[{"label":"Narayana Health","url":"https://www.narayanahealth.org"}],"tags":[],"related":[],"cancers":["all-leukemia","dlbcl","head-and-neck","breast-hr-positive"],"sections":["cell-therapy","surgery"],"technologies":["car-t","allogeneic-cell-therapy"],"targets":[],"drugs":[],"companies":["immuneel"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["shetty-devi","mazumdar-shaw-kiran"],"bottlenecks":["b-global-access"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Bengaluru","country":"IN","lat":12.815,"lng":77.694,"institutionType":"hospital","website":"https://www.narayanahealth.org","programs":["Mazumdar Shaw Medical Centre","Bone marrow transplant","Paediatric haematology-oncology","Low-cost surgical care"]},{"id":"nkua-athens","kind":"institution","name":"National and Kapodistrian University of Athens, School of Medicine","aka":["NKUA","University of Athens","Alexandra Hospital","Andreas Sygros Hospital"],"tldr":"Greece's oldest university, whose medical school hosts Meletios Dimopoulos's myeloma department at Alexandra Hospital and Alexander Stratigos's dermatology department at Andreas Sygros Hospital.","summary":"The School of Medicine of the National and Kapodistrian University of Athens runs its clinical departments in Athens hospitals. The Department of Clinical Therapeutics at Alexandra Hospital, under Meletios Dimopoulos, is one of the most productive myeloma trial centres in Europe, and the 1st Department of Dermatology-Venereology at Andreas Sygros Hospital, under Alexander Stratigos, led the trial of cemiplimab in advanced basal cell carcinoma and writes the European skin cancer guidelines.","asOf":"2026-09-18","links":[{"label":"NKUA","url":"https://en.uoa.gr"}],"tags":[],"related":[],"cancers":["multiple-myeloma","basal-cell-carcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["saint-savvas-athens"],"pathways":[],"terms":[],"trials":[],"people":["meletios-dimopoulos","alexander-stratigos"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Athens","country":"GR","lat":37.983,"lng":23.727,"institutionType":"university","website":"https://en.uoa.gr","programs":["Multiple myeloma","Dermato-oncology","Clinical therapeutics"]},{"id":"ncc-japan","kind":"institution","name":"National Cancer Center Hospital","aka":[],"tldr":"The National Cancer Center Hospital is Japan's national cancer centre and the leading site for Daiichi Sankyo's DXd ADC trials.","summary":"The National Cancer Center Hospital in Tokyo is Japan's national cancer centre, a government institution ranked thirteenth in the Newsweek/Statista oncology list, with a sister campus at National Cancer Center Hospital East in Kashiwa. Together they run Japan's largest phase 1 programme and the SCRUM-Japan genomic screening network, and they led the early studies of Daiichi Sankyo's DXd antibody-drug conjugates, including trastuzumab deruxtecan and datopotamab deruxtecan, with Noboru Yamamoto, Ken Kato, Kohei Shitara and Kan Yonemori among their investigators. OnCo links the centre to CIRCULATE-Japan and the GALAXY paper, to SPOTLIGHT, to the Japan Clinical Oncology Group and the PMDA, and to the idea of one multiregional trial without bridging studies. Regulatory divergence between regions is the bottleneck its work most often meets. Its ADC programme is the reason to read on.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.ncc.go.jp/en/"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["trastuzumab-deruxtecan","datopotamab-deruxtecan"],"companies":["daiichi-sankyo"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["nakagama-hitoshi","yamamoto-noboru","kohno-takashi","ken-kato","yonemori-kan","shitara-kohei","goto-koichi","yoshino-takayuki","doi-toshihiko","ohe-yuichiro"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Tokyo","country":"JP","lat":35.665,"lng":139.767,"institutionType":"government","website":"https://www.ncc.go.jp/en/","newsweekOncology2026":13,"programs":["Phase 1 ADC trials","SCRUM-Japan","Proton therapy (East)"]},{"id":"ncc-hospital-east","kind":"institution","name":"National Cancer Center Hospital East","aka":["NCCHE","国立がん研究センター東病院"],"tldr":"National Cancer Center Hospital East in Kashiwa is one of the world's most productive trial sites for gastrointestinal, thoracic and head and neck cancer; it runs the SCRUM-Japan genomic screening platform, a large phase 1 unit and one of Japan's first hospital-based proton facilities.","summary":"NCC Hospital East opened in 1992 in Kashiwa as the second hospital of the National Cancer Center and has become one of the most productive trial sites in the world for gastrointestinal, thoracic and head and neck cancer. It hosts the Exploratory Oncology Research and Clinical Trial Center (EPOC), a large phase 1 unit, one of Japan's first hospital-based proton therapy facilities, and the SCRUM-Japan nationwide genomic screening platform (GI-SCREEN, LC-SCRN, MONSTAR-SCREEN, CIRCULATE-Japan) led by Takayuki Yoshino. Kohei Shitara and Toshihiko Doi have led pivotal gastric and oesophageal cancer trials of trastuzumab deruxtecan, zolbetuximab and nivolumab, and Koichi Goto's thoracic group has led ALK, ROS1 and RET programmes. The campus includes the National Cancer Center's photoimmunotherapy and surgical innovation groups.","asOf":"2026-09-09","links":[{"label":"NCC Hospital East","url":"https://www.ncc.go.jp/en/ncce/"},{"label":"SCRUM-Japan","url":"https://www.scrum-japan.ncc.go.jp"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":["gastric","esophageal","colorectal","nsclc","head-and-neck"],"sections":["targeted-therapy","radiation","diagnostics"],"technologies":["proton-therapy","cgp","liquid-biopsy","mrd-testing","photoimmunotherapy","proton-therapy-systems"],"targets":["her2","cldn18-2","ret","alk"],"drugs":["trastuzumab-deruxtecan","nivolumab"],"companies":["jcog"],"institutions":["ncc-japan"],"pathways":[],"terms":["ctdna","mrd"],"trials":[],"people":["yoshino-takayuki","shitara-kohei","doi-toshihiko","goto-koichi"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Kashiwa, Chiba","country":"JP","lat":35.878,"lng":139.935,"institutionType":"cancer-center","website":"https://www.ncc.go.jp/en/ncce/","programs":["SCRUM-Japan and CIRCULATE-Japan","Phase 1 (EPOC)","Gastric and oesophageal cancer trials","Proton therapy","Photoimmunotherapy"]},{"id":"ncc-korea","kind":"institution","name":"National Cancer Center Korea","aka":["NCC Korea","국립암센터"],"tldr":"Korea's government cancer centre, home of the national cancer registry and screening programme and the country's first proton therapy facility.","summary":"The National Cancer Center Korea opened in 2000 in Goyang, north of Seoul, as the state-run hospital, research institute and graduate school for cancer, and it administers the Korea Central Cancer Registry, the National Cancer Screening Program (stomach, liver, colorectal, breast, cervix and lung) and the National Cancer Control Institute. Korea's national gastric cancer endoscopy screening, which it evaluates, is credited with high early-detection rates and falling mortality. The centre opened Korea's first proton therapy centre in 2007, runs one of the country's largest clinical trial programmes, and hosts research on hepatocellular carcinoma, gastric and colorectal cancer, lung cancer screening and cancer survivorship. It also trains cancer-control professionals for the Asia-Pacific region with IARC and WHO.","asOf":"2026-09-09","links":[{"label":"National Cancer Center Korea","url":"https://www.ncc.re.kr"},{"label":"Korea Central Cancer Registry","url":"https://ncc.re.kr/main.ncc?uri=english/sub04_ControlPrograms"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":["cancer-registries-surveillance","stage-shift"],"cancers":["gastric","hcc","colorectal","nsclc","thyroid"],"sections":["early-detection","prevention","radiation"],"technologies":["proton-therapy","ct","mammography","proton-therapy-systems"],"targets":[],"drugs":[],"companies":[],"institutions":["iarc"],"pathways":[],"terms":[],"trials":[],"people":["han-kwang-yang"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Goyang","country":"KR","lat":37.633,"lng":126.832,"institutionType":"cancer-center","website":"https://www.ncc.re.kr","programs":["Korea Central Cancer Registry","National Cancer Screening Program","Proton therapy","Cancer control research"]},{"id":"ncc-china","kind":"institution","name":"National Cancer Center of China","aka":["NCC China","国家癌症中心","National Central Cancer Registry of China"],"tldr":"The National Cancer Center is the body that counts China's cancers, sets national screening and quality programmes and publishes the country's official cancer statistics.","summary":"Established in 2011 and hosted by the Cancer Hospital of the Chinese Academy of Medical Sciences, the National Cancer Center runs the National Central Cancer Registry (more than 700 population-based registries), the Cancer Screening Program in Rural China and urban screening programmes, national quality control for cancer care, and the Journal of the National Cancer Center. Its 2024 report estimated about 4.8 million new cases and 2.6 million deaths in 2022 (age-standardised incidence 201.61 and mortality 96.47 per 100,000), with lung, colorectal, thyroid, liver and stomach cancers making up 57.42% of cases and mortality rates falling about 1.3% a year since 2000.","asOf":"2026-09-10","links":[{"label":"National Cancer Center","url":"https://www.chinancpcn.org.cn/"},{"label":"Han B, Zheng R, Zeng H, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Cent 2024","url":"https://doi.org/10.1016/j.jncc.2024.01.006"}],"tags":["china"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cams-cancer-hospital","nmpa-cde","nhsa","iarc"],"pathways":[],"terms":[],"trials":[],"people":["he-jie"],"bottlenecks":["b-early-detection","b-data-silos"],"keyPapers":["paper-han-j-natl-cancer-cent"],"journals":[],"dependsOn":[],"notes":[],"city":"Beijing","country":"CN","lat":39.87,"lng":116.451,"institutionType":"government","website":"https://www.chinancpcn.org.cn/","programs":["National Central Cancer Registry","Cancer Screening Program in Rural China","National cancer quality control","Journal of the National Cancer Center"]},{"id":"nccs","kind":"institution","name":"National Cancer Centre Singapore","aka":["NCCS","SingHealth Duke-NUS Oncology Academic Clinical Programme"],"tldr":"Singapore's national cancer centre and the largest cancer facility in the country, with a proton centre and leading Asian research in liver and lung cancer genomics.","summary":"The National Cancer Centre Singapore opened in 1999 and moved into a new purpose-built building on the Outram campus in 2023 that houses South-east Asia's first hospital-based proton therapy centre (Goh Cheng Liang Proton Therapy Centre). It treats the majority of Singapore's public-sector cancer patients and, with Duke-NUS Medical School and the Genome Institute of Singapore, has produced influential research on Asian lung cancer in never-smokers, hepatocellular carcinoma and cholangiocarcinoma genomics (including the liver-fluke associated cholangiocarcinoma genome), nasopharyngeal cancer and cancer immunotherapy. NCCS runs the Singapore Translational Cancer Consortium, a large phase 1 unit, and cell therapy programmes with the Singapore Immunology Network, and it coordinates national screening and survivorship initiatives.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/National_Cancer_Centre_Singapore","links":[{"label":"National Cancer Centre Singapore","url":"https://www.nccs.com.sg"},{"label":"Duke-NUS Medical School","url":"https://www.duke-nus.edu.sg"},{"label":"SingHealth","url":"https://www.singhealth.com.sg"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":["nsclc","hcc","cholangiocarcinoma","head-and-neck","colorectal"],"sections":["radiation","diagnostics","cell-therapy"],"technologies":["proton-therapy","wes-wgs","car-t","til-therapy","proton-therapy-systems"],"targets":["egfr","fgfr2","idh"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["mutational-signature"],"trials":[],"people":["goh-cheng-liang","lim-soon-thye","rebecca-dent"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Singapore","country":"SG","lat":1.28,"lng":103.836,"institutionType":"cancer-center","website":"https://www.nccs.com.sg","university":"Duke-NUS Medical School","programs":["Proton therapy","Asian lung and liver cancer genomics","Phase 1 unit","Cholangiocarcinoma research","Cell therapy"]},{"id":"national-cancer-grid","kind":"institution","name":"National Cancer Grid of India","aka":["NCG","NCG India"],"tldr":"A network of more than 360 Indian cancer centres, run from Tata Memorial, that agrees common treatment guidelines, buys cancer drugs together at a fraction of list price and runs shared tumour boards and trials.","summary":"The National Cancer Grid was set up by the Tata Memorial Centre with support from the Department of Atomic Energy to give every Indian patient the same standard of care wherever they are treated. Its secretariat sits at Tata Memorial Hospital, Mumbai, and its membership has grown to a network of more than 360 cancer centres, research institutes, patient groups and charities across India.\n\nThe Grid publishes resource-stratified NCG guidelines, runs virtual tumour boards, an e-learning portal and quality programmes (EQAS and EQUIP), trains oncologists in research methods through the CReDO workshops (more than 250 trained since 2015) and issued India's Choosing Wisely list of low-value practices. Its pooled procurement pilot pooled demand for 40 anticancer drugs from 23 centres worth about 15.6 billion rupees at maximum retail price and cut the bill by about 13.2 billion rupees, with savings of 23% to 99% per drug (median 82%). A national electronic medical record initiative for cancer centres followed in 2025. The NCG is the practical backbone of Indian cancer care and the reason low-cost trial results from Mumbai spread quickly across the country.","asOf":"2026-09-10","links":[{"label":"National Cancer Grid","url":"https://www.ncgindia.org"},{"label":"Pooled procurement initiative (Bull WHO 2023)","url":"https://doi.org/10.2471/BLT.23.289714"},{"label":"EMR initiative (Bull WHO 2025)","url":"https://doi.org/10.2471/BLT.24.292230"},{"label":"The National Cancer Grid of India (2014)","url":"https://doi.org/10.4103/0971-5851.142040"},{"label":"CReDO workshops (Lancet Oncol 2021)","url":"https://doi.org/10.1016/S1470-2045(21)00077-2"}],"tags":[],"related":[],"cancers":[],"sections":["chemotherapy","supportive-care"],"technologies":["global-oncology-access","cancer-registries-surveillance"],"targets":[],"drugs":[],"companies":[],"institutions":["tata-memorial","actrec","aiims-delhi","cancer-institute-adyar","kidwai-memorial-institute-of-oncology","tata-medical-center-kolkata","homi-bhabha-cancer-hospital-varanasi"],"pathways":[],"terms":[],"trials":[],"people":["pramesh-c-s","gupta-sudeep","badwe-rajendra"],"bottlenecks":["b-drug-pricing","b-global-access","b-care-fragmentation","b-data-silos","b-workforce"],"keyPapers":["paper-pramesh-ncg-pooled-procurement-2023","paper-ranganathan-lancet-oncol","paper-pramesh-bull-world-health-organ","paper-pramesh-indian-j-med-paediatr-oncol"],"journals":[],"dependsOn":[],"notes":[],"city":"Mumbai","country":"IN","lat":19.005,"lng":72.843,"institutionType":"consortium","website":"https://www.ncgindia.org","programs":["NCG treatment guidelines","Pooled drug procurement","Virtual tumour boards","CReDO research methods workshops","Choosing Wisely India","Cancer EMR initiative"]},{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","aka":[],"tldr":"The NCI is the US government's cancer research agency, spending ~$7B a year and running the Cancer Centers Program, TCGA, and Rosenberg's cell therapy lab.","summary":"The National Cancer Institute, part of the US National Institutes of Health in Bethesda, is the US government's cancer research agency; it runs the Cancer Centers Program that designates seventy-four centres, The Cancer Genome Atlas and its Genomic Data Commons, the RAS Initiative, the SEER registry and the cooperative groups NRG, SWOG, Alliance and ECOG-ACRIN. Its Surgery Branch under Rosenberg developed tumour-infiltrating lymphocyte therapy and neoantigen TCR-T, and its Pediatric MATCH and myeloMATCH trials, its CPTAC and PDQ resources and the JNCI journal all sit in OnCo. It is linked to bottlenecks on data silos, hidden failures, funding that follows fashion and slow translation, and to ideas for a national non-profit CRO and perpetual platform trials. Whether it can fund infrastructure rather than projects is the standing question. Douglas R. Lowy is among the people listed. The institutions linked below are the NCI-designated cancer centres in OnCo, its intramural Center for Cancer Research and the Frederick National Laboratory; the trials are those whose sponsor field names the NCI.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.cancer.gov"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["til-therapy","tcr-t"],"targets":[],"drugs":[],"companies":[],"institutions":["nci-ccr","frederick-national-lab","arizona-cancer-center","baylor-duncan","cancer-center-at-illinois","case-ccc","city-of-hope","cleveland-clinic","cold-spring-harbor","colorado-cancer-center","columbia-hicc","dana-farber","dartmouth-cancer-center","duke-cancer-institute","emory-winship","fox-chase","fred-hutch","georgetown-lombardi","hawaii-cancer-center","huntsman","iowa-holden","iu-simon","jackson-laboratory","jefferson-kimmel","johns-hopkins","karmanos","kentucky-markey","ku-cancer-center","maryland-greenebaum","mayo-clinic","mayo-clinic-arizona","mayo-clinic-florida","mays-cancer-center","md-anderson","mgh","michigan-rogel","minnesota-masonic","mit-koch","moffitt","montefiore-einstein","mount-sinai","mskcc","musc-hollings","nebraska-buffett","northwestern-lurie","nyu-perlmutter","ohsu-knight","oneal-uab","osu-james","penn-abramson","purdue-cancer-research","roswell-park","rutgers-cinj","salk-institute","sanford-burnham-prebys","st-jude","stanford","stephenson-oklahoma","sylvester-miami","uc-davis-cancer","uchicago-cancer","uci-chao","ucla-jonsson","ucsd-moores","ucsf","uf-health-cancer-center","unc-lineberger","unm-cancer-center","upmc-hillman","usc-norris","utsw-simmons","uva-cancer-center","uw-carbone","vanderbilt-ingram","vcu-massey","wake-forest-cancer","wilmot","wistar","wustl-siteman","yale-cancer-center","yale-school-of-medicine"],"pathways":[],"terms":[],"trials":["alchemist","ccss","combomatch","dart-s1609","lung-map","lung-map-s1400i","lung-map-s1800a","myelomatch","pediatric-match","nci-match","nlst-nelson","nci-anetumab-pembrolizumab-mpm","zen-3694-abemaciclib-nut","zen-3694-platinum-nut"],"people":["anthony-letai","mark-schiffman","brigitte-widemann","douglas-lowy","james-gulley","louis-staudt","nirali-shah","raffit-hassan","steven-rosenberg","frank-mccormick","wyndham-wilson","senthil-muthuswamy","emil-frei","emil-freireich"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Bethesda, MD","country":"US","lat":39.003,"lng":-77.104,"institutionType":"government","website":"https://www.cancer.gov","programs":["Cancer Centers Program (74 centres)","TCGA / GDC","Cooperative groups","Surgery Branch cell therapy"]},{"id":"nci-ukraine","kind":"institution","name":"National Cancer Institute of Ukraine","aka":["Національний інститут раку","National Cancer Institute, Kyiv"],"tldr":"Ukraine's national cancer institute in Kyiv, the country's main specialist cancer hospital and research centre, and an associate member of the Organisation of European Cancer Institutes.","summary":"The National Cancer Institute of Ukraine (Національний інститут раку) in Kyiv is the country's leading specialist cancer hospital and research institute under the Ministry of Health, providing surgery, radiotherapy and drug treatment and training oncologists for the national network. It is an associate member of the Organisation of European Cancer Institutes (OECI); its representative on the OECI list is Olena Yefimenko.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://unci.org.ua/"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":["kavetsky-institute-kyiv"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["olena-yefimenko"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Kyiv","country":"UA","lat":50.45,"lng":30.524,"institutionType":"cancer-center","website":"https://unci.org.ua/","programs":[]},{"id":"nci-cairo","kind":"institution","name":"National Cancer Institute, Cairo University","aka":["NCI Cairo","NCI Egypt","المعهد القومي للأورام"],"tldr":"Egypt's national cancer institute and the largest cancer hospital in Africa and the Arab world, treating patients from across the region since 1969.","summary":"The National Cancer Institute of Cairo University was established in 1969 and is the largest specialised cancer institute in Egypt, Africa and the Middle East, providing surgical, medical, radiation and paediatric oncology, haematology and bone marrow transplant, pathology and nuclear medicine, and training the majority of Egypt's oncologists through Cairo University. It hosts a large research programme and tumour registry, contributes to Egypt's national cancer registry and to studies of hepatocellular carcinoma driven by the country's hepatitis C epidemic, schistosomiasis-associated bladder cancer, breast cancer and paediatric leukaemia, and it participates in international multicentre trials and in regional cancer control initiatives with the WHO Eastern Mediterranean office.","asOf":"2026-09-09","links":[{"label":"NCI Cairo University","url":"https://nci.cu.edu.eg"},{"label":"Cairo University","url":"https://cu.edu.eg"}],"tags":[],"related":["global-oncology-access","cancer-registries-surveillance"],"cancers":["hcc","urothelial","breast-hr-positive","all-leukemia","dlbcl"],"sections":["chemotherapy","radiation"],"technologies":["allogeneic-cell-therapy","imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["mohamed-abdel-moaty-samra","sherif-abouel-naga"],"bottlenecks":[],"keyPapers":[],"journals":["journal-of-the-egyptian-national-cancer-institute"],"dependsOn":[],"notes":[],"city":"Cairo","country":"EG","lat":30.019,"lng":31.229,"institutionType":"cancer-center","website":"https://nci.cu.edu.eg","university":"Cairo University","programs":["Largest cancer institute in Africa and the Arab world","Hepatocellular and bladder cancer research","Paediatric oncology and transplant","Oncology training"]},{"id":"nci-vilnius","kind":"institution","name":"National Cancer Institute, Lithuania","aka":["Nacionalinis vėžio institutas","NVI"],"tldr":"Lithuania's dedicated cancer hospital and research institute in Vilnius, accredited by OECI as a Cancer Centre.","summary":"The National Cancer Institute (Nacionalinis vėžio institutas) is Lithuania's specialised state cancer treatment and research institution, combining a cancer hospital with research laboratories in tumour biology, immunology and biobanking. It provides surgical oncology, radiotherapy, medical oncology and nuclear medicine, runs the country's largest oncology clinical trials portfolio, and works with Vilnius University on translational research and training. It is accredited by the Organisation of European Cancer Institutes as a Cancer Centre and coordinates national screening and cancer control programmes with the Ministry of Health.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://nvi.lt"}],"tags":["oeci-accredited","oeci-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["valdas-peceliunas"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Vilnius","country":"LT","lat":54.717,"lng":25.285,"institutionType":"cancer-center","website":"https://nvi.lt","programs":["Cancer hospital and research institute","Radiotherapy","Biobank and tumour immunology"]},{"id":"icmr-ncrp","kind":"institution","name":"National Cancer Registry Programme (ICMR-NINE, Bengaluru)","aka":["NCRP","ICMR-NCDIR","National Centre for Disease Informatics and Research","ICMR-National Institute of Noncommunicable Disease Epidemiology"],"tldr":"The programme that counts cancer in India: population and hospital registries whose reports give the country its official estimates of new cases, leading cancers and stage at diagnosis.","summary":"The ICMR National Cancer Registry Programme has run since 1982, coordinated from Bengaluru by what was the National Centre for Disease Informatics and Research and is now the ICMR-National Institute of Noncommunicable Disease Epidemiology (ICMR-NINE). Its 2020 report drew on 28 population-based and 58 hospital-based registries covering 2012-2016 (667,666 cases) and projected 1,392,179 new cancers for 2020, with breast, lung, mouth, cervix and tongue the five leading sites; a 2022 update estimated 1,461,427 cases (crude rate 100.4 per 100,000) and a 12.8% rise by 2025, and put lifetime risk at about one in nine.\n\nThe registries also show where India is different: most breast (57%), cervical (60%) and head and neck (66.6%) cancers present at a locally advanced stage, the north-east has the highest incidence rates in the country, and tobacco-related cancers dominate in men. These numbers drive the National Cancer Grid's priorities and the screening and tobacco-control programmes.","asOf":"2026-09-10","links":[{"label":"ICMR-NINE (formerly NCDIR)","url":"https://icmrnine.org"},{"label":"Cancer Statistics 2020 (JCO Glob Oncol)","url":"https://doi.org/10.1200/GO.20.00122"},{"label":"Cancer incidence estimates 2022 and projection 2025 (IJMR)","url":"https://doi.org/10.4103/ijmr.ijmr_1821_22"},{"label":"ICMR-NCDIR, Report of National Cancer Registry Programme 2020 (2012-2016), Chapter 5, Fig. 5.12: gall bladder (C23-C24), comparison of age-adjusted incidence rates of 28 PBCRs","url":"https://ncdirindia.org/All_Reports/Report_2020/resources/Chapter5ComparisonofcancerincidenceandpatternsofallPopulationBasedCancerRegistries.pdf"}],"tags":[],"related":[],"cancers":["head-and-neck","cervical","breast-hr-positive","nsclc","gallbladder"],"sections":["prevention","ai-computation"],"technologies":["cancer-registries-surveillance"],"targets":[],"drugs":[],"companies":[],"institutions":["icmr","iarc","kidwai-memorial-institute-of-oncology","cancer-institute-adyar"],"pathways":[],"terms":[],"trials":[],"people":["mathur-prashant"],"bottlenecks":["b-data-silos","b-early-detection"],"keyPapers":["paper-mathur-ncrp-cancer-statistics-2020"],"journals":[],"dependsOn":[],"notes":[],"city":"Bengaluru","country":"IN","lat":12.972,"lng":77.594,"institutionType":"research-institute","website":"https://icmrnine.org","programs":["Population-based cancer registries","Hospital-based cancer registries","National cancer estimates and projections","Stage-at-diagnosis and survival studies"]},{"id":"ncbs","kind":"institution","name":"National Centre for Biological Sciences","aka":["NCBS","NCBS-TIFR","Bangalore Life Science Cluster"],"tldr":"A basic biology institute of the Department of Atomic Energy in Bengaluru whose cell signalling, genetics and imaging groups underpin Indian cancer research, on a shared campus with inStem and C-CAMP.","summary":"The National Centre for Biological Sciences was founded in 1992 as a centre of the Tata Institute of Fundamental Research under the Department of Atomic Energy, the same department that runs Tata Memorial Centre. Its research spans biochemistry, biophysics, cellular organisation and signalling, genetics and development, and theory and modelling, with groups working on cell polarity, membrane trafficking, DNA repair and growth control that bear directly on cancer biology. NCBS anchors the Bangalore Life Science Cluster with the Institute for Stem Cell Science and Regenerative Medicine (inStem) and the Centre for Cellular and Molecular Platforms (C-CAMP), sharing imaging, genomics and animal facilities and a joint graduate programme.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/National_Centre_for_Biological_Sciences","links":[{"label":"NCBS","url":"https://www.ncbs.res.in"}],"tags":[],"related":[],"cancers":[],"sections":["drug-discovery"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["instem","iisc","tata-memorial"],"pathways":[],"terms":[],"trials":[],"people":["ls-shashidhara"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Bengaluru","country":"IN","lat":13.071,"lng":77.58,"institutionType":"research-institute","website":"https://www.ncbs.res.in","programs":["Cell signalling and growth control","Genetics and development","Bangalore Life Science Cluster core facilities"]},{"id":"nccn-org","kind":"institution","name":"National Comprehensive Cancer Network (NCCN)","aka":[],"tldr":"The NCCN is an alliance of 33 US cancer centres whose guidelines decide, in practice, what US oncologists do and what insurers pay for.","summary":"The National Comprehensive Cancer Network, based in Plymouth Meeting, Pennsylvania, is an alliance of thirty-three US cancer centres founded in 1995, including Memorial Sloan Kettering, MD Anderson and Dana-Farber, whose guidelines decide in practice what US oncologists do and what insurers pay for. It publishes the NCCN Clinical Practice Guidelines in Oncology, more than eighty guidelines updated continuously, alongside patient guidelines and the Oncology Research Program; the guidelines have a separate OnCo record. OnCo connects it to the standard of care term and to bottlenecks on fragmented care, slow translation and prices, and to the idea of living guidelines published as computable rules. Whether guidelines written by centres can stay independent of the drugs those centres test is the fair question. Its programmes are listed below.","asOf":"2026-09-06","links":[{"label":"Official website","url":"https://www.nccn.org"}],"tags":[],"related":["nccn"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mskcc","md-anderson","dana-farber"],"pathways":[],"terms":["standard-of-care"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Plymouth Meeting, PA","country":"US","lat":40.102,"lng":-75.274,"institutionType":"consortium","website":"https://www.nccn.org","programs":["NCCN Guidelines","Patient guidelines","Oncology Research Program"]},{"id":"nha-pmjay","kind":"institution","name":"National Health Authority (Ayushman Bharat PM-JAY)","aka":["NHA","PM-JAY","Ayushman Bharat","Pradhan Mantri Jan Arogya Yojana"],"tldr":"The agency that runs India's public health insurance for the poorest 40% of the population, which pays for cancer surgery, chemotherapy and radiotherapy up to a yearly limit per family.","summary":"Ayushman Bharat Pradhan Mantri Jan Arogya Yojana was launched on 23 September 2018 and is administered by the National Health Authority with state health agencies. It offers a cashless cover of 5 lakh rupees per family per year for secondary and tertiary hospital care to roughly the poorest 40% of Indians (the original target was about 10 crore households, around 50 crore people), and in September 2024 was extended to everyone aged 70 and over regardless of income. Oncology packages (surgery, chemotherapy, radiotherapy and supportive care) are among the most used tertiary benefits, and public and empanelled private cancer hospitals, including the Tata Memorial units, treat PM-JAY patients.\n\nEvidence so far: a 2025 study of 6,695 cancer patients at seven centres in six states found that PM-JAY enrolment was associated with a large improvement in starting treatment within 30 days of diagnosis, and that patients diagnosed after 2018 had 36% higher odds of timely treatment than those diagnosed earlier. Gaps remain: outpatient care, most oral drugs and diagnostics are outside the cover, and package rates for newer drugs are low.","asOf":"2026-09-10","links":[{"label":"National Health Authority: PM-JAY","url":"https://nha.gov.in/PM-JAY"},{"label":"Timely cancer treatment initiation and PM-JAY (Lancet Reg Health SE Asia 2025)","url":"https://doi.org/10.1016/j.lansea.2024.100514"}],"tags":[],"related":[],"cancers":[],"sections":["supportive-care"],"technologies":["global-oncology-access"],"targets":[],"drugs":[],"companies":[],"institutions":["tata-memorial","national-cancer-grid","aiims-network"],"pathways":[],"terms":[],"trials":[],"people":["sunil-kumar-barnwal"],"bottlenecks":["b-global-access","b-drug-pricing"],"keyPapers":["paper-halder-lancet-reg-health-southeast-asia"],"journals":[],"dependsOn":[],"notes":[],"city":"New Delhi","country":"IN","lat":28.628,"lng":77.219,"institutionType":"government","website":"https://nha.gov.in/PM-JAY","programs":["PM-JAY hospital insurance","Oncology benefit packages","Empanelment of cancer hospitals","Health and Wellness Centres (screening)"]},{"id":"nhsa","kind":"institution","name":"National Healthcare Security Administration","aka":["NHSA","国家医疗保障局"],"tldr":"The NHSA runs China's public health insurance and negotiates once a year which new cancer drugs are reimbursed, and at what price, through the National Reimbursement Drug List.","summary":"Created in 2018 to merge the urban employee, urban resident and rural insurance schemes, the NHSA administers basic medical insurance for more than 1.3 billion people and the National Reimbursement Drug List (NRDL). Since 2017 (15 targeted anticancer drugs, average 48.9% cut in cost per defined daily dose) and the dedicated 2018 oncology round (17 drugs), it has run annual price negotiations in which manufacturers accept steep discounts, typically more than half, for national reimbursement; renewals are renegotiated and a dual-channel policy (2021) lets designated pharmacies dispense listed drugs when hospitals do not stock them. It also runs volume-based procurement of generics and the DRG payment reform.","asOf":"2026-09-10","links":[{"label":"NHSA","url":"https://www.nhsa.gov.cn/"},{"label":"Zhang Y, et al. The impacts of government reimbursement negotiation on targeted anticancer medication price, volume and spending in China. BMJ Glob Health 2021","url":"https://doi.org/10.1136/bmjgh-2021-006196"},{"label":"Cai L, et al. Impact of the national drug price negotiation policy on the utilization, cost, and accessibility of anticancer medicines in China. J Glob Health 2022","url":"https://doi.org/10.7189/jogh.12.11016"}],"tags":["china"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nmpa-cde","nice","ncc-china"],"pathways":[],"terms":["hta","financial-toxicity"],"trials":[],"people":[],"bottlenecks":["b-drug-pricing","b-global-access"],"keyPapers":["paper-zhang-bmj-glob-health","paper-cai-j-glob-health"],"journals":[],"dependsOn":[],"notes":[],"city":"Beijing","country":"CN","lat":39.904,"lng":116.407,"institutionType":"government","website":"https://www.nhsa.gov.cn/","programs":["National Reimbursement Drug List annual negotiation","Dual-channel pharmacy access for negotiated drugs","Volume-based procurement","DRG/DIP payment reform"]},{"id":"nice","kind":"institution","name":"National Institute for Health and Care Excellence","aka":["NICE"],"tldr":"England's health technology assessment body, which decides whether the NHS should pay for each new cancer drug on cost per quality-adjusted life year and runs the Cancer Drugs Fund.","summary":"Established in 1999, NICE appraises new medicines for the NHS in England (and by adoption Wales and Northern Ireland) and issues clinical guidelines and quality standards. Its technology appraisals judge cost-effectiveness against a threshold of £25,000 to £35,000 per QALY, raised from £20,000 to £30,000 by a government direction that took effect on 2 April 2026, with a higher weight for severe conditions, and its decisions determine whether patients in England can access new cancer drugs on the NHS. The Cancer Drugs Fund, reformed in 2016, provides managed access to promising drugs while further evidence is collected, and NICE has pioneered the use of real-world data from the fund in re-appraisal. NICE guidance is influential in HTA globally, and it partners with the MHRA on the Innovative Licensing and Access Pathway.","asOf":"2026-09-09","links":[{"label":"NICE","url":"https://www.nice.org.uk"},{"label":"Cancer guidance","url":"https://www.nice.org.uk/guidance/conditions-and-diseases/cancer"}],"tags":[],"related":["nice-guidance","src-nice-ta"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mhra","smc","cruk","macmillan-cancer-support","ema","royal-marsden"],"pathways":[],"terms":["real-world-evidence","os","pfs","hazard-ratio"],"trials":[],"people":["jonathan-benger"],"bottlenecks":["b-drug-pricing","b-real-world-evidence","b-global-access"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"London","country":"GB","lat":51.521,"lng":-0.083,"institutionType":"government","website":"https://www.nice.org.uk","programs":["Technology appraisals (cost per QALY)","Cancer Drugs Fund managed access","Clinical guidelines (NG series)","Innovative Licensing and Access Pathway"]},{"id":"nicrh-dhaka","kind":"institution","name":"National Institute of Cancer Research and Hospital","aka":["NICRH","National Institute of Cancer Research & Hospital, Mohakhali"],"tldr":"The National Institute of Cancer Research and Hospital in Dhaka is Bangladesh's apex public cancer institute; it runs the national hospital-based cancer registry and trains oncologists for a country of around 170 million people with limited radiotherapy capacity.","summary":"The National Institute of Cancer Research and Hospital in Mohakhali, Dhaka, is Bangladesh's apex public cancer institute under the Directorate General of Health Services. It provides surgical oncology, medical oncology, radiotherapy, paediatric oncology, nuclear medicine and palliative care for a country of around 170 million people with very limited radiotherapy capacity, runs the national hospital-based cancer registry, and trains oncologists through postgraduate courses under Bangabandhu Sheikh Mujib Medical University. The government is expanding the institute and building divisional cancer centres to relieve pressure on Dhaka.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://nicrh.gov.bd"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["radiotherapy","palliative-treatment"],"trials":[],"people":["mostafa-aziz-sumon"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Dhaka","country":"BD","lat":23.777,"lng":90.4,"institutionType":"cancer-center","website":"https://nicrh.gov.bd","programs":["National cancer institute","Radiotherapy","Hospital-based cancer registry","Postgraduate training"]},{"id":"nio-gliwice","kind":"institution","name":"National Institute of Oncology, Gliwice Branch","aka":["Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie, Oddział w Gliwicach","Oncology Center Gliwice","Centrum Onkologii Gliwice"],"tldr":"The Gliwice branch of Poland's Maria Skłodowska-Curie National Institute of Oncology, a large cancer hospital and research centre in Silesia founded in 1947, listed by the Organisation of European Cancer Institutes as a linked institution.","summary":"The Gliwice branch of the Maria Skłodowska-Curie National Institute of Oncology (Narodowy Instytut Onkologii, Oddział w Gliwicach) is a cancer hospital and research centre in Upper Silesia, founded in 1947, with radiotherapy, nuclear medicine, surgery and clinical oncology departments and a large research programme. The Organisation of European Cancer Institutes (OECI) lists it as a linked institution of the Warsaw institute.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://gliwice.nio.gov.pl/"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q9186375"}],"tags":[],"related":["nio-warsaw"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Gliwice","country":"PL","lat":50.303,"lng":18.664,"institutionType":"cancer-center","website":"https://gliwice.nio.gov.pl/","programs":[]},{"id":"noi-budapest","kind":"institution","name":"National Institute of Oncology, Hungary","aka":["Országos Onkológiai Intézet","OOI","National Tumour Biology Laboratory"],"tldr":"Hungary's national cancer institute, home to the national cancer registry and a leading breast brachytherapy programme.","summary":"The National Institute of Oncology in Budapest, founded in 1936, is Hungary's national cancer hospital and research institute and the seat of the Hungarian National Cancer Registry. Under Csaba Polgár, a radiation oncologist known for accelerated partial breast irradiation and the GEC-ESTRO breast brachytherapy trials, the institute coordinates the national cancer control programme and the National Tumour Biology Laboratory. It provides surgical, medical and radiation oncology, haematology, nuclear medicine and pathology for the whole country, hosts a molecular tumour board and an increasing number of international trials, and is OECI-accredited. It collaborates closely with Semmelweis University and the Central and Eastern European oncology groups.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.onkol.hu"},{"label":"Hungarian National Cancer Registry","url":"https://www.onkol.hu/nemzeti-rakregiszter"}],"tags":[],"related":[],"cancers":["breast-hr-positive","melanoma","colorectal","head-and-neck"],"sections":["radiation"],"technologies":["brachytherapy","imrt-igrt","cgp"],"targets":[],"drugs":[],"companies":[],"institutions":["oeci","nio-warsaw"],"pathways":[],"terms":[],"trials":[],"people":["magdolna-dank"],"bottlenecks":["b-global-access"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Budapest","country":"HU","lat":47.497,"lng":19.012,"institutionType":"cancer-center","website":"https://www.onkol.hu","university":"Semmelweis Egyetem","programs":["National cancer registry","Breast brachytherapy (GEC-ESTRO)","National Tumour Biology Laboratory","Molecular tumour board"]},{"id":"koranyi-institute-budapest","kind":"institution","name":"National Korányi Institute for Pulmonology","aka":["Országos Korányi Pulmonológiai Intézet","Korányi Institute"],"tldr":"Hungary's national institute for lung disease in Budapest, the country's main centre for lung cancer diagnosis and treatment, and a full member of the Organisation of European Cancer Institutes.","summary":"The National Korányi Institute for Pulmonology (Országos Korányi Pulmonológiai Intézet) in the Buda hills of Budapest is Hungary's national institute for respiratory medicine and its main centre for lung cancer, covering bronchoscopy, thoracic surgery, oncology and radiotherapy. It is a full member of the Organisation of European Cancer Institutes (OECI); its representative on the OECI list is Krisztina Bogos.","asOf":"2026-09-09","links":[{"label":"Official website","url":"http://www.koranyi.hu"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q30282217"}],"tags":[],"related":["noi-budapest"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["krisztina-bogos"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Budapest","country":"HU","lat":47.52,"lng":18.947,"institutionType":"hospital","website":"http://www.koranyi.hu","programs":[]},{"id":"nmpa-cde","kind":"institution","name":"National Medical Products Administration / Center for Drug Evaluation","aka":["NMPA","CDE","CFDA","China FDA"],"tldr":"China's drug regulator and its review centre, whose reforms since 2015 turned China into the world's second-largest source of new cancer drugs and a leader in ADCs and bispecifics.","summary":"The National Medical Products Administration (formerly CFDA) and its Center for Drug Evaluation regulate medicines in China. Reforms beginning in 2015 cleared a backlog of applications, accepted overseas clinical data, introduced breakthrough, conditional and priority review pathways, and brought China into ICH in 2017, cutting approval times and enabling domestic companies to develop PD-1 antibodies, antibody-drug conjugates, bispecifics and CAR-T at pace. The CDE publishes technical guidelines including those on single-arm trials and oncology endpoints, and its decisions on domestic PD-1s, ivonescimab and Chinese ADCs are followed closely by global companies licensing Chinese assets. Reimbursement is decided separately through the National Reimbursement Drug List negotiations.","asOf":"2026-09-09","links":[{"label":"CDE","url":"https://www.cde.org.cn"},{"label":"NMPA","url":"https://www.nmpa.gov.cn"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["adc","bispecific-antibody","car-t"],"targets":[],"drugs":["ivonescimab","disitamab-vedotin"],"companies":["akeso","beone","kelun-biotech"],"institutions":["csco","cams-cancer-hospital","sysucc","fuscc","fda-oce"],"pathways":[],"terms":[],"trials":[],"people":["huang-guo"],"bottlenecks":["b-regulatory-fragmentation","b-trial-diversity"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Beijing","country":"CN","lat":39.904,"lng":116.407,"institutionType":"government","website":"https://www.cde.org.cn","programs":["Breakthrough, conditional and priority review pathways","ICH implementation and acceptance of overseas data","Oncology endpoint and single-arm trial guidance","Cell and gene therapy regulation"]},{"id":"nmrrc-moscow","kind":"institution","name":"National Medical Research Radiological Centre (NMRRC)","aka":["Национальный медицинский исследовательский центр радиологии","НМИЦ радиологии","Herzen Moscow Oncology Research Institute"],"tldr":"Russia's federal radiology and oncology research centre, headquartered in Moscow with the Herzen institute and a branch in Obninsk, and an associate member of the Organisation of European Cancer Institutes.","summary":"The National Medical Research Radiological Centre (NMRRC) of the Russian Ministry of Health groups the P. A. Herzen Moscow Oncology Research Institute, the Medical Radiological Research Centre in Obninsk and the Lopatkin urology institute. It is an associate member of the Organisation of European Cancer Institutes (OECI).","asOf":"2026-09-09","links":[{"label":"Official website","url":"http://www.mnioi.nmicr.ru"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q110319413"}],"tags":[],"related":["blokhin-cancer-center","petrov-institute","russco"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Moscow","country":"RU","lat":55.756,"lng":37.617,"institutionType":"research-institute","website":"http://www.mnioi.nmicr.ru","programs":[]},{"id":"ntuh","kind":"institution","name":"National Taiwan University Hospital","aka":["NTUH","臺大醫院","National Taiwan University Cancer Center"],"tldr":"Taiwan's leading academic hospital and the birthplace of the hepatitis B vaccination programme that cut childhood liver cancer, with a new dedicated cancer centre.","summary":"NTUH, founded in 1895, is the teaching hospital of National Taiwan University College of Medicine and opened the National Taiwan University Cancer Center in 2019 with proton therapy. NTU investigators led the world's first national hepatitis B vaccination programme and the epidemiological studies (Ding-Shinn Chen, Mei-Hwei Chang) demonstrating its effect on hepatocellular carcinoma incidence, and its liver, lung (James Chih-Hsin Yang's EGFR trials including LUX-Lung and FLAURA), breast (Ann-Lii Cheng, Chiun-Shen Huang) and haematology groups are among Asia's most cited. Pei-Jer Chen and Ann-Lii Cheng have led global HCC trials of sorafenib, lenvatinib and atezolizumab-bevacizumab. The hospital runs Taiwan's largest cell therapy and transplant programmes and an early-phase unit.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/National_Taiwan_University_Hospital","links":[{"label":"NTUH","url":"https://www.ntuh.gov.tw"},{"label":"NTU Cancer Center","url":"https://www.ntucc.gov.tw"},{"label":"NTU College of Medicine","url":"https://www.mc.ntu.edu.tw"}],"tags":[],"related":[],"cancers":["hcc","nsclc","breast-her2-positive","aml","colorectal"],"sections":["prevention","targeted-therapy","radiation"],"technologies":["proton-therapy","kinase-inhibitors","hpv-vaccine"],"targets":["egfr","vegf","pdl1"],"drugs":["osimertinib","afatinib","atezolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["chong-jen-yu","ann-lii-cheng"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Taipei","country":"TW","lat":25.041,"lng":121.519,"institutionType":"hospital","website":"https://www.ntuh.gov.tw","university":"National Taiwan University","programs":["Hepatitis B and liver cancer","EGFR-mutant lung cancer trials","Proton therapy (NTU Cancer Center)","Breast cancer","Haematology"]},{"id":"nuh-ncis","kind":"institution","name":"National University Hospital / National University Cancer Institute, Singapore","aka":["NCIS","NUH","NUS Yong Loo Lin School of Medicine","Cancer Science Institute of Singapore"],"tldr":"Singapore's university hospital cancer institute, paired with the Cancer Science Institute of Singapore and known for gastric cancer, haematology and drug development research.","summary":"The National University Cancer Institute, Singapore (NCIS) is the cancer arm of the National University Hospital and the National University Health System, working alongside the Cancer Science Institute of Singapore, a research centre of excellence founded in 2008 that has produced leading work on gastric cancer genomics (Patrick Tan), leukaemia biology, RNA editing and cancer epigenetics. NCIS runs Singapore's largest haematology and stem cell transplant programme, a phase 1 unit with a long record of first-in-human trials, and genomic and pharmacogenomic research on Asian populations (Goh Boon Cher, Soo Ross). The Yong Loo Lin School of Medicine's Saw Swee Hock School of Public Health contributes to the Singapore Chinese Health Study and cancer epidemiology. Patients have access to CAR-T, transplant, robotic surgery and trials across all major tumour types.","asOf":"2026-09-09","links":[{"label":"NCIS","url":"https://www.ncis.com.sg"},{"label":"Cancer Science Institute of Singapore","url":"https://www.csi.nus.edu.sg"},{"label":"NUS Medicine","url":"https://medicine.nus.edu.sg"}],"tags":[],"related":[],"cancers":["gastric","aml","dlbcl","nsclc","breast-hr-positive"],"sections":["drug-discovery","cell-therapy","diagnostics"],"technologies":["car-t","wes-wgs","epigenetic-drugs","robotic-surgery"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["chee-cheng-ean","goh-boon-cher","jimmy-so"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Singapore","country":"SG","lat":1.294,"lng":103.783,"institutionType":"hospital","website":"https://www.ncis.com.sg","university":"National University of Singapore","programs":["Cancer Science Institute of Singapore","Gastric cancer genomics","Haematology and transplant","Phase 1 drug development","Cancer epidemiology"]},{"id":"nngm","kind":"institution","name":"nationales Netzwerk Genomische Medizin Lungenkrebs","aka":["nNGM","Network Genomic Medicine","NGM Cologne"],"tldr":"The German network that gets comprehensive molecular testing to lung cancer patients anywhere in the country, paid for by selective contracts with 66 sickness funds rather than by waiting for the national benefits catalogue.","summary":"The nationale Netzwerk Genomische Medizin Lungenkrebs grew out of the Cologne Network Genomic Medicine, which from 2012 ran comprehensive molecular pathology for referring hospitals on a single diagnostic platform at University Hospital Cologne under Jürgen Wolf and Reinhard Büttner. Deutsche Krebshilfe rolled the model out nationally with one of its largest single grants from 1 April 2018. The network lists 29 centres and more than 500 partner hospitals and specialist practices, and reports on the actionable alterations in non-small-cell lung cancer: KRAS, EGFR, ALK, BRAF, MET, RET, ROS1, HER2 and NTRK.\n\nThe financing is the distinctive part. Testing and a second opinion are paid for under selective contracts for besondere Versorgung under section 140a SGB V, which expressly permit terms departing from the ordinary reimbursement rules; 66 cooperating sickness funds covering 94.79 percent of patients had signed as at June 2025, with contracts dating from 2019. A historical cohort linking the nNGM database to AOK claims found median overall survival of 10.5 months against 8.7 for patients treated outside the network (hazard ratio 0.84) and more first-line use of approved targeted drugs; it was funded by the insurers themselves. Coverage is uneven geographically: 668 German hospitals treating 26 percent of lung cancer cases belong to no network at all.","asOf":"2026-09-25","links":[{"label":"nNGM Lungenkrebs","url":"https://www.nngm.de"},{"label":"Cooperating sickness funds","url":"https://nngm.de/ueber-das-nngm/kooperationskrankenkassen/"},{"label":"Kästner 2024, outcomes (Lancet Reg Health Eur)","url":"https://doi.org/10.1016/j.lanepe.2023.100788"},{"label":"Büttner 2019, the Cologne model (Der Pathologe)","url":"https://doi.org/10.1007/s00292-019-0605-4"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["ngs","genomic-profiling"],"targets":["egfr","alk","kras","met","ret","ros1"],"drugs":[],"companies":[],"institutions":["uniklinik-koeln","deutsche-krebshilfe","dkfz","lungenclinic-grosshansdorf","charite"],"pathways":[],"terms":[],"trials":[],"people":["juergen-wolf","reinhard-buettner","martin-reck"],"bottlenecks":["b-biomarker-validation","b-data-silos"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Cologne","country":"DE","lat":50.938,"lng":6.96,"institutionType":"consortium","website":"https://www.nngm.de","programs":["Comprehensive molecular diagnostics for NSCLC","Second opinion consultations at network centres","Selective contracts under section 140a SGB V","nNGM registry (NCT05934032)"]},{"id":"nationwide-childrens","kind":"institution","name":"Nationwide Children's Hospital","aka":[],"tldr":"Columbus children's hospital with a leading paediatric cancer genomics institute and pioneering oncolytic virus trials in childhood sarcomas.","summary":"Nationwide Children's Hospital, affiliated with The Ohio State University, is one of the largest paediatric hospitals in the US and hosts the Abigail Wexner Research Institute. Its Steve and Cindy Rasmussen Institute for Genomic Medicine, led since 2016 by Elaine Mardis and Richard Wilson (who had directed the first cancer genome sequencing at Washington University), sequences every child with cancer or a suspected genetic disorder and is a founding member of the Children's Brain Tumor Network. Timothy Cripe ran the first paediatric trials of oncolytic herpes simplex virus in sarcomas, and Ryan Roberts's laboratory studies osteosarcoma metastasis. The hospital is a major Children's Oncology Group site and offers CAR-T and transplant.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Nationwide_Children's_Hospital","links":[{"label":"Nationwide Children's Hospital","url":"https://www.nationwidechildrens.org"}],"tags":[],"related":[],"cancers":["osteosarcoma","ewing-sarcoma","rhabdomyosarcoma","medulloblastoma"],"sections":[],"technologies":["oncolytic-virus","wes-wgs","car-t"],"targets":[],"drugs":[],"companies":["childrens-oncology-group"],"institutions":["osu-james"],"pathways":[],"terms":[],"trials":[],"people":["timothy-robinson"],"bottlenecks":["b-rare-cancers","b-metastasis-biology"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Columbus, OH","country":"US","lat":39.953,"lng":-82.979,"institutionType":"hospital","website":"https://www.nationwidechildrens.org","university":"The Ohio State University","programs":["Paediatric cancer genomics (IGM)","Oncolytic virotherapy","Sarcoma biology","Children's Brain Tumor Network"]},{"id":"nci-ccr","kind":"institution","name":"NCI Center for Cancer Research (intramural programme)","aka":["CCR","NCI intramural"],"tldr":"The NCI's own laboratories and clinic at the NIH Clinical Center, home of Rosenberg's cell therapy branch, the HPV vaccine and lymphoma genomics.","summary":"The Center for Cancer Research is the NCI's intramural research programme, with laboratories in Bethesda and Frederick and a clinical arm at the NIH Clinical Center, the largest hospital in the world devoted to research, where patients on protocol are treated free of charge. Steven Rosenberg's Surgery Branch produced the first effective cancer immunotherapy (high-dose IL-2), the first gene-modified T cells (1990), TIL therapy and neoantigen-directed TCR therapy; Douglas Lowy and John Schiller invented the virus-like-particle technology behind HPV vaccines; Louis Staudt's lymphoma genomics defined the ABC and GCB subtypes of DLBCL. The Pediatric Oncology Branch (Brigitte Widemann, Nirali Shah) led selumetinib for NF1 and CD22 CAR-T, and James Gulley and Raffit Hassan run immunotherapy and mesothelin programmes. Most CCR trials are open to referral from any physician.","asOf":"2026-09-09","links":[{"label":"Center for Cancer Research","url":"https://ccr.cancer.gov"},{"label":"CCR clinical trials","url":"https://ccr.cancer.gov/clinical-trials"},{"label":"NIH Clinical Center","url":"https://clinicalcenter.nih.gov"}],"tags":[],"related":[],"cancers":["melanoma","dlbcl","cervical","mesothelioma"],"sections":["cell-therapy","immunotherapy"],"technologies":["til-therapy","tcr-t","car-t","hpv-vaccine","cytokine-therapy"],"targets":["cd22","mesothelin"],"drugs":["aldesleukin"],"companies":[],"institutions":["nci","frederick-national-lab"],"pathways":[],"terms":[],"trials":[],"people":["steven-rosenberg","louis-staudt","douglas-lowy","james-gulley","brigitte-widemann","nirali-shah","raffit-hassan","senthil-muthuswamy","wyndham-wilson"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Bethesda, MD","country":"US","lat":39.002,"lng":-77.105,"institutionType":"government","website":"https://ccr.cancer.gov","programs":["Surgery Branch (TIL, TCR-T)","HPV vaccine science","Lymphoid malignancies","Pediatric Oncology Branch","NIH Clinical Center trials"]},{"id":"nct-dresden","kind":"institution","name":"NCT/UCC Dresden, University Hospital Carl Gustav Carus","aka":["National Center for Tumor Diseases Dresden","University Cancer Center Dresden","OncoRay","National Cancer Center Dresden","NCT Dresden"],"tldr":"The second National Center for Tumor Diseases site, known for proton therapy research at OncoRay and AI in pathology and surgery.","summary":"NCT/UCC Dresden was founded in 2015 as a partnership between the DKFZ, the University Hospital Carl Gustav Carus, TU Dresden's medical faculty and the Helmholtz-Zentrum Dresden-Rossendorf. The OncoRay centre and the University Proton Therapy Dresden facility (treating since 2014) pursue biologically adapted, image-guided and laser-driven particle therapy; the DKFZ's chairman Michael Baumann previously directed radiation oncology there. The Else Kröner Fresenius Center for Digital Health hosts groups such as Jakob Nikolas Kather's on deep learning in pathology, and the hospital's surgical oncology programme develops AI-assisted surgery. Clinical strengths include haematology and transplantation, gastrointestinal surgery and precision oncology through a DKTK-wide molecular tumour board.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.nct-dresden.de"},{"label":"OncoRay","url":"https://www.oncoray.de"},{"label":"EKFZ for Digital Health","url":"https://digitalhealth.tu-dresden.de"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":["head-and-neck","aml","colorectal","pancreatic"],"sections":["radiation","ai-computation"],"technologies":["proton-therapy","flash-rt","digital-pathology-ai","pathology-foundation-model","imrt-igrt","proton-therapy-systems"],"targets":[],"drugs":[],"companies":[],"institutions":["dkfz","heidelberg-nct"],"pathways":[],"terms":[],"trials":[],"people":["michael-baumann","martin-bornhauser","hanno-glimm","jurgen-weitz","jakob-nikolas-kather"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Dresden","country":"DE","lat":51.056,"lng":13.78,"institutionType":"cancer-center","website":"https://www.nct-dresden.de","university":"Technische Universität Dresden","programs":["OncoRay and proton therapy","Digital health and computational pathology","Haematology","Surgical oncology","Precision oncology (DKTK MASTER)"]},{"id":"nki","kind":"institution","name":"Netherlands Cancer Institute (NKI-AvL)","aka":[],"tldr":"Dutch national cancer centre that pioneered neoadjuvant immunotherapy (NADINA, NICHE) and TIL therapy in Europe.","summary":"The Netherlands Cancer Institute, NKI-AvL in Amsterdam, is the Dutch national cancer centre, ranked forty-fifth in the Newsweek/Statista oncology list, and the place where neoadjuvant immunotherapy and TIL therapy were pioneered in Europe. Its NADINA trial in melanoma and NICHE-2 trial in mismatch-repair-deficient colon cancer changed practice, John Haanen's randomised trial of TIL therapy against ipilimumab was the first of its kind, and MammaPrint originated here with van 't Veer; Christian Blank, Myriam Chalabi, René Bernards and Emile Voest are also listed. OnCo links it to OVHIPEC-1, to the DRUP model for off-label targeted drugs in rare tumours, and to HOVON and the KWF Dutch Cancer Society. Getting academic cell therapies to patients at scale is the bottleneck it now faces. Its neoadjuvant, TIL and breast genomics programmes are listed below.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.nki.nl"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["til-therapy","checkpoint-inhibitor","mr-linac"],"targets":[],"drugs":["tacquell"],"companies":[],"institutions":[],"pathways":[],"terms":["neoadjuvant-adjuvant"],"trials":[],"people":["rene-bernards","sabine-linn","willemien-van-driel","winette-van-der-graaf","paul-baas","christian-blank","emile-voest","john-haanen","myriam-chalabi","ton-schumacher","maurice-van-den-bosch","rene-medema"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Amsterdam","country":"NL","lat":52.348,"lng":4.855,"institutionType":"cancer-center","website":"https://www.nki.nl","newsweekOncology2026":45,"programs":["Neoadjuvant immunotherapy","TIL therapy","Breast genomics"]},{"id":"iknl","kind":"institution","name":"Netherlands Comprehensive Cancer Organisation (IKNL)","aka":["IKNL","Integraal Kankercentrum Nederland","Netherlands Comprehensive Cancer Organisation"],"tldr":"IKNL is the Dutch national cancer organisation that runs the Netherlands Cancer Registry and supports quality of care and research across the country, and a full member of the Organisation of European Cancer Institutes.","summary":"The Netherlands Comprehensive Cancer Organisation (Integraal Kankercentrum Nederland, IKNL) is the independent knowledge institute for oncological and palliative care in the Netherlands. It maintains the Netherlands Cancer Registry, a population-based registry covering every cancer diagnosis in the country, publishes national incidence, survival and treatment figures, and works with hospitals and professional groups on guidelines, quality registration and research. It is listed by the Organisation of European Cancer Institutes as a full member. Programme, trial and leadership details are not yet recorded here and should be checked on the hospital's own pages.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://iknl.nl"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":["nki"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["ernst-j-kuipers"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Utrecht","country":"NL","lat":52.09,"lng":5.11,"institutionType":"consortium","website":"https://iknl.nl","programs":[]},{"id":"new-york-proton-center","kind":"institution","name":"New York Proton Center","aka":[],"tldr":"The New York Proton Center is a free-standing proton beam therapy centre in Manhattan treating solid tumours, bookable through an oncology referral.","summary":"The New York Proton Center delivers proton beam radiotherapy for solid tumours in adults and children, a form of radiation that stops at a set depth and spares tissue beyond the target. Its own site says it was created through a partnership with three academic medical centres, Memorial Sloan Kettering Cancer Center, Montefiore and Mount Sinai, and is the first and only proton therapy centre in New York; Charles Simone is its chief medical officer. Future of Cancer Care Today lists it as patient-bookable through oncology referral.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.nyproton.com/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":["fcct-directory"],"related":[],"cancers":[],"sections":[],"technologies":["proton-therapy","proton-therapy-systems"],"targets":[],"drugs":[],"companies":[],"institutions":["mskcc","montefiore-einstein","mount-sinai"],"pathways":[],"terms":[],"trials":[],"people":["charles-simone"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"New York","country":"US","lat":40.805,"lng":-73.935,"institutionType":"hospital","website":"https://www.nyproton.com/","programs":[]},{"id":"newcastle-cancer-centre","kind":"institution","name":"Newcastle Cancer Centre / Northern Centre for Cancer Care","aka":["Newcastle upon Tyne Hospitals NHS Foundation Trust","Freeman Hospital","Newcastle University Centre for Cancer"],"tldr":"Newcastle's cancer centre serves the North East and Cumbria; its chemists and pharmacologists discovered rucaparib, the first PARP inhibitor to reach patients, and Ruth Plummer led its first-in-human trial in 2003, while the Wolfson centre leads medulloblastoma research.","summary":"The Northern Centre for Cancer Care at the Freeman Hospital and the Great North Children's Hospital provide tertiary cancer care for the North East and Cumbria, while Newcastle University's Centre for Cancer is a Cancer Research UK centre with a drug discovery unit. Newcastle chemists and pharmacologists (Hilary Calvert, Nicola Curtin, Herbie Newell, Bernard Golding) discovered rucaparib with Agouron, and Ruth Plummer led the first-in-human trial of a PARP inhibitor in 2003. The Wolfson Childhood Cancer Research Centre is a leader in medulloblastoma and childhood leukaemia biology, and the Sir Bobby Robson Cancer Trials Research Centre runs early-phase trials. Newcastle also hosts national programmes in ageing and cancer and in mitochondrial disease.","asOf":"2026-09-09","links":[{"label":"Cancer services","url":"https://www.newcastle-hospitals.nhs.uk/services/cancer-services/"},{"label":"Newcastle University Centre for Cancer","url":"https://www.ncl.ac.uk/cancer/"}],"tags":[],"related":[],"cancers":["ovarian","neuroblastoma","all-leukemia","glioblastoma","pancreatic","colorectal","nsclc","lung-cancer","skin-cancer","basal-cell-carcinoma"],"sections":["targeted-therapy","drug-discovery"],"technologies":["parp-inhibitor","synthetic-lethality-approaches","ai-drug-design"],"targets":["parp","brca"],"drugs":[],"companies":[],"institutions":["cruk"],"pathways":[],"terms":["synthetic-lethality"],"trials":["capp2"],"people":["ruth-plummer","steven-clifford","graham-jackson","john-burn","alastair-greystoke"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Newcastle upon Tyne","country":"GB","lat":54.999,"lng":-1.616,"institutionType":"hospital","website":"https://www.newcastle-hospitals.nhs.uk/services/cancer-services/","university":"Newcastle University","programs":["PARP inhibitor discovery (rucaparib)","Sir Bobby Robson early-phase trials unit","Childhood cancer research","CRUK Newcastle Drug Discovery Unit"]},{"id":"niguarda-cancer-center","kind":"institution","name":"Niguarda Cancer Center, ASST Grande Ospedale Metropolitano Niguarda","aka":["Ospedale Niguarda","Niguarda Ca' Granda Hospital","Falck Division of Medical Oncology"],"tldr":"Milan's largest public hospital, whose cancer centre under Salvatore Siena and Andrea Sartore-Bianchi ran HERACLES, the trial that proved HER2 is a target in bowel cancer.","summary":"The Niguarda Cancer Center is the oncology department of Milan's Niguarda hospital, a large public teaching hospital of the University of Milan. Under Salvatore Siena it built a programme in molecular oncology of colorectal cancer, running HERACLES, the first trial to show that HER2-directed therapy works in HER2-amplified colorectal cancer, contributing to the panitumumab trials that established RAS testing, and hosting the phase 1 unit that led DESTINY-CRC01. Andrea Sartore-Bianchi directs its clinical research and precision oncology programme.","asOf":"2026-09-18","links":[{"label":"Ospedale Niguarda","url":"https://www.ospedaleniguarda.it"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["heracles"],"people":["salvatore-siena","andrea-sartore-bianchi"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Milan","country":"IT","lat":45.51,"lng":9.19,"institutionType":"hospital","website":"https://www.ospedaleniguarda.it","university":"Università degli Studi di Milano","programs":["Colorectal cancer molecular oncology","Phase 1 trials","Precision oncology"]},{"id":"ninewells-dundee","kind":"institution","name":"Ninewells Hospital, Dundee","aka":["NHS Tayside","Tayside HPB unit"],"tldr":"A surgical centre for NHS Scotland North; a Precision-Panc and ginisortamab trial site and home of the TAYCAN liquid biopsy study.","summary":"Pancreatic Cancer UK lists Ninewells Hospital as one of the surgical centres for NHS Scotland North, which covers NHS Grampian, NHS Highland and NHS Tayside and serves Orkney, Shetland and the Western Isles. Ninewells recruited to the Precision Panc master protocol and is a site of the phase 2 ginisortamab trial; NHS Tayside sponsors TAYCAN (ISRCTN93548632), a liquid biopsy study in pancreatic and colorectal cancer recruiting to May 2027.","asOf":"2026-09-24","links":[{"label":"NHS Tayside: hepatobiliary and pancreatic surgery","url":"https://www.nhstayside.scot.nhs.uk/"},{"label":"ISRCTN93548632: TAYCAN","url":"https://www.isrctn.com/ISRCTN93548632"}],"tags":["hpb","nhs","uk"],"related":[],"cancers":["pancreatic","gallbladder","biliary-tract-cancer","cholangiocarcinoma","hcc"],"sections":["surgery"],"technologies":["whipple","liquid-biopsy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["precision-panc"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Dundee","country":"GB","lat":56.462,"lng":-3.037,"institutionType":"hospital","website":"https://www.nhstayside.scot.nhs.uk/","university":"University of Dundee","programs":["HPB surgery","North of Scotland HPB MDT","Liquid biopsy research"]},{"id":"north-central-london-cancer-alliance","kind":"institution","name":"North Central London Cancer Alliance","aka":["NCL Cancer Alliance"],"tldr":"The NHS England Cancer Alliance for the five North Central London boroughs of Barnet, Camden, Enfield, Haringey and Islington: the partnership that plans and improves cancer services across its hospitals, GPs and community services.","summary":"One of the 20 Cancer Alliances set up by NHS England from 2016, following the Independent Cancer Taskforce strategy, to bring together the hospital trusts, integrated care boards, primary care, hospices and charities serving the five North Central London boroughs of Barnet, Camden, Enfield, Haringey and Islington. Alliances lead local delivery of the NHS cancer ambitions: earlier diagnosis (including rapid diagnostic centres and targeted lung health checks), the Faster Diagnosis Standard, personalised care and follow-up, and workforce and pathway improvement. They hold transformation funding from NHS England and publish local performance and improvement plans.","asOf":"2026-09-09","links":[{"label":"North Central London Cancer Alliance","url":"https://www.nclcanceralliance.nhs.uk"},{"label":"NHS England: Cancer Alliances","url":"https://www.england.nhs.uk/cancer/cancer-alliances-improving-care-locally/"}],"tags":["nhs-cancer-alliance"],"related":[],"cancers":[],"sections":["early-detection"],"technologies":["low-dose-ct-screening"],"targets":[],"drugs":[],"companies":[],"institutions":["uclh","great-ormond-street","francis-crick"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"London","country":"GB","lat":51.525,"lng":-0.135,"institutionType":"consortium","website":"https://www.nclcanceralliance.nhs.uk","programs":["Earlier diagnosis and rapid diagnostic centres","Faster Diagnosis Standard","Personalised care and follow-up","Cancer pathway improvement"]},{"id":"north-east-london-cancer-alliance","kind":"institution","name":"North East London Cancer Alliance","aka":["NEL Cancer Alliance"],"tldr":"The NHS England Cancer Alliance for the seven North East London boroughs, including Tower Hamlets, Newham, Hackney, Redbridge, Havering, Barking and Dagenham, and Waltham Forest: the partnership that plans and improves cancer services across its hospitals, GPs and community services.","summary":"One of the 20 Cancer Alliances set up by NHS England from 2016, following the Independent Cancer Taskforce strategy, to bring together the hospital trusts, integrated care boards, primary care, hospices and charities serving the seven North East London boroughs, including Tower Hamlets, Newham, Hackney, Redbridge, Havering, Barking and Dagenham, and Waltham Forest. Alliances lead local delivery of the NHS cancer ambitions: earlier diagnosis (including rapid diagnostic centres and targeted lung health checks), the Faster Diagnosis Standard, personalised care and follow-up, and workforce and pathway improvement. They hold transformation funding from NHS England and publish local performance and improvement plans.","asOf":"2026-09-09","links":[{"label":"North East London Cancer Alliance","url":"https://www.nelcanceralliance.nhs.uk"},{"label":"NHS England: Cancer Alliances","url":"https://www.england.nhs.uk/cancer/cancer-alliances-improving-care-locally/"}],"tags":["nhs-cancer-alliance"],"related":[],"cancers":[],"sections":["early-detection"],"technologies":["low-dose-ct-screening"],"targets":[],"drugs":[],"companies":[],"institutions":["barts-cancer-institute"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"London","country":"GB","lat":51.54,"lng":0.02,"institutionType":"consortium","website":"https://www.nelcanceralliance.nhs.uk","programs":["Earlier diagnosis and rapid diagnostic centres","Faster Diagnosis Standard","Personalised care and follow-up","Cancer pathway improvement"]},{"id":"north-estonia-medical-centre","kind":"institution","name":"North Estonia Medical Centre","aka":["Regionaalhaigla","Põhja-Eesti Regionaalhaigla","PERH"],"tldr":"The North Estonia Medical Centre in Tallinn is one of Estonia's two main cancer treatment hospitals and a full member of the Organisation of European Cancer Institutes.","summary":"The North Estonia Medical Centre (Põhja-Eesti Regionaalhaigla) is a large hospital in Tallinn, formed in 2001 from several earlier hospitals, with its main building in the Mustamäe district. It provides specialised cancer diagnosis and treatment for northern Estonia and is one of the country's two principal cancer treatment centres alongside Tartu University Hospital. It is listed by the Organisation of European Cancer Institutes as a full member. Programme, trial and leadership details are not yet recorded here.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/North_Estonia_Medical_Centre","links":[{"label":"Official website","url":"https://www.regionaalhaigla.ee"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/North_Estonia_Medical_Centre"}],"tags":[],"related":["east-tallinn-central-hospital"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["kristo-erikson"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Tallinn","country":"EE","lat":59.395,"lng":24.671,"institutionType":"hospital","website":"https://www.regionaalhaigla.ee","programs":[]},{"id":"northern-cancer-alliance","kind":"institution","name":"Northern Cancer Alliance","aka":["NCA"],"tldr":"The NHS England Cancer Alliance for the North East of England and North Cumbria, from Northumberland and Tyne and Wear to Teesside and Carlisle: the partnership that plans and improves cancer services across its hospitals, GPs and community services.","summary":"One of the 20 Cancer Alliances set up by NHS England from 2016, following the Independent Cancer Taskforce strategy, to bring together the hospital trusts, integrated care boards, primary care, hospices and charities serving the North East of England and North Cumbria, from Northumberland and Tyne and Wear to Teesside and Carlisle. Alliances lead local delivery of the NHS cancer ambitions: earlier diagnosis (including rapid diagnostic centres and targeted lung health checks), the Faster Diagnosis Standard, personalised care and follow-up, and workforce and pathway improvement. They hold transformation funding from NHS England and publish local performance and improvement plans.","asOf":"2026-09-09","links":[{"label":"Northern Cancer Alliance","url":"https://www.northerncanceralliance.nhs.uk"},{"label":"NHS England: Cancer Alliances","url":"https://www.england.nhs.uk/cancer/cancer-alliances-improving-care-locally/"}],"tags":["nhs-cancer-alliance"],"related":[],"cancers":[],"sections":["early-detection"],"technologies":["low-dose-ct-screening"],"targets":[],"drugs":[],"companies":[],"institutions":["newcastle-cancer-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Newcastle upon Tyne","country":"GB","lat":54.978,"lng":-1.617,"institutionType":"consortium","website":"https://www.northerncanceralliance.nhs.uk","programs":["Earlier diagnosis and rapid diagnostic centres","Faster Diagnosis Standard","Personalised care and follow-up","Cancer pathway improvement"]},{"id":"northern-ireland-cancer-centre","kind":"institution","name":"Northern Ireland Cancer Centre, Belfast City Hospital","aka":["NICC","Belfast Health and Social Care Trust"],"tldr":"Northern Ireland's regional cancer centre, opened at Belfast City Hospital in 2006 and paired with Queen's University Belfast's Patrick G Johnston Centre for Cancer Research.","summary":"The Northern Ireland Cancer Centre opened in 2006 on the Belfast City Hospital site as the single regional centre for radiotherapy and specialist cancer treatment for Northern Ireland's population, run by the Belfast Health and Social Care Trust. It provides radiotherapy, systemic therapy, haematology and clinical trials, and is linked with the Patrick G Johnston Centre for Cancer Research at Queen's University Belfast, whose research in colorectal and prostate cancer, DNA damage response and digital pathology feeds the centre's Experimental Cancer Medicine Centre and the Northern Ireland Biobank.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://belfasttrust.hscni.net"}],"tags":["nhs-specialist-cancer-centre"],"related":[],"cancers":["prostate","colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["radiotherapy"],"trials":[],"people":["jennifer-welsh"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Belfast","country":"GB","lat":54.583,"lng":-5.947,"institutionType":"cancer-center","website":"https://belfasttrust.hscni.net","university":"Queen's University Belfast","programs":["Regional radiotherapy centre","Experimental Cancer Medicine Centre","Colorectal and prostate cancer research"]},{"id":"northwell-cancer-institute","kind":"institution","name":"Northwell Health Cancer Institute","aka":["Northwell Cancer Institute","R. J. Zuckerberg Cancer Center"],"tldr":"Northwell Health Cancer Institute coordinates cancer care across New York State's largest health system, from Long Island to Connecticut; its Feinstein Institutes carry the chronic lymphocytic leukaemia research tradition founded by Kanti Rai, whose staging system is still used.","summary":"Northwell Health Cancer Institute coordinates cancer care across Northwell, New York State's largest health system, from the R. J. Zuckerberg Cancer Center in Lake Success to hospitals across Long Island, Queens, Manhattan and Westchester, and, after the 2025 merger with Nuvance Health, into Connecticut and the Hudson Valley. Its research arm, the Feinstein Institutes for Medical Research, carries a chronic lymphocytic leukaemia tradition founded by Kanti Rai, whose staging system is still used, and continued by Nicholas Chiorazzi's work on IGHV mutation status and CLL biology. Richard Barakat, formerly of MSK, directs the institute with strengths in gynaecologic oncology, and the Cohen Children's Medical Center provides paediatric oncology. The institute is expanding cellular therapy and clinical trials across its network.","asOf":"2026-09-09","links":[{"label":"Northwell Health Cancer Institute","url":"https://www.northwell.edu/cancer-institute"},{"label":"Feinstein Institutes","url":"https://feinstein.northwell.edu"}],"tags":[],"related":[],"cancers":["cll","ovarian","endometrial"],"sections":[],"technologies":["car-t"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["ighv-status"],"trials":[],"people":["richard-barakat","richard-carvajal"],"bottlenecks":["b-care-fragmentation","b-trial-enrolment"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"New Hyde Park, NY","country":"US","lat":40.77,"lng":-73.717,"institutionType":"hospital","website":"https://www.northwell.edu/cancer-institute","programs":["Chronic lymphocytic leukaemia research (Feinstein)","Gynaecologic oncology","Network clinical trials"]},{"id":"nottingham-cancer-centre","kind":"institution","name":"Nottingham University Hospitals Cancer Centre (City Hospital)","aka":["Nottingham City Hospital","NUH"],"tldr":"Nottingham's City Hospital campus is the East Midlands' regional cancer centre; research with the University of Nottingham produced the Nottingham Prognostic Index for breast cancer and hosts the Children's Brain Tumour Research Centre.","summary":"Nottingham University Hospitals NHS Trust delivers cancer services principally from its City Hospital campus, which houses radiotherapy, medical oncology, haematology, breast and urological surgery and the Nottingham Breast Institute, serving Nottinghamshire and much of the East Midlands as the regional cancer centre. Research with the University of Nottingham includes the Nottingham Prognostic Index for breast cancer, developed from the Nottingham Tenovus breast cancer series, the Children's Brain Tumour Research Centre, and biomarker work in breast and colorectal cancer, and the trust hosts a large clinical trials portfolio.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.nuh.nhs.uk"}],"tags":["nhs-cancer-centre"],"related":[],"cancers":["colorectal","pancreatic","nsclc","lung-cancer","basal-cell-carcinoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["prognosis","clinical-trial"],"trials":["nottingham-fob","sins-trial"],"people":["anthony-may","david-baldwin","hywel-williams"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Nottingham","country":"GB","lat":52.983,"lng":-1.17,"institutionType":"hospital","website":"https://www.nuh.nhs.uk","university":"University of Nottingham","programs":["Breast cancer (Nottingham Prognostic Index)","Children's brain tumour research","Radiotherapy"]},{"id":"nova-scotia-cancer-care","kind":"institution","name":"Nova Scotia Health Cancer Care Program (QEII)","aka":["Cancer Care Nova Scotia","QEII Health Sciences Centre"],"tldr":"Nova Scotia's provincial cancer programme, centred on the QEII Health Sciences Centre in Halifax with Dalhousie University.","summary":"The Nova Scotia Health Cancer Care Program (formerly Cancer Care Nova Scotia) plans and delivers cancer services across the province, with its principal treatment site at the QEII Health Sciences Centre in Halifax and a second radiotherapy centre, the Cape Breton Cancer Centre in Sydney. It runs the provincial breast, cervical and colon screening programmes and the Nova Scotia Cancer Registry, and is the tertiary cancer centre for the Maritime provinces for services such as stem cell transplantation. Research is carried out with Dalhousie University's Beatrice Hunter Cancer Research Institute and through Canadian Cancer Trials Group participation.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.nshealth.ca"}],"tags":["provincial-cancer-agency"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["canadian-cancer-society"],"pathways":[],"terms":[],"trials":[],"people":["nicole-boutilier"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Halifax","country":"CA","lat":44.638,"lng":-63.585,"institutionType":"government","website":"https://www.nshealth.ca","university":"Dalhousie University","programs":["Provincial cancer programme","QEII and Cape Breton cancer centres","Screening programmes","Beatrice Hunter Cancer Research Institute"]},{"id":"oneal-uab","kind":"institution","name":"O'Neal Comprehensive Cancer Center at UAB","aka":["UAB Comprehensive Cancer Center"],"tldr":"Alabama's only NCI-designated comprehensive cancer centre, one of the original 1971 designees, serving the Deep South and studying cancer disparities.","summary":"One of the first cancer centres designated under the 1971 National Cancer Act, O'Neal is the only NCI comprehensive centre in Alabama and a reference centre for Mississippi and the Deep South. Research strengths include gynaecologic oncology and ovarian cancer, pancreatic cancer, neuro-oncology and head and neck cancer, with a long-running focus on rural and Black population health disparities. The UAB Proton Center, which opened in 2020, added proton beam therapy to the state. Selwyn Vickers, now MSK's president, was previously UAB's dean and a pancreatic surgeon here. Patients have access to phase 1 through phase 3 trials via UAB's Cancer Clinical Trials Office.","asOf":"2026-09-09","links":[{"label":"O'Neal Comprehensive Cancer Center","url":"https://www.uab.edu/onealcancercenter/"},{"label":"Clinical trials","url":"https://www.uab.edu/onealcancercenter/patient-care/clinical-trials"}],"tags":[],"related":[],"cancers":["ovarian","pancreatic","head-and-neck","glioblastoma"],"sections":["radiation"],"technologies":["proton-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["selwyn-vickers"],"bottlenecks":["b-trial-diversity"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Birmingham, AL","country":"US","lat":33.505,"lng":-86.806,"institutionType":"cancer-center","website":"https://www.uab.edu/onealcancercenter/","nci":"comprehensive","university":"University of Alabama at Birmingham","programs":["Gynaecologic oncology","Pancreatic cancer","Proton therapy","Cancer disparities in the Deep South"]},{"id":"ocean-road-cancer-institute","kind":"institution","name":"Ocean Road Cancer Institute","aka":["ORCI"],"tldr":"Ocean Road Cancer Institute in Dar es Salaam has been Tanzania's national cancer institute since 1996 and for two decades was the country's only public cancer treatment facility; its caseload is dominated by cervical cancer, Kaposi sarcoma, breast and oesophageal cancer.","summary":"Ocean Road Cancer Institute in Dar es Salaam occupies the former Ocean Road Hospital, built in 1897 during German colonial rule, and became Tanzania's national cancer institute in 1996. It was for two decades the country's only public cancer treatment facility and remains the national referral centre, providing radiotherapy (cobalt and now linear accelerators and brachytherapy), chemotherapy, palliative care and cervical cancer screening, and hosting the national cancer registry and training with the Muhimbili University of Health and Allied Sciences. ORCI's caseload is dominated by cervical cancer, Kaposi sarcoma, breast and oesophageal cancer, and it partners on HPV vaccination, screen-and-treat and access-to-medicines programmes for East Africa.","asOf":"2026-09-09","links":[{"label":"Ocean Road Cancer Institute","url":"https://www.orci.or.tz"},{"label":"MUHAS","url":"https://www.muhas.ac.tz"}],"tags":[],"related":["global-oncology-access","who-essential-medicines"],"cancers":["cervical","breast-hr-positive","esophageal","head-and-neck"],"sections":["radiation","prevention"],"technologies":["brachytherapy","imrt-igrt","hpv-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["diwani-msemo"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Dar es Salaam","country":"TZ","lat":-6.808,"lng":39.29,"institutionType":"cancer-center","website":"https://www.orci.or.tz","university":"Muhimbili University of Health and Allied Sciences","programs":["National cancer institute","Radiotherapy and brachytherapy","Cervical cancer screening","Cancer registry"]},{"id":"odense-university-hospital","kind":"institution","name":"Odense University Hospital","aka":["OUH","Odense Universitetshospital"],"tldr":"Odense University Hospital is the university hospital of the Region of Southern Denmark and a full member of the Organisation of European Cancer Institutes.","summary":"Odense University Hospital (OUH) is the university hospital for the Region of Southern Denmark, with a history going back to 1919, and one of the Danish hospitals that provide specialised cancer treatment within the national Danish Comprehensive Cancer Center framework. It is listed by the Organisation of European Cancer Institutes as a full member. OnCo holds this record so that Denmark's regional cancer care is represented beyond Copenhagen and Aarhus; programme details, trial activity and leadership are not yet recorded and should be checked on the hospital's own pages.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Odense_University_Hospital","links":[{"label":"Official website","url":"https://ouh.dk"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Odense_University_Hospital"}],"tags":[],"related":["rigshospitalet","aarhus-university-hospital"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["niels-norgaard-pedersen"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Odense","country":"DK","lat":55.385,"lng":10.37,"institutionType":"hospital","website":"https://ouh.dk","programs":[]},{"id":"ohsu-knight","kind":"institution","name":"OHSU Knight Cancer Institute","aka":["Knight Cancer Institute"],"tldr":"Brian Druker's institute, where imatinib was proven in CML and precision oncology was born; now focused on early detection and functional genomics.","summary":"NCI-designated since 1997, the Knight Cancer Institute is led by Brian Druker, whose clinical development of imatinib for BCR-ABL-positive chronic myeloid leukaemia in the late 1990s established targeted therapy as a paradigm. A $1 billion fundraising campaign completed in 2015 funded the Cancer Early Detection Advanced Research (CEDAR) centre and new research buildings on Portland's South Waterfront. Jeffrey Tyner's functional drug screening created the Beat AML programme, Joe Gray's SMMART trials pursue serial multi-omic profiling of individual patients, and Lisa Coussens leads work on myeloid cells in the tumour microenvironment. Charles Blanke chairs SWOG from OHSU.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Knight_Cancer_Institute","links":[{"label":"Knight Cancer Institute","url":"https://www.ohsu.edu/knight-cancer-institute"},{"label":"CEDAR","url":"https://www.ohsu.edu/knight-cancer-institute/cedar"}],"tags":[],"related":[],"cancers":["cml","aml"],"sections":["early-detection","targeted-therapy"],"technologies":["kinase-inhibitors","functional-drug-testing","n-of-1-platforms"],"targets":["bcr-abl"],"drugs":["imatinib"],"companies":["novartis","swog"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["charles-blanke","shivaani-kummar"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Portland, OR","country":"US","lat":45.499,"lng":-122.686,"institutionType":"cancer-center","website":"https://www.ohsu.edu/knight-cancer-institute","nci":"comprehensive","university":"Oregon Health & Science University","programs":["CML and targeted therapy","Early detection (CEDAR)","Functional genomics (Beat AML)","SMMART n-of-1 trials"]},{"id":"onj-cancer-centre","kind":"institution","name":"Olivia Newton-John Cancer Wellness and Research Centre","aka":["ONJ Centre","Olivia Newton-John Cancer Research Institute","Austin Health"],"tldr":"The Olivia Newton-John Cancer Centre at Melbourne's Austin Hospital runs one of Australia's busiest phase 1 units for immunotherapies and antibody-drug conjugates; its research institute grew out of the Ludwig Institute's Melbourne branch and leads antibody PET, FAPI and PSMA imaging work.","summary":"The Olivia Newton-John Cancer Wellness and Research Centre opened at Austin Health in Heidelberg, Melbourne, in 2012, and the Olivia Newton-John Cancer Research Institute (a La Trobe University school of cancer medicine) grew out of the Melbourne branch of the Ludwig Institute for Cancer Research, which produced landmark tumour immunology and antibody work under Andrew Scott and Jonathan Cebon. The centre runs one of Australia's busiest phase 1 units for immunotherapies and antibody-drug conjugates, hosts a leading molecular imaging programme (antibody PET, FAPI and PSMA imaging), and combines cancer care with a wellness model that includes exercise and supportive therapies. Its investigators have led international trials in gastrointestinal cancers, melanoma and glioma.","asOf":"2026-09-09","links":[{"label":"ONJ Cancer Centre","url":"https://www.onjcancercentre.org"},{"label":"Olivia Newton-John Cancer Research Institute","url":"https://www.onjcri.org.au"}],"tags":[],"related":[],"cancers":["melanoma","colorectal","glioblastoma","gastric"],"sections":["immunotherapy","imaging","supportive-care"],"technologies":["immuno-pet","checkpoint-inhibitor","adc","exercise-oncology"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["marco-herold"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Melbourne","country":"AU","lat":-37.756,"lng":145.06,"institutionType":"cancer-center","website":"https://www.onjcancercentre.org","university":"La Trobe University","programs":["Phase 1 immunotherapy trials","Tumour immunology (Ludwig lineage)","Molecular imaging","Wellness and supportive care"]},{"id":"oncological-institute-moldova","kind":"institution","name":"Oncological Institute of Moldova","aka":["Public Health Institution Oncological Institute","Institutul Oncologic","IMSP Institutul Oncologic"],"tldr":"Oncological Institute of Moldova is Moldova's national cancer institute in Chișinău, the country's main centre for cancer diagnosis, treatment and registration, and an associate member of the Organisation of European Cancer Institutes.","summary":"Oncological Institute of Moldova is Moldova's national cancer institute in Chișinău, the country's main centre for cancer diagnosis, treatment and registration. It is listed by the Organisation of European Cancer Institutes as an associate member, which is why it has a page on OnCo. Programme, trial and leadership details are not yet recorded here and should be checked on the institution's own pages.","asOf":"2026-09-09","links":[{"label":"Official website","url":"http://onco.md"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["ruslan-baltaga"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Chișinău","country":"MD","lat":47.019,"lng":28.832,"institutionType":"cancer-center","website":"http://onco.md","programs":[]},{"id":"iosi-bellinzona","kind":"institution","name":"Oncology Institute of Southern Switzerland (IOSI)","aka":["Istituto Oncologico della Svizzera Italiana","IOSI","Ente Ospedaliero Cantonale (EOC) oncology"],"tldr":"The cancer institute of the Italian-speaking Swiss canton of Ticino, led by prostate cancer trialist Silke Gillessen and home to the lymphoma group that co-founded the IELSG.","summary":"The Oncology Institute of Southern Switzerland (IOSI) is the oncology arm of the Ente Ospedaliero Cantonale, the public hospital group of Ticino, and works with the Università della Svizzera italiana and the Institute of Oncology Research in Bellinzona. Its medical and scientific director, Silke Gillessen, co-led the STAMPEDE platform trial and the Advanced Prostate Cancer Consensus Conference; its lymphoma unit, under Emanuele Zucca, hosts the International Extranodal Lymphoma Study Group.","asOf":"2026-09-18","links":[{"label":"EOC","url":"https://www.eoc.ch"}],"tags":[],"related":[],"cancers":["prostate","dlbcl"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["ielsg"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["silke-gillessen"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Bellinzona","country":"CH","lat":46.195,"lng":9.021,"institutionType":"cancer-center","website":"https://www.eoc.ch","university":"Università della Svizzera italiana","programs":["Prostate cancer trials","Lymphoma (IELSG)","Institute of Oncology Research"]},{"id":"oncology-institute-of-vojvodina","kind":"institution","name":"Oncology Institute of Vojvodina","aka":["Institut za onkologiju Vojvodine"],"tldr":"The Oncology Institute of Vojvodina, near Novi Sad, is the cancer centre for northern Serbia and an associate member of the Organisation of European Cancer Institutes.","summary":"The Oncology Institute of Vojvodina (Institut za onkologiju Vojvodine) in Sremska Kamenica, across the Danube from Novi Sad, was founded in 1963 and is the specialised cancer hospital and teaching base for the Faculty of Medicine of the University of Novi Sad, serving the northern Serbian province of Vojvodina with surgery, medical oncology, radiotherapy and nuclear medicine. It is listed by the Organisation of European Cancer Institutes as an associate member. Programme, trial and leadership details are not yet recorded here and should be checked on the hospital's own pages.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.onk.ns.ac.rs"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["jasna-trifunovic"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Sremska Kamenica","country":"RS","lat":45.217,"lng":19.856,"institutionType":"cancer-center","website":"https://www.onk.ns.ac.rs","programs":[]},{"id":"oncosalud-auna","kind":"institution","name":"Oncosalud (AUNA)","aka":["Clínica Oncosalud - AUNA","Clínica Oncosalud","AUNA"],"tldr":"Oncosalud is a private cancer care provider in Lima, part of the AUNA health group, and one of the few OECI members outside Europe, and an associate member of the Organisation of European Cancer Institutes.","summary":"Oncosalud is a private cancer care provider in Lima, part of the AUNA health group, and one of the few OECI members outside Europe. It is listed by the Organisation of European Cancer Institutes as an associate member, which is why it has a page on OnCo. Programme, trial and leadership details are not yet recorded here and should be checked on the institution's own pages.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://oncosalud.pe"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["giuliana-cardenas-gamarra"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Lima","country":"PE","lat":-12.098,"lng":-77.03,"institutionType":"cancer-center","website":"https://oncosalud.pe","programs":[]},{"id":"oncozon","kind":"institution","name":"OncoZON Comprehensive Cancer Network","aka":["Oncologisch Netwerk Zuidoost-Nederland"],"tldr":"The regional cancer network of the south-east Netherlands, linking Maastricht UMC+ with regional hospitals, and accredited by OECI as a Comprehensive Cancer Network.","summary":"OncoZON (Oncologisch Netwerk Zuidoost-Nederland) is a formal collaboration between Maastricht UMC+, the Maastro radiotherapy clinic and the general hospitals of Limburg and south-east Brabant. It organises shared tumour-specific care pathways, regional multidisciplinary tumour boards, concentration of complex surgery and joint participation in clinical trials so that patients receive the same standard of care wherever in the region they present. OncoZON is one of the few networks accredited by the Organisation of European Cancer Institutes under its Comprehensive Cancer Network designation.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.oncozon.nl"}],"tags":["oeci-accredited","oeci-comprehensive-cancer-network"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci","maastricht-umc"],"pathways":[],"terms":["multidisciplinary-tumour-board"],"trials":[],"people":["valery-lemmens","r-r-w-j-van-der-hulst"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Maastricht","country":"NL","lat":50.85,"lng":5.69,"institutionType":"consortium","website":"https://www.oncozon.nl","programs":["Regional care pathways","Shared tumour boards","Network clinical trials"]},{"id":"ontario-health-cancer-care-ontario","kind":"institution","name":"Ontario Health (Cancer Care Ontario)","aka":["Cancer Care Ontario","CCO"],"tldr":"Ontario Health's cancer programme, formerly Cancer Care Ontario, steers cancer care for Canada's most populous province; it runs the Ontario Cancer Plan, provincial screening programmes, the Ontario Cancer Registry and the funding and quality standards for regional cancer centres.","summary":"Cancer Care Ontario was the Government of Ontario's cancer advisor and system steward, responsible for the Ontario Cancer Plan, provincial screening programmes (breast, cervical, colorectal and lung), the Ontario Cancer Registry, funding and quality standards for the regional cancer centres, and evidence-based clinical guidelines through its Program in Evidence-Based Care. In 2019 it was merged with other provincial agencies into Ontario Health, where its functions continue as the cancer programme. It coordinates the network of regional cancer centres, including the Princess Margaret, Sunnybrook Odette, Juravinski, Ottawa Hospital and London's Verspeeten Family Cancer Centre, and publishes system performance data.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.cancercareontario.ca"}],"tags":["provincial-cancer-agency"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["princess-margaret","sunnybrook-odette","juravinski","ottawa-hospital","lhsc-verspeeten","oicr"],"pathways":[],"terms":[],"trials":[],"people":["jon-irish"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Toronto","country":"CA","lat":43.657,"lng":-79.386,"institutionType":"government","website":"https://www.cancercareontario.ca","programs":["Ontario Cancer Plan","Screening programmes","Ontario Cancer Registry","Program in Evidence-Based Care"]},{"id":"oicr","kind":"institution","name":"Ontario Institute for Cancer Research","aka":["OICR"],"tldr":"Ontario's provincially funded cancer research institute, which coordinated the International Cancer Genome Consortium and runs pancreatic cancer genomics trials.","summary":"Founded in 2005 and funded by the Government of Ontario, the Ontario Institute for Cancer Research in Toronto's MaRS Discovery District is a translational institute that hosted the secretariat and data coordination centre of the International Cancer Genome Consortium, with Lincoln Stein co-leading the Pan-Cancer Analysis of Whole Genomes. Steven Gallinger's COMPASS study brought real-time whole-genome sequencing to advanced pancreatic cancer, and Faiyaz Notta's work revealed how pancreatic tumours evolve. OICR runs drug discovery programmes (including WDR5 and other epigenetic targets), imaging and computational biology platforms, the Ontario Health Study and, through the FACIT commercialisation arm, spins out companies. It works closely with Princess Margaret and other Ontario centres. Its leadership page lists Aaron Schimmer as President and Scientific Director and Lincoln Stein as Head of Adaptive Oncology; Trevor Pugh directs its genomics programme and Janet Dancey led its precision medicine work before moving to the Canadian Cancer Trials Group.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Ontario_Institute_for_Cancer_Research","links":[{"label":"OICR","url":"https://oicr.on.ca"},{"label":"OICR leadership","url":"https://oicr.on.ca/about-us/leadership/"},{"label":"ICGC ARGO","url":"https://www.icgc-argo.org"}],"tags":[],"related":[],"cancers":["pancreatic","ovarian","colorectal"],"sections":["drug-discovery","ai-computation"],"technologies":["wes-wgs","cgp"],"targets":[],"drugs":[],"companies":[],"institutions":["princess-margaret"],"pathways":[],"terms":[],"trials":[],"people":["aaron-schimmer","trevor-pugh","dancey-janet"],"bottlenecks":["b-data-silos","b-tumor-heterogeneity"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Toronto, ON","country":"CA","lat":43.659,"lng":-79.389,"institutionType":"research-institute","website":"https://oicr.on.ca","programs":["Cancer genomics (ICGC, PCAWG)","Pancreatic cancer (COMPASS)","Drug discovery","Commercialisation (FACIT)"]},{"id":"orebro-university-hospital","kind":"institution","name":"Örebro University Hospital","aka":["Universitetssjukhuset Örebro","USÖ","Örebro Comprehensive Cancer Centre"],"tldr":"Örebro University Hospital is the university hospital of central Sweden's Region Örebro and a full member of the Organisation of European Cancer Institutes as the Örebro Comprehensive Cancer Centre.","summary":"Örebro University Hospital (Universitetssjukhuset Örebro) is the university hospital for Region Örebro County in central Sweden, with hospital roots going back to 1778 and a medical faculty at Örebro University. Its cancer services are organised as the Örebro Comprehensive Cancer Centre, which is listed by the Organisation of European Cancer Institutes as a full member alongside Karolinska. Programme, trial and leadership details are not yet recorded here and should be checked on the hospital's own pages.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/%C3%96rebro_University_Hospital","links":[{"label":"Official website","url":"https://www.regionorebrolan.se/uso"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Örebro_University_Hospital"}],"tags":[],"related":["karolinska"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["jonas-claesson"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Örebro","country":"SE","lat":59.276,"lng":15.225,"institutionType":"hospital","website":"https://www.regionorebrolan.se/uso","programs":[]},{"id":"oeci","kind":"institution","name":"Organisation of European Cancer Institutes","aka":["OECI","OECI-EEIG"],"tldr":"The network of European cancer centres that runs the accreditation and designation programme awarding 'Comprehensive Cancer Centre' status.","summary":"Founded in Vienna in 1979 and organised as a European Economic Interest Grouping in Brussels, the Organisation of European Cancer Institutes brings together cancer centres and institutes across Europe. Its Accreditation and Designation Programme, launched in 2008, audits members against quality standards and designates them as Cancer Centres or Comprehensive Cancer Centres, a status now held by institutions from the Netherlands Cancer Institute and Gustave Roussy to centres in Portugal, Slovenia and the Czech Republic. OECI working groups cover cancer economics, pathobiology and biobanking, digital health and outcomes research, and it contributes to EU projects on comprehensive cancer infrastructures under Europe's Beating Cancer Plan.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.oeci.eu"},{"label":"Accreditation and Designation (archived copy)","url":"https://web.archive.org/web/20230702005939/https://www.oeci.eu/Accreditation/"}],"tags":[],"related":[],"cancers":[],"sections":["supportive-care"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nki","gustave-roussy","ieo-milan","karolinska","vall-dhebron","erasmus-mc","uz-leuven","mou-brno","ipo-porto","ecco","az-groeninge-kortrijk","vejle-cancer-centre","tartu-university-hospital","kuopio-university-hospital","turku-university-hospital","tays-cancer-centre","linkoping-university-hospital","riga-east-university-hospital","nci-vilnius","icm-montpellier","centre-jean-perrin","centre-henri-becquerel","centre-eugene-marquis","ico-angers-nantes","centre-francois-baclesse","aphp-nord-cancer-institute","iuc-aphp-sorbonne","carpem-aphp-centre","trinity-st-jamess-cancer-institute","st-vincents-ucd-cancer-centre","cork-university-hospital","galway-university-hospital-cancer-centre","beaumont-rcsi-cancer-centre","spedali-civili-brescia","sacro-cuore-don-calabria","crob-rionero","istituto-tumori-bari","san-martino-genoa","ausl-irccs-reggio-emilia","cro-aviano","ipo-coimbra","fundacion-jimenez-diaz","ico-catalonia","ivo-valencia","umcg-groningen","rijnstate-arnhem","anadolu-medical-center","saint-savvas-athens","mother-teresa-hospital-tirana","tatarstan-cancer-center","nmrrc-moscow","sgccn"],"pathways":[],"terms":[],"trials":[],"people":["iwona-lugowska","claudio-lombardo","patrick-morris","david-fennelly"],"bottlenecks":["b-care-fragmentation","b-knowledge-diffusion"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Brussels","country":"BE","lat":50.847,"lng":4.363,"institutionType":"consortium","website":"https://www.oeci.eu","programs":["Accreditation and Designation Programme","Working groups (economics, biobanking, digital)","EU cancer infrastructure projects"]},{"id":"orlando-health-cancer-institute","kind":"institution","name":"Orlando Health Cancer Institute","aka":["UF Health Cancer Center - Orlando Health","Orlando Health"],"tldr":"Cancer centre of the Orlando Health system in central Florida, where Eleftherios Mamounas directs the breast programme and chairs the NRG Oncology breast committee.","summary":"The Orlando Health Cancer Institute is the cancer service of Orlando Health, a not-for-profit health system in central Florida, and formerly operated as the UF Health Cancer Center - Orlando Health. Its Comprehensive Breast Program is directed by Eleftherios Mamounas, a surgical oncologist who chairs the NRG Oncology Breast Committee and was a lead investigator of the NSABP B-series and KATHERINE trials.","asOf":"2026-09-18","links":[],"tags":[],"related":[],"cancers":["breast-her2-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["nrg-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["eleftherios-mamounas"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Orlando, FL","country":"US","lat":28.525,"lng":-81.379,"institutionType":"cancer-center","programs":["Breast cancer surgery and trials (NRG Oncology)","Community cancer care"]},{"id":"osaka-international-cancer-institute","kind":"institution","name":"Osaka International Cancer Institute","aka":["OICI","Osaka Medical Center for Cancer and Cardiovascular Diseases","大阪国際がんセンター"],"tldr":"The Osaka International Cancer Institute is the Osaka prefectural cancer centre, rebuilt as a dedicated cancer hospital in 2017; it performs high volumes of gastric, oesophageal and colorectal surgery and runs the Osaka Cancer Registry, one of Japan's most complete population registries.","summary":"The Osaka International Cancer Institute traces its history to the Osaka Adult Disease Center founded in 1959 and moved into a new dedicated cancer hospital in central Osaka in 2017. It is a designated prefectural cancer centre with high surgical volumes in gastric, oesophageal, colorectal, hepatobiliary and lung cancer, strong endoscopy (early gastric cancer ESD), and a research institute covering cancer epidemiology, molecular pathology and immunology. The institute runs the long-established Osaka Cancer Registry, one of Japan's most complete population-based registries, and participates in JCOG, WJOG and international registration trials. Patients have access to a phase 1 unit and genomic profiling under Japan's national cancer genome medicine programme.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Osaka_International_Cancer_Institute","links":[{"label":"Osaka International Cancer Institute","url":"https://oici.jp"}],"tags":[],"related":["cancer-registries-surveillance"],"cancers":["gastric","esophageal","colorectal","nsclc","hcc"],"sections":["surgery","early-detection"],"technologies":["cgp","robotic-surgery"],"targets":[],"drugs":[],"companies":["jcog"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["nariaki-matsuura"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Osaka","country":"JP","lat":34.688,"lng":135.52,"institutionType":"cancer-center","website":"https://oici.jp","programs":["Gastrointestinal cancer surgery and endoscopy","Osaka Cancer Registry","Thoracic oncology","Cancer genome medicine"]},{"id":"osaka-university","kind":"institution","name":"Osaka University Graduate School of Medicine / Osaka University Hospital","aka":["Osaka University","大阪大学","Immunology Frontier Research Center (IFReC)","WPI-IFReC"],"tldr":"Japanese national university whose medical school led CheckMate 648 in oesophageal cancer and whose Immunology Frontier Research Center is home to Shimon Sakaguchi, discoverer of regulatory T cells.","summary":"Osaka University is one of Japan's leading research universities; its Graduate School of Medicine and University Hospital are on the Suita campus north of Osaka. The Department of Gastroenterological Surgery, under Yuichiro Doki, led CheckMate 648, the 2022 trial that established nivolumab-based first-line treatment for advanced oesophageal squamous-cell carcinoma. The Immunology Frontier Research Center (IFReC) hosts Shimon Sakaguchi, who discovered regulatory T cells and the role of FOXP3, work that underlies much of cancer immunotherapy. The Osaka International Cancer Institute is a separate prefectural cancer centre in the city.","asOf":"2026-09-18","links":[{"label":"Osaka University","url":"https://www.osaka-u.ac.jp/en"}],"tags":[],"related":[],"cancers":["oesophageal-squamous-cell-carcinoma","esophageal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["osaka-international-cancer-institute"],"pathways":[],"terms":[],"trials":[],"people":["yuichiro-doki","shimon-sakaguchi"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Suita, Osaka","country":"JP","lat":34.819,"lng":135.522,"institutionType":"university","website":"https://www.osaka-u.ac.jp/en","programs":["Gastroenterological surgery","Immunology (IFReC)","Oesophageal cancer trials"]},{"id":"oslo-radium-hospital","kind":"institution","name":"Oslo University Hospital, The Norwegian Radium Hospital","aka":["Radiumhospitalet","Institute for Cancer Research Oslo","OUS"],"tldr":"Norway's national cancer hospital and research institute, where the alpha emitter radium-223 (Xofigo) and Photocure's bladder imaging agent were born.","summary":"The Norwegian Radium Hospital opened in 1932 as Norway's specialist cancer hospital and became part of Oslo University Hospital in 2009; its Institute for Cancer Research dates from 1954 and is a European reference for cancer genomics, immunology and radiation biology. Roy Larsen and Øyvind Bruland developed radium-223 there and founded Algeta, whose Xofigo became the first approved targeted alpha therapy after Bayer's acquisition, and the hospital also spun out Photocure and Ultimovacs. Current groups include Johanna Olweus on T-cell receptor therapies, Ragnhild Lothe on colorectal genomics, Ola Myklebost on sarcoma and Åslaug Helland, who leads the national IMPRESS-Norway precision medicine trial. The campus is being rebuilt with a new clinic and Norway's first proton therapy centre, and it anchors the Oslo Cancer Cluster innovation park.","asOf":"2026-09-09","links":[{"label":"Institute for Cancer Research","url":"https://www.ous-research.no/institute/"},{"label":"Oslo University Hospital","url":"https://www.oslo-universitetssykehus.no"},{"label":"Oslo Cancer Cluster","url":"https://oslocancercluster.no"}],"tags":[],"related":[],"cancers":["prostate","sarcoma","colorectal","urothelial","melanoma"],"sections":["radiopharma","targeted-therapy"],"technologies":["targeted-alpha-therapy","radioligand-therapy","tcr-t","proton-therapy","cgp"],"targets":[],"drugs":[],"companies":["bayer"],"institutions":["karolinska"],"pathways":[],"terms":["alpha-vs-beta","basket-umbrella-platform"],"trials":[],"people":["kjetil-tasken","bjorn-atle-bjornbeth"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Oslo","country":"NO","lat":59.933,"lng":10.66,"institutionType":"cancer-center","website":"https://www.ous-research.no/institute/","university":"University of Oslo","programs":["Institute for Cancer Research","Targeted alpha therapy heritage (radium-223)","IMPRESS-Norway precision medicine","Sarcoma and rare cancers","Proton therapy centre"]},{"id":"oulu-university-hospital","kind":"institution","name":"Oulu University Hospital","aka":["OYS","Oulun yliopistollinen sairaala"],"tldr":"Oulu University Hospital is the northernmost of Finland's five university hospitals and a full member of the Organisation of European Cancer Institutes.","summary":"Oulu University Hospital (OYS) is the northernmost of Finland's five university hospitals and serves the large, sparsely populated north of the country. It hosts the northern regional centre of the Finnish Cancer Center (FICAN North), the national network that coordinates cancer care and research across Finland's university hospital regions, and it is listed by the Organisation of European Cancer Institutes as a full member. OnCo records it alongside Tays Cancer Centre as one of the FICAN regional centres; programme and trial details are not yet recorded here.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Oulu_University_Hospital","links":[{"label":"Official website","url":"https://oys.fi"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Oulu_University_Hospital"}],"tags":[],"related":["tays-cancer-centre"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["juha-korpelainen"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Oulu","country":"FI","lat":65.007,"lng":25.519,"institutionType":"hospital","website":"https://oys.fi","programs":[]},{"id":"oxford-cancer","kind":"institution","name":"Oxford Cancer (Oxford University Hospitals and University of Oxford)","aka":["Churchill Hospital Oxford Cancer and Haematology Centre","CRUK Oxford Centre","Oxford Institute for Radiation Oncology"],"tldr":"Oxford's cancer partnership, combining the Churchill Hospital with the university's radiation oncology, Ludwig and early detection institutes and a deep drug and diagnostics spin-out tradition.","summary":"Oxford Cancer unites the Oxford University Hospitals cancer and haematology services at the Churchill Hospital with the University of Oxford's Department of Oncology, the Oxford Institute for Radiation Oncology (descended from the Gray Laboratory's hypoxia research), the Ludwig Institute for Cancer Research Oxford branch and the Weatherall Institute of Molecular Medicine. The CRUK Oxford Centre and Oxford Centre for Early Cancer Detection focus on prevention, screening and liquid biopsy, while the Oxford Cancer and Haematology Centre runs early-phase and radiotherapy trials. Oxford science underpins companies such as Immunocore (from Avidex, whose tebentafusp became the first TCR bispecific approved for uveal melanoma) and Oxford Nanopore, and the ChAdOx vaccine platform is being tested for cancer vaccines. Patients access one of the UK's largest haematology and transplant programmes and a growing sarcoma and colorectal service.","asOf":"2026-09-09","links":[{"label":"Oxford Cancer","url":"https://www.cancer.ox.ac.uk"},{"label":"Department of Oncology","url":"https://www.oncology.ox.ac.uk"},{"label":"OUH cancer services","url":"https://www.ouh.nhs.uk/cancer/"}],"tags":[],"related":[],"cancers":["melanoma","colorectal","ovarian","aml","pancreatic","prostate"],"sections":["early-detection","radiation","immunotherapy"],"technologies":["t-cell-engager","liquid-biopsy","imrt-igrt","shared-antigen-vaccine","wes-wgs"],"targets":["gp100"],"drugs":["tebentafusp"],"companies":["immunocore"],"institutions":["cruk"],"pathways":[],"terms":[],"trials":["quasar","scot","coin","protect"],"people":["mark-middleton","freddie-hamdy","richard-gray","richard-peto","rachel-kerr","tim-maughan"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Oxford","country":"GB","lat":51.751,"lng":-1.214,"institutionType":"university","website":"https://www.cancer.ox.ac.uk","university":"University of Oxford","programs":["Oxford Institute for Radiation Oncology","Early cancer detection","Ludwig Oxford","Immunotherapy and vaccine platforms","Haematology and transplant"]},{"id":"pan-mass-challenge","kind":"institution","name":"Pan-Mass Challenge","aka":["PMC"],"tldr":"The bike ride Billy Starr founded in 1980 after his mother died of melanoma; it has raised $1.125 billion for Dana-Farber and passes on every rider-raised dollar.","summary":"The Pan-Mass Challenge is an annual two-day bike ride across Massachusetts. Its founder Billy Starr organised the first ride in 1980 with 36 riders and 10 volunteers; it now involves more than 6,800 riders and 3,500 volunteers. The PMC states that since 1980 it has raised $1.125 billion for Dana-Farber Cancer Institute, that 100 percent of all rider-raised funds go directly to cancer research and treatment at Dana-Farber and the Jimmy Fund, and that it provides 67 percent of the Jimmy Fund's annual revenue. It is the largest athletic fundraiser for a single institution in the United States.","asOf":"2026-09-10","links":[{"label":"About the PMC","url":"https://www.pmc.org/about"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["dana-farber","jimmy-fund"],"pathways":[],"terms":[],"trials":[],"people":["billy-starr"],"bottlenecks":["b-funding-allocation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Needham, MA","country":"US","lat":42.283,"lng":-71.233,"institutionType":"consortium","website":"https://www.pmc.org","programs":["Annual Pan-Mass Challenge ride","PMC Kids Rides","PMC Winter Cycle"]},{"id":"pancreatic-cancer-action","kind":"institution","name":"Pancreatic Cancer Action","aka":[],"tldr":"A UK charity founded by a pancreatic cancer survivor that works on early diagnosis: symptom awareness campaigns and education for GPs and the public.","summary":"Pancreatic Cancer Action (registered charity 1137689 in England and Wales and SC049777 in Scotland, registered office in Guildford) describes itself as the only UK charity focused specifically on improving pancreatic cancer survival through early diagnosis. Founded by a survivor, it runs symptom and risk factor awareness campaigns through the year and education for health professionals, and publishes news for people affected by the disease.","asOf":"2026-09-24","links":[{"label":"Pancreatic Cancer Action: about us","url":"https://pancreaticcanceraction.org/about-us/"}],"tags":["charity","uk","pancreatic","early-detection"],"related":[],"cancers":["pancreatic"],"sections":["early-detection"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Guildford","country":"GB","lat":51.236,"lng":-0.573,"institutionType":"consortium","website":"https://pancreaticcanceraction.org/","programs":["Symptom awareness campaigns","Early diagnosis education","Support and information"]},{"id":"pancreatic-cancer-uk","kind":"institution","name":"Pancreatic Cancer UK","aka":["PCUK"],"tldr":"The UK's pancreatic cancer charity: a specialist nurse Support Line, the list of NHS specialist centres, the Optimal Care Pathway that GIRFT and the national audit measure against, research funding and the campaign to end PERT shortages.","summary":"Pancreatic Cancer UK (registered charity 1112708 in England and Wales and SC046392 in Scotland) runs a free Support Line staffed by specialist nurses (0808 801 0707, also by email and WhatsApp), publishes patient information including the fact sheet on pancreatic enzyme replacement therapy, keeps the list of UK specialist centres that the National Pancreatic Cancer Audit uses to define its HPB centres, and funds research into early detection and treatment. In 2021 it launched the Optimal Care Pathway initiative, bringing together 300 health professionals and people with lived experience to agree six recommendations: dedicated expert support from diagnosis, a 24/7 rapid access enhanced care service, an HPB or upper GI clinical nurse specialist as lead contact, diagnosis within 21 days of referral, standardised treatment pathways by stage, and treatment within 21 days of diagnosis (42 days from referral). Its current campaign calls for an end to shortages of PERT, which it says affect at least 61,000 people; its past Don't Write Me Off campaign pressed governments on treatment rates.","asOf":"2026-09-24","links":[{"label":"Pancreatic Cancer UK","url":"https://www.pancreaticcancer.org.uk/"},{"label":"Optimal Care Pathway hub","url":"https://www.pancreaticcancer.org.uk/health-professionals/resources-for-health-professionals/optimal-care-pathway-hub/"},{"label":"Your local specialist centre","url":"https://www.pancreaticcancer.org.uk/information-and-support/your-care/your-local-pancreatic-cancer-specialist-centre/"},{"label":"Statistics","url":"https://www.pancreaticcancer.org.uk/about-us/who-we-are/media-centre/pancreatic-cancer-statistics/"}],"tags":["charity","uk","pancreatic"],"related":["uk-hpb-specialist-centres"],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["macmillan-cancer-support"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"London","country":"GB","lat":51.492,"lng":-0.122,"institutionType":"consortium","website":"https://www.pancreaticcancer.org.uk/","programs":["Specialist nurse Support Line","Your local specialist centre list","Optimal Care Pathway (2021)","PERT shortage campaign","Research funding: early detection and treatment","Clinical trial finder","Pancreatic Cancer Awareness Month (November)"]},{"id":"parker-institute","kind":"institution","name":"Parker Institute for Cancer Immunotherapy","aka":["PICI"],"tldr":"Sean Parker's 2016 institute that runs cancer immunotherapy research as one network across a dozen leading cancer centres, sharing data, samples and intellectual property.","summary":"The Parker Institute for Cancer Immunotherapy was founded in 2016 with a founding grant from Sean Parker. It describes itself as an active research institute rather than a grant maker: its mission is to develop breakthrough immune therapies to turn all cancers into curable diseases faster, and its model removes barriers between institutions so that ideas move into real-world treatments. Its network page lists seven primary research institutions, Weill Cornell Medicine, Stanford Medicine, the Gladstone Institutes, UCLA, UCSF, the University of Pennsylvania and Dana-Farber, and six member collaborators added since launch: Memorial Sloan Kettering, MD Anderson, the Tisch Cancer Institute at Mount Sinai, Washington University School of Medicine, Fred Hutchinson Cancer Center and City of Hope. Sean Parker is founder and chairman, Jeffrey Bluestone was the founding chief executive and Karen Knudsen is chief executive today. PICI funds investigators, coordinates multi-centre trials of CAR-T and checkpoint combinations, and has spun out companies to carry results forward: its own news pages describe ArsenalBio as a company it launched, list Tmunity Therapeutics as a partner and record a collaboration with Immunai to build one of the largest single-cell datasets in cancer. No trial in OnCo yet names PICI as sponsor, so the trials list stays empty until one does.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Parker_Institute_for_Cancer_Immunotherapy","links":[{"label":"About PICI","url":"https://www.parkerici.org/about/"},{"label":"PICI network: research institutions","url":"https://www.parkerici.org/network/research-institutions/"},{"label":"PICI leadership and board","url":"https://www.parkerici.org/about/leadership-staff/"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["immunotherapy","car-t","checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":["arsenal-bio","tmunity-therapeutics","immunai"],"institutions":["stanford","ucsf","penn-abramson","dana-farber","mskcc","md-anderson","ucla-jonsson","mount-sinai","wustl-siteman","fred-hutch","city-of-hope"],"pathways":[],"terms":[],"trials":[],"people":["carl-june","james-allison","sean-parker","jeffrey-bluestone","karen-knudsen","padmanee-sharma","jedd-wolchok"],"bottlenecks":["b-ip-collaboration","b-immunotherapy-response","b-funding-allocation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"San Francisco","country":"US","lat":37.767,"lng":-122.391,"institutionType":"research-institute","website":"https://www.parkerici.org","programs":["Network research across member cancer centres","CAR-T and cell therapy engineering","Checkpoint combination trials","Shared data and intellectual property model"]},{"id":"paul-ehrlich-institut","kind":"institution","name":"Paul-Ehrlich-Institut","aka":["PEI","Federal Institute for Vaccines and Biomedicines","Bundesinstitut für Impfstoffe und biomedizinische Arzneimittel"],"tldr":"The German federal agency for vaccines and biomedicines, which regulates every CAR-T, gene therapy and cancer vaccine in Germany, often leads their assessment for the whole EU, and grants the hospital-exemption permissions that let a university hospital supply its own cell therapy.","summary":"Section 77(2) of the Arzneimittelgesetz gives the Paul-Ehrlich-Institut, based in Langen near Frankfurt and reporting to the Federal Ministry of Health, competence for sera, vaccines, blood preparations, tissue preparations, allergens, advanced therapy medicinal products, xenogeneic medicines and genetically engineered blood components; its own portfolio pages add monoclonal antibodies. For oncology that means the CAR-T products, oncolytic viruses, gene-modified and tumour-infiltrating cell therapies and therapeutic cancer vaccines. It authorises clinical trials of those products and says it frequently takes the rapporteur or co-rapporteur role in the EMA centralised procedure at the Committee for Advanced Therapies and the CHMP, often leading the assessment of the CAR-T products.\n\nIts most distinctive power is the hospital exemption. Section 4b AMG disapplies the marketing authorisation chapter for an advanced therapy prescribed for an individual patient, not routinely manufactured and used in a specialised healthcare facility under a doctor's responsibility, but supplying it still needs a permission from PEI, with the facilities named, the expected number of patients a year stated and a risk-management plan. PEI's published table of gene therapy medicinal products carries seventeen EU-authorised products and one national permission: HD-CAR-19 (heidagen-lecleucel), held by Universitätsklinikum Heidelberg since 23 September 2025. Four further national permissions appear in its somatic cell therapy and tissue-engineered product tables.","asOf":"2026-09-25","links":[{"label":"Paul-Ehrlich-Institut","url":"https://www.pei.de"},{"label":"The institute","url":"https://www.pei.de/EN/institute/institute-node.html"},{"label":"Gene therapy medicinal products authorised in Germany","url":"https://www.pei.de/DE/arzneimittel/atmp/gentherapeutika/gentherapeutika-node.html"},{"label":"Permissions under section 4b(3) AMG","url":"https://www.pei.de/DE/regulation/genehmigungen/atmp-4b-amg/atmp-4b-amg-node.html"},{"label":"Section 4b AMG","url":"https://www.gesetze-im-internet.de/amg_1976/__4b.html"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["car-t"],"targets":[],"drugs":[],"companies":[],"institutions":["ema","bfarm","heidelberg-nct","g-ba-iqwig"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-regulatory-fragmentation","b-manufacturing-cell-therapy"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Langen","country":"DE","lat":50.006,"lng":8.672,"institutionType":"government","website":"https://www.pei.de","programs":["Authorisation and batch release of biomedicines","(Co-)rapporteur for ATMPs at CAT and CHMP","Clinical trial authorisation for biologicals","Hospital exemption permissions under section 4b AMG"]},{"id":"pauls-stradins-clinical-university-hospital","kind":"institution","name":"Pauls Stradiņš Clinical University Hospital","aka":["Pauls Stradins Clinical University Hospital","PSCUH","Stradiņi"],"tldr":"Pauls Stradiņš Clinical University Hospital in Riga is one of Latvia's two main university hospitals and a full member of the Organisation of European Cancer Institutes.","summary":"Pauls Stradiņš Clinical University Hospital is a large hospital in Riga, founded in 1910, that combines outpatient and inpatient care with medical education and research for Riga Stradiņš University. Alongside Riga East University Hospital, which hosts the national oncology centre, it provides specialised cancer care for Latvia and is listed by the Organisation of European Cancer Institutes as a full member. Programme, trial and leadership details are not yet recorded here and should be checked on the hospital's own pages.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Pauls_Stradi%C5%86%C5%A1_Clinical_University_Hospital","links":[{"label":"Official website","url":"https://www.stradini.lv"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Pauls_Stradiņš_Clinical_University_Hospital"}],"tags":[],"related":["riga-east-university-hospital"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["lauris-vidzis"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Riga","country":"LV","lat":56.932,"lng":24.065,"institutionType":"hospital","website":"https://www.stradini.lv","programs":[]},{"id":"pumch","kind":"institution","name":"Peking Union Medical College Hospital","aka":["PUMCH","协和医院"],"tldr":"China's most prestigious general hospital, founded with Rockefeller money in 1921, and a national referral centre for rare, endocrine and gynaecological tumours.","summary":"PUMCH was established in 1921 by the Rockefeller Foundation's China Medical Board and remains the teaching hospital of Peking Union Medical College under the Chinese Academy of Medical Sciences. It is the national flagship for difficult diagnoses, with strong departments in gynaecological oncology (gestational trophoblastic disease, ovarian and cervical cancer), pancreatic and hepatobiliary surgery, neuroendocrine tumours, thyroid and pituitary disease, and rare-disease genetics. PUMCH hosts the National Rare Diseases Registry and several national quality-control centres, and its investigators sit on many CSCO guideline panels. Patients can access phase 1-3 trials in gynaecological, pancreatic and neuroendocrine cancers alongside multidisciplinary tumour boards.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Peking_Union_Medical_College_Hospital","links":[{"label":"PUMCH","url":"https://www.pumch.cn"},{"label":"Peking Union Medical College","url":"https://www.pumc.edu.cn"}],"tags":[],"related":[],"cancers":["ovarian","cervical","pancreatic","neuroendocrine","thyroid"],"sections":["surgery","diagnostics"],"technologies":["robotic-surgery","germline-testing"],"targets":[],"drugs":[],"companies":[],"institutions":["cams-cancer-hospital"],"pathways":[],"terms":["csco-guidelines","rare-cancers","multidisciplinary-tumour-board"],"trials":[],"people":["zhang-shuyang"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Beijing","country":"CN","lat":39.913,"lng":116.417,"institutionType":"hospital","website":"https://www.pumch.cn","university":"Peking Union Medical College / Chinese Academy of Medical Sciences","programs":["Gynaecological oncology","Pancreatic and hepatobiliary surgery","Neuroendocrine tumours","Rare-disease genetics"]},{"id":"pku-cancer-hospital","kind":"institution","name":"Peking University Cancer Hospital","aka":["Beijing Cancer Hospital","Beijing Institute for Cancer Research","北京大学肿瘤医院"],"tldr":"Beijing's dedicated cancer hospital and the leading Chinese centre for gastric cancer trials, where claudin 18.2 CAR-T and PD-1 combinations were first tested in gastric disease.","summary":"Founded in 1976 as the Beijing Institute for Cancer Research, the hospital is Peking University's cancer centre and a nationally designated clinical speciality in gastrointestinal oncology, gastric surgery, lymphoma, melanoma and sarcoma. Lin Shen's GI oncology department has led or co-led the pivotal Chinese trials of PD-1 antibodies in gastric and oesophageal cancer, the first-in-human claudin 18.2 CAR-T study (satricabtagene autoleucel with CARsgen), and early ADC programmes. Jun Guo's melanoma group defined the biology and treatment of acral and mucosal melanoma, which dominate in East Asia. The hospital runs a large phase 1 unit and the Beijing cancer registry.","asOf":"2026-09-09","links":[{"label":"Peking University Cancer Hospital","url":"https://www.bjcancer.org"},{"label":"Peking University Health Science Center","url":"https://www.bjmu.edu.cn"}],"tags":[],"related":[],"cancers":["gastric","esophageal","melanoma","colorectal","dlbcl","sarcoma"],"sections":["cell-therapy","immunotherapy"],"technologies":["car-t","checkpoint-inhibitor","adc"],"targets":["cldn18-2","pd1","her2"],"drugs":["satricabtagene-autoleucel","disitamab-vedotin"],"companies":["carsgen","remegen"],"institutions":[],"pathways":[],"terms":["csco-guidelines"],"trials":[],"people":["shen-lin","qi-changsong","ziyu-li","yuqin-song","guo-jun"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Beijing","country":"CN","lat":39.939,"lng":116.291,"institutionType":"cancer-center","website":"https://www.bjcancer.org","university":"Peking University","programs":["Gastric and oesophageal cancer","Claudin 18.2 CAR-T","Acral and mucosal melanoma","Lymphoma","Phase 1 unit"]},{"id":"pku-peoples-hospital","kind":"institution","name":"Peking University People's Hospital","aka":["PKUPH","Peking University Institute of Hematology","北京大学人民医院"],"tldr":"Peking University People's Hospital is the world's largest haploidentical stem cell transplant centre and the home of the Beijing Protocol that lets almost any patient find a donor.","summary":"Its Institute of Hematology, led by Huang Xiaojun, developed the Beijing Protocol for haploidentical transplantation without in vitro T-cell depletion (Bone Marrow Transplantation 2006), now the dominant transplant approach in China and adopted by centres elsewhere; it performs more than a thousand transplants a year. Also a major site for CAR-T, leukaemia and lymphoma trials and the hospital's Breast Center and hepatobiliary units.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Peking_University_People's_Hospital","links":[{"label":"Official website","url":"https://www.pkuph.cn/"},{"label":"Huang XJ et al. Bone Marrow Transplant 2006","url":"https://doi.org/10.1038/sj.bmt.1705445"}],"tags":["china"],"related":[],"cancers":["aml","all-leukemia"],"sections":[],"technologies":["allogeneic-cell-therapy","car-t"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["huang-xiaojun"],"bottlenecks":[],"keyPapers":["paper-huang-bone-marrow-transplant"],"journals":[],"dependsOn":[],"notes":[],"city":"Beijing","country":"CN","lat":39.933,"lng":116.362,"institutionType":"hospital","website":"https://www.pkuph.cn/","university":"Peking University","programs":["Haploidentical transplantation (Beijing Protocol)","Leukaemia and lymphoma trials","CAR-T"]},{"id":"peninsula-cancer-alliance","kind":"institution","name":"Peninsula Cancer Alliance","aka":["PCA"],"tldr":"The NHS England Cancer Alliance for Devon, Cornwall and the Isles of Scilly: the partnership that plans and improves cancer services across its hospitals, GPs and community services.","summary":"One of the 20 Cancer Alliances set up by NHS England from 2016, following the Independent Cancer Taskforce strategy, to bring together the hospital trusts, integrated care boards, primary care, hospices and charities serving Devon, Cornwall and the Isles of Scilly. Alliances lead local delivery of the NHS cancer ambitions: earlier diagnosis (including rapid diagnostic centres and targeted lung health checks), the Faster Diagnosis Standard, personalised care and follow-up, and workforce and pathway improvement. They hold transformation funding from NHS England and publish local performance and improvement plans.","asOf":"2026-09-09","links":[{"label":"Peninsula Cancer Alliance","url":"https://peninsulacanceralliance.nhs.uk/"},{"label":"NHS England: Cancer Alliances","url":"https://www.england.nhs.uk/cancer/cancer-alliances-improving-care-locally/"}],"tags":["nhs-cancer-alliance"],"related":["swag-cancer-alliance"],"cancers":[],"sections":["early-detection"],"technologies":["low-dose-ct-screening"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Exeter","country":"GB","lat":50.718,"lng":-3.534,"institutionType":"consortium","website":"https://peninsulacanceralliance.nhs.uk/","programs":["Earlier diagnosis and rapid diagnostic centres","Faster Diagnosis Standard","Personalised care and follow-up","Cancer pathway improvement"]},{"id":"peter-mac","kind":"institution","name":"Peter MacCallum Cancer Centre","aka":[],"tldr":"Peter Mac is Australia's only dedicated cancer hospital and a leader in theranostics, CAR-T, and radiation oncology.","summary":"Peter MacCallum Cancer Centre in Melbourne is Australia's only dedicated cancer hospital, the core of the Victorian Comprehensive Cancer Centre, and ranks fourteenth in the Newsweek/Statista oncology list. It pioneered PSMA PET imaging and lutetium-177 PSMA radioligand therapy through Hofman's TheraP and proPSMA trials, became Australia's first CAR-T centre, and has a strong radiation oncology programme, with Sarah-Jane Dawson, Joseph Trapani, Declan G. Murphy, Andrew H. Wei and Grant McArthur among its people. OnCo links it to prostate cancer, to the CROWN and DYNAMIC papers, to ANZUP and other Australian trial groups, and to ideas for a rapid research autopsy network and a shared cyclotron network for new tracers. Getting radioligand supply and regulation to match demand is the open problem its theranostics work exposes. Its trial and people pages carry the detail.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Peter_MacCallum_Cancer_Centre","links":[{"label":"Official website","url":"https://www.petermac.org"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["psma-pet","radioligand-therapy"],"targets":[],"drugs":["pluvicto"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["dawson-sarah-jane","trapani-joseph","prudence-francis","declan-murphy","linda-mileshkin","andrew-wei","michael-dickinson","john-seymour","shankar-siva","solomon-benjamin","mcarthur-grant","hofman-michael","sandhu-shahneen","loi-sherene"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Melbourne","country":"AU","lat":-37.799,"lng":144.956,"institutionType":"cancer-center","website":"https://www.petermac.org","newsweekOncology2026":14,"programs":["PSMA theranostics (TheraP, proPSMA)","CAR-T","Radiation oncology"]},{"id":"pbac","kind":"institution","name":"Pharmaceutical Benefits Advisory Committee","aka":["PBAC","Pharmaceutical Benefits Scheme"],"tldr":"The independent committee that decides which medicines Australia's Pharmaceutical Benefits Scheme subsidises, and at what price, on cost-effectiveness evidence.","summary":"The PBAC is an independent expert body appointed by the Australian Government under the National Health Act 1953; no new medicine can be listed on the Pharmaceutical Benefits Scheme without a positive PBAC recommendation. It assesses comparative effectiveness and cost-effectiveness, publishes Public Summary Documents for every decision, and negotiates risk-sharing and managed-access arrangements for expensive cancer drugs with uncertain evidence. The PBS is one of the oldest universal medicines subsidy schemes and its rejections and deferrals of high-cost oncology drugs are closely watched by companies and patient groups. Registration by the TGA must precede or run in parallel with PBAC consideration.","asOf":"2026-09-09","links":[{"label":"PBAC","url":"https://www.pbs.gov.au/industry/listing/participants/pbac"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["tga","cancer-council-australia","nice","peter-mac"],"pathways":[],"terms":["real-world-evidence","os"],"trials":[],"people":["robyn-ward"],"bottlenecks":["b-drug-pricing","b-global-access"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Canberra","country":"AU","lat":-35.281,"lng":149.129,"institutionType":"government","website":"https://www.pbs.gov.au/industry/listing/participants/pbac","programs":["PBS listing recommendations","Public Summary Documents","Managed access and risk-sharing arrangements","Parallel TGA-PBAC process"]},{"id":"pmda","kind":"institution","name":"Pharmaceuticals and Medical Devices Agency","aka":["PMDA","独立行政法人医薬品医療機器総合機構"],"tldr":"Japan's drug and device review agency, which works with the health ministry to approve cancer drugs and has largely closed the historical 'drug lag' with the US and Europe.","summary":"Established in 2004, the PMDA conducts scientific review of new drugs, devices and regenerative medicine products, with final approval by the Ministry of Health, Labour and Welfare. It introduced the SAKIGAKE fast-track designation, conditional early approval for regenerative medicines, and the Orphan and Conditional approval pathways, and it has been a full participant in ICH harmonisation. Japan approved many antibody-drug conjugates and targeted lung cancer agents at or near the same time as the FDA, and its requirements for Japanese patient data shaped global trial designs. The PMDA also runs post-marketing safety surveillance and the relief system for adverse drug reactions.","asOf":"2026-09-09","links":[{"label":"PMDA","url":"https://www.pmda.go.jp/english/"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["adc","photoimmunotherapy"],"targets":[],"drugs":["trastuzumab-deruxtecan","osimertinib"],"companies":[],"institutions":["ncc-japan","jsmo","fda-oce","ema"],"pathways":[],"terms":[],"trials":[],"people":["yasuhiro-fujiwara"],"bottlenecks":["b-regulatory-fragmentation","b-global-access"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Tokyo","country":"JP","lat":35.674,"lng":139.762,"institutionType":"government","website":"https://www.pmda.go.jp/english/","programs":["New drug and device review","SAKIGAKE designation","Conditional and time-limited approval for regenerative medicine","Post-marketing safety"]},{"id":"philippine-general-hospital","kind":"institution","name":"Philippine General Hospital","aka":["PGH","UP-PGH","UP Manila Cancer Institute"],"tldr":"The Philippines' national university hospital, whose Cancer Institute is the country's main public referral centre for oncology and the site of its cancer control research.","summary":"The Philippine General Hospital opened in 1907 and is the tertiary teaching hospital of the University of the Philippines Manila and the largest government hospital in the country. Its Cancer Institute provides surgical, medical, radiation and paediatric oncology to a predominantly indigent population, hosts the Philippine Cancer Society's Manila registry collaboration, and leads national work on cervical cancer screening, HPV vaccination, breast cancer early detection and paediatric leukaemia outcomes. PGH researchers and the UP National Institutes of Health inform the National Integrated Cancer Control Act implementation, and the hospital's radiotherapy expansion and philanthropic cancer funds aim to reduce treatment abandonment.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Philippine_General_Hospital","links":[{"label":"Philippine General Hospital","url":"https://www.pgh.gov.ph"},{"label":"UP Manila","url":"https://www.upm.edu.ph"}],"tags":[],"related":["global-oncology-access","financial-toxicity"],"cancers":["cervical","breast-hr-positive","all-leukemia","head-and-neck"],"sections":["prevention"],"technologies":["hpv-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["gerardo-legaspi"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Manila","country":"PH","lat":14.578,"lng":120.986,"institutionType":"hospital","website":"https://www.pgh.gov.ph","university":"University of the Philippines Manila","programs":["Cancer Institute","Cervical cancer screening and HPV vaccination","Paediatric oncology","Cancer control policy"]},{"id":"gemelli","kind":"institution","name":"Policlinico Universitario A. Gemelli","aka":[],"tldr":"Gemelli is Rome's Catholic university hospital and a leader in gynaecologic oncology.","summary":"Policlinico Universitario A. Gemelli is Rome's Catholic university hospital and a leader in gynaecologic oncology, ranked twenty-ninth in the Newsweek/Statista World's Best Specialized Hospitals list for oncology. Its gynaecologic oncology programme, associated with Giovanni Scambia, sits alongside radiotherapy and gastrointestinal surgery, with Anna Fagotti, Vincenzo Valentini and Giampaolo Tortora among the people OnCo lists, and it plays a role in ovarian, cervical and endometrial cancer trials. OnCo links it to the KEYNOTE-A18 cervical cancer paper and to PAOLA-1 in ovarian cancer, and to the European Society of Gynaecological Oncology and Fondazione AIRC. How to extend PARP inhibitor benefit beyond HRD-positive ovarian tumours is the question its trial work keeps returning to. Its gynaecologic programme is the reason to read this page.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.policlinicogemelli.it"}],"tags":[],"related":[],"cancers":["ovarian","cervical","endometrial"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["giampaolo-tortora","anna-fagotti","giovanni-scambia","vincenzo-valentini","daniele-piacentini"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Rome","country":"IT","lat":41.933,"lng":12.428,"institutionType":"university","website":"https://www.policlinicogemelli.it","newsweekOncology2026":29,"programs":["Gynaecologic oncology"]},{"id":"polish-mothers-memorial-hospital","kind":"institution","name":"Polish Mother's Memorial Hospital Research Institute","aka":["Instytut Centrum Zdrowia Matki Polki","ICZMP","Polish Mothers Memorial Hospital Research Institute"],"tldr":"The Polish Mother's Memorial Hospital Research Institute in Łódź is a national research hospital for women's and children's health, including gynaecological and paediatric cancers, and a full member of the Organisation of European Cancer Institutes.","summary":"The Polish Mother's Memorial Hospital Research Institute (Instytut Centrum Zdrowia Matki Polki) in Łódź is a national research institute and hospital for obstetrics, gynaecology and paediatrics, whose cancer work covers gynaecological oncology and children's cancers. It is listed by the Organisation of European Cancer Institutes as a full member, one of five Polish institutions on the list. Programme, trial and leadership details are not yet recorded here and should be checked on the hospital's own pages.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.iczmp.edu.pl"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":["nio-warsaw","uck-gdansk"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["iwona-maroszynska"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Łódź","country":"PL","lat":51.707,"lng":19.482,"institutionType":"research-institute","website":"https://www.iczmp.edu.pl","programs":[]},{"id":"pgimer-chandigarh","kind":"institution","name":"Postgraduate Institute of Medical Education and Research, Chandigarh","aka":["PGIMER","PGI Chandigarh"],"tldr":"PGIMER Chandigarh is the main tertiary referral hospital for north-west India and the regional cancer centre for Punjab and Haryana; its nuclear medicine department is among India's most active in PSMA and FAPI PET imaging and lutetium radioligand therapy.","summary":"PGIMER was established in 1962 and is the main tertiary referral centre for north-west India. Its oncology services span a regional cancer centre with radiotherapy and brachytherapy, medical and surgical oncology, and paediatric haematology-oncology, and its Department of Nuclear Medicine is among India's most active in PSMA and FAPI PET imaging and lutetium-based radioligand therapy. PGIMER researchers publish extensively on cervical cancer screening, gallbladder cancer, chronic myeloid leukaemia and cancer epidemiology in Punjab, and the institute leads the population cancer registries for the region and Indian cooperative trials.","asOf":"2026-09-09","links":[{"label":"PGIMER Chandigarh","url":"https://pgimer.edu.in"}],"tags":[],"related":[],"cancers":["prostate","cervical","cholangiocarcinoma","all-leukemia","neuroendocrine"],"sections":["radiopharma","radiation"],"technologies":["radioligand-therapy","psma-pet","fapi-pet","brachytherapy"],"targets":[],"drugs":["lutathera","pluvicto"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["vivek-lal"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Chandigarh","country":"IN","lat":30.765,"lng":76.775,"institutionType":"hospital","website":"https://pgimer.edu.in","programs":["Nuclear medicine and theranostics","Radiotherapy and brachytherapy","Haematology","Cancer registry"]},{"id":"prince-of-wales-hospital-cuhk","kind":"institution","name":"Prince of Wales Hospital / Chinese University of Hong Kong","aka":["PWH","CUHK Faculty of Medicine","Sir Y.K. Pao Centre for Cancer","威爾斯親王醫院"],"tldr":"The hospital where plasma EBV DNA screening for nasopharyngeal cancer and cell-free DNA cancer detection were invented by Dennis Lo's group.","summary":"Prince of Wales Hospital in Sha Tin is the teaching hospital of the Chinese University of Hong Kong and houses the Sir Y.K. Pao Centre for Cancer and the Hong Kong Cancer Institute. Dennis Lo's laboratory at CUHK discovered plasma cell-free fetal DNA and then showed that plasma EBV DNA can screen asymptomatic men for early nasopharyngeal carcinoma, work that founded liquid biopsy and led to spin-outs including Cirina and GRAIL's early technology. Anthony Chan's group established concurrent chemoradiotherapy and EBV-DNA-guided treatment in NPC, and Joseph Sung's team advanced colorectal cancer screening across Asia. The hospital is a major site for gastrointestinal, hepatocellular and lung cancer trials in Hong Kong.","asOf":"2026-09-09","links":[{"label":"CUHK Faculty of Medicine","url":"https://www.med.cuhk.edu.hk"},{"label":"Hong Kong Cancer Institute","url":"https://www.hkci.cuhk.edu.hk"}],"tags":[],"related":["plasma-ebv-dna"],"cancers":["head-and-neck","colorectal","hcc","nsclc"],"sections":["early-detection","diagnostics"],"technologies":["liquid-biopsy","mced","methylation-profiling"],"targets":[],"drugs":[],"companies":["grail"],"institutions":[],"pathways":[],"terms":["ctdna"],"trials":[],"people":["philip-chiu","tony-mok","anthony-chan"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Hong Kong","country":"HK","lat":22.38,"lng":114.201,"institutionType":"hospital","website":"https://www.med.cuhk.edu.hk","university":"Chinese University of Hong Kong","programs":["Plasma EBV DNA and liquid biopsy","Nasopharyngeal carcinoma","Colorectal cancer screening","Hong Kong Cancer Institute"]},{"id":"princess-margaret","kind":"institution","name":"Princess Margaret Cancer Centre","aka":[],"tldr":"Princess Margaret is Canada's leading cancer centre and a pioneer in immunotherapy and cancer stem cell research.","summary":"Princess Margaret Cancer Centre in Toronto is Canada's leading cancer centre and ranks ninth in the Newsweek/Statista oncology list. It is where John E. Dick's group identified cancer stem cells, and it runs a major phase 1 unit under Lillian L. Siu alongside tumour-infiltrating lymphocyte and radiation medicine research, with Tak W. Mak, Pamela S. Ohashi and Aaron D. Schimmer among its scientists. OnCo links it to the CHALLENGE colon cancer exercise trial, to cBioPortal, to the cancer stem cell and phenotypic plasticity pathway, and to Ontario Health, the Ontario Institute for Cancer Research and the Canadian Cancer Society. Whether stem cell biology can yet be turned into treatments patients feel is still open. Its people page shows who to read.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Princess_Margaret_Cancer_Centre","links":[{"label":"Official website","url":"https://www.uhn.ca/PrincessMargaret"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["john-dick","lillian-siu","tak-mak","pamela-ohashi","aaron-schimmer","natasha-leighl","trevor-pugh","ian-tannock","keith-stewart","amit-oza"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Toronto","country":"CA","lat":43.657,"lng":-79.39,"institutionType":"cancer-center","website":"https://www.uhn.ca/PrincessMargaret","newsweekOncology2026":9,"university":"University of Toronto","programs":["Cancer stem cells","Phase 1","Radiation medicine"]},{"id":"princess-maxima","kind":"institution","name":"Princess Máxima Center for Pediatric Oncology","aka":["Prinses Máxima Centrum","Máxima"],"tldr":"The national children's cancer centre of the Netherlands, which concentrates all Dutch paediatric oncology care and research on one Utrecht campus.","summary":"Opened in 2018, the Princess Máxima Center brought together paediatric oncology from the Dutch university hospitals into a single specialised hospital and research institute next to UMC Utrecht and the Wilhelmina Children's Hospital. Every child is offered whole-genome and transcriptome sequencing at diagnosis, and research groups led by figures such as Jarno Drost, Monique den Boer and Michel Zwaan develop tumour organoids, leukaemia genomics and early-phase drug trials through the ITCC European consortium. Alexander Eggermont serves as chief scientific officer. The centre treats leukaemias, brain tumours, neuroblastoma, sarcomas and renal tumours, offers CAR-T and transplantation, and runs one of Europe's largest paediatric cancer survivorship programmes.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.prinsesmaximacentrum.nl/en"},{"label":"Research","url":"https://research.prinsesmaximacentrum.nl"}],"tags":[],"related":[],"cancers":["all-leukemia","aml","neuroblastoma","glioblastoma","sarcoma"],"sections":["diagnostics","cell-therapy"],"technologies":["wes-wgs","organoids","car-t","rna-seq","proton-therapy"],"targets":[],"drugs":[],"companies":["curie-nki-eortc"],"institutions":["umc-utrecht"],"pathways":[],"terms":[],"trials":[],"people":["alexander-eggermont","rene-medema"],"bottlenecks":["b-rare-cancers","b-survivorship"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Utrecht","country":"NL","lat":52.085,"lng":5.171,"institutionType":"cancer-center","website":"https://www.prinsesmaximacentrum.nl/en","university":"Utrecht University","programs":["National paediatric oncology hospital","Whole-genome sequencing for every child","Paediatric organoids","ITCC early-phase trials","Survivorship (LATER)"]},{"id":"pcf","kind":"institution","name":"Prostate Cancer Foundation","aka":["PCF","CaP CURE"],"tldr":"The foundation Michael Milken started in 1993 after his own diagnosis; it funds prostate cancer research worldwide and helped pay for the science behind two of the drugs men now take.","summary":"Founded in 1993 by Michael Milken after he was diagnosed with advanced prostate cancer, the Prostate Cancer Foundation funds investigators and teams rather than running its own labs. Its history page credits $8 million of PCF funding toward the development of abiraterone (Zytiga) and $14.75 million toward enzalutamide (Xtandi), and a $65 million partnership with the US Department of Veterans Affairs in 2016 that set up 22 precision oncology centres of excellence for veterans. PCF runs Young Investigator and Challenge awards, an annual scientific retreat, and awareness campaigns. Headquartered in Santa Monica, California.","asOf":"2026-09-10","links":[{"label":"PCF: our history","url":"https://www.pcf.org/about/our-history/"}],"tags":[],"related":["prostate-cancer-foundation"],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["abiraterone","enzalutamide"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["charles-sawyers","michael-milken"],"bottlenecks":["b-funding-allocation","b-translational-valley"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Santa Monica, CA","country":"US","lat":34.017,"lng":-118.496,"institutionType":"consortium","website":"https://www.pcf.org","programs":["Young Investigator Awards","Challenge Awards for team science","VA Precision Oncology Centers of Excellence","Annual scientific retreat"]},{"id":"prostate-cancer-uk","kind":"institution","name":"Prostate Cancer UK","aka":[],"tldr":"The UK charity that funds prostate cancer research, answers the questions the NHS has no time for through a team of Specialist Nurses, and is paying for half of TRANSFORM, the trial that will decide whether Britain ever screens for this disease.","summary":"Prostate Cancer UK (registered charity 1005541 in England and Wales and SC039332 in Scotland, at The Counting House, 53 Tooley Street, London) runs a free Specialist Nurse service on 0800 074 8383, reachable by telephone, WhatsApp, email and online chat, and a separate Risk Information Service on 0800 448 0821 for men who have not been diagnosed and want to talk through their risk and the PSA test before deciding anything.\n\nIts campaigning centres on the fact that has been known since 2015 and acted on slowly: one in four Black men will get prostate cancer, roughly double the risk of other men. Its Stronger Knowing More campaign, its 30-second online risk checker, which it says more than 190,000 Black men have completed, and a one-to-one peer support service that matches a man with a trained Black volunteer who has had the disease, all exist to close that gap. It called the UK National Screening Committee's March 2026 recommendation a positive first step while saying plainly that the committee did not recommend screening Black men over 45.\n\nIt is the larger funder of TRANSFORM, the multi-arm screening trial run from Imperial College London that began recruiting on 21 November 2025, and it is the body that will publish the answer on Black men when stage 2 opens to all eligible Black men aged 45 to 74.","asOf":"2026-09-25","links":[{"label":"Prostate Cancer UK","url":"https://prostatecanceruk.org/"},{"label":"Get support","url":"https://prostatecanceruk.org/prostate-information-and-support/get-support"},{"label":"Black men and prostate cancer","url":"https://prostatecanceruk.org/prostate-information-and-support/risk-and-symptoms/black-men-and-prostate-cancer"},{"label":"The risk checker","url":"https://prostatecanceruk.org/risk-checker"},{"label":"The TRANSFORM trial","url":"https://prostatecanceruk.org/research/transform-trial"}],"tags":["charity","uk","prostate"],"related":[],"cancers":["prostate","prostate-mhspc","prostate-mcrpc","prostate-low-risk"],"sections":["early-detection"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["macmillan-cancer-support"],"pathways":[],"terms":["psa"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"London","country":"GB","lat":51.505,"lng":-0.086,"institutionType":"consortium","website":"https://prostatecanceruk.org/","programs":["Specialist Nurse service, 0800 074 8383, by telephone, WhatsApp, email and online chat","Risk Information Service, 0800 448 0821, for undiagnosed men","The 30-second online risk checker","Stronger Knowing More: the Black men and prostate cancer campaign and its one-to-one peer support service","Co-funder and co-sponsor of the TRANSFORM screening trial with the NIHR","Research grants across diagnosis, treatment and survivorship"]},{"id":"providence-health","kind":"institution","name":"Providence Health & Services","aka":[],"tldr":"Providence is a 51-hospital US health system whose 1.3 billion pathology tiles trained Prov-GigaPath with Microsoft.","summary":"Providence Health and Services, based in Renton, Washington, is a fifty-one hospital US health system whose pathology archive trained Prov-GigaPath with Microsoft. It contributed 171,189 whole slides from more than thirty thousand patients, amounting to 1.3 billion image tiles, to the model, and it runs one of the larger real-world genomics programmes in US community oncology, with Erik G. Wexler among the people linked. OnCo connects it to the Prov-GigaPath technology record. Whether a community health system's data can keep feeding foundation models without patients losing control of their records is the open question its partnership raises. Its Prov-GigaPath and community genomics programmes are listed below.","asOf":"2026-09-08","wikipedia":"https://en.wikipedia.org/wiki/Providence_Health_%26_Services","links":[{"label":"Official website","url":"https://www.providence.org"}],"tags":["ai"],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["erik-wexler"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Renton, WA","country":"US","lat":47.48,"lng":-122.217,"institutionType":"hospital","website":"https://www.providence.org","programs":["Prov-GigaPath (with Microsoft)","Community oncology genomics"]},{"id":"purdue-cancer-research","kind":"institution","name":"Purdue Institute for Cancer Research","aka":["Purdue University Center for Cancer Research"],"tldr":"Purdue's NCI basic cancer centre, where Philip Low's folate- and PSMA-targeted ligands created Endocyte, the company Novartis bought for its radioligand programme.","summary":"NCI-designated since 1978, the Purdue Institute for Cancer Research is a basic laboratory centre built on chemistry, engineering and analytical science rather than a hospital. Philip Low's folate receptor-targeted imaging agents and small-molecule drug conjugates founded Endocyte, which later licensed the PSMA radioligand that became Pluvicto and was acquired by Novartis in 2018; his laboratory also produced the tumour-targeted fluorescent agents used in fluorescence-guided surgery. Graham Cooks's ambient mass spectrometry (DESI) is being applied to intra-operative tumour margin assessment, and structural and medicinal chemistry programmes feed drug discovery. Purdue partners with Indiana University's Simon Comprehensive Cancer Center for clinical translation.","asOf":"2026-09-09","links":[{"label":"Purdue Institute for Cancer Research","url":"https://www.cancerresearch.purdue.edu"},{"label":"Purdue University","url":"https://www.purdue.edu"}],"tags":[],"related":[],"cancers":[],"sections":["drug-discovery","radiopharma"],"technologies":["radioligand-therapy","fluorescence-guided-surgery","peptide-drug-conjugate"],"targets":["psma","folr1"],"drugs":["pluvicto"],"companies":["novartis"],"institutions":["iu-simon"],"pathways":[],"terms":[],"trials":[],"people":["andrew-mesecar"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"West Lafayette, IN","country":"US","lat":40.424,"lng":-86.921,"institutionType":"research-institute","website":"https://www.cancerresearch.purdue.edu","nci":"basic","university":"Purdue University","programs":["Ligand-targeted drugs and imaging agents","Mass spectrometry for surgical margins","Medicinal chemistry"]},{"id":"qimr-berghofer","kind":"institution","name":"QIMR Berghofer Medical Research Institute","aka":["QIMR","Queensland Institute of Medical Research"],"tldr":"Queensland's medical research institute, a world leader in melanoma and skin cancer genetics, cancer epidemiology and adoptive T-cell therapy for virus-associated cancers.","summary":"QIMR Berghofer was founded in 1945 as the Queensland Institute of Medical Research and works alongside the Royal Brisbane and Women's Hospital in Herston. Its cancer research is anchored in genetic epidemiology, with leading roles in melanoma and skin cancer genetics (Nicholas Hayward, David Whiteman), the QSkin cohort, and the Australian breast and ovarian cancer family studies (Georgia Chenevix-Trench, kConFab collaborations), and in immunology, where Rajiv Khanna's group developed EBV- and CMV-specific T-cell therapies for nasopharyngeal carcinoma and glioblastoma and Mark Smyth's laboratory shaped NK-cell and checkpoint immunology. The institute operates a GMP cell therapy facility (Q-Gen) and a clinical trials centre.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/QIMR_Berghofer","links":[{"label":"QIMR Berghofer","url":"https://www.qimrberghofer.edu.au"}],"tags":[],"related":[],"cancers":["melanoma","breast-hr-positive","ovarian","glioblastoma","head-and-neck"],"sections":["prevention","cell-therapy"],"technologies":["tcr-t","germline-testing","car-nk-macrophage"],"targets":["brca"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["brandon-wainwright"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Brisbane","country":"AU","lat":-27.448,"lng":153.028,"institutionType":"research-institute","website":"https://www.qimrberghofer.edu.au","university":"University of Queensland","programs":["Melanoma and skin cancer genetics","Cancer epidemiology and cohorts","Virus-specific T-cell therapy","Q-Gen cell manufacturing"]},{"id":"qst-hospital","kind":"institution","name":"QST Hospital (National Institutes for Quantum Science and Technology)","aka":["NIRS Hospital","HIMAC","QST病院"],"tldr":"The world's first carbon-ion therapy hospital (HIMAC, 1994), which established the clinical evidence base for heavy-ion radiotherapy.","summary":"QST Hospital, formerly the National Institute of Radiological Sciences hospital, began treating patients with carbon ions at the Heavy Ion Medical Accelerator in Chiba (HIMAC) in 1994, the first dedicated medical heavy-ion facility. Over three decades it has treated more carbon-ion patients than any other centre, developed hypofractionated protocols for prostate, lung, liver, pancreatic, bone and soft-tissue sarcoma and head and neck tumours, and pioneered scanning beam delivery, respiratory gating and the rotating gantry now used in newer facilities. The institute leads Japan's quantum-scanning carbon-ion programme, radiopharmaceutical research including astatine-211 targeted alpha therapy, and international training for centres in Europe and Asia.","asOf":"2026-09-09","links":[{"label":"QST Hospital (page moved; nearest live section)","url":"https://www.qst.go.jp/"},{"label":"QST","url":"https://www.qst.go.jp/site/qst-english/"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":["prostate","pancreatic","sarcoma","hcc","head-and-neck"],"sections":["radiation","radiopharma"],"technologies":["carbon-ion","targeted-alpha-therapy","carbon-ion-synchrotrons"],"targets":[],"drugs":[],"companies":[],"institutions":["gunma-heavy-ion-medical-center"],"pathways":[],"terms":["alpha-vs-beta"],"trials":[],"people":["hitoshi-ishikawa"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Chiba","country":"JP","lat":35.634,"lng":140.104,"institutionType":"research-institute","website":"https://www.qst.go.jp/","programs":["Carbon-ion therapy (HIMAC)","Compact carbon-ion technology","Astatine-211 alpha therapy","Radiation biology"]},{"id":"queen-mary-hospital-hku","kind":"institution","name":"Queen Mary Hospital / University of Hong Kong","aka":["QMH","HKU Li Ka Shing Faculty of Medicine","瑪麗醫院"],"tldr":"Hong Kong's principal teaching hospital, where living-donor liver transplantation for liver cancer and nasopharyngeal cancer research were advanced.","summary":"Queen Mary Hospital, opened in 1937, is the teaching hospital of the University of Hong Kong's Li Ka Shing Faculty of Medicine and hosts the HKU Clinical Trials Centre and the Hong Kong Cancer Registry's largest referral base. HKU surgeons under Sheung-Tat Fan and Chung-Mau Lo pioneered adult right-lobe living-donor liver transplantation and set standards for hepatocellular carcinoma resection, while HKU's Centre for Nasopharyngeal Carcinoma Research and its clinical oncologists have shaped EBV-DNA based staging and induction chemotherapy in NPC. The hospital also runs the territory's bone marrow transplant service and phase 1 unit, and HKU pathology contributed to early CAR-T and hepatitis-B related HCC studies. HKU is a partner of the Hong Kong Genome Project.","asOf":"2026-09-09","links":[{"label":"HKU Li Ka Shing Faculty of Medicine","url":"https://www.med.hku.hk"},{"label":"HKU Clinical Trials Centre","url":"https://www.hkuctc.com"},{"label":"Hospital Authority: Queen Mary Hospital","url":"https://www.ha.org.hk"}],"tags":[],"related":["plasma-ebv-dna"],"cancers":["hcc","head-and-neck","nsclc","aml"],"sections":["surgery","diagnostics"],"technologies":["liquid-biopsy","robotic-surgery"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["chak-sing-lau"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Hong Kong","country":"HK","lat":22.27,"lng":114.131,"institutionType":"hospital","website":"https://www.hku.hk","university":"University of Hong Kong","programs":["Liver transplantation and HCC surgery","Nasopharyngeal carcinoma","Haematology and transplant","Phase 1 Clinical Trials Centre"]},{"id":"queens-centre-hull","kind":"institution","name":"Queen's Centre for Oncology and Haematology, Castle Hill Hospital","aka":["Hull University Teaching Hospitals","Castle Hill Hospital"],"tldr":"The regional cancer centre for Hull, East Yorkshire and northern Lincolnshire, opened at Castle Hill Hospital in 2008.","summary":"The Queen's Centre for Oncology and Haematology at Castle Hill Hospital opened in 2008 as the purpose-built cancer centre for Hull University Teaching Hospitals, bringing radiotherapy, chemotherapy, haematology, inpatient oncology and a clinical trials unit onto one site for Hull, the East Riding and northern Lincolnshire. It works with Hull York Medical School and the University of Hull's cancer research groups, including the Jack Brignall PET-CT Centre and the Daisy Appeal-funded Molecular Imaging Research Centre, and is part of the Humber and North Yorkshire cancer alliance.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.hull.nhs.uk"}],"tags":["nhs-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["radiotherapy","clinical-trial"],"trials":[],"people":["lyn-simpson"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Cottingham (Hull)","country":"GB","lat":53.781,"lng":-0.441,"institutionType":"hospital","website":"https://www.hull.nhs.uk","university":"Hull York Medical School","programs":["Radiotherapy","Molecular imaging research","Clinical trials"]},{"id":"queens-university-kingston","kind":"institution","name":"Queen's University / Kingston Health Sciences Centre","aka":["Queen's University Department of Oncology","Cancer Centre of Southeastern Ontario","Kingston General Hospital"],"tldr":"Ontario university and hospital that host the Canadian Cancer Trials Group and Christopher Booth's programme on the real-world value of cancer treatments.","summary":"Queen's University in Kingston, Ontario, and its teaching hospital, the Kingston Health Sciences Centre with the Cancer Centre of Southeastern Ontario, are the home of the Canadian Cancer Trials Group. The university's Department of Oncology and Division of Cancer Care and Epidemiology include Christopher Booth, whose work on the gap between trial and real-world benefit helped found the Common Sense Oncology movement, and who was a lead investigator of the CHALLENGE exercise trial.","asOf":"2026-09-18","links":[{"label":"Queen's University","url":"https://www.queensu.ca"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["cctg"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["christopher-booth"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Kingston, ON","country":"CA","lat":44.225,"lng":-76.495,"institutionType":"university","website":"https://www.queensu.ca","programs":["Cancer care and epidemiology","Common Sense Oncology","Canadian Cancer Trials Group"]},{"id":"kavetsky-institute-kyiv","kind":"institution","name":"R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology","aka":["RE Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology of National Academy of Sciences of Ukraine (IEPOR)","IEPOR","Kavetsky Institute"],"tldr":"R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology is the cancer research institute of the National Academy of Sciences of Ukraine in Kyiv, and an associate member of the Organisation of European Cancer Institutes.","summary":"R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology is the cancer research institute of the National Academy of Sciences of Ukraine in Kyiv. It is listed by the Organisation of European Cancer Institutes as an associate member, which is why it has a page on OnCo. Programme, trial and leadership details are not yet recorded here and should be checked on the institution's own pages.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.iepor.site"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["vasyl-f-chekhun"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Kyiv","country":"UA","lat":50.45,"lng":30.524,"institutionType":"research-institute","website":"https://www.iepor.site","programs":[]},{"id":"radboudumc","kind":"institution","name":"Radboudumc Centre for Oncology","aka":["Radboud University Medical Center"],"tldr":"The university hospital of Nijmegen, a leading Dutch centre for prostate imaging, dendritic cell vaccines and tumour immunology, currently in OECI accreditation.","summary":"Radboud University Medical Center is the academic hospital of Radboud University and a tertiary cancer centre for the east of the Netherlands. Its Centre for Oncology integrates medical oncology, radiotherapy, haematology, surgical oncology and urology, and its research is internationally recognised in prostate MRI and PSMA imaging, dendritic cell vaccination and tumour immunology (Radboud Institute for Molecular Life Sciences), hereditary cancer, and hepatobiliary and pancreatic surgery. Radboudumc is listed by the Organisation of European Cancer Institutes as in accreditation.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.radboudumc.nl"}],"tags":["oeci-in-accreditation"],"related":[],"cancers":["prostate"],"sections":[],"technologies":["psma-pet"],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["bertine-lahuis","haiko-bloemendal"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Nijmegen","country":"NL","lat":51.824,"lng":5.86,"institutionType":"hospital","website":"https://www.radboudumc.nl","university":"Radboud University","programs":["Prostate imaging and PSMA","Dendritic cell vaccines","Tumour immunology","Hereditary cancer"]},{"id":"raigmore-inverness","kind":"institution","name":"Raigmore Hospital, Inverness","aka":["NHS Highland"],"tldr":"The surgical centre for the Highland area of NHS Scotland North.","summary":"Pancreatic Cancer UK lists Raigmore Hospital, NHS Highland, as the surgical centre for NHS Scotland North in the Highland area.","asOf":"2026-09-24","links":[{"label":"NHS Highland","url":"https://www.nhshighland.scot.nhs.uk/"},{"label":"Pancreatic Cancer UK centres list","url":"https://www.pancreaticcancer.org.uk/information-and-support/your-care/your-local-pancreatic-cancer-specialist-centre/"}],"tags":["hpb","nhs","uk"],"related":[],"cancers":["pancreatic","gallbladder","biliary-tract-cancer","cholangiocarcinoma","hcc"],"sections":["surgery"],"technologies":["whipple"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Inverness","country":"GB","lat":57.464,"lng":-4.196,"institutionType":"hospital","website":"https://www.nhshighland.scot.nhs.uk/","programs":["Pancreatic surgery","North of Scotland HPB MDT"]},{"id":"rgci","kind":"institution","name":"Rajiv Gandhi Cancer Institute and Research Centre","aka":["RGCIRC","RGCI"],"tldr":"The Rajiv Gandhi Cancer Institute in Delhi opened in 1996 as a charitable hospital and is North India's largest private not-for-profit cancer centre; it was among the first Indian centres to offer robotic cancer surgery, in-house next-generation sequencing and a large bone marrow transplant unit.","summary":"The Rajiv Gandhi Cancer Institute and Research Centre opened in Rohini, Delhi, in 1996 as a charitable cancer hospital and has become one of the largest dedicated cancer centres in India, with a second campus at Niti Bagh. It was among the first Indian centres to offer robotic cancer surgery, a large bone marrow transplant unit, in-house next-generation sequencing and molecular diagnostics, and modern radiotherapy including tomotherapy and stereotactic techniques. RGCI runs a DNB training programme, a tumour registry and a research wing, and participates in Indian and international multicentre trials in breast, head and neck, lung and haematological cancers.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Rajiv_Gandhi_Cancer_Institute_and_Research_Centre","links":[{"label":"RGCIRC","url":"https://www.rgcirc.org"}],"tags":[],"related":[],"cancers":["head-and-neck","breast-hr-positive","nsclc","dlbcl","cervical"],"sections":["surgery","radiation"],"technologies":["robotic-surgery","cgp","imrt-igrt","sbrt"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["dharmendra-singh-gangwar"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"New Delhi","country":"IN","lat":28.712,"lng":77.114,"institutionType":"cancer-center","website":"https://www.rgcirc.org","programs":["Robotic cancer surgery","Bone marrow transplant","Molecular diagnostics","Radiation oncology"]},{"id":"ramathibodi-hospital","kind":"institution","name":"Ramathibodi Hospital, Mahidol University","aka":["Faculty of Medicine Ramathibodi Hospital","โรงพยาบาลรามาธิบดี"],"tldr":"Mahidol's second great teaching hospital, with leading Thai programmes in paediatric oncology, haematology, cancer genetics and hepatobiliary surgery.","summary":"Ramathibodi Hospital opened in 1969 as Mahidol University's second faculty of medicine and is one of Thailand's top research hospitals. It is known for paediatric haematology-oncology and thalassaemia, adult haematology and stem cell transplant, the Ramathibodi cancer genetics and pharmacogenomics programmes, hepatobiliary and colorectal surgery, and a large radiation oncology service; it also participates widely in international trials in breast, lung and gastrointestinal cancer. The Chakri Naruebodindra Medical Institute campus and the Ramathibodi Comprehensive Cancer Center expand its capacity, and Mahidol's Institute of Molecular Biosciences supports cholangiocarcinoma and liver-fluke research relevant to north-east Thailand.","asOf":"2026-09-09","links":[{"label":"Ramathibodi Hospital","url":"https://www.rama.mahidol.ac.th"},{"label":"Mahidol University","url":"https://mahidol.ac.th"}],"tags":[],"related":[],"cancers":["all-leukemia","aml","cholangiocarcinoma","breast-hr-positive","colorectal"],"sections":["diagnostics","chemotherapy"],"technologies":["germline-testing","allogeneic-cell-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["atiporn-ingsathit"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Bangkok","country":"TH","lat":13.766,"lng":100.526,"institutionType":"hospital","website":"https://www.rama.mahidol.ac.th","university":"Mahidol University","programs":["Paediatric oncology","Haematology and transplant","Cancer genetics and pharmacogenomics","Comprehensive Cancer Center"]},{"id":"rambam","kind":"institution","name":"Rambam Health Care Campus","aka":["Rambam Medical Center","Rambam Hospital"],"tldr":"Northern Israel's tertiary hospital, affiliated with the Technion, where the ubiquitin-proteasome discoveries behind proteasome inhibitors and degraders were made.","summary":"Rambam Health Care Campus is the largest hospital in northern Israel and the teaching hospital of the Technion's Rappaport Faculty of Medicine, where Aaron Ciechanover and Avram Hershko carried out the Nobel-recognised work on ubiquitin-mediated protein degradation that underlies bortezomib and targeted protein degraders. Its Joseph Fishman Oncology Center provides medical, radiation and surgical oncology, haematology and transplantation, and paediatric haemato-oncology for a diverse population; Irit Ben-Aharon leads gastrointestinal oncology with a research focus on early-onset colorectal cancer. Rambam participates in Israeli cooperative and international trials and hosts translational research in cancer metabolism and immunology.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Rambam_Health_Care_Campus","links":[{"label":"Homepage","url":"https://www.rambam.org.il/en/"}],"tags":[],"related":[],"cancers":["colorectal","multiple-myeloma","breast-hr-positive","aml"],"sections":["targeted-therapy","drug-discovery"],"technologies":["protac-degrader","allogeneic-cell-therapy","imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":["sheba","weizmann","technion"],"pathways":[],"terms":[],"trials":[],"people":["michal-mekel"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Haifa","country":"IL","lat":32.836,"lng":34.985,"institutionType":"hospital","website":"https://www.rambam.org.il/en/","university":"Technion, Israel Institute of Technology","programs":["Joseph Fishman Oncology Center","Ubiquitin-proteasome heritage (Technion)","Gastrointestinal oncology","Haematology and transplantation"]},{"id":"renji-hospital","kind":"institution","name":"Renji Hospital, Shanghai Jiao Tong University","aka":["Renji Hospital","仁济医院","Shanghai Cancer Institute"],"tldr":"Renji Hospital and the Shanghai Cancer Institute on its campus are where CARsgen's solid-tumour CAR-T work began, including the Claudin 18.2 CAR-T satri-cel for stomach cancer.","summary":"Home of the State Key Laboratory of Oncogenes and Related Genes (Shanghai Cancer Institute), where Li Zonghai developed GPC3 and Claudin 18.2 CAR-T cells before founding CARsgen; a large gastrointestinal oncology and liver programme and one of the first sites for CT041 (satricabtagene autoleucel) trials.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.renji.com/"}],"tags":["china"],"related":[],"cancers":["gastric","hcc"],"sections":[],"technologies":["car-t"],"targets":[],"drugs":["satricabtagene-autoleucel","zevorcabtagene-autoleucel"],"companies":["carsgen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["li-zonghai"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Shanghai","country":"CN","lat":31.209,"lng":121.532,"institutionType":"hospital","website":"https://www.renji.com/","university":"Shanghai Jiao Tong University","programs":["Shanghai Cancer Institute","Solid tumour CAR-T trials","Gastrointestinal oncology"]},{"id":"riga-east-university-hospital","kind":"institution","name":"Riga East University Hospital / Oncology Centre of Latvia","aka":["Rīgas Austrumu klīniskā universitātes slimnīca","Latvijas Onkoloģijas centrs"],"tldr":"Latvia's largest hospital group, whose Oncology Centre of Latvia is the country's main cancer hospital and holds OECI Cancer Centre accreditation.","summary":"Riga East University Hospital is the largest multi-profile hospital in Latvia and the clinical base for Riga Stradins University and the University of Latvia. Its Oncology Centre of Latvia is the national referral centre for cancer, providing surgical oncology, medical oncology, radiotherapy and nuclear medicine for the whole country, and it hosts the national cancer registry functions and Latvia's participation in European clinical trials. The centre is accredited by the Organisation of European Cancer Institutes as a Cancer Centre.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.aslimnica.lv"}],"tags":["oeci-accredited","oeci-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["vadims-beluns","alinta-hegmane"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Riga","country":"LV","lat":56.953,"lng":24.188,"institutionType":"hospital","website":"https://www.aslimnica.lv","programs":["Oncology Centre of Latvia","Radiotherapy","Nuclear medicine"]},{"id":"rigshospitalet","kind":"institution","name":"Rigshospitalet, Copenhagen University Hospital","aka":["Rigshospitalet","Copenhagen University Hospital","Copenhagen Comprehensive Cancer Center","Copenhagen Comprehensive Cancer Center (CCCC)"],"tldr":"Denmark's national referral hospital, a leading Nordic centre for haematology, phase 1 trials and, with Herlev, tumour-infiltrating lymphocyte therapy.","summary":"Rigshospitalet is Denmark's national referral hospital for specialised care and the largest partner in the Danish Comprehensive Cancer Center. Its haematology department under Kirsten Grønbæk and colleagues leads Danish and Nordic leukaemia and lymphoma trials and CAR-T delivery, the phase 1 unit under Ulrik Lassen runs the Copenhagen Prospective Personalized Oncology programme, and radiation oncology has a long record in lymphoma and breast radiotherapy trials. Copenhagen University Hospital's Herlev site hosts the National Center for Cancer Immune Therapy (CCIT-DK, Inge Marie Svane), which co-led the phase 3 trial of TIL therapy in melanoma with the Netherlands Cancer Institute. Denmark's population registries and biobanks make the hospital a hub for real-world and epidemiological cancer research.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.rigshospitalet.dk/english"},{"label":"Danish Comprehensive Cancer Center","url":"https://www.dccc.dk/english/"},{"label":"CCIT-DK","url":"https://www.herlevhospital.dk/ccit-dk/"}],"tags":[],"related":[],"cancers":["cll","aml","dlbcl","melanoma","nsclc"],"sections":["cell-therapy","immunotherapy"],"technologies":["til-therapy","car-t","cgp","imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":["nki","aarhus-university-hospital"],"pathways":[],"terms":["real-world-evidence"],"trials":[],"people":["rasmus-mogelvang","mansoor-raza-mirza","jannick-brennum"],"bottlenecks":["b-real-world-evidence"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Copenhagen","country":"DK","lat":55.696,"lng":12.57,"institutionType":"hospital","website":"https://www.rigshospitalet.dk/english","university":"University of Copenhagen","programs":["Haematology and CAR-T","Phase 1 unit (CoPPO)","TIL therapy (CCIT-DK, Herlev)","Danish Comprehensive Cancer Center","Registry-based research"]},{"id":"rijnstate-arnhem","kind":"institution","name":"Rijnstate","aka":["Rijnstate Hospital Arnhem"],"tldr":"A large Dutch teaching hospital in Arnhem whose oncology centre is accredited by OECI as a Cancer Centre.","summary":"Rijnstate is a top-clinical teaching hospital serving Arnhem and the surrounding Gelderland region. Its oncology centre concentrates medical oncology, radiotherapy (with the Radiotherapiegroep), haematology, surgical oncology and supportive care in multidisciplinary pathways, and it is one of the few non-academic hospitals in Europe accredited by the Organisation of European Cancer Institutes as a Cancer Centre. The hospital participates in Dutch cooperative group trials and works with Radboudumc in Nijmegen on complex and rare cancers.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.rijnstate.nl"}],"tags":["oeci-accredited","oeci-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci","radboudumc"],"pathways":[],"terms":[],"trials":[],"people":["geraline-leusink","rosaline-den-blanken"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Arnhem","country":"NL","lat":51.985,"lng":5.898,"institutionType":"hospital","website":"https://www.rijnstate.nl","programs":["Oncology centre","Surgical oncology","Clinical trials"]},{"id":"northwestern-lurie","kind":"institution","name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University","aka":["Lurie Cancer Center"],"tldr":"Chicago's Northwestern cancer centre, a world leader in brain tumour therapy from Tumour Treating Fields to ultrasound opening of the blood-brain barrier.","summary":"NCI-designated since 1993 and comprehensive since 1997, the Lurie Cancer Center is anchored at Northwestern Memorial Hospital on Chicago's Streeterville campus. Roger Stupp, who defined the temozolomide chemoradiation standard for glioblastoma, led the EF-14 trial that brought Tumour Treating Fields (Optune) into first-line glioblastoma care; Adam Sonabend's team has shown that implantable ultrasound can open the blood-brain barrier to deliver chemotherapy and antibodies. Other strengths include breast oncology (William Gradishar), haematologic malignancies, prostate cancer and cancer survivorship research. The centre serves the Chicago metropolitan area through Northwestern Medicine's regional network.","asOf":"2026-09-09","links":[{"label":"Lurie Cancer Center","url":"https://www.cancer.northwestern.edu"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":["glioblastoma","breast-hr-positive","prostate"],"sections":["devices"],"technologies":["ttfields","bbb-focused-ultrasound","proton-therapy","proton-therapy-systems"],"targets":[],"drugs":["optune","temozolomide"],"companies":["novocure"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["roger-stupp","ann-lurie","maha-hussain"],"bottlenecks":["b-brain-delivery"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Chicago, IL","country":"US","lat":41.895,"lng":-87.62,"institutionType":"cancer-center","website":"https://www.cancer.northwestern.edu","nci":"comprehensive","university":"Northwestern University","programs":["Neuro-oncology (Malnati Brain Tumor Institute)","Tumour Treating Fields","Ultrasound blood-brain barrier opening","Breast oncology"]},{"id":"mcgill-goodman","kind":"institution","name":"Rosalind and Morris Goodman Cancer Institute, McGill University","aka":["Goodman Cancer Institute","McGill Cancer Centre"],"tldr":"McGill's Goodman Cancer Institute builds on the 1965 discovery here of carcinoembryonic antigen, the first clinically used tumour marker; its groups study breast cancer metastasis, mRNA translation control and tumour metabolism, and William Muller's HER2 mouse models are used worldwide.","summary":"Founded in 1978 as the McGill Cancer Centre, the Goodman Cancer Institute builds on Phil Gold and Samuel Freedman's 1965 discovery at McGill of carcinoembryonic antigen (CEA), the first clinically used tumour marker and today the target of CEACAM5 antibody-drug conjugates. William Muller's MMTV-driven mouse models of HER2/Neu breast cancer are used worldwide; Morag Park and Peter Siegel study the breast tumour microenvironment and metastasis; Nahum Sonenberg's work on mRNA translation control (eIF4E) opened a therapeutic axis; and metabolism researchers including Julie St-Pierre link mitochondrial biology to tumour progression. The institute partners with McGill's teaching hospitals, the Jewish General Hospital's Segal Cancer Centre and the McGill University Health Centre, for translation.","asOf":"2026-09-09","links":[{"label":"Goodman Cancer Institute","url":"https://www.mcgill.ca/gci/"},{"label":"McGill University","url":"https://www.mcgill.ca"}],"tags":[],"related":[],"cancers":["breast-her2-positive","melanoma","colorectal"],"sections":["drug-discovery"],"technologies":["metabolic-therapy","pdx-models"],"targets":["ceacam5","her2"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["john-stagg","jonathan-spicer"],"bottlenecks":["b-metastasis-biology","b-preclinical-models"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Montréal, QC","country":"CA","lat":45.504,"lng":-73.577,"institutionType":"research-institute","website":"https://www.mcgill.ca/gci/","university":"McGill University","programs":["Metastasis and tumour microenvironment","Mouse models of breast cancer","Translation control and metabolism"]},{"id":"roswell-park","kind":"institution","name":"Roswell Park Comprehensive Cancer Center","aka":[],"tldr":"Roswell Park is America's first cancer centre (1898), with strengths in immunotherapy and cell therapy manufacturing.","summary":"Roswell Park Comprehensive Cancer Center in Buffalo is America's first cancer centre, founded in 1898, and holds NCI comprehensive designation; its strengths are immunotherapy and cell therapy manufacturing. It runs GMP cell manufacturing, developed the SurVaxM glioblastoma vaccine, and is the origin of photodynamic therapy through Dougherty, with Candace S. Johnson, Renier J. Brentjens, Igor Puzanov, Eunice S. Wang, Pawel Kalinski and Robert A. Fenstermaker and Kara M. Kelly among the people OnCo lists, and Gilda Radner also linked. OnCo connects it to photoimmunotherapy and photodynamic therapy and to Generate:Biomedicines. Whether academic GMP capacity can lower the cost of cell therapies is the question its manufacturing programme tests. Its cell therapy and photodynamic programmes are listed below.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Roswell_Park_Comprehensive_Cancer_Center","links":[{"label":"Official website","url":"https://www.roswellpark.org"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["photoimmunotherapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["candace-johnson","renier-brentjens","igor-puzanov","robert-fenstermaker","eunice-wang","pawel-kalinski","gilda-radner","kara-kelly"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Buffalo, NY","country":"US","lat":42.899,"lng":-78.867,"institutionType":"cancer-center","website":"https://www.roswellpark.org","nci":"comprehensive","programs":["Cell therapy manufacturing","Photodynamic therapy"]},{"id":"roy-castle-lung-cancer-foundation","kind":"institution","name":"Roy Castle Lung Cancer Foundation","aka":[],"tldr":"The only UK charity that works on lung cancer alone: a nurse-answered helpline, information days and support groups around the country, research fellowships, and the campaigning that pushed the NHS towards a national screening programme.","summary":"Roy Castle Lung Cancer Foundation (registered charity 1046854 in England and Wales, SC037596 in Scotland and 1277 in the Isle of Man, a company limited by guarantee registered as 03059425, at the Cotton Exchange Building, Old Hall Street, Liverpool) describes itself as the only UK charity dedicated exclusively to supporting everyone affected by lung cancer. It runs the free Ask the Nurse helpline on 0800 358 7200, staffed by experienced lung cancer nurses, and the Keep in Touch service, which gives a person or their carer fortnightly calls for up to twelve sessions; it holds free information days around the UK with oncologists, thoracic surgeons, nurses, physiotherapists and dietitians, and supports nurse-led local groups.\n\nIts history is a research history. The Liverpool thoracic surgeon Ray Donnelly set up the Lung Cancer Fund on 18 April 1990 after failing to persuade anyone else to pay for work on early detection; the first grant, in May 1993, went to the study of early genetic changes in lung cancer. Roy Castle's Tour of Hope raised a million pounds in 1994 towards what became the world's first lung cancer research centre, opened in May 1998, and the following year the charity paid for the first UK mobile laboratory to recruit high-risk people into screening. It has funded clinical research fellowships since 2012 and is named in the funding statement of the UK Lung Cancer Screening trial's mortality paper. Its campaigns address the thing that makes lung cancer different: Let Go of the Labels argues that the words smoker and never-smoker distort what is going on and deny people an earlier diagnosis, and its policy asks include that no one should wait longer than 14 days for genomic testing.","asOf":"2026-09-25","links":[{"label":"Roy Castle Lung Cancer Foundation","url":"https://roycastle.org/"},{"label":"Telephone support","url":"https://roycastle.org/our-support/telephone-support/"},{"label":"Research","url":"https://roycastle.org/about-us/research/"},{"label":"Campaigns","url":"https://roycastle.org/about-us/campaigns/"},{"label":"Useful contacts and support organisations","url":"https://roycastle.org/our-support/useful-contacts-and-support-organisations/"}],"tags":["charity","uk","lung"],"related":[],"cancers":["nsclc","sclc","lung-cancer"],"sections":["early-detection"],"technologies":["low-dose-ct-screening"],"targets":[],"drugs":[],"companies":[],"institutions":["macmillan-cancer-support"],"pathways":[],"terms":[],"trials":[],"people":["john-field"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Liverpool","country":"GB","lat":53.411,"lng":-2.994,"institutionType":"consortium","website":"https://roycastle.org/","programs":["Ask the Nurse helpline, 0800 358 7200","Keep in Touch telephone support","Information days and nurse-led support groups across the UK","Lung cancer clinical research fellowships","Self-request chest X-ray resource hub for commissioners","Let Go of the Labels and This is Lung Cancer campaigns"]},{"id":"royal-adelaide-hospital","kind":"institution","name":"Royal Adelaide Hospital","aka":["RAH","Central Adelaide Local Health Network","Australian Bragg Centre for Proton Therapy"],"tldr":"The Royal Adelaide Hospital is South Australia's largest hospital and its main cancer referral centre, with a phase 1 unit run with SAHMRI; the adjacent Australian Bragg Centre was built to house Australia's first proton therapy facility.","summary":"The Royal Adelaide Hospital, founded in 1840 and rebuilt on a new North Terrace site in 2017, is South Australia's largest hospital and the state's main cancer referral centre, with comprehensive surgical, medical and radiation oncology, haematology and bone marrow transplant, and a phase 1 unit run with the South Australian Health and Medical Research Institute (SAHMRI). The adjacent Australian Bragg Centre for Proton Therapy, named for the Adelaide-born Bragg father and son who described the Bragg peak, was built to house Australia's first proton therapy facility. Adelaide research strengths include haematological malignancy (Centre for Cancer Biology), prostate and breast cancer biology, and gastrointestinal cancer, and the hospital enrols into Australasian cooperative-group trials (AGITG, TROG, ALLG).","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Royal_Adelaide_Hospital","links":[{"label":"Royal Adelaide Hospital","url":"https://www.rah.sa.gov.au"},{"label":"Australian Bragg Centre","url":"https://www.sahmri.org/australian-bragg-centre/"}],"tags":[],"related":[],"cancers":["aml","prostate","breast-hr-positive","colorectal"],"sections":["radiation","chemotherapy"],"technologies":["proton-therapy","imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["timothy-hughes"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Adelaide","country":"AU","lat":-34.921,"lng":138.586,"institutionType":"hospital","website":"https://www.rah.sa.gov.au","university":"University of Adelaide","programs":["Comprehensive cancer centre","Australian Bragg Centre for Proton Therapy","Haematology and transplant","SAHMRI translational research"]},{"id":"royal-blackburn-elht","kind":"institution","name":"Royal Blackburn Hospital (East Lancashire HPB MDT)","aka":["East Lancashire Hospitals NHS Trust","ELHT"],"tldr":"The East Lancashire specialist HPB cancer MDT, one of the 23 English HPB specialist centres; the trust site blocks automated readers, so its listing rests on the audit and Pancreatic Cancer UK.","summary":"East Lancashire Hospitals NHS Trust (trust code RXR) is one of the 23 HPB specialist centres in the National Pancreatic Cancer Audit; Pancreatic Cancer UK lists the East Lancashire Specialist HPB Cancer MDT at Royal Blackburn Hospital for the North West. The trust website answered OnCo with an Incapsula block page on the check date, so no service page is quoted.","asOf":"2026-09-24","links":[{"label":"Pancreatic Cancer UK centres list","url":"https://www.pancreaticcancer.org.uk/information-and-support/your-care/your-local-pancreatic-cancer-specialist-centre/"},{"label":"NPaCA 2026 methodology supplement, Table 7","url":"https://www.natcan.org.uk/wp-content/uploads/2026/09/NPaCA-SotN-2026-Methodology-Supplement.pdf"}],"tags":["hpb","nhs","uk"],"related":[],"cancers":["pancreatic","gallbladder","biliary-tract-cancer","cholangiocarcinoma","hcc"],"sections":["surgery"],"technologies":["whipple"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Blackburn","country":"GB","lat":53.736,"lng":-2.46,"institutionType":"hospital","website":"https://elht.nhs.uk/","programs":["HPB surgery","East Lancashire HPB MDT"]},{"id":"royal-free-hospital","kind":"institution","name":"Royal Free Hospital, Royal Free London NHS Foundation Trust","aka":["Royal Free London","Royal Free"],"tldr":"North London teaching hospital that is a European Centre of Excellence for neuroendocrine tumours, where Martyn Caplin led the CLARINET trial of lanreotide.","summary":"The Royal Free Hospital in Hampstead is the main site of the Royal Free London NHS Foundation Trust and a teaching hospital of University College London. Its Neuroendocrine Tumour Unit, led by Martyn Caplin, is an ENETS Centre of Excellence and coordinated CLARINET, the 2014 New England Journal of Medicine trial in which lanreotide lengthened progression-free survival in non-functioning enteropancreatic neuroendocrine tumours. The hospital is also a national centre for liver transplantation and hepatobiliary cancer.","asOf":"2026-09-18","links":[{"label":"Royal Free London","url":"https://www.royalfree.nhs.uk"}],"tags":[],"related":[],"cancers":["neuroendocrine","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["martyn-caplin"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"London","country":"GB","lat":51.553,"lng":-0.165,"institutionType":"hospital","website":"https://www.royalfree.nhs.uk","university":"University College London","programs":["Neuroendocrine tumours (ENETS Centre of Excellence)","Hepatobiliary cancer","Liver transplantation"]},{"id":"royal-infirmary-edinburgh","kind":"institution","name":"Royal Infirmary of Edinburgh","aka":["NHS Lothian","Edinburgh HPB unit"],"tldr":"The HPB surgical centre for the South East Scotland Cancer Network, with liver transplantation; non-surgical treatment at the Western General.","summary":"Pancreatic Cancer UK lists the Royal Infirmary of Edinburgh as the surgical centre for the South East Scotland Cancer Network, with the Edinburgh Cancer Centre at the Western General Hospital providing non-surgical treatment. It is on AMMF's list of UK centres with cholangiocarcinoma expertise and hosts Scotland's liver transplant unit.","asOf":"2026-09-24","links":[{"label":"NHS Lothian","url":"https://www.nhslothian.scot/"},{"label":"AMMF centres list","url":"https://ammf.org.uk/second-opinions-and-liver-disease-centres/"}],"tags":["hpb","nhs","uk"],"related":[],"cancers":["gallbladder","biliary-tract-cancer","cholangiocarcinoma","pancreatic","hcc"],"sections":["surgery"],"technologies":["hepatectomy"],"targets":[],"drugs":[],"companies":[],"institutions":["edinburgh-cancer-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Edinburgh","country":"GB","lat":55.921,"lng":-3.136,"institutionType":"hospital","website":"https://www.nhslothian.scot/","university":"University of Edinburgh","programs":["HPB surgery","Liver transplantation","South East Scotland HPB MDT"]},{"id":"royal-papworth","kind":"institution","name":"Royal Papworth Hospital NHS Foundation Trust","aka":[],"tldr":"The specialist heart and lung hospital on the Cambridge Biomedical Campus, and one of the 26 NHS thoracic units in England that operate on lung cancer.","summary":"Royal Papworth Hospital NHS Foundation Trust moved to the Cambridge Biomedical Campus in 2019 and runs lung cancer, thoracic surgery, interstitial lung disease and lung infection services alongside its cardiac work; the Heart and Lung Research Institute sits beside it. The National Lung Cancer Audit's 2026 data tables record 236 lung cancer resections at the trust in 2024, with no deaths within 90 days of surgery. It was one of the two hospitals that delivered the UK Lung Cancer Screening trial, and it is a site for the Fit 4 Surgery 2 prehabilitation trial.","asOf":"2026-09-25","links":[{"label":"Royal Papworth Hospital","url":"https://royalpapworth.nhs.uk/"},{"label":"National Lung Cancer Audit data tables 2026","url":"https://www.natcan.org.uk/wp-content/uploads/2026/02/NLCA-SotN-2026-Data-Tables.xlsx"}],"tags":["nhs","uk","thoracic-surgery"],"related":[],"cancers":["nsclc","lung-cancer","resectable-nsclc"],"sections":["surgery"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["lobectomy"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Cambridge","country":"GB","lat":52.175,"lng":0.14,"institutionType":"hospital","website":"https://royalpapworth.nhs.uk/","programs":["Thoracic surgery","Lung cancer service","Heart and Lung Research Institute"]},{"id":"royal-stoke-uhnm","kind":"institution","name":"Royal Stoke University Hospital","aka":["University Hospitals of North Midlands NHS Trust","UHNM"],"tldr":"The HPB specialist centre for Staffordshire, Shropshire (including part of mid Wales) and Wolverhampton.","summary":"University Hospitals of North Midlands NHS Trust (trust code RJE) is one of the 23 HPB specialist centres in the National Pancreatic Cancer Audit. Pancreatic Cancer UK lists Royal Stoke University Hospital as covering Staffordshire, Shropshire including part of mid Wales, and Wolverhampton, and notes that some patients from mid Wales are referred to Stoke-on-Trent.","asOf":"2026-09-24","links":[{"label":"University Hospitals of North Midlands","url":"https://www.uhnm.nhs.uk/"},{"label":"Pancreatic Cancer UK centres list","url":"https://www.pancreaticcancer.org.uk/information-and-support/your-care/your-local-pancreatic-cancer-specialist-centre/"}],"tags":["hpb","nhs","uk"],"related":[],"cancers":["pancreatic","gallbladder","biliary-tract-cancer","cholangiocarcinoma","hcc"],"sections":["surgery"],"technologies":["whipple"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Stoke-on-Trent","country":"GB","lat":53.003,"lng":-2.213,"institutionType":"hospital","website":"https://www.uhnm.nhs.uk/","programs":["HPB surgery","Specialist HPB MDT","Cross-border care for mid Wales"]},{"id":"royal-surrey-guildford","kind":"institution","name":"Royal Surrey County Hospital, Guildford","aka":["Royal Surrey NHS Foundation Trust","Regional HPB Unit, Guildford"],"tldr":"The regional hepato-pancreato-biliary unit for Surrey and its neighbours, one of the 23 English HPB specialist centres.","summary":"Royal Surrey County Hospital NHS Foundation Trust (trust code RA2) is one of the 23 HPB specialist centres in the National Pancreatic Cancer Audit; Pancreatic Cancer UK lists its Regional Hepato-pancreato-biliary Unit for the South East. The trust's HPB service page describes diagnosis, treatment and management of complex disorders of the liver, pancreas and biliary tract.","asOf":"2026-09-24","links":[{"label":"Royal Surrey: HPB service","url":"https://www.royalsurrey.nhs.uk/hpb"},{"label":"Pancreatic Cancer UK centres list","url":"https://www.pancreaticcancer.org.uk/information-and-support/your-care/your-local-pancreatic-cancer-specialist-centre/"}],"tags":["hpb","nhs","uk"],"related":[],"cancers":["pancreatic","gallbladder","biliary-tract-cancer","cholangiocarcinoma","hcc"],"sections":["surgery"],"technologies":["whipple"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Guildford","country":"GB","lat":51.241,"lng":-0.608,"institutionType":"hospital","website":"https://www.royalsurrey.nhs.uk/","programs":["HPB surgery","Specialist HPB MDT"]},{"id":"ruijin-hospital","kind":"institution","name":"Ruijin Hospital, Shanghai Jiao Tong University","aka":["Ruijin Hospital","瑞金医院","Shanghai Institute of Hematology"],"tldr":"The hospital where all-trans retinoic acid and arsenic cured acute promyelocytic leukaemia, and still China's leading haematology centre.","summary":"Ruijin Hospital dates to 1907 and is home to the Shanghai Institute of Hematology, where Zhen-Yi Wang and Zhu Chen established differentiation therapy of acute promyelocytic leukaemia with all-trans retinoic acid and then arsenic trioxide, turning a lethal leukaemia into one of the most curable. The institute remains a global reference for APL, AML genomics and lymphoma, and hosts national CAR-T and haematopoietic transplant programmes. Ruijin is also a major centre for gastric cancer surgery, pancreatic surgery, endocrine tumours and burns, and runs one of Shanghai's proton therapy projects.","asOf":"2026-09-09","links":[{"label":"Ruijin Hospital","url":"https://www.rjh.com.cn"},{"label":"Shanghai Jiao Tong University School of Medicine","url":"https://www.shsmu.edu.cn"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":["aml","dlbcl","all-leukemia","gastric","pancreatic"],"sections":["chemotherapy","cell-therapy","epigenetics"],"technologies":["car-t","proton-therapy","epigenetic-drugs","proton-therapy-systems"],"targets":[],"drugs":["arsenic-trioxide","tretinoin-atra"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["chen-saijuan","chen-zhu"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Shanghai","country":"CN","lat":31.213,"lng":121.467,"institutionType":"hospital","website":"https://www.rjh.com.cn","university":"Shanghai Jiao Tong University","programs":["Shanghai Institute of Hematology","APL differentiation therapy","Lymphoma","Gastric and pancreatic surgery","Proton therapy"]},{"id":"russco","kind":"institution","name":"Russian Society of Clinical Oncology (RUSSCO)","aka":["Российское общество клинической онкологии","RUSSCO","РОКО"],"tldr":"The professional society that writes Russia's clinical oncology treatment guidelines, runs the annual Russian Oncological Congress and funds a national molecular testing programme.","summary":"RUSSCO publishes practice guidelines for the treatment of malignant tumours (Клинические рекомендации по лечению злокачественных опухолей RUSSCO), guidelines on the prevention and management of treatment complications, and anti-tumour drug therapy protocols; it issues the journal Malignant Tumours (Злокачественные опухоли) and advertises the thirtieth Russian Oncological Congress for 10 to 12 December 2026 at Crocus Expo in Moscow. It also runs a national molecular and genetic diagnosis programme for cancer patients through cancergenome.ru. The separate All-Russian national union Association of Oncologists of Russia (Общероссийский национальный союз «Ассоциация онкологов России»), a union of scientific societies and specialists, carries clinical guidelines and drafts of them on its own site.","asOf":"2026-09-25","links":[{"label":"RUSSCO (Russian)","url":"https://www.rosoncoweb.ru"},{"label":"Association of Oncologists of Russia (Russian)","url":"https://oncology-association.ru/"},{"label":"National molecular diagnosis programme","url":"https://cancergenome.ru"}],"tags":[],"related":["blokhin-cancer-center","nmrrc-moscow","petrov-institute"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Moscow","country":"RU","lat":55.756,"lng":37.617,"institutionType":"consortium","website":"https://www.rosoncoweb.ru","programs":["RUSSCO treatment guidelines","Russian Oncological Congress","National molecular and genetic diagnosis programme","Journal Malignant Tumours"]},{"id":"rutgers-cinj","kind":"institution","name":"Rutgers Cancer Institute of New Jersey","aka":["CINJ"],"tldr":"New Jersey's only NCI comprehensive cancer centre, which opened the state's first free-standing cancer hospital in 2025 with RWJBarnabas Health.","summary":"NCI-designated in 1997 and comprehensive since 2002, Rutgers Cancer Institute is New Jersey's only NCI comprehensive centre and works with RWJBarnabas Health across the state. The Jack and Sheryl Morris Cancer Center, New Jersey's first free-standing cancer hospital, opened in New Brunswick in 2025. Research strengths include precision medicine and genomic tumour boards, Eileen White's foundational work on autophagy and cancer metabolism, neuroendocrine and adrenal tumours under director Steven Libutti, and the ScreenNJ statewide screening initiative. Christian Hinrichs moved his HPV-targeted TCR-T programme here from the NCI.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Rutgers_Cancer_Institute_of_New_Jersey","links":[{"label":"Rutgers Cancer Institute","url":"https://www.cinj.org"},{"label":"Clinical trials","url":"https://www.cinj.org/clinical-trials"}],"tags":[],"related":[],"cancers":["neuroendocrine","adrenocortical","cervical"],"sections":["early-detection"],"technologies":["cgp","tcr-t","metabolic-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["nci-ccr"],"pathways":[],"terms":[],"trials":[],"people":["steven-k-libutti"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"New Brunswick, NJ","country":"US","lat":40.496,"lng":-74.448,"institutionType":"cancer-center","website":"https://www.cinj.org","nci":"comprehensive","university":"Rutgers University","programs":["Precision medicine","Autophagy and metabolism","ScreenNJ","TCR-T for HPV cancers"]},{"id":"sahlgrenska","kind":"institution","name":"Sahlgrenska University Hospital / Sahlgrenska Center for Cancer Research","aka":["Sahlgrenska","Gothenburg University Hospital"],"tldr":"Western Sweden's university hospital, with a cancer research centre known for melanoma models, radionuclide dosimetry and childhood cancer.","summary":"Sahlgrenska University Hospital is one of the largest hospitals in northern Europe and the cancer centre for the Västra Götaland region. The Sahlgrenska Center for Cancer Research at the University of Gothenburg hosts groups including Jonas Nilsson's on patient-derived melanoma models and immunotherapy, Eva Forssell-Aronsson's on radionuclide therapy dosimetry and Göran Landberg's on breast cancer microenvironment, and the Queen Silvia Children's Hospital is a national paediatric oncology centre. The hospital runs regional radiotherapy, surgical oncology including high-volume colorectal and oesophageal surgery, and haematology with CAR-T, and contributes to Swedish quality registers used in outcomes research.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.sahlgrenska.se/en/"}],"tags":[],"related":[],"cancers":["melanoma","neuroblastoma","colorectal","esophageal"],"sections":["radiopharma","surgery"],"technologies":["pdx-models","radioligand-therapy","car-t","robotic-surgery"],"targets":[],"drugs":[],"companies":[],"institutions":["karolinska","lund-skane"],"pathways":[],"terms":["dosimetry"],"trials":[],"people":["boubou-hallberg","erik-johnsson"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Gothenburg","country":"SE","lat":57.683,"lng":11.96,"institutionType":"hospital","website":"https://www.sahlgrenska.se/en/","university":"University of Gothenburg","programs":["Melanoma patient-derived models","Radionuclide therapy dosimetry","Paediatric oncology","Surgical oncology","Quality registers"]},{"id":"saint-savvas-athens","kind":"institution","name":"Saint Savvas General Oncology Hospital of Athens","aka":["Agios Savvas","Άγιος Σάββας"],"tldr":"Greece's largest dedicated cancer hospital, in Athens, accredited by OECI as a Cancer Centre.","summary":"The General Anticancer Oncology Hospital of Athens 'Saint Savvas' is the largest specialised cancer hospital in Greece and a national referral centre for cancer. It provides surgical oncology, medical oncology, radiotherapy, haematology, nuclear medicine and palliative care, trains oncologists for the Greek health system, and participates in Hellenic Cooperative Oncology Group and European trials. It is the only Greek centre accredited by the Organisation of European Cancer Institutes, as a Cancer Centre.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.agsavvas-hosp.gr"}],"tags":["oeci-accredited","oeci-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["christos-fasianos","panagiotis-klirides"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Athens","country":"GR","lat":37.99,"lng":23.76,"institutionType":"cancer-center","website":"https://www.agsavvas-hosp.gr","programs":["Dedicated cancer hospital","Radiotherapy","Cooperative group trials"]},{"id":"salk-institute","kind":"institution","name":"Salk Institute Cancer Center","aka":["Salk Institute for Biological Studies"],"tldr":"Jonas Salk's institute, an NCI basic cancer centre since 1973, where tyrosine phosphorylation and much of nuclear receptor and metabolism biology were discovered.","summary":"The Salk Institute's cancer centre has held NCI basic laboratory designation since 1973. Tony Hunter discovered tyrosine phosphorylation here in 1979, the biochemical foundation of every kinase inhibitor; Inder Verma pioneered retroviral and lentiviral gene delivery; Ronald Evans's nuclear receptor work led to vitamin D receptor-targeted stromal reprogramming in pancreatic cancer; Reuben Shaw dissected the LKB1-AMPK metabolic checkpoint. Geoffrey Wahl's breast cancer stem cell biology and Susan Kaech's T-cell exhaustion research connect the institute to immunotherapy. Salk has no clinic and works through collaborations with UC San Diego and other La Jolla institutions.","asOf":"2026-09-09","links":[{"label":"Salk Cancer Center","url":"https://www.salk.edu/science/research-centers/salk-cancer-center/"},{"label":"Salk Institute","url":"https://www.salk.edu"}],"tags":[],"related":[],"cancers":["pancreatic","tnbc"],"sections":["drug-discovery","targeted-therapy"],"technologies":["kinase-inhibitors","metabolic-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["ucsd-moores"],"pathways":[],"terms":[],"trials":[],"people":["reuben-shaw"],"bottlenecks":["b-tme-immunosuppression"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"La Jolla, CA","country":"US","lat":32.887,"lng":-117.246,"institutionType":"research-institute","website":"https://www.salk.edu/science/research-centers/salk-cancer-center/","nci":"basic","programs":["Kinase signalling","Nuclear receptors and the tumour stroma","Cancer metabolism","T-cell biology"]},{"id":"samsung-medical-center","kind":"institution","name":"Samsung Medical Center","aka":[],"tldr":"Samsung Medical Center in Seoul is Korea's highest-ranked cancer hospital and one of Asia's largest enrolling sites for lung, gastric and breast antibody-drug conjugate trials; it also runs a proton therapy centre. How far its largely Korean trial results generalise to other regions is a question regulators keep asking.","summary":"Samsung Medical Center in Seoul is Korea's highest-ranked cancer hospital, placed third in the Newsweek/Statista World's Best Specialized Hospitals list for oncology, and home to the Samsung Comprehensive Cancer Center. It matters to global drug development because it is a leading enroller in non-small-cell lung cancer, gastric cancer and breast antibody-drug conjugate trials, and it operates a proton therapy centre. OnCo links it to gastric and gastro-oesophageal junction cancer, to the DeLLphi-301 tarlatamab paper in small-cell lung cancer, to the Korean Cancer Study Group and to clinicians including Jeeyun Lee, Won Ki Kang and Woong-Yang Park. How far results from its largely Korean trial populations generalise to other regions is an open question that regulators keep asking. Its lung and gastric programmes are the ones to follow.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Samsung_Medical_Center","links":[{"label":"Official website","url":"https://www.samsunghospital.com"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":["newsweek-hospitals"],"cancers":[],"sections":[],"technologies":["proton-therapy","proton-therapy-systems","gamma-knife","radiosurgery-srs"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["lee-jeeyun","kang-won-ki","park-woong-yang","lim-ho-yeong","ahn-myung-ju","park-yeon-hee"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Seoul","country":"KR","lat":37.488,"lng":127.085,"institutionType":"hospital","website":"https://www.samsunghospital.com","newsweekOncology2026":3,"programs":["Lung cancer trials","Gastric cancer","Proton therapy"]},{"id":"weill-cornell-meyer-cancer-center","kind":"institution","name":"Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine","aka":["Weill Cornell Medicine","Weill Cornell Medical College","Meyer Cancer Center","NewYork-Presbyterian/Weill Cornell"],"tldr":"Cornell's medical school and cancer centre in Manhattan, led by immunotherapy pioneer Jedd Wolchok, with major programmes in lymphoma, gastrointestinal and breast cancer.","summary":"The Sandra and Edward Meyer Cancer Center is the cancer centre of Weill Cornell Medicine, Cornell University's medical school on the Upper East Side of Manhattan, and delivers care with NewYork-Presbyterian Hospital. Jedd Wolchok, who led the CheckMate 067 and nivolumab-relatlimab melanoma trials, became its director in 2022. John Leonard's lymphoma programme led AUGMENT; Manish Shah's gastrointestinal oncology group led GLOW in claudin 18.2-positive gastric cancer; and Massimo Cristofanilli directs breast medical oncology and circulating tumour cell research.","asOf":"2026-09-18","links":[{"label":"Meyer Cancer Center","url":"https://meyercancer.weill.cornell.edu"}],"tags":[],"related":[],"cancers":["melanoma","follicular-lymphoma","gastric","breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["mskcc"],"pathways":[],"terms":[],"trials":[],"people":["jedd-wolchok","john-leonard","manish-shah","massimo-cristofanilli"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"New York, NY","country":"US","lat":40.765,"lng":-73.954,"institutionType":"cancer-center","website":"https://meyercancer.weill.cornell.edu","university":"Cornell University","programs":["Immunotherapy","Lymphoma","Gastrointestinal oncology","Breast oncology"]},{"id":"sanford-burnham-prebys","kind":"institution","name":"Sanford Burnham Prebys Medical Discovery Institute","aka":["Sanford Burnham Prebys","La Jolla Cancer Research Foundation"],"tldr":"Sanford Burnham Prebys in La Jolla is an NCI basic laboratory cancer centre whose founding work on integrins and RGD adhesion peptides created the field of tumour-homing peptides; its Prebys Center for Chemical Genomics is one of the largest non-profit drug-screening facilities in academia.","summary":"Founded in 1976 by Erkki Ruoslahti as the La Jolla Cancer Research Foundation and NCI-designated since 1981, Sanford Burnham Prebys is a basic laboratory cancer centre whose founding discoveries in integrins and RGD adhesion peptides created the field of tumour-homing peptides. The Conrad Prebys Center for Chemical Genomics is one of the largest non-profit drug discovery and high-throughput screening facilities in academia. Current programmes span cancer metabolism, the tumour microenvironment and immune evasion, paediatric cancers and computational biology. The institute works alongside Salk, Scripps and UC San Diego on the Torrey Pines mesa.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Sanford_Burnham_Prebys","links":[{"label":"Sanford Burnham Prebys","url":"https://sbpdiscovery.org"},{"label":"NCI-designated Cancer Center","url":"https://sbpdiscovery.org/research/cancer-center/"}],"tags":[],"related":[],"cancers":[],"sections":["drug-discovery"],"technologies":["peptide-drug-conjugate","functional-drug-testing"],"targets":[],"drugs":[],"companies":[],"institutions":["ucsd-moores"],"pathways":[],"terms":[],"trials":[],"people":["paul-boutros"],"bottlenecks":["b-undruggable-targets","b-tme-immunosuppression"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"La Jolla, CA","country":"US","lat":32.896,"lng":-117.24,"institutionType":"research-institute","website":"https://sbpdiscovery.org","nci":"basic","programs":["Drug discovery (Prebys Center)","Cell adhesion and tumour microenvironment","Cancer metabolism"]},{"id":"sarcoma-oncology-center","kind":"institution","name":"Sarcoma Oncology Center","aka":[],"tldr":"The Sarcoma Oncology Center in Santa Monica, the practice of Sant Chawla, offers sarcoma second opinions, clinical trials and multimodal treatment planning.","summary":"The Sarcoma Oncology Center is a sarcoma-focused practice in Santa Monica, California, offering second opinions, access to clinical trials and multimodal treatment planning; its director Sant Chawla led the aldoxorubicin trials and co-founded Gemini Therapeutics. Patient-bookable.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://sarcomaoncology.com/"},{"label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)","url":"https://sijbrandijfoundation.org/fcct"}],"tags":["fcct-directory"],"related":["aldoxorubicin"],"cancers":["sarcoma","osteosarcoma"],"sections":[],"technologies":["multidisciplinary-tumour-board"],"targets":[],"drugs":[],"companies":["gemini-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["aldoxorubicin-phase-3-sts"],"people":["sant-chawla"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Santa Monica","country":"US","lat":34.03,"lng":-118.48,"institutionType":"hospital","website":"https://sarcomaoncology.com/","programs":[]},{"id":"saskatchewan-cancer-agency","kind":"institution","name":"Saskatchewan Cancer Agency","aka":["Allan Blair Cancer Centre","Saskatoon Cancer Centre"],"tldr":"Saskatchewan's provincial cancer agency, running the Allan Blair Cancer Centre in Regina and the Saskatoon Cancer Centre.","summary":"The Saskatchewan Cancer Agency is the provincial body responsible for cancer prevention, screening, treatment and research in Saskatchewan. It operates two treatment centres, the Allan Blair Cancer Centre in Regina and the Saskatoon Cancer Centre, providing radiotherapy, systemic therapy and supportive care, and delivers community oncology through partner hospitals so that patients in a large, sparsely populated province can receive chemotherapy closer to home. The agency runs the provincial breast, cervical and colorectal screening programmes and the Saskatchewan Cancer Registry, and works with the University of Saskatchewan on clinical trials and population health research.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.saskcancer.ca"}],"tags":["provincial-cancer-agency"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["canadian-cancer-society"],"pathways":[],"terms":[],"trials":[],"people":["deb-bulych"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Regina","country":"CA","lat":50.445,"lng":-104.618,"institutionType":"government","website":"https://www.saskcancer.ca","university":"University of Saskatchewan","programs":["Provincial cancer agency","Allan Blair and Saskatoon Cancer Centres","Screening programmes","Cancer registry"]},{"id":"smc","kind":"institution","name":"Scottish Medicines Consortium","aka":["SMC"],"tldr":"Scotland's health technology assessment body, which advises NHS Scotland on new medicines and applies a more flexible approach for end-of-life and orphan cancer drugs.","summary":"Established in 2001, the Scottish Medicines Consortium advises NHS Scotland on the clinical and cost-effectiveness of all newly licensed medicines, working separately from NICE. Its Patient and Clinician Engagement process, introduced in 2014, gives additional weight to patient and clinician evidence for end-of-life and very rare conditions, and its ultra-orphan pathway allows access while evidence is collected, so some cancer drugs are available in Scotland before or without a NICE recommendation. The SMC is part of Healthcare Improvement Scotland and works with the MHRA and NICE on the Innovative Licensing and Access Pathway.","asOf":"2026-09-09","links":[{"label":"Scottish Medicines Consortium","url":"https://scottishmedicines.org.uk"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nice","mhra","cruk"],"pathways":[],"terms":["real-world-evidence"],"trials":[],"people":["robert-peel"],"bottlenecks":["b-drug-pricing","b-rare-cancers"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Glasgow","country":"GB","lat":55.864,"lng":-4.252,"institutionType":"government","website":"https://scottishmedicines.org.uk","programs":["Health technology assessment for NHS Scotland","Patient and Clinician Engagement (PACE) process","Ultra-orphan pathway","Innovative Licensing and Access Pathway partner"]},{"id":"seattle-childrens","kind":"institution","name":"Seattle Children's Hospital","aka":["Seattle Children's","Ben Towne Center for Childhood Cancer Research"],"tldr":"Children's hospital in Seattle whose Cancer and Blood Disorders Center runs one of the largest paediatric CAR-T programmes and leads Children's Oncology Group brain tumour trials.","summary":"Seattle Children's Hospital is the paediatric teaching hospital of the University of Washington and works with Fred Hutchinson Cancer Center. Its Cancer and Blood Disorders Center runs the Ben Towne Center for Childhood Cancer Research, one of the earliest and largest academic CAR-T programmes for children, and its neuro-oncology group, including Sarah Leary, leads Children's Oncology Group trials such as ACNS0332 in high-risk medulloblastoma.","asOf":"2026-09-18","wikipedia":"https://en.wikipedia.org/wiki/Seattle_Children's","links":[{"label":"Seattle Children's","url":"https://www.seattlechildrens.org"}],"tags":[],"related":[],"cancers":["medulloblastoma","childhood-cancers"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["fred-hutch"],"pathways":[],"terms":[],"trials":[],"people":["sarah-leary"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Seattle, WA","country":"US","lat":47.663,"lng":-122.282,"institutionType":"hospital","website":"https://www.seattlechildrens.org","university":"University of Washington","programs":["Paediatric CAR-T (Ben Towne Center)","Paediatric neuro-oncology","Children's Oncology Group"]},{"id":"snu-bundang-hospital","kind":"institution","name":"Seoul National University Bundang Hospital","aka":["SNUBH","분당서울대학교병원"],"tldr":"Seoul National University's hospital south of Seoul, a leading centre of laparoscopic stomach cancer surgery where Hyung-Ho Kim led the KLASS-01 trial.","summary":"Seoul National University Bundang Hospital opened in 2003 in Seongnam as the second hospital of Seoul National University College of Medicine, separate from the main hospital in central Seoul. Its Department of Surgery, under Hyung-Ho Kim, is a leading centre of minimally invasive gastric cancer surgery and led the Korean Laparoendoscopic Gastrointestinal Surgery Study group's KLASS-01 trial, which showed that laparoscopic distal gastrectomy gave the same survival as open surgery in early stomach cancer.","asOf":"2026-09-18","wikipedia":"https://en.wikipedia.org/wiki/Seoul_National_University_Bundang_Hospital","links":[{"label":"SNUBH","url":"https://www.snubh.org"}],"tags":[],"related":[],"cancers":["gastric"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["snuh"],"pathways":[],"terms":[],"trials":[],"people":["hyung-ho-kim"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Seongnam","country":"KR","lat":37.352,"lng":127.124,"institutionType":"hospital","website":"https://www.snubh.org","university":"Seoul National University","programs":["Gastric cancer surgery","Minimally invasive surgery","Digital hospital systems"]},{"id":"snuh","kind":"institution","name":"Seoul National University Hospital","aka":[],"tldr":"Seoul National University Hospital is Korea's national university hospital and a top global enroller for gastric and lung cancer trials.","summary":"Seoul National University Hospital is Korea's national university hospital and, through the Seoul National University Cancer Hospital, ranks eighth in the Newsweek/Statista World's Best Specialized Hospitals list for oncology. It is a top global enroller for gastric and lung cancer trials and has led work in gastric cancer on Claudin 18.2 and HER2, in non-small-cell lung cancer, and in radiotherapy. OnCo links it to gastric and gastro-oesophageal junction cancer and hepatocellular carcinoma, to the Korean Cancer Study Group, and to clinicians including Do-Youn Oh, Dong-Wan Kim, Seock-Ah Im and Tae-You Kim. As with other Korean centres, how its trial findings transfer to Western populations is a recurring question. Its gastric programme is the one to follow first.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Seoul_National_University_Hospital","links":[{"label":"Official website","url":"https://www.snuh.org"}],"tags":[],"related":[],"cancers":["gastric","nsclc"],"sections":[],"technologies":["gamma-knife","radiosurgery-srs"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["oh-do-youn","kim-dong-wan","lee-se-hoon","im-seock-ah","kim-tae-you","bang-yung-jue"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Seoul","country":"KR","lat":37.58,"lng":126.999,"institutionType":"hospital","website":"https://www.snuh.org","newsweekOncology2026":8,"university":"Seoul National University","programs":["Gastric cancer","Lung cancer"]},{"id":"seoul-st-marys-hospital","kind":"institution","name":"Seoul St. Mary's Hospital","aka":["Catholic University of Korea Seoul St. Mary's Hospital","서울성모병원"],"tldr":"Korea's largest blood cancer centre, where much of the country's haematopoietic transplant and leukaemia expertise was built.","summary":"Seoul St. Mary's Hospital, the flagship of the Catholic Medical Center, opened its current campus in 2009 and houses the Catholic Hematology Hospital, Korea's highest-volume haematopoietic stem cell transplant programme and a national leader in acute leukaemia, myeloma and chronic myeloid leukaemia research (including early Asian trials of tyrosine kinase inhibitors led by Dong-Wook Kim). The hospital also runs a comprehensive cancer hospital with breast, thyroid, colorectal and lung programmes, robotic surgery, and a proton therapy project, and it is a frequent Korean site for haematology and solid tumour registration trials.","asOf":"2026-09-09","links":[{"label":"Seoul St. Mary's Hospital","url":"https://www.cmcseoul.or.kr"},{"label":"Catholic University of Korea","url":"https://www.catholic.ac.kr"}],"tags":[],"related":[],"cancers":["aml","all-leukemia","multiple-myeloma","dlbcl"],"sections":["cell-therapy","chemotherapy"],"technologies":["car-t","allogeneic-cell-therapy","robotic-surgery"],"targets":[],"drugs":["imatinib","nilotinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["yoon-seung-kew"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Seoul","country":"KR","lat":37.502,"lng":127.005,"institutionType":"hospital","website":"https://www.cmcseoul.or.kr","university":"Catholic University of Korea","programs":["Catholic Hematology Hospital","Haematopoietic stem cell transplant","Chronic myeloid leukaemia","Robotic surgery"]},{"id":"severance","kind":"institution","name":"Severance Hospital, Yonsei University","aka":[],"tldr":"Severance Hospital houses Yonsei Cancer Center and Korea's first heavy-ion (carbon) therapy centre (2023).","summary":"Severance Hospital, part of Yonsei University in Seoul, houses the Yonsei Cancer Center and opened Korea's first heavy-ion carbon therapy centre in 2023; it ranks twenty-second in the Newsweek/Statista oncology list. It matters for its carbon-ion programme, for lung and gastric cancer trials, and for leadership in robotic and minimally invasive surgery, with Byoung Chul Cho, Hye Ryun Kim, Sun Young Rha, Joohyuk Sohn and Sang Joon Shin among its clinicians. OnCo links it to the MARIPOSA paper on amivantamab plus lazertinib in EGFR-mutated lung cancer and to the Korean Cancer Study Group. Whether carbon ions deliver benefits that justify the cost over protons and photons is still being worked out. Its carbon-ion and robotic surgery programmes are the reasons to read on.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://sev.severance.healthcare"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["carbon-ion","robotic-surgery","carbon-ion-synchrotrons","gamma-knife","radiosurgery-srs"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["kim-hye-ryun","cho-byoung-chul","sohn-joohyuk","shin-sang-joon","rha-sun-young"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Seoul","country":"KR","lat":37.562,"lng":126.941,"institutionType":"hospital","website":"https://sev.severance.healthcare","newsweekOncology2026":22,"university":"Yonsei University","programs":["Carbon-ion therapy","Robotic surgery"]},{"id":"shaare-zedek","kind":"institution","name":"Shaare Zedek Medical Center","aka":["Sha'are Zedek","Shaarei Tzedek"],"tldr":"Jerusalem's community-facing academic hospital, home of ESMO-MCBS architect Nathan Cherny and leading BRCA population screening research.","summary":"Founded in 1902, Shaare Zedek Medical Center is one of Jerusalem's two large academic hospitals. Nathan Cherny, who directs its cancer pain and palliative medicine service, chairs the working group behind the ESMO Magnitude of Clinical Benefit Scale used to grade the value of cancer treatments, and Ephrat Levy-Lahad's Medical Genetics Institute has led studies showing the feasibility of population-based BRCA1/2 screening in Ashkenazi Jewish women. The hospital's oncology and haematology institutes provide comprehensive treatment, and the centre has a strong tradition in supportive and palliative care, medical ethics and access to medicines research.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Shaare_Zedek_Medical_Center","links":[{"label":"Homepage","url":"https://www.szmc.org.il/eng/"},{"label":"ESMO-MCBS","url":"https://www.esmo.org/guidelines/esmo-mcbs"}],"tags":[],"related":[],"cancers":["breast-hr-positive","ovarian","colorectal"],"sections":["supportive-care","prevention"],"technologies":["germline-testing","geriatric-assessment"],"targets":["brca"],"drugs":[],"companies":[],"institutions":["esmo","hadassah","hebrew-university-of-jerusalem"],"pathways":[],"terms":[],"trials":[],"people":["nathan-cherny","ofer-merin","ephrat-levy-lahad","rachel-michaelson-cohen","alberto-gabizon"],"bottlenecks":["b-palliative","b-hereditary-risk","b-drug-pricing"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Jerusalem","country":"IL","lat":31.774,"lng":35.198,"institutionType":"hospital","website":"https://www.szmc.org.il/eng/","university":"Hebrew University of Jerusalem","programs":["Palliative medicine and ESMO-MCBS","Medical genetics and BRCA population screening","Oncology and haematology institutes"]},{"id":"shandong-cancer-hospital","kind":"institution","name":"Shandong Cancer Hospital and Institute","aka":["Shandong First Medical University Affiliated Cancer Hospital","山东省肿瘤医院"],"tldr":"Shandong Cancer Hospital runs one of China's largest radiotherapy departments under Jinming Yu, with a proton therapy centre and PET-guided adaptive radiotherapy; it has led Chinese trials combining radiotherapy with immunotherapy in lung and oesophageal cancer and studies of brain metastasis management.","summary":"Shandong Cancer Hospital and Institute, founded in 1958 and affiliated to Shandong First Medical University and the Shandong Academy of Medical Sciences, is best known for radiation oncology under Jinming Yu, with one of the largest radiotherapy departments in China, a proton therapy centre and heavy investment in PET-guided and adaptive radiotherapy. It has led Chinese trials combining radiotherapy with immunotherapy in lung and oesophageal cancer and studies of brain metastasis management. The hospital also runs strong thoracic surgery, breast and gynaecological programmes and a provincial cancer registry.","asOf":"2026-09-09","links":[{"label":"Shandong Cancer Hospital","url":"https://www.sdzlyy.org.cn"},{"label":"Shandong First Medical University","url":"https://www.sdfmu.edu.cn"}],"tags":[],"related":[],"cancers":["nsclc","sclc","esophageal","head-and-neck"],"sections":["radiation"],"technologies":["proton-therapy","imrt-igrt","sbrt","pet-ct","checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["abscopal-effect"],"trials":[],"people":["yu-jinming"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Jinan","country":"CN","lat":36.651,"lng":117.12,"institutionType":"cancer-center","website":"https://www.sdzlyy.org.cn","university":"Shandong First Medical University","programs":["Radiation oncology","Proton therapy","Radio-immunotherapy trials","Thoracic oncology"]},{"id":"shanghai-chest-hospital","kind":"institution","name":"Shanghai Chest Hospital","aka":["Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine","上海市胸科医院"],"tldr":"Shanghai Chest Hospital, China's first specialist chest hospital (1957), performs one of the world's largest volumes of lung and oesophageal operations and houses the Shanghai Lung Cancer Center; its investigators led the Chinese registration trials of EGFR, ALK and ROS1 inhibitors.","summary":"Founded in 1957 as China's first specialist chest hospital, Shanghai Chest performs one of the largest volumes of lung and oesophageal operations in the world each year and houses the Shanghai Lung Cancer Center directed by Shun Lu. Its investigators have led Chinese registration trials of EGFR, ALK and ROS1 inhibitors and PD-1 combinations, and contributed to the global osimertinib, lorlatinib and amivantamab programmes. Thoracic surgery, oesophageal cancer, thymic tumours and interventional bronchoscopy are core strengths, with robotic and uniportal video-assisted surgery widely used. The hospital is a national clinical research centre for respiratory disease.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Shanghai_Chest_Hospital","links":[{"label":"Shanghai Chest Hospital","url":"https://www.shxkyy.com"},{"label":"Shanghai Jiao Tong University School of Medicine","url":"https://www.shsmu.edu.cn"}],"tags":[],"related":[],"cancers":["nsclc","sclc","esophageal","mesothelioma"],"sections":["targeted-therapy","surgery"],"technologies":["kinase-inhibitors","robotic-surgery"],"targets":["egfr","alk","ret","met"],"drugs":["osimertinib","lorlatinib","amivantamab","ivonescimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["lu-shun"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Shanghai","country":"CN","lat":31.218,"lng":121.437,"institutionType":"hospital","website":"https://www.shxkyy.com","university":"Shanghai Jiao Tong University","programs":["Lung cancer targeted therapy trials","Thoracic surgery","Oesophageal cancer","Thymic tumours"]},{"id":"shanghai-pulmonary-hospital","kind":"institution","name":"Shanghai Pulmonary Hospital","aka":["Shanghai Pulmonary Hospital, Tongji University","上海市肺科医院"],"tldr":"Shanghai Pulmonary Hospital is a lung-only hospital with one of the largest thoracic surgery volumes anywhere; Caicun Zhou's medical oncology department was the Chinese lead site for the first-generation EGFR inhibitor trials and for camrelizumab, sintilimab and tislelizumab combinations in lung cancer.","summary":"Shanghai Pulmonary Hospital, affiliated to Tongji University, is a national clinical research centre for lung disease and one of the highest-volume thoracic surgery centres anywhere, known for uniportal and robotic lobectomy and for large early-stage screening cohorts. Caicun Zhou's Department of Medical Oncology has been the Chinese lead site for first-generation EGFR inhibitor trials, camrelizumab, sintilimab and tislelizumab combinations, and ADC studies in NSCLC. The hospital publishes extensively on ground-glass nodules, minimally invasive surgery and the molecular epidemiology of lung cancer in never-smokers.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Shanghai_Pulmonary_Hospital","links":[{"label":"Shanghai Pulmonary Hospital","url":"https://www.shsfkyy.com"},{"label":"Tongji University","url":"https://www.tongji.edu.cn"}],"tags":[],"related":[],"cancers":["nsclc","sclc"],"sections":["targeted-therapy","immunotherapy","early-detection"],"technologies":["checkpoint-inhibitor","kinase-inhibitors","robotic-surgery","ct"],"targets":["egfr","pd1","alk"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["zhou-caicun"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Shanghai","country":"CN","lat":31.29,"lng":121.48,"institutionType":"hospital","website":"https://www.shsfkyy.com","university":"Tongji University","programs":["Lung cancer medical oncology trials","Thoracic surgery","Lung nodule management"]},{"id":"shaukat-khanum","kind":"institution","name":"Shaukat Khanum Memorial Cancer Hospital and Research Centre","aka":["SKMCH&RC","Shaukat Khanum"],"tldr":"Pakistan's leading cancer hospital network, founded in 1994 in Lahore by Imran Khan in memory of his mother, treating most patients free of charge.","summary":"Shaukat Khanum Memorial Cancer Hospital and Research Centre opened in Lahore in 1994, founded by the cricketer and later prime minister Imran Khan and named after his mother, who died of cancer. Funded largely by donations and zakat, it provides comprehensive cancer care, including surgical oncology, medical oncology, radiotherapy, bone marrow transplantation, nuclear medicine and paediatric oncology, to a majority of patients free of charge. A second hospital opened in Peshawar in 2015 and a third in Karachi, and the network runs a large diagnostic laboratory collection system across Pakistan. Shaukat Khanum is accredited by Joint Commission International and hosts a clinical research programme and hospital-based cancer registry.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://shaukatkhanum.org.pk"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["aku-karachi"],"pathways":[],"terms":[],"trials":[],"people":["faisal-sultan"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Lahore","country":"PK","lat":31.47,"lng":74.271,"institutionType":"cancer-center","website":"https://shaukatkhanum.org.pk","programs":["Charitable comprehensive cancer care","Radiotherapy","Bone marrow transplantation","Peshawar and Karachi hospitals"]},{"id":"sheba","kind":"institution","name":"Sheba Medical Center","aka":["Chaim Sheba Medical Center","Tel HaShomer","Sheba Cancer Center"],"tldr":"Israel's largest hospital, whose cancer centre led the POLO trial of olaparib in pancreatic cancer and runs one of the world's few TIL therapy programmes.","summary":"Sheba Medical Center at Tel HaShomer describes itself as the largest hospital in Israel and hosts the Jusidman Cancer Center. Talia Golan led the POLO trial that established maintenance olaparib for germline BRCA-mutated pancreatic cancer, the Ella Lemelbaum Institute for Immuno-Oncology under Jacob Schachter, Michal Besser and Gal Markel has treated melanoma patients with tumour-infiltrating lymphocytes since 2006, and the haematology division runs point-of-care CAR-T manufacturing. Sheba's ARC innovation centre and its large breast, gastrointestinal, thoracic and paediatric oncology services make it Israel's most active oncology trial site, and its Sackler-affiliated researchers publish widely on precision oncology.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Sheba_Medical_Center","links":[{"label":"Homepage","url":"https://www.shebaonline.org"},{"label":"Cancer Center","url":"https://www.shebaonline.org/departments/cancer-center/"}],"tags":[],"related":[],"cancers":["pancreatic","melanoma","breast-hr-positive","dlbcl"],"sections":["targeted-therapy","cell-therapy"],"technologies":["parp-inhibitor","til-therapy","car-t","checkpoint-inhibitor"],"targets":["brca","parp"],"drugs":["olaparib"],"companies":["astrazeneca"],"institutions":["tel-aviv-university","israel-national-cancer-registry"],"pathways":[],"terms":[],"trials":[],"people":["yitshak-kreiss","talia-golan","jacob-schachter","michal-besser","eitan-friedman"],"bottlenecks":["b-manufacturing-cell-therapy"],"keyPapers":["paper-besser-til-melanoma-intent-to-treat-ccr-2013"],"journals":[],"dependsOn":[],"notes":[],"city":"Ramat Gan","country":"IL","lat":32.045,"lng":34.842,"institutionType":"hospital","website":"https://www.shebaonline.org","university":"Tel Aviv University","programs":["POLO trial and BRCA-mutated pancreatic cancer","TIL therapy (Ella Lemelbaum Institute)","CAR-T manufacturing","ARC innovation centre","Paediatric oncology"]},{"id":"shizuoka-cancer-center","kind":"institution","name":"Shizuoka Cancer Center","aka":["静岡県立静岡がんセンター"],"tldr":"A prefectural cancer centre near Mount Fuji with a proton facility and Project HOPE, one of Japan's largest multi-omics cancer profiling programmes.","summary":"Shizuoka Cancer Center opened in 2002 as a purpose-built prefectural cancer hospital and research institute and quickly became one of Japan's most research-active cancer centres. Its Project HOPE has performed whole-exome, gene expression and germline analysis on many thousands of consecutive surgical patients, feeding a large regional genomic database, and the centre runs a proton therapy facility, a phase 1 unit and a well-regarded supportive and palliative care programme. It is a frequent lead site for JCOG and WJOG trials in lung, gastric and colorectal cancer and for Japanese registration trials of targeted agents.","asOf":"2026-09-09","links":[{"label":"Shizuoka Cancer Center","url":"https://www.scchr.jp"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":["nsclc","gastric","colorectal","head-and-neck"],"sections":["radiation","diagnostics"],"technologies":["proton-therapy","wes-wgs","rna-seq","germline-testing","proton-therapy-systems"],"targets":[],"drugs":[],"companies":["jcog"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["katsuhiko-uesaka"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Nagaizumi, Shizuoka","country":"JP","lat":35.14,"lng":138.89,"institutionType":"cancer-center","website":"https://www.scchr.jp","programs":["Project HOPE multi-omics","Proton therapy","Thoracic oncology","Supportive care"]},{"id":"sichuan-cancer-hospital","kind":"institution","name":"Sichuan Cancer Hospital","aka":["Sichuan Cancer Hospital and Institute","四川省肿瘤医院"],"tldr":"Sichuan Cancer Hospital in Chengdu is a large provincial cancer centre known for oesophageal and head and neck cancer radiotherapy and a partner of the city's ADC companies.","summary":"Sichuan Cancer Hospital in Chengdu, also the Sichuan Cancer Hospital and Institute, is a large provincial cancer centre known for oesophageal and head and neck cancer radiotherapy and for partnering with the city's antibody-drug conjugate companies. Its radiotherapy programme is among the largest in China, it treats high oesophageal cancer volumes from Sichuan's high-incidence areas, and it takes part in trials with the Chengdu-based Sichuan Kelun-Biotech and SystImmune, part of Sichuan Biokin, on their ADCs. OnCo connects it to oesophageal cancer and head and neck squamous cell carcinoma and to both companies. Whether a provincial hospital can be both trial site and neighbour to the sponsors without conflicts is a fair question. Its radiation oncology and ADC trial programmes are listed below.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.sichuancancer.org/"}],"tags":["china"],"related":[],"cancers":["esophageal","head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["kelun-biotech","systimmune"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["lin-tongyu"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Chengdu","country":"CN","lat":30.64,"lng":104.083,"institutionType":"cancer-center","website":"https://www.sichuancancer.org/","programs":["Radiation oncology","Oesophageal and head and neck cancer","ADC trials"]},{"id":"jefferson-kimmel","kind":"institution","name":"Sidney Kimmel Comprehensive Cancer Center at Jefferson Health","aka":["SKCC Jefferson"],"tldr":"Thomas Jefferson University's NCI-designated cancer centre, known for prostate cancer biology and GUCY2C-targeted colorectal cancer immunotherapy.","summary":"NCI-designated since 1996, the Sidney Kimmel Comprehensive Cancer Center serves Philadelphia and southern New Jersey through Jefferson Health's hospital network. Scott Waldman identified guanylyl cyclase C (GUCY2C) as a colorectal cancer antigen and has carried vaccines and CAR-T against it into trials. Karen Knudsen, former director and later CEO of the American Cancer Society, built its androgen receptor and prostate cancer programme with urologist Leonard Gomella; Adam Dicker leads radiation oncology. The centre is a member of the NCI's cooperative group network and runs a community outreach programme across its catchment.","asOf":"2026-09-09","links":[{"label":"Sidney Kimmel Comprehensive Cancer Center","url":"https://www.jeffersonhealth.org/clinical-specialties/cancer"}],"tags":[],"related":[],"cancers":["prostate","colorectal"],"sections":["radiation","immunotherapy"],"technologies":["shared-antigen-vaccine","car-t"],"targets":["androgen-receptor"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["marcia-brose"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Philadelphia, PA","country":"US","lat":39.949,"lng":-75.157,"institutionType":"cancer-center","website":"https://www.jeffersonhealth.org/clinical-specialties/cancer","nci":"comprehensive","university":"Thomas Jefferson University","programs":["Prostate cancer and AR biology","GUCY2C immunotherapy","Radiation oncology"]},{"id":"siop-europe","kind":"institution","name":"SIOP Europe (European Society for Paediatric Oncology)","aka":["SIOPE","SIOP","International Society of Paediatric Oncology"],"tldr":"The European paediatric oncology society and the umbrella for the European clinical trial groups that treat most children with cancer on shared protocols.","summary":"SIOP Europe is the European branch of the International Society of Paediatric Oncology (SIOP, founded 1969) and the only pan-European organisation representing children's cancer professionals. It coordinates the European Clinical Trial Groups for leukaemia, neuroblastoma (SIOPEN, whose HR-NBL1 trial defined high-risk neuroblastoma therapy), brain tumours, renal tumours, sarcomas and lymphomas, and runs the Strategic Plan for children's cancer with the European Parliament. SIOPE advocates on the EU Paediatric Regulation, ACCELERATE platform for paediatric drug development, and cross-border access to trials, and organises the annual SIOP Europe congress. SIOP itself is a global society with its annual congress and PODC programme for low- and middle-income countries.","asOf":"2026-09-09","links":[{"label":"SIOP Europe","url":"https://siope.eu"},{"label":"SIOP International","url":"https://siop-online.org"}],"tags":[],"related":[],"cancers":["neuroblastoma","all-leukemia","sarcoma","glioblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["cclg","childrens-oncology-group","curie-nki-eortc"],"institutions":["charite"],"pathways":[],"terms":[],"trials":["hr-nbl1","euro-ewing-2012","interfant-06"],"people":["uta-dirksen","gilles-vassal"],"bottlenecks":["b-rare-cancers"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Brussels","country":"BE","lat":50.85,"lng":4.352,"institutionType":"consortium","website":"https://siope.eu","programs":["European Clinical Trial Groups (SIOPEN, I-BFM, SIOP brain tumour group)","HR-NBL1 (high-risk neuroblastoma)","ACCELERATE paediatric drug development","European Standards of Care for Children with Cancer"]},{"id":"siriraj-hospital","kind":"institution","name":"Siriraj Hospital, Mahidol University","aka":["Faculty of Medicine Siriraj Hospital","โรงพยาบาลศิริราช"],"tldr":"Thailand's oldest and largest hospital, with the country's leading academic oncology, haematology and hepatobiliary programmes and a new proton-equipped cancer centre.","summary":"Siriraj Hospital was founded in 1888 by King Chulalongkorn and is the flagship of Mahidol University's Faculty of Medicine and Thailand's largest hospital. Its oncology strengths include hepatobiliary surgery and liver transplantation for hepatocellular carcinoma and cholangiocarcinoma, haematology and stem cell transplant, breast and head and neck surgery, and radiation oncology, and it is one of the most active Thai sites for international registration trials. The Siriraj Piyamaharajkarun campus and the Siriraj Center of Excellence in cancer research support genomics under the Genomics Thailand initiative and cell therapy development, including locally manufactured CAR-T studies. It also hosts Thailand's largest palliative care and cancer nursing training programmes.","asOf":"2026-09-09","links":[{"label":"Siriraj Hospital","url":"https://www.si.mahidol.ac.th"},{"label":"Mahidol University","url":"https://mahidol.ac.th"}],"tags":[],"related":[],"cancers":["hcc","cholangiocarcinoma","aml","breast-hr-positive","head-and-neck"],"sections":["surgery","cell-therapy"],"technologies":["car-t","imrt-igrt","robotic-surgery"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["yongyut-sirivatanauksorn"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Bangkok","country":"TH","lat":13.759,"lng":100.486,"institutionType":"hospital","website":"https://www.si.mahidol.ac.th","university":"Mahidol University","programs":["Hepatobiliary surgery and transplant","Haematology and CAR-T","Radiation oncology","Genomics Thailand"]},{"id":"wustl-siteman","kind":"institution","name":"Siteman Cancer Center, Washington University","aka":[],"tldr":"Sequenced the first cancer genome (2008) and leads in neoantigen vaccine science and CIViC.","summary":"Siteman Cancer Center at Washington University in St Louis, NCI-designated as comprehensive, is where the first cancer genome was sequenced in 2008, when the McDonnell Genome Institute performed whole-genome sequencing of an acute myeloid leukaemia, and it leads in neoantigen vaccine science. It is home to the CIViC clinical variant knowledge base built by Malachi Griffith and Obi L. Griffith, the pVACtools neoantigen prediction software and personalised vaccine trials, with Timothy J. Ley, Li Ding, John F. DiPersio and Ramaswamy Govindan among its people. OnCo links it to whole-genome sequencing, to personalised neoantigen mRNA vaccines, to the antigen presentation pathway, and to St Jude Children's Research Hospital. What makes a neoantigen actually immunogenic is the open question its programme exists to answer. Its genomics, CIViC and vaccine programmes are listed below.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://siteman.wustl.edu"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["wes-wgs","neoantigen-mrna-vaccine","proton-therapy","proton-therapy-systems","mr-linac"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["neoantigen"],"trials":[],"people":["timothy-ley","li-ding","malachi-griffith","obi-griffith","john-dipersio","ramaswamy-govindan","robert-schreiber","timothy-eberlein"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"St. Louis, MO","country":"US","lat":38.636,"lng":-90.264,"institutionType":"cancer-center","website":"https://siteman.wustl.edu","nci":"comprehensive","university":"Washington University in St. Louis","programs":["Cancer genomics","CIViC","Neoantigen vaccines"]},{"id":"lund-skane","kind":"institution","name":"Skåne University Hospital / Lund University Cancer Centre","aka":["SUS","LUCC","Lund University Cancer Centre"],"tldr":"Southern Sweden's university hospital and Lund University's cancer centre, known for the population-wide SCAN-B breast cancer sequencing project.","summary":"Skåne University Hospital in Lund and Malmö is the tertiary cancer centre for southern Sweden, and Lund University Cancer Centre coordinates research across its Medicon Village campus. Åke Borg and Lao Saal established the Sweden Cancerome Analysis Network-Breast (SCAN-B), which has sequenced the transcriptomes of breast cancers from consecutive patients across the region since 2010 and reports gene expression subtypes back into care, and Lund groups are strong in melanoma and prostate genomics, paediatric oncology and radiation physics linked to the MAX IV synchrotron. Lund also spun out antibody company BioInvent and hosts a Swedish node for CAR-T and haematological trials.","asOf":"2026-09-09","links":[{"label":"Skåne University Hospital","url":"https://www.skane.se/en/skane-university-hospital"},{"label":"Lund University Cancer Centre","url":"https://www.lucc.lu.se"},{"label":"SCAN-B","url":"https://www.scan-b.lu.se"}],"tags":[],"related":[],"cancers":["breast-hr-positive","tnbc","prostate","melanoma"],"sections":["diagnostics"],"technologies":["rna-seq","wes-wgs","germline-testing","monoclonal-antibody"],"targets":[],"drugs":[],"companies":[],"institutions":["karolinska"],"pathways":[],"terms":["pam50"],"trials":[],"people":["carolina-samuelsson","kristina-lang","pamela-buchwald"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Lund","country":"SE","lat":55.712,"lng":13.2,"institutionType":"hospital","website":"https://www.skane.se/en/skane-university-hospital","university":"Lund University","programs":["SCAN-B breast cancer sequencing","Cancer genomics","Paediatric oncology","Radiation physics","Medicon Village"]},{"id":"skcin","kind":"institution","name":"Skcin (the Karen Clifford Skin Cancer Charity)","aka":[],"tldr":"The prevention charity that campaigns on the one lever in skin cancer that is bigger than any drug: what the country does about ultraviolet exposure, and what it charges for sunscreen.","summary":"Skcin was founded in 2006 and works on skin cancer prevention and early detection across both melanoma and the keratinocyte cancers, running accreditation schemes for schools, nurseries, workplaces and outdoor venues.\n\nIts most visible policy work is the VAT Burn campaign, which asks the government to reclassify SPF30 and above sunscreen as an essential healthcare item rather than a luxury subject to the standard 20 percent rate of VAT. The campaign page cites research conducted for Tesco with Skcin in 2021 in which 57 percent of the UK population considered sunscreen expensive, 31 percent of parents said they could not always afford it for the whole family and 44 percent said they put it on their children but not on themselves or their partner because of the cost. It also publishes the government's reply: that VAT brings in vital public funds, that changing it for an individual product involves a trade-off, and that sunscreen is available to some on prescription. The exchange is worth reading beside NICE PH32, which excluded fiscal and legislative actions, including reducing VAT on sunscreen, from its remit entirely.","asOf":"2026-09-25","links":[{"label":"VAT Burn campaign","url":"https://www.skcin.org/resources/vat-burn-campaign/"}],"tags":["uk","charity","prevention","skin"],"related":[],"cancers":["skin-cancer","melanoma","basal-cell-carcinoma","cutaneous-scc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Nottingham","country":"GB","lat":52.954,"lng":-1.149,"institutionType":"consortium","website":"https://www.skcin.org/","programs":[]},{"id":"sitc","kind":"institution","name":"Society for Immunotherapy of Cancer","aka":["SITC","International Society for Biological Therapy of Cancer","iSBTc"],"tldr":"The society of cancer immunologists and immuno-oncologists, whose annual meeting, guidelines and immune-related adverse event management resources track the immunotherapy era.","summary":"Founded in 1984 as the Society for Biological Therapy and renamed in 2010, SITC grew with checkpoint inhibitors into the main professional home of cancer immunotherapy. Its annual meeting each November presents cellular therapy, checkpoint, vaccine and bispecific data and translational immunology; it publishes the Journal for ImmunoTherapy of Cancer, issues Cancer Immunotherapy Guidelines by disease and on immune-related toxicities, and runs the Immuno-Oncology Biomarkers task forces, the Sparkathon early-career programme and the SITC Cancer Immunotherapy Winter School. SITC also produces the primer on CAR-T toxicity management and works with FDA on regulatory science for immunotherapy combinations.","asOf":"2026-09-09","links":[{"label":"SITC","url":"https://www.sitcancer.org"},{"label":"Guidelines","url":"https://www.sitcancer.org/research/cancer-immunotherapy-guidelines"}],"tags":[],"related":[],"cancers":[],"sections":["immunotherapy","cell-therapy"],"technologies":["checkpoint-inhibitor","car-t","til-therapy","t-cell-engager","neoantigen-mrna-vaccine","oncolytic-virus"],"targets":[],"drugs":[],"companies":[],"institutions":["aacr","asco","moffitt"],"pathways":[],"terms":["irae","crs","icans","cold-vs-hot"],"trials":[],"people":["patrick-hwu","drew-pardoll","f-stephen-hodi","suzanne-topalian","sandra-demaria"],"bottlenecks":["b-immunotherapy-response","b-tme-immunosuppression"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Milwaukee, WI","country":"US","lat":43.039,"lng":-87.906,"institutionType":"consortium","website":"https://www.sitcancer.org","programs":["SITC Annual Meeting","Journal for ImmunoTherapy of Cancer","Cancer Immunotherapy Guidelines (disease and toxicity)","Biomarker task forces","Winter School and Sparkathon"]},{"id":"sgo","kind":"institution","name":"Society of Gynecologic Oncology","aka":["SGO"],"tldr":"The US society of gynaecologic oncologists, whose Annual Meeting on Women's Cancer is where the PARP inhibitor and immunotherapy trials in ovarian, endometrial and cervical cancer are presented.","summary":"Founded in 1969, SGO represents more than 2,000 gynaecologic oncologists, surgeons who also deliver systemic therapy, and allied professionals. Its Annual Meeting on Women's Cancer each March hosts the major trials in ovarian, endometrial, cervical and vulvar cancer (PAOLA-1, RUBY, NRG-GY018, KEYNOTE-A18 and MIRASOL were presented at SGO or the concurrent plenaries), and it publishes Gynecologic Oncology and Gynecologic Oncology Reports. SGO issues clinical practice statements on genetic testing, HPV vaccination, minimally invasive surgery after LACC, and molecular classification of endometrial cancer, and it runs the Foundation for Women's Cancer, advocacy on screening and the Winter Meeting for translational science.","asOf":"2026-09-09","links":[{"label":"SGO","url":"https://www.sgo.org"}],"tags":[],"related":[],"cancers":["ovarian","endometrial","cervical"],"sections":["surgery","targeted-therapy"],"technologies":["parp-inhibitor","checkpoint-inhibitor","hrd-testing","robotic-surgery","hpv-vaccine"],"targets":[],"drugs":[],"companies":["gog-foundation","nrg-oncology"],"institutions":["esgo"],"pathways":[],"terms":[],"trials":["paola-1","ruby","nrg-gy018-keynote-868","keynote-a18","lacc"],"people":["ursula-matulonis","matthew-powell","karen-lu"],"bottlenecks":[],"keyPapers":[],"journals":["gynecologic-oncology"],"dependsOn":[],"notes":[],"city":"Chicago, IL","country":"US","lat":41.881,"lng":-87.63,"institutionType":"consortium","website":"https://www.sgo.org","programs":["Annual Meeting on Women's Cancer","Gynecologic Oncology journal","Clinical practice statements","Foundation for Women's Cancer"]},{"id":"snmmi","kind":"institution","name":"Society of Nuclear Medicine and Molecular Imaging","aka":["SNMMI","Society of Nuclear Medicine"],"tldr":"The Society of Nuclear Medicine and Molecular Imaging represents US nuclear medicine and publishes the Journal of Nuclear Medicine; its annual meeting is where new PET tracers and radioligand therapy results are presented, and its procedure standards guide PSMA and somatostatin receptor imaging.","summary":"Founded in 1954 as the Society of Nuclear Medicine, SNMMI represents physicians, technologists and scientists in nuclear medicine and molecular imaging and publishes the Journal of Nuclear Medicine and the Journal of Nuclear Medicine Technology. Its annual meeting is where new PET tracers and radioligand therapy results are presented, its procedure standards and appropriate use criteria guide PSMA PET, FDG PET and somatostatin receptor imaging, and its Clinical Trials Network qualifies sites and scanners for multicentre trials. SNMMI runs the Mars Shot fund for radiopharmaceutical research, the Value Initiative on access and reimbursement, and dosimetry and radiation safety education, and it partners with EANM on joint guidelines and the theranostics centres of excellence programme.","asOf":"2026-09-09","links":[{"label":"SNMMI","url":"https://www.snmmi.org"}],"tags":[],"related":["src-snmmi"],"cancers":[],"sections":["radiopharma","imaging"],"technologies":["pet","pet-ct","psma-pet","fdg-pet","radioligand-therapy","targeted-alpha-therapy","spect"],"targets":[],"drugs":["pluvicto","lutathera","pylarify"],"companies":[],"institutions":["eanm","astro"],"pathways":[],"terms":["theranostics","dosimetry","suv"],"trials":[],"people":["virginia-pappas"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Reston, VA","country":"US","lat":38.958,"lng":-77.357,"institutionType":"consortium","website":"https://www.snmmi.org","programs":["SNMMI Annual Meeting","Journal of Nuclear Medicine","Clinical Trials Network","Appropriate use criteria and procedure standards","Mars Shot Fund"]},{"id":"sso","kind":"institution","name":"Society of Surgical Oncology","aka":["SSO","James Ewing Society"],"tldr":"The international society of cancer surgeons, publisher of Annals of Surgical Oncology and co-author of the margin and de-escalation guidelines that changed breast and melanoma surgery.","summary":"Founded in 1940 as the James Ewing Society, the SSO represents surgical oncologists worldwide, publishes Annals of Surgical Oncology and runs the annual SSO International Conference on Surgical Cancer Care. Its joint SSO-ASTRO consensus on breast-conserving surgery margins ('no ink on tumour') reduced re-excisions, and its guidelines with ASCO on sentinel node biopsy and melanoma surgery translated MSLT-II into practice. SSO accredits complex general surgical oncology fellowships and its Breast Surgical Oncology and Complex General Surgical Oncology training programmes, and it partners with ESSO and the Asian and Latin American societies on global surgical oncology.","asOf":"2026-09-09","links":[{"label":"SSO","url":"https://www.surgonc.org"}],"tags":[],"related":[],"cancers":["melanoma","breast-hr-positive","sarcoma"],"sections":["surgery"],"technologies":["sentinel-node","robotic-surgery","fluorescence-guided-surgery","hipec"],"targets":[],"drugs":[],"companies":[],"institutions":["esso","astro","asco"],"pathways":[],"terms":[],"trials":["mslt-ii"],"people":["timothy-eberlein","selwyn-vickers","kenneth-tanabe","tari-king"],"bottlenecks":["b-surgery-radiation-innovation"],"keyPapers":[],"journals":["annals-of-surgical-oncology"],"dependsOn":[],"notes":[],"city":"Rosemont, IL","country":"US","lat":41.995,"lng":-87.884,"institutionType":"consortium","website":"https://www.surgonc.org","programs":["Annals of Surgical Oncology","SSO International Conference","SSO-ASTRO margins consensus and melanoma guidelines","Fellowship accreditation"]},{"id":"swag-cancer-alliance","kind":"institution","name":"Somerset, Wiltshire, Avon and Gloucestershire Cancer Alliance","aka":["SWAG Cancer Alliance"],"tldr":"The NHS England Cancer Alliance for Somerset, Wiltshire, Bristol, Bath, North Somerset, South Gloucestershire and Gloucestershire: the partnership that plans and improves cancer services across its hospitals, GPs and community services.","summary":"One of the 20 Cancer Alliances set up by NHS England from 2016, following the Independent Cancer Taskforce strategy, to bring together the hospital trusts, integrated care boards, primary care, hospices and charities serving Somerset, Wiltshire, Bristol, Bath, North Somerset, South Gloucestershire and Gloucestershire. Alliances lead local delivery of the NHS cancer ambitions: earlier diagnosis (including rapid diagnostic centres and targeted lung health checks), the Faster Diagnosis Standard, personalised care and follow-up, and workforce and pathway improvement. They hold transformation funding from NHS England and publish local performance and improvement plans.","asOf":"2026-09-09","links":[{"label":"Somerset, Wiltshire, Avon and Gloucestershire Cancer Alliance","url":"https://www.swagcanceralliance.nhs.uk/"},{"label":"NHS England: Cancer Alliances","url":"https://www.england.nhs.uk/cancer/cancer-alliances-improving-care-locally/"}],"tags":["nhs-cancer-alliance"],"related":[],"cancers":[],"sections":["early-detection"],"technologies":["low-dose-ct-screening"],"targets":[],"drugs":[],"companies":[],"institutions":["bristol-haematology-oncology-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Bristol","country":"GB","lat":51.455,"lng":-2.588,"institutionType":"consortium","website":"https://www.swagcanceralliance.nhs.uk/","programs":["Earlier diagnosis and rapid diagnostic centres","Faster Diagnosis Standard","Personalised care and follow-up","Cancer pathway improvement"]},{"id":"soroka-medical-center","kind":"institution","name":"Soroka University Medical Center","aka":[],"tldr":"Soroka University Medical Center in Beersheba is the only tertiary hospital for Israel's Negev and Ben-Gurion University's teaching hospital; its oncology institute serves more than a million people, and its research using Clalit health records produces large epidemiological studies.","summary":"Soroka University Medical Center in Beersheba is the sole tertiary hospital for the Negev, serving more than a million people including the Bedouin population, and is the teaching hospital of Ben-Gurion University of the Negev's Faculty of Health Sciences. Its oncology institute provides medical oncology, radiotherapy, haematology, paediatric oncology and surgical oncology, and the hospital's research, using Clalit's health records, is known for large-scale epidemiological studies. A new dedicated cancer centre has been developed on the campus to expand radiotherapy and outpatient capacity for the region.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.soroka.org"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["sheba","hadassah"],"pathways":[],"terms":[],"trials":[],"people":["shlomi-codish"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Beersheba","country":"IL","lat":31.258,"lng":34.8,"institutionType":"hospital","website":"https://www.soroka.org","university":"Ben-Gurion University of the Negev","programs":["Oncology institute","Radiotherapy","Population-based cancer epidemiology"]},{"id":"saigenci-adelaide","kind":"institution","name":"South Australian immunoGENomics Cancer Institute (SAiGENCI), University of Adelaide","aka":["SAiGENCI","University of Adelaide cancer institute"],"tldr":"Cancer research institute founded at the University of Adelaide in 2021 and directed by Christopher Sweeney, who led the CHAARTED trial that brought docetaxel into first-line treatment of metastatic prostate cancer.","summary":"The South Australian immunoGENomics Cancer Institute (SAiGENCI) was established at the University of Adelaide in 2021 with Australian government funding to link cancer genomics and immunology with clinical trials. Its founding director, Christopher Sweeney, returned from Dana-Farber Cancer Institute in 2022; he was first author of the 2015 New England Journal of Medicine report of CHAARTED, in which adding docetaxel to androgen deprivation lengthened survival in metastatic hormone-sensitive prostate cancer. It works alongside the Royal Adelaide Hospital and SAHMRI.","asOf":"2026-09-18","links":[],"tags":[],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["royal-adelaide-hospital"],"pathways":[],"terms":[],"trials":[],"people":["christopher-sweeney"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Adelaide","country":"AU","lat":-34.921,"lng":138.606,"institutionType":"research-institute","university":"University of Adelaide","programs":["Prostate cancer","Cancer immunogenomics","Clinical trials"]},{"id":"south-east-london-cancer-alliance","kind":"institution","name":"South East London Cancer Alliance","aka":["SELCA"],"tldr":"The NHS England Cancer Alliance for the six South East London boroughs, including Lambeth, Southwark, Lewisham, Greenwich, Bromley and Bexley: the partnership that plans and improves cancer services across its hospitals, GPs and community services.","summary":"One of the 20 Cancer Alliances set up by NHS England from 2016, following the Independent Cancer Taskforce strategy, to bring together the hospital trusts, integrated care boards, primary care, hospices and charities serving the six South East London boroughs, including Lambeth, Southwark, Lewisham, Greenwich, Bromley and Bexley. Alliances lead local delivery of the NHS cancer ambitions: earlier diagnosis (including rapid diagnostic centres and targeted lung health checks), the Faster Diagnosis Standard, personalised care and follow-up, and workforce and pathway improvement. They hold transformation funding from NHS England and publish local performance and improvement plans.","asOf":"2026-09-09","links":[{"label":"South East London Cancer Alliance","url":"https://www.selca.nhs.uk"},{"label":"NHS England: Cancer Alliances","url":"https://www.england.nhs.uk/cancer/cancer-alliances-improving-care-locally/"}],"tags":["nhs-cancer-alliance"],"related":[],"cancers":[],"sections":["early-detection"],"technologies":["low-dose-ct-screening"],"targets":[],"drugs":[],"companies":[],"institutions":["guys-st-thomas"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"London","country":"GB","lat":51.475,"lng":-0.05,"institutionType":"consortium","website":"https://www.selca.nhs.uk","programs":["Earlier diagnosis and rapid diagnostic centres","Faster Diagnosis Standard","Personalised care and follow-up","Cancer pathway improvement"]},{"id":"south-yorkshire-bassetlaw-cancer-alliance","kind":"institution","name":"South Yorkshire and Bassetlaw Cancer Alliance","aka":["SYB Cancer Alliance"],"tldr":"The NHS England Cancer Alliance for Sheffield, Rotherham, Doncaster, Barnsley and Bassetlaw: the partnership that plans and improves cancer services across its hospitals, GPs and community services.","summary":"One of the 20 Cancer Alliances set up by NHS England from 2016, following the Independent Cancer Taskforce strategy, to bring together the hospital trusts, integrated care boards, primary care, hospices and charities serving Sheffield, Rotherham, Doncaster, Barnsley and Bassetlaw. Alliances lead local delivery of the NHS cancer ambitions: earlier diagnosis (including rapid diagnostic centres and targeted lung health checks), the Faster Diagnosis Standard, personalised care and follow-up, and workforce and pathway improvement. They hold transformation funding from NHS England and publish local performance and improvement plans.","asOf":"2026-09-09","links":[{"label":"South Yorkshire and Bassetlaw Cancer Alliance","url":"https://www.canceralliancesybnd.co.uk"},{"label":"NHS England: Cancer Alliances","url":"https://www.england.nhs.uk/cancer/cancer-alliances-improving-care-locally/"}],"tags":["nhs-cancer-alliance"],"related":[],"cancers":[],"sections":["early-detection"],"technologies":["low-dose-ct-screening"],"targets":[],"drugs":[],"companies":[],"institutions":["weston-park-sheffield"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Sheffield","country":"GB","lat":53.381,"lng":-1.47,"institutionType":"consortium","website":"https://www.canceralliancesybnd.co.uk","programs":["Earlier diagnosis and rapid diagnostic centres","Faster Diagnosis Standard","Personalised care and follow-up","Cancer pathway improvement"]},{"id":"aecc","kind":"institution","name":"Spanish Association Against Cancer (AECC)","aka":["Asociación Española Contra el Cáncer","Contra el Cáncer"],"tldr":"Spain's national cancer charity, founded in 1953 and based in Madrid, which funds research through its scientific foundation and supports patients across the country, and an associate member of the Organisation of European Cancer Institutes.","summary":"The Asociación Española Contra el Cáncer (AECC) is Spain's national cancer charity, founded in 1953 and headquartered in Madrid, with provincial boards across the country. It funds cancer research through its scientific foundation, supports patients and families and campaigns on prevention and policy. It is an associate member of the Organisation of European Cancer Institutes (OECI); its representative on the OECI list is Ramón Reyes Bori.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.contraelcancer.es/es"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q5708626"}],"tags":[],"related":["ico-catalonia","cnio"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["ramon-reyes-bori"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Madrid","country":"ES","lat":40.417,"lng":-3.703,"institutionType":"consortium","website":"https://www.contraelcancer.es/es","programs":[]},{"id":"st-vincents-ucd-cancer-centre","kind":"institution","name":"St Vincent's University Hospital / UCD Cancer Centre","aka":["St Vincent's UCD Cancer Centre"],"tldr":"One of Ireland's eight designated cancer centres, run with University College Dublin and accredited by OECI as a Cancer Centre.","summary":"St Vincent's University Hospital is one of the eight designated cancer centres of Ireland's National Cancer Control Programme and the principal teaching hospital of University College Dublin. Its cancer centre provides medical oncology, radiation oncology (with St Luke's Radiation Oncology Network), surgical oncology and haematology, and hosts national programmes including liver transplantation and pancreatic surgery. Research with UCD's Conway Institute and Systems Biology Ireland covers breast cancer, colorectal cancer and computational oncology, and the hospital is accredited by the Organisation of European Cancer Institutes as a Cancer Centre.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.stvincents.ie"}],"tags":["oeci-accredited","oeci-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["david-fennelly"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Dublin","country":"IE","lat":53.317,"lng":-6.216,"institutionType":"hospital","website":"https://www.stvincents.ie","university":"University College Dublin","programs":["Designated cancer centre","Hepatobiliary and pancreatic surgery","Systems biology"]},{"id":"st-anna-ccri-vienna","kind":"institution","name":"St. Anna Children's Hospital and Children's Cancer Research Institute (CCRI)","aka":["St. Anna Kinderspital","St. Anna Kinderkrebsforschung","CCRI Vienna"],"tldr":"Vienna's children's cancer hospital and its research institute, the coordinating centre of the European SIOPEN neuroblastoma trials led by Ruth Ladenstein.","summary":"St. Anna Children's Hospital is Austria's largest paediatric oncology centre and is affiliated with the Medical University of Vienna; the adjoining St. Anna Children's Cancer Research Institute (CCRI) carries out laboratory and clinical research. The hospital's Studies and Statistics unit, led by Ruth Ladenstein, coordinates the SIOP Europe Neuroblastoma Group (SIOPEN) high-risk neuroblastoma trials, including the HR-NBL1 trial that established busulfan-melphalan conditioning and dinutuximab beta immunotherapy in Europe.","asOf":"2026-09-18","links":[],"tags":[],"related":[],"cancers":["neuroblastoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["ruth-ladenstein"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Vienna","country":"AT","lat":48.219,"lng":16.35,"institutionType":"hospital","university":"Medizinische Universität Wien","programs":["Paediatric oncology","Neuroblastoma (SIOPEN)","Childhood leukaemia and sarcoma research"]},{"id":"st-baldricks-foundation","kind":"institution","name":"St. Baldrick's Foundation","aka":["St. Baldrick's"],"tldr":"A volunteer-powered charity, born from a head-shaving dare in 2000, that says it funds more childhood cancer research grants than any organisation besides the US government.","summary":"St. Baldrick's began as a head-shaving event among colleagues in 2000 and became a foundation whose thousands of volunteer-run shave events fund childhood cancer research. The foundation states that it funds more grants than any organisation besides the US government, that every grant it makes is for childhood cancer research, and that it keeps staff small and expenses low so that every possible dollar goes to research. Its grants support fellows, scholars, consortium research and infrastructure such as the Children's Oncology Group. Headquartered in Monrovia, California.","asOf":"2026-09-10","links":[{"label":"About St. Baldrick's","url":"https://www.stbaldricks.org/about-us"}],"tags":[],"related":["st-baldricks"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["kathleen-ruddy"],"bottlenecks":["b-rare-cancers","b-funding-allocation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Monrovia, CA","country":"US","lat":34.144,"lng":-118,"institutionType":"consortium","website":"https://www.stbaldricks.org","programs":["Volunteer head-shaving events","Fellowship and scholar grants","Consortium and infrastructure grants","Children's Oncology Group support"]},{"id":"st-jude","kind":"institution","name":"St. Jude Children's Research Hospital","aka":["St. Jude"],"tldr":"The only NCI comprehensive cancer centre devoted to children, where Total Therapy protocols made childhood leukaemia curable; families are never billed for care.","summary":"Founded by Danny Thomas in 1962 and NCI comprehensive since 2008, St. Jude treats children with cancer and catastrophic diseases without charging families for treatment, travel, housing or food. Donald Pinkel's Total Therapy protocols pioneered combination chemotherapy with CNS-directed therapy in acute lymphoblastic leukaemia; by St. Jude's own figures ALL survival rose from about 4% when the hospital opened to about 94% today. The Pediatric Cancer Genome Project with Washington University (2010) sequenced hundreds of paediatric tumours, and St. Jude Cloud shares the data; the hospital opened the first proton centre dedicated to children in 2015 and runs molecularly risk-adapted trials in medulloblastoma, neuroblastoma and retinoblastoma. St. Jude Global works to raise childhood cancer survival in low- and middle-income countries, and Julie Park chairs its Department of Oncology.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/St._Jude_Children's_Research_Hospital","links":[{"label":"St. Jude Children's Research Hospital","url":"https://www.stjude.org"},{"label":"Clinical trials","url":"https://www.stjude.org/treatment/clinical-trials.html"},{"label":"St. Jude Cloud","url":"https://www.stjude.cloud"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":["all-leukemia","medulloblastoma","neuroblastoma","retinoblastoma","osteosarcoma"],"sections":[],"technologies":["proton-therapy","wes-wgs","car-t","proton-therapy-systems"],"targets":[],"drugs":[],"companies":["childrens-oncology-group"],"institutions":["wustl-siteman"],"pathways":[],"terms":[],"trials":[],"people":["julie-park","james-r-downing","ching-hon-pui","amar-gajjar","robbie-majzner"],"bottlenecks":["b-global-access","b-rare-cancers"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Memphis, TN","country":"US","lat":35.152,"lng":-90.043,"institutionType":"cancer-center","website":"https://www.stjude.org","nci":"comprehensive","programs":["Acute lymphoblastic leukaemia (Total Therapy)","Pediatric Cancer Genome Project","Proton therapy for children","St. Jude Global"]},{"id":"stand-up-to-cancer","kind":"institution","name":"Stand Up To Cancer","aka":["SU2C"],"tldr":"An entertainment-industry charity that funds multi-institution Dream Teams, with AACR as scientific partner, to move discoveries into trials quickly.","summary":"Founded in 2008 by film and television leaders, Stand Up To Cancer raises money through televised specials and channels it through the American Association for Cancer Research, its scientific partner, into Dream Teams that bring institutions together around a single translational goal with milestone-based funding. Dream Teams have covered prostate cancer (with the Prostate Cancer Foundation), pancreatic cancer (with the Lustgarten Foundation), lung cancer, paediatric cancer, immunotherapy and early detection, and SU2C also funds Innovative Research Grants and a Health Equity Initiative to diversify trial enrolment. Stand Up To Cancer Canada and UK partnerships extend the model.","asOf":"2026-09-09","links":[{"label":"Stand Up To Cancer","url":"https://standuptocancer.org"},{"label":"Research","url":"https://standuptocancer.org/research/"}],"tags":[],"related":["prostate-cancer-foundation"],"cancers":["prostate","pancreatic","nsclc"],"sections":["immunotherapy","early-detection"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["aacr","lustgarten-foundation","cruk"],"pathways":[],"terms":[],"trials":[],"people":["charles-sawyers","david-tuveson","howard-scher","sherry-lansing","julian-adams","william-nelson"],"bottlenecks":["b-translational-valley","b-trial-diversity"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Los Angeles","country":"US","lat":34.052,"lng":-118.244,"institutionType":"consortium","website":"https://standuptocancer.org","programs":["Dream Teams (prostate, pancreatic, lung, paediatric, immunotherapy)","Innovative Research Grants","Health Equity Initiative","Televised fundraising"]},{"id":"stanford","kind":"institution","name":"Stanford Health Care / Stanford Cancer Institute","aka":[],"tldr":"Stanford is home to CAR-T innovation (Mackall, Majzner), the CD47 discovery (Weissman), and AI in medicine.","summary":"Stanford Health Care and the Stanford Cancer Institute in California hold NCI comprehensive designation and thirtieth place in the Newsweek/Statista oncology ranking, and they matter for CAR-T innovation, the CD47 discovery and AI in medicine. Crystal L. Mackall and Majzner developed GD2 CAR-T for diffuse intrinsic pontine glioma, Irving L. Weissman's CD47 work is the origin of magrolimab, Adler invented the CyberKnife, and Ronald Levy leads its lymphoma tradition, with Ash A. Alizadeh, Christina Curtis and Heather A. Wakelee also listed. OnCo links it to Evo 2, GenePT and the Merlin CT vision-language model, to pathways from chromosomal instability to ferroptosis, and to funders including the Chan Zuckerberg Biohub and the Parker Institute. Getting CAR-T past the blood-brain barrier durably is the bottleneck its glioma work confronts. Programmes and people are listed below.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://cancer.stanford.edu"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["car-t","sbrt","cyberknife","radiosurgery-srs","biology-guided-radiotherapy"],"targets":["cd47"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["steven-artandi","crystal-mackall","irving-weissman","ronald-levy","heather-wakelee","ash-alizadeh","maximilian-diehn","lipika-goyal","michelle-monje","christina-curtis","quynh-thu-le"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Stanford","country":"US","lat":37.434,"lng":-122.175,"institutionType":"university","website":"https://cancer.stanford.edu","nci":"comprehensive","newsweekOncology2026":30,"university":"Stanford University","programs":["CAR-T for paediatric brain tumours","AI in oncology","Lymphoma"]},{"id":"stephenson-oklahoma","kind":"institution","name":"Stephenson Cancer Center, OU Health","aka":[],"tldr":"Oklahoma's only NCI-designated centre, consistently among the top enrollers in NRG gynaecologic trials and home of the SOLO1 and MIRASOL ovarian cancer lead investigator.","summary":"NCI-designated in 2018, Stephenson Cancer Center is the only NCI centre in Oklahoma and serves a state with large American Indian populations. Its gynaecologic oncology group is one of the most productive in the NCI's National Clinical Trials Network: Kathleen Moore led SOLO1, which established olaparib maintenance in newly diagnosed BRCA-mutated ovarian cancer, and MIRASOL, which confirmed the folate receptor alpha ADC mirvetuximab soravtansine in platinum-resistant disease. The Oklahoma Tobacco Research Center and TSET-funded cancer control programmes address the state's high smoking rates, and the centre runs an active phase 1 programme.","asOf":"2026-09-09","links":[{"label":"Stephenson Cancer Center","url":"https://www.ouhealth.com/stephenson-cancer-center/"},{"label":"Clinical trials","url":"https://www.ouhealth.com/stephenson-cancer-center/research-clinical-trials/"}],"tags":[],"related":[],"cancers":["ovarian","cervical","endometrial"],"sections":[],"technologies":["parp-inhibitor","adc"],"targets":["parp","folr1"],"drugs":["olaparib","mirvetuximab-soravtansine"],"companies":["nrg-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["kathleen-moore"],"bottlenecks":["b-trial-diversity"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Oklahoma City, OK","country":"US","lat":35.48,"lng":-97.497,"institutionType":"cancer-center","website":"https://www.ouhealth.com/stephenson-cancer-center/","nci":"clinical","university":"University of Oklahoma","programs":["Gynaecologic oncology trials (NRG)","Ovarian cancer (PARP inhibitors, FRα ADCs)","Tobacco research"]},{"id":"steve-biko-academic-hospital","kind":"institution","name":"Steve Biko Academic Hospital / University of Pretoria","aka":["Pretoria Academic Hospital"],"tldr":"Steve Biko Academic Hospital is the University of Pretoria's teaching hospital and Gauteng's northern tertiary centre; its large nuclear medicine department has led South African research on PSMA-targeted radioligand therapy for a largely public-sector population.","summary":"Steve Biko Academic Hospital, formerly Pretoria Academic Hospital, is the central tertiary and quaternary hospital of Gauteng's northern region and the principal teaching hospital of the University of Pretoria's Faculty of Health Sciences. Its cancer services include radiation oncology, medical oncology, haematology and stem cell transplantation, paediatric oncology and a large nuclear medicine department that has been active in South African radioligand therapy research, including PSMA-targeted treatments. The hospital works with the Medical Research Council and the university on cancer epidemiology and clinical trials for a largely public-sector population.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.sbah.org.za"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["radioligand-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["wits-charlotte-maxeke"],"pathways":[],"terms":[],"trials":[],"people":["lehlohonolo-majake"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Pretoria","country":"ZA","lat":-25.732,"lng":28.2,"institutionType":"hospital","website":"https://www.sbah.org.za","university":"University of Pretoria","programs":["Radiation oncology","Nuclear medicine and radioligand therapy","Haematology and transplant"]},{"id":"sgccn","kind":"institution","name":"Stockholm Gotland Comprehensive Cancer Network (SGCCN)","aka":["RCC Stockholm Gotland","Regionalt cancercentrum Stockholm Gotland"],"tldr":"The cancer network for the Stockholm and Gotland regions, built on the regional cancer centre RCC Stockholm Gotland, listed by the Organisation of European Cancer Institutes as a linked institution.","summary":"The Stockholm Gotland Comprehensive Cancer Network (SGCCN) brings together the hospitals and the regional cancer centre (RCC Stockholm Gotland) serving Region Stockholm and Region Gotland. The Organisation of European Cancer Institutes (OECI) lists it as a linked institution of its Stockholm members.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://cancercentrum.se/omrcc/kontaktochorganisation/rccstockholmgotland.1334.html"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci","karolinska"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Stockholm","country":"SE","lat":59.334,"lng":18.02,"institutionType":"consortium","website":"https://cancercentrum.se/omrcc/kontaktochorganisation/rccstockholmgotland.1334.html","programs":[]},{"id":"sultan-qaboos-cccrc","kind":"institution","name":"Sultan Qaboos Comprehensive Cancer Care and Research Centre","aka":["SQCCCRC","CCCRC Oman"],"tldr":"Oman's national comprehensive cancer centre in Muscat, built to bring specialist cancer treatment and research to the country.","summary":"The Sultan Qaboos Comprehensive Cancer Care and Research Centre is Oman's dedicated national cancer centre, established by royal decree and opened in Muscat to provide comprehensive treatment that previously required travel abroad. It offers medical oncology, radiation oncology, haematology and bone marrow transplantation, surgical oncology, nuclear medicine and PET-CT, paediatric oncology and palliative care, together with research laboratories, a clinical trials unit and training programmes. The centre works with the Ministry of Health and Sultan Qaboos University Hospital and is developing regional collaborations across the Gulf.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://cccrc.gov.om"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["kfshrc","hamad-medical-corporation"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Muscat","country":"OM","lat":23.588,"lng":58.408,"institutionType":"cancer-center","website":"https://cccrc.gov.om","programs":["National comprehensive cancer centre","Radiation oncology","Bone marrow transplantation","Research and trials unit"]},{"id":"sysucc","kind":"institution","name":"Sun Yat-sen University Cancer Center","aka":[],"tldr":"Sun Yat-sen University Cancer Center is one of China's largest cancer centres, the global leader in nasopharyngeal carcinoma and a top enroller for Chinese ADC and PD-1 trials.","summary":"Sun Yat-sen University Cancer Center in Guangzhou is one of China's largest cancer centres, the global leader in nasopharyngeal carcinoma, and a top enroller for Chinese antibody-drug conjugate and PD-1 trials; it ranks sixtieth in the Newsweek/Statista oncology list. Jun Ma's group set the treatment standards for nasopharyngeal carcinoma, the centre ran the JUPITER-02 toripalimab trial and camrelizumab studies, and it leads trials of izalontamab brengitecan, with Mu-Sheng Zeng, Feng Wang and Rui-Hua Xu also listed. OnCo links it to head and neck, gastric, oesophageal and liver cancers, to plasma EBV DNA, to the idea of blood EBV DNA screening across southern China and Southeast Asia, and to the CSCO guidelines. Whether Chinese trial results are accepted by regulators elsewhere is the open question its work keeps testing. Its nasopharyngeal and ADC programmes are the ones to read.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Sun_Yat-sen_University_Cancer_Center","links":[{"label":"Official website","url":"https://www.sysucc.org.cn"}],"tags":[],"related":[],"cancers":["head-and-neck"],"sections":[],"technologies":[],"targets":[],"drugs":["izalontamab-brengitecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["ma-jun","zeng-mu-sheng","wang-feng-sysucc","zhang-li-sysucc","xu-rui-hua","fang-wenfeng"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Guangzhou","country":"CN","lat":23.132,"lng":113.294,"institutionType":"cancer-center","website":"https://www.sysucc.org.cn","newsweekOncology2026":60,"programs":["Nasopharyngeal carcinoma","ADC and IO trials"]},{"id":"sunnybrook-odette","kind":"institution","name":"Sunnybrook Odette Cancer Centre","aka":["Odette Cancer Centre","Sunnybrook Health Sciences Centre"],"tldr":"One of Canada's largest cancer centres, where focused ultrasound first opened the blood-brain barrier in a patient and Canada's first MR-linac was installed.","summary":"The Odette Cancer Centre at Sunnybrook Health Sciences Centre is one of Canada's largest cancer programmes and a University of Toronto teaching site. Sunnybrook Research Institute's Kullervo Hynynen pioneered MR-guided focused ultrasound, and in 2015 neurosurgeon Todd Mainprize used it to open the blood-brain barrier non-invasively in a brain tumour patient for the first time, work now in trials for glioblastoma and brain metastases with Insightec. Radiation oncology is a signature strength: Arjun Sahgal led the CCTG SC.24 trial of stereotactic radiotherapy for spinal metastases, Gregory Czarnota develops ultrasound-stimulated microbubble radiosensitisation, and Sunnybrook installed Canada's first MR-linac. The Odette Breast Centre and a large GU programme (including prostate brachytherapy) complete the picture.","asOf":"2026-09-09","links":[{"label":"Odette Cancer Centre","url":"https://sunnybrook.ca/content/?page=odette-cancer-centre"},{"label":"Sunnybrook Research Institute","url":"https://sunnybrook.ca/research/"}],"tags":[],"related":[],"cancers":["glioblastoma","prostate","breast-hr-positive"],"sections":[],"technologies":["bbb-focused-ultrasound","hifu-histotripsy","mr-linac","sbrt","brachytherapy","gamma-knife","radiosurgery-srs"],"targets":[],"drugs":[],"companies":["insightec","elekta","cctg"],"institutions":["princess-margaret"],"pathways":[],"terms":["oligometastatic"],"trials":[],"people":["monika-krzyzanowska","simron-singh"],"bottlenecks":["b-brain-delivery"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Toronto, ON","country":"CA","lat":43.723,"lng":-79.375,"institutionType":"cancer-center","website":"https://sunnybrook.ca/content/?page=odette-cancer-centre","university":"University of Toronto","programs":["Focused ultrasound and blood-brain barrier opening","MR-linac and stereotactic radiotherapy","Breast cancer","Genitourinary oncology"]},{"id":"surrey-sussex-cancer-alliance","kind":"institution","name":"Surrey and Sussex Cancer Alliance","aka":["SSCA"],"tldr":"The NHS England Cancer Alliance for Surrey and Sussex, from Guildford and Frimley to Brighton and Hastings: the partnership that plans and improves cancer services across its hospitals, GPs and community services.","summary":"One of the 20 Cancer Alliances set up by NHS England from 2016, following the Independent Cancer Taskforce strategy, to bring together the hospital trusts, integrated care boards, primary care, hospices and charities serving Surrey and Sussex, from Guildford and Frimley to Brighton and Hastings. Alliances lead local delivery of the NHS cancer ambitions: earlier diagnosis (including rapid diagnostic centres and targeted lung health checks), the Faster Diagnosis Standard, personalised care and follow-up, and workforce and pathway improvement. They hold transformation funding from NHS England and publish local performance and improvement plans.","asOf":"2026-09-09","links":[{"label":"Surrey and Sussex Cancer Alliance","url":"https://surreyandsussexcanceralliance.nhs.uk/"},{"label":"NHS England: Cancer Alliances","url":"https://www.england.nhs.uk/cancer/cancer-alliances-improving-care-locally/"}],"tags":["nhs-cancer-alliance"],"related":["kent-medway-cancer-alliance","wessex-cancer-alliance","thames-valley-cancer-alliance","south-east-london-cancer-alliance"],"cancers":[],"sections":["early-detection"],"technologies":["low-dose-ct-screening"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Guildford","country":"GB","lat":51.236,"lng":-0.57,"institutionType":"consortium","website":"https://surreyandsussexcanceralliance.nhs.uk/","programs":["Earlier diagnosis and rapid diagnostic centres","Faster Diagnosis Standard","Personalised care and follow-up","Cancer pathway improvement"]},{"id":"swissmedic","kind":"institution","name":"Swissmedic","aka":["Swiss Agency for Therapeutic Products"],"tldr":"Swissmedic authorises medicines and devices in Switzerland and Liechtenstein; because Switzerland sits outside the EU it runs its own approvals, but it shares work with the FDA through Project Orbis and the Access Consortium and relies on decisions by comparable regulators.","summary":"Established in 2002, Swissmedic authorises and supervises medicines and medical devices in Switzerland and Liechtenstein. Because Switzerland sits outside the EU, it runs its own approval process, and it has joined international work-sharing through the FDA's Project Orbis, the Access Consortium and reliance procedures for products already approved by comparable regulators. It offers fast-track and temporary authorisation for medicines against serious diseases and regulates the advanced therapies produced by the Swiss pharmaceutical industry. Pricing and reimbursement are decided separately by the Federal Office of Public Health.","asOf":"2026-09-09","links":[{"label":"Swissmedic","url":"https://www.swissmedic.ch"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["roche-genentech","novartis"],"institutions":["fda-oce","ema","mhra","tga","health-canada"],"pathways":[],"terms":[],"trials":[],"people":["vincenza-trivigno"],"bottlenecks":["b-regulatory-fragmentation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Bern","country":"CH","lat":46.948,"lng":7.447,"institutionType":"government","website":"https://www.swissmedic.ch","programs":["Marketing authorisation and fast-track procedures","Project Orbis and Access Consortium","Reliance on foreign approvals","Market surveillance"]},{"id":"sydney-childrens-hospitals-network","kind":"institution","name":"Sydney Children's Hospitals Network / Children's Cancer Institute","aka":["Children's Cancer Institute Australia","Kids Cancer Centre, Sydney Children's Hospital Randwick","Cancer Centre for Children, Westmead","ZERO Childhood Cancer"],"tldr":"Australia's largest paediatric hospital network, which with the Children's Cancer Institute runs ZERO Childhood Cancer, a national precision medicine programme for every child with cancer.","summary":"The Sydney Children's Hospitals Network comprises the Children's Hospital at Westmead and Sydney Children's Hospital Randwick, whose oncology units are the largest in Australia. With the Children's Cancer Institute, a UNSW-affiliated research institute founded in 1976 by parents of children with cancer, they created the ZERO Childhood Cancer programme, which since 2017 has offered whole-genome, RNA and methylation profiling plus high-throughput drug testing to children with high-risk and now all cancers across Australia, one of the first national paediatric precision oncology programmes anywhere. Research strengths include neuroblastoma biology (Michelle Haber, Glenn Marshall, Murray Norris), leukaemia minimal residual disease testing, and the Australian and New Zealand Children's Haematology/Oncology Group trials.","asOf":"2026-09-09","links":[{"label":"Sydney Children's Hospitals Network","url":"https://www.schn.health.nsw.gov.au"},{"label":"Children's Cancer Institute","url":"https://www.ccia.org.au"},{"label":"ZERO Childhood Cancer","url":"https://www.zerochildhoodcancer.org.au"}],"tags":[],"related":[],"cancers":["neuroblastoma","all-leukemia","glioblastoma","sarcoma"],"sections":["diagnostics","chemotherapy"],"technologies":["wes-wgs","rna-seq","methylation-profiling","functional-drug-testing","mrd-testing"],"targets":[],"drugs":[],"companies":["childrens-oncology-group"],"institutions":[],"pathways":[],"terms":["mrd"],"trials":[],"people":["cathryn-cox","louis-chesler"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Sydney","country":"AU","lat":-33.918,"lng":151.239,"institutionType":"hospital","website":"https://www.schn.health.nsw.gov.au","university":"UNSW Sydney","programs":["ZERO Childhood Cancer precision medicine","Neuroblastoma research","Leukaemia MRD","ANZCHOG trials"]},{"id":"sylvester-miami","kind":"institution","name":"Sylvester Comprehensive Cancer Center, University of Miami","aka":["Sylvester"],"tldr":"South Florida's NCI-designated cancer centre, serving a largely Hispanic catchment, with strengths in myeloma, myeloid malignancies and proton therapy.","summary":"NCI-designated in 2019, Sylvester is the University of Miami's cancer centre and the only NCI-designated centre in South Florida, with a catchment that is majority Hispanic and a gateway to the Caribbean and Latin America. Director Stephen Nimer is a leukaemia and epigenetics researcher; Ola Landgren's myeloma programme focuses on MRD-driven treatment strategies. The Dwoskin Proton Therapy Center added proton beam therapy to the region, and Sylvester's Firefighter Cancer Initiative and Game Changer mobile screening vehicles are notable community programmes. It runs a substantial phase 1 unit.","asOf":"2026-09-09","links":[{"label":"Sylvester Comprehensive Cancer Center","url":"https://umiamihealth.org/sylvester-comprehensive-cancer-center"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":["multiple-myeloma","aml","mds"],"sections":[],"technologies":["mrd-testing","proton-therapy","proton-therapy-systems"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["mrd"],"trials":[],"people":["ola-landgren"],"bottlenecks":["b-trial-diversity"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Miami, FL","country":"US","lat":25.79,"lng":-80.213,"institutionType":"cancer-center","website":"https://umiamihealth.org/sylvester-comprehensive-cancer-center","nci":"clinical","university":"University of Miami","programs":["Multiple myeloma (MRD-guided therapy)","Myeloid malignancies","Proton therapy","Community screening"]},{"id":"taipei-veterans-general-hospital","kind":"institution","name":"Taipei Veterans General Hospital","aka":["TVGH","臺北榮民總醫院"],"tldr":"Taipei Veterans General Hospital, founded in 1958, is one of Taiwan's three great medical centres; it opened Taiwan's first carbon-ion therapy centre in 2023, enrols heavily into EGFR and immunotherapy lung cancer trials, and runs Taiwan Cooperative Oncology Group studies.","summary":"Taipei Veterans General Hospital, founded in 1958, is a national medical centre affiliated to National Yang Ming Chiao Tung University and one of Taiwan's most active clinical research sites. Its oncology strengths include thoracic oncology (a leading enroller in EGFR and immunotherapy trials), hepatocellular carcinoma and portal hypertension research, gastric and colorectal surgery, and paediatric oncology. The hospital opened Taiwan's first heavy ion (carbon-ion) therapy centre in 2023 and runs a large cancer immunotherapy and cell therapy programme under Taiwan's special-access regulations. TVGH also hosts extensive registry-based research and Taiwan Cooperative Oncology Group trials.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Taipei_Veterans_General_Hospital","links":[{"label":"Taipei Veterans General Hospital","url":"https://www.vghtpe.gov.tw"},{"label":"Heavy Ion Therapy Center","url":"https://www.vghtpe.gov.tw/Index.action?lang=EN"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":["nsclc","hcc","colorectal","gastric"],"sections":["radiation","cell-therapy"],"technologies":["carbon-ion","checkpoint-inhibitor","car-t","carbon-ion-synchrotrons","gamma-knife","radiosurgery-srs"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["chen-wei-ming"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Taipei","country":"TW","lat":25.121,"lng":121.52,"institutionType":"hospital","website":"https://www.vghtpe.gov.tw","university":"National Yang Ming Chiao Tung University","programs":["Heavy ion (carbon-ion) therapy","Thoracic oncology","Hepatocellular carcinoma","Cell therapy"]},{"id":"tartu-university-hospital","kind":"institution","name":"Tartu University Hospital","aka":["Tartu Ülikooli Kliinikum"],"tldr":"Estonia's university hospital and its main cancer treatment and research centre, accredited by OECI as a Cancer Centre.","summary":"Tartu University Hospital is Estonia's only university hospital and the teaching hospital of the University of Tartu. Its Haematology and Oncology Clinic delivers medical oncology, radiotherapy and haematology for the whole country alongside surgical oncology in the hospital's other clinics, and it is the Estonian hub for international cancer trials and for population-based research using the Estonian Cancer Registry and the Estonian Biobank. The hospital is accredited by the Organisation of European Cancer Institutes as a Cancer Centre and coordinates the national cancer control plan's specialist pathways with the North Estonia Medical Centre in Tallinn.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.kliinikum.ee"}],"tags":["oeci-accredited","oeci-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["priit-perens"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Tartu","country":"EE","lat":58.378,"lng":26.729,"institutionType":"hospital","website":"https://www.kliinikum.ee","university":"University of Tartu","programs":["Haematology and Oncology Clinic","Radiotherapy","Registry and biobank research"]},{"id":"tata-medical-center-kolkata","kind":"institution","name":"Tata Medical Center, Kolkata","aka":["TMC Kolkata","Tata Medical Centre"],"tldr":"Eastern India's leading cancer hospital, opened by the Tata Trusts in 2011 with a strong paediatric and haematology programme and a translational research institute.","summary":"Tata Medical Center opened in New Town, Kolkata, in 2011 as a not-for-profit cancer hospital funded by the Tata Trusts to serve eastern India, Bangladesh and Nepal, with half its beds reserved for subsidised care. It provides the full range of surgical, medical, radiation and paediatric oncology, has one of India's largest paediatric haematology-oncology and bone marrow transplant programmes, and runs the Tata Translational Cancer Research Centre for genomics, immunology and health-economics research. The centre participates in national and international cooperative trials (including the Indian Pediatric Oncology Group and the National Cancer Grid) and hosts a nursing and DM/MCh training programme.","asOf":"2026-09-09","links":[{"label":"Tata Medical Center","url":"https://tmckolkata.com"}],"tags":[],"related":["global-oncology-access"],"cancers":["all-leukemia","aml","head-and-neck","breast-hr-positive","dlbcl"],"sections":["chemotherapy","radiation"],"technologies":["allogeneic-cell-therapy","imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":["tata-memorial","tata-trusts"],"pathways":[],"terms":[],"trials":[],"people":["ratan-tata"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Kolkata","country":"IN","lat":22.577,"lng":88.485,"institutionType":"cancer-center","website":"https://tmckolkata.com","programs":["Paediatric haematology-oncology","Bone marrow transplant","Translational Cancer Research Centre","Subsidised care"]},{"id":"tata-memorial","kind":"institution","name":"Tata Memorial Centre","aka":[],"tldr":"India's largest cancer centre, a leader in low-cost, high-impact trials such as low-dose immunotherapy and oral metronomic chemotherapy.","summary":"Tata Memorial Centre in Mumbai is India's largest cancer centre, seeing seventy thousand new patients a year, and a leader in low-cost, high-impact trials such as low-dose nivolumab with metronomic chemotherapy in head and neck cancer, visual cervical screening and affordable radiotherapy. Its trials in OnCo include elective versus therapeutic neck dissection in oral cancer, gefitinib with or without chemotherapy in EGFR-mutant lung cancer and the IARC India HPV vaccine dose study, and it anchors the National Cancer Grid of India and the CAR-T talicabtagene autoleucel from ImmunoACT. OnCo links it to bottlenecks on the absence of cancer care in most of the world and to ideas for a Global Fund for cancer care. Whether its low-cost regimens are adopted in richer countries is the open question. Its programmes are listed below.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Tata_Memorial_Centre","links":[{"label":"Official website","url":"https://tmc.gov.in"}],"tags":[],"related":[],"cancers":["head-and-neck","cervical"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["pop-rt"],"people":["pramesh-c-s","narula-gaurav","jain-hasmukh","prabhash-kumar","chaturvedi-pankaj","badwe-rajendra","gupta-sudeep","shastri-surendra","noronha-vanita","patil-vijay"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Mumbai","country":"IN","lat":19.005,"lng":72.843,"institutionType":"cancer-center","website":"https://tmc.gov.in","newsweekOncology2026":80,"programs":["Low-cost immunotherapy trials","Cervical screening","Head and neck cancer"]},{"id":"tata-trusts","kind":"institution","name":"Tata Trusts","aka":["Sir Dorabji Tata Trust","Sir Ratan Tata Trust"],"tldr":"India's oldest philanthropic trusts, which built the Tata Memorial Hospital in 1941 and since 2017 have been building a network of 20 cancer hospitals across seven states so that treatment is closer to home.","summary":"The Sir Dorabji Tata Trust was established in 1932 and, with the Sir Ratan Tata Trust and allied trusts, forms Tata Trusts. The Trusts' own history records the Tata Memorial Centre for Cancer Research and Treatment opening in 1941, called the first large contribution of India to the international fight against cancer. The Tata Medical Center in Kolkata followed in 2012 for eastern and north-eastern India. The Cancer Care Programme launched in 2017 aims to make affordable, high-quality care available closer to patients' homes through a distributed model covering access, quality, affordability, and awareness, early detection and palliative care: a network of 20 hospitals across Andhra Pradesh, Assam, Jharkhand, Maharashtra, Uttar Pradesh, Odisha and Gujarat, and the Assam Cancer Care Foundation, a partnership with the Government of Assam that built a three-level network of two apex centres, twelve district facilities and five day-care centres. The stated aim is to reverse India's 30:70 ratio of early to late detection.","asOf":"2026-09-10","links":[{"label":"Tata Trusts: cancer care","url":"https://www.tatatrusts.org/our-work/healthcare/cancer-care"},{"label":"Tata Trusts history 1907-2000","url":"https://www.tatatrusts.org/about-tatatrusts/our-history/our-history-1907-2000"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["tata-memorial","tata-medical-center-kolkata"],"pathways":[],"terms":[],"trials":[],"people":["ratan-tata"],"bottlenecks":["b-global-access","b-early-detection","b-care-fragmentation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Mumbai","country":"IN","lat":18.93,"lng":72.83,"institutionType":"consortium","website":"https://www.tatatrusts.org","programs":["Cancer Care Programme (2017)","Assam Cancer Care Foundation","Tata Memorial Centre (1941)","Tata Medical Center, Kolkata (2012)"]},{"id":"tatarstan-cancer-center","kind":"institution","name":"Tatarstan Cancer Center, Kazan","aka":["Republican Clinical Oncology Dispensary of Tatarstan","Республиканский клинический онкологический диспансер","TCC"],"tldr":"The regional cancer hospital for the Republic of Tatarstan in Kazan, founded in 1946, and an associate member of the Organisation of European Cancer Institutes.","summary":"The Tatarstan Cancer Center (Republican Clinical Oncology Dispensary of the Ministry of Health of the Republic of Tatarstan) in Kazan is the regional cancer hospital for Tatarstan, founded in 1946, providing surgery, radiotherapy and drug treatment for the republic. It is an associate member of the Organisation of European Cancer Institutes (OECI).","asOf":"2026-09-09","links":[{"label":"Official website","url":"http://oncort.ru"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q30270574"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Kazan","country":"RU","lat":55.813,"lng":49.174,"institutionType":"cancer-center","website":"http://oncort.ru","programs":[]},{"id":"tawam-hospital","kind":"institution","name":"Tawam Hospital","aka":["Tawam Hospital Oncology Institute","SEHA Tawam","مستشفى توام"],"tldr":"The UAE's national referral hospital for cancer, with the country's first comprehensive oncology institute, bone marrow transplant service and long-standing Johns Hopkins affiliation.","summary":"Tawam Hospital in Al Ain, opened in 1979 and now part of PureHealth/SEHA and the Abu Dhabi health system, is the UAE's designated national referral centre for oncology and hosts its longest-established comprehensive cancer programme, with medical, surgical and radiation oncology, paediatric oncology, nuclear medicine and the country's first bone marrow transplant service. It was managed for many years in affiliation with Johns Hopkins Medicine and is the main teaching hospital of the United Arab Emirates University College of Medicine, contributing to the UAE national cancer registry and to research on breast cancer in young Arab women, colorectal screening and hereditary cancer. Tawam anchors the Abu Dhabi cancer care network alongside Cleveland Clinic Abu Dhabi.","asOf":"2026-09-09","links":[{"label":"SEHA Tawam Hospital","url":"https://www.seha.ae"},{"label":"UAE University College of Medicine","url":"https://cmhs.uaeu.ac.ae"}],"tags":[],"related":[],"cancers":["breast-hr-positive","colorectal","all-leukemia","thyroid"],"sections":["chemotherapy","radiation"],"technologies":["allogeneic-cell-therapy","imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":["johns-hopkins","cleveland-clinic-abu-dhabi"],"pathways":[],"terms":[],"trials":[],"people":["sultan-mohamed-alkaram"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Al Ain","country":"AE","lat":24.209,"lng":55.74,"institutionType":"hospital","website":"https://www.seha.ae","university":"United Arab Emirates University","programs":["National oncology referral centre","Bone marrow transplant","Paediatric oncology","UAE cancer registry"]},{"id":"tays-cancer-centre","kind":"institution","name":"Tays Cancer Centre, Tampere University Hospital","aka":["FICAN Mid","Tampere University Hospital"],"tldr":"The university hospital of central Finland and host of the FICAN Mid regional cancer centre, accredited by OECI as a Cancer Centre.","summary":"Tampere University Hospital (Tays) serves the Pirkanmaa region and is the teaching hospital of Tampere University. Its Cancer Centre hosts the Central Finland Cancer Centre (FICAN Mid) within the Finnish Cancer Centre network and was accredited by the Organisation of European Cancer Institutes as a Cancer Centre. Tampere's cancer research is known for prostate cancer genetics and genomics, gastrointestinal surgery, and radiotherapy, working with Tampere University's Faculty of Medicine and Health Technology and with the Finnish Cancer Registry on national screening evaluation.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.tays.fi"}],"tags":["oeci-accredited","oeci-cancer-centre"],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci","helsinki-hus"],"pathways":[],"terms":[],"trials":[],"people":["annika-auranen"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Tampere","country":"FI","lat":61.498,"lng":23.761,"institutionType":"hospital","website":"https://www.tays.fi","university":"Tampere University","programs":["FICAN Mid regional cancer centre","Prostate cancer genomics","Radiotherapy"]},{"id":"technion","kind":"institution","name":"Technion, Israel Institute of Technology","aka":["Technion","Technion Israel Institute of Technology","Rappaport Faculty of Medicine","Rappaport-Technion Integrated Cancer Center","R-TICC"],"tldr":"Israel's engineering and science university in Haifa, where Aaron Ciechanover and Avram Hershko worked out how cells tag proteins for destruction, the discovery behind proteasome inhibitors and today's targeted protein degraders.","summary":"The Technion is Israel's institute of technology in Haifa, describing itself on its own site as eighteen faculties with about 15,000 students, 60 research centres and roughly 100,000 graduates. Its Ruth and Bruce Rappaport Faculty of Medicine, whose teaching hospital is the Rambam Health Care Campus, is where Avram Hershko and Aaron Ciechanover, with Irwin Rose, worked out ubiquitin-mediated protein degradation; the three shared the 2004 Nobel Prize in Chemistry, a third each, \"for the discovery of ubiquitin-mediated protein degradation\". The debt modern drugs owe that work is at the level of the pathway rather than the molecule, and the distinction is worth keeping: bortezomib and carfilzomib inhibit the proteasome, the protease at the end of the line, not the conjugation machinery the laureates characterised, and PROTACs and molecular glues were invented independently two decades later by exploiting the E1 to E3 cascade this work defined. The Nobel press release itself names no drug. Both laureates still publish from the Rappaport Faculty: Hershko from the Department of Biochemistry on how the anaphase-promoting complex is regulated, Ciechanover from the Rappaport-Technion Integrated Cancer Center on the ubiquitin-proteasome system in cancer and on degrader chemistry. The Technion also supplies much of Israel's medical-device and imaging engineering, and its technology transfer company is T3 (Technion Technology Transfer).","asOf":"2026-09-25","wikipedia":"https://en.wikipedia.org/wiki/Technion_%E2%80%93_Israel_Institute_of_Technology","links":[{"label":"Technion homepage","url":"https://www.technion.ac.il/en/"},{"label":"Nobel Prize in Chemistry 2004 (Nobel Prize API record)","url":"https://api.nobelprize.org/2.1/nobelPrize/che/2004"},{"label":"Ciechanover et al., The landscape of the ubiquitin-proteasome system in cancer","url":"https://europepmc.org/search?query=AUTH%3A%22Ciechanover%20A%22%20AND%20AFF%3A%22Technion%22"}],"tags":[],"related":[],"cancers":["multiple-myeloma"],"sections":["drug-discovery","targeted-therapy"],"technologies":["protac-degrader","molecular-glue-platforms"],"targets":[],"drugs":["bortezomib"],"companies":[],"institutions":["rambam","weizmann"],"pathways":[],"terms":[],"trials":[],"people":["aaron-ciechanover","avram-hershko"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Haifa","country":"IL","lat":32.777,"lng":35.023,"institutionType":"university","website":"https://www.technion.ac.il/en/","programs":["Ubiquitin-proteasome system (Ciechanover, Hershko)","Rappaport-Technion Integrated Cancer Center","Rappaport Faculty of Medicine","Medical devices and imaging engineering"]},{"id":"teenage-cancer-trust","kind":"institution","name":"Teenage Cancer Trust","aka":[],"tldr":"The UK charity that built specialist hospital units and nursing for teenagers and young adults with cancer, so that they are treated alongside their peers rather than on children's or elderly wards.","summary":"Teenage Cancer Trust was founded in 1990 to change how young people with cancer are treated in the NHS. It funds and runs specialist units inside NHS hospitals, employs specialist nurses and youth support coordinators, and campaigns for age-appropriate care for 13 to 24 year olds, an age band whose cancers are rare and often diagnosed late. Its annual concerts at the Royal Albert Hall are its best-known fundraiser. Stephen Sutton's 2014 campaign, which raised more than £5 million for the charity, remains the largest individual fundraising story in its history.","asOf":"2026-09-10","links":[{"label":"Teenage Cancer Trust","url":"https://www.teenagecancertrust.org/"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["aya-oncology"],"trials":[],"people":["stephen-sutton"],"bottlenecks":["b-rare-cancers","b-care-fragmentation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"London","country":"GB","lat":51.52,"lng":-0.13,"institutionType":"consortium","website":"https://www.teenagecancertrust.org","programs":["Specialist teenage and young adult units in NHS hospitals","Specialist nursing and youth support","Royal Albert Hall concerts","Education and awareness in schools"]},{"id":"tel-aviv-sourasky","kind":"institution","name":"Tel Aviv Sourasky Medical Center","aka":["Ichilov Hospital","Sourasky","Tel Aviv Medical Center"],"tldr":"Tel Aviv Sourasky Medical Center (Ichilov) is Tel Aviv University's main teaching hospital; its oncology division runs a large trial programme in gastrointestinal, breast and genitourinary cancers, and Ofer Merimsky's unit is Israel's reference centre for sarcoma.","summary":"The Tel Aviv Sourasky Medical Center (Ichilov) is the primary teaching hospital of Tel Aviv University's medical faculty and one of Israel's largest hospitals. Its oncology division under Ido Wolf runs a large clinical trials programme in gastrointestinal, breast and genitourinary cancers, Ofer Merimsky's unit is Israel's reference for sarcoma, Ravit Geva leads gastrointestinal oncology, and the hospital has strong neurosurgical oncology, haematology and radiotherapy departments. Sourasky participates in international precision oncology and immunotherapy trials and hosts translational laboratories in cancer immunology and genomics.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Tel_Aviv_Sourasky_Medical_Center","links":[{"label":"Homepage","url":"https://www.tasmc.org.il/sites/en/"}],"tags":[],"related":[],"cancers":["colorectal","sarcoma","glioblastoma","breast-hr-positive"],"sections":["targeted-therapy"],"technologies":["checkpoint-inhibitor","cgp","imrt-igrt"],"targets":[],"drugs":[],"companies":[],"institutions":["sheba","tel-aviv-university"],"pathways":[],"terms":[],"trials":[],"people":["eli-sprecher"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Tel Aviv","country":"IL","lat":32.08,"lng":34.789,"institutionType":"hospital","website":"https://www.tasmc.org.il/sites/en/","university":"Tel Aviv University","programs":["Oncology clinical trials","Sarcoma","Gastrointestinal oncology","Neuro-oncology","Haematology"]},{"id":"tel-aviv-university","kind":"institution","name":"Tel Aviv University","aka":["TAU","Gray Faculty of Medical and Health Sciences","Sackler Faculty of Medicine","Ramot"],"tldr":"Israel's largest university and the academic parent of the Sheba, Sourasky and Rabin hospitals, so most Israeli oncology papers carry its name; its physics department is where the alpha-emitter radiotherapy behind Alpha Tau began.","summary":"Tel Aviv University's Gray Faculty of Medical and Health Sciences (formerly Sackler) is the academic affiliation of Sheba Medical Center, Tel Aviv Sourasky (Ichilov) and Rabin Medical Center, which is why a large share of Israeli clinical oncology publications carry a Tel Aviv University address alongside a hospital one. Its distinctive contribution of its own is Diffusing Alpha-emitters Radiation Therapy: Itzhak Kelson in physics and Yona Keisari in immunology devised seeds that release short-lived alpha-emitting daughter atoms which diffuse a few millimetres through a tumour, a route to alpha radiation that does not require a targeting molecule, and the work was licensed through the university's technology transfer company Ramot to Alpha Tau Medical. Zelig Eshhar, whose 1989 chimeric receptor is the ancestor of every CAR-T product, ran his later laboratory at Tel Aviv Sourasky within the same faculty.","asOf":"2026-09-25","wikipedia":"https://en.wikipedia.org/wiki/Tel_Aviv_University","links":[{"label":"Tel Aviv University","url":"https://english.tau.ac.il"},{"label":"Ramot at Tel Aviv University","url":"https://ramot.org"},{"label":"Alpha Tau Medical","url":"https://alphatau.com/"}],"tags":[],"related":[],"cancers":[],"sections":["radiation","cell-therapy"],"technologies":["targeted-alpha-therapy","car-t"],"targets":[],"drugs":[],"companies":["alpha-tau-medical"],"institutions":["sheba","tel-aviv-sourasky","rabin-davidoff-center"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Tel Aviv","country":"IL","lat":32.113,"lng":34.804,"institutionType":"university","website":"https://english.tau.ac.il","programs":["Gray Faculty of Medical and Health Sciences","Diffusing alpha-emitters radiation therapy (Kelson, Keisari)","Ramot technology transfer"]},{"id":"tennessee-oncology","kind":"institution","name":"Tennessee Oncology / Greco-Hainsworth Centers for Research","aka":["Tennessee Oncology PLLC","Greco-Hainsworth Centers for Research"],"tldr":"Large community oncology practice in Nashville, the founding clinical partner of Sarah Cannon Research Institute, whose myeloma research under Jesús Berdeja led early CAR-T trials.","summary":"Tennessee Oncology is one of the largest independent community oncology practices in the United States, with clinics across Middle Tennessee. It founded the Sarah Cannon Research Institute with HCA Healthcare in the 1990s, and its Greco-Hainsworth Centers for Research, named for the founders of that model, continue to run trials in the practice. Jesús Berdeja, its director of myeloma research, was a lead investigator of CARTITUDE-1, the trial that established ciltacabtagene autoleucel in relapsed multiple myeloma.","asOf":"2026-09-18","links":[{"label":"Tennessee Oncology","url":"https://tennonc.com"}],"tags":[],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["sarah-cannon-research-institute"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["jesus-berdeja"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Nashville, TN","country":"US","lat":36.153,"lng":-86.802,"institutionType":"hospital","website":"https://tennonc.com","programs":["Community oncology","Myeloma cell therapy trials","Early-phase trials"]},{"id":"terry-fox-foundation","kind":"institution","name":"Terry Fox Foundation","aka":["Terry Fox Research Institute","TFRI"],"tldr":"The foundation that grew out of Terry Fox's 1980 Marathon of Hope; with the Terry Fox Research Institute it funds cancer research across Canada from the annual Terry Fox Run.","summary":"The Terry Fox Foundation carries on the Marathon of Hope that Terry Fox began in 1980 after losing a leg to osteosarcoma. It runs the annual Terry Fox Run in Canada and abroad, and works with the Terry Fox Research Institute, founded in 2007, which funds team science and the Marathon of Hope Cancer Centres Network linking Canadian cancer centres around shared data and precision medicine. The Foundation and Institute describe their work as pursuit of Terry's dream to end cancer through research. The Run remains one of the largest single-day cancer fundraisers in the world.","asOf":"2026-09-10","links":[{"label":"Terry Fox Foundation","url":"https://terryfox.org/"},{"label":"Terry Fox Research Institute","url":"https://www.tfri.ca/"}],"tags":[],"related":["terry-fox-research-institute"],"cancers":["osteosarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["terry-fox"],"bottlenecks":["b-funding-allocation","b-data-silos"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Vancouver","country":"CA","lat":49.263,"lng":-123.117,"institutionType":"consortium","website":"https://terryfox.org","programs":["Terry Fox Run","Terry Fox Research Institute team grants","Marathon of Hope Cancer Centres Network"]},{"id":"terry-fox-research-institute","kind":"institution","name":"Terry Fox Research Institute","aka":["TFRI","Marathon of Hope Cancer Centres Network"],"tldr":"The Canadian cancer research institute funded by the Terry Fox Foundation, which runs the pan-Canadian Marathon of Hope Cancer Centres Network for precision oncology.","summary":"The Terry Fox Research Institute was created by the Terry Fox Foundation to invest the proceeds of the annual Terry Fox Run in translational cancer research across Canada. It funds multi-institutional programme project grants and, through the Marathon of Hope Cancer Centres Network, links Canada's major cancer centres and research institutes in a shared precision medicine effort that harmonises genomic profiling, data sharing and clinical trials so that findings from one province can benefit patients in another. TFRI is a virtual institute headquartered in Vancouver with nodes in every region and works with the Canadian Cancer Society, the Canadian Institutes of Health Research and provincial agencies.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.tfri.ca"}],"tags":[],"related":["terry-fox-foundation"],"cancers":[],"sections":[],"technologies":["cgp"],"targets":[],"drugs":[],"companies":[],"institutions":["bc-cancer","princess-margaret","oicr","canadian-cancer-society"],"pathways":[],"terms":[],"trials":[],"people":["jim-woodgett"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Vancouver","country":"CA","lat":49.263,"lng":-123.114,"institutionType":"consortium","website":"https://www.tfri.ca","programs":["Marathon of Hope Cancer Centres Network","Programme project grants","Pan-Canadian data sharing"]},{"id":"texas-childrens","kind":"institution","name":"Texas Children's Cancer and Hematology Center","aka":["Texas Children's Hospital"],"tldr":"One of the largest paediatric cancer centres in the US, Baylor's children's hospital, and founder of the Global HOPE programme for childhood cancer in Africa.","summary":"Texas Children's Cancer and Hematology Center in the Texas Medical Center is the paediatric arm of Baylor College of Medicine's Dan L Duncan Comprehensive Cancer Center and one of the largest paediatric oncology programmes in the country. Baylor's Center for Cell and Gene Therapy ran the first GD2 CAR-T and virus-specific T-cell trials in its patients, and its neuro-oncology group, joined in 2023 by medulloblastoma geneticist Michael Taylor, is among the largest in North America. Global HOPE, founded by David Poplack in 2017, trains paediatric oncologists and treats children in Botswana, Malawi, Uganda and other sub-Saharan countries. Director Susan Blaney chairs the Pediatric Brain Tumor Consortium, and the centre is a major Children's Oncology Group site.","asOf":"2026-09-09","links":[{"label":"Texas Children's Cancer and Hematology Center","url":"https://www.texaschildrens.org/departments/cancer-and-hematology-center"}],"tags":[],"related":[],"cancers":["neuroblastoma","medulloblastoma","all-leukemia","osteosarcoma"],"sections":["cell-therapy"],"technologies":["car-t","allogeneic-cell-therapy"],"targets":["gd2"],"drugs":[],"companies":["childrens-oncology-group"],"institutions":["baylor-duncan"],"pathways":[],"terms":[],"trials":[],"people":["tammy-kang","michael-taylor"],"bottlenecks":["b-global-access","b-rare-cancers"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Houston, TX","country":"US","lat":29.709,"lng":-95.401,"institutionType":"hospital","website":"https://www.texaschildrens.org/departments/cancer-and-hematology-center","university":"Baylor College of Medicine","programs":["Cell therapy for paediatric cancers","Neuro-oncology","Global HOPE (sub-Saharan Africa)","Paediatric brain tumour consortium"]},{"id":"thames-valley-cancer-alliance","kind":"institution","name":"Thames Valley Cancer Alliance","aka":["TVCA"],"tldr":"The NHS England Cancer Alliance for Oxfordshire, Buckinghamshire, Berkshire and parts of Swindon and Wiltshire: the partnership that plans and improves cancer services across its hospitals, GPs and community services.","summary":"One of the 20 Cancer Alliances set up by NHS England from 2016, following the Independent Cancer Taskforce strategy, to bring together the hospital trusts, integrated care boards, primary care, hospices and charities serving Oxfordshire, Buckinghamshire, Berkshire and parts of Swindon and Wiltshire. Alliances lead local delivery of the NHS cancer ambitions: earlier diagnosis (including rapid diagnostic centres and targeted lung health checks), the Faster Diagnosis Standard, personalised care and follow-up, and workforce and pathway improvement. They hold transformation funding from NHS England and publish local performance and improvement plans.","asOf":"2026-09-09","links":[{"label":"Thames Valley Cancer Alliance","url":"https://thamesvalleycanceralliance.nhs.uk/"},{"label":"NHS England: Cancer Alliances","url":"https://www.england.nhs.uk/cancer/cancer-alliances-improving-care-locally/"}],"tags":["nhs-cancer-alliance"],"related":[],"cancers":[],"sections":["early-detection"],"technologies":["low-dose-ct-screening"],"targets":[],"drugs":[],"companies":[],"institutions":["oxford-cancer"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Oxford","country":"GB","lat":51.752,"lng":-1.258,"institutionType":"consortium","website":"https://thamesvalleycanceralliance.nhs.uk/","programs":["Earlier diagnosis and rapid diagnostic centres","Faster Diagnosis Standard","Personalised care and follow-up","Cancer pathway improvement"]},{"id":"aga-khan-hospital-dar-es-salaam","kind":"institution","name":"The Aga Khan Hospital, Dar es Salaam","aka":["Aga Khan Hospital Dar es Salaam","AKHD"],"tldr":"The Aga Khan Hospital, Dar es Salaam is a private teaching hospital of the Aga Khan Health Services with a cancer centre that is one of Tanzania's few comprehensive cancer services, and an associate member of the Organisation of European Cancer Institutes.","summary":"The Aga Khan Hospital, Dar es Salaam is a private teaching hospital of the Aga Khan Health Services with a cancer centre that is one of Tanzania's few comprehensive cancer services. It is listed by the Organisation of European Cancer Institutes as an associate member, which is why it has a page on OnCo. Programme, trial and leadership details are not yet recorded here and should be checked on the institution's own pages.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.akdn.org/our-agencies/aga-khan-health-services"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["sulaiman-shahabuddin"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Dar es Salaam","country":"TZ","lat":-6.801,"lng":39.284,"institutionType":"hospital","website":"https://www.akdn.org/our-agencies/aga-khan-health-services","programs":[]},{"id":"the-christie","kind":"institution","name":"The Christie NHS Foundation Trust","aka":[],"tldr":"The Christie is Europe's largest single-site cancer centre and the UK's first NHS proton therapy centre.","summary":"The Christie NHS Foundation Trust in Manchester is Europe's largest single-site cancer centre and the first NHS proton beam therapy centre, opened in 2018; it ranks twenty-third in the Newsweek/Statista oncology list and is tied to the University of Manchester. It runs one of the largest early-phase trial units in Europe and, with Cancer Research UK, the Manchester Cancer Research Centre, with Corinne Faivre-Finn, Caroline Dive, Ananya Choudhury, Andrew Wardley and Juan W. Valle among its people. OnCo links it to bladder cancer, lymphoma and mesothelioma, and to ideas on core-funded radiotherapy trials, evening trial clinics for working-age patients and lung screening in supermarket car parks. Fragmented care and guideline gaps are the bottleneck it most often meets. Its proton and early-phase programmes are the place to start.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/The_Christie_NHS_Foundation_Trust","links":[{"label":"Official website","url":"https://www.christie.nhs.uk"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":["tnbc","nsclc","lung-cancer","sclc"],"sections":[],"technologies":["proton-therapy","proton-therapy-systems","mr-linac","tomotherapy"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["convert","violet"],"people":["ashya-king","corinne-faivre-finn","juan-valle","ananya-choudhury","andrew-wardley","caroline-dive","fiona-blackhall","rob-bristow","anne-armstrong","philip-crosbie"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Manchester","country":"GB","lat":53.43,"lng":-2.23,"institutionType":"cancer-center","website":"https://www.christie.nhs.uk","newsweekOncology2026":23,"university":"University of Manchester","programs":["Proton therapy","Early-phase trials","Radiotherapy research"]},{"id":"clatterbridge","kind":"institution","name":"The Clatterbridge Cancer Centre NHS Foundation Trust","aka":["Clatterbridge Cancer Centre Liverpool"],"tldr":"One of England's few specialist cancer hospital trusts, serving Merseyside and Cheshire, with the UK's first proton therapy service (for eye tumours) and a new Liverpool hospital opened in 2020.","summary":"The Clatterbridge Cancer Centre is a specialist NHS cancer trust with sites in Liverpool city centre, Wirral (Clatterbridge) and Aintree, providing non-surgical cancer treatment for Cheshire, Merseyside and surrounding areas. Its Wirral site has run the UK's first proton beam therapy service, for ocular tumours, since 1989, and its purpose-built Liverpool hospital opened in 2020 next to the Royal Liverpool University Hospital and the University of Liverpool. The trust delivers radiotherapy, chemotherapy, immunotherapy, haemato-oncology and CAR-T, hosts the Liverpool Experimental Cancer Medicine Centre with the university, and is a member of the Liverpool Health Partners academic health science system.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/Clatterbridge_Cancer_Centre_NHS_Foundation_Trust","links":[{"label":"Official website","url":"https://www.clatterbridgecc.nhs.uk"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":["nhs-specialist-cancer-centre"],"related":[],"cancers":["uveal-melanoma"],"sections":[],"technologies":["proton-therapy","car-t","proton-therapy-systems"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["joan-spencer"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Liverpool","country":"GB","lat":53.409,"lng":-2.967,"institutionType":"cancer-center","website":"https://www.clatterbridgecc.nhs.uk","programs":["Ocular proton therapy","Radiotherapy network","Haemato-oncology and CAR-T","Experimental Cancer Medicine Centre"]},{"id":"francis-crick","kind":"institution","name":"The Francis Crick Institute","aka":[],"tldr":"The Francis Crick Institute is Europe's largest biomedical research institute, home of the TRACERx tumour evolution studies (Swanton).","summary":"The Francis Crick Institute in London is Europe's largest biomedical research institute and the home of the TRACERx studies of lung cancer evolution led by Charles Swanton, which is why it appears wherever OnCo discusses tumour heterogeneity. Its cancer work spans clonal evolution, circulating tumour DNA biology, chromosomal instability and immune surveillance, with Erik Sahai, Caetano Reis e Sousa and Paul Nurse also listed, in partnership with Cancer Research UK, UCL, Imperial and King's. OnCo links it to the TRACERx first 100 and TRACERx 421 papers, to Gerlinger's single-biopsy paper, and to ideas such as banking three spatially separate tumour blocks from every resection. Whether evolutionary insight can be turned into treatments, not just prognosis, is the open question. Its TRACERx and ctDNA programmes are the ones to read.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.crick.ac.uk"}],"tags":[],"related":[],"cancers":["nsclc","lung-cancer"],"sections":[],"technologies":["liquid-biopsy","wes-wgs"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["tracerx"],"people":["caetano-reis-e-sousa","charles-swanton","erik-sahai","paul-nurse"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"London","country":"GB","lat":51.532,"lng":-0.129,"institutionType":"research-institute","website":"https://www.crick.ac.uk","programs":["TRACERx tumour evolution","ctDNA biology"]},{"id":"sickkids","kind":"institution","name":"The Hospital for Sick Children (SickKids)","aka":["SickKids","Garron Family Cancer Centre"],"tldr":"Canada's largest children's hospital, where brain tumour stem cells were first isolated and where the Li-Fraumeni surveillance protocol was developed.","summary":"SickKids is Canada's largest paediatric hospital and a University of Toronto teaching site whose Garron Family Cancer Centre and Research Institute have an outsized record in paediatric oncology. Peter Dirks first isolated cancer stem cells from human brain tumours in 2003-04; Michael Taylor (now at Texas Children's) defined the four molecular subgroups of medulloblastoma; Cynthia Hawkins's group characterised H3K27M diffuse midline glioma. David Malkin and Uri Tabori developed the 'Toronto protocol' of whole-body MRI surveillance for Li-Fraumeni syndrome, now adopted internationally, and Tabori's international consortium showed hypermutant, replication-repair-deficient childhood cancers respond to checkpoint inhibitors. SickKids is a major Children's Oncology Group site with programmes in leukaemia, neuroblastoma and sarcoma.","asOf":"2026-09-09","links":[{"label":"SickKids","url":"https://www.sickkids.ca"},{"label":"Garron Family Cancer Centre","url":"https://www.sickkids.ca/en/care-services/centres/garron-family-cancer-centre/"}],"tags":[],"related":[],"cancers":["glioblastoma","medulloblastoma","neuroblastoma","all-leukemia"],"sections":[],"technologies":["germline-testing","whole-body-mri","checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":["childrens-oncology-group"],"institutions":["texas-childrens","princess-margaret"],"pathways":[],"terms":["li-fraumeni"],"trials":[],"people":["ronald-cohn","stephen-scherer","meredith-irwin","sumit-gupta"],"bottlenecks":["b-hereditary-risk","b-rare-cancers"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Toronto, ON","country":"CA","lat":43.657,"lng":-79.387,"institutionType":"hospital","website":"https://www.sickkids.ca","university":"University of Toronto","programs":["Brain tumour research","Cancer predisposition and surveillance","Paediatric leukaemia and solid tumours"]},{"id":"icr-london","kind":"institution","name":"The Institute of Cancer Research","aka":[],"tldr":"Discovered more cancer drugs than any other academic institution, including abiraterone and the clinical use of PARP inhibitors.","summary":"The Institute of Cancer Research in London has discovered more cancer drugs than any other academic institution, including abiraterone through Johann de Bono and the clinical use of PARP inhibitors through Andrew Tutt and Alan Ashworth's synthetic lethality work, and it is the research partner of The Royal Marsden. Its Cancer Therapeutics Unit is also the origin of capivasertib, and its people include Christopher Lord, Kristian Helin, Mel Greaves, Mitch Dowsett and Judith M. Bliss. OnCo links it to olaparib, capivasertib, abiraterone and STAMPEDE, to the DNA replication stress pathway, and to ideas including a non-profit phase 1b combination unit. The valley of death between lab and product is the bottleneck it exists to cross. Its drug discovery, prostate and synthetic lethality programmes are listed below.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/Institute_of_Cancer_Research","links":[{"label":"Official website","url":"https://www.icr.ac.uk"}],"tags":[],"related":["royal-marsden"],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":["olaparib","capivasertib"],"companies":[],"institutions":[],"pathways":[],"terms":["synthetic-lethality"],"trials":["import-low","start-b","chhip","pace-b","stampede"],"people":["kristian-helin","mel-greaves","mitch-dowsett","judith-bliss","chris-lord","kevin-harrington","paul-workman"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"London","country":"GB","lat":51.343,"lng":-0.191,"institutionType":"research-institute","website":"https://www.icr.ac.uk","programs":["Drug discovery","Prostate cancer","Synthetic lethality"]},{"id":"jackson-laboratory","kind":"institution","name":"The Jackson Laboratory Cancer Center","aka":["JAX"],"tldr":"The Jackson Laboratory in Maine breeds the world's genetically defined laboratory mice, including the immunodeficient NSG strain behind patient-derived xenograft research, and has held NCI basic cancer centre status since 1983; its PDX repository is open to academic and industry researchers.","summary":"Founded in 1929 by Clarence Cook Little, The Jackson Laboratory is the world's principal source of genetically defined laboratory mice, including the immunodeficient NSG strain that underpins patient-derived xenograft research, and has held NCI basic laboratory designation since 1983. Its cancer centre studies cancer genetics and genomics, the tumour microenvironment and drug response using mouse and PDX resources, with a large PDX repository available to academic and industry researchers. JAX Genomic Medicine in Farmington, Connecticut, extends the institute into human genomics and computational biology, and the Mouse Genome Informatics database is a core community resource.","asOf":"2026-09-09","links":[{"label":"The Jackson Laboratory","url":"https://www.jax.org"}],"tags":[],"related":[],"cancers":[],"sections":["drug-discovery"],"technologies":["pdx-models","wes-wgs","crispr-screens"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["karolina-palucka"],"bottlenecks":["b-preclinical-models","b-reproducibility"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Bar Harbor, ME","country":"US","lat":44.388,"lng":-68.204,"institutionType":"research-institute","website":"https://www.jax.org","nci":"basic","programs":["Mouse models and PDX resource","Cancer genetics and genomics","Mouse Genome Informatics"]},{"id":"jimmy-fund","kind":"institution","name":"The Jimmy Fund","aka":["Jimmy Fund"],"tldr":"Dana-Farber's fundraising arm since 1948, born from a radio broadcast at a boy's bedside; the Boston Red Sox have been its partner since 1953 and the Pan-Mass Challenge its largest source of money.","summary":"The Jimmy Fund began in 1948 when a national radio broadcast from the bedside of a 12-year-old patient of Sidney Farber, known only as Jimmy, brought in donations for the Children's Cancer Research Foundation. It has been part of Dana-Farber Cancer Institute since then and funds its research and patient care. The Boston Red Sox have partnered with the Jimmy Fund since 1953, with Ted Williams as its best-known champion. The Pan-Mass Challenge bike ride has raised over $1 billion for Dana-Farber through the Jimmy Fund and now accounts for most of its annual revenue.","asOf":"2026-09-10","links":[{"label":"About the Jimmy Fund","url":"https://www.jimmyfund.org/about-us/"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["dana-farber"],"pathways":[],"terms":[],"trials":[],"people":["einar-gustafson","sidney-farber","ted-williams"],"bottlenecks":["b-funding-allocation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Boston","country":"US","lat":42.337,"lng":-71.107,"institutionType":"consortium","website":"https://www.jimmyfund.org","programs":["Pan-Mass Challenge","Boston Red Sox partnership","Jimmy Fund Walk and Radio-Telethon","Jimmy Fund Clinic support"]},{"id":"mark-foundation","kind":"institution","name":"The Mark Foundation for Cancer Research","aka":["Mark Foundation"],"tldr":"A philanthropic funder that backs high-risk cancer biology, tumour-immunology and computational projects and invests in start-ups translating them.","summary":"Founded in 2017 by Alex Knaster, the Mark Foundation funds cancer research through Emerging Leader Awards for early-career investigators, Endeavor Awards for multi-institution team science, ASPIRE awards for high-risk ideas, and the Mark Foundation Institutes and centres at institutions including the Francis Crick Institute, Cambridge and Yale. It has an active venture arm that invests in companies emerging from funded science. Priority areas include the mechanisms of drug resistance, metastasis, tumour-immune interactions, early detection and computational oncology, and it partners with AACR, Cancer Research UK and the Damon Runyon Foundation on joint programmes.","asOf":"2026-09-09","links":[{"label":"Mark Foundation","url":"https://themarkfoundation.org"}],"tags":[],"related":[],"cancers":[],"sections":["drug-discovery","ai-computation","immunotherapy"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["francis-crick","aacr","cruk","damon-runyon"],"pathways":[],"terms":[],"trials":[],"people":["ryan-schoenfeld"],"bottlenecks":["b-resistance","b-metastasis-biology","b-translational-valley"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"New York","country":"US","lat":40.758,"lng":-73.979,"institutionType":"consortium","website":"https://themarkfoundation.org","programs":["Emerging Leader Awards","Endeavor team-science awards","ASPIRE high-risk awards","Venture investments"]},{"id":"mount-sinai","kind":"institution","name":"The Mount Sinai Hospital / Tisch Cancer Institute","aka":["Mount Sinai Tisch Cancer Center","Tisch Cancer Institute"],"tldr":"Mount Sinai is a New York academic centre with strengths in myeloma and cancer immunology.","summary":"The Mount Sinai Hospital and its Tisch Cancer Institute form a New York academic centre with NCI clinical designation, ranked thirty-fourth in the Newsweek/Statista oncology list, and its strengths are multiple myeloma and cancer immunology. Its myeloma programme is associated with Sundar Jagannath, its immunology with Miriam Merad and Nina Bhardwaj, and it has a record in neoadjuvant immunotherapy, with Joshua Brody, Thomas U. Marron, Matthew D. Galsky, Josep M. Llovet and Ramon E. Parsons among the people OnCo lists. OnCo links it to the tumour dormancy pathway, to the NIAGARA bladder cancer paper, and to ideas on keeping disseminated cells asleep and on turning one tumour into a vaccine for the others. What decides which disseminated cells ever colonise is the open question its dormancy work asks. Its myeloma and tumour immunology programmes are the ones to read.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.mountsinai.org/care/cancer"}],"tags":[],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["ramon-parsons","miriam-merad","sundar-jagannath","joshua-brody","nina-bhardwaj","thomas-marron","joseph-sparano","josep-llovet","thomas-fuchs","matthew-galsky"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"New York","country":"US","lat":40.79,"lng":-73.953,"institutionType":"hospital","website":"https://www.mountsinai.org/care/cancer","nci":"clinical","newsweekOncology2026":34,"programs":["Myeloma","Tumour immunology"]},{"id":"aiims-network","kind":"institution","name":"The new AIIMS network (PMSSY)","aka":["AIIMS","Pradhan Mantri Swasthya Suraksha Yojana","PMSSY"],"tldr":"India has multiplied its flagship AIIMS medical institutes from one to more than twenty, each with an oncology department, to bring specialist cancer care and training to states that had none.","summary":"The All India Institute of Medical Sciences in New Delhi (1956) was for half a century India's only institute of its kind. Under the Pradhan Mantri Swasthya Suraksha Yojana, announced in 2003 and launched in March 2006, six new AIIMS were built in under-served states (Bhopal, Bhubaneswar, Jodhpur, Patna, Raipur and Rishikesh) and further waves followed; by January 2023 twenty AIIMS were operating, with more under construction or planned.\n\nEach new AIIMS carries medical, surgical and radiation oncology, and several have dedicated cancer blocks; together with the Tata Memorial expansion and the state cancer institutes funded under the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke, they form the public backbone that PM-JAY patients are referred into. The network also multiplies India's oncology training capacity, which has been a binding constraint on care.","asOf":"2026-09-10","links":[{"label":"PMSSY, Ministry of Health and Family Welfare","url":"https://pmssy.mohfw.gov.in"},{"label":"AIIMS New Delhi","url":"https://www.aiims.edu"}],"tags":[],"related":["nha-pmjay"],"cancers":[],"sections":["radiation","surgery"],"technologies":["global-oncology-access"],"targets":[],"drugs":[],"companies":[],"institutions":["aiims-delhi","national-cancer-grid"],"pathways":[],"terms":[],"trials":[],"people":["ankita-mishra-bundela"],"bottlenecks":["b-workforce","b-global-access","b-care-fragmentation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"New Delhi","country":"IN","lat":28.614,"lng":77.209,"institutionType":"consortium","website":"https://pmssy.mohfw.gov.in","programs":["New AIIMS in under-served states","Oncology departments and cancer blocks","Specialist training capacity"]},{"id":"osu-james","kind":"institution","name":"The Ohio State University Comprehensive Cancer Center, James Cancer Hospital and Solove Research Institute","aka":["OSUCCC-James","The James"],"tldr":"Where John Byrd's team turned ibrutinib into the drug that transformed chronic lymphocytic leukaemia; Ohio State's NCI comprehensive centre.","summary":"NCI-designated since 1976, the OSUCCC-James is one of the few free-standing cancer hospitals in the US and Ohio's largest cancer research enterprise. John Byrd and colleagues ran the defining early and phase 3 trials of ibrutinib (RESONATE) and acalabrutinib in CLL, and Clara Bloomfield's cytogenetic and molecular classification of acute myeloid leukaemia underpins today's ELN risk groups. Carlo Croce discovered the role of microRNAs in cancer and mapped BCL2 to the t(14;18) translocation in follicular lymphoma. Former director Michael Caligiuri built its NK cell and immunology programme, and Raphael Pollock leads a national sarcoma programme. Pelotonia, an annual cycling event, funds much of the centre's research.","asOf":"2026-09-09","links":[{"label":"OSUCCC-James","url":"https://cancer.osu.edu"},{"label":"Clinical trials","url":"https://cancer.osu.edu/for-patients-and-caregivers/clinical-trials"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":["cll","aml","follicular-lymphoma","sarcoma"],"sections":[],"technologies":["kinase-inhibitors","proton-therapy","proton-therapy-systems"],"targets":["btk","bcl2"],"drugs":["ibrutinib","acalabrutinib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["resonate"],"people":["michael-caligiuri","jennifer-woyach"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Columbus, OH","country":"US","lat":39.994,"lng":-83.016,"institutionType":"cancer-center","website":"https://cancer.osu.edu","nci":"comprehensive","university":"The Ohio State University","programs":["CLL and BTK inhibitors","AML classification","MicroRNA biology","Sarcoma"]},{"id":"ottawa-hospital","kind":"institution","name":"The Ottawa Hospital Cancer Centre / Ottawa Hospital Research Institute","aka":["OHRI","TOH Cancer Centre"],"tldr":"Ottawa's academic cancer centre, a world leader in oncolytic viruses (John Bell), the first made-in-Canada CAR-T trial and pragmatic REaCT trials.","summary":"The Ottawa Hospital Cancer Centre and the Ottawa Hospital Research Institute (OHRI) form eastern Ontario's academic cancer programme with the University of Ottawa. John Bell's laboratory is one of the world's leading oncolytic virus groups, developing the Maraba MG1 and vaccinia platforms and co-founding Turnstone Biologics; Rebecca Auer studies perioperative immunotherapy to prevent metastasis after surgery. Natasha Kekre led CLIC-01, the first clinical trial of a CAR-T product manufactured in Canada, and the Rethinking Clinical Trials (REaCT) programme, led by Mark Clemons and Dean Fergusson, embeds pragmatic randomised trials into routine cancer care. The centre also hosts a large radiation oncology and haematology service.","asOf":"2026-09-09","links":[{"label":"The Ottawa Hospital cancer program","url":"https://www.ottawahospital.on.ca/en/clinical-services/deptpgrmcs/programs/cancer-program/"},{"label":"Ottawa Hospital Research Institute","url":"https://www.ohri.ca"}],"tags":[],"related":[],"cancers":["breast-hr-positive","colorectal","dlbcl"],"sections":[],"technologies":["oncolytic-virus","car-t"],"targets":[],"drugs":[],"companies":["cctg"],"institutions":[],"pathways":[],"terms":["real-world-evidence"],"trials":[],"people":["rebecca-auer"],"bottlenecks":["b-manufacturing-cell-therapy","b-trial-design","b-trial-enrolment"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Ottawa, ON","country":"CA","lat":45.401,"lng":-75.648,"institutionType":"hospital","website":"https://www.ottawahospital.on.ca","university":"University of Ottawa","programs":["Oncolytic viruses","Made-in-Canada CAR-T (CLIC-01)","Pragmatic trials (REaCT)","Perioperative immunotherapy"]},{"id":"royal-marsden","kind":"institution","name":"The Royal Marsden","aka":[],"tldr":"The Royal Marsden was the world's first hospital dedicated to cancer (1851) and is paired with the Institute of Cancer Research.","summary":"The Royal Marsden in London was the world's first hospital dedicated to cancer, opened in 1851, and works as a pair with The Institute of Cancer Research; it ranks seventh in the Newsweek/Statista oncology list. Together they discovered abiraterone and worked out the clinical path for olaparib and PARP inhibition in BRCA-mutated cancers, with Johann de Bono and Andrew Tutt central, and the hospital leads the STAMPEDE prostate platform and breast trials while pioneering MR-linac adaptive radiotherapy. OnCo links it to the KEYNOTE-048 head and neck paper, to prostate, mesothelioma, sarcoma and neuroendocrine tumour pages, and to bottlenecks about surgery and radiotherapy being under-funded relative to drugs. The question it keeps raising is how to fund trials of treatments no company owns. Stephen Johnston and James Larkin are among the people listed here.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/The_Royal_Marsden_NHS_Foundation_Trust","links":[{"label":"Official website","url":"https://www.royalmarsden.nhs.uk"}],"tags":[],"related":["icr-london"],"cancers":["colorectal","nsclc","lung-cancer","prostate","prostate-mcrpc"],"sections":[],"technologies":["mr-linac","parp-inhibitor"],"targets":[],"drugs":["olaparib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["mercury","pace-b"],"people":["stephen-johnston","andrew-tutt","david-cunningham","james-larkin","johann-de-bono","nicholas-james","nicholas-turner","uwe-oelfke","karl-munslow-ong","naureen-starling","ian-chau","sanjay-popat","nicholas-van-as","ros-eeles"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"London","country":"GB","lat":51.49,"lng":-0.172,"institutionType":"cancer-center","website":"https://www.royalmarsden.nhs.uk","newsweekOncology2026":7,"programs":["Prostate cancer (abiraterone, PARP)","MR-linac","Breast cancer"]},{"id":"ku-cancer-center","kind":"institution","name":"The University of Kansas Cancer Center","aka":["KU Cancer Center"],"tldr":"The NCI comprehensive centre for Kansas and western Missouri, active in drug repurposing, triple-negative breast cancer trials and rural access.","summary":"NCI-designated in 2012 and comprehensive since 2022, KU Cancer Center covers Kansas and western Missouri and reaches rural communities through the Masonic Cancer Alliance. Priyanka Sharma leads SWOG triple-negative breast cancer trials from here, and the Institute for Advancing Medical Innovation runs drug discovery and repurposing programmes. Research strengths include liquid biopsy, cancer biology and clinical trials in haematologic malignancies and breast cancer. The centre partners with Children's Mercy Kansas City for paediatric oncology.","asOf":"2026-09-09","links":[{"label":"KU Cancer Center","url":"https://www.kucancercenter.org"},{"label":"Clinical trials","url":"https://www.kucancercenter.org/clinical-trials"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":["tnbc","multiple-myeloma"],"sections":[],"technologies":["drug-repurposing","liquid-biopsy","proton-therapy","proton-therapy-systems"],"targets":[],"drugs":[],"companies":["swog"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["priyanka-sharma"],"bottlenecks":["b-trial-enrolment","b-generic-repurposing"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Kansas City, KS","country":"US","lat":39.056,"lng":-94.609,"institutionType":"cancer-center","website":"https://www.kucancercenter.org","nci":"comprehensive","university":"University of Kansas","programs":["Triple-negative breast cancer (SWOG)","Drug repurposing","Rural outreach (Masonic Cancer Alliance)"]},{"id":"uq-frazer-institute","kind":"institution","name":"The University of Queensland Frazer Institute","aka":["Frazer Institute","UQ Diamantina Institute","Translational Research Institute Brisbane"],"tldr":"Brisbane research institute, renamed in 2022 for Ian Frazer, who with Jian Zhou invented the virus-like particle technology behind the HPV vaccines while at the University of Queensland.","summary":"The Frazer Institute, formerly the UQ Diamantina Institute, is a University of Queensland research institute at the Translational Research Institute on the Princess Alexandra Hospital campus in Brisbane. It was renamed in 2022 for Ian Frazer, who with Jian Zhou created the papillomavirus virus-like particles at the University of Queensland in 1991 that became the HPV vaccines, and who was its founding director. Its research covers cancer immunology, immunotherapy and skin cancer.","asOf":"2026-09-18","links":[{"label":"The University of Queensland","url":"https://www.uq.edu.au"}],"tags":[],"related":[],"cancers":["cervical"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["qimr-berghofer"],"pathways":[],"terms":[],"trials":[],"people":["ian-frazer"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Brisbane","country":"AU","lat":-27.499,"lng":153.031,"institutionType":"research-institute","website":"https://www.uq.edu.au","university":"The University of Queensland","programs":["Cancer immunology","HPV vaccine research","Skin cancer"]},{"id":"us-oncology-network","kind":"institution","name":"The US Oncology Network / US Oncology Research","aka":["US Oncology","Texas Oncology","McKesson US Oncology"],"tldr":"McKesson-owned network of community oncology practices, including Texas Oncology, whose research arm has enrolled tens of thousands of patients in trials and is led scientifically by gynaecological oncologist Robert Coleman.","summary":"The US Oncology Network is a McKesson-owned network of independent community oncology practices across the United States, of which Texas Oncology is the largest. US Oncology Research, its research arm, runs one of the country's biggest community-based trial programmes and co-owns Sarah Cannon Research Institute. Robert Coleman, formerly of MD Anderson and a leader of the Gynecologic Oncology Group, is its chief scientific officer and practises with Texas Oncology.","asOf":"2026-09-18","links":[{"label":"The US Oncology Network","url":"https://www.usoncology.com"}],"tags":[],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["sarah-cannon-research-institute"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["robert-coleman"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"The Woodlands, TX","country":"US","lat":30.166,"lng":-95.461,"institutionType":"consortium","website":"https://www.usoncology.com","programs":["Community oncology trials","Gynaecological oncology research"]},{"id":"v-foundation","kind":"institution","name":"The V Foundation for Cancer Research","aka":["V Foundation","Jimmy V Foundation"],"tldr":"The US charity founded by ESPN and coach Jim Valvano that funds translational and early-career cancer research, with every donated dollar going to grants.","summary":"Founded in 1993 by ESPN and basketball coach Jim Valvano shortly before his death, the V Foundation funds cancer research through Translational Grants, V Scholar awards for early-career investigators, Designated Grants and the Stuart Scott Memorial Cancer Research Fund for minority researchers and health disparities. Grants are peer-reviewed by a scientific advisory committee of leading oncologists and awarded at NCI-designated cancer centres and comparable institutions. Fundraising through ESPN's V Week, the Dick Vitale Gala and the Jimmy V Classic makes it one of the most visible cancer research charities in the United States.","asOf":"2026-09-09","links":[{"label":"V Foundation","url":"https://www.v.org"}],"tags":[],"related":[],"cancers":[],"sections":["drug-discovery"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["nci","dana-farber","md-anderson"],"pathways":[],"terms":[],"trials":[],"people":["brandi-williams-broome"],"bottlenecks":["b-translational-valley","b-trial-diversity"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Cary, NC","country":"US","lat":35.791,"lng":-78.781,"institutionType":"consortium","website":"https://www.v.org","programs":["Translational Grants","V Scholar early-career awards","Stuart Scott Memorial Cancer Research Fund","Paediatric cancer research (Dick Vitale Fund)"]},{"id":"wistar","kind":"institution","name":"The Wistar Institute","aka":["Wistar Institute Cancer Center"],"tldr":"America's first independent biomedical research institute (1892), an NCI basic cancer centre known for melanoma biology, monoclonal antibodies and DNA vaccines.","summary":"The Wistar Institute, founded in 1892 on the University of Pennsylvania campus, has held NCI basic laboratory designation since 1972. Hilary Koprowski and Zenon Steplewski's 17-1A antibody (edrecolomab) was among the first monoclonal antibodies tested in cancer patients; Meenhard Herlyn built one of the world's leading melanoma biology programmes and 3D skin and tumour models; David Weiner pioneered DNA vaccines, including candidates for glioblastoma; Rugang Zhang identified the ARID1A-EZH2 synthetic lethality in ovarian clear-cell carcinoma. President Dario Altieri studies survivin and mitochondrial signalling. Wistar has no clinic and translates through Penn, Jefferson, Fox Chase and industry partners.","asOf":"2026-09-09","links":[{"label":"The Wistar Institute","url":"https://wistar.org"},{"label":"Cancer Center","url":"https://wistar.org/our-scientists/research-centers/cancer-center"}],"tags":[],"related":[],"cancers":["melanoma","ovarian","glioblastoma"],"sections":[],"technologies":["monoclonal-antibody","shared-antigen-vaccine"],"targets":["ezh2"],"drugs":[],"companies":[],"institutions":["penn-abramson"],"pathways":[],"terms":["synthetic-lethality"],"trials":[],"people":["dario-altieri"],"bottlenecks":["b-preclinical-models"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Philadelphia, PA","country":"US","lat":39.951,"lng":-75.196,"institutionType":"research-institute","website":"https://wistar.org","nci":"basic","programs":["Melanoma biology","Immunotherapy and vaccines","Ovarian cancer epigenetics","Antibody engineering"]},{"id":"tga","kind":"institution","name":"Therapeutic Goods Administration","aka":["TGA"],"tldr":"Australia's medicines and devices regulator, a Project Orbis and Access Consortium partner that registers cancer drugs before PBAC decides whether to subsidise them.","summary":"Part of the Australian Government Department of Health, the TGA regulates medicines, devices, blood and tissues and maintains the Australian Register of Therapeutic Goods. It participates in the FDA's Project Orbis and in the Access Consortium with Canada, Singapore, Switzerland and the UK, sharing assessments so cancer drugs can be approved in Australia at close to the same time as in the US. Priority and provisional approval pathways allow earlier registration of promising drugs on preliminary data, and the TGA also regulates radiopharmaceuticals, which matters for Australia's leadership in PSMA theranostics. Subsidy is a separate decision by the Pharmaceutical Benefits Advisory Committee.","asOf":"2026-09-09","links":[{"label":"TGA","url":"https://www.tga.gov.au"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["radioligand-therapy"],"targets":[],"drugs":[],"companies":["anzup"],"institutions":["pbac","fda-oce","mhra","health-canada","swissmedic"],"pathways":[],"terms":[],"trials":[],"people":["anthony-lawler"],"bottlenecks":["b-regulatory-fragmentation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Canberra","country":"AU","lat":-35.281,"lng":149.129,"institutionType":"government","website":"https://www.tga.gov.au","programs":["Project Orbis and Access Consortium","Priority and provisional approval pathways","Radiopharmaceutical regulation","Device and software-as-a-medical-device regulation"]},{"id":"tmucih","kind":"institution","name":"Tianjin Medical University Cancer Institute and Hospital","aka":["TMUCIH","Tianjin Cancer Hospital","天津医科大学肿瘤医院"],"tldr":"The birthplace of Chinese oncology (an 1861 mission hospital, made a cancer hospital in 1952 under Jin Xianzhai) and a national centre for breast and pancreatic cancer.","summary":"TMUCIH traces its origins to 1861 and became China's first specialised cancer hospital in 1952 under Jin Xianzhai, the founder of Chinese oncology. It is a national clinical research centre for cancer, hosts the Key Laboratory of Cancer Prevention and Therapy, and runs one of China's largest breast cancer programmes alongside strong pancreatic, lung, head and neck and gynaecological services. Its epidemiology group produces long-running cancer incidence data for Tianjin, and the hospital has been an early adopter of intraoperative radiotherapy, tomotherapy and robotic surgery. It is a frequent lead site for Chinese breast and pancreatic trials.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Tianjin_Medical_University_Cancer_Institute_and_Hospital","links":[{"label":"TMUCIH","url":"https://www.tjmuch.com"},{"label":"Tianjin Medical University","url":"https://www.tmu.edu.cn"}],"tags":[],"related":[],"cancers":["breast-hr-positive","breast-her2-positive","tnbc","pancreatic","head-and-neck"],"sections":["radiation","surgery"],"technologies":["imrt-igrt","robotic-surgery","mammography"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["csco-guidelines","intraoperative-radiotherapy"],"trials":[],"people":["jihui-hao"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Tianjin","country":"CN","lat":39.104,"lng":117.163,"institutionType":"cancer-center","website":"https://www.tjmuch.com","university":"Tianjin Medical University","programs":["Breast cancer","Pancreatic cancer","Cancer epidemiology","Radiotherapy technology"]},{"id":"tikur-anbessa-hospital","kind":"institution","name":"Tikur Anbessa Specialized Hospital, Addis Ababa University","aka":["Black Lion Hospital"],"tldr":"Ethiopia's largest referral and teaching hospital, for decades the country's only radiotherapy centre and the base of its oncology training.","summary":"Tikur Anbessa (Black Lion) Specialized Hospital is the main teaching hospital of Addis Ababa University's College of Health Sciences and Ethiopia's largest referral hospital. Its oncology centre was for many years the only radiotherapy service in a country of more than 100 million people, and it remains the hub for medical oncology, paediatric oncology, gynaecological oncology and the national oncology residency programme as the government expands regional cancer centres. Research partnerships, including with the Martin Luther University Halle-Wittenberg and the Addis Ababa city cancer registry, have documented breast and cervical cancer presentation and outcomes in Ethiopia.","asOf":"2026-09-10","links":[{"label":"Addis Ababa University","url":"http://www.aau.edu.et"}],"tags":[],"related":[],"cancers":["cervical"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["radiotherapy"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Addis Ababa","country":"ET","lat":9.012,"lng":38.762,"institutionType":"hospital","website":"http://www.aau.edu.et","university":"Addis Ababa University","programs":["Radiotherapy","Oncology residency training","Addis Ababa cancer registry research"]},{"id":"tohoku-university-hospital","kind":"institution","name":"Tohoku University Hospital","aka":["東北大学病院"],"tldr":"Sendai's university hospital and the clinical arm of the Tohoku Medical Megabank, with strengths in breast cancer, gastroenterology and imaging.","summary":"Tohoku University Hospital is the leading academic hospital of north-eastern Japan and a designated core hospital for cancer genome medicine. Tohoku University's Institute of Development, Aging and Cancer and the Tohoku Medical Megabank Organization, created after the 2011 earthquake, provide large genomic and cohort resources, and the hospital is known for breast cancer research (including steroid receptor pathology under Hironobu Sasano), gastrointestinal endoscopy and surgery, thoracic surgery and radiological sciences. Its investigators are active in JCOG, the Japan Breast Cancer Research Group and hepatology trials, and the Tohoku region operates one of Japan's newer proton facilities nearby.","asOf":"2026-09-09","links":[{"label":"Tohoku University Hospital","url":"https://www.hosp.tohoku.ac.jp"},{"label":"Tohoku Medical Megabank Organization","url":"https://www.megabank.tohoku.ac.jp"}],"tags":[],"related":[],"cancers":["breast-hr-positive","gastric","colorectal","nsclc"],"sections":["diagnostics","prevention"],"technologies":["germline-testing","wes-wgs","histopathology-ihc"],"targets":["estrogen-receptor"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["takashi-kamei"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Sendai","country":"JP","lat":38.273,"lng":140.862,"institutionType":"hospital","website":"https://www.hosp.tohoku.ac.jp","university":"Tohoku University","programs":["Breast cancer pathology and trials","Tohoku Medical Megabank cohorts","Gastroenterology","Radiological sciences"]},{"id":"tongji-hospital-wuhan","kind":"institution","name":"Tongji Hospital, Huazhong University of Science and Technology","aka":["Tongji Hospital Wuhan","同济医院"],"tldr":"Tongji Hospital in Wuhan is Central China's largest hospital; its cancer centre enrols into domestic PD-1, antibody-drug conjugate and targeted therapy registration trials, and Ding Ma's group leads national research on cervical and ovarian cancer and HPV.","summary":"Tongji Hospital, founded in Shanghai in 1900 and relocated to Wuhan in 1955, is the flagship of Tongji Medical College of Huazhong University of Science and Technology. Its Cancer Center is one of the largest in China with wide participation in domestic PD-1, ADC and targeted therapy registration trials, and the hospital is a national leader in gynaecological oncology (Ding Ma's group on cervical and ovarian cancer and HPV), haematology, urology and hepatobiliary surgery. Tongji is a national clinical research centre for obstetric and gynaecological disease and runs a large biobank and organoid platform.","asOf":"2026-09-09","links":[{"label":"Tongji Hospital","url":"https://www.tjh.com.cn"},{"label":"Tongji Medical College, HUST","url":"https://www.tjmu.edu.cn"}],"tags":[],"related":[],"cancers":["cervical","ovarian","endometrial","hcc","dlbcl"],"sections":["immunotherapy","prevention"],"technologies":["hpv-vaccine","organoids","checkpoint-inhibitor","car-t"],"targets":[],"drugs":[],"companies":[],"institutions":["union-hospital-wuhan"],"pathways":[],"terms":[],"trials":[],"people":["hu-junbo"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Wuhan","country":"CN","lat":30.584,"lng":114.269,"institutionType":"hospital","website":"https://www.tjh.com.cn","university":"Huazhong University of Science and Technology","programs":["Gynaecological oncology","Cancer Center trial portfolio","Haematology","Hepatobiliary surgery"]},{"id":"tgen","kind":"institution","name":"Translational Genomics Research Institute (TGen)","aka":["TGen","City of Hope TGen","HonorHealth Research Institute"],"tldr":"Arizona genomics institute, part of City of Hope, whose pancreatic cancer programme under Daniel Von Hoff produced the MPACT trial that established nab-paclitaxel plus gemcitabine.","summary":"The Translational Genomics Research Institute (TGen) is a non-profit genomics research institute in Phoenix, an affiliate of City of Hope since 2016. Its clinical programme, run with the HonorHealth Research Institute in Scottsdale, was led by Daniel Von Hoff, who was first author of the 2013 New England Journal of Medicine report of MPACT, in which nab-paclitaxel plus gemcitabine lengthened survival in metastatic pancreatic cancer. TGen also runs precision medicine programmes in paediatric cancer and glioblastoma.","asOf":"2026-09-18","links":[{"label":"TGen","url":"https://www.tgen.org"}],"tags":[],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["daniel-von-hoff"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Phoenix, AZ","country":"US","lat":33.457,"lng":-112.07,"institutionType":"research-institute","website":"https://www.tgen.org","programs":["Pancreatic cancer","Precision medicine","Paediatric genomics"]},{"id":"trinity-st-jamess-cancer-institute","kind":"institution","name":"Trinity St James's Cancer Institute","aka":["TSJCI","St James's Hospital Dublin"],"tldr":"Ireland's first OECI-accredited Comprehensive Cancer Centre, a partnership between St James's Hospital and Trinity College Dublin.","summary":"Trinity St James's Cancer Institute brings together the cancer services of St James's Hospital, Ireland's largest academic health campus, with the cancer research of Trinity College Dublin. It is, in its own words, the first Irish cancer institute accredited by the Organisation of European Cancer Institutes, and holds Comprehensive Cancer Centre status. The institute hosts national services in cancer genomics and immunology, Ireland's stem cell transplant and CAR-T programmes, a large clinical trials unit, and dedicated pathways for adolescents and young adults, older adults and young-onset cancer. Research strengths include haematological malignancies, lung cancer, oesophageal cancer and cancer immunology.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.stjames.ie/cancer/"}],"tags":["oeci-accredited","oeci-comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":["car-t"],"targets":[],"drugs":[],"companies":[],"institutions":["oeci","irish-cancer-society"],"pathways":[],"terms":[],"trials":[],"people":["john-kennedy","maeve-lowery"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Dublin","country":"IE","lat":53.339,"lng":-6.297,"institutionType":"cancer-center","website":"https://www.stjames.ie/cancer/","university":"Trinity College Dublin","programs":["Stem cell transplant and CAR-T","Cancer genomics and immunology","Clinical trials","Adolescent and young adult oncology"]},{"id":"tum-munich","kind":"institution","name":"TUM Klinikum rechts der Isar / CCC München","aka":["Klinikum rechts der Isar","Technical University of Munich","Comprehensive Cancer Center Munich (TUM)"],"tldr":"Munich's technical university hospital, one half of the Comprehensive Cancer Center Munich and a leader in PSMA imaging and radiopharmaceutical chemistry.","summary":"The Klinikum rechts der Isar is the university hospital of the Technical University of Munich and, with the LMU, forms the CCC München, a German Cancer Aid Oncology Center of Excellence and DKTK partner site. Its nuclear medicine and radiopharmacy groups developed the radiohybrid PSMA ligands (rhPSMA) that became flotufolastat F-18, and run large theranostic programmes in prostate and neuroendocrine cancer. The TranslaTUM centre houses translational oncology, imaging and immunology, and the hospital has strong pancreatic surgery, haematology and gastrointestinal oncology programmes. Patients access molecular tumour boards and early-phase trials across both Munich university sites.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.mri.tum.de"},{"label":"CCC München","url":"https://www.ccc-muenchen.de"},{"label":"TranslaTUM","url":"https://www.translatum.tum.de"}],"tags":[],"related":[],"cancers":["prostate","pancreatic","neuroendocrine","colorectal"],"sections":["radiopharma","imaging"],"technologies":["psma-pet","radioligand-therapy","pet-mri","fapi-pet","mr-linac"],"targets":[],"drugs":["pluvicto","lutathera"],"companies":[],"institutions":["lmu-munich","dkfz"],"pathways":[],"terms":["theranostics"],"trials":[],"people":["martin-siess","wolfgang-weber"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Munich","country":"DE","lat":48.137,"lng":11.6,"institutionType":"university","website":"https://www.mri.tum.de","university":"Technische Universität München","programs":["Radiopharmaceutical chemistry and PSMA theranostics","TranslaTUM","Pancreatic surgery","Haematology","CCC München (with LMU)"]},{"id":"turku-university-hospital","kind":"institution","name":"Turku University Hospital Cancer Centre","aka":["Tyks","FICAN West"],"tldr":"The university hospital of south-west Finland and host of FICAN West, with OECI Cancer Centre accreditation and a strong PET imaging tradition.","summary":"Turku University Hospital (Tyks) is the tertiary hospital for the Wellbeing Services County of Southwest Finland and the teaching hospital of the University of Turku. Its Cancer Centre hosts the Western Finland Cancer Centre (FICAN West) within the national Finnish Cancer Centre network and is accredited by the Organisation of European Cancer Institutes as a Cancer Centre. Turku is home to the national Turku PET Centre, which supports molecular imaging and radiopharmaceutical research in oncology, and the hospital's research groups are active in prostate cancer, breast cancer and haematological malignancies alongside the University of Turku's Institute of Biomedicine.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.varha.fi"}],"tags":["oeci-accredited","oeci-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":["psma-pet"],"targets":[],"drugs":[],"companies":[],"institutions":["oeci","helsinki-hus"],"pathways":[],"terms":[],"trials":[],"people":["pia-vihinen","sirkku-jyrkkio"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Turku","country":"FI","lat":60.451,"lng":22.267,"institutionType":"hospital","website":"https://www.varha.fi","university":"University of Turku","programs":["FICAN West regional cancer centre","PET imaging (Turku PET Centre)","Prostate and breast cancer research"]},{"id":"tygerberg-hospital","kind":"institution","name":"Tygerberg Hospital / Stellenbosch University","aka":["Tygerberg Academic Hospital"],"tldr":"Tygerberg Hospital in Cape Town, opened in 1976, is one of the Western Cape's two central academic hospitals and Stellenbosch University's teaching hospital; it provides public-sector oncology and radiotherapy and leads research in paediatric oncology and HIV-associated cancers.","summary":"Tygerberg Hospital opened in 1976 in Cape Town's northern suburbs and is, with Groote Schuur, one of the two central academic hospitals of the Western Cape provincial health department. It is the teaching hospital of Stellenbosch University's Faculty of Medicine and Health Sciences and provides medical oncology, radiation oncology, haematology, paediatric oncology and surgical oncology for a large public-sector population. Research strengths include paediatric oncology and the South African Children's Cancer Study Group, breast and cervical cancer in the public sector, HIV-associated malignancies, and nuclear medicine and theranostics.","asOf":"2026-09-10","links":[{"label":"Stellenbosch University","url":"https://www.su.ac.za"},{"label":"Western Cape Government Health and Wellness","url":"https://www.westerncape.gov.za/health-wellness"}],"tags":[],"related":[],"cancers":["cervical"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["groote-schuur-uct"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Cape Town","country":"ZA","lat":-33.909,"lng":18.611,"institutionType":"hospital","website":"https://www.su.ac.za","university":"Stellenbosch University","programs":["Radiation oncology","Paediatric oncology","HIV-associated malignancies","Nuclear medicine"]},{"id":"uc-davis-cancer","kind":"institution","name":"UC Davis Comprehensive Cancer Center","aka":[],"tldr":"UC Davis Comprehensive Cancer Center serves California's Central Valley and runs comparative oncology trials in pet dogs with naturally occurring cancers alongside the veterinary school, a model for speeding up immunotherapy and radiotherapy development; its director Primo Lara leads SWOG genitourinary and lung cancer trials.","summary":"NCI-designated in 2002 and comprehensive since 2012, UC Davis serves California's Central Valley and Sierra region. Its comparative oncology programme runs trials in pet dogs with naturally occurring cancers alongside the UC Davis School of Veterinary Medicine, a model for accelerating immunotherapy and radiotherapy development. Director Primo Lara is a long-standing SWOG leader in genitourinary and lung cancer trials. The centre also hosts a large lung cancer programme and community outreach to rural and agricultural populations.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/UC_Davis_Comprehensive_Cancer_Center","links":[{"label":"UC Davis Comprehensive Cancer Center","url":"https://health.ucdavis.edu/cancer/"},{"label":"Clinical trials","url":"https://health.ucdavis.edu/cancer/clinical-trials/"}],"tags":[],"related":[],"cancers":["nsclc","prostate","urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["swog"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["primo-lara"],"bottlenecks":["b-preclinical-models","b-trial-diversity"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Sacramento, CA","country":"US","lat":38.554,"lng":-121.455,"institutionType":"cancer-center","website":"https://health.ucdavis.edu/cancer/","nci":"comprehensive","university":"University of California, Davis","programs":["Comparative oncology","Lung cancer","Genitourinary oncology"]},{"id":"ucsd-moores","kind":"institution","name":"UC San Diego Moores Cancer Center","aka":["Moores Comprehensive Cancer Center"],"tldr":"San Diego's NCI comprehensive cancer centre, where the anti-GD2 antibody dinutuximab and the ROR1 antibody behind zilovertamab were developed.","summary":"NCI-designated since 1978 and comprehensive since 2001, Moores sits at the heart of the La Jolla biomedical cluster with the Salk Institute, Sanford Burnham Prebys and Scripps. Alice Yu led the Children's Oncology Group trial that established the anti-GD2 antibody dinutuximab in high-risk neuroblastoma. Thomas Kipps's CLL laboratory generated the humanised anti-ROR1 antibody (cirmtuzumab, UC-961) that became the targeting arm of the ADC zilovertamab vedotin. The centre also runs a large precision-oncology and phase 1 programme and hosts the Sanford Stem Cell Institute.","asOf":"2026-09-09","links":[{"label":"Moores Cancer Center","url":"https://moorescancercenter.ucsd.edu"},{"label":"Clinical trials","url":"https://clinicaltrials.ucsd.edu"}],"tags":[],"related":[],"cancers":["neuroblastoma","cll","head-and-neck"],"sections":[],"technologies":["monoclonal-antibody","adc"],"targets":["gd2","ror1"],"drugs":["dinutuximab","zilovertamab-vedotin"],"companies":["childrens-oncology-group"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["alice-yu","diane-simeone","rana-mckay","j-silvio-gutkind","ramez-eskander","ezra-cohen","ludmil-alexandrov"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"La Jolla, CA","country":"US","lat":32.877,"lng":-117.223,"institutionType":"cancer-center","website":"https://moorescancercenter.ucsd.edu","nci":"comprehensive","university":"University of California, San Diego","programs":["Neuroblastoma immunotherapy (anti-GD2)","CLL and ROR1","Precision oncology"]},{"id":"ucla-jonsson","kind":"institution","name":"UCLA Jonsson Comprehensive Cancer Center","aka":[],"tldr":"Where trastuzumab (Slamon) and palbociclib were developed clinically, and a leader in PSMA PET and melanoma immunotherapy (Ribas).","summary":"The UCLA Jonsson Comprehensive Cancer Center in Los Angeles holds NCI comprehensive designation and is where trastuzumab was developed clinically through Slamon's HER2 work, where palbociclib entered the clinic, and where Antoni Ribas built a leading melanoma immunotherapy programme in checkpoint and TIL research. Johannes Czernin and Jeremie Calais made it a centre for PSMA PET, Hurvitz ran its breast trials programme before moving to Fred Hutch, and Michael A. Teitell, Amar U. Kishan, Aditya Bardia, Denise R. Aberle and the patient Barbara Bradfield are also listed. OnCo links it to HER2 and PSMA as targets, to trastuzumab, palbociclib and gallium-68 PSMA-11, and to melanoma and prostate cancer. How to extend the HER2 model of target, drug and companion test to new targets remains its recurring theme. Its HER2, melanoma and PSMA programmes are the ones to read.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.uclahealth.org/cancer"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["psma-pet","mr-linac"],"targets":["her2","psma"],"drugs":["trastuzumab","palbociclib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["michael-teitell","antoni-ribas","johannes-czernin","jeremie-calais","amar-kishan","barbara-bradfield","richard-finn","aditya-bardia","denise-aberle","zev-wainberg","timothy-cloughesy","dennis-slamon","owen-witte"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Los Angeles","country":"US","lat":34.066,"lng":-118.446,"institutionType":"cancer-center","website":"https://www.uclahealth.org/cancer","nci":"comprehensive","university":"University of California, Los Angeles","programs":["HER2 (Slamon)","Melanoma immunotherapy (Ribas)","PSMA PET"]},{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","aka":[],"tldr":"UCSF is the birthplace of oncogene biology (Bishop, Varmus) and KRAS G12C drugging (Shokat), and a leader in I-SPY adaptive breast trials.","summary":"The UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco is the birthplace of oncogene biology, where Bishop and Varmus made their Nobel-winning discovery, and of KRAS G12C drugging through Shokat's switch-II pocket; it holds NCI comprehensive designation and ranks thirty-third in the Newsweek/Statista oncology list. It leads the I-SPY 2 adaptive platform trial in breast cancer under Laura J. Esserman, runs the UCSF500 panel, and pioneered PSMA PET with Thomas A. Hope, alongside neuro-oncology and prostate programmes. OnCo links it to KRAS and PSMA, to gallium-68 PSMA-11, to the Ostrem and Shokat paper, and to the MYC and telomere pathways. Whether MYC can be drugged directly, and tolerated, is the open question it is linked to. Alan Ashworth, Eric J. Small and Alan P. Venook are among the people listed.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/UCSF_Helen_Diller_Family_Comprehensive_Cancer_Center","links":[{"label":"Official website","url":"https://cancer.ucsf.edu"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["psma-pet","gamma-knife","radiosurgery-srs"],"targets":["kras","psma"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["basket-umbrella-platform"],"trials":[],"people":["alan-ashworth","eric-small","rahul-aggarwal","alan-venook","laura-esserman","thomas-hope","emily-bergsland","katherine-matthay","helen-diller","sanford-weill","mitchel-berger","ajai-chari","frank-mccormick","kevan-shokat"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"San Francisco","country":"US","lat":37.765,"lng":-122.458,"institutionType":"cancer-center","website":"https://cancer.ucsf.edu","nci":"comprehensive","newsweekOncology2026":33,"university":"University of California, San Francisco","programs":["I-SPY 2 platform trial","KRAS chemistry","PSMA PET","Neuro-oncology"]},{"id":"uganda-cancer-institute","kind":"institution","name":"Uganda Cancer Institute","aka":["UCI","UCI-Fred Hutch Cancer Centre"],"tldr":"East Africa's oldest cancer research institute, founded in 1967 to study Burkitt lymphoma, and now a national cancer centre with a Fred Hutch partnership and Africa's first purpose-built cancer research facility.","summary":"The Uganda Cancer Institute was established in 1967 at Mulago Hospital in Kampala by US National Cancer Institute and Makerere University researchers to study Burkitt lymphoma, the tumour first described in Uganda by Denis Burkitt, and early chemotherapy cure of Burkitt lymphoma and combination chemotherapy for Kaposi sarcoma were tested there. Since 2004 it has partnered with the Fred Hutchinson Cancer Center, which built the UCI-Fred Hutch Cancer Centre in 2015, the first comprehensive cancer research and training facility in sub-Saharan Africa built for that purpose, and the institute now runs Uganda's national cancer services, radiotherapy, paediatric oncology, cancer registries and regional cancer centres, and research on infection-related cancers (EBV, KSHV, HPV, HIV), cervical cancer screening and access to essential cancer medicines.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Uganda_Cancer_Institute","links":[{"label":"Uganda Cancer Institute","url":"https://www.uci.or.ug"},{"label":"UCI-Fred Hutch collaboration","url":"https://www.fredhutch.org/en/research/institutes-networks-ircs/global-oncology/uganda.html"}],"tags":[],"related":["global-oncology-access","who-essential-medicines"],"cancers":["dlbcl","cervical","hcc","breast-hr-positive"],"sections":["chemotherapy","prevention"],"technologies":["cytotoxic-chemotherapy","hpv-vaccine","brachytherapy"],"targets":[],"drugs":[],"companies":[],"institutions":["fred-hutch","nci"],"pathways":[],"terms":[],"trials":[],"people":["jackson-orem"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Kampala","country":"UG","lat":0.339,"lng":32.577,"institutionType":"cancer-center","website":"https://www.uci.or.ug","programs":["Burkitt lymphoma and infection-related cancers","UCI-Fred Hutch Cancer Centre","National cancer services","Radiotherapy and regional centres"]},{"id":"ulm-university-hospital","kind":"institution","name":"Ulm University Hospital / Comprehensive Cancer Center Ulm","aka":["Universitätsklinikum Ulm","CCCU"],"tldr":"German university hospital whose Department of Internal Medicine III, under Hartmut Döhner, coordinates the AML Study Group and shaped the genetic classification of acute myeloid leukaemia used worldwide.","summary":"Ulm University Hospital is the academic hospital of the University of Ulm in Baden-Württemberg and hosts the Comprehensive Cancer Center Ulm. Its Department of Internal Medicine III, directed by Hartmut Döhner, is the coordinating centre of the German-Austrian AML Study Group (AMLSG) and of the European LeukemiaNet recommendations for acute myeloid leukaemia, which define the genetic risk groups used in the clinic. The department also runs trials in chronic lymphocytic leukaemia and lymphoma.","asOf":"2026-09-18","links":[{"label":"Universitätsklinikum Ulm","url":"https://www.uniklinik-ulm.de"}],"tags":[],"related":[],"cancers":["aml","cll"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["hartmut-dohner"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Ulm","country":"DE","lat":48.423,"lng":9.955,"institutionType":"hospital","website":"https://www.uniklinik-ulm.de","university":"Universität Ulm","programs":["Acute myeloid leukaemia (AMLSG)","European LeukemiaNet","Chronic lymphocytic leukaemia"]},{"id":"umc-utrecht","kind":"institution","name":"UMC Utrecht Cancer Center","aka":["University Medical Center Utrecht","Utrecht Cancer Center"],"tldr":"The Dutch university cancer centre that invented the MR-linac and sits at the heart of the Utrecht organoid and Oncode ecosystem.","summary":"UMC Utrecht's radiotherapy department under Jan Lagendijk and Bas Raaymakers conceived and built the first integrated MRI-guided linear accelerator, commercialised by Elekta as Unity and used to treat the first patients in Utrecht in 2017. The Cancer Center works with the neighbouring Hubrecht Institute, where Hans Clevers's group grew the first adult stem cell-derived organoids, and with the Princess Máxima Center for paediatric oncology on the same campus; Utrecht is also the seat of the Dutch Oncode Institute. Clinical strengths include image-guided and adaptive radiotherapy, head and neck and gastrointestinal oncology, haematology and a phase 1 unit, and the centre holds OECI accreditation. Patients access MR-guided radiotherapy trials, organoid-guided drug testing studies and molecular tumour boards.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.umcutrecht.nl/en"},{"label":"Hubrecht Institute","url":"https://www.hubrecht.eu"},{"label":"Oncode Institute","url":"https://www.oncode.nl"}],"tags":[],"related":[],"cancers":["prostate","head-and-neck","colorectal","pancreatic"],"sections":["radiation","diagnostics"],"technologies":["mr-linac","organoids","functional-drug-testing","imrt-igrt","sbrt"],"targets":[],"drugs":[],"companies":["elekta"],"institutions":["princess-maxima","nki","oeci"],"pathways":[],"terms":[],"trials":[],"people":["wouter-de-laat","jurgen-kuball","bas-raaymakers"],"bottlenecks":["b-preclinical-models"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Utrecht","country":"NL","lat":52.087,"lng":5.18,"institutionType":"cancer-center","website":"https://www.umcutrecht.nl/en","university":"Utrecht University","programs":["MR-linac and adaptive radiotherapy","Organoid research (with Hubrecht Institute)","Head and neck oncology","Haematology","Oncode Institute"]},{"id":"umea-university-hospital","kind":"institution","name":"Umeå University Hospital (Norrland University Hospital)","aka":["University Hospital of Umeå","Norrlands universitetssjukhus","NUS Umeå"],"tldr":"Umeå University Hospital is the university hospital for northern Sweden, run by Region Västerbotten with Umeå University, and an associate member of the Organisation of European Cancer Institutes.","summary":"Umeå University Hospital is the university hospital for northern Sweden, run by Region Västerbotten with Umeå University. It is listed by the Organisation of European Cancer Institutes as an associate member, which is why it has a page on OnCo. Programme, trial and leadership details are not yet recorded here and should be checked on the institution's own pages.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.regionvasterbotten.se"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["pia-nasvall"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Umeå","country":"SE","lat":63.817,"lng":20.306,"institutionType":"hospital","website":"https://www.regionvasterbotten.se","programs":[]},{"id":"unc-lineberger","kind":"institution","name":"UNC Lineberger Comprehensive Cancer Center","aka":[],"tldr":"Where Charles Perou defined the PAM50 intrinsic subtypes of breast cancer; a public university centre with in-house CAR-T manufacturing.","summary":"NCI-designated since 1975 and comprehensive since 1990, UNC Lineberger is a public-university cancer centre with a statewide remit across North Carolina. Charles Perou's intrinsic subtypes and the PAM50 assay reshaped breast cancer classification; Norman Sharpless, later NCI director, worked on CDK4/6 and cellular senescence here and co-founded G1 Therapeutics. Gianpietro Dotti and Barbara Savoldo run one of the few academic in-house CAR-T programmes, and Ethan Basch's patient-reported outcome trials changed how symptoms are monitored during chemotherapy. Blossom Damania and Dirk Dittmer lead research on Kaposi sarcoma herpesvirus and virus-associated cancers.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/UNC_Lineberger_Comprehensive_Cancer_Center","links":[{"label":"UNC Lineberger","url":"https://unclineberger.org"},{"label":"Clinical trials","url":"https://unclineberger.org/patientcare/clinical-trials/"}],"tags":[],"related":[],"cancers":["breast-hr-positive","tnbc","kaposi-sarcoma","dlbcl"],"sections":[],"technologies":["car-t","cdk46-inhibitor"],"targets":[],"drugs":[],"companies":[],"institutions":["nci"],"pathways":[],"terms":["pam50"],"trials":[],"people":["charles-perou","ethan-basch"],"bottlenecks":["b-patient-voice","b-toxicity-qol"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Chapel Hill, NC","country":"US","lat":35.905,"lng":-79.053,"institutionType":"cancer-center","website":"https://unclineberger.org","nci":"comprehensive","university":"University of North Carolina at Chapel Hill","programs":["Breast cancer subtyping (PAM50)","Academic CAR-T","Patient-reported outcomes","Viral oncology"]},{"id":"uniklinik-koeln","kind":"institution","name":"Uniklinik Köln (CIO)","aka":[],"tldr":"Uniklinik Köln runs the Centre for Integrated Oncology and leads lung cancer genomics via the Network Genomic Medicine.","summary":"Uniklinik Köln runs the Centre for Integrated Oncology at the University of Cologne and ranks thirty-second in the Newsweek/Statista oncology list. It leads lung cancer genomics through the Network Genomic Medicine Lung Cancer, associated with Wolf and Thomas, which has sequenced tens of thousands of non-small-cell lung cancer patients, and it leads chronic lymphocytic leukaemia research through Hallek and the German CLL Study Group; Reinhard Büttner, Barbara Eichhorst, Kirsten Fischer, Andreas Engert and Peter Borchmann are among the people OnCo lists here. OnCo links it to the German Hodgkin Study Group, to fellow centres in Düsseldorf and Essen and to Deutsche Krebshilfe. Whether a regional sequencing network can be copied in health systems without Germany's payer support is the question it raises. Its lung genomics and CLL programmes are the ones to read.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://www.uk-koeln.de"}],"tags":[],"related":[],"cancers":["nsclc","cll"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["reinhard-buettner","roman-thomas","peter-borchmann","andreas-engert","kirsten-fischer","barbara-eichhorst","juergen-wolf","michael-hallek"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Cologne","country":"DE","lat":50.925,"lng":6.918,"institutionType":"university","website":"https://www.uk-koeln.de","newsweekOncology2026":32,"university":"University of Cologne","programs":["Lung cancer genomics","CLL"]},{"id":"uicc","kind":"institution","name":"Union for International Cancer Control","aka":["UICC"],"tldr":"The Geneva-based membership body of more than 1,100 cancer organisations that runs World Cancer Day, the World Cancer Congress and the TNM staging system.","summary":"Founded in 1933, UICC unites cancer societies, ministries of health, research institutes and patient groups in more than 170 countries and is the largest cancer-fighting organisation of its kind. It owns and publishes the TNM Classification of Malignant Tumours with the AJCC, leads World Cancer Day on 4 February, convenes the World Cancer Congress and the World Cancer Leaders' Summit, and runs capacity-building programmes such as the City Cancer Challenge, ATOM Coalition on access to medicines, and technical fellowships. UICC holds official relations with WHO and advocates for cancer in the UN non-communicable disease agenda.","asOf":"2026-09-09","links":[{"label":"UICC","url":"https://www.uicc.org"},{"label":"TNM","url":"https://www.uicc.org/resources/tnm"}],"tags":[],"related":[],"cancers":[],"sections":["prevention"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["who","iarc","gates-foundation","american-cancer-society"],"pathways":[],"terms":["tnm-staging"],"trials":[],"people":["cary-adams"],"bottlenecks":["b-global-access","b-knowledge-diffusion"],"keyPapers":[],"journals":["international-journal-of-cancer"],"dependsOn":[],"notes":[],"city":"Geneva","country":"CH","lat":46.204,"lng":6.143,"institutionType":"consortium","website":"https://www.uicc.org","programs":["TNM Classification (with AJCC)","World Cancer Day and World Cancer Congress","ATOM Coalition (access to oncology medicines)","City Cancer Challenge and fellowships"]},{"id":"union-hospital-wuhan","kind":"institution","name":"Union Hospital, Tongji Medical College","aka":["Wuhan Union Hospital","Xiehe Hospital Wuhan","武汉协和医院"],"tldr":"Wuhan Union Hospital, founded in 1866, is a national regional medical centre whose cancer centre runs breast, lymphoma, myeloma and radiotherapy programmes and one of China's newer proton therapy centres; it is a frequent lead site for Chinese CAR-T and breast antibody-drug conjugate trials.","summary":"Wuhan Union Hospital was founded in 1866 by the London Missionary Society and is a national regional medical centre attached to Tongji Medical College. Its Cancer Center is among the larger oncology units in central China with strong breast cancer, lymphoma and myeloma, thoracic and radiation oncology programmes, and it operates one of the country's newer proton therapy centres. The hospital is a common lead site for Chinese haematology trials, including CAR-T for myeloma and lymphoma, and for breast cancer ADC studies.","asOf":"2026-09-09","links":[{"label":"Wuhan Union Hospital","url":"https://www.whuh.com"},{"label":"Tongji Medical College, HUST","url":"https://www.tjmu.edu.cn"}],"tags":[],"related":["pumch"],"cancers":["breast-her2-positive","dlbcl","multiple-myeloma","nsclc"],"sections":["radiation","cell-therapy"],"technologies":["proton-therapy","car-t","adc"],"targets":["bcma","cd19"],"drugs":[],"companies":[],"institutions":["tongji-hospital-wuhan"],"pathways":[],"terms":[],"trials":[],"people":["xia-jiahong"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Wuhan","country":"CN","lat":30.585,"lng":114.279,"institutionType":"hospital","website":"https://www.whuh.com","university":"Huazhong University of Science and Technology","programs":["Breast cancer","Lymphoma and myeloma","Proton therapy","Radiation oncology"]},{"id":"uke-hamburg","kind":"institution","name":"Universitätsklinikum Hamburg-Eppendorf","aka":[],"tldr":"UKE Hamburg is a German university cancer centre with strengths in prostate cancer surgery (Martini-Klinik) and haematology.","summary":"Universitätsklinikum Hamburg-Eppendorf is a German university cancer centre ranked twenty-fourth in the Newsweek/Statista World's Best Specialized Hospitals list for oncology. Its Martini-Klinik is the world's highest-volume prostatectomy centre, and the Hubertus Wald Tumour Centre brings together its haematology and medical oncology, with Markus Graefen, Carsten Bokemeyer and Klaus Pantel among the people OnCo lists here. OnCo links it to prostate cancer and neuroendocrine tumours and to Deutsche Krebshilfe. Whether very high surgical volume alone explains its prostate outcomes, or whether its outcome-tracking model is the transferable lesson, is the question other centres ask. Its prostate surgery and haematology programmes are listed below.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/University_Medical_Center_Hamburg-Eppendorf","links":[{"label":"Official website","url":"https://www.uke.de"}],"tags":[],"related":[],"cancers":["prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["markus-graefen","carsten-bokemeyer","klaus-pantel"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Hamburg","country":"DE","lat":53.59,"lng":9.975,"institutionType":"university","website":"https://www.uke.de","newsweekOncology2026":24,"programs":["Prostate surgery (Martini-Klinik)","Haematology"]},{"id":"uct-frankfurt","kind":"institution","name":"University Cancer Center Frankfurt (UCT)","aka":["Universitäres Centrum für Tumorerkrankungen Frankfurt","UCT Frankfurt-Marburg","Universitätsklinikum Frankfurt"],"tldr":"The University Cancer Center Frankfurt, founded in 2008, is a German Cancer Aid centre of excellence; it inherits Paul Ehrlich's Georg-Speyer-Haus, where the 'magic bullet' idea behind antibody-drug conjugates was born, and its clinical strengths are acute leukaemia, CAR-T and neuro-oncology.","summary":"The UCT was founded in 2008 at Universitätsklinikum Frankfurt and is a German Cancer Aid Oncology Center of Excellence and DKTK partner site; since 2020 it forms UCT Frankfurt-Marburg with the University Hospital Marburg. Frankfurt's Georg-Speyer-Haus, where Paul Ehrlich developed Salvarsan and the concept of targeted 'magic bullets' that underpins today's antibody-drug conjugates, is now an institute for tumour biology of the Goethe University, and the Frankfurt Cancer Institute unites basic and clinical groups. Clinical strengths include acute leukaemia and the German AML study group activities, CAR-T and stem cell transplantation, neuro-oncology and paediatric oncology. Marburg's pathology under Carsten Denkert brings the German Breast Group's translational research into the alliance.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.uct-frankfurt.de"},{"label":"Georg-Speyer-Haus","url":"https://www.georg-speyer-haus.de"},{"label":"Frankfurt Cancer Institute","url":"https://fci.health"}],"tags":[],"related":[],"cancers":["aml","glioblastoma","dlbcl","all-leukemia"],"sections":["cell-therapy","adcs"],"technologies":["car-t","adc","monoclonal-antibody"],"targets":[],"drugs":[],"companies":["gbg"],"institutions":["dkfz"],"pathways":[],"terms":[],"trials":[],"people":["carsten-denkert","christian-brandts","florian-greten","hubert-serve","nicola-gokbuget"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Frankfurt am Main","country":"DE","lat":50.094,"lng":8.657,"institutionType":"cancer-center","website":"https://www.uct-frankfurt.de","university":"Goethe-Universität Frankfurt","programs":["Acute leukaemia","CAR-T and transplantation","Neuro-oncology","Frankfurt Cancer Institute","UCT Frankfurt-Marburg"]},{"id":"uct-mainz","kind":"institution","name":"University Cancer Center Mainz (UCT Mainz) / Universitätsmedizin Mainz","aka":["Universitätsmedizin der Johannes Gutenberg-Universität Mainz","TRON","HI-TRON Mainz"],"tldr":"The university medical centre where Uğur Şahin and Özlem Türeci built the science behind BioNTech and personalised mRNA cancer vaccines.","summary":"Universitätsmedizin Mainz is the home institution of Uğur Şahin and Özlem Türeci, who founded BioNTech in Mainz in 2008 and the translational institute TRON in 2010 to pursue individualised neoantigen mRNA vaccines, the concept later tested as autogene cevumeran with Genentech. The Helmholtz Institute for Translational Oncology (HI-TRON), a DKFZ partnership, and the UCT Mainz make the site a German Cancer Aid Oncology Center of Excellence and DKTK partner. Clinical strengths include haematology, dermato-oncology (a large melanoma trial site for BioNTech's programmes), neuro-oncology and the Mainz Research Center for Immunotherapy (FZI). The city has become a hub for mRNA and immunotherapy companies around the university.","asOf":"2026-09-09","links":[{"label":"UCT Mainz","url":"https://www.unimedizin-mainz.de/uct"},{"label":"TRON","url":"https://tron-mainz.de"},{"label":"HI-TRON Mainz (archived copy)","url":"https://web.archive.org/web/20250121103628/https://www.dkfz.de/en/hi-tron/"}],"tags":[],"related":[],"cancers":["melanoma","pancreatic","colorectal"],"sections":["immunotherapy"],"technologies":["neoantigen-mrna-vaccine","bispecific-antibody","car-t"],"targets":[],"drugs":["autogene-cevumeran"],"companies":["biontech","roche-genentech"],"institutions":["dkfz"],"pathways":[],"terms":["neoantigen"],"trials":[],"people":["thomas-kindler","ugur-sahin"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Mainz","country":"DE","lat":49.993,"lng":8.259,"institutionType":"university","website":"https://www.unimedizin-mainz.de/uct","university":"Johannes Gutenberg-Universität Mainz","programs":["Individualised mRNA cancer vaccines (TRON, BioNTech)","HI-TRON Mainz","Research Center for Immunotherapy","Melanoma","Haematology"]},{"id":"university-clinic-radiotherapy-oncology-skopje","kind":"institution","name":"University Clinic for Radiotherapy and Oncology, Skopje","aka":["PHI University Clinic for Radiotherapy and Oncology Skopje","Univerzitetska klinika za radioterapija i onkologija"],"tldr":"University Clinic for Radiotherapy and Oncology, Skopje is North Macedonia's national centre for radiotherapy and medical oncology, on the Skopje clinical campus, and an associate member of the Organisation of European Cancer Institutes.","summary":"University Clinic for Radiotherapy and Oncology, Skopje is North Macedonia's national centre for radiotherapy and medical oncology, on the Skopje clinical campus. It is listed by the Organisation of European Cancer Institutes as an associate member, which is why it has a page on OnCo. Programme, trial and leadership details are not yet recorded here and should be checked on the institution's own pages.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.oncology.org.mk"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["igor-stojkovski"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Skopje","country":"MK","lat":41.996,"lng":21.431,"institutionType":"cancer-center","website":"https://www.oncology.org.mk","programs":[]},{"id":"uck-gdansk","kind":"institution","name":"University Clinical Centre, Gdańsk","aka":["Uniwersyteckie Centrum Kliniczne","UCK Gdańsk","University Clinical Center (UCK) of Medical University of Gdansk"],"tldr":"The University Clinical Centre in Gdańsk is the teaching hospital of the Medical University of Gdańsk, the largest hospital in northern Poland, and a full member of the Organisation of European Cancer Institutes.","summary":"The University Clinical Centre (Uniwersyteckie Centrum Kliniczne) is the main teaching hospital of the Medical University of Gdańsk, formed in 2001 and described as the largest hospital in northern Poland and one of the largest in the country. Its cancer services span surgical, medical and radiation oncology and haematology, and it is listed by the Organisation of European Cancer Institutes as a full member alongside the National Research Institute of Oncology in Warsaw. Programme, trial and leadership details are not yet recorded here and should be checked on the hospital's own pages.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://uck.pl"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/University_Clinical_Centre,_Gdańsk"}],"tags":[],"related":["nio-warsaw"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["jakub-kraszewski"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Gdańsk","country":"PL","lat":54.366,"lng":18.625,"institutionType":"hospital","website":"https://uck.pl","programs":[]},{"id":"uch-ibadan","kind":"institution","name":"University College Hospital, Ibadan","aka":["UCH Ibadan"],"tldr":"Nigeria's first teaching hospital, founded in 1957, and a leading centre for oncology, radiotherapy and cancer research in West Africa.","summary":"The University College Hospital in Ibadan was established in 1957 as Nigeria's first teaching hospital, attached to the University of Ibadan's College of Medicine. It has one of the country's longest-running radiotherapy departments and provides medical oncology, haematology, paediatric oncology and surgical oncology for south-western Nigeria. UCH Ibadan is a major site for cancer research in Africa, including the Ibadan Cancer Registry, genetic studies of breast cancer in Nigerian women with the University of Chicago, and the Nigerian Breast Cancer Study, and it hosts an Institute for Advanced Medical Research and Training.","asOf":"2026-09-10","wikipedia":"https://en.wikipedia.org/wiki/University_College_Hospital,_Ibadan","links":[{"label":"Official website","url":"https://uch-ibadan.org.ng"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["luth-lagos","uchicago-cancer"],"pathways":[],"terms":[],"trials":[],"people":["jesse-otegbayo"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Ibadan","country":"NG","lat":7.402,"lng":3.902,"institutionType":"hospital","website":"https://uch-ibadan.org.ng","university":"University of Ibadan","programs":["Radiotherapy","Breast cancer genetics research","Ibadan Cancer Registry"]},{"id":"uclh","kind":"institution","name":"University College London Hospitals / UCL Cancer Institute","aka":["UCLH","UCL Cancer Institute","UCLH Proton Beam Therapy Centre"],"tldr":"Central London's university hospital and one of two NHS proton beam therapy centres, backed by UCL's cancer institute and its CAR-T and lung cancer evolution research.","summary":"UCLH runs one of the UK's largest cancer services, including the University College Hospital Macmillan Cancer Centre, a national proton beam therapy centre that opened in 2021, and a teenage and young adult cancer unit. The UCL Cancer Institute hosts the TRACERx lung cancer evolution study with the Francis Crick Institute under Charles Swanton, Martin Pule's CAR-T engineering group that spun out Autolus, and Sergio Quezada's work on clonal neoantigen T-cell therapy behind Achilles Therapeutics. The MRC Clinical Trials Unit at UCL coordinated the STAMPEDE prostate cancer platform trial and the Cancer Research UK & UCL Cancer Trials Centre runs many national trials. UCLH is also a major site for lung screening studies and adult ALL cell therapy.","asOf":"2026-09-09","links":[{"label":"UCLH cancer services","url":"https://www.uclh.nhs.uk/our-services/find-service/cancer-services"},{"label":"UCL Cancer Institute","url":"https://www.ucl.ac.uk/cancer"},{"label":"Proton beam therapy","url":"https://www.uclh.nhs.uk/our-services/find-service/cancer-services/proton-beam-therapy"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":["nsclc","all-leukemia","prostate","dlbcl","pancreatic","lung-cancer"],"sections":["radiation","cell-therapy"],"technologies":["proton-therapy","car-t","liquid-biopsy","wes-wgs","til-therapy","proton-therapy-systems","gamma-knife","radiosurgery-srs","hifu-histotripsy"],"targets":[],"drugs":[],"companies":[],"institutions":["francis-crick","cruk","great-ormond-street"],"pathways":[],"terms":["ctdna","neoantigen","basket-umbrella-platform"],"trials":["tracerx","summit-lung","lungsearch","promis","transform-prostate","stampede"],"people":["charles-swanton","nicholas-james","david-probert","mark-emberton","jonathan-ledermann","usha-menon","mary-mccormack","mahesh-parmar","caroline-moore"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"London","country":"GB","lat":51.525,"lng":-0.136,"institutionType":"hospital","website":"https://www.uclh.nhs.uk/our-services/find-service/cancer-services","university":"University College London","programs":["Proton beam therapy","TRACERx and cancer evolution","CAR-T engineering","MRC Clinical Trials Unit (STAMPEDE)","Teenage and young adult cancer"]},{"id":"usb-basel","kind":"institution","name":"University Hospital Basel / Tumour Centre","aka":["USB","Universitätsspital Basel","Tumorzentrum Basel"],"tldr":"University Hospital Basel coordinates cancer care in the home city of Roche and Novartis; its groups run early-phase tumour immunology trials, study breast cancer metastasis, and develop peptide radioligands such as exendin-based imaging of insulinomas.","summary":"The Tumour Centre of University Hospital Basel coordinates cancer care in a city that is also headquarters to Roche and Novartis and home to the Friedrich Miescher Institute and the University of Basel's Department of Biomedicine. Alfred Zippelius and Heinz Läubli lead tumour immunology and early-phase immunotherapy trials, Mohamed Bentires-Alj studies breast cancer metastasis, Viola Heinzelmann-Schwarz heads gynaecological oncology, and the nuclear medicine and radiopharmaceutical chemistry groups (Damian Wild, Melpomeni Fani) develop novel peptide radioligands, including exendin-based imaging of insulinomas. The hospital runs haematology and CAR-T, thoracic and visceral surgery, and radiotherapy, and hosts SAKK and pharma-sponsored trials.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.unispital-basel.ch/en/"},{"label":"Tumorzentrum","url":"https://www.unispital-basel.ch/en/tumorzentrum"}],"tags":[],"related":[],"cancers":["breast-hr-positive","nsclc","neuroendocrine","ovarian"],"sections":["immunotherapy","radiopharma"],"technologies":["radioligand-therapy","checkpoint-inhibitor","car-t","pet-ct"],"targets":[],"drugs":[],"companies":["novartis","roche-genentech"],"institutions":["inselspital-bern","usz-zurich"],"pathways":[],"terms":[],"trials":[],"people":["rakesh-padiyath","astrid-beiglbock","benjamin-kasenda","daniel-staub"],"bottlenecks":["b-metastasis-biology"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Basel","country":"CH","lat":47.561,"lng":7.582,"institutionType":"hospital","website":"https://www.unispital-basel.ch/en/","university":"Universität Basel","programs":["Tumour immunology and early-phase immunotherapy","Radiopharmaceutical chemistry","Breast cancer metastasis research","Gynaecological oncology","Haematology and CAR-T"]},{"id":"mother-teresa-hospital-tirana","kind":"institution","name":"University Hospital Center \"Mother Teresa\", Tirana","aka":["Qendra Spitalore Universitare Nënë Tereza","QSUT","Mother Teresa Hospital"],"tldr":"Albania's main university hospital in Tirana, the country's largest, and an associate member of the Organisation of European Cancer Institutes.","summary":"The University Hospital Center \"Mother Teresa\" (Qendra Spitalore Universitare Nënë Tereza) is the largest hospital in Albania and the teaching hospital of the University of Medicine, Tirana. Its oncology service is the national referral centre for cancer care in Albania. The centre is an associate member of the Organisation of European Cancer Institutes (OECI), Europe's network of cancer centres.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.qsut.gov.al/"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikidata","url":"https://www.wikidata.org/wiki/Q6917439"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Tirana","country":"AL","lat":41.34,"lng":19.835,"institutionType":"hospital","website":"https://www.qsut.gov.al/","programs":[]},{"id":"uhcw-coventry","kind":"institution","name":"University Hospital Coventry","aka":["University Hospitals Coventry and Warwickshire NHS Trust","UHCW"],"tldr":"The HPB specialist centre for Coventry and Warwickshire; its Macmillan HPB clinical nurse specialist sits on the GIRFT pancreatic cancer team.","summary":"University Hospitals Coventry and Warwickshire NHS Trust (trust code RKB) is one of the 23 HPB specialist centres in the National Pancreatic Cancer Audit and is listed by Pancreatic Cancer UK for the West Midlands. Claire Pearce, a Macmillan hepatobiliary and pancreatic clinical nurse specialist at the trust, is the clinical nurse specialist on the GIRFT pancreatic cancer workstream and deputy chair of the West Midlands HPB expert advisory group.","asOf":"2026-09-24","links":[{"label":"University Hospitals Coventry and Warwickshire","url":"https://www.uhcw.nhs.uk/"},{"label":"GIRFT pancreatic cancer workstream","url":"https://gettingitrightfirsttime.co.uk/medical_specialties/pancreatic-cancer/"}],"tags":["hpb","nhs","uk"],"related":[],"cancers":["pancreatic","gallbladder","biliary-tract-cancer","cholangiocarcinoma","hcc"],"sections":["surgery"],"technologies":["whipple"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Coventry","country":"GB","lat":52.421,"lng":-1.438,"institutionType":"hospital","website":"https://www.uhcw.nhs.uk/","programs":["HPB surgery","Specialist HPB MDT","HPB clinical nurse specialists"]},{"id":"uk-duesseldorf","kind":"institution","name":"University Hospital Düsseldorf / CIO Düsseldorf","aka":["Universitätsklinikum Düsseldorf","UKD","Centrum für Integrierte Onkologie Aachen Bonn Köln Düsseldorf"],"tldr":"Düsseldorf's university hospital, a partner in the CIO cancer centre alliance and a leading site for FAPI and PSMA imaging under Frederik Giesel.","summary":"University Hospital Düsseldorf forms, with Aachen, Bonn and Cologne, the Centrum für Integrierte Onkologie (CIO ABCD), a German Cancer Aid Oncology Center of Excellence. Its nuclear medicine department is directed by Frederik Giesel, co-inventor of FAPI PET tracers at Heidelberg, and runs theranostic programmes in prostate and neuroendocrine cancers. The hospital has a large paediatric oncology and haematology department, hepatology and liver cancer programmes, and neurosurgical oncology. Trials from the CIO network give patients access to early-phase immunotherapy and cell therapy studies.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.uniklinik-duesseldorf.de"}],"tags":[],"related":[],"cancers":["prostate","neuroendocrine","hcc","all-leukemia"],"sections":["radiopharma","imaging"],"technologies":["fapi-pet","psma-pet","radioligand-therapy"],"targets":["fap","psma"],"drugs":["fap-2286","pluvicto"],"companies":[],"institutions":["uniklinik-koeln","heidelberg-nct"],"pathways":[],"terms":[],"trials":[],"people":["frederik-giesel","kirsten-schmieder","sascha-dietrich"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Düsseldorf","country":"DE","lat":51.194,"lng":6.788,"institutionType":"hospital","website":"https://www.uniklinik-duesseldorf.de","university":"Heinrich-Heine-Universität Düsseldorf","programs":["FAPI and PSMA PET","Theranostics","Paediatric oncology","CIO ABCD"]},{"id":"sestre-milosrdnice-tumors","kind":"institution","name":"University Hospital for Tumors, Sestre milosrdnice University Hospital Centre","aka":["Klinika za tumore","KBC Sestre milosrdnice","Sestre milosrdnice University Hospital Centre"],"tldr":"University Hospital for Tumors, Sestre milosrdnice University Hospital Centre is Croatia's dedicated cancer hospital, part of the Sestre milosrdnice University Hospital Centre in Zagreb, and a full member of the Organisation of European Cancer Institutes.","summary":"University Hospital for Tumors, Sestre milosrdnice University Hospital Centre is Croatia's dedicated cancer hospital, part of the Sestre milosrdnice University Hospital Centre in Zagreb. It is listed by the Organisation of European Cancer Institutes as a full member, which is why it has a page on OnCo. Programme, trial and leadership details are not yet recorded here and should be checked on the institution's own pages.","asOf":"2026-09-09","links":[{"label":"Official website","url":"http://www.kbcsm.hr/klinike/klinika-za-tumore"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["robert-separovic"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Zagreb","country":"HR","lat":45.813,"lng":15.968,"institutionType":"cancer-center","website":"http://www.kbcsm.hr/klinike/klinika-za-tumore","programs":[]},{"id":"hospital-universitario-salamanca","kind":"institution","name":"University Hospital of Salamanca / IBSAL","aka":["Hospital Universitario de Salamanca","Complejo Asistencial Universitario de Salamanca","Instituto de Investigación Biomédica de Salamanca"],"tldr":"Spanish university hospital whose haematology department, home of María-Victoria Mateos and the Spanish Myeloma Group, led the trials that defined treatment of smouldering and newly diagnosed myeloma.","summary":"The University Hospital of Salamanca and its research institute IBSAL form one of Europe's leading myeloma centres. Its haematology department, long associated with Jesús San Miguel and now with María-Victoria Mateos, coordinates the Spanish Myeloma Group (GEM/PETHEMA) and led the trials of lenalidomide in high-risk smouldering myeloma, the ALCYONE trial of daratumumab in transplant-ineligible patients and the flow cytometry methods for measuring minimal residual disease.","asOf":"2026-09-18","links":[],"tags":[],"related":[],"cancers":["multiple-myeloma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["maria-victoria-mateos"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Salamanca","country":"ES","lat":40.959,"lng":-5.672,"institutionType":"hospital","university":"Universidad de Salamanca","programs":["Multiple myeloma (GEM/PETHEMA)","Minimal residual disease","Haematology"]},{"id":"university-hospital-wales-cardiff","kind":"institution","name":"University Hospital of Wales, Cardiff","aka":["Cardiff and Vale University Health Board","UHW"],"tldr":"Cardiff's liver surgery service, listed by AMMF as a UK centre with cholangiocarcinoma expertise; oncology at Velindre.","summary":"The University Hospital of Wales (Cardiff and Vale University Health Board) provides liver surgery and is on AMMF's list of UK centres with cholangiocarcinoma expertise. Non-surgical cancer treatment for the region is delivered by Velindre Cancer Centre.","asOf":"2026-09-24","links":[{"label":"Cardiff and Vale University Health Board","url":"https://cavuhb.nhs.wales/"},{"label":"AMMF centres list","url":"https://ammf.org.uk/second-opinions-and-liver-disease-centres/"}],"tags":["hpb","nhs","uk"],"related":[],"cancers":["gallbladder","biliary-tract-cancer","cholangiocarcinoma","pancreatic","hcc"],"sections":["surgery"],"technologies":["hepatectomy"],"targets":[],"drugs":[],"companies":[],"institutions":["velindre-cardiff"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Cardiff","country":"GB","lat":51.507,"lng":-3.19,"institutionType":"hospital","website":"https://cavuhb.nhs.wales/","university":"Cardiff University","programs":["Liver surgery","HPB MDT"]},{"id":"southampton-cancer","kind":"institution","name":"University Hospital Southampton / Centre for Cancer Immunology","aka":["UHS","Southampton Centre for Cancer Immunology","CRUK Southampton Centre"],"tldr":"Southampton's university hospital and the UK's first purpose-built cancer immunology centre, known for antibody engineering and lymphoma trials.","summary":"University Hospital Southampton is the tertiary cancer centre for central southern England, and the University of Southampton opened the Centre for Cancer Immunology in 2018, describing it as the UK's first dedicated centre of its kind. Martin Glennie and Mark Cragg's antibody groups defined how Fc receptors and antibody isotype govern anti-CD20, anti-CD40 and other immunomodulatory antibodies, and Peter Johnson led the RATHL trial that established PET-adapted treatment for advanced Hodgkin lymphoma. The Southampton Clinical Trials Unit and CRUK Southampton Centre run national trials in lymphoma, lung and gastrointestinal cancers and in DNA and peptide vaccines. The hospital houses a large children's oncology service and a Wessex regional genomics laboratory.","asOf":"2026-09-09","links":[{"label":"UHS cancer services (page moved; nearest live section)","url":"https://www.uhs.nhs.uk/"},{"label":"Centre for Cancer Immunology","url":"https://www.southampton.ac.uk/research/institutes-centres/centre-for-cancer-immunology"}],"tags":[],"related":[],"cancers":["hodgkin-lymphoma","dlbcl","cll","nsclc","pancreatic","tnbc"],"sections":["immunotherapy","imaging"],"technologies":["monoclonal-antibody","fdg-pet","checkpoint-inhibitor","shared-antigen-vaccine"],"targets":["cd20"],"drugs":[],"companies":[],"institutions":["cruk"],"pathways":[],"terms":["fc-effector","adcc"],"trials":[],"people":["peter-johnson","ellen-copson"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Southampton","country":"GB","lat":50.933,"lng":-1.435,"institutionType":"hospital","website":"https://www.uhs.nhs.uk/","university":"University of Southampton","programs":["Centre for Cancer Immunology","Antibody biology and Fc engineering","Lymphoma trials (RATHL)","Southampton Clinical Trials Unit","Cancer vaccines"]},{"id":"university-hospital-waterford","kind":"institution","name":"University Hospital Waterford","aka":["UHW","Waterford Regional Hospital"],"tldr":"University Hospital Waterford is the regional hospital for the south-east of Ireland, run by the Health Service Executive, with a cancer centre providing surgery, medical oncology and radiotherapy, and a full member of the Organisation of European Cancer Institutes.","summary":"University Hospital Waterford is the regional hospital for the south-east of Ireland, run by the Health Service Executive, with a cancer centre providing surgery, medical oncology and radiotherapy. It is listed by the Organisation of European Cancer Institutes as a full member, which is why it has a page on OnCo. Programme, trial and leadership details are not yet recorded here and should be checked on the institution's own pages.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www2.hse.ie/services/hospitals/university-hospital-waterford/"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["ben-o-sullivan"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Waterford","country":"IE","lat":52.246,"lng":-7.128,"institutionType":"hospital","website":"https://www2.hse.ie/services/hospitals/university-hospital-waterford/","programs":[]},{"id":"usz-zurich","kind":"institution","name":"University Hospital Zurich / Comprehensive Cancer Center Zurich","aka":["USZ","CCCZ","UniversitätsSpital Zürich"],"tldr":"Zurich's university hospital and cancer centre, a world reference in neuro-oncology, melanoma and single-cell tumour imaging.","summary":"The Comprehensive Cancer Center Zurich brings together the University Hospital Zurich, the University of Zurich and ETH Zurich. Michael Weller's neurology department chairs the EORTC Brain Tumor Group and shapes glioma guidelines, and Zurich was a leading site in the glioblastoma trials that introduced temozolomide and tumour-treating fields. Reinhard Dummer's dermatology clinic is one of Europe's foremost melanoma centres and led oncolytic virus and targeted therapy studies, Bernd Bodenmiller's laboratory developed imaging mass cytometry for spatial single-cell tumour analysis, and the haematology and nuclear medicine departments run CAR-T and theranostics programmes. The centre is OECI-accredited and hosts a large early-phase unit.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.usz.ch/en/"},{"label":"Comprehensive Cancer Center Zurich","url":"https://www.cccz.ch"}],"tags":[],"related":[],"cancers":["glioblastoma","melanoma","dlbcl","nsclc"],"sections":["immunotherapy","devices"],"technologies":["single-cell-spatial","oncolytic-virus","ttfields","checkpoint-inhibitor","radioligand-therapy"],"targets":[],"drugs":["optune","talimogene-laherparepvec"],"companies":["novocure","curie-nki-eortc"],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["michael-weller","monika-janicke","reinhard-dummer","markus-g-manz"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Zurich","country":"CH","lat":47.376,"lng":8.551,"institutionType":"hospital","website":"https://www.usz.ch/en/","university":"University of Zurich","programs":["Neuro-oncology (EORTC Brain Tumor Group)","Melanoma and dermato-oncology","Imaging mass cytometry","CAR-T and haematology","Theranostics"]},{"id":"birmingham-cancer-centre","kind":"institution","name":"University Hospitals Birmingham / University of Birmingham Cancer Research Centre","aka":["Queen Elizabeth Hospital Birmingham","CRUK Clinical Trials Unit Birmingham","Institute of Cancer and Genomic Sciences"],"tldr":"Birmingham's Queen Elizabeth Hospital is the West Midlands' cancer centre, with one of the UK's largest stem cell transplant programmes; the university's Cancer Research UK Clinical Trials Unit ran POUT in upper-tract urothelial cancer and FOxTROT in colon cancer, plus paediatric leukaemia trials.","summary":"The Queen Elizabeth Hospital Birmingham is the tertiary cancer centre for the West Midlands, with one of the largest stem cell transplant programmes in the UK and a regional CAR-T service. The University of Birmingham's Cancer Research UK Clinical Trials Unit has run practice-defining trials such as POUT (adjuvant chemotherapy in upper-tract urothelial cancer), FOxTROT with Leeds, and numerous paediatric and leukaemia trials for the UK's children's cancer groups. The Institute of Cancer and Genomic Sciences studies Epstein-Barr virus-driven cancers, lymphoma biology and cancer inflammation, and Birmingham Children's Hospital is a principal treatment centre. The city hosts a CRUK Centre and the Birmingham Health Partners academic health science system.","asOf":"2026-09-09","links":[{"label":"UHB cancer services","url":"https://www.uhb.nhs.uk/services/cancer"},{"label":"CRUK Clinical Trials Unit","url":"https://www.birmingham.ac.uk/research/crctu"}],"tags":[],"related":[],"cancers":["urothelial","colorectal","all-leukemia","hodgkin-lymphoma","pancreatic","rectal-cancer","nsclc","lung-cancer","skin-cancer","merkel-cell-carcinoma"],"sections":["chemotherapy","cell-therapy"],"technologies":["car-t","cytotoxic-chemotherapy","allogeneic-cell-therapy"],"targets":[],"drugs":[],"companies":[],"institutions":["cruk","leeds-cancer-centre"],"pathways":[],"terms":["neoadjuvant-adjuvant"],"trials":["foxtrot","star-trec","national-lung-matrix-trial","violet","mcc-rational-treatment"],"people":["jonathan-brotherton","hisham-mehanna","dion-morton","gary-middleton"],"bottlenecks":["b-trial-design"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Birmingham","country":"GB","lat":52.453,"lng":-1.939,"institutionType":"hospital","website":"https://www.uhb.nhs.uk/services/cancer","university":"University of Birmingham","programs":["CRUK Clinical Trials Unit","Stem cell transplantation and CAR-T","Urothelial and colorectal trials","Paediatric oncology","EBV and lymphoma research"]},{"id":"umcg-groningen","kind":"institution","name":"University Medical Center Groningen Comprehensive Cancer Center","aka":["UMCG","UMCG Cancer Center"],"tldr":"The university hospital of the northern Netherlands, home of the country's first proton therapy centre and accredited by OECI as a Comprehensive Cancer Centre.","summary":"The University Medical Center Groningen is the academic hospital of the University of Groningen and the tertiary cancer centre for the northern Netherlands. Its Comprehensive Cancer Center integrates medical oncology, radiotherapy, haematology, surgical oncology, paediatric oncology and molecular imaging, and it opened the first proton therapy centre in the Netherlands in 2018. UMCG is known for molecular imaging with radiolabelled antibodies and drugs (immuno-PET), for lung and breast cancer research, for radiotherapy model-based selection, and for large-scale population research through the Lifelines cohort. It is accredited by the Organisation of European Cancer Institutes as a Comprehensive Cancer Centre.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.umcg.nl"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":["oeci-accredited","oeci-comprehensive-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":["proton-therapy","proton-therapy-systems"],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["ate-van-der-zee","lukas-b-been"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Groningen","country":"NL","lat":53.221,"lng":6.575,"institutionType":"hospital","website":"https://www.umcg.nl","university":"University of Groningen","programs":["Proton therapy","Molecular imaging (immuno-PET)","Lung and breast cancer research","Paediatric oncology"]},{"id":"university-of-alberta","kind":"institution","name":"University of Alberta","aka":["UAlberta","Faculty of Kinesiology, Sport, and Recreation"],"tldr":"Edmonton university whose exercise oncology group under Kerry Courneya led the CHALLENGE trial, the first to show that a structured exercise programme lengthens survival after colon cancer.","summary":"The University of Alberta is a public research university in Edmonton. Its Faculty of Kinesiology, Sport, and Recreation houses one of the world's leading exercise oncology groups, led by Kerry Courneya, who was first author of the 2025 New England Journal of Medicine report of the CHALLENGE trial, in which a three-year structured exercise programme improved disease-free and overall survival after adjuvant chemotherapy for colon cancer. Clinical cancer care in Edmonton is provided by the Cross Cancer Institute of Cancer Care Alberta.","asOf":"2026-09-18","wikipedia":"https://en.wikipedia.org/wiki/University_of_Alberta","links":[{"label":"University of Alberta","url":"https://www.ualberta.ca"}],"tags":[],"related":[],"cancers":["colorectal"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["cctg"],"institutions":["cancer-care-alberta"],"pathways":[],"terms":[],"trials":[],"people":["kerry-courneya"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Edmonton, AB","country":"CA","lat":53.523,"lng":-113.526,"institutionType":"university","website":"https://www.ualberta.ca","programs":["Exercise oncology","Cancer survivorship research"]},{"id":"arizona-cancer-center","kind":"institution","name":"University of Arizona Cancer Center","aka":["UACC","Arizona Cancer Center"],"tldr":"The University of Arizona Cancer Center in Tucson has been an NCI comprehensive centre since 1990; it built its reputation on skin cancer chemoprevention trials and on colorectal and prostate prevention studies, and it now runs a phase 1 programme and border-health research for a catchment with large Hispanic and Native American populations.","summary":"NCI-designated since 1978 and comprehensive since 1990, the University of Arizona Cancer Center serves a Southwestern catchment with large Hispanic and Native American populations. It built its reputation on cancer prevention science, notably skin cancer chemoprevention trials led from Tucson, and on colorectal and prostate prevention studies. It runs a phase 1 programme, a Skin Cancer Institute and population-science programmes on border health. Clinical care is delivered with Banner Health in Tucson and Phoenix.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/University_of_Arizona_Cancer_Center","links":[{"label":"University of Arizona Cancer Center","url":"https://cancercenter.arizona.edu"}],"tags":[],"related":[],"cancers":["melanoma","cutaneous-scc","basal-cell-carcinoma","colorectal"],"sections":["prevention"],"technologies":["chemoprevention"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["dan-theodorescu"],"bottlenecks":["b-prevention-adoption","b-trial-diversity"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Tucson, AZ","country":"US","lat":32.24,"lng":-110.944,"institutionType":"cancer-center","website":"https://cancercenter.arizona.edu","nci":"comprehensive","university":"University of Arizona","programs":["Skin cancer prevention","Chemoprevention trials","Border and Native American health"]},{"id":"uchicago-cancer","kind":"institution","name":"University of Chicago Medicine Comprehensive Cancer Center","aka":["UCCCC"],"tldr":"Where Charles Huggins proved hormones drive prostate cancer and Janet Rowley found the chromosome translocations behind leukaemia; strong in tumour immunology today.","summary":"NCI-designated since 1973 and comprehensive since 2008, the University of Chicago has two foundational cancer discoveries to its name: Charles Huggins's demonstration that castration controls prostate cancer (Nobel Prize 1966), the origin of hormonal therapy, and Janet Rowley's identification of recurrent chromosomal translocations, including the 9;22 translocation that produces BCR-ABL. Today Thomas Gajewski's laboratory defined the T-cell-inflamed ('hot') tumour phenotype and the gut microbiome's influence on checkpoint response; Everett Vokes established chemoradiotherapy for head and neck cancer; Susan Cohn leads international neuroblastoma risk classification. The centre is building a dedicated cancer hospital on its Hyde Park campus.","asOf":"2026-09-09","links":[{"label":"UChicago Medicine Comprehensive Cancer Center","url":"https://cancer.uchicago.edu"},{"label":"Clinical trials","url":"https://cancer.uchicago.edu/clinical-trials/"}],"tags":[],"related":[],"cancers":["prostate","head-and-neck","neuroblastoma","cml"],"sections":["hormonal","immunotherapy"],"technologies":["androgen-deprivation","microbiome-modulation-io","checkpoint-inhibitor"],"targets":["bcr-abl","androgen-receptor"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["cold-vs-hot"],"trials":[],"people":["everett-vokes","susan-cohn","kunle-odunsi","ralph-weichselbaum","hedy-kindler","thomas-gajewski"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Chicago, IL","country":"US","lat":41.789,"lng":-87.604,"institutionType":"cancer-center","website":"https://cancer.uchicago.edu","nci":"comprehensive","university":"University of Chicago","programs":["Tumour immunology and microbiome","Head and neck cancer","Neuroblastoma (INRG)","Leukaemia genetics"]},{"id":"cincinnati-cancer-center","kind":"institution","name":"University of Cincinnati Cancer Center","aka":["UC Cancer Center","UC Health","University of Cincinnati College of Medicine"],"tldr":"Cancer centre of the University of Cincinnati and UC Health, where John Byrd, who led the ibrutinib trials in chronic lymphocytic leukaemia, chairs the Department of Internal Medicine.","summary":"The University of Cincinnati Cancer Center is the joint cancer centre of the University of Cincinnati College of Medicine, UC Health and Cincinnati Children's Hospital. John Byrd, whose trials at Ohio State established ibrutinib and then acalabrutinib in chronic lymphocytic leukaemia, moved to Cincinnati in 2021 as chair of the Department of Internal Medicine and leads its leukaemia research programme.","asOf":"2026-09-18","links":[],"tags":[],"related":[],"cancers":["cll"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["john-byrd"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Cincinnati, OH","country":"US","lat":39.138,"lng":-84.503,"institutionType":"cancer-center","university":"University of Cincinnati","programs":["Leukaemia","Chronic lymphocytic leukaemia","Experimental haematology"]},{"id":"colorado-cancer-center","kind":"institution","name":"University of Colorado Cancer Center","aka":["CU Cancer Center"],"tldr":"The University of Colorado Cancer Center serves the Rocky Mountain states; its thoracic oncology group defined how ALK, ROS1 and NTRK fusion-driven lung cancers behave and helped bring crizotinib, entrectinib and larotrectinib to patients, and it holds a lung cancer SPORE grant.","summary":"NCI-designated since 1988 and comprehensive since 1997, the CU Cancer Center on the Anschutz Medical Campus serves Colorado and the surrounding mountain states. Its thoracic oncology group, built by Paul Bunn and Fred Hirsch and continued by Ross Camidge and Robert Doebele, defined the clinical behaviour of ALK, ROS1 and NTRK fusion-driven lung cancers and helped bring crizotinib, entrectinib and larotrectinib to patients. The centre holds a lung cancer SPORE, and its partners include UCHealth and Children's Hospital Colorado.","asOf":"2026-09-09","links":[{"label":"University of Colorado Cancer Center","url":"https://medschool.cuanschutz.edu/colorado-cancer-center"},{"label":"Clinical trials","url":"https://medschool.cuanschutz.edu/colorado-cancer-center/clinical-trials"}],"tags":[],"related":[],"cancers":["nsclc"],"sections":["targeted-therapy"],"technologies":["kinase-inhibitors"],"targets":["alk","ros1","ntrk"],"drugs":["crizotinib","entrectinib","larotrectinib","lorlatinib"],"companies":[],"institutions":[],"pathways":[],"terms":["gene-fusion","oncogene-addiction"],"trials":[],"people":["richard-schulick","ross-camidge","sapna-patel"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Aurora, CO","country":"US","lat":39.745,"lng":-104.838,"institutionType":"cancer-center","website":"https://medschool.cuanschutz.edu/colorado-cancer-center","nci":"comprehensive","university":"University of Colorado Anschutz Medical Campus","programs":["Oncogene-driven lung cancer","Lung cancer SPORE","Paediatric oncology (Children's Colorado)"]},{"id":"uf-health-cancer-center","kind":"institution","name":"University of Florida Health Cancer Center","aka":["UF Health Cancer Institute"],"tldr":"Florida's newest NCI-designated centre (2023), with a pioneering proton institute in Jacksonville and personalised mRNA vaccine work in brain tumours.","summary":"UF Health Cancer Center received NCI designation in 2023 and covers north-central Florida from Gainesville. The UF Health Proton Therapy Institute in Jacksonville, opened in 2006, was among the first US proton centres and has treated large numbers of paediatric and prostate patients. Duane Mitchell and Elias Sayour's neuro-oncology immunotherapy programme developed RNA-loaded dendritic cell vaccines and, in 2024, reported a personalised mRNA-lipid particle vaccine that rapidly reprogrammed the immune response in glioblastoma patients. The centre also hosts a large paediatric oncology programme and rural community outreach.","asOf":"2026-09-09","links":[{"label":"UF Health Cancer Center","url":"https://cancer.ufl.edu"},{"label":"UF Health Proton Therapy Institute","url":"https://www.floridaproton.org"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":["glioblastoma","medulloblastoma","prostate"],"sections":["radiation","immunotherapy"],"technologies":["proton-therapy","neoantigen-mrna-vaccine","proton-therapy-systems"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["thomas-george"],"bottlenecks":["b-brain-delivery"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Gainesville, FL","country":"US","lat":29.64,"lng":-82.344,"institutionType":"cancer-center","website":"https://cancer.ufl.edu","nci":"clinical","university":"University of Florida","programs":["Proton therapy (Jacksonville)","Brain tumour immunotherapy and mRNA vaccines","Paediatric oncology"]},{"id":"galway-university-hospital-cancer-centre","kind":"institution","name":"University of Galway / Saolta Cancer Centre","aka":["Galway University Hospitals","HSE West North West Cancer Centre"],"tldr":"The designated cancer centre for the west and north-west of Ireland, run by the Saolta hospital group with the University of Galway and accredited by OECI as a Cancer Centre.","summary":"Galway University Hospitals form one of the eight designated cancer centres of Ireland's National Cancer Control Programme and the academic cancer centre for HSE West North West, in partnership with the University of Galway. The centre provides medical oncology, radiation oncology, surgical oncology and haematology for the western seaboard and hosts the Lambe Institute for Translational Research and the university's Cancer Research programme, with strengths in breast cancer, prostate cancer and translational biomarker work. It is accredited by the Organisation of European Cancer Institutes as a Cancer Centre.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.saolta.ie"}],"tags":["oeci-accredited","oeci-cancer-centre"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["michael-kerin","joseph-martin"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Galway","country":"IE","lat":53.277,"lng":-9.066,"institutionType":"hospital","website":"https://www.saolta.ie","university":"University of Galway","programs":["Designated cancer centre","Lambe Institute translational research","Radiation oncology"]},{"id":"hawaii-cancer-center","kind":"institution","name":"University of Hawai'i Cancer Center","aka":[],"tldr":"The only NCI-designated centre in the Pacific, co-founder of the Multiethnic Cohort Study of cancer risk across Asian, Pacific Islander and other populations.","summary":"NCI-designated since 1996, the University of Hawai'i Cancer Center serves Hawai'i and the US-affiliated Pacific islands and is the only NCI centre in the region. With USC it founded the Multiethnic Cohort Study in 1993, following Japanese American, Native Hawaiian, Latino, Black and white participants to dissect ethnic differences in cancer risk, diet and genetics. Research strengths follow the population: liver and stomach cancer linked to viral hepatitis and H. pylori, tobacco and betel use, and disparities affecting Native Hawaiians and Pacific Islanders. The centre runs early-phase trials with Hawai'i's hospitals through the Hawai'i Cancer Consortium.","asOf":"2026-09-09","links":[{"label":"University of Hawai'i Cancer Center","url":"https://www.uhcancercenter.org"},{"label":"Clinical trials","url":"https://www.uhcancercenter.org/clinical-trials"}],"tags":[],"related":[],"cancers":["hcc","gastric","nsclc"],"sections":["prevention"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["usc-norris"],"pathways":[],"terms":["real-world-evidence"],"trials":[],"people":["naoto-ueno"],"bottlenecks":["b-trial-diversity"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Honolulu, HI","country":"US","lat":21.297,"lng":-157.865,"institutionType":"cancer-center","website":"https://www.uhcancercenter.org","nci":"clinical","university":"University of Hawai'i at Mānoa","programs":["Multiethnic Cohort Study","Pacific Islander cancer disparities","Hawai'i Cancer Consortium trials"]},{"id":"ummc-kuala-lumpur","kind":"institution","name":"University of Malaya Medical Centre","aka":["UMMC","Pusat Perubatan Universiti Malaya","UM Cancer Research Institute"],"tldr":"Malaysia's leading academic hospital, with the UM Cancer Research Institute and landmark multi-ethnic breast cancer genetics and outcomes studies.","summary":"The University of Malaya Medical Centre opened in 1968 as the teaching hospital of Malaysia's oldest university and remains its top research hospital. Its oncology programmes include breast surgery and medical oncology, whose Malaysian Breast Cancer Genetic Study with Cancer Research Malaysia (Teo Soo-Hwang) produced the largest Asian breast cancer genetic risk datasets and polygenic risk research; clinical oncology and radiotherapy with early adoption of advanced techniques; haematology and transplant; and colorectal and hepatobiliary surgery. The UM Cancer Research Institute and the Faculty of Medicine's cohort studies inform Malaysia's national cancer control policy and Asian-specific risk models.","asOf":"2026-09-09","links":[{"label":"UMMC","url":"https://www.ummc.edu.my"},{"label":"Cancer Research Malaysia","url":"https://www.cancerresearch.my"}],"tags":[],"related":[],"cancers":["breast-hr-positive","tnbc","colorectal","head-and-neck"],"sections":["prevention","diagnostics"],"technologies":["germline-testing","imrt-igrt"],"targets":["brca"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["mohd-zukiflee-abu-bakar"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Kuala Lumpur","country":"MY","lat":3.113,"lng":101.654,"institutionType":"hospital","website":"https://www.ummc.edu.my","university":"University of Malaya","programs":["Breast cancer genetics (Malaysian Breast Cancer Genetic Study)","Clinical oncology","Haematology","UM Cancer Research Institute"]},{"id":"maryland-greenebaum","kind":"institution","name":"University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center","aka":["UMGCCC"],"tldr":"Baltimore's second NCI comprehensive centre, with the Maryland Proton Treatment Center and the GammaPod breast radiotherapy system invented on campus.","summary":"NCI-designated in 2008 and comprehensive since 2016, the Greenebaum Comprehensive Cancer Center serves Baltimore and the state of Maryland alongside Johns Hopkins. Radiation oncology is a signature strength: the Maryland Proton Treatment Center opened in 2016, and the GammaPod, a stereotactic radiotherapy device for breast cancer, was invented at the University of Maryland. The centre runs a large blood and marrow transplant programme and early engineered T-cell trials in myeloma, and studies cancer disparities in Baltimore's Black population.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/University_of_Maryland_Marlene_and_Stewart_Greenebaum_Comprehensive_Cancer_Center","links":[{"label":"Greenebaum Comprehensive Cancer Center","url":"https://www.umgccc.org"},{"label":"Maryland Proton Treatment Center","url":"https://www.mdproton.com"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":["multiple-myeloma","breast-hr-positive"],"sections":["radiation"],"technologies":["proton-therapy","sbrt","allogeneic-hsct","tcr-t","proton-therapy-systems"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["taofeek-owonikoko"],"bottlenecks":["b-trial-diversity"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Baltimore, MD","country":"US","lat":39.288,"lng":-76.625,"institutionType":"cancer-center","website":"https://www.umgccc.org","nci":"comprehensive","university":"University of Maryland, Baltimore","programs":["Proton therapy","Stereotactic breast radiotherapy (GammaPod)","Transplant and cellular therapy"]},{"id":"michigan-rogel","kind":"institution","name":"University of Michigan Rogel Cancer Center","aka":[],"tldr":"Michigan's Rogel Cancer Center is home to the TMPRSS2-ERG discovery, MI-ONCOSEQ, and pioneering degrader chemistry (Wang).","summary":"The University of Michigan Rogel Cancer Center in Ann Arbor holds NCI comprehensive designation and is home to the TMPRSS2-ERG discovery in prostate cancer, the MI-ONCOSEQ precision oncology sequencing programme, and pioneering targeted protein degradation chemistry. Arul M. Chinnaiyan's prostate genomics and Shaomeng Wang's MDM2 and BET degraders are its best-known contributions, with Eric R. Fearon, Max S. Wicha, Weiping Zou, Costas A. Lyssiotis and Lori J. Pierce among the people OnCo lists. OnCo links it to prostate cancer and to PROTACs and molecular glues. Whether degraders can reach targets that inhibitors could not, and do so safely, is the open question its chemistry programme faces. Its prostate genomics, degrader chemistry and precision oncology programmes are listed below.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/University_of_Michigan_Rogel_Cancer_Center","links":[{"label":"Official website","url":"https://www.rogelcancercenter.org"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":["prostate"],"sections":[],"technologies":["protac-degrader","proton-therapy","proton-therapy-systems"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["eric-fearon","arul-chinnaiyan","shaomeng-wang","max-wicha","weiping-zou","costas-lyssiotis","lori-pierce","richard-rogel","theodore-lawrence"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Ann Arbor, MI","country":"US","lat":42.283,"lng":-83.728,"institutionType":"cancer-center","website":"https://www.rogelcancercenter.org","nci":"comprehensive","university":"University of Michigan","programs":["Prostate genomics","Degrader chemistry","Precision oncology"]},{"id":"unm-cancer-center","kind":"institution","name":"University of New Mexico Comprehensive Cancer Center","aka":["UNM Cancer Center"],"tldr":"New Mexico's only cancer centre, an NCI comprehensive centre serving a majority-minority state and home of the state-wide HPV Pap Registry.","summary":"NCI-designated in 2005 and comprehensive since 2015, the UNM Comprehensive Cancer Center is the only cancer centre in New Mexico, a state with large Hispanic and Native American populations and unusual exposures such as uranium mining. Cosette Wheeler's New Mexico HPV Pap Registry is the only US state-wide cervical screening registry and has informed national HPV testing policy. Cheryl Willman, now Mayo's cancer centre director, led the centre for two decades while defining Philadelphia-like acute lymphoblastic leukaemia. The UNM Center for Molecular Discovery pioneered high-throughput flow cytometry for drug screening.","asOf":"2026-09-09","links":[{"label":"UNM Comprehensive Cancer Center","url":"https://cancer.unm.edu"}],"tags":[],"related":[],"cancers":["cervical","all-leukemia"],"sections":["prevention"],"technologies":["hpv-testing","hpv-vaccine","functional-drug-testing"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["cheryl-willman"],"bottlenecks":["b-trial-diversity"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Albuquerque, NM","country":"US","lat":35.087,"lng":-106.618,"institutionType":"cancer-center","website":"https://cancer.unm.edu","nci":"comprehensive","university":"University of New Mexico","programs":["Cervical screening (NM HPV Pap Registry)","Leukaemia genomics","Native American and Hispanic cancer health"]},{"id":"university-of-pisa","kind":"institution","name":"University of Pisa / Azienda Ospedaliero-Universitaria Pisana","aka":["Università di Pisa","AOUP","Pisa University Hospital"],"tldr":"Italian university and hospital whose endocrinology department, under Rossella Elisei, is one of Europe's largest thyroid cancer centres and led the EXAM trial of cabozantinib.","summary":"The University of Pisa and its hospital, the Azienda Ospedaliero-Universitaria Pisana, run one of Europe's largest thyroid disease units. The Endocrinology Unit's thyroid cancer group, led by Rossella Elisei, coordinated EXAM, the phase 3 trial reported in the Journal of Clinical Oncology in 2013 in which cabozantinib lengthened progression-free survival in progressive medullary thyroid cancer, and studies the prognostic value of RET mutations and calcitonin doubling time.","asOf":"2026-09-18","links":[{"label":"Università di Pisa","url":"https://www.unipi.it"}],"tags":[],"related":[],"cancers":["medullary-thyroid-cancer","thyroid"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["rossella-elisei"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Pisa","country":"IT","lat":43.717,"lng":10.401,"institutionType":"university","website":"https://www.unipi.it","programs":["Thyroid cancer","Endocrinology","RET-driven cancers"]},{"id":"university-of-western-australia","kind":"institution","name":"University of Western Australia","aka":["UWA","National Centre for Asbestos Related Diseases (NCARD)"],"tldr":"Perth university whose medical school and National Centre for Asbestos Related Diseases, led by Anna Nowak, run the world's largest clinical research programme in mesothelioma.","summary":"The University of Western Australia in Perth hosts the National Centre for Asbestos Related Diseases (NCARD), a joint centre with the Institute for Respiratory Health and Sir Charles Gairdner Hospital, where Western Australia's history of blue asbestos mining at Wittenoom has produced one of the world's largest mesothelioma cohorts. Anna Nowak, medical oncologist and dean of medicine, led the DREAM trials of durvalumab with chemotherapy in mesothelioma and chairs the Australasian Lung Cancer Trials Group's mesothelioma programme.","asOf":"2026-09-18","wikipedia":"https://en.wikipedia.org/wiki/University_of_Western_Australia","links":[{"label":"University of Western Australia","url":"https://www.uwa.edu.au"}],"tags":[],"related":[],"cancers":["mesothelioma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["anna-nowak"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Perth","country":"AU","lat":-31.98,"lng":115.818,"institutionType":"university","website":"https://www.uwa.edu.au","programs":["Mesothelioma (NCARD)","Thoracic oncology trials","Medical education"]},{"id":"uw-carbone","kind":"institution","name":"University of Wisconsin Carbone Cancer Center","aka":["UWCCC","McArdle Laboratory"],"tldr":"One of the original 1973 NCI comprehensive centres, where 5-fluorouracil was synthesised, reverse transcriptase was discovered and TomoTherapy was invented.","summary":"UW Carbone is one of the original NCI comprehensive centres (1973) and grew out of the McArdle Laboratory for Cancer Research, founded in 1940 as the first US university department devoted to cancer research. Charles Heidelberger synthesised 5-fluorouracil at McArdle in 1957; Howard Temin discovered reverse transcriptase here (Nobel Prize 1975); Rock Mackie invented TomoTherapy, the first CT-integrated intensity-modulated radiotherapy system. Paul Sondel's anti-GD2 immunotherapy programme helped establish dinutuximab for neuroblastoma through the Children's Oncology Group, and Douglas McNeel develops DNA vaccines for prostate cancer. The centre is named for Paul Carbone, long-time chair of ECOG.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/University_of_Wisconsin_Carbone_Cancer_Center","links":[{"label":"UW Carbone Cancer Center","url":"https://cancer.wisc.edu"},{"label":"Clinical trials (archived copy)","url":"https://web.archive.org/web/20250905154857/https://cancer.wisc.edu/research/clinical-trials/"}],"tags":[],"related":[],"cancers":["neuroblastoma","prostate","colorectal"],"sections":[],"technologies":["imrt-igrt","cytotoxic-chemotherapy","shared-antigen-vaccine","mr-linac","tomotherapy"],"targets":["gd2"],"drugs":["dinutuximab"],"companies":["childrens-oncology-group","ecog-acrin"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["christian-capitini"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Madison, WI","country":"US","lat":43.077,"lng":-89.43,"institutionType":"cancer-center","website":"https://cancer.wisc.edu","nci":"comprehensive","university":"University of Wisconsin-Madison","programs":["Radiation oncology (TomoTherapy heritage)","Paediatric immunotherapy (anti-GD2)","Prostate cancer vaccines","Cancer biology (McArdle)"]},{"id":"upmc-hillman","kind":"institution","name":"UPMC Hillman Cancer Center","aka":["University of Pittsburgh Cancer Institute"],"tldr":"UPMC Hillman is Pittsburgh's NCI comprehensive centre; Bernard Fisher ran the NSABP breast trials here, Yuan Chang and Patrick Moore discovered Kaposi sarcoma herpesvirus and Merkel cell polyomavirus, and its LAG-3 biology underpins the melanoma drug relatlimab.","summary":"NCI comprehensive since 1990, UPMC Hillman spans western Pennsylvania through UPMC's network. Bernard Fisher led the NSABP from Pittsburgh, proving with B-06 that lumpectomy plus radiation equals mastectomy and with P-1 that tamoxifen prevents breast cancer; NSABP lives on within NRG Oncology. Yuan Chang and Patrick Moore discovered Kaposi sarcoma herpesvirus in 1994 and Merkel cell polyomavirus in 2008. Dario Vignali's LAG-3 biology underpins relatlimab, Hassane Zarour and Diwakar Davar showed faecal microbiota transplant can overcome anti-PD-1 resistance in melanoma, and Greg Delgoffe studies T-cell metabolism in tumours. The centre also has a large head and neck cancer immunotherapy programme.","asOf":"2026-09-09","links":[{"label":"UPMC Hillman Cancer Center","url":"https://hillman.upmc.com"},{"label":"Clinical trials","url":"https://hillman.upmc.com/research/clinical-trials"}],"tags":[],"related":[],"cancers":["kaposi-sarcoma","merkel-cell-carcinoma","melanoma","head-and-neck","breast-hr-positive"],"sections":[],"technologies":["microbiome-modulation-io","gamma-knife","radiosurgery-srs","cyberknife"],"targets":["lag3"],"drugs":["tamoxifen","relatlimab-nivolumab","cetuximab"],"companies":["nrg-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["jason-luke"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Pittsburgh, PA","country":"US","lat":40.455,"lng":-79.96,"institutionType":"cancer-center","website":"https://hillman.upmc.com","nci":"comprehensive","university":"University of Pittsburgh","programs":["Breast cancer trials (NSABP heritage)","Tumour virology","Melanoma immunotherapy and microbiome","LAG-3 biology"]},{"id":"uppsala-akademiska","kind":"institution","name":"Uppsala University Hospital / Uppsala University","aka":["Akademiska sjukhuset","Skandion Clinic","Rudbeck Laboratory"],"tldr":"Uppsala University Hospital is Sweden's oldest; its neuroendocrine tumour centre built by Kjell Öberg is an ENETS Centre of Excellence with long experience of somatostatin analogues and radionuclide therapy, and Sweden's national Skandion proton clinic opened next door in 2015.","summary":"Akademiska sjukhuset and Uppsala University form one of Scandinavia's leading cancer research environments. Uppsala's neuroendocrine tumour centre, built by Kjell Öberg, is an ENETS Centre of Excellence with long experience of somatostatin analogues and peptide receptor radionuclide therapy, and Bengt Glimelius's group shaped Nordic rectal cancer radiotherapy trials. The Skandion Clinic, Sweden's national proton therapy facility co-owned by the university regions, opened in Uppsala in 2015 using IBA equipment. Tobias Sjöblom's laboratory contributed to the first colorectal cancer exome sequencing and runs the U-CAN biobank, Uppsala scientists founded Olink Proteomics, and the Uppsala Clinical Research Center supports national trials.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.akademiska.se"},{"label":"Skandion Clinic","url":"https://www.skandionkliniken.se"}],"tags":[],"related":[],"cancers":["neuroendocrine","colorectal","prostate","glioblastoma"],"sections":["radiopharma","radiation"],"technologies":["proton-therapy","radioligand-therapy","proteomics","wes-wgs"],"targets":["sstr2"],"drugs":["lutathera"],"companies":["iba"],"institutions":["karolinska"],"pathways":[],"terms":[],"trials":[],"people":["marianne-van-rooijen"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Uppsala","country":"SE","lat":59.849,"lng":17.637,"institutionType":"hospital","website":"https://www.akademiska.se","university":"Uppsala University","programs":["Neuroendocrine tumour centre","Skandion proton clinic","Gastrointestinal radiotherapy trials","U-CAN biobank","Proteomics"]},{"id":"usc-norris","kind":"institution","name":"USC Norris Comprehensive Cancer Center","aka":[],"tldr":"USC Norris was one of the first eight NCI comprehensive cancer centres in 1973; Peter Jones's work here on 5-azacytidine and DNA methylation founded cancer epigenetic therapy, Heinz-Josef Lenz leads its gastrointestinal and SWOG colorectal trials, and its Multiethnic Cohort Study tracks cancer risk across ethnic groups.","summary":"USC Norris was among the first eight centres to receive NCI comprehensive designation in 1973. Peter Jones's work here on 5-azacytidine and DNA methylation in the early 1980s founded the field of cancer epigenetic therapy. Heinz-Josef Lenz leads GI oncology and SWOG colorectal trials, and the Multiethnic Cohort Study run with the University of Hawai'i is one of the largest studies of cancer risk across ethnic groups. The centre serves Los Angeles County's diverse population and runs a broad early-phase trial programme.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/USC_Norris_Comprehensive_Cancer_Center","links":[{"label":"USC Norris Comprehensive Cancer Center","url":"https://uscnorriscancer.usc.edu"},{"label":"Clinical trials","url":"https://uscnorriscancer.usc.edu/clinical-trials/"}],"tags":[],"related":[],"cancers":["colorectal","aml","mds"],"sections":["epigenetics"],"technologies":["epigenetic-drugs","methylation-profiling"],"targets":[],"drugs":["azacitidine"],"companies":["swog"],"institutions":["hawaii-cancer-center"],"pathways":[],"terms":[],"trials":[],"people":["heinz-josef-lenz"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Los Angeles, CA","country":"US","lat":34.062,"lng":-118.202,"institutionType":"cancer-center","website":"https://uscnorriscancer.usc.edu","nci":"comprehensive","university":"University of Southern California","programs":["Cancer epigenetics","GI oncology (SWOG)","Multiethnic Cohort Study"]},{"id":"uva-cancer-center","kind":"institution","name":"UVA Comprehensive Cancer Center","aka":["University of Virginia Cancer Center"],"tldr":"Virginia's first NCI comprehensive centre (2021), a leader in melanoma peptide vaccines and therapeutic focused ultrasound.","summary":"NCI-designated in 1987, UVA became Virginia's first comprehensive cancer centre in 2021 and serves Charlottesville and the Appalachian south-west of the state. Craig Slingluff's decades of melanoma peptide vaccine trials made UVA a reference site for cancer vaccine immunology, complemented by Timothy Bullock's T-cell work. UVA is one of the world's leading centres for therapeutic focused ultrasound, with the Focused Ultrasound Foundation based in Charlottesville and trials in tumour ablation and immune priming. Director Thomas Loughran is the leading authority on large granular lymphocytic leukaemia, and the centre has a busy transplant and haematology service.","asOf":"2026-09-09","links":[{"label":"UVA Comprehensive Cancer Center","url":"https://uvahealth.com/services/cancer"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":["immunotherapy"],"technologies":["shared-antigen-vaccine","hifu-histotripsy","bbb-focused-ultrasound","histotripsy-immune-priming"],"targets":[],"drugs":[],"companies":["insightec"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["thomas-loughran"],"bottlenecks":["b-immunotherapy-response"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Charlottesville, VA","country":"US","lat":38.031,"lng":-78.499,"institutionType":"cancer-center","website":"https://uvahealth.com/services/cancer","nci":"comprehensive","university":"University of Virginia","programs":["Melanoma vaccines","Focused ultrasound","Haematologic malignancies"]},{"id":"uz-leuven","kind":"institution","name":"UZ Leuven / Leuven Cancer Institute","aka":["Leuvens Kankerinstituut","LKI","University Hospitals Leuven"],"tldr":"Belgium's largest university hospital and an OECI-accredited comprehensive cancer centre, with world-class gastrointestinal, gynaecological and angiogenesis research.","summary":"The Leuven Cancer Institute coordinates cancer care and research across UZ Leuven and KU Leuven and holds OECI comprehensive cancer centre status. Eric Van Cutsem's gastrointestinal group led the CRYSTAL and other trials that defined anti-EGFR therapy in RAS wild-type colorectal cancer, Ignace Vergote shaped surgical and medical management of ovarian cancer through EORTC and ENGOT trials, and Frédéric Amant founded the international network on cancer during pregnancy. The VIB-KU Leuven Center for Cancer Biology (Peter Carmeliet, Diether Lambrechts, Jean-Christophe Marine) is a leading site for angiogenesis, tumour genomics and melanoma research, and Hans Wildiers is a reference in geriatric oncology. The ParTICLe proton therapy centre opened on the Gasthuisberg campus in 2020.","asOf":"2026-09-09","links":[{"label":"Leuven Cancer Institute","url":"https://www.uzleuven.be"},{"label":"VIB-KU Leuven Center for Cancer Biology","url":"https://cancerbiology.sites.vib.be"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":["colorectal","ovarian","pancreatic","melanoma","cervical"],"sections":["targeted-therapy","radiation"],"technologies":["proton-therapy","antiangiogenic","geriatric-assessment","monoclonal-antibody","proton-therapy-systems"],"targets":["egfr","vegf"],"drugs":[],"companies":["iba","curie-nki-eortc"],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["paul-herijgers","eric-van-cutsem","ignace-vergote"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Leuven","country":"BE","lat":50.879,"lng":4.674,"institutionType":"cancer-center","website":"https://www.uzleuven.be","university":"KU Leuven","programs":["Gastrointestinal oncology","Gynaecological oncology","VIB-KU Leuven Center for Cancer Biology","ParTICLe proton therapy","Geriatric oncology"]},{"id":"vall-dhebron","kind":"institution","name":"Vall d'Hebron University Hospital / VHIO","aka":["Vall d’Hebron Barcelona Hospital Campus","Vall d'Hebron Barcelona Hospital Campus"],"tldr":"Vall d'Hebron is Spain's leading cancer research hospital and a global leader in phase 1 and breast cancer ADC trials.","summary":"Vall d'Hebron University Hospital and its research arm VHIO in Barcelona are Spain's leading cancer research centre and rank twenty-eighth in the Newsweek/Statista oncology list. Under Tabernero and Javier Cortés it has led DESTINY-Breast03 and DESTINY-Breast09, the TROPION-Breast programme, and the BEACON and BREAKWATER colorectal trials that established encorafenib in BRAF V600E-mutated disease, and it runs one of Europe's largest phase 1 units, with Elena Garralda, Cristina Saura, Enriqueta Felip and Elena Élez also listed. OnCo links it to the MYC and TGF-beta pathways, to the SOLTI and CNIO networks, and to ideas on drugging MYC directly and on hospital-exemption cell therapies. Keeping academic independence while leading so many company trials is the standing question. Its breast ADC and colorectal programmes are the ones to read.","asOf":"2026-09-04","links":[{"label":"Official website","url":"https://vhio.net"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["encorafenib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["destiny-breast03","destiny-breast09"],"people":["elena-garralda","cristina-saura","elena-elez","enriqueta-felip","javier-cortes","joaquin-arribas","josep-tabernero","albert-salazar-soler"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Barcelona","country":"ES","lat":41.427,"lng":2.141,"institutionType":"cancer-center","website":"https://vhio.net","newsweekOncology2026":28,"programs":["Breast ADC trials (Cortés)","Colorectal (Tabernero)","Phase 1"]},{"id":"vanderbilt-ingram","kind":"institution","name":"Vanderbilt-Ingram Cancer Center","aka":["VICC"],"tldr":"Tennessee's NCI comprehensive centre, birthplace of the My Cancer Genome knowledge base and the molecular subtypes of triple-negative breast cancer.","summary":"NCI-designated in 1995 and comprehensive since 2001, Vanderbilt-Ingram serves Tennessee and the mid-South. William Pao, who had discovered the EGFR T790M resistance mutation, launched My Cancer Genome here in 2011, one of the first public precision-oncology knowledge bases. Brian Lehmann and Jennifer Pietenpol defined the molecular subtypes of triple-negative breast cancer, Justin Balko studies immunotherapy in TNBC, and Douglas Johnson's work on immune-related adverse events shaped their management. The Southern Community Cohort Study, run from Vanderbilt, is a major resource on cancer disparities in the South. Kimryn Rathmell moved from chairing medicine here to directing the NCI in 2023.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Vanderbilt-Ingram_Cancer_Center","links":[{"label":"Vanderbilt-Ingram Cancer Center","url":"https://www.vicc.org"},{"label":"Clinical trials","url":"https://www.vicc.org/clinical-trials"},{"label":"My Cancer Genome","url":"https://www.mycancergenome.org"}],"tags":[],"related":[],"cancers":["tnbc","nsclc","melanoma","colorectal"],"sections":[],"technologies":["cgp"],"targets":["egfr","pik3ca"],"drugs":["osimertinib"],"companies":[],"institutions":["nci"],"pathways":[],"terms":["irae"],"trials":[],"people":["martha-ingram","brian-rini"],"bottlenecks":["b-trial-diversity"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Nashville, TN","country":"US","lat":36.141,"lng":-86.803,"institutionType":"cancer-center","website":"https://www.vicc.org","nci":"comprehensive","university":"Vanderbilt University","programs":["Precision oncology (My Cancer Genome)","TNBC subtypes","Immune-related adverse events","Southern Community Cohort"]},{"id":"vcu-massey","kind":"institution","name":"VCU Massey Comprehensive Cancer Center","aka":["Massey Cancer Center"],"tldr":"Richmond's NCI comprehensive cancer centre, led by Robert Winn and known for community-engaged research on cancer health equity.","summary":"NCI-designated since 1975 and now a comprehensive centre, VCU Massey serves central and southern Virginia from Richmond. Under director Robert Winn it has made community-engaged research and health equity its organising principle, pairing population science across a catchment that includes rural Southside Virginia with basic research in haematologic malignancies and cancer cell signalling led by Steven Grant and Paul Dent. Massey runs VCU Health's cancer service line, a phase 1 programme and NCI cooperative group trials, and the 'Facts & Faith Fridays' partnership with Black churches became a national model for outreach.","asOf":"2026-09-09","links":[{"label":"VCU Massey Comprehensive Cancer Center","url":"https://www.masseycancercenter.org"},{"label":"Clinical trials","url":"https://www.masseycancercenter.org/clinical-trials"}],"tags":[],"related":[],"cancers":["aml","multiple-myeloma","nsclc"],"sections":["prevention"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["real-world-evidence"],"trials":[],"people":["robert-winn"],"bottlenecks":["b-trial-diversity","b-care-fragmentation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Richmond, VA","country":"US","lat":37.54,"lng":-77.43,"institutionType":"cancer-center","website":"https://www.masseycancercenter.org","nci":"comprehensive","university":"Virginia Commonwealth University","programs":["Community-engaged research","Haematologic malignancies","Cancer cell signalling"]},{"id":"vejle-cancer-centre","kind":"institution","name":"Vejle Hospital Cancer Centre (Lillebaelt Hospital)","aka":["Sygehus Lillebælt Vejle","Vejle Sygehus"],"tldr":"Denmark's designated 'patients' cancer hospital', a regional centre in Vejle with OECI Cancer Centre accreditation and a strong record in patient-reported outcomes research.","summary":"Vejle Hospital is part of Lillebaelt Hospital, University Hospital of Southern Denmark, and was designated by the Region of Southern Denmark as its specialist cancer hospital. Its departments of oncology, radiotherapy, clinical genetics, pathology and radiology are organised around fast diagnostic pathways, and the hospital has built an international profile in patient-reported outcome measures, geriatric oncology and colorectal and prostate cancer research. It holds OECI Cancer Centre accreditation and works with the University of Southern Denmark on clinical research, including the Danish Colorectal Cancer Center South.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.sygehuslillebaelt.dk"}],"tags":["oeci-accredited","oeci-cancer-centre"],"related":[],"cancers":["colorectal","prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["christian-sauvr"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Vejle","country":"DK","lat":55.709,"lng":9.536,"institutionType":"hospital","website":"https://www.sygehuslillebaelt.dk","programs":["Patient-reported outcomes","Colorectal cancer research","Radiotherapy"]},{"id":"velindre-cardiff","kind":"institution","name":"Velindre Cancer Centre","aka":["Velindre University NHS Trust","Canolfan Ganser Felindre"],"tldr":"Wales's specialist non-surgical cancer centre, providing radiotherapy and systemic therapy for south-east Wales and hosting the Wales Cancer Research Centre.","summary":"Velindre Cancer Centre, part of Velindre University NHS Trust, has provided specialist cancer treatment in Cardiff since 1956 and is the tertiary radiotherapy and medical oncology centre for south-east Wales. With Cardiff University it hosts the Wales Cancer Research Centre and the Wales Cancer Trials Unit, which coordinates UK and international trials in lung, colorectal, prostate and rare cancers, and works with the Wales Research and Diagnostic PET Imaging Centre. A new Velindre Cancer Centre is being built to expand radiotherapy, stereotactic and clinical trials capacity. The trust also runs the Welsh Blood Service and supports outreach clinics across the region.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Velindre_Cancer_Centre","links":[{"label":"Homepage","url":"https://velindre.nhs.wales"},{"label":"Wales Cancer Research Centre","url":"https://www.walescancerresearchcentre.org"}],"tags":[],"related":[],"cancers":["nsclc","colorectal","prostate","head-and-neck","skin-cancer","cutaneous-scc"],"sections":["radiation","chemotherapy"],"technologies":["imrt-igrt","sbrt","brachytherapy","pet-ct"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["coin","spot-it","scc-after"],"people":["carl-james","jacinta-abraham"],"bottlenecks":["b-care-fragmentation"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Cardiff","country":"GB","lat":51.521,"lng":-3.228,"institutionType":"cancer-center","website":"https://velindre.nhs.wales","university":"Cardiff University","programs":["Radiotherapy and stereotactic radiotherapy","Wales Cancer Trials Unit","Wales Cancer Research Centre","Systemic anticancer therapy outreach"]},{"id":"lhsc-verspeeten","kind":"institution","name":"Verspeeten Family Cancer Centre, London Health Sciences Centre","aka":["London Regional Cancer Program"],"tldr":"The Verspeeten Family Cancer Centre at London Health Sciences Centre is the regional cancer centre for south-western Ontario; with Western University it led SABR-COMET, the Canadian trial of stereotactic radiotherapy for patients with a few metastases.","summary":"The Verspeeten Family Cancer Centre, formerly the London Regional Cancer Program, is the Ontario Health regional cancer centre for south-western Ontario, located at London Health Sciences Centre's Victoria Hospital. It provides radiation oncology, medical oncology, haematology and stem cell transplantation, surgical oncology and supportive care, and hosts a large clinical trials programme. Research with Western University and Lawson Research Institute includes radiotherapy trials (the centre led the Canadian trials of stereotactic radiotherapy for oligometastatic disease, SABR-COMET), imaging and translational oncology, and Western's Cancer Research Laboratory Program.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.lhsc.on.ca"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["sbrt"],"targets":[],"drugs":[],"companies":[],"institutions":["ontario-health-cancer-care-ontario"],"pathways":[],"terms":[],"trials":[],"people":["tammy-quigley"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"London, ON","country":"CA","lat":42.961,"lng":-81.225,"institutionType":"hospital","website":"https://www.lhsc.on.ca","university":"Western University","programs":["Regional cancer centre","Radiotherapy trials (SABR-COMET)","Stem cell transplantation"]},{"id":"k-hospital-hanoi","kind":"institution","name":"Vietnam National Cancer Hospital (K Hospital)","aka":["K Hospital","Bệnh viện K","National Cancer Institute of Vietnam"],"tldr":"Vietnam's national cancer hospital and institute, the country's largest cancer facility and the coordinator of its cancer registry and control programme.","summary":"K Hospital, formally the Vietnam National Cancer Hospital, was founded in Hanoi in 1969 on the site of the French-era Institut du Radium de l'Indochine (1923) and is the top-level cancer hospital of Vietnam's Ministry of Health, with three campuses including the large Tan Trieu site. It houses the National Cancer Institute of Vietnam, coordinates the Hanoi and national cancer registries and the national cancer control programme, and delivers the country's largest volumes of surgical, medical and radiation oncology, nuclear medicine and paediatric oncology. K Hospital is increasingly active in international trials in lung, gastric, liver and nasopharyngeal cancer and in partnerships to expand radiotherapy and palliative care across Vietnam.","asOf":"2026-09-09","links":[{"label":"K Hospital","url":"https://benhvienk.vn"}],"tags":[],"related":["global-oncology-access","cancer-registries-surveillance"],"cancers":["hcc","nsclc","gastric","head-and-neck","cervical"],"sections":["radiation","prevention"],"technologies":["imrt-igrt","pet-ct"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["le-van-quang"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Hanoi","country":"VN","lat":21.029,"lng":105.847,"institutionType":"cancer-center","website":"https://benhvienk.vn","programs":["National Cancer Institute of Vietnam","Cancer registry and control","Radiation oncology","Nasopharyngeal and liver cancer"]},{"id":"santaros-klinikos","kind":"institution","name":"Vilnius University Hospital Santaros Klinikos","aka":["Santaros klinikos","Vilniaus universiteto ligoninė Santaros klinikos","Vilnius University Hospital Santaros Clinics"],"tldr":"Santaros Klinikos is the teaching hospital of Vilnius University's Faculty of Medicine and a full member of the Organisation of European Cancer Institutes.","summary":"Vilnius University Hospital Santaros Klinikos is a teaching hospital of the Vilnius University Faculty of Medicine, co-funded by the Lithuanian Ministry of Health and the university, with a history going back to 1980. It provides specialised cancer care, including haematology and transplantation, alongside the National Cancer Institute in Vilnius, and is listed by the Organisation of European Cancer Institutes as a full member. Programme, trial and leadership details are not yet recorded here and should be checked on the hospital's own pages.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Vilnius_University_Hospital_Santaros_Clinics","links":[{"label":"Official website","url":"https://www.santa.lt"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Vilnius_University_Hospital_Santaros_Clinics"}],"tags":[],"related":["nci-vilnius","klaipeda-university-hospital"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["tomas-jovaisa"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Vilnius","country":"LT","lat":54.753,"lng":25.278,"institutionType":"hospital","website":"https://www.santa.lt","programs":[]},{"id":"vivli","kind":"institution","name":"Vivli","aka":["Vivli Center for Global Clinical Research Data"],"tldr":"The non-profit platform through which pharmaceutical companies and funders share anonymised individual patient data from completed trials, including thousands of oncology studies.","summary":"Launched in 2018 out of the Multi-Regional Clinical Trials Center at Harvard and Brigham and Women's Hospital, Vivli is an independent platform that hosts, or links to, anonymised participant-level data from completed clinical trials contributed by more than 40 members including most large oncology sponsors, the Wellcome Trust, the Gates Foundation and academic groups. Researchers submit proposals reviewed by independent panels, and approved analyses run in a secure research environment; the platform has enabled pooled analyses of oncology trials on toxicity, subgroups and endpoint validation. Vivli complements the YODA Project and Project Data Sphere and works with CDISC on data standards and with funders on data-sharing policy.","asOf":"2026-09-09","links":[{"label":"Vivli","url":"https://vivli.org"}],"tags":[],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cdisc","yoda-project","wellcome","gates-foundation","mgh"],"pathways":[],"terms":["real-world-evidence","hazard-ratio"],"trials":[],"people":["rebecca-li"],"bottlenecks":["b-data-silos","b-negative-results","b-reproducibility"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Cambridge, MA","country":"US","lat":42.373,"lng":-71.11,"institutionType":"consortium","website":"https://vivli.org","programs":["Individual participant data sharing platform","Independent review of data requests","Secure research environment","Data-sharing policy with funders"]},{"id":"wehi","kind":"institution","name":"Walter and Eliza Hall Institute of Medical Research","aka":["WEHI","Walter and Eliza Hall Institute"],"tldr":"Australia's oldest medical research institute, where the BCL-2 family of cell-death proteins was discovered, leading to venetoclax.","summary":"WEHI was founded in 1915 in Parkville, Melbourne, and is best known in cancer for the discovery by David Vaux, Suzanne Cory, Jerry Adams and Andreas Strasser that BCL-2 blocks programmed cell death, which after decades of work with Genentech and AbbVie produced venetoclax, the first BH3-mimetic drug, tested in Melbourne under Andrew Roberts and John Seymour. The institute also discovered colony-stimulating factors (Donald Metcalf) that underpin G-CSF supportive care, and has strong programmes in blood cancer, colorectal cancer, breast cancer stem cells (Jane Visvader, Geoffrey Lindeman), structural biology and cancer immunology. WEHI runs clinical translation with the Royal Melbourne Hospital and Peter MacCallum through the Victorian Comprehensive Cancer Centre alliance.","asOf":"2026-09-09","links":[{"label":"WEHI","url":"https://www.wehi.edu.au"},{"label":"Victorian Comprehensive Cancer Centre","url":"https://www.viccompcancerctr.org"}],"tags":[],"related":["g-csf-growth-factors"],"cancers":["cll","aml","breast-hr-positive","colorectal"],"sections":["drug-discovery","targeted-therapy"],"technologies":["crispr-screens","organoids"],"targets":["bcl2"],"drugs":["venetoclax"],"companies":["abbvie","roche-genentech"],"institutions":["peter-mac"],"pathways":[],"terms":[],"trials":[],"people":["ken-smith","jeanne-tie"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Melbourne","country":"AU","lat":-37.799,"lng":144.956,"institutionType":"research-institute","website":"https://www.wehi.edu.au","university":"University of Melbourne","programs":["BCL-2 and apoptosis (venetoclax)","Colony-stimulating factors","Breast and colorectal cancer biology","Blood cancer"]},{"id":"weizmann","kind":"institution","name":"Weizmann Institute of Science","aka":["Weizmann Institute","Moross Integrated Cancer Center"],"tldr":"Israel's basic research institute, whose HER receptor, p53, single-cell immunology and microbiome discoveries have shaped cancer biology.","summary":"Founded in 1934 as the Daniel Sieff Institute, the Weizmann Institute of Science created the Moross Integrated Cancer Center in 2016 to link its cancer groups with clinical partners. Yosef Yarden's work on ErbB/HER receptor signalling and antibody combinations, Moshe Oren and Varda Rotter's on p53, Ido Amit's single-cell immunology of tumour myeloid cells, Eran Elinav's microbiome studies and Yardena Samuels's neoantigen discovery in melanoma are widely cited, and Michael Sela's group's early work on combining anti-EGFR antibodies with chemotherapy underpinned patents relevant to cetuximab. The institute's Yeda technology transfer arm has licensed numerous cancer diagnostics and therapeutics, and its scientists collaborate with Sheba, Rambam and international centres.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.weizmann.ac.il"},{"label":"Moross Integrated Cancer Center","url":"https://www.weizmann.ac.il/MICC/"}],"tags":[],"related":[],"cancers":["melanoma","breast-her2-positive","colorectal","aml"],"sections":["drug-discovery","immunotherapy"],"technologies":["monoclonal-antibody","single-cell-spatial","crispr-screens","proteomics"],"targets":["her2","egfr","tp53"],"drugs":[],"companies":[],"institutions":["sheba","rambam"],"pathways":[],"terms":["neoantigen"],"trials":[],"people":["alon-chen","zelig-eshhar","yardena-samuels","yosef-yarden","moshe-oren"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Rehovot","country":"IL","lat":31.907,"lng":34.811,"institutionType":"research-institute","website":"https://www.weizmann.ac.il","programs":["Moross Integrated Cancer Center","HER receptor and antibody biology","p53 biology","Single-cell immunology","Microbiome and cancer"]},{"id":"wellcome","kind":"institution","name":"Wellcome","aka":["Wellcome Trust"],"tldr":"One of the world's largest charitable science funders and a founding partner of the Francis Crick Institute and the Wellcome Sanger Institute, home of the COSMIC cancer mutation database.","summary":"Established in 1936 from the estate of Henry Wellcome, Wellcome is a politically and financially independent foundation that funds discovery science, and its portfolio underpins cancer research even though it is not a cancer-specific funder. It co-founded the Francis Crick Institute with Cancer Research UK and the Medical Research Council, and it established the Wellcome Sanger Institute, whose Cancer Genome Project produced COSMIC and much of the mutational-signature literature. Wellcome funds investigator awards, clinical research career development and the Human Cell Atlas, and it drove open-access publishing policy through Plan S and Europe PMC.","asOf":"2026-09-09","links":[{"label":"Wellcome","url":"https://wellcome.org"},{"label":"Wellcome Sanger Institute","url":"https://www.sanger.ac.uk"}],"tags":[],"related":[],"cancers":[],"sections":["ai-computation","drug-discovery"],"technologies":["wes-wgs","single-cell-spatial"],"targets":[],"drugs":[],"companies":[],"institutions":["francis-crick","cruk"],"pathways":[],"terms":["mutational-signature"],"trials":[],"people":["paul-nurse","charles-swanton","john-arne-rottingen"],"bottlenecks":["b-data-silos"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"London","country":"GB","lat":51.526,"lng":-0.134,"institutionType":"consortium","website":"https://wellcome.org","programs":["Wellcome Sanger Institute (COSMIC, mutational signatures)","Francis Crick Institute founding partner","Discovery research awards","Open access and Europe PMC"]},{"id":"wellcome-sanger","kind":"institution","name":"Wellcome Sanger Institute","aka":["Sanger Institute","Sanger Centre"],"tldr":"The UK genome institute whose Cancer Genome Project found the BRAF mutation in melanoma, built COSMIC and defined mutational signatures.","summary":"Founded in 1992 to sequence the human genome, the Wellcome Sanger Institute launched the Cancer Genome Project under Michael Stratton in 2000. It reported the BRAF V600E mutation in melanoma in 2002, created the COSMIC catalogue of somatic mutations, defined the mutational signatures framework with Ludmil Alexandrov in 2013, and with the Broad Institute built the cancer dependency map and Genomics of Drug Sensitivity in Cancer resources led by Mathew Garnett. Sanger co-founded Open Targets with EMBL-EBI and industry partners and the Human Cell Atlas, and leads the Mutographs Grand Challenge on cancer causes. Its tools underpin much of modern tumour sequencing and target discovery.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Wellcome_Sanger_Institute","links":[{"label":"Homepage","url":"https://www.sanger.ac.uk"},{"label":"Cancer, Ageing and Somatic Mutation programme","url":"https://www.sanger.ac.uk/programme/cancer-ageing-and-somatic-mutation/"},{"label":"COSMIC","url":"https://cancer.sanger.ac.uk/cosmic"}],"tags":[],"related":["cosmic","depmap","open-targets","cellxgene-hca"],"cancers":["melanoma","esophageal","colorectal"],"sections":["diagnostics","drug-discovery"],"technologies":["wes-wgs","crispr-screens","single-cell-spatial","organoids","functional-drug-testing"],"targets":["braf"],"drugs":[],"companies":[],"institutions":["broad-institute","embl-ebi","cruk"],"pathways":[],"terms":["mutational-signature","vus"],"trials":[],"people":["matthew-hurles","michael-stratton"],"bottlenecks":["b-undruggable-targets"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Hinxton","country":"GB","lat":52.079,"lng":0.187,"institutionType":"research-institute","website":"https://www.sanger.ac.uk","programs":["Cancer Genome Project","COSMIC","Mutational signatures (Mutographs)","Cancer dependency map and GDSC","Open Targets","Human Cell Atlas"]},{"id":"wessex-cancer-alliance","kind":"institution","name":"Wessex Cancer Alliance","aka":["WCA"],"tldr":"The NHS England Cancer Alliance for Hampshire, the Isle of Wight and Dorset: the partnership that plans and improves cancer services across its hospitals, GPs and community services.","summary":"One of the 20 Cancer Alliances set up by NHS England from 2016, following the Independent Cancer Taskforce strategy, to bring together the hospital trusts, integrated care boards, primary care, hospices and charities serving Hampshire, the Isle of Wight and Dorset. Alliances lead local delivery of the NHS cancer ambitions: earlier diagnosis (including rapid diagnostic centres and targeted lung health checks), the Faster Diagnosis Standard, personalised care and follow-up, and workforce and pathway improvement. They hold transformation funding from NHS England and publish local performance and improvement plans.","asOf":"2026-09-09","links":[{"label":"Wessex Cancer Alliance","url":"https://wessexcanceralliance.nhs.uk/"},{"label":"NHS England: Cancer Alliances","url":"https://www.england.nhs.uk/cancer/cancer-alliances-improving-care-locally/"}],"tags":["nhs-cancer-alliance"],"related":[],"cancers":[],"sections":["early-detection"],"technologies":["low-dose-ct-screening"],"targets":[],"drugs":[],"companies":[],"institutions":["southampton-cancer"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Southampton","country":"GB","lat":50.91,"lng":-1.404,"institutionType":"consortium","website":"https://wessexcanceralliance.nhs.uk/","programs":["Earlier diagnosis and rapid diagnostic centres","Faster Diagnosis Standard","Personalised care and follow-up","Cancer pathway improvement"]},{"id":"west-china","kind":"institution","name":"West China Hospital, Sichuan University","aka":[],"tldr":"West China Hospital is one of the largest hospitals in the world and a top-4 Nature Index healthcare institution, strong in oncology and biotherapy.","summary":"West China Hospital of Sichuan University in Chengdu is one of the largest hospitals in the world and was ranked fourth among healthcare institutions in the Nature Index 2025, with oncology and biotherapy among its strengths. It houses the State Key Laboratory of Biotherapy, performs high-volume cancer surgery and is building an early-phase trial programme, with Yuquan Wei, You Lu and Weimin Li among the people OnCo lists. OnCo links it to the Chinese Society of Clinical Oncology and to the bottleneck that most of the world has almost no cancer care, since a single hospital of this size serves a very large region. How its research output translates into trials that regulators outside China accept is the open question. Its biotherapy and early-phase programmes are the entry points.","asOf":"2026-09-04","wikipedia":"https://en.wikipedia.org/wiki/West_China_Hospital","links":[{"label":"Official website","url":"https://www.wchscu.cn"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["wei-yuquan","lu-you","li-weimin"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Chengdu","country":"CN","lat":30.642,"lng":104.043,"institutionType":"hospital","website":"https://www.wchscu.cn","programs":["Biotherapy","Early-phase trials"]},{"id":"essen-wtz","kind":"institution","name":"West German Cancer Center (WTZ), University Hospital Essen","aka":["Westdeutsches Tumorzentrum","Universitätsklinikum Essen","NCT West"],"tldr":"One of Germany's oldest and largest cancer centres, home to the West German Proton Therapy Centre and a leading melanoma and theranostics programme.","summary":"Founded in 1967, the Westdeutsches Tumorzentrum at University Hospital Essen was among the first German Cancer Aid Oncology Centers of Excellence and became a National Center for Tumor Diseases site (NCT West, with Cologne) in 2023. It operates the West German Proton Therapy Centre Essen (WPE), Europe's largest university-based proton facility, treating many paediatric patients. The dermato-oncology group under Dirk Schadendorf has led melanoma immunotherapy and adjuvant trials, and the nuclear medicine department under Ken Herrmann is a high-volume theranostics centre for PSMA and somatostatin-receptor radioligands. Other strengths include sarcoma, uveal melanoma, stem cell transplantation and neuro-oncology.","asOf":"2026-09-09","links":[{"label":"Homepage","url":"https://www.wtz-essen.de"},{"label":"WPE proton centre","url":"https://www.wpe-uk.de"},{"label":"NCT West","url":"https://www.nct-west.de"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":["melanoma","prostate","neuroendocrine","sarcoma","aml"],"sections":["radiation","radiopharma","immunotherapy"],"technologies":["proton-therapy","radioligand-therapy","psma-pet","checkpoint-inhibitor","proton-therapy-systems"],"targets":[],"drugs":["pluvicto","lutathera","nivolumab","ipilimumab"],"companies":["iba"],"institutions":["uniklinik-koeln","dkfz"],"pathways":[],"terms":[],"trials":["checkmate-067","vision"],"people":["dirk-schadendorf","martin-schuler","ken-herrmann"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Essen","country":"DE","lat":51.437,"lng":6.992,"institutionType":"cancer-center","website":"https://www.wtz-essen.de","university":"Universität Duisburg-Essen","programs":["West German Proton Therapy Centre","Melanoma and dermato-oncology","Theranostics and nuclear medicine","Stem cell transplantation","NCT West"]},{"id":"west-midlands-cancer-alliance","kind":"institution","name":"West Midlands Cancer Alliance","aka":["WMCA"],"tldr":"The NHS England Cancer Alliance for the West Midlands, including Birmingham, the Black Country, Coventry, Warwickshire, Herefordshire, Worcestershire, Shropshire and Staffordshire: the partnership that plans and improves cancer services across its hospitals, GPs and community services.","summary":"One of the 20 Cancer Alliances set up by NHS England from 2016, following the Independent Cancer Taskforce strategy, to bring together the hospital trusts, integrated care boards, primary care, hospices and charities serving the West Midlands, including Birmingham, the Black Country, Coventry, Warwickshire, Herefordshire, Worcestershire, Shropshire and Staffordshire. Alliances lead local delivery of the NHS cancer ambitions: earlier diagnosis (including rapid diagnostic centres and targeted lung health checks), the Faster Diagnosis Standard, personalised care and follow-up, and workforce and pathway improvement. They hold transformation funding from NHS England and publish local performance and improvement plans.","asOf":"2026-09-09","links":[{"label":"West Midlands Cancer Alliance","url":"https://wmcanceralliance.nhs.uk/"},{"label":"NHS England: Cancer Alliances","url":"https://www.england.nhs.uk/cancer/cancer-alliances-improving-care-locally/"}],"tags":["nhs-cancer-alliance"],"related":[],"cancers":[],"sections":["early-detection"],"technologies":["low-dose-ct-screening"],"targets":[],"drugs":[],"companies":[],"institutions":["birmingham-cancer-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Birmingham","country":"GB","lat":52.486,"lng":-1.89,"institutionType":"consortium","website":"https://wmcanceralliance.nhs.uk/","programs":["Earlier diagnosis and rapid diagnostic centres","Faster Diagnosis Standard","Personalised care and follow-up","Cancer pathway improvement"]},{"id":"west-yorkshire-harrogate-cancer-alliance","kind":"institution","name":"West Yorkshire and Harrogate Cancer Alliance","aka":["WYH Cancer Alliance"],"tldr":"The NHS England Cancer Alliance for West Yorkshire and Harrogate, including Leeds, Bradford, Wakefield, Kirklees and Calderdale: the partnership that plans and improves cancer services across its hospitals, GPs and community services.","summary":"One of the 20 Cancer Alliances set up by NHS England from 2016, following the Independent Cancer Taskforce strategy, to bring together the hospital trusts, integrated care boards, primary care, hospices and charities serving West Yorkshire and Harrogate, including Leeds, Bradford, Wakefield, Kirklees and Calderdale. Alliances lead local delivery of the NHS cancer ambitions: earlier diagnosis (including rapid diagnostic centres and targeted lung health checks), the Faster Diagnosis Standard, personalised care and follow-up, and workforce and pathway improvement. They hold transformation funding from NHS England and publish local performance and improvement plans.","asOf":"2026-09-09","links":[{"label":"West Yorkshire and Harrogate Cancer Alliance","url":"https://canceralliance.wyhpartnership.co.uk"},{"label":"NHS England: Cancer Alliances","url":"https://www.england.nhs.uk/cancer/cancer-alliances-improving-care-locally/"}],"tags":["nhs-cancer-alliance"],"related":[],"cancers":[],"sections":["early-detection"],"technologies":["low-dose-ct-screening"],"targets":[],"drugs":[],"companies":[],"institutions":["leeds-cancer-centre"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Leeds","country":"GB","lat":53.8,"lng":-1.549,"institutionType":"consortium","website":"https://canceralliance.wyhpartnership.co.uk","programs":["Earlier diagnosis and rapid diagnostic centres","Faster Diagnosis Standard","Personalised care and follow-up","Cancer pathway improvement"]},{"id":"weston-park-sheffield","kind":"institution","name":"Weston Park Cancer Centre, Sheffield Teaching Hospitals","aka":["Weston Park Hospital"],"tldr":"One of only a handful of dedicated cancer hospitals in England, serving South Yorkshire and beyond since 1970.","summary":"Weston Park Hospital opened in 1970 and is one of a small number of dedicated NHS cancer hospitals in England, now run by Sheffield Teaching Hospitals NHS Foundation Trust as the Weston Park Cancer Centre. It provides radiotherapy, chemotherapy, immunotherapy, teenage and young adult cancer care and a large clinical trials unit for South Yorkshire, North Derbyshire and parts of Lincolnshire and Nottinghamshire. Research with the University of Sheffield includes bone oncology and bone metastasis (the Mellanby Centre), sarcoma, and radiotherapy, and the Weston Park Cancer Charity funds research and patient support on site.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.westonparkcancercentre.nhs.uk"}],"tags":["nhs-specialist-cancer-centre"],"related":[],"cancers":["pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["radiotherapy","bone-metastases","clinical-trial"],"trials":[],"people":["kirsten-major"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Sheffield","country":"GB","lat":53.379,"lng":-1.492,"institutionType":"cancer-center","website":"https://www.westonparkcancercentre.nhs.uk","university":"University of Sheffield","programs":["Radiotherapy","Bone metastasis research","Clinical trials","Teenage and young adult cancer"]},{"id":"wilmot","kind":"institution","name":"Wilmot Cancer Institute, University of Rochester","aka":[],"tldr":"Upstate New York's Wilmot Cancer Institute, NCI-designated in 2024 and a national leader in geriatric oncology and cancer-control research.","summary":"Wilmot Cancer Institute at the University of Rochester Medical Center received NCI designation in 2024 and serves a largely rural 27-county region of upstate New York. It hosts one of the NCI Community Oncology Research Program's national research bases, historically led by Gary Morrow, whose trials on nausea, fatigue and exercise defined cancer-control research; Karen Mustian's exercise oncology and Supriya Mohile's geriatric assessment trials (GAP70+) showed that assessing older patients reduces chemotherapy toxicity. Jonathan Friedberg, editor-in-chief of the Journal of Clinical Oncology, leads its lymphoma programme. Director Jonathan Friedberg and cancer biologist Hartmut Land have built basic programmes in tumour evolution and haematologic malignancy.","asOf":"2026-09-09","links":[{"label":"Wilmot Cancer Institute","url":"https://www.urmc.rochester.edu/cancer-institute"},{"label":"Clinical trials","url":"https://www.urmc.rochester.edu/cancer-institute/clinical-trials.aspx"}],"tags":[],"related":[],"cancers":["dlbcl","follicular-lymphoma"],"sections":["supportive-care"],"technologies":["geriatric-assessment","exercise-oncology"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["supriya-mohile"],"bottlenecks":["b-aging-comorbidity","b-toxicity-qol"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Rochester, NY","country":"US","lat":43.123,"lng":-77.626,"institutionType":"cancer-center","website":"https://www.urmc.rochester.edu/cancer-institute","nci":"clinical","university":"University of Rochester","programs":["Geriatric oncology","Cancer control and survivorship (NCORP Research Base)","Lymphoma"]},{"id":"emory-winship","kind":"institution","name":"Winship Cancer Institute of Emory University","aka":[],"tldr":"Winship is Georgia's only NCI comprehensive cancer centre; its myeloma programme under Sagar Lonial shaped daratumumab development, Suresh Ramalingam led the FLAURA trial that made osimertinib first-line for EGFR-mutant lung cancer, and it runs one of the South's largest phase 1 units.","summary":"Founded in 1937 and NCI-designated in 2009, Winship achieved comprehensive status in 2017 and is Georgia's only NCI comprehensive centre. Sagar Lonial's myeloma programme has been central to daratumumab and other anti-CD38 and immunomodulatory drug development; Suresh Ramalingam led the FLAURA trial that made osimertinib the first-line standard in EGFR-mutant lung cancer. Kevin Kalinsky led RxPONDER, which defined which node-positive, HR-positive breast cancer patients benefit from chemotherapy. Winship opened a dedicated cancer tower at Emory Midtown in 2023 and runs one of the South's largest phase 1 units.","asOf":"2026-09-09","links":[{"label":"Winship Cancer Institute","url":"https://winshipcancer.emory.edu"},{"label":"Clinical trials","url":"https://winshipcancer.emory.edu/clinical-trials/"},{"label":"PTCOG: particle therapy facilities in operation","url":"https://www.ptcog.site/index.php/facilities-in-operation-public"}],"tags":[],"related":[],"cancers":["multiple-myeloma","nsclc","breast-hr-positive"],"sections":[],"technologies":["proton-therapy","proton-therapy-systems"],"targets":["cd38","egfr"],"drugs":["daratumumab","osimertinib","oncotype-dx"],"companies":["swog","nrg-oncology"],"institutions":[],"pathways":[],"terms":[],"trials":["rxponder"],"people":["deborah-bruner","robert-woodruff","suresh-ramalingam","kevin-kalinsky","sagar-lonial"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Atlanta, GA","country":"US","lat":33.792,"lng":-84.322,"institutionType":"cancer-center","website":"https://winshipcancer.emory.edu","nci":"comprehensive","university":"Emory University","programs":["Multiple myeloma","EGFR-mutant lung cancer (FLAURA)","Breast cancer (RxPONDER)","Phase 1 unit"]},{"id":"wolfson-wohl-cancer-research-centre","kind":"institution","name":"Wolfson Wohl Cancer Research Centre, University of Glasgow","aka":["Institute of Cancer Sciences, Glasgow","Glasgow Precision Oncology Laboratory"],"tldr":"The University of Glasgow's cancer research centre on the Garscube estate, home to Andrew Biankin's pancreatic cancer genomics group and the Precision-Panc programme that ran the PRIMUS trials through NHS Greater Glasgow and Clyde.","summary":"The Wolfson Wohl Cancer Research Centre houses the University of Glasgow's Institute of Cancer Sciences at Garscube, Bearsden. Andrew Biankin, Regius Chair of Surgery, leads pancreatic cancer genomics there and directs ICGC-ARGO; the Precision-Panc master protocol (ISRCTN14879538), sponsored by NHS Greater Glasgow and Clyde, profiled pancreatic tumours at 27 UK sites between December 2017 and March 2022 to route patients into the PRIMUS trials, and its team co-authored the STARPAC2 protocol. Clinical care for the West of Scotland is at Glasgow Royal Infirmary and the Beatson.","asOf":"2026-09-24","links":[{"label":"School of Cancer Sciences: Andrew Biankin","url":"https://www.gla.ac.uk/schools/cancersciences/staff/andrewbiankin/"},{"label":"ISRCTN14879538: Precision Panc","url":"https://www.isrctn.com/ISRCTN14879538"}],"tags":["research","uk","pancreatic","genomics"],"related":[],"cancers":["pancreatic"],"sections":["targeted-therapy","diagnostics"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["glasgow-royal-infirmary","beatson-glasgow"],"pathways":[],"terms":["genomic-profiling"],"trials":["precision-panc"],"people":["andrew-biankin"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Glasgow","country":"GB","lat":55.905,"lng":-4.321,"institutionType":"research-institute","website":"https://www.gla.ac.uk/schools/cancersciences/","university":"University of Glasgow","programs":["Pancreatic cancer genomics","Precision-Panc and the PRIMUS trials","ICGC-ARGO"]},{"id":"who","kind":"institution","name":"World Health Organization Cancer Programme","aka":["WHO","World Health Organization"],"tldr":"The UN health agency that sets global cancer policy: the cervical cancer elimination strategy, the essential medicines list, the childhood cancer initiative and the classification of tumours.","summary":"WHO's cancer work spans its Geneva headquarters, regional offices and the International Agency for Research on Cancer in Lyon. Headquarters leads the Global Strategy to Eliminate Cervical Cancer (90-70-90 targets for vaccination, screening and treatment), the Global Initiative for Childhood Cancer, the Global Breast Cancer Initiative, and the WHO Model List of Essential Medicines, which now includes many targeted and immunotherapy agents. Through IARC it produces the WHO Classification of Tumours (the Blue Books) and GLOBOCAN statistics, and it runs the Framework Convention on Tobacco Control. WHO prequalification and guidance shape what low- and middle-income health systems buy and how they screen.","asOf":"2026-09-09","links":[{"label":"WHO cancer","url":"https://www.who.int/health-topics/cancer"},{"label":"Cervical cancer elimination","url":"https://www.who.int/initiatives/cervical-cancer-elimination-initiative"}],"tags":[],"related":["globocan"],"cancers":["cervical","breast-hr-positive","all-leukemia"],"sections":["prevention"],"technologies":["hpv-vaccine"],"targets":[],"drugs":[],"companies":[],"institutions":["iarc","uicc","iaea","gates-foundation"],"pathways":[],"terms":["who-essential-medicines"],"trials":[],"people":["ilbawi-andre","weiderpass-elisabete","tedros-adhanom-ghebreyesus"],"bottlenecks":["b-global-access"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Geneva","country":"CH","lat":46.232,"lng":6.134,"institutionType":"government","website":"https://www.who.int/health-topics/cancer","programs":["Cervical cancer elimination strategy","Global Initiative for Childhood Cancer","Model List of Essential Medicines","WHO Classification of Tumours (via IARC)","Framework Convention on Tobacco Control"]},{"id":"worldwide-cancer-research","kind":"institution","name":"Worldwide Cancer Research","aka":["Association for International Cancer Research","AICR"],"tldr":"A Scottish charity that funds early-stage discovery research on cancer anywhere in the world, rather than only in the UK.","summary":"Founded in 1979 in St Andrews as the Association for International Cancer Research, Worldwide Cancer Research funds curiosity-driven basic and discovery science on any cancer in any country, on the principle that discoveries come from unexpected places. Its grants typically support three-year laboratory projects at universities and institutes across Europe, North America, Australia and beyond. The charity has funded more than 2,000 projects since its founding and highlights alumni whose early work later underpinned drugs and diagnostics. It is now headquartered in Edinburgh.","asOf":"2026-09-09","links":[{"label":"Worldwide Cancer Research","url":"https://www.worldwidecancerresearch.org"}],"tags":[],"related":[],"cancers":[],"sections":["drug-discovery"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["cruk"],"pathways":[],"terms":[],"trials":[],"people":["laura-brady"],"bottlenecks":["b-funding-allocation","b-translational-valley"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Edinburgh","country":"GB","lat":55.953,"lng":-3.188,"institutionType":"consortium","website":"https://www.worldwidecancerresearch.org","programs":["International discovery research grants","Early-career and high-risk project funding"]},{"id":"yale-cancer-center","kind":"institution","name":"Yale Cancer Center / Smilow Cancer Hospital","aka":["YCC","Smilow Cancer Hospital at Yale New Haven"],"tldr":"Connecticut's only NCI-designated comprehensive cancer centre, on the campus where nitrogen mustard was first given to a cancer patient in 1942, the beginning of chemotherapy.","summary":"Yale Cancer Center was founded in 1974 under the National Cancer Act and is one of the NCI's comprehensive cancer centres; Smilow Cancer Hospital, its clinical home within Yale New Haven Hospital, opened in 2009 and now runs a network of Smilow Cancer Care Centers across Connecticut. Yale's cancer history runs deep: the first clinical use of nitrogen mustard chemotherapy took place at New Haven Hospital in 1942, and Yale established the first US university department of clinical pharmacology and chemotherapy in 1965. Current strengths include cancer immunology (Lieping Chen's PD-L1 work), thoracic oncology and EGFR resistance biology (Katerina Politi), head and neck cancer (Barbara Burtness), breast oncology under director Eric Winer, and a large early-phase trials programme. Yale's Center for Thoracic Cancers and the Yale Center for Immuno-Oncology anchor its translational research.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://medicine.yale.edu/cancer/"},{"label":"NCI designation","url":"https://medicine.yale.edu/cancer/about/ncidesignation/"},{"label":"History","url":"https://medicine.yale.edu/cancer/about/history/"}],"tags":["nci-designated","comprehensive"],"related":[],"cancers":["nsclc","head-and-neck"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":["pdl1"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":["eric-winer"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"New Haven, CT","country":"US","lat":41.304,"lng":-72.936,"institutionType":"cancer-center","website":"https://medicine.yale.edu/cancer/","nci":"comprehensive","university":"Yale University","programs":["Cancer immunology (PD-L1 biology)","Thoracic oncology","Head and neck cancer","Breast oncology","Early-phase trials"]},{"id":"yale-school-of-medicine","kind":"institution","name":"Yale School of Medicine / Yale Cancer Center","aka":[],"tldr":"Home of the Cell2Sentence single-cell language models built with Google, and an NCI-designated comprehensive cancer centre.","summary":"Yale School of Medicine and Yale Cancer Center in New Haven form an NCI-designated comprehensive cancer centre and the home of the Cell2Sentence single-cell language models built with Google. David van Dijk's lab developed Cell2Sentence and C2S-Scale with Google DeepMind and Google Research, representing cells as text so that general language models can reason about them, and a C2S-Scale hypothesis about interferon sensitisation was validated in vitro in 2025. OnCo connects it to the Cell2Sentence technology record, to the Yale University Open Data Access Project, and to the virtual cell roadmap. Whether language-model reasoning over cells produces hypotheses that hold up in patients is the open question. Its Cell2Sentence and Yale Cancer Center programmes are listed below.","asOf":"2026-09-08","links":[{"label":"Official website","url":"https://medicine.yale.edu"}],"tags":["ai","virtual-cell"],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"New Haven, CT","country":"US","lat":41.303,"lng":-72.934,"institutionType":"university","website":"https://medicine.yale.edu","nci":"comprehensive","university":"Yale University","programs":["Cell2Sentence / C2S-Scale","Yale Cancer Center"]},{"id":"yoda-project","kind":"institution","name":"Yale University Open Data Access (YODA) Project","aka":["YODA Project","YODA"],"tldr":"The Yale programme that acts as independent steward of clinical trial data from Johnson & Johnson and other sponsors, letting outside researchers re-analyse trials including oncology studies.","summary":"Founded in 2011 by Harlan Krumholz and Joseph Ross at Yale, the YODA Project pioneered independent, transparent sharing of participant-level clinical trial data: sponsors (Johnson & Johnson since 2014, with Medtronic and others) hand over data and clinical study reports, and YODA reviews researcher requests against pre-specified criteria, publishing decisions and resulting publications. Its holdings include Janssen oncology trials of abiraterone, daratumumab, ibrutinib and CAR-T, enabling re-analyses of subgroups, toxicity and endpoints. YODA's model influenced the ICMJE data-sharing statement requirements and sits alongside Vivli and Project Data Sphere as the main academic trial data-sharing infrastructure.","asOf":"2026-09-09","links":[{"label":"YODA Project","url":"https://yoda.yale.edu"}],"tags":[],"related":[],"cancers":[],"sections":["ai-computation"],"technologies":[],"targets":[],"drugs":["ciltacabtagene-autoleucel","teclistamab"],"companies":["johnson-johnson"],"institutions":["yale-school-of-medicine","vivli","cdisc"],"pathways":[],"terms":["real-world-evidence"],"trials":[],"people":["harlan-krumholz","joseph-ross"],"bottlenecks":["b-data-silos","b-reproducibility","b-negative-results"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"New Haven, CT","country":"US","lat":41.308,"lng":-72.928,"institutionType":"consortium","website":"https://yoda.yale.edu","programs":["Independent trial data stewardship for Johnson & Johnson and others","Transparent request review and reporting","Data-sharing policy research"]},{"id":"zealand-university-hospital","kind":"institution","name":"Zealand University Hospital","aka":["Sjællands Universitetshospital","SUH","Køge Hospital","Roskilde Hospital"],"tldr":"Zealand University Hospital, on the Køge and Roskilde sites, is the university hospital of Denmark's Region Zealand and a full member of the Organisation of European Cancer Institutes.","summary":"Zealand University Hospital (Sjællands Universitetshospital) is the university hospital of Region Zealand, formed from the Køge and Roskilde hospitals, with a new main hospital under construction in Køge and university links to the University of Copenhagen. It provides the region's specialised cancer treatment and takes part in the Danish Comprehensive Cancer Center. It is listed by the Organisation of European Cancer Institutes as a full member. Programme, trial and leadership details are not yet recorded here and should be checked on the hospital's own pages.","asOf":"2026-09-09","links":[{"label":"Official website","url":"https://www.sjaellandsuniversitetshospital.dk"},{"label":"OECI membership list","url":"https://www.oeci.eu/Membership.aspx"}],"tags":[],"related":["rigshospitalet","odense-university-hospital"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["oeci"],"pathways":[],"terms":[],"trials":[],"people":["ricco-norman-dyhr"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Køge","country":"DK","lat":55.477,"lng":12.166,"institutionType":"hospital","website":"https://www.sjaellandsuniversitetshospital.dk","programs":[]},{"id":"zfkd-rki","kind":"institution","name":"Zentrum für Krebsregisterdaten am Robert Koch-Institut","aka":["ZfKD","German Centre for Cancer Registry Data","Robert Koch-Institut","RKI","krebsdaten.de"],"tldr":"The federal centre at the Robert Koch Institute that pools what Germany's sixteen state cancer registries record, checks how complete it is, and publishes the national figures in Krebs in Deutschland.","summary":"The Bundeskrebsregisterdatengesetz of 10 August 2009 established the Zentrum für Krebsregisterdaten at the Robert Koch Institute in Berlin, which began work in January 2010 in succession to the institute's earlier Dachdokumentation Krebs. The Act defines a Krebsregister as both the clinical registries the Länder must run under section 65c SGB V and their epidemiological registries, and section 5 sets out exactly which fields flow to the centre: person, tumour including method of diagnostic confirmation and TNM stage, treatment, course and death. Data are due by 31 December of the following calendar year, and each annual dataset must be deleted after two years.\n\nThe centre checks completeness against a regression-based expectation, deduplicates across state borders using control numbers, runs a public register of approved data applications and a central application office, and publishes Krebs in Deutschland with Deutsche Krebsregister e.V. every two years. The fifteenth edition, for 2021 to 2023, reports 517,800 new cancers and 228,960 cancer deaths in 2023 excluding non-melanoma skin cancer, relative five-year survival of 65 percent in women and 61 percent in men, and rates standardised against the old European population rather than the World standard used internationally, which is why German and IARC figures are not directly comparable. The centre is candid that this remains an estimate rather than a count: twelve of sixteen registries met the reference-region criteria for 2023, and Saxony-Anhalt never has.","asOf":"2026-09-25","links":[{"label":"Zentrum für Krebsregisterdaten","url":"https://www.krebsdaten.de"},{"label":"Tasks","url":"https://www.krebsdaten.de/Krebs/DE/Content/ZfKD/Aufgaben/aufgaben_node.html"},{"label":"Krebs in Deutschland 2025 (PDF)","url":"https://www.krebsdaten.de/Krebs/DE/Content/Publikationen/Krebs_in_Deutschland/krebs_in_deutschland_2025.pdf?__blob=publicationFile"},{"label":"Bundeskrebsregisterdatengesetz","url":"https://www.gesetze-im-internet.de/bkrg/BJNR270700009.html"},{"label":"Section 65c SGB V","url":"https://www.gesetze-im-internet.de/sgb_5/__65c.html"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["cancer-registries-surveillance"],"targets":[],"drugs":[],"companies":[],"institutions":["deutsche-krebsgesellschaft","dkfz","g-ba-iqwig","iarc"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-data-silos","b-real-world-evidence"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Berlin","country":"DE","lat":52.47,"lng":13.383,"institutionType":"government","website":"https://www.krebsdaten.de","programs":["Pooling and quality-checking the Länder registry data","Krebs in Deutschland (biennial)","Completeness and incidence estimation","Public register of approved data applications","CancerWatch Joint Action and EUCanScreen"]},{"id":"zhejiang-cancer-hospital","kind":"institution","name":"Zhejiang Cancer Hospital","aka":["Cancer Hospital of the University of Chinese Academy of Sciences","浙江省肿瘤医院"],"tldr":"Zhejiang's provincial cancer centre and a leading Chinese site for thoracic radiotherapy, oesophageal and lung cancer trials, and cancer screening.","summary":"Founded in 1963, Zhejiang Cancer Hospital became the Cancer Hospital of the University of Chinese Academy of Sciences in 2019 and runs the Zhejiang provincial cancer registry and screening programmes. It is known for thoracic oncology and radiotherapy, oesophageal cancer, head and neck cancer and gynaecological oncology, and has been a top enroller in Chinese PD-1 and ADC trials in lung and oesophageal cancer. The hospital has a proton therapy project and a phase 1 ward, and its collaboration with the CAS Hangzhou Institute of Medicine links it to the Chinese Academy of Sciences basic-science network.","asOf":"2026-09-09","wikipedia":"https://en.wikipedia.org/wiki/Zhejiang_Cancer_Hospital","links":[{"label":"Zhejiang Cancer Hospital","url":"https://www.zjcc.org.cn"},{"label":"University of Chinese Academy of Sciences","url":"https://www.ucas.ac.cn"}],"tags":[],"related":[],"cancers":["nsclc","esophageal","head-and-neck","cervical"],"sections":["radiation","early-detection"],"technologies":["imrt-igrt","proton-therapy","checkpoint-inhibitor"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["cancer-registries-surveillance"],"trials":[],"people":["tan-weihong"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Hangzhou","country":"CN","lat":30.279,"lng":120.145,"institutionType":"cancer-center","website":"https://www.zjcc.org.cn","university":"University of Chinese Academy of Sciences","programs":["Thoracic oncology and radiotherapy","Oesophageal cancer","Cancer screening and registry","Proton therapy"]},{"id":"zhongshan-hospital-fudan","kind":"institution","name":"Zhongshan Hospital, Fudan University","aka":["Zhongshan Hospital","复旦大学附属中山医院"],"tldr":"Shanghai's leading general hospital and a world centre for liver cancer surgery and research, home of the Liver Cancer Institute.","summary":"Zhongshan Hospital, founded in 1937, houses Fudan University's Liver Cancer Institute, which under Zhao-You Tang pioneered subclinical hepatocellular carcinoma detection with alpha-fetoprotein screening and small-HCC resection, and under Jia Fan and Jian Zhou continues to lead in liver transplantation for HCC, downstaging and conversion therapy, and circulating tumour cell research. The hospital is also strong in colorectal liver metastasis surgery, endoscopic resection of early gastrointestinal cancers and thoracic surgery, and its investigators contributed to the Chinese HCC immunotherapy trials. It is a national clinical research centre for interventional medicine.","asOf":"2026-09-09","links":[{"label":"Zhongshan Hospital","url":"https://www.zs-hospital.sh.cn"},{"label":"Fudan University","url":"https://www.fudan.edu.cn"}],"tags":[],"related":[],"cancers":["hcc","cholangiocarcinoma","colorectal","gastric"],"sections":["surgery","early-detection"],"technologies":["liquid-biopsy","thermal-ablation","robotic-surgery"],"targets":["gpc3","vegf","pd1"],"drugs":[],"companies":[],"institutions":["fuscc"],"pathways":[],"terms":[],"trials":[],"people":["fan-jia"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"city":"Shanghai","country":"CN","lat":31.196,"lng":121.457,"institutionType":"hospital","website":"https://www.zs-hospital.sh.cn","university":"Fudan University","programs":["Liver Cancer Institute","Liver transplantation for HCC","Colorectal liver metastases","Early GI cancer endoscopy"]}]